Lactobacillus 0 NOUN T
plantarum 0 NOUN F
CECT7315 0 NOUN T
and 0 CCONJ F
CECT7316 0 NOUN T
stimulate 0 PUNCT F
immunoglobulin B-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
after 0 ADP F
influenza 0 NOUN F
vaccination 0 NOUN F
in 0 ADP F
elderly 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
effectiveness 0 NOUN F
of 0 ADP F
influenza 0 NOUN F
vaccination 0 NOUN F
in 0 ADP F
preventing 0 VERB F
illness 0 NOUN F
is 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
elderly 0 ADJ F
; 0 PUNCT F
this 0 PUNCT F
is 0 NUM F
why 0 ADP F
the 0 DET F
ability 0 NOUN F
of 0 ADP F
Lactobacillus 0 NOUN T
plantarum 0 NOUN F
CECT 0 NOUN T
7315/7316 0 NOUN F
to 0 PART F
stimulate 0 ADJ F
the 0 DET F
response 0 NOUN F
to B-PHYSICAL ADP F
influenza I-PHYSICAL NOUN F
vaccination I-PHYSICAL NOUN F
in 0 ADP F
elderly 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESEARCH 0 NOUN T
METHODS 0 NOUN T
AND 0 CCONJ T
PROCEDURES 0 NOUN T
A 0 NUM T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
human 0 NOUN F
trial 0 NOUN F
including 0 VERB F
60 0 NUM F
institutionalized 0 ADV F
volunteers 0 NOUN F
aged 0 PROPN F
65-85 0 NUM F
years 0 NOUN F
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

All 0 DET T
the 0 DET F
volunteers 0 NOUN F
were 0 VERB F
vaccinated 0 VERB F
with 0 ADP F
a 0 DET F
trivalent 0 ADJ F
influenza 0 NOUN F
vaccine 0 NOUN F
( 0 PUNCT F
A/Wisconsin/67/2005 0 NOUN T
NYMC 0 NOUN T
X-161B 0 NOUN T
( 0 PUNCT F
H3N2 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
A/Solomon 0 NOUN T
Islands/3/2006 0 PUNCT T
( 0 PUNCT F
H1N1 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
B/Malaysia/2506/2004 0 PUNCT T
) 0 PUNCT F
for 0 ADP F
the 0 DET F
Spanish 0 NOUN T
vaccine 0 NOUN F
campaign 0 VERB F
2006/2007 0 NOUN F
. 0 PUNCT F

The 0 DET T
consumption 0 NOUN F
of 0 ADP F
the 0 DET F
probiotic 0 ADJ F
began 0 VERB F
between 0 ADP F
three 0 NUM F
and 0 CCONJ F
four 0 NUM F
months 0 NOUN F
after 0 ADP F
the 0 DET F
vaccination 0 NOUN F
. 0 PUNCT F

Volunteers 0 NOUN T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
three 0 NUM F
following 0 ADP F
groups 0 NOUN F
: 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
receiving 0 PUNCT F
5*10 0 NOUN F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
cfu/day 0 NUM F
of 0 ADP F
L. 0 NOUN T
plantarum 0 NOUN F
CECT 0 NOUN T
7315/7316 0 NOUN F
in 0 ADP F
20 0 NUM F
g 0 NOUN F
powdered 0 CCONJ F
skim 0 ADJ F
milk 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
receiving 0 PUNCT F
5*10 0 NOUN F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
cfu/day 0 NUM F
of 0 ADP F
L. 0 NOUN T
plantarum 0 NOUN F
CECT 0 NOUN T
7315/7316 0 NOUN F
in 0 ADP F
20 0 NUM F
g 0 NOUN F
powdered 0 CCONJ F
skim 0 ADJ F
milk 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
C 0 NOUN T
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
20 0 NUM F
g 0 NOUN F
powered 0 CCONJ F
skim 0 ADJ F
milk 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
participants 0 NOUN F
consumed 0 PUNCT F
the 0 DET F
probiotic 0 ADP F
during 0 ADP F
3 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
consumption 0 NOUN F
of 0 ADP F
L. 0 NOUN T
plantarum 0 NOUN F
CECT 0 NOUN T
7315/7316 0 NOUN F
during 0 ADP F
3 0 NUM F
months 0 NOUN F
after 0 ADP F
influenza 0 NOUN F
vaccination 0 NOUN F
increased 0 VERB F
the 0 DET F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
influenza-specific I-PHYSICAL ADJ F
IgA I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
IgG I-PHYSICAL NOUN T
antibodies I-PHYSICAL NOUN F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
a 0 DET F
trend 0 NOUN F
towards 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
influenza-specific B-PHYSICAL ADJ F
IgM I-PHYSICAL NOUN T
antibodies I-PHYSICAL NOUN F
was 0 VERB F
also 0 ADV F
observed 0 VERB F
. 0 PUNCT F

CONCLUSION 0 NOUN T
L. 0 NOUN T
plantarum 0 NOUN F
CECT7315/7316 0 ADJ T
has 0 PUNCT F
an 0 DET F
immunostimulating 0 ADP F
effect 0 NOUN F
and 0 CCONJ F
could 0 ADJ F
be 0 VERB F
used 0 VERB F
to 0 PART F
improve 0 ADJ F
the 0 DET F
response 0 NOUN F
to 0 ADP F
influenza 0 NOUN F
vaccination 0 NOUN F
in 0 ADP F
elderly 0 NOUN F
. 0 PUNCT F

Computer-navigated 0 VERB T
versus 0 CCONJ F
conventional 0 ADJ F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
a 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
literature 0 NOUN F
lacks 0 NOUN F
studies 0 NOUN F
that 0 ADP F
confirm 0 VERB F
whether 0 ADP F
the 0 DET F
improved 0 VERB F
radiographic 0 ADJ F
alignment 0 NOUN F
that 0 ADP F
can 0 VERB F
be 0 VERB F
achieved 0 VERB F
with 0 ADP F
computer-navigated 0 VERB F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
improves 0 PUNCT F
patients? 0 NOUN F
activities 0 NOUN F
of 0 ADP F
daily 0 PUNCT F
living 0 ADP F
or 0 CCONJ F
the 0 DET F
durability 0 NOUN F
of 0 ADP F
total 0 ADJ F
knee 0 NOUN F
prostheses 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
computer-navigated 0 VERB F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
improves 0 NOUN F
the 0 DET F
clinical 0 ADJ F
function 0 NOUN F
, 0 PUNCT F
alignment 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
survivorship 0 NOUN F
of 0 ADP F
the 0 DET F
components 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
prospectively 0 ADV F
compared 0 ADP F
the 0 DET F
results 0 NOUN F
of 0 ADP F
520 0 NUM F
patients 0 NOUN F
with 0 ADP F
osteoarthritis 0 NOUN F
who 0 ADP F
underwent 0 VERB F
computer-navigated 0 DET F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
for 0 ADP F
one 0 NUM F
knee 0 NOUN F
and 0 CCONJ F
conventional 0 ADJ F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
for 0 ADP F
the 0 DET F
other 0 PUNCT F
. 0 PUNCT F

The 0 DET T
assignment 0 NOUN F
of 0 ADP F
the 0 DET F
knee 0 NOUN F
to 0 ADP F
navigation 0 NOUN F
or 0 CCONJ F
not 0 ADV F
was 0 PUNCT F
done 0 PUNCT F
randomly 0 ADV F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
452 0 NUM F
women 0 NOUN F
( 0 PUNCT F
904 0 NUM F
knees 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
sixty-eight 0 PUNCT F
men 0 NOUN F
( 0 PUNCT F
136 0 NUM F
knees 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
age 0 NOUN F
of 0 ADP F
sixty-eight 0 PUNCT F
years 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
forty-nine 0 NOUN F
to 0 ADP F
eighty-eight 0 PUNCT F
years 0 NOUN F
) 0 PUNCT F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
the 0 DET F
index 0 NOUN F
arthroplasty 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
follow-up 0 NOUN F
period 0 NOUN F
was 0 VERB F
10.8 0 NUM F
years 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
ten 0 NUM F
to 0 ADP F
twelve 0 PUNCT F
years 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
assessed 0 VERB F
clinically 0 ADV F
and 0 CCONJ F
radiographically 0 ADV F
with 0 ADP F
the 0 DET F
rating 0 VERB F
system 0 NOUN F
of 0 ADP F
the 0 DET F
Knee B-PHYSICAL NOUN T
Society I-PHYSICAL NOUN T
and 0 CCONJ F
with 0 ADP F
the 0 DET F
Western 0 NOUN T
Ontario 0 NOUN T
and 0 CCONJ F
McMaster 0 ADJ T
Universities 0 PROPN T
Osteoarthritis 0 NOUN T
Index 0 NOUN T
( 0 PUNCT F
WOMAC 0 NOUN T
) 0 PUNCT F
score 0 NOUN F
at 0 ADP F
three 0 NUM F
months 0 NOUN F
, 0 PUNCT F
one 0 NUM F
year 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
annually 0 ADV F
thereafter 0 ADV F
. 0 PUNCT F

RESULTS 0 DET T
Total 0 VERB T
knee B-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
, 0 PUNCT F
knee B-PHYSICAL NOUN F
function I-PHYSICAL ADV F
scores I-PHYSICAL NOUN F
, 0 PUNCT F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
, 0 PUNCT F
WOMAC B-PHYSICAL ADP T
scores I-PHYSICAL NOUN F
, 0 PUNCT F
knee B-PHYSICAL NOUN F
motion I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
activity B-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
show 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
preoperatively 0 ADV F
or 0 CCONJ F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
the 0 DET F
final 0 ADJ F
follow-up 0 NOUN F
. 0 PUNCT F

Alignment 0 ADJ T
and 0 CCONJ F
the 0 DET F
survivorship 0 NOUN F
of 0 ADP F
the 0 DET F
components 0 NOUN F
were 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
Kaplan-Meier 0 ADJ T
survivorship 0 NOUN F
with 0 ADP F
revision 0 NOUN F
as 0 ADP F
the 0 DET F
end 0 NOUN F
point 0 NOUN F
at 0 ADP F
10.8 0 NUM F
years 0 NOUN F
was 0 VERB F
98.8 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
[ 0 PUNCT F
CI 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
0.96 0 NUM F
to 0 ADP F
1.00 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
computernavigated 0 VERB F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
99.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
, 0 PUNCT F
0.96 0 NUM F
to 0 ADP F
1.00 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
conventional 0 ADJ F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 ADP T
Our 0 PUNCT T
data 0 NOUN F
demonstrated 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
clinical 0 ADJ F
function 0 NOUN F
or 0 CCONJ F
alignment 0 NOUN F
and 0 CCONJ F
survivorship 0 NOUN F
of 0 ADP F
the 0 DET F
components 0 NOUN F
between 0 ADP F
the 0 DET F
knees 0 NOUN F
that 0 PUNCT F
underwent 0 PROPN F
computer-navigated 0 DET F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 ADJ F
and 0 CCONJ F
those 0 ADP F
that 0 PUNCT F
underwent 0 PROPN F
conventional 0 ADJ F
total 0 ADJ F
knee 0 NOUN F
arthroplasty 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Methodologic 0 ADJ T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
polyfrequency 0 NOUN F
oscillation 0 NOUN F
method 0 NOUN F
, 0 PUNCT F
transcutaneous 0 ADJ F
oxygen 0 NOUN F
pressure 0 NOUN F
measurement 0 NOUN F
and 0 CCONJ F
body 0 NOUN F
plethysmography 0 NOUN F
in 0 ADP F
bronchial 0 ADJ F
provocation 0 NOUN F
with 0 ADP F
methacholine 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

A 0 DET T
bronchial 0 ADJ F
provocation 0 NOUN F
challenge 0 NOUN F
test 0 NOUN F
was 0 VERB F
conducted 0 VERB F
with 0 ADP F
30 0 NUM F
subjects 0 NOUN F
using 0 VERB F
metacholin 0 NOUN F
. 0 PUNCT F

In 0 ADP T
randomised 0 VERB F
sequence 0 NOUN F
lung 0 NOUN F
function 0 NOUN F
analysis 0 NOUN F
tests 0 NOUN F
were 0 VERB F
carried 0 VERB F
out 0 ADP F
with 0 ADP F
the 0 DET F
bodyplethysmograph 0 ADJ F
( 0 PUNCT F
Raw 0 NOUN T
, 0 PUNCT F
FEV1 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
polyfrequent 0 NOUN F
oscillation 0 NOUN F
method 0 NOUN F
( 0 PUNCT F
resistance 0 NOUN F
, 0 PUNCT F
reactance 0 NOUN F
between 0 ADP F
2 0 NUM F
and 0 CCONJ F
52 0 NUM F
Hz 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
transcutaneous 0 ADJ F
oxygen 0 NOUN F
pressure 0 NOUN F
( 0 PUNCT F
tc-PO2 0 NOUN F
) 0 PUNCT F
was 0 VERB F
measured 0 VERB F
continuously 0 ADV F
. 0 PUNCT F

Correlations 0 NOUN T
between 0 ADP F
the 0 DET F
various 0 ADJ F
parameters 0 NOUN F
, 0 PUNCT F
the 0 DET F
change 0 NOUN F
of 0 ADP F
the 0 DET F
values 0 NOUN F
at 0 ADP F
PD60 0 NOUN T
sGaw 0 PUNCT F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
the 0 DET F
initial 0 ADJ F
values 0 NOUN F
, 0 PUNCT F
the 0 DET F
interindividual 0 ADJ F
variability 0 NOUN F
and 0 CCONJ F
the 0 DET F
reactivity 0 NOUN F
were 0 VERB F
determined 0 VERB F
. 0 PUNCT F

Medium 0 ADJ T
correlations 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
the 0 DET F
oscillatory B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
and 0 CCONJ F
Raw B-PHYSICAL NOUN T
, 0 PUNCT F
whereas 0 CCONJ F
for 0 ADP F
tc-PO2 B-PHYSICAL NOUN F
and 0 CCONJ F
Raw B-PHYSICAL NOUN T
the 0 DET F
correlation 0 NOUN F
was 0 VERB F
markedly 0 ADV F
lower 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
terms 0 NOUN F
of 0 ADP F
percentage 0 NOUN F
the 0 DET F
greatest 0 PUNCT F
change 0 NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
reactance 0 NOUN F
, 0 PUNCT F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
the 0 DET F
initial 0 ADJ F
value 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
Raw B-PHYSICAL NOUN T
and 0 CCONJ F
FEV1 B-PHYSICAL NOUN T
. 0 PUNCT F

The 0 DET T
interindividual 0 ADJ F
variability 0 NOUN F
resulted 0 VERB F
in 0 ADP F
the 0 DET F
highest 0 PUNCT F
values 0 NOUN F
for 0 ADP F
the 0 DET F
reactance 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
Raw B-PHYSICAL NOUN T
and 0 CCONJ F
FEV1 B-PHYSICAL NOUN T
. 0 PUNCT F

Interindividual 0 ADJ T
variability 0 NOUN F
showed 0 VERB F
the 0 DET F
highest 0 PUNCT F
values 0 NOUN F
for 0 ADP F
the 0 DET F
reactance 0 NOUN F
before 0 ADP F
oscillatory B-PHYSICAL ADJ F
resistance I-PHYSICAL NOUN F
and 0 CCONJ F
Raw B-PHYSICAL NOUN T
. 0 PUNCT F

In 0 ADP T
respect 0 NOUN F
of 0 ADP F
reactivity 0 NOUN F
, 0 PUNCT F
reactance 0 NOUN F
also 0 ADV F
had 0 CCONJ F
the 0 DET F
highest 0 PUNCT F
values 0 NOUN F
. 0 PUNCT F

Overall 0 ADJ T
evaluation 0 NOUN F
showed 0 VERB F
that 0 ADP F
bodyplethysmography 0 NOUN F
and 0 CCONJ F
the 0 DET F
polyfrequent 0 NOUN F
oscillation 0 NOUN F
method 0 NOUN F
( 0 PUNCT F
reactance 0 NOUN F
or 0 CCONJ F
resonance 0 NOUN F
frequency 0 NOUN F
) 0 PUNCT F
are 0 VERB F
comparably 0 ADV F
sensitive 0 ADJ F
. 0 PUNCT F

Acute 0 ADJ T
effects 0 NOUN F
of 0 ADP F
decaffeinated 0 VERB F
coffee 0 ADJ F
and 0 CCONJ F
the 0 DET F
major 0 ADJ F
coffee 0 NOUN F
components 0 NOUN F
chlorogenic 0 ADJ F
acid 0 NOUN F
and 0 CCONJ F
trigonelline 0 VERB F
on 0 ADP F
glucose B-PHYSICAL NOUN F
tolerance 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Coffee 0 NOUN T
consumption 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
associated 0 VERB F
with 0 ADP F
lower 0 PUNCT F
risk 0 NOUN F
of 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
the 0 DET F
acute 0 ADJ F
effects 0 NOUN F
of 0 ADP F
decaffeinated 0 VERB F
coffee 0 ADJ F
and 0 CCONJ F
the 0 DET F
major 0 ADJ F
coffee 0 NOUN F
components 0 NOUN F
chlorogenic 0 ADJ F
acid 0 NOUN F
and 0 CCONJ F
trigonelline 0 VERB F
on 0 ADP F
glucose 0 NOUN F
tolerance 0 NOUN F
. 0 PUNCT F

RESEARCH 0 NOUN T
DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
randomized 0 VERB F
crossover 0 NOUN F
trial 0 NOUN F
of 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
12 0 NUM F
g 0 NOUN F
decaffeinated 0 NOUN F
coffee 0 ADJ F
, 0 PUNCT F
1 0 NUM F
g 0 NOUN F
chlorogenic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
trigonelline 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
1 0 NUM F
g 0 NOUN F
mannitol 0 NOUN F
) 0 PUNCT F
on 0 ADP F
glucose 0 NOUN F
and 0 CCONJ F
insulin 0 NOUN F
concentrations 0 NOUN F
during 0 ADP F
a 0 DET F
2-h 0 NOUN F
oral 0 ADJ F
glucose 0 NOUN F
tolerance 0 NOUN F
test 0 NOUN F
( 0 PUNCT F
OGTT 0 NOUN T
) 0 PUNCT F
in 0 ADP F
15 0 NUM F
overweight 0 ADP F
men 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADJ T
Chlorogenic 0 ADJ T
acid 0 NOUN F
and 0 CCONJ F
trigonelline 0 ADJ F
ingestion 0 NOUN F
significantly 0 ADV F
reduced 0 CCONJ F
glucose B-PHYSICAL NOUN F
( 0 PUNCT F
-0.7 0 NUM F
mmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.007 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
-0.5 0 PUNCT F
mmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.024 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
( 0 PUNCT F
-73 0 NUM F
pmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.038 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
-117 0 NUM F
pmol/l 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.007 0 NUM F
) 0 PUNCT F
concentrations 0 NOUN F
15 0 NUM F
min 0 NOUN F
following 0 VERB F
an 0 DET F
OGTT 0 NOUN T
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

None 0 NUM T
of 0 ADP F
the 0 DET F
treatments 0 NOUN F
affected 0 PUNCT F
insulin B-PHYSICAL NOUN F
or I-PHYSICAL CCONJ F
glucose I-PHYSICAL NOUN F
area 0 NOUN F
under 0 ADP F
the 0 DET F
curve 0 NOUN F
values 0 NOUN F
during 0 ADP F
the 0 DET F
OGTT 0 NOUN T
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Chlorogenic 0 ADJ T
acid 0 NOUN F
and 0 CCONJ F
trigonelline 0 VERB F
reduced 0 ADP F
early 0 ADJ F
glucose B-PHYSICAL NOUN F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
during 0 ADP F
an 0 DET F
OGTT 0 NOUN T
. 0 PUNCT F

PROCLAIM 0 NOUN T
: 0 PUNCT F
pilot 0 NOUN F
study 0 PUNCT F
to 0 DET F
examine 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
on 0 ADP F
inflammatory 0 ADJ F
markers 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
metabolic 0 ADJ F
syndrome 0 NOUN F
receiving 0 VERB F
low-dose 0 NOUN F
aspirin 0 NOUN F
. 0 PUNCT F

Metabolic 0 ADJ T
syndrome 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
intravascular 0 PUNCT F
inflammation 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
determined 0 VERB F
by 0 ADP F
increased 0 VERB F
levels 0 NOUN F
of 0 ADP F
inflammatory 0 ADJ F
biomarkers 0 CCONJ F
and 0 CCONJ F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
ischemic 0 ADJ F
atherothrombotic 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

Evidence 0 NOUN T
suggests 0 NOUN F
that 0 ADP F
atherothrombosis 0 NOUN F
and 0 CCONJ F
intravascular 0 PUNCT F
inflammation 0 NOUN F
share 0 VERB F
predictive 0 ADJ F
biomarkers 0 CCONJ F
, 0 PUNCT F
including 0 VERB F
high-sensitivity 0 NOUN F
C-reactive 0 ADJ T
protein 0 NOUN F
, 0 PUNCT F
CD40 0 NOUN T
ligand 0 NOUN F
, 0 PUNCT F
P-selectin 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
N-terminal 0 ADJ T
pro-brain 0 NOUN F
natriuretic 0 ADJ F
peptide 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADP F
had 0 ADJ F
metabolic 0 ADJ F
syndrome 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
clopidogrel 0 NOUN F
75 0 NUM F
mg/day 0 NOUN F
plus 0 CCONJ F
aspirin 0 NOUN F
81 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
89 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
plus 0 CCONJ F
aspirin 0 NOUN F
81 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
92 0 NUM F
) 0 PUNCT F
for 0 ADP F
9 0 NUM F
weeks 0 NOUN F
to 0 PUNCT F
assess 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
each 0 DET F
treatment 0 NOUN F
in 0 ADP F
suppression 0 NOUN F
of 0 ADP F
inflammatory 0 ADJ F
markers 0 NOUN F
. 0 PUNCT F

Change 0 NOUN T
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
levels 0 NOUN F
of 0 ADP F
high-sensitivity B-PHYSICAL NOUN F
C-reactive I-PHYSICAL ADJ T
protein I-PHYSICAL NOUN F
, 0 PUNCT F
CD40 B-PHYSICAL NOUN T
ligand I-PHYSICAL NOUN F
, 0 PUNCT F
P-selectin B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
N-terminal B-PHYSICAL ADJ T
pro-brain I-PHYSICAL NOUN F
natriuretic I-PHYSICAL ADJ F
peptide I-PHYSICAL NOUN F
at 0 ADP F
6 0 NUM F
weeks 0 NOUN F
was 0 VERB F
assessed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
each 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
difference 0 NOUN F
at 0 ADP F
Week 0 NOUN T
6 0 NUM F
in 0 ADP F
model-adjusted B-PHYSICAL ADJ F
CD40-ligand I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
in 0 ADP F
favor 0 NOUN F
of 0 ADP F
clopidogrel 0 NOUN F
plus 0 CCONJ F
aspirin 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
plus 0 CCONJ F
aspirin 0 NOUN F
in 0 ADP F
both 0 CCONJ F
the 0 DET F
intent-to-treat 0 NOUN F
population 0 NOUN F
( 0 PUNCT F
difference 0 NOUN F
between 0 ADP F
least-squares 0 ADJ F
means 0 NOUN F
= 0 ADJ F
-186.5 0 ADJ F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
-342.3 0 NUM F
to 0 ADP F
-30.8 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
per-protocol 0 NOUN F
population 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
observed 0 VERB F
between 0 ADP F
the 0 DET F
treatment 0 NOUN F
arms 0 NOUN F
for 0 ADP F
high-sensitivity B-PHYSICAL NOUN F
C-reactive I-PHYSICAL ADJ T
protein I-PHYSICAL NOUN F
, 0 PUNCT F
P-selectin B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
N-terminal B-PHYSICAL ADJ T
pro-brain I-PHYSICAL NOUN F
natriuretic I-PHYSICAL ADJ F
peptide I-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
deaths B-MORTALITY ADV F
or 0 CCONJ F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
either 0 CCONJ F
treatment 0 NOUN F
arm 0 ADP F
. 0 PUNCT F

Data 0 NOUN T
from 0 ADP F
this 0 DET F
study 0 NOUN F
suggest 0 VERB F
that 0 ADP F
clopidogrel 0 NOUN F
can 0 PART F
decrease 0 VERB F
the 0 DET F
expression 0 NOUN F
of 0 ADP F
the 0 DET F
CD40-ligand B-PHYSICAL PUNCT T
biomarker I-PHYSICAL NOUN F
. 0 PUNCT F

Timing 0 VERB T
for 0 ADP F
delivering 0 VERB F
individualized 0 PUNCT F
patient 0 NOUN F
education 0 NOUN F
intervention 0 NOUN F
to 0 ADP F
Coronary 0 ADJ T
Artery 0 NOUN T
Bypass 0 NOUN T
Graft 0 NOUN T
patients 0 NOUN F
: 0 PUNCT F
An 0 DET T
RCT 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
primary 0 ADJ F
focus 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
is 0 VERB F
on 0 ADP F
the 0 DET F
timing 0 VERB F
of 0 ADP F
the 0 DET F
delivery 0 NOUN F
of 0 ADP F
education 0 NOUN F
to 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
CABG 0 NOUN T
surgery 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
an 0 DET F
individualized 0 VERB F
telephone 0 NOUN F
patient 0 NOUN F
education 0 NOUN F
intervention 0 NOUN F
, 0 PUNCT F
delivered 0 VERB F
at 0 ADP F
two 0 NUM F
different 0 ADJ F
points 0 DET F
in 0 ADP F
time 0 NOUN F
( 0 PUNCT F
1-2 0 NUM F
days 0 NOUN F
pre-discharge 0 NOUN F
versus 0 CCONJ F
1-2 0 NUM F
days 0 NOUN F
post-discharge 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
enhancing 0 VERB F
the 0 DET F
CABG 0 NOUN T
patient 0 NOUN F
's 0 PUNCT F
knowledge 0 NOUN F
of 0 ADP F
self-care 0 PUNCT F
behaviours 0 NOUN F
, 0 PUNCT F
performance 0 NOUN F
of 0 ADP F
self-care 0 PUNCT F
behaviours 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
symptom 0 NOUN F
frequency 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
that 0 ADP F
included 0 VERB F
a 0 DET F
convenience 0 NOUN F
sample 0 NOUN F
of 0 ADP F
first 0 VERB F
time 0 NOUN F
CABG 0 NOUN T
patients 0 NOUN F
. 0 PUNCT F

Individuals 0 NOUN T
who 0 PROPN F
received 0 VERB F
education 0 NOUN F
pre-discharge 0 NOUN F
were 0 VERB F
compared 0 VERB F
to 0 ADP F
individuals 0 NOUN F
who 0 PROPN F
received 0 VERB F
education 0 NOUN F
post-discharge 0 PUNCT F
on 0 ADP F
the 0 DET F
outcomes 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Results 0 ADJ T
indicated 0 VERB F
no 0 ADP F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
outcomes 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
time 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

As 0 CCONJ T
well 0 PUNCT F
, 0 PUNCT F
anxiety B-MENTAL NOUN F
levels I-MENTAL NOUN F
were 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
pre-discharge 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
the 0 DET F
post-discharge 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
individualized 0 VERB F
nature 0 NOUN F
of 0 ADP F
the 0 DET F
educational 0 ADJ F
intervention 0 NOUN F
may 0 VERB F
have 0 PUNCT F
accounted 0 VERB F
for 0 ADP F
non-significant 0 ADJ F
findings 0 NOUN F
reported 0 VERB F
in 0 ADP F
outcomes 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
time 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

PRACTICE 0 NOUN T
IMPLICATIONS 0 DET T
Nurses 0 PUNCT T
may 0 PROPN F
consider 0 VERB F
assessing 0 CCONJ F
anxiety B-MENTAL NOUN F
levels I-MENTAL NOUN F
prior 0 PUNCT F
to 0 ADP F
delivery 0 NOUN F
of 0 ADP F
educational 0 ADJ F
interventions 0 NOUN F
, 0 PUNCT F
implement 0 ADP F
interventions 0 NOUN F
aimed 0 VERB F
at 0 ADP F
reducing 0 ADJ F
anxiety 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
provide 0 VERB F
individualized 0 VERB F
teaching 0 ADV F
. 0 PUNCT F

Randomized 0 VERB T
trial 0 NOUN F
of 0 ADP F
fenretinide 0 NOUN F
in 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
using 0 VERB F
DNA 0 NOUN T
flow 0 NOUN F
cytometry 0 NOUN F
as 0 ADP F
an 0 DET F
intermediate 0 ADJ F
end 0 NOUN F
point 0 NOUN F
. 0 PUNCT F

Retinoids 0 NOUN T
have 0 CCONJ F
shown 0 VERB F
a 0 DET F
potential 0 ADJ F
activity 0 NOUN F
in 0 ADP F
preventing 0 VERB F
tumor 0 NOUN F
recurrence 0 NOUN F
in 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

We 0 PRON T
assessed 0 VERB F
the 0 DET F
activity 0 NOUN F
of 0 ADP F
the 0 DET F
synthetic 0 ADJ F
retinoid 0 NOUN F
fenretinide 0 ADP F
in 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
using 0 VERB F
DNA 0 NOUN T
flow 0 NOUN F
cytometry 0 NOUN F
and 0 CCONJ F
conventional 0 ADJ F
cytology 0 NOUN F
as 0 ADP F
surrogate 0 ADJ F
biomarkers 0 CCONJ F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
99 0 NUM F
subjects 0 NOUN F
with 0 ADP F
resected 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
pTa 0 NOUN F
, 0 PUNCT F
pT1 0 NOUN F
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
fenretinide 0 NOUN F
( 0 PUNCT F
200 0 NUM F
mg 0 NOUN F
day 0 NOUN F
p.o 0 ADV F
. 0 PUNCT F

for 0 ADP F
24 0 NUM F
months 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
no 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

Cystoscopy 0 NOUN T
and 0 CCONJ F
bladder 0 NOUN F
washing 0 CCONJ F
for 0 ADP F
DNA 0 NOUN T
flow 0 NOUN F
cytometry 0 NOUN F
end 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
proportion 0 NOUN F
of 0 ADP F
DNA 0 NOUN T
aneuploid 0 NOUN F
histograms 0 NOUN F
, 0 PUNCT F
hyperdiploid 0 PUNCT F
fraction 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
percentage 0 NOUN F
of 0 ADP F
apoptotic 0 ADJ F
cells 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
proportion 0 NOUN F
of 0 ADP F
abnormal B-PHYSICAL ADJ F
cytological I-PHYSICAL ADJ F
examinations I-PHYSICAL NOUN F
were 0 ADV F
repeated 0 VERB F
every 0 DET F
4 0 NUM F
months 0 NOUN F
for 0 ADP F
up 0 PUNCT F
to 0 ADV F
36 0 NUM F
months 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
study 0 NOUN F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
the 0 DET F
proportion 0 NOUN F
of 0 ADP F
DNA B-PHYSICAL NOUN T
aneuploid I-PHYSICAL NOUN F
histograms I-PHYSICAL NOUN F
after 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

This 0 DET T
figure 0 NOUN F
was 0 ADP F
48.9 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
fenretinide 0 NOUN F
arm 0 NOUN F
and 0 CCONJ F
41.9 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
odds 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
1.16 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.44-3.07 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
any 0 DET F
other 0 ADJ F
response 0 NOUN F
biomarker B-PHYSICAL NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
up 0 PUNCT F
to 0 ADP F
36 0 NUM F
months 0 NOUN F
, 0 PUNCT F
nor 0 CCONJ F
was 0 VERB F
any 0 DET F
biomarker 0 NOUN F
able 0 ADJ F
to 0 PART F
predict 0 NOUN F
recurrence 0 NOUN F
risk 0 NOUN F
. 0 PUNCT F

Recurrence-free B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
was 0 VERB F
comparable 0 ADJ F
between 0 ADP F
the 0 DET F
arms 0 NOUN F
( 0 PUNCT F
27 0 NUM F
events 0 NOUN F
in 0 ADP F
the 0 DET F
fenretinide 0 NOUN F
arm 0 NOUN F
versus 0 CCONJ F
21 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
arm 0 ADP F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.36 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Twelve 0 PUNCT T
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
fenretinide 0 NOUN F
arm 0 NOUN F
complained 0 PUNCT F
of 0 ADP F
diminished 0 VERB F
dark B-ADVERSE-EFFECTS ADJ F
adaptability I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
nine 0 NUM F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
fenretinide 0 NOUN F
arm 0 NOUN F
versus 0 CCONJ F
one 0 NUM F
control 0 NUM F
subject 0 NOUN F
had 0 PUNCT F
mild B-PHYSICAL ADJ F
dermatological I-PHYSICAL ADJ F
alterations I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
fenretinide 0 NOUN F
showed 0 VERB F
a 0 DET F
lack 0 NOUN F
of 0 ADP F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
DNA 0 NOUN T
content B-PHYSICAL NOUN F
distribution I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
morphology 0 NOUN F
of 0 ADP F
urothelial B-PHYSICAL ADJ F
cells I-PHYSICAL NOUN F
obtained 0 VERB F
in 0 ADP F
serial 0 ADJ F
bladder 0 NOUN F
washings 0 NOUN F
. 0 PUNCT F

Recurrence-free B-MORTALITY ADJ T
survival I-MORTALITY NOUN F
was 0 VERB F
comparable 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

Because 0 PUNCT T
our 0 ADP F
data 0 NOUN F
are 0 VERB F
hampered 0 VERB F
by 0 ADP F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
predictivity 0 NOUN F
of 0 ADP F
the 0 DET F
selected 0 VERB F
biomarkers 0 CCONJ F
, 0 PUNCT F
additional 0 ADJ F
studies 0 NOUN F
are 0 VERB F
necessary 0 ADJ F
to 0 PART F
assess 0 NOUN F
the 0 DET F
activity 0 NOUN F
of 0 ADP F
fenretinide 0 NOUN F
in 0 ADP F
preventing 0 VERB F
bladder 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Lack 0 NOUN T
of 0 ADP F
effect 0 NOUN F
of 0 ADP F
food 0 NOUN F
on 0 ADP F
the 0 DET F
steady B-OTHER ADJ F
state I-OTHER NOUN F
pharmacokinetics I-OTHER NOUN F
of I-OTHER ADP F
BMS-181101 I-OTHER NOUN T
, 0 PUNCT F
an 0 DET F
antidepressant 0 NOUN F
, 0 PUNCT F
in 0 ADP F
healthy 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of B-OTHER ADP F
food I-OTHER NOUN F
on I-OTHER ADP F
the I-OTHER DET F
pharmacokinetics I-OTHER NOUN F
of I-OTHER ADP F
BMS-181101 B-OTHER NOUN T
, 0 PUNCT F
a 0 DET F
new 0 ADJ F
anti-depressant 0 ADJ F
under 0 ADP F
development 0 NOUN F
, 0 PUNCT F
was 0 VERB F
investigated 0 VERB F
in 0 ADP F
12 0 NUM F
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
at 0 ADP F
steady 0 ADJ F
state 0 NOUN F
. 0 PUNCT F

Each 0 DET T
subject 0 NOUN F
received 0 VERB F
a 0 DET F
15 0 NUM F
mg 0 NOUN F
oral 0 ADJ F
dose 0 NOUN F
of 0 ADP F
BMS-181101 0 NOUN T
twice 0 ADV F
a 0 DET F
day 0 NOUN F
( 0 PUNCT F
q 0 NOUN F
12 0 NUM F
h 0 NOUN F
) 0 PUNCT F
for 0 ADP F
11 0 NUM F
days 0 NOUN F
and 0 CCONJ F
a 0 DET F
morning 0 NOUN F
dose 0 NOUN F
of 0 ADP F
BMS-181101 0 NOUN T
on 0 ADP F
day 0 NOUN F
12 0 NUM F
. 0 PUNCT F

Six 0 NUM T
subjects 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
BMS-181101 0 NOUN T
under 0 ADP F
fasted 0 VERB F
conditions 0 NOUN F
from 0 ADP F
days 0 NOUN F
1 0 NUM F
to 0 ADP F
6 0 NUM F
and 0 CCONJ F
then 0 ADV F
crossed 0 VERB F
over 0 PUNCT F
to 0 PUNCT F
fed 0 PUNCT F
conditions 0 NOUN F
from 0 ADP F
days 0 NOUN F
7 0 NUM F
to 0 ADP F
12 0 NUM F
. 0 PUNCT F

The 0 DET T
other 0 ADJ F
six 0 NUM F
subjects 0 NOUN F
received 0 VERB F
the 0 DET F
reverse 0 ADJ F
conditions 0 NOUN F
, 0 PUNCT F
fed 0 ADJ F
for 0 ADP F
days 0 NOUN F
1-6 0 NUM F
and 0 CCONJ F
fasted 0 VERB F
for 0 ADP F
days 0 NOUN F
7-12 0 NUM F
. 0 PUNCT F

Serial 0 ADJ T
blood 0 NOUN F
samples 0 NOUN F
were 0 VERB F
collected 0 VERB F
up 0 CCONJ F
to 0 ADP F
12 0 NUM F
h 0 NOUN F
on 0 ADP F
days 0 NOUN F
6 0 NUM F
and 0 CCONJ F
12 0 NUM F
following 0 VERB F
the 0 DET F
administration 0 NOUN F
of 0 ADP F
the 0 DET F
morning 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
trough 0 PUNCT F
blood 0 NOUN F
samples 0 NOUN F
were 0 VERB F
collected 0 VERB F
on 0 ADP F
days 0 NOUN F
4 0 NUM F
, 0 PUNCT F
5 0 NUM F
, 0 PUNCT F
10 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
11 0 NUM F
prior 0 PUNCT F
to 0 ADP F
the 0 DET F
morning 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

Plasma 0 NOUN T
samples 0 NOUN F
were 0 VERB F
analyzed 0 VERB F
for 0 ADP F
intact B-PHYSICAL ADJ F
BMS-181101 B-PHYSICAL NOUN T
using 0 VERB F
a 0 DET F
validated 0 VERB F
high-performance 0 NOUN F
liquid 0 NOUN F
chromatography 0 NOUN F
method 0 NOUN F
with 0 ADP F
an 0 DET F
electrochemical 0 ADJ F
detector 0 NOUN F
. 0 PUNCT F

BMS-181101 0 NOUN T
was 0 VERB F
well 0 ADV F
tolerated B-OTHER PUNCT F
both 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
ingestion 0 NOUN F
of 0 ADP F
food 0 NOUN F
. 0 PUNCT F

The 0 DET T
statistical 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
the 0 DET F
Cmin B-OTHER NOUN T
values I-OTHER NOUN F
indicated 0 VERB F
that 0 ADP F
steady B-OTHER ADJ F
state I-OTHER NOUN F
of 0 ADP F
BMS-181101 0 NOUN T
was 0 VERB F
achieved 0 VERB F
by 0 ADP F
the 0 DET F
fourth 0 ADJ F
day 0 NOUN F
of 0 ADP F
dosing 0 VERB F
regardless 0 PUNCT F
of 0 ADP F
whether 0 ADP F
the 0 DET F
subject 0 NOUN F
was 0 VERB F
fasted 0 VERB F
or 0 CCONJ F
fed 0 DET F
. 0 PUNCT F

When 0 ADP T
BMS-181101 0 NOUN T
was 0 VERB F
administered 0 VERB F
with 0 ADP F
food 0 NOUN F
, 0 PUNCT F
Cmax B-OTHER NOUN T
was B-OTHER VERB F
reduced I-OTHER VERB F
by 0 ADP F
about 0 VERB F
25 0 NUM F
% 0 PUNCT F
and 0 PUNCT F

A 0 DET T
randomized 0 VERB F
controlled 0 DET F
study 0 NOUN F
of 0 ADP F
parent-assisted 0 VERB F
Children 0 NOUN T
's 0 PUNCT F
Friendship 0 NOUN T
Training 0 PROPN T
with 0 ADP F
children 0 NOUN F
having 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
Children 0 ADP T
's 0 PUNCT F
Friendship 0 NOUN T
Training 0 PROPN T
( 0 PUNCT F
CFT 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
manualized 0 VERB F
parent-assisted 0 VERB F
intervention 0 NOUN F
to 0 PART F
improve 0 VERB F
social 0 ADJ F
skills 0 NOUN F
among 0 ADP F
second 0 ADJ F
to 0 PUNCT F
fifth 0 ADJ F
grade 0 NOUN F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
was 0 VERB F
made 0 VERB F
with 0 ADP F
a 0 DET F
delayed 0 VERB F
treatment 0 NOUN F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
DTC 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Targeted 0 VERB T
skills 0 NOUN F
included 0 ADP F
conversational B-MENTAL ADJ F
skills I-MENTAL NOUN F
, 0 PUNCT F
peer B-MENTAL NOUN F
entry I-MENTAL NOUN F
skills I-MENTAL NOUN F
, 0 PUNCT F
developing 0 ADP F
friendship B-MENTAL NOUN F
networks 0 NOUN F
, 0 PUNCT F
good B-MENTAL ADJ F
sportsmanship I-MENTAL NOUN F
, 0 PUNCT F
good B-MENTAL ADJ F
host I-MENTAL NOUN F
behavior I-MENTAL NOUN F
during I-MENTAL ADP F
play I-MENTAL VERB F
dates I-MENTAL PUNCT F
, 0 PUNCT F
and 0 CCONJ F
handling B-MENTAL ADP F
teasing I-MENTAL PUNCT F
. 0 PUNCT F

At 0 ADP T
post-testing 0 PUNCT F
, 0 PUNCT F
the 0 DET F
CFT 0 NOUN T
group 0 NOUN F
was 0 VERB F
superior 0 ADJ F
to 0 ADP F
the 0 DET F
DTC 0 NOUN T
group 0 NOUN F
on 0 ADP F
parent 0 NOUN F
measures 0 NOUN F
of 0 ADP F
social B-MENTAL ADJ F
skill I-MENTAL NOUN F
and 0 CCONJ F
play B-MENTAL ADJ F
date I-MENTAL NOUN F
behavior I-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
child 0 NOUN F
measures 0 NOUN F
of 0 ADP F
popularity B-MENTAL NOUN F
and 0 CCONJ F
loneliness B-MENTAL NOUN F
, 0 PUNCT F
At 0 ADP T
3-month 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
parent 0 NOUN F
measures 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
improvement 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Post-hoc 0 PUNCT T
analysis 0 NOUN F
indicated 0 VERB F
more 0 ADP F
than 0 ADP F
87 0 NUM F
% 0 SYM F
of 0 ADP F
children 0 NOUN F
receiving 0 VERB F
CFT 0 NOUN T
showed 0 VERB F
reliable 0 ADJ F
change 0 NOUN F
on 0 ADP F
at 0 ADP F
least 0 ADV F
one 0 NUM F
measure 0 VERB F
at 0 ADP F
post-test 0 ADV F
and 0 CCONJ F
66.7 0 NUM F
% 0 SYM F
after 0 ADP F
3 0 NUM F
months 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

1999 0 NUM F
WHO/ISH 0 NUM T
Guidelines 0 PROPN T
applied 0 VERB F
to 0 ADP F
a 0 PUNCT F
1999 0 NUM F
MONICA 0 ADJ T
sample 0 NOUN F
from 0 ADP F
northern 0 ADJ F
Sweden 0 NUM T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Treating 0 PUNCT T
hypertension 0 NOUN F
with 0 ADP F
drugs 0 NOUN F
is 0 VERB F
so 0 ADP F
far 0 ADP F
the 0 DET F
most 0 PUNCT F
cost-effective 0 ADJ F
way 0 NOUN F
to 0 PROPN F
reduce 0 VERB F
this 0 DET F
important 0 ADJ F
risk 0 NOUN F
factor 0 NOUN F
for 0 ADP F
cardiovascular 0 ADJ F
disease 0 NOUN F
( 0 PUNCT F
CVD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
important 0 ADJ F
to 0 PART F
determine 0 ADJ F
absolute 0 ADJ F
risk 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thereby 0 ADP F
estimate 0 ADV F
indication 0 NOUN F
for 0 ADP F
drug 0 NOUN F
treatment 0 NOUN F
, 0 PUNCT F
in 0 ADP F
order 0 NOUN F
to 0 PART F
maintain 0 ADV F
a 0 DET F
cost-effective 0 ADJ F
drug 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

WHO/ISH 0 NUM T
Hypertension 0 NOUN T
Guidelines 0 PROPN T
from 0 ADP F
1999 0 NUM F
propose 0 ADJ F
a 0 DET F
risk 0 NOUN F
stratification 0 NOUN F
for 0 ADP F
estimating 0 VERB F
absolute 0 ADJ F
risk 0 NOUN F
for 0 ADP F
CVD 0 NOUN T
based 0 VERB F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
and 0 CCONJ F
additional 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
, 0 PUNCT F
target 0 ADP F
organ 0 NOUN F
damage 0 VERB F
( 0 PUNCT F
TOD 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
CVD 0 NOUN T
. 0 PUNCT F

OBJECTIVES 0 NOUN T
We 0 PRON T
studied 0 VERB F
the 0 DET F
consequences 0 NOUN F
of 0 ADP F
applying 0 VERB F
the 0 DET F
recent 0 ADJ F
WHO/ISH 0 CCONJ T
risk 0 NOUN F
stratification 0 NOUN F
scheme 0 ADJ F
to 0 ADP F
a 0 DET F
MONICA 0 ADJ T
sample 0 NOUN F
of 0 ADP F
6000 0 NUM F
subjects 0 NOUN F
from 0 ADP F
a 0 DET F
geographically 0 ADV F
defined 0 VERB F
population 0 NOUN F
in 0 ADP F
northern 0 ADJ F
Sweden 0 PUNCT T
, 0 PUNCT F
regarding 0 VERB F
indications 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
target 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
and 0 CCONJ F
risk 0 NOUN F
distribution 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
have 0 PUNCT F
risk-classified 0 PROPN F
each 0 DET F
of 0 ADP F
these 0 DET F
patients 0 NOUN F
using 0 VERB F
a 0 DET F
computer 0 NOUN F
program 0 NOUN F
, 0 PUNCT F
according 0 CCONJ F
to 0 ADP F
the 0 DET F
WHO/ISH 0 PUNCT T
scheme 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
on 0 ADP F
TOD 0 NOUN T
were 0 VERB F
not 0 ADV F
available 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
all 0 PUNCT F
, 0 PUNCT F
917 0 NUM F
( 0 PUNCT F
15 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
drug-treated 0 VERB F
hypertension 0 NOUN F
. 0 PUNCT F

Three-quarters 0 ADJ T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
737 0 NUM F
) 0 PUNCT F
were 0 VERB F
inadequately 0 ADV F
treated 0 VERB F
, 0 PUNCT F
with 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
at 0 ADP F
or 0 CCONJ F
above 0 ADP F
140 0 NUM F
or 0 CCONJ F
90 0 NUM F
mmHg 0 NOUN F
. 0 PUNCT F

1773 0 NUM F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
of 0 ADP F
5997 0 NUM F
) 0 PUNCT F
untreated 0 VERB F
subjects 0 NOUN F
had 0 PUNCT F
a 0 DET F
blood 0 NOUN F
pressure 0 NOUN F
of 0 ADP F
140/90 0 PUNCT F
or 0 CCONJ F
above 0 ADP F
; 0 PUNCT F
16 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
low- 0 ADJ F
, 0 PUNCT F
62 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
medium- 0 NOUN F
, 0 PUNCT F
8 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
high- 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
14 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
very-high-risk 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
corresponding 0 VERB F
risk-group 0 NOUN F
pattern 0 NOUN F
for 0 ADP F
the 0 DET F
inadequately 0 ADV F
treated 0 ADP F
hypertensives 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
737 0 NUM F
) 0 PUNCT F
was 0 VERB F
5.5 0 NUM F
, 0 PUNCT F
48.3 0 NUM F
, 0 PUNCT F
11.1 0 NUM F
and 0 CCONJ F
35.2 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

If 0 ADP T
we 0 PRON F
shifted 0 VERB F
the 0 DET F
target 0 NOUN F
blood 0 NOUN F
pressure 0 NOUN F
from 0 ADP F
below 0 ADP F
140/90 0 PUNCT F
to 0 ADP F
below 0 PUNCT F
130/85 0 NOUN F
for 0 ADP F
drug-treated 0 ADJ F
subjects 0 NOUN F
under 0 ADP F
60 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
278 0 NUM F
) 0 PUNCT F
the 0 DET F
number 0 NOUN F
of 0 ADP F
inadequately B-OTHER ADV F
treated I-OTHER PUNCT F
subjects I-OTHER NOUN F
increased 0 VERB F
by 0 ADP F
34 0 NUM F
( 0 PUNCT F
12.2 0 NUM F
% 0 SYM F
of 0 ADP F
278 0 PUNCT F
) 0 PUNCT F
; 0 PUNCT F
14 0 NUM F
in 0 ADP F
the 0 DET F
low-risk 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
15 0 NUM F
in 0 ADP F
the 0 DET F
medium-risk 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
only 0 ADV F
five 0 NUM F
in 0 ADP F
the 0 DET F
high- 0 NOUN F
or 0 CCONJ F
very-high-risk 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Only 0 ADJ T
one-fifth 0 NOUN F
of 0 ADP F
the 0 DET F
drug-treated 0 ADJ F
hypertensives 0 NOUN F
were 0 VERB F
well 0 VERB F
controlled 0 CCONJ F
. 0 PUNCT F

Moreover 0 ADV T
, 0 PUNCT F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
newly B-OTHER ADV F
detected I-OTHER PUNCT F
blood I-OTHER NOUN F
pressure I-OTHER NOUN F
elevation I-OTHER NOUN F
was 0 VERB F
high 0 ADJ F
. 0 PUNCT F

The 0 DET T
majority 0 NOUN F
of 0 ADP F
younger 0 PUNCT F
subjects 0 NOUN F
with 0 ADP F
high 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
had 0 PUNCT F
low 0 ADJ F
risk 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
in 0 ADP F
those 0 PUNCT F
aged 0 PROPN F
45-54 0 NUM F
this 0 PUNCT F
had 0 PUNCT F
already 0 ADV F
risen 0 PROPN F
to 0 ADP F
a 0 DET F
medium 0 ADJ F
risk 0 NOUN F
. 0 PUNCT F

Changing 0 PROPN T
the 0 DET F
target 0 NOUN F
blood 0 NOUN F
pressure 0 NOUN F
to 0 ADP F
below 0 PUNCT F
130/85 0 NOUN F
, 0 PUNCT F
for 0 ADP F
subjects 0 NOUN F
aged 0 VERB F
below 0 ADP F
60 0 NUM F
, 0 PUNCT F
as 0 PUNCT F
recommended 0 VERB F
by 0 ADP F
WHO/ISH 0 ADV T
, 0 PUNCT F
affects 0 VERB F
predominantly 0 ADV F
low- 0 ADJ F
and 0 CCONJ F
medium-risk 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Effects 0 PROPN T
of 0 ADP F
small 0 ADJ F
needle-knife 0 NOUN F
comprehensive 0 ADJ F
therapy 0 NOUN F
on 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
lumbar 0 ADJ F
flexion 0 NOUN F
range 0 NOUN F
in 0 ADP F
the 0 DET F
chronic 0 ADJ F
nonspecific 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
patient 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
observe 0 NOUN F
therapeutic 0 ADJ F
effect 0 NOUN F
of 0 ADP F
small 0 ADJ F
needle-knife 0 NOUN F
comprehensive 0 ADJ F
therapy 0 NOUN F
on 0 ADP F
pain B-PAIN NOUN F
and 0 CCONJ F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
chronic 0 ADJ F
nonspecific 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
patient 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Three 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
five 0 NUM F
cases 0 NOUN F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
a 0 DET F
needle-knife 0 NOUN F
group 0 NOUN F
of 0 ADP F
153 0 NUM F
cases 0 NOUN F
and 0 CCONJ F
a 0 DET F
physiotherapy 0 NOUN F
group 0 NOUN F
of 0 ADP F
152 0 NUM F
cases 0 NOUN F
. 0 PUNCT F

The 0 DET T
needle-knife 0 NOUN F
group 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
small 0 ADJ F
needle-knife 0 NOUN F
releasing 0 DET F
therapy 0 NOUN F
, 0 PUNCT F
blocking 0 VERB F
and 0 CCONJ F
functional 0 ADJ F
training 0 VERB F
. 0 PUNCT F

The 0 DET T
physiotherapy 0 NOUN F
group 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
ultra-short 0 ADJ F
wave 0 NOUN F
, 0 PUNCT F
modulated 0 ADP F
medium 0 ADJ F
frequency 0 NOUN F
current 0 NOUN F
, 0 PUNCT F
massage 0 NOUN F
and 0 CCONJ F
functional 0 ADJ F
training 0 VERB F
. 0 PUNCT F

Pain B-PAIN NOUN T
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
( 0 PUNCT F
VAS 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
pain B-PAIN NOUN F
and 0 CCONJ F
the 0 DET F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
were 0 VERB F
significantly 0 ADV F
improved 0 VERB F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
VAS 0 NOUN T
score 0 NOUN F
and 0 CCONJ F
the 0 DET F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
were 0 VERB F
( 0 PUNCT F
1.60 0 NUM F
+/- 0 SYM F
0.38 0 NUM F
) 0 PUNCT F
points 0 DET F
and 0 CCONJ F
( 0 PUNCT F
65.76 0 NUM F
+/- 0 SYM F
15.11 0 NUM F
) 0 PUNCT F
cm 0 NOUN F
in 0 ADP F
the 0 DET F
needle-knife 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
( 0 PUNCT F
4.59 0 NUM F
+/- 0 SYM F
1.09 0 NUM F
) 0 PUNCT F
points 0 DET F
and 0 CCONJ F
( 0 PUNCT F
53.74 0 ADP F
+/- 0 SYM F
15.13 0 NUM F
) 0 PUNCT F
cm 0 NOUN F
in 0 ADP F
the 0 DET F
physiotherapy 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
the 0 DET F
needle-knife 0 NOUN F
group 0 NOUN F
being 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
than 0 VERB F
the 0 DET F
physiotherapy 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Follow-up 0 NOUN T
survey 0 NOUN F
of 0 ADP F
6-36 0 NUM F
months 0 NOUN F
showed 0 VERB F
that 0 ADP F
the 0 DET F
VAS 0 NOUN T
score 0 NOUN F
and 0 CCONJ F
the 0 DET F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
needle-knife 0 NOUN F
group 0 NOUN F
were 0 VERB F
superior 0 ADJ F
to 0 ADP F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
physiotherapy 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Small 0 ADJ T
needle-knife 0 NOUN F
comprehensive 0 ADJ F
therapy 0 NOUN F
can 0 VERB F
significantly 0 ADV F
improve 0 VERB F
pain B-PAIN NOUN F
and 0 CCONJ F
lumbar B-PHYSICAL ADJ F
flexion I-PHYSICAL NOUN F
range I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
chronic 0 ADJ F
nonspecific 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
patient 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
stable 0 ADJ F
long-term 0 NOUN F
therapeutic 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

Observer 0 PUNCT T
variation 0 NOUN F
in 0 ADP F
the 0 DET F
assessment B-OTHER NOUN F
of I-OTHER ADP F
outcome I-OTHER NOUN F
in 0 ADP F
traumatic 0 ADJ F
brain 0 NOUN F
injury 0 NOUN F
: 0 PUNCT F
experience 0 CCONJ F
from 0 ADP F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
international 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Accurate 0 ADJ T
and 0 CCONJ F
consistent 0 ADJ F
outcome 0 NOUN F
assessment B-OTHER NOUN F
is 0 VERB F
essential 0 ADJ F
to 0 ADP F
randomized 0 VERB F
clinical 0 ADJ F
trials 0 NOUN F
. 0 PUNCT F

We 0 PRON T
aimed 0 VERB F
to 0 PART F
explore 0 NOUN F
observer 0 PUNCT F
variation 0 NOUN F
in 0 ADP F
the 0 DET F
assessment B-OTHER NOUN F
of I-OTHER ADP F
outcome I-OTHER NOUN F
in 0 ADP F
a 0 DET F
recently 0 ADV F
completed 0 VERB F
trial 0 NOUN F
of 0 ADP F
dexanabinol 0 NOUN F
in 0 ADP F
head 0 NOUN F
injury 0 NOUN F
and 0 CCONJ F
to 0 PART F
consider 0 ADJ F
steps 0 NOUN F
to 0 PART F
reduce 0 NOUN F
such 0 DET F
variation 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eight 0 NUM T
hundred 0 NUM F
sixty-one 0 ADJ F
patients 0 NOUN F
with 0 ADP F
severe 0 ADJ F
traumatic 0 ADJ F
brain 0 NOUN F
injury 0 NOUN F
who 0 ADP F
were 0 VERB F
admitted 0 VERB F
to 0 ADP F
86 0 NUM F
centers 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
Phase 0 NOUN T
III 0 NUM T
trial 0 NOUN F
. 0 PUNCT F

Outcome 0 NOUN T
was 0 VERB F
assessed 0 VERB F
at 0 ADP F
3 0 NUM F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
postinjury 0 NOUN F
using 0 VERB F
the 0 DET F
extended B-PHYSICAL PUNCT F
Glasgow I-PHYSICAL PUNCT T
Outcome 0 NOUN T
Scale B-PHYSICAL NOUN T
; 0 PUNCT F
standardized 0 VERB F
assessment 0 NOUN F
was 0 VERB F
facilitated 0 VERB F
by 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
structured 0 VERB F
interview 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
initiation 0 NOUN F
of 0 ADP F
trial 0 NOUN F
centers 0 NOUN F
, 0 PUNCT F
outcome 0 NOUN F
ratings B-OTHER NOUN F
were 0 VERB F
obtained 0 VERB F
for 0 ADP F
sample 0 NOUN F
cases 0 NOUN F
to 0 PART F
establish 0 ADJ F
initial 0 ADJ F
levels 0 NOUN F
of 0 ADP F
agreement 0 NOUN F
. 0 PUNCT F

Training 0 VERB T
sessions 0 NOUN F
in 0 ADP F
outcome 0 NOUN F
assessment 0 NOUN F
were 0 VERB F
held 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
problems 0 NOUN F
in 0 ADP F
assigning 0 PUNCT F
outcome 0 NOUN F
were 0 VERB F
investigated 0 VERB F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
trial 0 NOUN F
, 0 PUNCT F
a 0 DET F
process 0 NOUN F
of 0 ADP F
central 0 ADJ F
review 0 NOUN F
was 0 VERB F
established 0 VERB F
to 0 ADJ F
monitor 0 NOUN F
performance 0 NOUN F
. 0 PUNCT F

Interobserver 0 PUNCT T
variation 0 NOUN F
was 0 VERB F
analyzed 0 VERB F
using 0 VERB F
the 0 DET F
kappa 0 NOUN F
statistic 0 ADJ F
. 0 PUNCT F

RESULTS 0 ADJ T
Substantial B-OTHER ADJ T
observer B-OTHER PUNCT F
variation I-OTHER NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
the 0 DET F
rating 0 PUNCT F
of 0 ADP F
sample 0 NOUN F
cases 0 NOUN F
( 0 PUNCT F
weighted 0 VERB F
kappa 0 NOUN F
, 0 PUNCT F
0.72 0 NUM F
; 0 PUNCT F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.68-0.75 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
assigning 0 PUNCT F
outcome 0 NOUN F
based 0 VERB F
on 0 ADP F
completed 0 VERB F
structured 0 VERB F
interviews 0 NOUN F
( 0 PUNCT F
weighted 0 VERB F
kappa 0 NOUN F
, 0 PUNCT F
0.61 0 NUM F
; 0 PUNCT F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.57-0.64 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
early 0 ADJ F
stages 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
, 0 PUNCT F
a 0 DET F
relatively 0 ADV F
large 0 ADJ F
number 0 NOUN F
of 0 ADP F
discrepancies B-OTHER NOUN F
( 0 PUNCT F
29-37 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
identified 0 VERB F
on 0 ADP F
central 0 ADJ F
review 0 NOUN F
. 0 PUNCT F

This 0 DET T
number 0 NOUN F
declined 0 PUNCT F
as 0 ADP F
the 0 DET F
trial 0 NOUN F
progressed 0 ADJ F
and 0 CCONJ F
coincided 0 VERB F
with 0 ADP F
investigator 0 NOUN F
training 0 VERB F
and 0 CCONJ F
feedback 0 NOUN F
from 0 ADP F
central 0 ADJ F
review 0 NOUN F
. 0 PUNCT F

Centers 0 NOUN T
with 0 ADP F
higher 0 PUNCT F
enrollment 0 NOUN F
rates 0 NOUN F
showed 0 VERB F
better 0 PUNCT F
performance 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 PUNCT T

Chemotherapy 0 NOUN T
of 0 ADP F
large 0 ADJ F
bowel 0 NOUN F
carcinoma 0 NOUN F
-- 0 PUNCT F
fluorouracil 0 NOUN F
( 0 PUNCT F
FU 0 NOUN T
) 0 PUNCT F
+ 0 SYM F
hydroxyurea 0 NOUN F
( 0 PUNCT F
HU 0 NOUN T
) 0 PUNCT F
vs. 0 CCONJ F
methyl-CCNU 0 NOUN F
, 0 PUNCT F
oncovin 0 NOUN F
, 0 PUNCT F
fluorouracil 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
streptozotocin 0 NOUN F
( 0 PUNCT F
MOF-Strep 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

An 0 DET T
Eastern 0 NUM T
Cooperative 0 NOUN T
Oncology 0 NOUN T
Group 0 NOUN T
study 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
study 0 NOUN F
of 0 ADP F
initial 0 ADJ F
chemotherapy 0 NOUN F
for 0 ADP F
advanced 0 VERB F
measurable 0 ADJ F
metastatic 0 ADJ F
large 0 ADJ F
bowel 0 NOUN F
carcinoma 0 NOUN F
, 0 PUNCT F
the 0 DET F
response 0 NOUN F
rate B-PHYSICAL NOUN F
was 0 VERB F
6/32 0 NOUN F
( 0 PUNCT F
19 0 NUM F
% 0 SYM F
) 0 PUNCT F
for 0 ADP F
FU 0 NOUN T
+ 0 SYM F
HU 0 NOUN T
and 0 CCONJ F
5/32 0 NOUN F
( 0 PUNCT F
16 0 NUM F
% 0 SYM F
) 0 PUNCT F
for 0 ADP F
MOF-Strep 0 NOUN T
; 0 PUNCT F
the 0 DET F
estimated 0 ADJ F
median 0 ADJ F
survival B-MORTALITY NOUN F
is 0 VERB F
43 0 NUM F
weeks 0 NOUN F
for 0 ADP F
both 0 PUNCT F
treatments 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 PROPN F
received 0 VERB F
MOF-Strep 0 NOUN T
experienced 0 ADP F
substantially 0 ADV F
greater 0 PUNCT F
vomiting B-ADVERSE-EFFECTS PUNCT F
and 0 CCONJ F
hematologic B-ADVERSE-EFFECTS ADJ F
toxicity I-ADVERSE-EFFECTS NOUN F
than 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
received 0 VERB F
FU 0 NOUN T
+ 0 SYM F
HU 0 NOUN T
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
H 0 NOUN T
reflex 0 NOUN F
and 0 CCONJ F
V 0 NUM T
wave 0 CCONJ F
following 0 VERB F
short-term 0 NOUN F
endurance 0 NOUN F
and 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
3 0 NUM F
wk 0 NOUN F
of 0 ADP F
either 0 PUNCT F
endurance 0 NOUN F
or 0 CCONJ F
strength 0 NOUN F
training 0 VERB F
on 0 ADP F
plasticity 0 NOUN F
of 0 ADP F
the 0 DET F
neural 0 ADJ F
mechanisms 0 NOUN F
involved 0 VERB F
in 0 ADP F
the 0 DET F
soleus 0 PUNCT F
H 0 NOUN T
reflex 0 NOUN F
and 0 CCONJ F
V 0 NUM T
wave 0 NOUN F
. 0 PUNCT F

Twenty-five 0 PUNCT T
sedentary 0 ADJ F
healthy 0 ADJ F
subjects 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
an 0 DET F
endurance 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
13 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
strength 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Evoked 0 VERB T
V-wave 0 PUNCT T
, 0 PUNCT F
H-reflex 0 PUNCT T
, 0 PUNCT F
and 0 CCONJ F
M-wave 0 NOUN T
recruitment 0 NOUN F
curves 0 NOUN F
, 0 PUNCT F
maximal 0 ADJ F
voluntary 0 PUNCT F
contraction 0 NOUN F
( 0 PUNCT F
MVC 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
time-to-task-failure 0 NOUN F
( 0 PUNCT F
isometric 0 ADJ F
contraction 0 NOUN F
at 0 ADP F
40 0 NUM F
% 0 SYM F
MVC 0 NOUN T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
plantar 0 NOUN F
flexors 0 NOUN F
were 0 VERB F
recorded 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
training 0 VERB F
. 0 PUNCT F

Following 0 ADP T
strength 0 NOUN F
training 0 VERB F
, 0 PUNCT F
MVC 0 NOUN T
of 0 ADP F
the 0 DET F
plantar B-PHYSICAL NOUN F
flexors I-PHYSICAL PUNCT F
increased 0 VERB F
by 0 ADP F
14.4 0 NUM F
? 0 PUNCT F

5.2 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
strength 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
time-to-task-failure 0 NOUN F
was 0 VERB F
prolonged 0 VERB F
in 0 ADP F
the 0 DET F
endurance 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
22.7 0 NUM F
? 0 PUNCT F

17.1 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
V B-PHYSICAL NOUN T
wave-to-maximal I-PHYSICAL ADJ F
M I-PHYSICAL NOUN T
wave I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
V/M I-PHYSICAL NUM T
( I-PHYSICAL PUNCT F
max I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
) I-PHYSICAL PUNCT F
ratio I-PHYSICAL NOUN F
increased 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
55.1 0 NUM F
? 0 PUNCT F

28.3 0 NUM F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
following 0 VERB F
strength 0 NOUN F
training 0 VERB F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
maximal 0 ADJ F
H B-PHYSICAL NOUN T
wave-to-maximal I-PHYSICAL ADJ F
M I-PHYSICAL NOUN T
wave I-PHYSICAL NOUN F
( 0 PUNCT F
H B-PHYSICAL NOUN T
( 0 PUNCT F
max B-PHYSICAL NOUN F
) 0 PUNCT F
/M B-PHYSICAL PUNCT F
( 0 PUNCT F
max B-PHYSICAL NOUN F
) 0 PUNCT F
) 0 PUNCT F
ratio B-PHYSICAL NOUN F
remained 0 VERB F
unchanged 0 VERB F
. 0 PUNCT F

Conversely 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
endurance 0 NOUN F
group 0 NOUN F
the 0 DET F
V/M B-PHYSICAL NUM T
( I-PHYSICAL PUNCT F
max I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
ratio I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
altered 0 VERB F
, 0 PUNCT F
whereas 0 ADP F
the 0 PUNCT F

Hydrogen 0 NOUN T
peroxide 0 NOUN F
mouth 0 NOUN F
rinse 0 NOUN F
: 0 PUNCT F
an 0 DET F
analgesic 0 ADP F
post-tonsillectomy 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
analgesic B-OTHER ADP F
efficacy I-OTHER NOUN F
of 0 ADP F
hydrogen 0 NOUN F
peroxide 0 NOUN F
( 0 PUNCT F
H2O2 0 NOUN T
) 0 PUNCT F
mouth 0 NOUN F
rinse 0 NOUN F
with 0 ADP F
control 0 NOUN F
for 0 ADP F
post-tonsillectomy B-PAIN NOUN F
pain I-PAIN NOUN F
management I-PAIN NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Double-blinded 0 PUNCT T
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Thirty-seven 0 PUNCT T
patients 0 NOUN F
from 0 ADP F
5 0 NUM F
to 0 ADP F
14 0 NUM F
years 0 NOUN F
old 0 ADJ F
undergoing 0 CCONJ F
electrocautery 0 NOUN F
tonsillectomy 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
H2O2 0 NOUN T
mouth 0 NOUN F
rinse 0 NOUN F
or 0 CCONJ F
the 0 DET F
water 0 NOUN F
rinse 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

For 0 ADP T
14 0 DET F
days 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
recorded 0 CCONJ F
pain 0 NOUN F
levels 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
using 0 ADP F
a 0 DET F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
. 0 PUNCT F

Analgesic 0 ADJ T
uses 0 ADJ F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
any 0 DET F
complications 0 NOUN F
, 0 PUNCT F
were 0 VERB F
also 0 ADV F
noted 0 VERB F
by 0 ADP F
the 0 DET F
patients 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-seven 0 PUNCT T
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
21 0 NUM F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
16 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Mean 0 PUNCT T
postoperative B-PAIN ADJ F
days I-PAIN NOUN F
of I-PAIN ADP F
pain I-PAIN NOUN F
were 0 VERB F
10.3 0 NUM F
and 0 CCONJ F
8.3 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
differed 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.008 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 PUNCT T
postoperative B-OTHER ADJ F
days I-OTHER NOUN F
of I-OTHER ADP F
analgesic I-OTHER PUNCT F
use 0 NOUN F
were 0 VERB F
9.0 0 NUM F
and 0 CCONJ F
6.7 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
differed 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.005 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Only 0 ADV T
one 0 NUM F
incidence 0 NOUN F
of 0 ADP F
postoperative B-ADVERSE-EFFECTS ADJ F
hemorrhage I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
in 0 ADP F
the 0 DET F
study 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
our 0 PUNCT F
study 0 NOUN F
, 0 PUNCT F
the 0 DET F
H2O2 0 NOUN T
mouth 0 NOUN F
rinse 0 NOUN F
does 0 PUNCT F
not 0 ADV F
provide 0 VERB F
a 0 DET F
better 0 PUNCT F
analgesic B-OTHER ADP F
effect 0 ADJ F
than 0 ADP F
the 0 DET F
water 0 NOUN F
rinse 0 NOUN F
for 0 ADP F
post-tonsillectomy B-PAIN NOUN F
pain I-PAIN NOUN F
relief I-PAIN NOUN F
. 0 PUNCT F

Pilot 0 NOUN T
study 0 NOUN F
of 0 ADP F
Panax 0 NOUN T
quinquefolius 0 NOUN F
( 0 PUNCT F
American 0 ADJ T
ginseng 0 PUNCT F
) 0 PUNCT F
to 0 PART F
improve 0 NOUN F
cancer-related 0 VERB F
fatigue 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
dose-finding 0 ADJ F
evaluation 0 NOUN F
: 0 PUNCT F
NCCTG 0 NUM T
trial 0 NOUN F
N03CA 0 NOUN T
. 0 PUNCT F

PURPOSE 0 NOUN T
This 0 PUNCT T
pilot 0 NOUN F
trial 0 NOUN F
sought 0 NOUN F
to 0 PART F
investigate 0 NOUN F
whether 0 ADP F
any 0 PUNCT F
of 0 ADP F
three 0 NUM F
doses 0 NOUN F
of 0 ADP F
American 0 ADJ T
ginseng 0 PUNCT F
( 0 PUNCT F
Panax 0 NOUN T
quinquefolius 0 NOUN F
) 0 PUNCT F
might 0 VERB F
help 0 VERB F
cancer-related 0 VERB F
fatigue 0 NOUN F
. 0 PUNCT F

A 0 DET T
secondary 0 ADJ F
aim 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
toxicity 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eligible 0 ADJ T
adults 0 NOUN F
with 0 ADP F
cancer 0 NOUN F
were 0 VERB F
randomized 0 VERB F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
manner 0 NOUN F
, 0 PUNCT F
to 0 PUNCT F
receive 0 NOUN F
American 0 ADJ T
ginseng 0 PUNCT F
in 0 ADP F
doses 0 NOUN F
of 0 ADP F
750 0 NUM F
, 0 PUNCT F
1,000 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
2,000 0 NUM F
mg/day 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
given 0 VERB F
in 0 ADP F
twice 0 PUNCT F
daily 0 ADJ F
dosing 0 ADP F
over 0 ADP F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Outcome 0 NOUN T
measures 0 NOUN F
included 0 VERB F
the 0 DET F
Brief B-PHYSICAL ADP T
Fatigue I-PHYSICAL NOUN T
Inventory I-PHYSICAL ADJ T
, 0 PUNCT F
vitality 0 NOUN F
subscale 0 NOUN F
of 0 ADP F
the 0 DET F
Medical 0 ADJ T
Outcome 0 NOUN T
Scale 0 NOUN T
Short 0 ADJ T
Form-36 0 PUNCT T
( 0 PUNCT F
SF-36 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Global B-PHYSICAL ADJ T
Impression I-PHYSICAL NOUN T
of I-PHYSICAL ADP F
Benefit I-PHYSICAL PUNCT T
Scale 0 NOUN T
at 0 ADP F
4 0 NUM F
and 0 CCONJ F
8 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Two 0 NUM T
hundred 0 NUM F
ninety 0 NOUN F
patients 0 NOUN F
were 0 VERB F
accrued 0 PUNCT F
to 0 ADP F
this 0 DET F
trial 0 NOUN F
. 0 PUNCT F

Nonsignificant 0 ADJ T
trends 0 NOUN F
for 0 ADP F
all 0 DET F
outcomes 0 NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
favor 0 NOUN F
of 0 ADP F
the 0 DET F
1,000- 0 PUNCT F
and 0 CCONJ F
2,000-mg/day 0 NOUN F
doses 0 NOUN F
of 0 ADP F
American 0 ADJ T
ginseng 0 PUNCT F
. 0 PUNCT F

Area 0 NOUN T
under 0 ADP F
the 0 DET F
curve 0 NOUN F
analysis 0 NOUN F
of 0 ADP F
activity 0 NOUN F
interference 0 NOUN F
from 0 ADP F
the 0 DET F
Brief B-PHYSICAL ADP T
Fatigue I-PHYSICAL NOUN T
Inventory I-PHYSICAL ADJ T
was 0 VERB F
460-467 0 NUM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
750 0 NUM F
mg/day 0 NOUN F
group 0 NOUN F
versus 0 CCONJ F
480-551 0 NUM F
in 0 ADP F
the 0 DET F
1,000- 0 PUNCT F
and 0 CCONJ F
2,000-mg/day 0 NOUN F
arms 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Change 0 NOUN T
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
vitality B-PHYSICAL NOUN F
subscale I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
SF-36 0 NOUN T
was 0 VERB F
7.3-7.8 0 PUNCT F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
and 0 CCONJ F
the 0 DET F
750-mg/day 0 PUNCT F
arm 0 NOUN F
, 0 PUNCT F
versus 0 CCONJ F
10.5-14.6 0 NUM F
in 0 ADP F
the 0 DET F
1,000- 0 PUNCT F
and 0 CCONJ F
2,000-mg/day 0 NOUN F
arms 0 NOUN F
. 0 PUNCT F

Over 0 PUNCT T
twice 0 VERB F
as 0 CCONJ F
many 0 DET F
patients 0 NOUN F
on 0 ADP F
ginseng 0 PUNCT F
perceived 0 VERB F
a 0 DET F
benefit 0 NOUN F
and 0 CCONJ F
were 0 VERB F
satisfied B-OTHER VERB F
with 0 ADP F
treatment 0 NOUN F
over 0 ADP F
those 0 PUNCT F
on 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
any 0 DET F
measured 0 PUNCT F
toxicities B-ADVERSE-EFFECTS NOUN F
between 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
arms 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
There 0 PUNCT T
appears 0 NOUN F
to 0 PART F
be 0 CCONJ F
some 0 DET F
activity 0 NOUN F
and 0 CCONJ F
tolerable 0 ADJ F
toxicity 0 NOUN F
at 0 ADP F
1,000-2,000 0 NUM F
mg/day 0 NOUN F
doses 0 NOUN F
of 0 ADP F
American 0 ADJ T
ginseng 0 PUNCT F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
cancer-related 0 VERB F
fatigue 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
further 0 DET F
study 0 NOUN F
of 0 ADP F
American 0 ADJ T
ginseng 0 PUNCT F
is 0 PUNCT F
warranted 0 VERB F
. 0 PUNCT F

Psychosocial 0 ADJ T
nursing 0 DET F
therapy 0 NOUN F
following 0 PUNCT F
sudden 0 ADJ F
cardiac 0 ADJ F
arrest 0 NOUN F
: 0 PUNCT F
impact 0 NOUN F
on 0 ADP F
two-year B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Although 0 ADP T
psychosocial 0 ADJ F
therapy 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
reduce 0 NOUN F
mortality B-MORTALITY NOUN F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
, 0 PUNCT F
it 0 PUNCT F
is 0 VERB F
unknown 0 VERB F
whether 0 ADP F
the 0 DET F
benefits 0 NOUN F
of 0 ADP F
psychosocial 0 ADJ F
therapy 0 NOUN F
on 0 ADP F
mortality 0 NOUN F
reduction 0 NOUN F
extend 0 ADJ F
to 0 ADP F
out-of-hospital 0 PUNCT F
sudden 0 ADJ F
cardiac 0 ADJ F
arrest 0 NOUN F
, 0 PUNCT F
a 0 DET F
main 0 ADJ F
cause 0 NOUN F
of 0 ADP F
cardiovascular B-MORTALITY ADJ F
mortality I-MORTALITY NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Describe 0 ADV T
efficacy 0 NOUN F
of 0 ADP F
psychosocial 0 ADJ F
therapy 0 NOUN F
on 0 ADP F
two-year 0 ADJ F
cardiovascular B-MORTALITY ADJ F
mortality I-MORTALITY NOUN F
in 0 ADP F
sudden 0 ADJ F
cardiac 0 ADJ F
arrest 0 ADV F
survivors 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
Survivors 0 NOUN T
of 0 ADP F
out-of-hospital 0 ADJ F
ventricular 0 ADJ F
fibrillation 0 NOUN F
or 0 CCONJ F
asystole 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
129 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
documented 0 VERB F
by 0 ADP F
electrocardiograms 0 NOUN F
from 0 ADP F
registries 0 ADJ F
of 0 ADP F
a 0 DET F
citywide 0 NOUN F
Medic 0 NOUN T
One 0 NUM T
unit 0 NOUN F
and 0 CCONJ F
two 0 NUM F
countywide 0 NOUN F
emergency 0 NOUN F
units 0 NOUN F
, 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
a 0 DET F
two 0 NUM F
group 0 NOUN F
, 0 PUNCT F
experimental 0 ADJ F
, 0 PUNCT F
longitudinal 0 ADJ F
design 0 NOUN F
. 0 PUNCT F

The 0 DET T
intervention 0 NOUN F
consisted 0 ADJ F
of 0 ADP F
11 0 NUM F
individual 0 ADJ F
sessions 0 NOUN F
, 0 PUNCT F
implementing 0 PUNCT F
three 0 NUM F
components 0 NOUN F
: 0 PUNCT F
physiologic 0 ADJ F
relaxation 0 NOUN F
with 0 ADP F
biofeedback 0 NOUN F
training 0 PUNCT F
focused 0 VERB F
on 0 ADP F
altering 0 VERB F
autonomic 0 ADJ F
tone 0 NOUN F
; 0 PUNCT F
cognitive 0 ADJ F
behavioral 0 ADJ F
therapy 0 NOUN F
aimed 0 VERB F
at 0 ADP F
self-management 0 ADJ F
and 0 CCONJ F
coping 0 PUNCT F
strategies 0 NOUN F
for 0 ADP F
depression 0 NOUN F
, 0 PUNCT F
anxiety 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
anger 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
cardiovascular 0 ADJ F
health 0 NOUN F
education 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
was 0 VERB F
cardiovascular B-MORTALITY ADJ F
mortality I-MORTALITY NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Risk 0 NOUN T
of 0 ADP F
cardiovascular B-MORTALITY ADJ F
death I-MORTALITY NOUN F
was 0 VERB F
significantly 0 ADV F
reduced 0 ADP F
86 0 NUM F
% 0 SYM F
by 0 ADP F
psychosocial 0 ADJ F
therapy 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.03 0 PUNCT F
. 0 PUNCT F

Six 0 PUNCT T
of 0 ADP F
the 0 DET F
seven 0 NUM F
cardiovascular B-MORTALITY ADJ F
deaths I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
caused 0 VERB F
by 0 ADP F
ventricular 0 ADJ F
arrhythmias 0 NOUN F
. 0 PUNCT F

The 0 DET T
cardiovascular B-MORTALITY ADJ F
death I-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
therapy 0 NOUN F
group 0 NOUN F
was 0 VERB F
due 0 CCONJ F
to 0 ADP F
stroke 0 NOUN F
. 0 PUNCT F

Controlling 0 ADJ T
for 0 ADP F
depression B-PHYSICAL NOUN F
, 0 PUNCT F
previous B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
low B-PHYSICAL ADJ F
ejection I-PHYSICAL NOUN F
fraction I-PHYSICAL NOUN F
, 0 PUNCT F
decreased 0 VERB F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
variability I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
ventricular B-PHYSICAL ADJ F
ectopic I-PHYSICAL ADJ F
beats I-PHYSICAL NOUN F
had 0 PUNCT F
little 0 DET F
impact 0 NOUN F
on 0 ADP F
estimated 0 VERB F
treatment 0 NOUN F
effect 0 NOUN F
. 0 PUNCT F

The 0 DET T
risk 0 NOUN F
of 0 ADP F
all-cause B-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
was 0 VERB F
reduced 0 VERB F
by 0 ADP F
62 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
therapy 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.13 0 NUM F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
a 0 DET F
total 0 NOUN F
of 0 ADP F
three 0 NUM F
deaths B-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
therapy 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
eight 0 NUM F
deaths B-MORTALITY NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Psychosocial 0 PUNCT T
therapy 0 NOUN F
significantly 0 ADV F
reduced 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
cardiovascular B-MORTALITY ADJ F
death I-MORTALITY NOUN F
in 0 ADP F
sudden 0 ADJ F
cardiac 0 ADJ F
arrest 0 ADV F
survivors 0 NOUN F
. 0 PUNCT F

Relation 0 NOUN T
of 0 ADP F
total 0 ADJ F
homocysteine 0 PUNCT F
and 0 CCONJ F
lipid 0 NOUN F
levels 0 NOUN F
in 0 ADP F
children 0 NOUN F
to 0 ADP F
premature 0 ADJ F
cardiovascular 0 ADJ F
death 0 NOUN F
in 0 ADP F
male 0 NOUN F
relatives 0 NOUN F
. 0 PUNCT F

We 0 PRON T
assessed 0 VERB F
the 0 DET F
relative B-OTHER ADJ F
importance I-OTHER NOUN F
of 0 ADP F
lipid B-PHYSICAL NOUN F
, I-PHYSICAL PUNCT F
apo I-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
, I-PHYSICAL PUNCT F
lipoprotein I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
a I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
[ I-PHYSICAL PUNCT F
Lp I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
a I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
] I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
total 0 ADJ F
homocysteine B-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
tHcy I-PHYSICAL PUNCT F
) I-PHYSICAL PUNCT F
levels B-PHYSICAL NOUN F
in 0 ADP F
children 0 NOUN F
in 0 ADP F
relation 0 NOUN F
to 0 ADP F
premature 0 ADJ F
cardiovascular 0 ADJ F
disease 0 NOUN F
in 0 ADP F
family 0 NOUN F
members 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
of 0 ADP F
381 0 NUM F
girls 0 NOUN F
and 0 CCONJ F
375 0 NUM F
boys 0 NOUN F
age 0 NOUN F
8-12 0 NUM F
y 0 NUM F
completed 0 VERB F
family 0 NOUN F
history 0 NOUN F
questionnaires 0 NOUN F
. 0 PUNCT F

Nonfasting B-PHYSICAL ADJ T
serum I-PHYSICAL NOUN F
lipid I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
lipoproteins I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
plasma B-PHYSICAL NOUN F
tHcy I-PHYSICAL PUNCT F
and I-PHYSICAL PUNCT F
cysteine I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
in 0 ADP F
the 0 DET F
children 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
folate I-PHYSICAL NOUN F
and B-PHYSICAL CCONJ F
vitamin B-PHYSICAL NOUN F
B12 I-PHYSICAL PUNCT T

Motion 0 NOUN T
style 0 NUM F
acupuncture 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
MSAT 0 NOUN T
) 0 PUNCT F
for 0 ADP F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
with 0 ADP F
severe 0 ADJ F
disability 0 NOUN F
: 0 PUNCT F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
protocol 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Acupuncture 0 ADP T
is 0 VERB F
widely-used 0 PUNCT F
to 0 ADJ F
treat 0 NOUN F
patients 0 NOUN F
with 0 ADP F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
, 0 PUNCT F
despite 0 ADP F
insufficient 0 ADJ F
evidence 0 NOUN F
of 0 ADP F
the 0 DET F
technique 0 NOUN F
's 0 PUNCT F
efficacy 0 NOUN F
for 0 ADP F
acute 0 ADJ F
back 0 ADP F
pain 0 NOUN F
. 0 PUNCT F

Motion 0 NOUN T
style 0 NUM F
acupuncture 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
MSAT 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
non-traditional 0 ADJ F
acupuncture 0 ADP F
treatment 0 NOUN F
requiring 0 VERB F
a 0 DET F
patient 0 NOUN F
to 0 ADP F
exercise 0 NOUN F
while 0 ADP F
receiving 0 ADP F
acupuncture 0 ADP F
. 0 PUNCT F

In 0 ADP T
Korea 0 NOUN T
, 0 PUNCT F
MSAT 0 NOUN T
is 0 VERB F
used 0 VERB F
to 0 PART F
reduce 0 NOUN F
musculoskeletal 0 ADJ F
pain 0 NOUN F
and 0 CCONJ F
improve 0 VERB F
functional 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
aims 0 PART F
to 0 PUNCT F
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
MSAT 0 NOUN T
on 0 ADP F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
with 0 ADP F
severe 0 ADJ F
disability 0 NOUN F
. 0 PUNCT F

METHODS/DESIGN 0 PUNCT T
This 0 DET T
study 0 NOUN F
is 0 VERB F
a 0 DET F
multicenter 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
active-controlled 0 VERB F
trial 0 NOUN F
with 0 ADP F
two 0 NUM F
parallel 0 ADJ F
arms 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
with 0 ADP F
acute 0 ADJ F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
severe 0 ADJ F
functional 0 ADJ F
disability 0 NOUN F
, 0 PUNCT F
defined 0 VERB F
as 0 ADP F
an 0 DET F
Oswestry 0 NOUN T
Disability 0 NOUN T
Index 0 NOUN T
( 0 PUNCT F
ODI 0 NOUN T
) 0 PUNCT F
value 0 NOUN F
> 0 SYM F
60 0 NUM F
% 0 SYM F
, 0 PUNCT F
will 0 VERB F
be 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
the 0 DET F
acupuncture 0 ADP F
group 0 NOUN F
and 0 CCONJ F
the 0 DET F
nonsteroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
( 0 PUNCT F
NSAID 0 NOUN T
) 0 PUNCT F
injection 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
acupuncture 0 PUNCT F
group 0 NOUN F
will 0 VERB F
receive 0 VERB F
MSAT 0 NOUN T
and 0 CCONJ F
the 0 DET F
NSAID 0 NOUN T
injection 0 NOUN F
group 0 NOUN F
will 0 VERB F
receive 0 VERB F
an 0 DET F
intramuscular 0 ADJ F
injection 0 NOUN F
of 0 ADP F
diclofenac 0 NOUN F
. 0 PUNCT F

All 0 DET T
procedures 0 NOUN F
will 0 CCONJ F
be 0 VERB F
limited 0 VERB F
to 0 ADP F
one 0 NUM F
session 0 NOUN F
and 0 CCONJ F
the 0 DET F
symptoms 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
will 0 VERB F
be 0 VERB F
measured 0 VERB F
by 0 ADP F
assessors 0 NOUN F
blinded 0 ADP F
to 0 ADP F
treatment 0 NOUN F
allocation 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
will 0 NOUN F
be 0 VERB F
measured 0 VERB F
at 0 ADP F
30 0 NUM F
minutes 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
using 0 VERB F
the 0 DET F
numerical 0 ADJ F
rating 0 VERB F
scale 0 NOUN F
( 0 PUNCT F
NRS 0 NOUN T
) 0 PUNCT F
of 0 ADP F
low 0 ADJ F
back 0 ADP F
pain 0 NOUN F
while 0 ADP F
the 0 DET F
patient 0 NOUN F
is 0 VERB F
moving 0 PUNCT F
. 0 PUNCT F

Secondary 0 ADJ T
outcomes 0 NOUN F
will 0 VERB F
be 0 VERB F
measured 0 VERB F
at 0 ADP F
30 0 NUM F
minutes 0 NOUN F
after 0 ADP F
treatment 0 NOUN F
using 0 VERB F
the 0 DET F
NRS 0 NOUN T
of 0 ADP F
leg B-PAIN NOUN F
pain I-PAIN NOUN F
, 0 PUNCT F
ODI B-PHYSICAL PUNCT T
, 0 PUNCT F
patient B-OTHER NOUN F
global I-OTHER ADJ F
impression I-OTHER NOUN F
of I-OTHER ADP F
change I-OTHER NOUN F
, 0 PUNCT F
range 0 NOUN F
of B-PHYSICAL ADP F
motion I-PHYSICAL NOUN F
( 0 PUNCT F
ROM B-PHYSICAL NOUN T
) 0 PUNCT F
of B-PHYSICAL ADP F
the I-PHYSICAL DET F
lumbar B-PHYSICAL ADJ F
spine I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
degrees 0 PUNCT F
of 0 ADP F
straight B-PHYSICAL NOUN F
leg B-PHYSICAL PUNCT F

Short-term 0 NOUN T
studies 0 NOUN F
on 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
glycerol 0 NOUN F
as 0 ADP F
an 0 DET F
osmotic 0 ADJ F
agent 0 NOUN F
in 0 ADP F
continuous 0 ADJ F
ambulatory 0 ADJ F
peritoneal 0 ADJ F
dialysis 0 NOUN F
( 0 PUNCT F
CAPD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
glycerol 0 NOUN F
as 0 ADP F
an 0 DET F
osmotic 0 ADJ F
agent 0 NOUN F
in 0 ADP F
two 0 NUM F
different 0 ADJ F
concentrations 0 NOUN F
( 0 PUNCT F
92 0 NUM F
mmol/l 0 NOUN F
and 0 CCONJ F
272 0 NUM F
mmol/l 0 NOUN F
) 0 PUNCT F
in 0 ADP F
peritoneal 0 ADJ F
dialysis 0 NOUN F
fluid 0 NOUN F
was 0 VERB F
investigated 0 VERB F
over 0 ADP F
3 0 NUM F
days 0 NOUN F
in 0 ADP F
six 0 NUM F
patients 0 NOUN F
on 0 ADP F
continuous 0 ADJ F
ambulatory 0 ADJ F
peritoneal 0 ADJ F
dialysis 0 NOUN F
and 0 CCONJ F
compared 0 VERB F
with 0 ADP F
two 0 NUM F
concentrations 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
( 0 PUNCT F
76 0 NUM F
mmol/l 0 NOUN F
and 0 CCONJ F
215 0 NUM F
mmol/l 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
same 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
calorific B-PHYSICAL ADJ F
value I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
absorbed 0 VERB F
osmotic 0 ADJ F
agent 0 NOUN F
was 0 VERB F
lower 0 PUNCT F
, 0 PUNCT F
by 0 ADP F
19 0 NUM F
% 0 SYM F
with 0 ADP F
isotonic 0 ADJ F
and 0 CCONJ F
22 0 NUM F
% 0 SYM F
with 0 ADP F
hypertonic 0 ADJ F
solutions 0 NOUN F
, 0 PUNCT F
when 0 ADP F
glycerol 0 NOUN F
was 0 VERB F
used 0 VERB F
in 0 ADP F
place 0 NOUN F
of 0 ADP F
glucose 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
glycerol 0 NOUN F
provided 0 PROPN F
significantly 0 ADV F
lower 0 PUNCT F
total 0 ADJ F
ultrafiltration B-PHYSICAL NOUN F
than 0 PUNCT F
glucose 0 NOUN F
at 0 ADP F
each 0 DET F
concentration 0 NOUN F
, 0 PUNCT F
despite 0 ADP F
a 0 DET F
higher 0 PUNCT F
initial 0 ADJ F
osmotic 0 ADJ F
pressure 0 NOUN F
of 0 ADP F
the 0 DET F
glycerol-based 0 VERB F
solutions 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
higher 0 PUNCT F
concentration 0 NOUN F
of 0 ADP F
glycerol 0 NOUN F
required 0 ADJ F
to 0 PART F
provide 0 NOUN F
equal B-PHYSICAL ADJ F
ultrafiltration I-PHYSICAL NOUN F
may 0 VERB F
offset 0 CCONJ F
any 0 DET F
calorific 0 ADJ F
advantage 0 NOUN F
. 0 PUNCT F

Equilibration 0 NOUN T
of 0 ADP F
creatinine B-PHYSICAL NOUN F
and 0 CCONJ F
urea B-PHYSICAL NOUN F
was 0 VERB F
slower 0 PUNCT F
and 0 CCONJ F
creatinine B-PHYSICAL NOUN F
clearance I-PHYSICAL NOUN F
lower 0 PUNCT F
with 0 ADP F
glycerol 0 NOUN F
. 0 PUNCT F

Solutions 0 NOUN T
containing 0 CCONJ F
glycerol 0 NOUN F
were 0 VERB F
initially 0 ADV F
less 0 DET F
acid 0 NOUN F
( 0 PUNCT F
pH 0 NOUN F
6.5 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
those 0 PUNCT F
containing 0 ADJ F
glucose 0 NOUN F
( 0 PUNCT F
pH 0 NOUN F
5.1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
glycerol I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
in 0 ADP F
the 0 DET F
physiological 0 ADJ F
range 0 NOUN F
with 0 ADP F
glucose 0 NOUN F
as 0 ADP F
the 0 DET F
osmotic 0 ADJ F
agent 0 NOUN F
, 0 PUNCT F
reached 0 VERB F
a 0 DET F
peak 0 ADJ F
80-fold 0 NOUN F
greater 0 PUNCT F
at 0 ADP F
4.3 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
mmol/l 0 NOUN F
during 0 ADP F
dialysis 0 NOUN F
with 0 ADP F
fluid 0 NOUN F
containing 0 DET F
glycerol 0 NOUN F
at 0 ADP F
272 0 NUM F
mmol/l 0 NOUN F
and 0 CCONJ F
eightfold 0 ADP F
higher 0 PUNCT F
at 0 ADP F
0.42 0 NUM F
+/- 0 SYM F
0.09 0 NUM F
mmol/l 0 NOUN F
with 0 ADP F
glycerol 0 NOUN F
at 0 ADP F
92 0 NUM F
mmol/l 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
evidence 0 NOUN F
of 0 ADP F
haemolysis B-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
other 0 ADJ F
toxic B-ADVERSE-EFFECTS ADJ F
effect 0 NOUN F
despite 0 ADP F
these 0 DET F
levels 0 NOUN F
. 0 PUNCT F

The 0 DET T
rise 0 NOUN F
in 0 ADP F
blood 0 NOUN F
glucose 0 NOUN F
and 0 CCONJ F
insulin 0 NOUN F
noted 0 VERB F
during 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
glucose-based 0 ADJ F
solutions 0 NOUN F
was 0 NUM F
not 0 ADV F
found 0 VERB F
with 0 ADP F
glycerol 0 NOUN F
. 0 PUNCT F

Circulating 0 PUNCT T
levels 0 NOUN F
of 0 ADP F
lactate 0 NOUN F
, 0 PUNCT F
pyruvate B-PHYSICAL NOUN F
, 0 PUNCT F
alanine B-PHYSICAL NOUN F
, 0 PUNCT F
non-esterified B-PHYSICAL PUNCT F
fatty I-PHYSICAL ADJ F
acids I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
ketone 0 NOUN F
bodies 0 NOUN F
were 0 VERB F
similar 0 ADJ F
with 0 ADP F
the 0 DET F
two 0 NUM F
agents 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
these 0 DET F
short-term 0 NOUN F
studies 0 NOUN F
have 0 CCONJ F
shown 0 VERB F
no 0 DET F
conclusive 0 ADJ F
advantage 0 NOUN F
of 0 ADP F
glycerol 0 NOUN F
over 0 ADP F
glucose 0 NOUN F
, 0 PUNCT F
long-term 0 NOUN F
effects 0 NOUN F
of 0 ADP F
glycerol 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
on 0 ADP F
circulating B-PHYSICAL VERB F
lipid I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
, 0 PUNCT F
will 0 VERB F
determine 0 VERB F
its 0 ADP F
future 0 ADJ F
role 0 NOUN F
as 0 ADP F
an 0 DET F
osmotic 0 ADJ F
agent 0 NOUN F
in 0 ADP F
continuous 0 ADJ F
ambulatory 0 ADJ F
peritoneal 0 ADJ F
dialysis 0 NOUN F
. 0 PUNCT F

Glibenclamide 0 ADV T
vs 0 CCONJ F
gliclazide 0 NOUN F
in 0 ADP F
reducing 0 VERB F
oxidative B-PHYSICAL ADJ F
stress I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
of 0 ADP F
noninsulin 0 NOUN F
dependent 0 ADJ F
diabetes 0 NOUN F
mellitus 0 NOUN F
-- 0 PUNCT F
a 0 DET F
double 0 ADJ F
blind 0 ADP F
randomized 0 VERB F
study 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 ADJ T
Parameters 0 NOUN T
of 0 ADP F
oxidative B-PHYSICAL ADJ F
stress I-PHYSICAL NOUN F
were 0 VERB F
quantitated 0 VERB F
in 0 ADP F
50 0 NUM F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
in 0 ADP F
uncontrolled 0 VERB F
state 0 NOUN F
and 0 CCONJ F
after 0 ADP F
control 0 NOUN F
using 0 SYM F
oral 0 ADJ F
glibenclamide 0 NUM F
or 0 CCONJ F
gliclazide 0 NOUN F
. 0 PUNCT F

The 0 DET T
estimates 0 NOUN F
were 0 VERB F
further 0 ADV F
compared 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
irrespective 0 ADJ F
of 0 ADP F
drug 0 NOUN F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
difference 0 NOUN F
, 0 PUNCT F
if 0 VERB F
any 0 DET F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
double 0 ADJ F
blind 0 ADP F
, 0 PUNCT F
uncontrolled 0 PUNCT F
, 0 PUNCT F
noncrossover 0 ADP F
and 0 CCONJ F
randomized 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Fifty 0 ADJ T
patients 0 NOUN F
of 0 ADP F
uncontrolled 0 VERB F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
were 0 VERB F
divided 0 VERB F
in 0 ADP F
to 0 PUNCT F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
I 0 NUM T
( 0 PUNCT F
25 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
received 0 VERB F
capsule 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
glibenclamide 0 NUM F
) 0 PUNCT F
while 0 ADP F
Group 0 NOUN T
II 0 NUM T
( 0 PUNCT F
25 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
received 0 ADV F
capsule 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
gliclazide 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
parameters 0 NOUN F
studied 0 VERB F
were 0 VERB F
Superoxide B-PHYSICAL NOUN T
dismutase I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
SOD I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
malonyl-dialdehyde B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
MDA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
reduced B-PHYSICAL VERB F
glutathione I-PHYSICAL NOUN F
( 0 PUNCT F
GSH B-PHYSICAL NOUN T
) 0 PUNCT F
. 0 PUNCT F

They 0 PRON T
were 0 PUNCT F
done 0 PUNCT F
at 0 ADP F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
uncontrolled 0 DET F
stage 0 NOUN F
( 0 PUNCT F
FBS 0 NOUN T
-- 0 PUNCT F
165 0 NUM F
+/- 0 SYM F
16.7 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
PP 0 NOUN T
-- 0 PUNCT F
240 0 NUM F
+/- 0 SYM F
30.1 0 NUM F
mg/dl 0 NOUN F
and 0 CCONJ F
HbA1 0 PUNCT T
-- 0 PUNCT F
10.5 0 NUM F
+/- 0 SYM F
0.9 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
and 0 CCONJ F
FBS 0 NOUN T
-- 0 PUNCT F
150 0 NUM F
+/- 0 SYM F
15.8 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
PP 0 NOUN T
-- 0 PUNCT F
246 0 NUM F
+/- 0 SYM F
29.1 0 NUM F
mg/dl 0 NOUN F
HbA1 0 NOUN T
10.6 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
) 0 PUNCT F
and 0 CCONJ F
during 0 ADP F
controlled 0 VERB F
stage 0 NOUN F
at 0 ADP F
12 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
FBS 0 NOUN T
-- 0 PUNCT F
120 0 NUM F
+/- 0 SYM F
18.5 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
PP 0 NOUN T
-- 0 PUNCT F
180 0 NUM F
+/- 0 SYM F
19.1 0 NUM F
mg/dl 0 NOUN F
and 0 CCONJ F
HbA1 0 PUNCT T
-- 0 PUNCT F
8.4 0 NUM F
+/- 0 SYM F
0.29 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
and 0 CCONJ F
FBS 0 NOUN T
-- 0 PUNCT F
118 0 NUM F
+/- 0 SYM F
17.6 0 NUM F
mg/dl 0 NOUN F
, 0 PUNCT F
PP 0 NOUN T
-- 0 PUNCT F
176 0 NUM F
+/- 0 SYM F
20.1 0 NUM F
mg/dl 0 NOUN F
and 0 CCONJ F
HbA1 0 PUNCT T
-- 0 PUNCT F
8.5 0 NUM F
+/- 0 SYM F
0.39 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
significantly 0 ADV F
raised 0 ADP F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
MDA I-PHYSICAL NOUN T
and 0 CCONJ F
SOD B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
decreased 0 ADV F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
reduced I-PHYSICAL VERB F
glutathione I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
GSH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
during 0 ADP F
uncontrolled 0 VERB F
stage 0 NOUN F
of 0 ADP F
diabetes 0 NOUN F
indicated 0 VERB F
free 0 ADJ F
radical 0 NOUN F
stress 0 NOUN F
induced 0 ADP F
lipid 0 NOUN F
peroxidation 0 NOUN F
. 0 PUNCT F

The 0 DET T
significant 0 ADJ F
fall 0 NOUN F
of 0 ADP F
MDA B-PHYSICAL NOUN T
and 0 CCONJ F
SOD B-PHYSICAL NOUN T
and 0 CCONJ F
increased 0 ADV F
levels B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
GSH I-PHYSICAL NOUN T
in 0 ADP F
blood 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
after 0 ADP F
control 0 NOUN F
revealed 0 VERB F
beneficial 0 ADJ F
effects 0 NOUN F
of 0 ADP F
glycemic 0 ADJ F
control 0 NOUN F
on 0 ADP F
oxidative B-PHYSICAL ADJ F
stress 0 NOUN F
. 0 PUNCT F

The 0 DET T
levels 0 NOUN F
were 0 ADJ F
not 0 ADV F
normalized 0 VERB F
and 0 CCONJ F
stayed 0 VERB F
higher 0 PUNCT F
than 0 CCONJ F
those 0 PUNCT F
in 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

On 0 ADP T
intergroup 0 NOUN F
comparison 0 NOUN F
; 0 PUNCT F
the 0 DET F
control 0 NOUN F
of 0 ADP F
diabetes 0 NOUN F
with 0 ADP F
gliclazide 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
II 0 NUM T
) 0 PUNCT F
showed 0 VERB F
improvement 0 NOUN F
in 0 ADP F
oxidative B-PHYSICAL ADJ F
stress 0 NOUN F
( 0 PUNCT F
MDA B-PHYSICAL NOUN T
, 0 PUNCT F
GSH B-PHYSICAL NOUN T
) 0 PUNCT F
better 0 PUNCT F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
glibenclamide 0 NUM F
( 0 PUNCT F
group 0 NOUN F
I 0 NUM T
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 PUNCT T

Prophylactic 0 ADJ T
vs 0 CCONJ F
therapeutic 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
for 0 ADP F
obstetric 0 ADJ F
patients 0 NOUN F
with 0 ADP F
accidental 0 ADJ F
dural 0 ADJ F
puncture 0 NOUN F
-- 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Epidural 0 ADJ T
blood 0 NOUN F
patch 0 NOUN F
is 0 VERB F
a 0 DET F
standard 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
obstetric 0 ADJ F
patients 0 NOUN F
experiencing 0 PUNCT F
a 0 DET F
severe 0 ADJ F
post-dural 0 ADJ F
puncture 0 NOUN F
headache 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADP F
sustained 0 VERB F
an 0 DET F
accidental 0 ADJ F
dural 0 ADJ F
puncture 0 NOUN F
during 0 ADP F
establishment 0 NOUN F
of 0 ADP F
epidural 0 ADJ F
analgesia 0 NOUN F
during 0 ADP F
labour 0 NOUN F
or 0 CCONJ F
at 0 ADP F
caesarean 0 NOUN F
delivery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
a 0 DET F
prophylactic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
or 0 CCONJ F
conservative 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
a 0 DET F
therapeutic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
if 0 ADP F
required 0 VERB F
. 0 PUNCT F

Eleven 0 ADJ T
of 0 ADP F
60 0 NUM F
( 0 PUNCT F
18.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
prophylactic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
group 0 NOUN F
developed 0 VERB F
a 0 DET F
post-dural B-ADVERSE-EFFECTS ADJ F
puncture I-ADVERSE-EFFECTS NOUN F
headache I-ADVERSE-EFFECTS NOUN F
compared 0 VERB F
with 0 ADP F
39 0 PUNCT F
of 0 ADP F
49 0 NUM F
( 0 PUNCT F
79.6 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
therapeutic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
blood 0 NOUN F
patch 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
36 0 NUM F
( 0 PUNCT F
73.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
therapeutic 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
of 0 ADP F
patients B-OTHER NOUN F
who I-OTHER DET F
needed I-OTHER VERB F
a I-OTHER DET F
second I-OTHER ADJ F
blood I-OTHER NOUN F
patch I-OTHER NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
significantly 0 ADV F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
6 0 NUM F
( 0 PUNCT F
10.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
for 0 ADP F
prophylactic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
and 0 CCONJ F
4 0 NUM F
( 0 PUNCT F
11.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
for 0 ADP F
therapeutic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
prophylactic 0 ADJ F
epidural 0 ADJ F
blood 0 NOUN F
patch 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
method 0 NOUN F
to 0 PART F
reduce 0 NOUN F
the 0 DET F
development 0 NOUN F
of 0 ADP F
post-dural 0 ADJ F
puncture 0 NOUN F
headache 0 NOUN F
in 0 ADP F
obstetric 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Combined 0 VERB T
typhoid 0 NOUN F
fever 0 NOUN F
and 0 CCONJ F
hepatitis 0 NOUN F
A 0 NOUN T
vaccine 0 NOUN F
: 0 PUNCT F
comparison 0 NOUN F
of 0 ADP F
immunogenicity B-OTHER ADJ F
and 0 CCONJ F
safety B-OTHER NOUN F
to 0 ADP F
concomitant 0 ADJ F
monovalent 0 ADJ F
vaccine 0 NOUN F
over 0 ADP F
3 0 NUM F
years 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
safety B-OTHER NOUN F
and 0 CCONJ F
immunogenicity B-OTHER NOUN F
of 0 ADP F
Viatim 0 NOUN T
, 0 PUNCT F
a 0 DET F
combined 0 VERB F
hepatitis 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
HA 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
typhoid 0 ADJ F
fever 0 NOUN F
( 0 PUNCT F
Vi 0 NOUN T
) 0 PUNCT F
vaccine 0 NOUN F
, 0 PUNCT F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
the 0 DET F
monovalent 0 ADJ F
component 0 NOUN F
vaccines 0 NOUN F
up 0 PUNCT F
to 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
month 0 NOUN F
after 0 ADP F
a 0 DET F
booster 0 NOUN F
dose 0 NOUN F
at 0 ADP F
3 0 NUM F
years 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Healthy 0 PUNCT T
, 0 PUNCT F
adult 0 NOUN F
volunteers 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
Viatim 0 NOUN T
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
179 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
separate 0 ADJ F
HA 0 NOUN T
and 0 CCONJ F
Vi 0 NOUN T
vaccines 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
181 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
subgroups 0 ADP F
were 0 VERB F
boosted 0 VERB F
after 0 ADP F
3 0 NUM F
years 0 NOUN F
with 0 ADP F
Viatim 0 NOUN T
( 0 PUNCT F
groups 0 NOUN F
C 0 NOUN T
and 0 CCONJ F
D 0 NOUN T
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
56 0 NUM F
and 0 CCONJ F
46 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Local 0 ADJ T
and 0 CCONJ F
systemic 0 ADJ F
reactions 0 NOUN F
were 0 VERB F
recorded 0 VERB F
for 0 ADP F
28 0 NUM F
days 0 NOUN F
postvaccination 0 NOUN F
. 0 PUNCT F

Seroconversion B-PHYSICAL NOUN T
and 0 CCONJ F
seroprotection B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
and 0 CCONJ F
geometric B-PHYSICAL ADJ F
mean 0 NOUN F
antibody B-PHYSICAL NOUN F
concentrations B-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
14 0 NUM F
and 0 CCONJ F
28 0 NUM F
days 0 NOUN F
, 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
years 0 NOUN F
postvaccination 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
28 0 NUM F
days 0 NOUN F
after 0 ADP F
the 0 DET F
booster 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Local B-OTHER ADJ T
and I-OTHER CCONJ F
systemic I-OTHER ADJ F
safety B-OTHER NOUN F
profiles I-OTHER NOUN F
were 0 VERB F
equivalent 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Immediate B-PHYSICAL ADJ T
local I-PHYSICAL ADJ F
reactions I-PHYSICAL NOUN F
were 0 VERB F
infrequent 0 ADJ F
( 0 PUNCT F
1 0 NUM F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
2 0 NUM F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Local B-PHYSICAL ADJ T
reactions I-PHYSICAL NOUN F
, 0 PUNCT F
consisting B-PAIN ADP F
mostly I-PAIN NUM F
of I-PAIN ADP F
mild B-PAIN ADJ F
or I-PAIN CCONJ F
moderate I-PAIN ADJ F
pain B-PAIN NOUN F
, 0 PUNCT F
were 0 PUNCT F
least 0 ADV F
frequent 0 ADJ F
with 0 ADP F
monovalent 0 ADJ F
HA 0 NOUN T
. 0 PUNCT F

Antibody B-PHYSICAL NOUN T
concentrations B-PHYSICAL NOUN F
to 0 ADP F
both 0 PUNCT F
antigens 0 NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
groups 0 NOUN F
A 0 DET T
and 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
HA B-PHYSICAL NOUN T
seroprotection B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
20 0 NUM F
mIU/mL 0 NOUN F
) 0 PUNCT F
were 0 VERB F
respectively 0 ADV F
, 0 PUNCT F
98.7 0 NUM F
% 0 SYM F
and 0 CCONJ F
100 0 NUM F
% 0 SYM F
at 0 ADP F
day 0 NOUN F
28 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
99.1 0 NUM F
% 0 SYM F
and 0 CCONJ F
99.0 0 NUM F
% 0 SYM F
after 0 ADP F
3 0 NUM F
years 0 NOUN F
, 0 PUNCT F
achieving 0 ADP F
100 0 NUM F
% 0 SYM F
after 0 ADP F
the 0 DET F
booster 0 NOUN F
. 0 PUNCT F

Vi B-PHYSICAL NOUN T
seroprotection I-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
1 0 NUM F
microg/mL 0 NOUN F
) 0 PUNCT F
of 0 ADP F
85.2 0 NUM F
% 0 SYM F
and 0 CCONJ F
84.9 0 NUM F
% 0 SYM F
after 0 ADP F
28 0 NUM F
days 0 NOUN F
fell 0 ADP F
to 0 ADP F
32.1 0 NUM F
% 0 SYM F
and 0 CCONJ F
35.6 0 NUM F
% 0 SYM F
after 0 ADP F
3 0 NUM F
years 0 NOUN F
, 0 PUNCT F
increasing 0 ADP F
to 0 ADP F
67.3 0 NUM F
% 0 SYM F
and 0 CCONJ F
69.8 0 NUM F
% 0 SYM F
after 0 ADP F
the 0 DET F
booster 0 NOUN F
dose 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
combined 0 VERB F
HA/Vi 0 NOUN T
vaccine 0 NOUN F
, 0 PUNCT F
Viatim 0 ADP T
, 0 PUNCT F
had 0 PUNCT F
equivalent 0 PUNCT F

A 0 DET T
randomized 0 VERB F
trial 0 NOUN F
of 0 ADP F
radiation 0 NOUN F
therapy 0 NOUN F
compared 0 VERB F
to 0 ADP F
split 0 ADJ F
course 0 NOUN F
radiation 0 NOUN F
therapy 0 NOUN F
combined 0 VERB F
with 0 ADP F
mitomycin 0 NUM F
C 0 NOUN T
and 0 CCONJ F
5 0 NUM F
fluorouracil 0 NOUN F
as 0 PUNCT F
initial 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
advanced 0 ADP F
laryngeal 0 ADJ F
and 0 CCONJ F
hypopharyngeal 0 PUNCT F
squamous 0 ADJ F
carcinoma 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
twelve 0 ADP F
patients 0 NOUN F
with 0 ADP F
previously 0 ADV F
untreated 0 VERB F
advanced 0 ADP F
squamous 0 ADJ F
carcinoma 0 NOUN F
of 0 ADP F
the 0 DET F
larynx 0 NOUN F
or 0 CCONJ F
hypopharynx 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
initial 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
radiotherapy 0 NOUN F
, 0 PUNCT F
50 0 NUM F
Gy 0 NOUN T
in 0 ADP F
20 0 NUM F
fractions 0 NOUN F
in 0 ADP F
28 0 NUM F
days 0 NOUN F
or 0 CCONJ F
split 0 PUNCT F
course 0 NOUN F
radiotherapy 0 NOUN F
and 0 CCONJ F
concurrent 0 ADJ F
chemotherapy 0 NOUN F
, 0 PUNCT F
25 0 NUM F
Gy 0 NOUN T
in 0 ADP F
10 0 NUM F
fractions 0 NOUN F
in 0 ADP F
14 0 DET F
days 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
4 0 NUM F
week 0 NOUN F
rest 0 NOUN F
and 0 CCONJ F
a 0 DET F
further 0 ADJ F
25 0 NUM F
Gy 0 NOUN T
in 0 ADP F
10 0 NUM F
fractions 0 NOUN F
in 0 ADP F
14 0 NUM F
days 0 NOUN F
starting 0 ADP F
on 0 ADP F
day 0 NOUN F
43 0 NUM F
; 0 PUNCT F
Mitomycin 0 NOUN T
C 0 NOUN T
was 0 VERB F
given 0 VERB F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
and 0 CCONJ F
day 0 NOUN F
43 0 NUM F
and 0 CCONJ F
5FU 0 PUNCT F
continuous 0 ADJ F
infusions 0 NOUN F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
-- 0 PUNCT F
4 0 NUM F
and 0 CCONJ F
days 0 NOUN F
43 0 NUM F
-- 0 PUNCT F
46 0 NUM F
. 0 PUNCT F

Surgery 0 NOUN T
was 0 VERB F
reserved 0 VERB F
for 0 ADP F
persistent 0 ADJ F
or 0 CCONJ F
recurrent 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
nine 0 NUM F
of 0 ADP F
the 0 DET F
212 0 NUM F
patients 0 NOUN F
randomized 0 VERB F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
analyses 0 NOUN F
. 0 PUNCT F

Outcome 0 NOUN T
analyses 0 NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
a 0 DET F
median 0 ADJ F
follow-up 0 NOUN F
interval 0 NOUN F
of 0 ADP F
4.4 0 NUM F
years 0 NOUN F
. 0 PUNCT F

No 0 DET T
patients 0 NOUN F
were 0 VERB F
lost 0 VERB F
to 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
arms 0 NOUN F
for 0 ADP F
the 0 DET F
end 0 NOUN F
points 0 NOUN F
of 0 ADP F
local B-PHYSICAL ADJ F
relapse-free I-PHYSICAL PUNCT F
rate I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.91 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
regional B-PHYSICAL ADJ F
relapse-free I-PHYSICAL PUNCT F
rate I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.17 0 NUM F
, 0 PUNCT F
adjusted 0 ADP F
) 0 PUNCT F
or 0 CCONJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.86 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Eight-eight 0 ADJ T
patients 0 NOUN F
had 0 PUNCT F
attempted 0 VERB F
surgical 0 ADJ F
resection 0 NOUN F
following 0 PUNCT F
radiotherapy 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

The 0 DET T
contribution 0 NOUN F
of 0 ADP F
salvage 0 NOUN F
surgery 0 NOUN F
to 0 ADP F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
was 0 VERB F
similar 0 ADJ F
for 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
as 0 PUNCT F
was 0 VERB F
the 0 DET F
surgical B-ADVERSE-EFFECTS ADJ F
complication I-ADVERSE-EFFECTS NOUN F
rate I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Serious B-ADVERSE-EFFECTS ADJ T
late I-ADVERSE-EFFECTS ADJ F
radiation I-ADVERSE-EFFECTS NOUN F
toxicity I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
minimal 0 ADJ F
( 0 PUNCT F
3 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
RT 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
0 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
radiation 0 NOUN F
therapy 0 NOUN F
plus 0 CCONJ F
chemotherapy 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
result 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
shows 0 NOUN F
no 0 DET F
advantage 0 NOUN F
in 0 ADP F
terms 0 NOUN F
of 0 ADP F
local 0 ADJ F
control 0 NOUN F
or 0 CCONJ F
survival 0 NOUN F
for 0 ADP F
the 0 DET F
experimental 0 ADJ F
treatment 0 NOUN F
arm 0 ADP F
of 0 ADP F
split 0 PUNCT F
course 0 NOUN F
radiotherapy 0 NOUN F
and 0 CCONJ F
concurrent 0 ADJ F
chemotherapy 0 NOUN F
with 0 ADP F
Mitomycin 0 NOUN T
C 0 NOUN T
and 0 CCONJ F
5 0 NUM F
Fluorouracil 0 NOUN T
compared 0 VERB F
to 0 ADP F
radiotherapy 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Gastric 0 ADJ T
ulcer 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
intravenous 0 ADJ F
human 0 NOUN F
epidermal 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
controlled 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

We 0 PRON T
introduced 0 VERB F
a 0 DET F
double-blind 0 ADJ F
controlled 0 VERB F
clinical 0 ADJ F
study 0 NOUN F
to 0 PART F
compare 0 NOUN F
intravenous 0 ADJ F
human 0 NOUN F
epidermal 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
hEGF 0 NOUN F
) 0 PUNCT F
to 0 PART F
cetraxate 0 PUNCT F
hydrochloride 0 NOUN F
( 0 PUNCT F
CH 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
an 0 DET F
antiulcer 0 NOUN F
drug 0 NOUN F
, 0 PUNCT F
for 0 ADP F
their 0 PUNCT F
healing 0 PROPN F
effect 0 NOUN F
on 0 ADP F
gastric B-PHYSICAL ADJ F
ulcers I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
also 0 ADV F
prospected 0 ADJ F
an 0 DET F
oral 0 ADJ F
use 0 NOUN F
of 0 ADP F
EGF 0 NOUN T
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
our 0 PUNCT F
experimental 0 ADJ F
evidence 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
ulcer B-PHYSICAL NOUN F
healing I-PHYSICAL VERB F
within 0 ADP F
8 0 NUM F
weeks 0 NOUN F
was 0 VERB F
77.9 0 NUM F
% 0 SYM F
( 0 PUNCT F
67/86 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
6 0 NUM F
micrograms 0 NOUN F
EGF 0 NOUN T
intravenously 0 ADV F
twice 0 NOUN F
a 0 DET F
week 0 NOUN F
, 0 PUNCT F
being 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
than 0 PUNCT F
51.7 0 NUM F
% 0 SYM F
( 0 PUNCT F
45/87 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
those 0 PUNCT F
given 0 VERB F
CH 0 NOUN T
. 0 PUNCT F

Taking 0 PUNCT T
together 0 ADV F
all 0 DET F
aspects 0 NOUN F
assessed 0 VERB F
including 0 VERB F
the 0 DET F
healing B-PHYSICAL VERB F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
examination I-PHYSICAL NOUN F
and 0 CCONJ F
adverse B-ADVERSE-EFFECTS ADJ F
reactions I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
we 0 PRON F
judged 0 VERB F
the 0 DET F
hEGF 0 NOUN F
to 0 PART F
be 0 PUNCT F
a 0 DET F
useful 0 ADJ F
and 0 CCONJ F
safe 0 ADJ F
anticuler 0 PUNCT F
drug 0 NOUN F
. 0 PUNCT F

In 0 ADP T
rats 0 NOUN F
, 0 PUNCT F
50 0 NUM F
micrograms/kg 0 NOUN F
mouse 0 NOUN F
EGF 0 NOUN T
( 0 PUNCT F
mEGF 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
% 0 SYM F
hydroxypropyl 0 NOUN F
cellulose 0 NOUN F
( 0 PUNCT F
HPC 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
1.0 0 NUM F
g/kg 0 NOUN F
sucralfate 0 NOUN F
given 0 VERB F
by 0 ADP F
gastric 0 ADJ F
intubation 0 NOUN F
significantly 0 ADV F
raised 0 VERB F
the 0 DET F
residual 0 ADJ F
mEGF B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
in 0 ADP F
both 0 CCONJ F
gastric 0 ADJ F
luminal 0 ADJ F
content 0 NOUN F
( 0 PUNCT F
HPC 0 NOUN T
: 0 PUNCT F
x 0 SYM F
30 0 NUM F
; 0 PUNCT F
sucralfate 0 NOUN F
: 0 PUNCT F
x 0 SYM F
300 0 NUM F
as 0 VERB F
high 0 ADJ F
as 0 ADJ F
those 0 PUNCT F
in 0 ADP F
EGF 0 NOUN T
alone 0 ADJ F
) 0 PUNCT F
and 0 CCONJ F
tissue 0 NOUN F
( 0 PUNCT F
HPC 0 NOUN T
: 0 PUNCT F
x 0 SYM F
60 0 NUM F
; 0 PUNCT F
sucralfate 0 NOUN F
: 0 PUNCT F
x 0 SYM F
100 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
the 0 DET F
combined 0 DET F
treatments 0 NOUN F
significantly 0 ADV F
promoted 0 PUNCT F
healing 0 VERB F
of 0 ADP F
rat B-PHYSICAL NOUN F
gastric I-PHYSICAL ADJ F
ulcers I-PHYSICAL NOUN F
whereas 0 ADP F
each 0 DET F
agent 0 NOUN F
alone 0 ADJ F
had 0 CCONJ F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
( 0 PUNCT F
saline 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
indicated 0 VERB F
the 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
on 0 ADP F
ulcers 0 NOUN F
of 0 ADP F
oral 0 ADJ F
administration 0 NOUN F
of 0 ADP F
EGF 0 NOUN T
with 0 ADP F
agents 0 NOUN F
allowing 0 VERB F
it 0 PRON F
to 0 PUNCT F
remain 0 ADP F
at 0 ADP F
high 0 ADJ F
levels 0 NOUN F
in 0 ADP F
the 0 DET F
stomach 0 NOUN F
, 0 PUNCT F
whereas 0 CCONJ F
most 0 DET F
reports 0 NOUN F
suggested 0 VERB F
less 0 DET F
effect 0 NOUN F
of 0 ADP F
oral 0 ADJ F
EGF 0 NOUN T
on 0 ADP F
healing 0 VERB F
of 0 ADP F
gastroduodenal 0 ADJ F
ulcers 0 NOUN F
. 0 PUNCT F

Subsequent 0 PUNCT T
to 0 ADP F
the 0 DET F
clinical 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
evaluation 0 NOUN F
of 0 ADP F
oral 0 ADJ F
use 0 NOUN F
of 0 ADP F
EGF 0 NOUN T
may 0 VERB F
be 0 VERB F
expected 0 VERB F
as 0 ADP F
the 0 DET F
next 0 ADJ F
step 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
ulcers 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
evidence 0 NOUN F
above 0 PUNCT F
would 0 PUNCT F
possibly 0 ADV F
be 0 ADP F
a 0 DET F
guide 0 NOUN F
for 0 ADP F
such 0 DET F
trial 0 NOUN F
. 0 PUNCT F

Long 0 ADJ T
pediatric 0 ADJ F
colonoscope 0 PUNCT F
versus 0 CCONJ F
intermediate 0 ADJ F
length 0 NOUN F
adult 0 NOUN F
colonoscope 0 ADJ F
for 0 ADP F
colonoscopy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Controversy 0 NOUN T
exists 0 NOUN F
on 0 ADP F
how 0 ADP F
the 0 DET F
length 0 NOUN F
and 0 CCONJ F
diameter 0 NOUN F
of 0 ADP F
colonoscopes 0 NOUN F
affect 0 VERB F
the 0 DET F
quality B-OTHER NOUN F
of I-OTHER ADP F
colonoscopy I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
a 0 DET F
long 0 ADJ F
pediatric 0 ADJ F
colonoscope 0 PUNCT F
with 0 ADP F
an 0 DET F
intermediate 0 ADJ F
length 0 NOUN F
adult 0 NOUN F
colonoscope 0 ADJ F
with 0 ADP F
regards 0 ADP F
to 0 ADP F
completion B-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
cecal B-OTHER ADJ F
intubation I-OTHER NOUN F
time I-OTHER NOUN F
. 0 PUNCT F

Whether 0 ADP T
either 0 PUNCT F
scope 0 PUNCT F
may 0 VERB F
be 0 VERB F
more 0 ADV F
efficient B-OTHER ADJ F
in 0 ADP F
any 0 DET F
subgroups 0 NOUN F
was 0 NUM F
also 0 ADV F
investigated 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
Asymptomatic 0 ADJ T
patients 0 NOUN F
admitted 0 VERB F
to 0 ADP F
the 0 DET F
physical 0 ADJ F
check-up 0 NOUN F
department 0 NOUN F
of 0 ADP F
Buddhist 0 NOUN T
Dalin 0 NOUN T
Tzu 0 NOUN T
Chi 0 NOUN T
General 0 ADJ T
Hospital 0 NOUN T
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

A 0 DET T
single 0 ADJ F
endoscopist 0 NOUN F
performed 0 VERB F
all 0 PUNCT F
of 0 ADP F
the 0 DET F
colonoscopic 0 ADJ F
examinations 0 NOUN F
under 0 ADP F
sedation 0 NOUN F
. 0 PUNCT F

Consecutive 0 ADJ T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADJ F
undergo 0 VERB F
colonoscopy 0 NOUN F
with 0 ADP F
either 0 CCONJ F
intermediate 0 ADJ F
length 0 NOUN F
adult 0 NOUN F
colonoscope 0 PUNCT F
( 0 PUNCT F
CF-240I 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
long 0 ADJ F
pediatric 0 ADJ F
colonoscope 0 ADJ F
( 0 PUNCT F
PCF-240L 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
success B-OTHER NOUN F
rate I-OTHER NOUN F
and 0 CCONJ F
time B-OTHER NOUN F
required I-OTHER ADJ F
to I-OTHER ADP F
reach I-OTHER PUNCT F
cecum I-OTHER NOUN F
were 0 VERB F
compared 0 VERB F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Between 0 ADP T
April 0 NOUN T
2005 0 NUM F
and 0 CCONJ F
February 0 PUNCT T
2006 0 NUM F
, 0 PUNCT F
a 0 DET F
total 0 NOUN F
of 0 ADP F
918 0 NUM F
patients 0 NOUN F
were 0 VERB F
enrolled 0 VERB F
. 0 PUNCT F

Incomplete B-OTHER PUNCT T
colonoscopy I-OTHER NOUN F
occurred 0 VERB F
in 0 ADP F
21 0 NUM F
( 0 PUNCT F
2.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
cases 0 NOUN F
( 0 PUNCT F
14 0 NUM F
in 0 ADP F
the 0 DET F
CF-240I 0 NOUN T
group 0 NOUN F
and 0 CCONJ F
seven 0 NUM F
in 0 ADP F
the 0 DET F
PCF-240L 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.1 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
overall B-OTHER ADJ F
cecal I-OTHER ADJ F
mean 0 NOUN F
insertion B-OTHER NOUN F
time B-OTHER NOUN F
was 0 VERB F
6.00 0 NUM F
+/- 0 SYM F
3.66 0 NUM F
min 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
CF-240I 0 NOUN T
and 0 CCONJ F
PCF 0 NOUN T
240L 0 NOUN F
groups 0 NOUN F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
the 0 DET F
cecal B-OTHER ADJ F
intubation I-OTHER NOUN F
rate B-OTHER NOUN F
( 0 PUNCT F
96.9 0 NUM F
% 0 SYM F
vs 0 CCONJ F
98.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.18 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
need 0 NOUN F
for 0 ADP F
abdominal B-OTHER ADJ F
pressure I-OTHER NOUN F
( 0 PUNCT F
71.7 0 NUM F
% 0 SYM F
vs 0 CCONJ F
73.4 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.55 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
change B-OTHER NOUN F
of I-OTHER ADP F
position 0 NOUN F
( 0 PUNCT F
13.5 0 NUM F
% 0 SYM F
vs 0 CCONJ F
11.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.37 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
cecal B-OTHER ADJ F
intubation I-OTHER NOUN F
time I-OTHER NOUN F
was 0 VERB F
shorter 0 PUNCT F
in 0 ADP F
the 0 DET F
CF-240I 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
5.75 0 NUM F
+/- 0 SYM F
3.18 0 NUM F
vs 0 CCONJ F
6.26 0 NUM F
+/- 0 SYM F
3.30 0 NUM F
min 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Subgroup 0 NOUN T
analysis 0 NOUN F
by 0 ADP F
sex 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
showed 0 VERB F
comparable 0 ADJ F
outcomes 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
except 0 CCONJ F
that 0 CCONJ F
the 0 PUNCT F

The 0 DET T
acute 0 ADJ F
effects 0 NOUN F
of 0 ADP F
fluid 0 NOUN F
intake 0 NOUN F
on 0 ADP F
urine 0 NOUN F
specific 0 ADJ F
gravity 0 NOUN F
and 0 CCONJ F
fluid 0 NOUN F
retention 0 NOUN F
in 0 ADP F
a 0 DET F
mildly 0 ADV F
dehydrated 0 PUNCT F
state 0 NOUN F
. 0 PUNCT F

Many 0 DET T
athletes 0 NOUN F
arrive 0 ADJ F
at 0 ADP F
training 0 ADP F
sessions 0 NOUN F
and 0 CCONJ F
competitions 0 NOUN F
in 0 ADP F
a 0 DET F
mildly 0 ADV F
hypohydrated 0 PUNCT F
( 0 PUNCT F
HYPO 0 NOUN T
) 0 PUNCT F
state 0 NOUN F
and 0 CCONJ F
are 0 VERB F
instructed 0 VERB F
to 0 ADP F
drink 0 NOUN F
fluids 0 NOUN F
before 0 ADP F
exercise 0 NOUN F
to 0 ADP F
reach 0 NOUN F
a 0 ADP F
euhydrated 0 ADP F
( 0 PUNCT F
HYD 0 NOUN T
) 0 PUNCT F
state 0 NOUN F
. 0 PUNCT F

Ten 0 NUM T
recreational 0 ADJ F
athletes 0 NOUN F
( 0 PUNCT F
6 0 NUM F
women 0 NOUN F
, 0 PUNCT F
4 0 NUM F
men 0 NOUN F
; 0 PUNCT F
71.9 0 NUM F
? 0 PUNCT F

4.6 0 NUM F
kg 0 NOUN F
, 0 PUNCT F
25.2 0 NUM F
? 0 PUNCT F

0.9 0 NUM F
years 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
the 0 DET F
studies 0 NOUN F
to 0 PART F
examine 0 NOUN F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
the 0 DET F
day-to-day 0 NOUN F
variability 0 NOUN F
of 0 ADP F
morning 0 NOUN F
urine 0 NOUN F
specific 0 ADJ F
gravity 0 NOUN F
( 0 PUNCT F
USG 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
consuming 0 SYM F
600 0 NUM F
ml 0 NOUN F
of 0 ADP F
water 0 NOUN F
on 0 ADP F
the 0 DET F
hydration 0 NOUN F
status 0 NOUN F
of 0 ADP F
HYD 0 NOUN T
and 0 CCONJ F
HYPO 0 NOUN T
( 0 PUNCT F
USG 0 NOUN T
> 0 SYM F
1.020 0 NUM F
) 0 PUNCT F
subjects 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
consuming 0 ADJ F
water 0 NOUN F
( 0 PUNCT F
W 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
salt-water 0 ADJ F
( 0 PUNCT F
SW 0 NOUN T
, 0 PUNCT F
40 0 NUM F
mM 0 NOUN F
Na 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
carbohydrate-electrolyte 0 NOUN F
solution 0 NOUN F
with 0 ADP F
3 0 NUM F
% 0 SYM F
or 0 CCONJ F
light 0 ADJ F
carbohydrate 0 NOUN F
( 0 PUNCT F
CES-L 0 NOUN T
, 0 PUNCT F
20 0 NUM F
mM 0 NOUN F
Na 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
CES 0 NOUN T
with 0 ADP F
6 0 NUM F
% 0 SYM F
carbohydrate 0 NOUN F
( 0 PUNCT F
CES 0 NOUN T
, 0 PUNCT F
20 0 NUM F
mM 0 NOUN F
Na 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
hydration 0 NOUN F
status 0 NOUN F
of 0 ADP F
HYPO 0 NOUN T
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
hydration 0 NOUN F
status 0 NOUN F
was 0 VERB F
assessed 0 VERB F
with 0 ADP F
USG 0 NOUN T
and 0 CCONJ F
body 0 NOUN F
mass 0 NOUN F
measures 0 NOUN F
and 0 CCONJ F
urine 0 NOUN F
volume 0 NOUN F
collections 0 NOUN F
. 0 PUNCT F

The 0 DET T
day-to-day 0 NOUN F
variability 0 NOUN F
in 0 ADP F
morning 0 NOUN F
USG 0 NOUN T
( 0 PUNCT F
coefficient 0 NOUN F
of 0 ADP F
variation 0 NOUN F
= 0 SYM F
0.2 0 NUM F
? 0 PUNCT F

0.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
was 0 VERB F
low 0 ADJ F
and 0 CCONJ F
the 0 DET F
responses 0 NOUN F
to 0 ADP F
600 0 NUM F
ml 0 NOUN F
of 0 ADP F
W 0 NOUN T
ingestion 0 NOUN F
were 0 VERB F
repeatable 0 ADJ F
. 0 PUNCT F

Pretrial 0 ADJ T
USG 0 NOUN T
was 0 VERB F
1.022 0 NUM F
? 0 PUNCT F

0.001 0 NUM F
in 0 ADP F
the 0 DET F
HYPO 0 NOUN T
trial 0 NOUN F
and 0 CCONJ F
decreased 0 VERB F
< 0 PROPN F
1.020 0 NUM F
by 0 ADP F
45 0 NUM F
minutes 0 NOUN F
( 0 PUNCT F
1.013 0 NUM F
? 0 PUNCT F

0.003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
CES 0 NOUN T
study 0 NOUN F
, 0 PUNCT F
HYPO 0 NOUN T
subjects 0 NOUN F
reached 0 PUNCT F
HYD 0 NOUN T
status 0 NOUN F
at 0 ADP F
45 0 NUM F
minutes 0 NOUN F
in 0 ADP F
all 0 DET F
conditions 0 NOUN F
( 0 PUNCT F
W 0 NOUN T
1.013 0 NUM F
? 0 PUNCT F

0.003 0 NUM F
, 0 PUNCT F
SW 0 NOUN T
1.013 0 NUM F
? 0 PUNCT F

0.003 0 NUM F
, 0 PUNCT F
CES-L 0 NOUN T
1.011 0 NUM F
? 0 PUNCT F

0.003 0 NUM F
, 0 PUNCT F
CES 0 NOUN T
1.017 0 NUM F
? 0 PUNCT F

0.004 0 NUM F
) 0 PUNCT F
because 0 PUNCT F
salt 0 ADP F
or 0 CCONJ F
CES 0 NOUN T
ingestion 0 NOUN F
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
fluid B-PHYSICAL NOUN F
retention I-PHYSICAL NOUN F
( 0 PUNCT F
W 0 NOUN T
68 0 NUM F
% 0 SYM F
, 0 PUNCT F
SW 0 NOUN T
72 0 NUM F
% 0 SYM F
, 0 PUNCT F
CES-L 0 NOUN T
68 0 NUM F
% 0 SYM F
, 0 PUNCT F
CES 0 ADP T
76 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
demonstrated 0 VERB F
that 0 PUNCT F
mildly 0 ADV F
HYPO 0 NOUN T
subjects 0 NOUN F
could 0 ADP F
reach 0 ADV F
euhydration 0 NOUN F
within 0 ADP F
45 0 NUM F
minutes 0 NOUN F
of 0 ADP F
the 0 DET F
ingestion 0 NOUN F
of 0 ADP F
600 0 NUM F
ml 0 NOUN F
of 0 ADP F
W 0 NOUN T
or 0 CCONJ F
a 0 DET F
combination 0 NOUN F
of 0 ADP F
salt 0 NOUN F
and 0 CCONJ F
CES 0 NOUN T
solutions 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
this 0 DET F
practice 0 NOUN F
will 0 VERB F
minimize 0 ADP F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
starting 0 PUNCT F
a 0 DET F
practice 0 NOUN F
or 0 CCONJ F
competition 0 NOUN F
hypohydrated 0 ADP F
. 0 PUNCT F

Use B-OTHER NOUN T
and 0 CCONJ F
limitations B-OTHER NOUN F
of 0 ADP F
Holter 0 NOUN T
electrocardiography 0 NOUN F
in 0 ADP F
assessing 0 VERB F
drug 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
ischemia 0 NOUN F
during 0 ADP F
the 0 DET F
peri-PTCA 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Incidence 0 NOUN T
and 0 CCONJ F
pattern 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
ischemia 0 NOUN F
during 0 ADP F
the 0 DET F
peri-PTCA 0 NOUN F
( 0 PUNCT F
percutaneous 0 ADJ F
transluminal 0 ADJ F
coronary 0 ADJ F
angioplasty 0 NOUN F
) 0 PUNCT F
period 0 NOUN F
and 0 CCONJ F
the 0 DET F
possible 0 ADJ F
role 0 NOUN F
of 0 ADP F
continuous 0 ADJ F
intravenous 0 ADJ F
isosorbide 0 NOUN F
dinitrate 0 PUNCT F
in 0 ADP F
its 0 PUNCT F
prevention 0 NOUN F
were 0 VERB F
examined 0 VERB F
prospectively 0 ADV F
in 0 ADP F
30 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Holter 0 NOUN T
electrocardiographic 0 ADJ F
monitoring 0 VERB F
was 0 VERB F
performed 0 VERB F
for 0 ADP F
21 0 NUM F
+/- 0 SYM F
3 0 NUM F
h 0 NOUN F
before 0 ADP F
PTCA 0 NOUN T
and 0 CCONJ F
continued 0 PUNCT F
during 0 ADP F
and 0 CCONJ F
for 0 ADP F
41 0 NUM F
+/- 0 SYM F
8 0 NUM F
h 0 NOUN F
after 0 ADP F
the 0 DET F
procedure 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
PTCA 0 NOUN T
, 0 PUNCT F
19 0 NUM F
ischemic 0 ADJ F
episodes 0 NOUN F
were 0 VERB F
present 0 ADJ F
in 0 ADP F
10 0 NUM F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
30 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

PTCA 0 NOUN T
produced 0 VERB F
an 0 DET F
abrupt 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
number 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.015 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
duration 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
of 0 ADP F
spontaneous B-PHYSICAL ADJ F
ischemic I-PHYSICAL ADJ F
episodes I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
rarity 0 NOUN F
of 0 ADP F
recurrent B-PHYSICAL ADJ F
myocardial I-PHYSICAL ADJ F
ischemic I-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
by 0 ADP F
Holter 0 NOUN T
monitoring 0 VERB F
after 0 PUNCT F
PTCA 0 NOUN T
negated 0 VERB F
any 0 DET F
attempt 0 NOUN F
at 0 ADP F
assessing 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
intravenous 0 ADJ F
isosorbide 0 NOUN F
dinitrate 0 PUNCT F
in 0 ADP F
their 0 ADJ F
prevention 0 NOUN F
. 0 PUNCT F

Holter 0 NOUN T
monitoring 0 VERB F
could 0 VERB F
not 0 ADV F
be 0 VERB F
used 0 VERB F
as 0 ADP F
an 0 DET F
early 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
late 0 ADJ F
coronary 0 ADJ F
restenosis 0 NOUN F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
cigarette 0 NOUN F
smoking 0 VERB F
on 0 ADP F
gastric 0 ADJ F
emptying 0 PUNCT F
of 0 ADP F
solids 0 NOUN F
in 0 ADP F
Japanese 0 ADJ T
smokers 0 NOUN F
: 0 PUNCT F
a 0 DET F
crossover 0 NOUN F
study 0 NOUN F
using 0 VERB F
the 0 DET F
13C-octanoic 0 PUNCT F
acid 0 NOUN F
breath 0 NOUN F
test 0 NUM F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Cigarette 0 NOUN T
smoking 0 PUNCT F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
increased 0 VERB F
risk 0 NOUN F
of 0 ADP F
peptic 0 ADJ F
ulcer 0 NOUN F
and 0 CCONJ F
gastroesophageal 0 ADJ F
reflux 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Gastric 0 ADJ T
emptying 0 PUNCT F
disorders 0 NOUN F
may 0 VERB F
play 0 VERB F
a 0 DET F
role 0 NOUN F
in 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
these 0 DET F
upper 0 ADJ F
gastrointestinal 0 ADJ F
diseases 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
studies 0 NOUN F
examining 0 VERB F
a 0 DET F
link 0 NOUN F
between 0 ADP F
smoking 0 PUNCT F
and 0 CCONJ F
gastric 0 ADJ F
emptying 0 PUNCT F
disorders 0 NOUN F
have 0 PUNCT F
clinical 0 ADJ F
relevance 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
smoking B-PHYSICAL VERB F
on 0 ADP F
gastric 0 ADJ F
emptying 0 PUNCT F
of 0 ADP F
solids 0 NOUN F
in 0 ADP F
Japanese 0 ADJ T
smokers 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
( 0 PUNCT F
13 0 NUM F
) 0 PUNCT F
C-octanoic 0 ADJ T
acid B-PHYSICAL NOUN F
breath I-PHYSICAL NOUN F
test I-PHYSICAL ADV F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
eight 0 NUM F
male 0 NOUN F
habitual 0 ADJ F
smokers 0 NOUN F
on 0 ADP F
two 0 NUM F
randomized 0 VERB F
occasions 0 NOUN F
( 0 PUNCT F
either 0 CCONJ F
sham 0 ADJ F
smoking 0 ADP F
or 0 CCONJ F
actively 0 ADV F
smoking 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
time 0 NOUN F
vs 0 CCONJ F
( 0 PUNCT F
13 0 NUM F
) 0 PUNCT F
CO 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
excretion B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
curve 0 NOUN F
was 0 VERB F
mathematically 0 ADV F
fitted 0 VERB F
to 0 ADP F
a 0 DET F
conventional 0 ADJ F
formula 0 NOUN F
of 0 ADP F
y 0 NOUN F
( 0 PUNCT F
t 0 NOUN F
) 0 PUNCT F
= 0 SYM F
m*k*beta*e 0 NOUN F
( 0 PUNCT F
-k*t 0 NOUN F
) 0 PUNCT F
* 0 ADJ F
( 0 PUNCT F
1 0 NUM F
- 0 PUNCT F
e 0 NOUN F
( 0 PUNCT F
-k*t 0 NOUN F
) 0 PUNCT F
) 0 PUNCT F
( 0 PUNCT F
beta-1 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
parameters 0 NOUN F
of 0 ADP F
k B-OTHER NOUN F
and 0 CCONJ F
beta B-OTHER NOUN F
were 0 VERB F
determined 0 VERB F
: 0 PUNCT F
under 0 ADP F
the 0 DET F
crossover 0 NOUN F
protocol 0 NOUN F
, 0 PUNCT F
a 0 DET F
larger 0 PUNCT F
( 0 PUNCT F
smaller 0 PUNCT F
) 0 PUNCT F
beta 0 NOUN F
indicates 0 NOUN F
slower 0 PUNCT F
( 0 PUNCT F
faster 0 PUNCT F
) 0 PUNCT F
emptying 0 ADJ F
in 0 ADP F
the 0 DET F
early 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
larger 0 PUNCT F
( 0 PUNCT F
smaller 0 PUNCT F
) 0 PUNCT F
k 0 NOUN F
indicates 0 ADP F
faster 0 PUNCT F
( 0 PUNCT F
slower 0 PUNCT F
) 0 PUNCT F
emptying 0 ADJ F
in 0 ADP F
the 0 DET F
later 0 PUNCT F
phase 0 NOUN F
. 0 PUNCT F

The 0 PUNCT T

Pedantic 0 ADJ T
speaking 0 PUNCT F
style 0 NUM F
differentiates 0 NOUN F
Asperger 0 ADJ T
syndrome 0 NOUN F
from 0 ADP F
high-functioning 0 VERB F
autism 0 NOUN F
. 0 PUNCT F

Asperger 0 ADJ T
syndrome 0 NOUN F
( 0 PUNCT F
AS 0 PUNCT T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
recently 0 ADV F
introduced 0 ADP F
as 0 ADP F
a 0 DET F
new 0 ADJ F
diagnostic 0 ADJ F
category 0 ADJ F
in 0 ADP F
the 0 DET F
ICD-10 0 NOUN T
and 0 CCONJ F
the 0 DET F
DSM-IV 0 NOUN T
. 0 PUNCT F

Along 0 PUNCT T
with 0 ADP F
motor 0 NOUN F
clumsiness 0 NOUN F
, 0 PUNCT F
pedantic 0 ADJ F
speech 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
proposed 0 VERB F
as 0 ADP F
a 0 DET F
clinical 0 ADJ F
feature 0 NOUN F
of 0 ADP F
AS 0 CCONJ T
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
few 0 ADJ F
attempts 0 PUNCT F
have 0 PUNCT F
been 0 PUNCT F
made 0 VERB F
to 0 PART F
define 0 NOUN F
and 0 CCONJ F
measure 0 ADP F
this 0 DET F
symptom 0 NOUN F
. 0 PUNCT F

We 0 PRON T
studied 0 VERB F
17 0 NUM F
patients 0 NOUN F
with 0 ADP F
AS 0 ADP T
( 0 PUNCT F
ICD-10 0 NOUN T
; 0 PUNCT F
14 0 NUM F
male 0 NOUN F
, 0 PUNCT F
3 0 NUM F
female 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
16.4 0 NUM F
years 0 NOUN F
, 0 PUNCT F
mean 0 VERB F
full-scale 0 NOUN F
IQ 0 NOUN T
97 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
compared 0 DET F
them 0 CCONJ F
with 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
of 0 ADP F
13 0 NUM F
patients 0 NOUN F
with 0 ADP F
normal-intelligence 0 NOUN F
autism 0 NOUN F
or 0 CCONJ F
high-functioning 0 ADP F
autism 0 NOUN F
( 0 PUNCT F
HFA 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
ICD-10/DSM-III-R 0 PUNCT T
; 0 PUNCT F
12 0 NUM F
male 0 NOUN F
, 0 PUNCT F
1 0 NUM F
female 0 NOUN F
; 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
15.5 0 NUM F
years 0 NOUN F
, 0 PUNCT F
mean 0 VERB F
full-scale 0 NOUN F
IQ 0 NOUN T
81.2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

An 0 DET T
operational 0 ADJ F
definition 0 NOUN F
of 0 ADP F
pedantic 0 ADJ F
speech 0 NOUN F
was 0 VERB F
formulated 0 VERB F
and 0 CCONJ F
a 0 DET F
rating 0 VERB F
scale 0 NOUN F
devised 0 VERB F
. 0 PUNCT F

13 0 NUM F
( 0 PUNCT F
76 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
AS 0 ADP T
patients 0 NOUN F
were 0 VERB F
rated 0 VERB F
as 0 ADP F
pedantic B-OTHER ADJ F
compared 0 VERB F
to 0 ADP F
4 0 NUM F
( 0 PUNCT F
31 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
the 0 DET F
HFA 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
chi 0 NOUN F
2 0 NUM F
= 0 SYM F
6.3 0 NUM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Results 0 CCONJ T
suggest 0 VERB F
that 0 ADP F
pedantic 0 ADJ F
speech 0 NOUN F
is 0 ADJ F
common 0 ADJ F
in 0 ADP F
AS 0 NOUN T
and 0 CCONJ F
may 0 VERB F
help 0 NOUN F
differentiate 0 PUNCT F
AS 0 PUNCT T
from 0 ADP F
high-functioning 0 VERB F
autism 0 NOUN F
. 0 PUNCT F

Comparative 0 ADJ T
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
twice 0 PUNCT F
daily 0 ADJ F
fluticasone 0 NOUN F
propionate 0 NOUN F
powder 0 NOUN F
versus 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
moderate 0 ADJ F
asthma 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Fluticasone 0 NOUN T
propionate 0 NOUN F
, 0 PUNCT F
an 0 DET F
inhaled 0 VERB F
corticosteroid 0 NOUN F
with 0 ADP F
negligible 0 ADJ F
systemic 0 ADJ F
bioavailability 0 NOUN F
via 0 ADP F
the 0 DET F
oral 0 ADJ F
route 0 NOUN F
, 0 PUNCT F
is 0 VERB F
efficacious 0 ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
asthma 0 NOUN F
when 0 ADP F
administered 0 VERB F
via 0 ADP F
metered-dose 0 NOUN F
inhaler 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
inhaled 0 VERB F
fluticasone 0 NOUN F
propionate 0 NOUN F
powder 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
asthma 0 NOUN F
previously 0 ADV F
treated 0 VERB F
with 0 ADP F
an 0 DET F
inhaled 0 VERB F
corticosteroid 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
parallel-group 0 NOUN F
, 0 PUNCT F
multicenter 0 NOUN F
study 0 NOUN F
of 0 ADP F
342 0 NUM F
adolescent 0 NOUN F
and 0 CCONJ F
adult 0 ADJ F
patients 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
asthma 0 NOUN F
[ 0 PUNCT F
forced B-PHYSICAL VERB F
expiratory I-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
1 I-PHYSICAL NUM F
second I-PHYSICAL ADJ F
( 0 PUNCT F
FEV1 B-PHYSICAL NOUN T
) 0 PUNCT F
between 0 ADP F
50 0 NUM F
% 0 SYM F
and 0 CCONJ F
80 0 NUM F
% 0 SYM F
of 0 ADP F
predicted 0 PUNCT F
] 0 PUNCT F
treated 0 ADP F
previously 0 ADV F
by 0 ADP F
beclomethasone 0 NOUN F
dipropionate 0 PUNCT F
or 0 CCONJ F
triamcinolone 0 ADV F
acetonide 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
fluticasone 0 NOUN F
propionate 0 NOUN F
powder 0 NOUN F
50 0 NUM F
micrograms 0 NOUN F
, 0 PUNCT F
100 0 NUM F
micrograms 0 NOUN F
, 0 PUNCT F
250 0 NUM F
micrograms 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
via 0 ADP F
a 0 DET F
breath-actuated 0 VERB F
inhalation 0 NOUN F
device 0 NOUN F
, 0 PUNCT F
the 0 DET F
Diskhaler 0 ADJ T
, 0 PUNCT F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Patients 0 NOUN T
in 0 ADP F
the 0 DET F
fluticasone 0 NOUN F
propionate 0 NOUN F
groups 0 NOUN F
experienced 0 VERB F
a 0 DET F
mean 0 NOUN F
increase 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to B-PHYSICAL PUNCT F
endpoint 0 CCONJ F
in B-PHYSICAL ADP F
FEV1 B-PHYSICAL NOUN T
ranging 0 VERB F
from 0 ADP F
0.43 0 NUM F
L 0 NOUN T
to 0 ADP F
0.47 0 NUM F
L. 0 ADV T
Patients 0 NOUN T
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
experienced 0 VERB F
a 0 DET F
mean 0 NOUN F
decrease 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
of 0 ADP F
0.22 0 NUM F
L 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
probability 0 NOUN F
of 0 ADP F
patients 0 NOUN F
remaining 0 CCONJ F
in 0 ADP F
the 0 DET F
study 0 NOUN F
over 0 ADP F
time 0 NOUN F
without 0 ADP F
developing 0 VERB F
signs 0 NOUN F
of 0 ADP F
exacerbating B-PHYSICAL ADV F
asthma I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
fluticasone 0 NOUN F
propionate 0 NOUN F
groups 0 NOUN F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Asthma B-PHYSICAL NOUN T
symptom I-PHYSICAL NOUN F
scores I-PHYSICAL NOUN F
, 0 PUNCT F
supplemental B-OTHER ADJ F
rescue I-OTHER NOUN F
albuterol I-OTHER NOUN F
use I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
number 0 NOUN F
of 0 ADP F
nighttime B-PHYSICAL VERB F
awakenings I-PHYSICAL NOUN F
due I-PHYSICAL VERB F
to I-PHYSICAL ADP F
asthma B-PHYSICAL NOUN F
requiring 0 VERB F
treatment 0 NOUN F
also 0 ADV F
improved 0 VERB F
significantly 0 ADV F
with 0 ADP F
all 0 DET F
fluticasone 0 NOUN F
propionate 0 NOUN F
treatment 0 NOUN F
regimens 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
at 0 ADP F
endpoint 0 NOUN F
among 0 ADP F
the 0 DET F
three 0 NUM F
fluticasone 0 NOUN F
propionate 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

No 0 DET T
serious B-ADVERSE-EFFECTS ADJ F
drug-related I-ADVERSE-EFFECTS VERB F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Fluticasone 0 NOUN T
propionate 0 NOUN F
powder 0 NOUN F
( 0 PUNCT F
50 0 NUM F
, 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
250 0 NUM F
micrograms 0 NOUN F
) 0 PUNCT F
was 0 PUNCT F

Clonidine 0 NOUN T
increases 0 PUNCT F
the 0 DET F
sweating B-PHYSICAL PUNCT F
threshold I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
reduce 0 VERB F
the 0 DET F
gain B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sweating I-PHYSICAL ADP F
. 0 PUNCT F

We 0 PRON T
tested 0 VERB F
the 0 DET F
hypothesis 0 NOUN F
that 0 VERB F
clonidine 0 NOUN F
produces 0 NOUN F
a 0 DET F
dose-dependent 0 ADJ F
increase 0 NOUN F
in 0 ADP F
the 0 DET F
sweating B-PHYSICAL PUNCT F
threshold I-PHYSICAL NOUN F
but 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
reduce 0 VERB F
the 0 DET F
gain 0 NOUN F
of 0 ADP F
sweating 0 ADP F
. 0 PUNCT F

Six 0 NUM T
healthy 0 ADJ F
male 0 NOUN F
volunteers 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
, 0 PUNCT F
each 0 CCONJ F
on 0 ADP F
three 0 NUM F
separate 0 ADJ F
days 0 NOUN F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
. 0 PUNCT F

In 0 ADP T
one 0 NUM F
, 0 PUNCT F
saline 0 NOUN F
was 0 VERB F
administered 0 VERB F
; 0 PUNCT F
in 0 ADP F
another 0 PUNCT F
, 0 PUNCT F
a 0 DET F
2-micrograms/kg 0 NOUN F
bolus 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
an 0 DET F
infusion 0 NOUN F
at 0 ADP F
2 0 NUM F
micrograms.kg-1.h-1 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
on 0 ADP F
a 0 DET F
third 0 ADJ F
day 0 NOUN F
, 0 PUNCT F
a 0 DET F
4-micrograms/kg 0 ADJ F
bolus 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
an 0 DET F
infusion 0 NOUN F
at 0 ADP F
4 0 NUM F
micrograms.kg-1.h-1 0 NOUN F
. 0 PUNCT F

Core B-PHYSICAL NOUN T
temperature I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
at 0 ADP F
the 0 DET F
tympanic 0 ADJ F
membrane 0 NOUN F
and 0 CCONJ F
mean 0 NOUN F
skin B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
from 0 ADP F
four 0 NUM F
sites 0 NOUN F
. 0 PUNCT F

A 0 PUNCT T
chest B-PHYSICAL NOUN F
sweating I-PHYSICAL PUNCT F
rate I-PHYSICAL NOUN F
of 0 ADP F
40 0 NUM F
g.m-2.h-1 0 PUNCT F
was 0 VERB F
considered 0 VERB F
significant 0 ADJ F
. 0 PUNCT F

The 0 DET T
core 0 NOUN F
temperature 0 NOUN F
triggering 0 VERB F
sweating B-PHYSICAL ADP F
, 0 PUNCT F
adjusted 0 ADP F
to 0 ADP F
a 0 DET F
designated 0 PUNCT F
mean 0 NOUN F
skin 0 NOUN F
temperature 0 NOUN F
of 0 ADP F
34 0 NUM F
degrees 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
identified 0 ADP F
the 0 DET F
threshold 0 NOUN F
for 0 ADP F
this 0 DET F
response 0 NOUN F
. 0 PUNCT F

Gain 0 NOUN T
was 0 VERB F
defined 0 VERB F
by 0 ADP F
the 0 DET F
adjusted 0 ADJ F
core B-PHYSICAL NOUN F
temperature I-PHYSICAL NOUN F
increase 0 NOUN F
required 0 ADV F
to 0 PART F
augment 0 ADV F
sweating 0 SYM F
from 0 ADP F
100 0 NUM F
to 0 ADP F
300 0 NUM F
g.m-2.h-1 0 ADV F
. 0 PUNCT F

degree 0 NOUN F
C-1 0 NOUN T
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
clonidine I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
were 0 VERB F
0.8 0 NUM F
+/- 0 SYM F
0.1 0 NUM F
and 0 CCONJ F
1.6 0 NUM F
+/- 0 SYM F
0.2 0 PUNCT F
ng/mL 0 NOUN F
on 0 ADP F
the 0 DET F
small- 0 NOUN F
and 0 CCONJ F
large-dose 0 NOUN F
days 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Clonidine 0 NOUN T
administration 0 NOUN F
increased 0 VERB F
the 0 DET F
sweating 0 PUNCT F
threshold 0 NOUN F
approximately 0 ADV F
0.4 0 NUM F
degree 0 NOUN F
C 0 NOUN T
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
increase 0 NOUN F
was 0 VERB F
comparable 0 ADJ F
at 0 ADP F
each 0 DET F
dose 0 NOUN F
. 0 PUNCT F

The 0 DET T
gain B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
sweating I-PHYSICAL SYM F
was 0 ADV F
approximately 0 ADV F
0.2 0 NUM F
degree 0 NOUN F
C 0 NOUN T
and 0 CCONJ F
was 0 VERB F
not 0 ADV F
influenced 0 VERB F
by 0 ADP F
clonidine 0 NOUN F
administration 0 NOUN F
. 0 PUNCT F

The 0 DET T
thermoregulatory B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
of 0 ADP F
clonidine 0 NOUN F
thus 0 ADP F
resemble 0 VERB F
those 0 PUNCT F
of 0 ADP F
volatile 0 ADJ F
anesthetics 0 NOUN F
, 0 PUNCT F
opioids 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
propofol 0 NOUN F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
antishivering 0 DET F
effect 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
results 0 NOUN F
from 0 ADP F
central 0 ADJ F
thermoregulatory 0 ADJ F
inhibition 0 NOUN F
rather 0 PUNCT F
than 0 ADP F
a 0 DET F
specific 0 ADJ F
peripheral 0 ADJ F
action 0 NOUN F
on 0 ADP F
thermogenic 0 ADJ F
muscular 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

Unlike 0 ADP T
other 0 ADJ F
sedatives 0 ADJ F
and 0 CCONJ F
anesthetics 0 NOUN F
, 0 PUNCT F
the 0 DET F
concentration-dependence 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
demonstrates 0 NOUN F
a 0 DET F
ceiling 0 PUNCT F
beyond 0 ADP F
which 0 ADP F
the 0 DET F
administration 0 NOUN F
of 0 ADP F
an 0 DET F
additional 0 ADJ F
drug 0 NOUN F
fails 0 NOUN F
to 0 PART F
enhance 0 NOUN F
the 0 DET F
effect 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
that 0 ADP F
the 0 DET F
thermoregulatory 0 ADJ F
effect 0 NOUN F
of 0 ADP F
clonidine 0 NOUN F
may 0 VERB F
be 0 VERB F
limited 0 VERB F
, 0 PUNCT F
even 0 ADV F
at 0 ADP F
high 0 ADJ F
plasma 0 NOUN F
concentrations 0 NOUN F
. 0 PUNCT F

The 0 DET T
gain 0 NOUN F
of 0 ADP F
sweating 0 ADP F
was 0 VERB F
well 0 VERB F
preserved 0 CCONJ F
indicating 0 VERB F
that 0 ADP F
this 0 DET F
response 0 NOUN F
remains 0 NOUN F
effective 0 ADJ F
in 0 ADP F
the 0 DET F
presence 0 NOUN F
of 0 ADP F
sedatives 0 ADV F
and 0 CCONJ F
anesthetics 0 NOUN F
. 0 PUNCT F

Coagulation 0 NOUN T
factor 0 NOUN F
concentrate 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
the 0 DET F
haemorrhagic B-PHYSICAL ADJ F
diathesis I-PHYSICAL NOUN F
of 0 ADP F
fulminant 0 ADJ F
hepatic 0 ADJ F
failure 0 NOUN F
. 0 PUNCT F

To 0 PART T
assess 0 NOUN F
the 0 DET F
value 0 NOUN F
of 0 ADP F
clotting 0 VERB F
factor 0 NOUN F
concentrate 0 VERB F
infusions 0 NOUN F
in 0 ADP F
fulminant 0 ADJ F
hepatic B-PHYSICAL ADJ F
failure I-PHYSICAL NOUN F
, 0 PUNCT F
a 0 DET F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
performed 0 VERB F
in 0 ADP F
which 0 DET F
nine 0 DET F
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 ADP F
treatment 0 NOUN F
with 0 ADP F
either 0 CCONJ F
concentrate 0 ADJ F
alone 0 ADJ F
or 0 CCONJ F
concentrate 0 NOUN F
plus 0 CCONJ F
heparin 0 NOUN F
. 0 PUNCT F

The 0 DET T
five 0 NUM F
patients 0 NOUN F
receiving 0 CCONJ F
concentrate 0 ADV F
alone 0 PUNCT F
all 0 PUNCT F
died B-MORTALITY ADP F
, 0 PUNCT F
with 0 ADP F
major B-ADVERSE-EFFECTS ADJ F
bleeding I-ADVERSE-EFFECTS VERB F
as 0 ADP F
the 0 DET F
direct 0 ADJ F
cause 0 ADJ F
of 0 ADP F
death 0 NOUN F
in 0 ADP F
three 0 NUM F
, 0 PUNCT F
whereas 0 CCONJ F
in 0 ADP F
the 0 DET F
four 0 PUNCT F
receiving 0 VERB F
heparin 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
only 0 ADV F
one 0 NUM F
instance 0 NOUN F
of 0 ADP F
bleeding B-ADVERSE-EFFECTS VERB F
and 0 CCONJ F
one 0 NUM F
patient 0 NOUN F
survived B-MORTALITY PUNCT F
. 0 PUNCT F

Clinical 0 ADJ T
evidence 0 NOUN F
of 0 ADP F
intravascular B-PHYSICAL PUNCT F
coagulation I-PHYSICAL NOUN F
appeared 0 VERB F
in 0 ADP F
two 0 NUM F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
concentrate 0 NOUN F
alone 0 ADJ F
and 0 CCONJ F
the 0 DET F
laboratory 0 NOUN F
evidence 0 NOUN F
of 0 ADP F
this 0 PUNCT F
progressed 0 VERB F
during 0 ADP F
the 0 DET F
period 0 NOUN F
of 0 ADP F
infusions 0 NOUN F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
in 0 ADP F
both 0 CCONJ F
treatment 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
although 0 ADP F
to 0 ADP F
a 0 DET F
lesser 0 PUNCT F
extent 0 NOUN F
in 0 ADP F
those 0 PUNCT F
receiving 0 VERB F
heparin 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
evidence 0 NOUN F
for 0 ADP F
intravascular 0 PUNCT F
coagulation 0 NOUN F
came 0 VERB F
from 0 ADP F
the 0 DET F
changes 0 NOUN F
observed 0 VERB F
in 0 ADP F
factor 0 NOUN F
VIII 0 NUM T
levels 0 NOUN F
which 0 ADP F
, 0 PUNCT F
although 0 ADP F
initially 0 ADV F
high 0 ADJ F
in 0 ADP F
all 0 DET F
patients 0 NOUN F
, 0 PUNCT F
fell 0 ADP F
subsequently 0 ADV F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
those 0 DET F
given 0 VERB F
concentrate 0 ADV F
alone 0 ADJ F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
some 0 DET F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
prothrombin B-PHYSICAL NOUN F
ratio I-PHYSICAL NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
of 0 ADP F
patients 0 NOUN F
but 0 CCONJ F
not 0 ADV F
complete 0 ADJ F
correction 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
serial 0 ADJ F
assays 0 NOUN F
of 0 ADP F
clotting 0 PROPN F
factors 0 NOUN F
showed 0 VERB F
that 0 ADP F
although 0 ADP F
factor 0 NOUN F
II B-PHYSICAL NUM T
rose 0 CCONJ F
to 0 ADP F
high 0 ADJ F
levels 0 NOUN F
during 0 ADP F
treatment 0 NOUN F
, 0 PUNCT F
factors B-PHYSICAL NOUN F
IX I-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
X I-PHYSICAL NUM T
showed 0 VERB F
little 0 DET F
response 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
concentrate 0 NOUN F
of 0 ADP F
factor 0 NOUN F
IX 0 NUM T
in 0 ADP F
this 0 DET F
trial 0 NOUN F
, 0 PUNCT F
as 0 CCONJ F
well 0 PUNCT F
as 0 CCONJ F
potentiating 0 PUNCT F
intravascular B-PHYSICAL ADJ F
coagulation I-PHYSICAL NOUN F
, 0 PUNCT F
was 0 VERB F
inadequate 0 ADJ F
as 0 VERB F
replacement 0 NOUN F
for 0 ADP F
the 0 DET F
clotting 0 VERB F
factor 0 NOUN F
deficiencies 0 NOUN F
. 0 PUNCT F

Maternal 0 ADJ T
breast-milk 0 NOUN F
and 0 CCONJ F
intestinal 0 ADJ F
bifidobacteria 0 NOUN F
guide 0 VERB F
the 0 DET F
compositional 0 ADJ F
development 0 NOUN F
of 0 ADP F
the 0 DET F
Bifidobacterium 0 NOUN T
microbiota 0 NOUN F
in 0 ADP F
infants 0 NOUN F
at 0 ADP F
risk 0 NOUN F
of 0 ADP F
allergic 0 ADJ F
disease 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
sources 0 NOUN F
and 0 CCONJ F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
maternal 0 ADJ F
bacteria 0 NOUN F
on 0 ADP F
the 0 DET F
initial 0 ADJ F
inoculum 0 NOUN F
of 0 ADP F
the 0 DET F
intestinal 0 ADJ F
microflora 0 NOUN F
of 0 ADP F
newborn 0 NOUN F
infants 0 NOUN F
remain 0 VERB F
elusive 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
the 0 DET F
association 0 NOUN F
between 0 ADP F
maternal 0 ADJ F
breast-milk 0 NOUN F
and 0 CCONJ F
fecal 0 ADJ F
bifidobacteria 0 NOUN F
and 0 CCONJ F
infants 0 NOUN F
' 0 PUNCT F
fecal 0 ADJ F
bifidobacteria 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty-one 0 ADJ T
mother-infant 0 NOUN F
pairs 0 NOUN F
were 0 VERB F
included 0 VERB F
, 0 PUNCT F
special 0 ADJ F
emphasis 0 NOUN F
being 0 VERB F
placed 0 VERB F
on 0 ADP F
the 0 DET F
maternal 0 ADJ F
allergic 0 ADJ F
status 0 NOUN F
. 0 PUNCT F

Bifidobacteria B-PHYSICAL ADV T
were 0 VERB F
analysed 0 VERB F
by 0 ADP F
a 0 DET F
direct 0 ADJ F
PCR 0 NOUN T
method 0 NOUN F
in 0 ADP F
fecal 0 ADJ F
samples 0 NOUN F
from 0 ADP F
mothers 0 NOUN F
at 0 ADP F
30-35 0 NUM F
weeks 0 NOUN F
of 0 ADP F
gestation 0 NOUN F
and 0 CCONJ F
from 0 ADP F
infants 0 NOUN F
at 0 ADP F
1 0 NUM F
month 0 NOUN F
of 0 ADP F
age 0 NOUN F
and 0 CCONJ F
from 0 ADP F
breast-milk 0 ADJ F
samples 0 NOUN F
1 0 NUM F
month 0 NOUN F
post-partum 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Fecal 0 ADJ T
Bifidobacterium 0 NOUN T
adolescentis 0 NOUN F
and 0 CCONJ F
Bifidobacterium 0 NOUN T
bifidum 0 PUNCT F
colonization 0 NOUN F
frequencies 0 NOUN F
and 0 CCONJ F
counts 0 NOUN F
among 0 ADP F
mother-infant 0 NOUN F
pairs 0 NOUN F
correlated 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
P=0.005 0 NOUN T
and 0 CCONJ F
0.02 0 NUM F
for 0 ADP F
frequencies 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
P=0.002 0 NOUN T
and 0 CCONJ F
0.01 0 NUM F
for 0 ADP F
counts 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

Only 0 DET T
infants 0 NOUN F
of 0 ADP F
allergic 0 ADJ F
, 0 PUNCT F
atopic 0 ADJ F
mothers 0 NOUN F
were 0 VERB F
colonized 0 VERB F
with 0 ADP F
B. 0 NOUN T
adolescentis 0 NOUN F
. 0 PUNCT F

Each 0 PUNCT T
of 0 ADP F
the 0 DET F
breast-milk 0 ADJ F
samples 0 NOUN F
contained 0 VERB F
bifidobacteria 0 NOUN F
[ 0 PUNCT F
median 0 ADJ F
1.4 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
bacterial 0 ADJ F
cells/mL 0 NOUN F
; 0 PUNCT F
interquartile 0 NOUN F
range 0 NOUN F
( 0 PUNCT F
IQR 0 NOUN T
) 0 PUNCT F
48.7-3.8 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

Bifidobacterium B-PHYSICAL NOUN T
longum I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
most 0 PUNCT F
frequently 0 ADV F
detected 0 ADJ F
species 0 DET F
in 0 ADP F
breast-milk 0 NOUN F
. 0 PUNCT F

Allergic 0 ADJ T
mothers 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
lower 0 PUNCT F
amounts 0 NOUN F
of 0 ADP F
bifidobacteria B-PHYSICAL NOUN F
in 0 ADP F
breast-milk 0 NOUN F
compared 0 VERB F
with 0 ADP F
non-allergic 0 ADJ F
mothers 0 NOUN F
[ 0 PUNCT F
median 0 ADJ F
1.3 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
bacterial 0 ADJ F
cells/mL 0 NOUN F
( 0 PUNCT F
IQR 0 NOUN T
22.4-3.0 0 PUNCT F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
vs. 0 CCONJ F
5.6 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
bacterial 0 ADJ F
cells/mL 0 NOUN F
( 0 PUNCT F
1.8 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
-1.8 0 NUM F
x 0 ADJ F
10 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
( 0 PUNCT F
P=0.004 0 NOUN T
) 0 PUNCT F
] 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
their 0 DET F
infants 0 NOUN F
had 0 PUNCT F
concurrently 0 ADV F
lower 0 ADP F
counts 0 NOUN F
of 0 ADP F
bifidobacteria B-PHYSICAL NOUN F
in 0 ADP F
feces 0 NOUN F
[ 0 PUNCT F
3.9 0 ADP F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
bacterial 0 ADJ F
cells/g 0 NOUN F
( 0 PUNCT F
IQR 0 NOUN T
6.5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
6 0 NUM F
) 0 PUNCT F
-1.5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
infants 0 NOUN F
of 0 ADP F
allergic 0 ADJ F
mothers 0 NOUN F
, 0 PUNCT F
vs. 0 CCONJ F
2.5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
bacterial 0 ADJ F
cells/g 0 NOUN F
( 0 PUNCT F
6.5 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
-3.2 0 ADP F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
10 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
in 0 ADP F
infants 0 NOUN F
of 0 ADP F
non-allergic 0 ADJ F
mothers 0 NOUN F
, 0 PUNCT F
P=0.013 0 NOUN T
] 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Breast-milk 0 ADJ T
contains 0 VERB F
significant 0 ADJ F
numbers 0 NOUN F
of 0 ADP F
bifidobacteria 0 NOUN F
and 0 CCONJ F
the 0 DET F
maternal 0 ADJ F
allergic 0 ADJ F
status 0 NOUN F
further 0 DET F
deranges 0 VERB F
the 0 DET F
counts 0 NOUN F
of 0 ADP F
bifidobacteria 0 NOUN F
in 0 ADP F
breast-milk 0 NOUN F
. 0 PUNCT F

Maternal 0 ADJ T
fecal 0 ADJ F
and 0 CCONJ F
breast-milk 0 NOUN F
bifidobacterial 0 ADP F
counts 0 NOUN F
impacted 0 VERB F
on 0 ADP F
the 0 DET F
infants 0 NOUN F
' 0 PUNCT F
fecal 0 ADJ F
Bifidobacterium 0 NOUN T
levels 0 NOUN F
. 0 PUNCT F

Breast-milk 0 ADV T
bacteria 0 NOUN F
should 0 SYM F
thus 0 ADV F
be 0 PUNCT F
considered 0 VERB F
an 0 DET F
important 0 ADJ F
source 0 NOUN F
of 0 ADP F
bacteria 0 NOUN F
in 0 ADP F
the 0 DET F
establishment 0 NOUN F
of 0 ADP F
infantile 0 ADJ F
intestinal 0 ADJ F
microbiota 0 NOUN F
. 0 PUNCT F

Psychoeducational 0 ADJ T
group 0 NOUN F
intervention 0 NOUN F
for 0 ADP F
wives 0 PUNCT F
of 0 ADP F
men 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
effects 0 NOUN F
of 0 ADP F
a 0 DET F
6-week 0 NOUN F
psychoeducational 0 ADJ F
group 0 NOUN F
intervention 0 NOUN F
on 0 ADP F
the 0 DET F
distress 0 NOUN F
, 0 PUNCT F
coping 0 ADP F
, 0 PUNCT F
personal 0 ADJ F
growth 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
marital 0 ADJ F
communication 0 NOUN F
of 0 ADP F
wives 0 PUNCT F
of 0 ADP F
men 0 NOUN F
diagnosed 0 VERB F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
using 0 VERB F
a 0 DET F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty 0 PUNCT T
wives 0 PUNCT F
completed 0 ADV F
measures 0 NOUN F
prior 0 PUNCT F
to 0 ADP F
random 0 ADJ F
assignment 0 NOUN F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
psychoeducational 0 ADJ F
group 0 NOUN F
intervention 0 NOUN F
or 0 CCONJ F
a 0 DET F
no-treatment 0 NOUN F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
month 0 NOUN F
after 0 ADP F
completion 0 NOUN F
of 0 ADP F
the 0 DET F
group 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
No 0 DET T
differences 0 NOUN F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
wives 0 PUNCT F
' 0 PUNCT F
general B-MENTAL ADJ F
distress I-MENTAL NOUN F
or 0 CCONJ F
cancer-specific B-MENTAL ADJ F
distress I-MENTAL NOUN F
were 0 VERB F
noted 0 VERB F
. 0 PUNCT F

In 0 ADP T
comparison 0 NOUN F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
participants 0 NOUN F
receiving 0 VERB F
the 0 DET F
intervention 0 NOUN F
perceived 0 CCONJ F
that 0 ADP F
having 0 VERB F
a 0 DET F
spouse 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
had 0 PUNCT F
made 0 PUNCT F
positive 0 ADJ F
contributions 0 NOUN F
to 0 ADP F
their 0 PUNCT F
lives 0 NOUN F
, 0 PUNCT F
reported 0 ADP F
gains 0 NOUN F
in 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
positive 0 ADJ F
reappraisal B-MENTAL ADJ F
coping I-MENTAL PUNCT F
and 0 CCONJ F
reductions 0 NOUN F
in 0 ADP F
denial B-MENTAL ADJ F
coping I-MENTAL DET F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Although 0 ADP T
the 0 DET F
psychoeducational 0 ADJ F
intervention 0 NOUN F
did 0 DET F
not 0 ADV F
result 0 VERB F
in 0 ADP F
changes 0 NOUN F
in 0 ADP F
psychological B-MENTAL ADJ F
distress I-MENTAL NOUN F
, 0 PUNCT F
improvements 0 ADJ F
in 0 ADP F
adaptive B-MENTAL ADJ F
coping I-MENTAL PUNCT F
and 0 CCONJ F
indicators B-MENTAL NOUN F
of I-MENTAL ADP F
psychological I-MENTAL ADJ F
growth I-MENTAL NOUN F
were 0 VERB F
found 0 VERB F
. 0 PUNCT F

The 0 DET T
utility 0 NOUN F
of 0 ADP F
group 0 NOUN F
interventions 0 NOUN F
for 0 ADP F
spouses 0 NOUN F
of 0 ADP F
men 0 NOUN F
with 0 ADP F
prostate 0 NOUN F
cancer 0 NOUN F
is 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

Study 0 NOUN T
of 0 ADP F
the 0 DET F
therapeutic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
hippotherapy 0 CCONJ F
simulator 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
cerebral 0 ADJ F
palsy 0 NOUN F
: 0 PUNCT F
a 0 DET F
stratified 0 ADJ F
single-blind 0 NOUN F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 ADJ F
whether 0 ADP F
hippotherapy 0 CCONJ F
( 0 PUNCT F
when 0 ADP F
applied 0 VERB F
by 0 ADP F
a 0 DET F
simulator 0 NOUN F
) 0 PUNCT F
improves 0 NOUN F
postural 0 ADJ F
control 0 NOUN F
and 0 CCONJ F
balance 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
cerebral 0 ADJ F
palsy 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Stratified 0 PUNCT T
single-blind 0 NOUN F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
with 0 ADP F
an 0 DET F
independent 0 ADJ F
assessor 0 NOUN F
. 0 PUNCT F

Stratification 0 NOUN T
was 0 VERB F
made 0 VERB F
by 0 ADP F
gross 0 ADJ F
motor 0 NOUN F
function 0 VERB F
classification 0 NOUN F
system 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
allocation 0 NOUN F
was 0 VERB F
concealed 0 PUNCT F
. 0 PUNCT F

SUBJECTS 0 NOUN T
Children 0 PROPN T
between 0 ADP F
4 0 NUM F
and 0 CCONJ F
18 0 NUM F
years 0 NOUN F
old 0 ADJ F
with 0 ADP F
cerebral 0 ADJ F
palsy 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
an 0 DET F
intervention 0 NOUN F
( 0 PUNCT F
simulator 0 NOUN F
ON 0 PUNCT T
) 0 PUNCT F
or 0 CCONJ F
control 0 NOUN F
( 0 PUNCT F
simulator 0 NOUN F
OFF 0 ADP T
) 0 PUNCT F
group 0 NOUN F
after 0 ADP F
getting 0 VERB F
informed 0 VERB F
consent 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
was 0 VERB F
provided 0 PROPN F
once 0 PUNCT F
a 0 DET F
week 0 NOUN F
( 0 PUNCT F
15 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
for 0 ADP F
10 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
MEASURES 0 NOUN T
Gross B-PHYSICAL ADJ T
Motor I-PHYSICAL NOUN T
Function I-PHYSICAL NOUN T
Measure I-PHYSICAL NOUN T
( 0 PUNCT F
dimension B-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
for I-PHYSICAL ADP F
balance I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
the I-PHYSICAL DET F
Total 0 ADJ T
Score 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
Sitting B-PHYSICAL PUNCT T
Assessment I-PHYSICAL NOUN T
Scale I-PHYSICAL NOUN T
were 0 VERB F
carried 0 VERB F
out 0 ADP F
at 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
prior 0 PUNCT F
to 0 ADP F
randomization 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
end 0 NOUN F
of 0 ADP F
intervention 0 NOUN F
and 0 CCONJ F
12 0 NUM F
weeks 0 NOUN F
after 0 ADP F
completing 0 VERB F
the 0 DET F
intervention 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-eight 0 PUNCT T
children 0 NOUN F
participated 0 VERB F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
were 0 VERB F
balanced 0 VERB F
at 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Sitting B-PHYSICAL ADP T
balance I-PHYSICAL NOUN F
( 0 PUNCT F
measured 0 PROPN F
by 0 ADP F
dimension 0 NOUN F
B 0 NOUN T
of 0 ADP F
the 0 DET F
Gross 0 ADJ T
Motor 0 NOUN T
Function 0 NOUN T
Measure 0 NOUN T
) 0 PUNCT F
improved 0 VERB F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
effect 0 NOUN F
size 0 NOUN F
= 0 SYM F
0.36 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.01-0.71 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
effect 0 NOUN F
size 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
severely 0 PROPN F
disabled 0 DET F
group 0 NOUN F
( 0 PUNCT F
effect 0 NOUN F
size 0 NOUN F
= 0 SYM F
0.80 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
0.13-1.47 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
improvements 0 NOUN F
in 0 ADP F
sitting B-PHYSICAL ADV F
balance I-PHYSICAL NOUN F
were 0 VERB F
not 0 ADV F
maintained 0 VERB F
over 0 ADP F
the 0 DET F
follow-up 0 NOUN F
period 0 NOUN F
. 0 PUNCT F

Changes 0 NOUN T
in 0 ADP F
the 0 DET F
total 0 ADJ F
score 0 NOUN F
of 0 ADP F
the B-PHYSICAL DET F
Gross I-PHYSICAL ADJ T
Motor I-PHYSICAL NOUN T
Function I-PHYSICAL NUM T
Measure I-PHYSICAL NOUN T
and 0 CCONJ F
the 0 DET F
Sitting B-PHYSICAL PUNCT T
Assessment I-PHYSICAL NOUN T
Scale I-PHYSICAL NOUN T
were 0 VERB F
not 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Hippotherapy 0 CCONJ T
with 0 ADP F
a 0 DET F
simulator 0 NOUN F
can 0 VERB F
improve 0 VERB F
sitting B-PHYSICAL ADP F
balance I-PHYSICAL NOUN F
in 0 ADP F
cerebral 0 ADJ F
palsy 0 NOUN F
children 0 NOUN F
who 0 DET F
have 0 PUNCT F
higher 0 PUNCT F
levels 0 NOUN F
of 0 ADP F
disability 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
this 0 PUNCT F
did 0 PUNCT F
not 0 ADV F
lead 0 VERB F
to 0 ADP F
a 0 DET F
change 0 NOUN F
in 0 ADP F
the 0 DET F
overall 0 ADJ F
function 0 NOUN F
of 0 ADP F
these 0 DET F
children 0 NOUN F
( 0 PUNCT F
Gross 0 ADJ T
Motor 0 NOUN T
Function 0 NOUN T
Classification 0 NOUN T
System 0 NOUN T
level 0 NOUN F
V 0 NUM T
) 0 PUNCT F
. 0 PUNCT F

[ 0 PUNCT F
Clinical 0 ADJ T
observation 0 NOUN F
on 0 ADP F
different 0 ADJ F
acupuncture 0 ADP F
and 0 CCONJ F
moxibustion 0 NOUN F
therapies 0 NOUN F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
postsurgical 0 ADJ F
gastroparesis 0 NOUN F
syndrome 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
optimize 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
acupuncture 0 ADP F
and 0 CCONJ F
moxibustion 0 NOUN F
for 0 ADP F
postsurgical 0 ADJ F
gastroparesis 0 NOUN F
syndrome 0 NOUN F
( 0 PUNCT F
PGS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Forty-one 0 NUM T
cases 0 NOUN F
of 0 ADP F
PGS 0 NOUN T
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
3 0 NUM F
groups 0 NOUN F
in 0 ADP F
order 0 NOUN F
of 0 ADP F
visiting 0 NUM F
. 0 PUNCT F

Group 0 NOUN T
A 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
by 0 ADP F
warming 0 VERB F
needle 0 NOUN F
moxibustion 0 NOUN F
, 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
by 0 ADP F
acupuncture 0 ADP F
plus 0 CCONJ F
auricular 0 ADJ F
point 0 NOUN F
sticking 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
group 0 NOUN F
C 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
by 0 ADP F
routine 0 ADJ F
acupuncture 0 ADP F
. 0 PUNCT F

Changes 0 NOUN T
of 0 ADP F
gastric B-PHYSICAL ADJ F
drainage I-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
, 0 PUNCT F
therapeutic 0 ADJ F
times 0 NOUN F
and 0 CCONJ F
cured 0 VERB F
rate 0 NOUN F
were 0 VERB F
investigated 0 VERB F
in 0 ADP F
the 0 DET F
3 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 ADP T
All 0 PUNCT T
the 0 DET F
3 0 NUM F
therapeutic 0 ADJ F
methods 0 NOUN F
could 0 ADP F
significantly 0 NOUN F
decrease 0 NOUN F
gastric B-PHYSICAL ADJ F
drainage I-PHYSICAL NOUN F
volume I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
cured B-PHYSICAL PUNCT F
rate I-PHYSICAL NOUN F
was 0 VERB F
100.0 0 CCONJ F
% 0 SYM F
and 0 CCONJ F
the 0 DET F
therapeutic B-PHYSICAL ADJ F
times I-PHYSICAL NOUN F
was 0 VERB F
( 0 PUNCT F
7.24 0 NUM F
+/- 0 SYM F
3.87 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
66.7 0 NUM F
% 0 SYM F
, 0 PUNCT F
( 0 PUNCT F
9.83 0 NUM F
+/- 0 SYM F
4.60 0 NUM F
) 0 PUNCT F
times 0 NOUN F
in 0 ADP F
the 0 DET F
group 0 NOUN F
B 0 NOUN T
and 0 CCONJ F
75.0 0 NUM F
% 0 SYM F
, 0 PUNCT F
( 0 PUNCT F
15.25 0 NUM F
+/- 0 SYM F
3.81 0 NUM F
) 0 PUNCT F
times 0 NOUN F
in 0 ADP F
the 0 DET F
group 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
with 0 ADP F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
cured B-PHYSICAL VERB F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
therapeutic B-PHYSICAL ADJ F
times I-PHYSICAL NOUN F
among 0 ADP F
the 0 DET F
3 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
warming 0 DET F
needle 0 NOUN F
moxibustion 0 NOUN F
is 0 VERB F
the 0 DET F
best 0 PUNCT F
method 0 NOUN F
for 0 ADP F
PGS 0 NOUN T
, 0 PUNCT F
with 0 ADP F
less 0 DET F
therapeutic B-PHYSICAL ADJ F
times I-PHYSICAL NOUN F
, 0 PUNCT F
high 0 ADJ F
cured B-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
rapid 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

Transcutaneous 0 ADJ T
electrical 0 ADJ F
nerve 0 NOUN F
stimulation 0 NOUN F
following 0 VERB F
appendicectomy 0 NOUN F
: 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
effect 0 NOUN F
. 0 PUNCT F

A 0 DET T
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
transcutaneous 0 ADJ F
electrical 0 ADJ F
nerve 0 NOUN F
stimulation 0 NOUN F
( 0 PUNCT F
TENS 0 NOUN T
) 0 PUNCT F
with 0 ADP F
standard 0 ADJ F
intramuscular 0 ADJ F
opiate 0 ADJ F
analgesia 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
postoperative 0 ADJ F
pain 0 NOUN F
following 0 VERB F
appendicectomy 0 NOUN F
. 0 PUNCT F

Consecutive 0 ADJ T
patients 0 NOUN F
undergoing 0 VERB F
emergency 0 NOUN F
appendicectomy 0 NOUN F
were 0 VERB F
randomised 0 VERB F
into 0 ADP F
control 0 NOUN F
, 0 PUNCT F
sham 0 ADJ F
TENS 0 NOUN T
and 0 CCONJ F
active 0 ADJ F
TENS 0 NOUN T
groups 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
pain B-PAIN NOUN F
severity I-PAIN NOUN F
and 0 CCONJ F
analgesic B-OTHER PUNCT F
intake I-OTHER NOUN F
in 0 ADP F
both 0 CCONJ F
active 0 ADJ F
and 0 CCONJ F
sham 0 ADJ F
TENS 0 NOUN T
groups 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
difference 0 NOUN F
was 0 VERB F
demonstrated 0 VERB F
in 0 ADP F
pain B-PAIN NOUN F
severity I-PAIN NOUN F
between 0 ADP F
active 0 ADJ F
and 0 CCONJ F
sham 0 ADJ F
TENS 0 NOUN T
groups 0 NOUN F
but 0 CCONJ F
the 0 DET F
active 0 ADJ F
TENS 0 NOUN T
group 0 NOUN F
required 0 PUNCT F
slightly 0 ADV F
less 0 ADV F
analgesia 0 NOUN F
. 0 PUNCT F

These 0 DET T
results 0 CCONJ F
suggest 0 VERB F
that 0 ADP F
the 0 DET F
major 0 ADJ F
benefit 0 NOUN F
of 0 ADP F
TENS 0 NOUN T
in 0 ADP F
the 0 DET F
postappendicectomy 0 NOUN F
patient 0 NOUN F
is 0 VERB F
due 0 CCONJ F
to 0 ADP F
its 0 PUNCT F
'placebo 0 PUNCT F
effect 0 NOUN F
' 0 PUNCT F
and 0 CCONJ F
its 0 PUNCT F
use 0 NOUN F
in 0 ADP F
this 0 DET F
situation 0 NOUN F
can 0 VERB F
not 0 ADV F
be 0 VERB F
recommended 0 VERB F
. 0 PUNCT F

Is 0 PUNCT T
a 0 DET F
calculated 0 VERB F
total 0 ADJ F
hip 0 NOUN F
BMD 0 NOUN T
of 0 ADP F
clinical B-OTHER ADJ F
use I-OTHER NOUN F
? 0 PUNCT F

The 0 DET T
diagnosis 0 NOUN F
of 0 ADP F
osteoporosis 0 NOUN F
is 0 VERB F
based 0 VERB F
on 0 ADP F
bone 0 NOUN F
mass 0 NOUN F
measurement 0 NOUN F
. 0 PUNCT F

To 0 DET T
avoid 0 NOUN F
the 0 DET F
errors 0 NOUN F
associated 0 VERB F
with 0 ADP F
the 0 DET F
measurement 0 NOUN F
of 0 ADP F
spinal 0 ADJ F
bone 0 NOUN F
density 0 NOUN F
the 0 DET F
total 0 ADJ F
hip 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
accepted 0 VERB F
as 0 ADP F
the 0 DET F
standard 0 ADJ F
measurement 0 NOUN F
site 0 NOUN F
. 0 PUNCT F

This 0 DET T
information 0 NOUN F
is 0 VERB F
not 0 ADV F
available 0 ADJ F
for 0 ADP F
many 0 CCONJ F
early 0 ADJ F
measurements 0 NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 ADP F
assessed 0 VERB F
whether 0 PUNCT F
it 0 PRON F
is 0 VERB F
possible 0 ADJ F
to 0 PART F
derive 0 ADJ F
clinically 0 ADV F
useful 0 ADJ F
information 0 NOUN F
about 0 PUNCT F
total 0 ADJ F
hip 0 NOUN F
bone 0 NOUN F
mineral 0 NOUN F
density 0 NOUN F
( 0 PUNCT F
BMD 0 NOUN T
) 0 PUNCT F
from 0 ADP F
measurements 0 NOUN F
at 0 ADP F
other 0 ADJ F
hip 0 NOUN F
sites 0 NOUN F
. 0 PUNCT F

The 0 DET T
bone 0 NOUN F
mass 0 NOUN F
measurements 0 NOUN F
of 0 ADP F
46 0 NUM F
patients 0 NOUN F
participating 0 VERB F
in 0 ADP F
a 0 DET F
current 0 ADJ F
trial 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
for 0 ADP F
osteoporosis 0 NOUN F
were 0 VERB F
reviewed 0 VERB F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
hip B-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
as 0 PUNCT F
directly 0 VERB F
measured 0 PUNCT F
was 0 VERB F
compared 0 VERB F
with 0 ADP F
that 0 PUNCT F
obtained 0 VERB F
from 0 ADP F
the 0 DET F
formula 0 NOUN F
: 0 PUNCT F
Total 0 ADJ T
hip B-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
= 0 SYM F
0.48 0 NUM F
x 0 SYM F
Neck B-PHYSICAL NOUN T
BMD I-PHYSICAL NOUN T
+ 0 SYM F
0.62 0 NUM F
x 0 SYM F
Trochanteric B-PHYSICAL NOUN T
BMD I-PHYSICAL NOUN T
+ 0 SYM F
0.03 0 NUM F
. 0 PUNCT F

In 0 ADP T
30 0 NUM F
patients 0 NOUN F
with 0 ADP F
follow-up 0 NOUN F
data 0 NOUN F
the 0 DET F
rate 0 NOUN F
of 0 ADP F
change B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
hip I-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
over 0 ADP F
a 0 DET F
year 0 NOUN F
was 0 VERB F
also 0 ADV F
determined 0 VERB F
by 0 ADP F
both 0 PUNCT F
methods 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
pretreatment 0 NOUN F
state 0 NOUN F
there 0 PUNCT F
was 0 VERB F
good 0 ADJ F
agreement 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
measures 0 NOUN F
( 0 PUNCT F
r2 0 NOUN F
= 0 SYM F
0.96 0 NUM F
, 0 PUNCT F
SEE 0 NOUN T
0.012 0 NUM F
g/cm2 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

If 0 PUNCT T
the 0 DET F
formula 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 ADJ F
compute 0 NOUN F
a 0 DET F
change 0 NOUN F
in 0 ADP F
total 0 ADJ F
hip B-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
, 0 PUNCT F
the 0 DET F
agreement 0 NOUN F
between 0 ADP F
both 0 PUNCT F
methods 0 NOUN F
remained 0 ADP F
good 0 ADJ F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
standard 0 ADJ F
error 0 NOUN F
of 0 ADP F
the 0 DET F
estimate 0 NOUN F
of 0 ADP F
the 0 DET F
change 0 NOUN F
represented 0 ADP F
59 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
observed 0 PUNCT F
change 0 NOUN F
. 0 PUNCT F

This 0 DET T
indicates 0 NOUN F
that 0 ADP F
the 0 DET F
error 0 NOUN F
associated 0 VERB F
with 0 ADP F
this 0 DET F
estimate 0 NOUN F
is 0 VERB F
too 0 ADV F
great 0 ADJ F
to 0 PART F
allow 0 ADJ F
clinically 0 ADJ F
meaningful 0 ADJ F
conclusions 0 NOUN F
to 0 PART F
be 0 PUNCT F
drawn 0 VERB F
from 0 ADP F
calculated B-PHYSICAL VERB F
total 0 ADJ F
hip B-PHYSICAL NOUN F
BMD B-PHYSICAL NOUN T
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
, 0 PUNCT F
whilst 0 CCONJ F
it 0 PRON F
may 0 VERB F
be 0 VERB F
possible 0 ADJ F
to 0 PART F
obtain 0 NOUN F
reasonable 0 ADJ F
point 0 NOUN F
estimates 0 NOUN F
of 0 ADP F
total 0 ADJ F
hip B-PHYSICAL NOUN F
BMD I-PHYSICAL NOUN T
from 0 ADP F
other 0 ADJ F
measures 0 NOUN F
in 0 ADP F
the 0 DET F
hip 0 NOUN F
, 0 PUNCT F
these 0 DET F
estimates 0 NOUN F
are 0 PROPN F
too 0 ADV F
imprecise 0 PUNCT F
to 0 PART F
allow 0 NOUN F
conclusions 0 NOUN F
about 0 PUNCT F

Autism-Spectrum 0 NOUN T
Quotient-Japanese 0 ADV T
version 0 NOUN F
and 0 CCONJ F
its 0 ADJ F
short 0 ADJ F
forms 0 NOUN F
for 0 ADP F
screening 0 PUNCT F
normally 0 ADP F
intelligent 0 VERB F
persons 0 NOUN F
with 0 ADP F
pervasive 0 ADJ F
developmental 0 ADJ F
disorders 0 NOUN F
. 0 PUNCT F

A 0 DET T
Japanese 0 ADJ T
version 0 NOUN F
of 0 ADP F
the 0 DET F
Autism 0 NOUN T
Spectrum 0 NOUN T
Quotient 0 NOUN T
( 0 PUNCT F
AQ 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
AQ-J 0 NOUN T
was 0 VERB F
administered 0 VERB F
to 0 ADP F
25 0 NUM F
normally 0 ADV F
intelligent 0 PUNCT F
high-functioning 0 ADP F
pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
( 0 PUNCT F
HPDD 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
24.2 0 NUM F
years 0 NOUN F
; 0 PUNCT F
24 0 NUM F
male 0 NOUN F
, 0 PUNCT F
one 0 NUM F
female 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
215 0 NUM F
controls 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
30.4 0 NUM F
years 0 NOUN F
; 0 PUNCT F
86 0 NUM F
male 0 NOUN F
, 0 PUNCT F
129 0 NUM F
female 0 NOUN F
) 0 PUNCT F
randomly 0 ADV F
selected 0 VERB F
from 0 ADP F
the 0 DET F
general 0 ADJ F
population 0 NOUN F
. 0 PUNCT F

The 0 DET T
AQ-J 0 NOUN T
had 0 PUNCT F
satisfactory B-OTHER ADJ F
internal I-OTHER ADJ F
consistency 0 NOUN F
reliability B-OTHER NOUN F
( 0 PUNCT F
Cronbach 0 NOUN T
's 0 PUNCT F
alpha 0 NOUN F
> 0 SYM F
0.70 0 NUM F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
test-retest B-OTHER ADV F
reliability I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
discriminant B-OTHER NOUN F
validity B-OTHER NOUN F
[ 0 PUNCT F
i.e 0 ADV F
. 0 PUNCT F

the 0 DET F
AQ-J 0 NOUN T
score 0 NOUN F
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
HPDD 0 NOUN T
( 0 PUNCT F
mean 0 NOUN F
, 0 PUNCT F
29.6 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
controls 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
, 0 PUNCT F
22.2 0 NUM F
) 0 PUNCT F
] 0 PUNCT F
. 0 PUNCT F

At 0 ADP T
a 0 DET F
cut-off 0 NOUN F
of 0 ADP F
26 0 NUM F
, 0 PUNCT F
the 0 DET F
AQ-J B-PHYSICAL NOUN T
had 0 PUNCT F
satisfactory B-OTHER ADJ F
sensitivity I-OTHER NOUN F
, 0 PUNCT F
specificity 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
negative 0 ADJ F
predictive B-OTHER ADJ F
value I-OTHER NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
had 0 PUNCT F
low B-OTHER ADJ F
positive 0 ADJ F
predictive B-OTHER ADJ F
value I-OTHER NOUN F
( 0 PUNCT F
0.24 0 NUM F
) 0 PUNCT F
possibly 0 ADV F
due 0 CCONJ F
to 0 ADP F
the 0 DET F
facts 0 NOUN F
that 0 ADP F
the 0 DET F
25 0 NUM F
mild 0 ADJ F
HPDD 0 NOUN T
patients 0 NOUN F
scored 0 DET F
lower 0 VERB F
and 0 CCONJ F
the 0 DET F
controls 0 NOUN F
scored 0 PUNCT F
higher 0 PUNCT F
on 0 ADP F
the 0 DET F
AQ-J 0 NOUN T
than 0 PUNCT F
British 0 NOUN T
counterparts 0 NOUN F
on 0 ADP F
the 0 DET F
AQ 0 NOUN T
. 0 PUNCT F

The 0 DET T
AQ-J-21 B-PHYSICAL NOUN T
( B-PHYSICAL PUNCT F
consisting B-PHYSICAL PUNCT F
of I-PHYSICAL ADP F
21 B-PHYSICAL NUM F
items I-PHYSICAL PUNCT F

Long-term 0 NOUN T
evaluation 0 NOUN F
of 0 ADP F
tamsulosin 0 NOUN F
in 0 ADP F
benign 0 ADJ F
prostatic 0 ADJ F
hyperplasia 0 NOUN F
: 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
extension 0 NOUN F
of 0 ADP F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
. 0 PUNCT F

Tamsulosin 0 NOUN T
Investigator 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
long-term 0 NOUN F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
once-daily 0 NOUN F
tamsulosin 0 NOUN F
( 0 PUNCT F
0.4 0 NUM F
and 0 CCONJ F
0.8 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
unique 0 ADJ F
selective 0 ADJ F
alpha1A-adrenoceptor 0 NOUN F
antagonist 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
benign 0 ADJ F
prostatic 0 ADJ F
hyperplasia 0 NOUN F
( 0 PUNCT F
BPH 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
trial 0 NOUN F
extended 0 CCONJ F
a 0 DET F
13-week 0 NOUN F
, 0 PUNCT F
Phase 0 NOUN T
III 0 NUM T
multicenter 0 NOUN F
placebo-controlled 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
outpatient 0 ADJ F
trial 0 NOUN F
for 0 ADP F
an 0 DET F
additional 0 ADJ F
40 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
618 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
418 0 NUM F
( 0 PUNCT F
68 0 NUM F
% 0 SYM F
) 0 PUNCT F
continued 0 VERB F
into 0 ADP F
the 0 DET F
extension 0 NOUN F
phase 0 NOUN F
on 0 ADP F
the 0 DET F
same 0 ADJ F
double-blind 0 ADJ F
medication 0 NOUN F
and 0 CCONJ F
dose 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
efficacy 0 NOUN F
parameters 0 NOUN F
were 0 VERB F
total 0 ADJ F
American B-PHYSICAL ADJ T
Urological I-PHYSICAL ADJ T
Association 0 NOUN T
( B-PHYSICAL PUNCT F
AUA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
symptom B-PHYSICAL NOUN F
score 0 NOUN F
and 0 CCONJ F
maximum B-PHYSICAL NOUN F
urinary I-PHYSICAL ADJ F
flow I-PHYSICAL NOUN F
( B-PHYSICAL PUNCT F
Qmax I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
mean 0 NOUN F
changes 0 NOUN F
in 0 ADP F
AUA B-PHYSICAL NOUN T
symptom B-PHYSICAL NOUN F
score B-PHYSICAL NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
end 0 NOUN F
point 0 NOUN F
were 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
in 0 ADP F
all 0 DET F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Significant 0 ADJ T
improvements 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
Qmax B-PHYSICAL NOUN T
for 0 ADP F
both 0 CCONJ F
tamsulosin 0 NOUN F
groups 0 NOUN F
but 0 CCONJ F
not 0 ADV F
for 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
statistically 0 ADJ F
significant B-PHYSICAL ADJ F
improvements B-OTHER NOUN F
from 0 ADP F
baseline 0 NOUN F
in 0 ADP F
efficacy 0 NOUN F
parameters 0 NOUN F
observed 0 VERB F
for 0 ADP F
each 0 DET F
tamsulosin 0 NOUN F
group 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
13-week 0 ADJ F
Phase 0 NOUN T
III 0 NUM T
trial 0 NOUN F
were 0 VERB F
maintained 0 VERB F
during 0 ADP F
the 0 DET F
long-term 0 NOUN F
extension 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

Tamsulosin 0 NOUN T
at 0 ADP F
both 0 PUNCT F
dosages 0 NOUN F
was 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
as 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Clinically 0 ADV T
significant 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
upper 0 ADJ F
arm 0 NOUN F
brachial 0 ADJ F
basilic 0 NOUN F
and 0 CCONJ F
prosthetic 0 ADJ F
forearm 0 NOUN F
arteriovenous 0 ADJ F
fistula 0 NOUN F
on 0 ADP F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
hypertrophy I-PHYSICAL NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Creation 0 NOUN T
of 0 ADP F
an 0 DET F
arteriovenous 0 PUNCT F
fistula 0 NOUN F
( 0 PUNCT F
AVF 0 NOUN T
) 0 PUNCT F
may 0 ADJ F
increase 0 NUM F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
hypertrophy I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
hemodialysis 0 NOUN F
population 0 NOUN F
. 0 PUNCT F

Aim 0 NOUN T
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
brachial-basilic 0 ADJ F
( 0 PUNCT F
BB 0 NOUN T
) 0 PUNCT F
AVF 0 NOUN T
and 0 CCONJ F
the 0 DET F
prosthetic 0 ADJ F
brachial-antecubital 0 ADJ F
forearm 0 NOUN F
loop 0 NOUN F
access 0 NOUN F
( 0 PUNCT F
PTFE 0 NOUN T
) 0 PUNCT F
on 0 ADP F
cardiac B-PHYSICAL ADJ F
performance I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Patients 0 NOUN T
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
BB-AVF 0 NOUN T
or 0 CCONJ F
prosthetic 0 ADJ F
brachial-antecubital 0 ADJ F
forearm 0 NOUN F
loop 0 NOUN F
access 0 NOUN F
. 0 PUNCT F

Before 0 PUNCT T
and 0 CCONJ F
three 0 NUM F
months 0 NOUN F
after 0 ADP F
AVF 0 NOUN T
creation 0 NOUN F
patients 0 NOUN F
underwent 0 VERB F
an 0 DET F
echocardiographic 0 ADJ F
examination 0 NOUN F
. 0 PUNCT F

Mann-Whitney B-PHYSICAL NOUN T
U-test I-PHYSICAL NOUN T
was 0 VERB F
used 0 VERB F
to 0 PART F
compare 0 NOUN F
relative 0 ADJ F
increase 0 NOUN F
between 0 ADP F
the 0 DET F
measured B-PHYSICAL PUNCT F
cardiac I-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
for 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Twenty-seven 0 PUNCT T
patients 0 NOUN F
participated 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
relative 0 ADJ F
increase 0 NOUN F
in 0 ADP F
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Only 0 ADJ T
left B-PHYSICAL ADJ F
ventricular I-PHYSICAL ADJ F
end-diastolic I-PHYSICAL ADJ F
diameter I-PHYSICAL NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
of 0 ADP F
significance 0 NOUN F
. 0 PUNCT F

Mean 0 PUNCT T
blood B-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
through 0 ADP F
the 0 DET F
brachial 0 ADJ F
artery 0 NOUN F
was 0 PRON F
1680+/-156 0 PUNCT F
and 0 CCONJ F
1450+/-221 0 NOUN F
mL/min 0 NOUN F
three 0 NUM F
months 0 NOUN F
after 0 ADP F
surgery 0 NOUN F
for 0 ADP F
the 0 DET F
PTFE 0 NOUN T
and 0 CCONJ F
the 0 DET F
BB-AVF 0 NOUN T
group 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
After 0 ADP T
three 0 NUM F
months 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
, 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
cardiac B-PHYSICAL ADJ F
structure I-PHYSICAL NOUN F
were 0 VERB F
comparable 0 ADJ F
between 0 ADP F
patients 0 NOUN F
with 0 ADP F
BB 0 NOUN T
and 0 CCONJ F
PTFE 0 NOUN T
AVFs 0 NOUN T
. 0 PUNCT F

Also 0 ADV T
access B-PHYSICAL NOUN F
flow I-PHYSICAL NOUN F
was 0 VERB F
comparable 0 ADJ F
at 0 ADP F
this 0 DET F
time 0 NOUN F
. 0 PUNCT F

In 0 ADP T
general 0 NOUN F
, 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
creation 0 NOUN F
of 0 ADP F
a 0 DET F
fistula 0 NOUN F
on 0 ADP F
LV 0 NOUN T
structure 0 NOUN F
were 0 VERB F
limited 0 VERB F
. 0 PUNCT F

Longer 0 PUNCT T
follow 0 CCONJ F
up 0 PUNCT F
time 0 NOUN F
may 0 ADP F
be 0 VERB F
needed 0 VERB F
to 0 PART F
explore 0 VERB F
the 0 DET F
long 0 ADJ F
term 0 NOUN F
effects 0 NOUN F
of 0 ADP F
different 0 ADJ F
vascular 0 ADJ F
accesses 0 CCONJ F
on 0 ADP F
cardiac B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

B-domain 0 NOUN T
deleted 0 VERB F
recombinant 0 ADJ F
factor 0 NOUN F
VIII 0 PUNCT T
preparations 0 NOUN F
are 0 NOUN F
bioequivalent 0 ADJ F
to 0 ADP F
a 0 DET F
monoclonal 0 ADJ F
antibody 0 NOUN F
purified 0 DET F
plasma-derived 0 VERB F
factor 0 NOUN F
VIII 0 PUNCT T
concentrate 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
three-way 0 PUNCT F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Deletion 0 NOUN T
of 0 ADP F
the 0 DET F
B-domain 0 NOUN T
of 0 ADP F
recombinant 0 ADJ F
blood 0 NOUN F
coagulation 0 NOUN F
factor 0 NOUN F
VIII 0 NUM T
( 0 PUNCT F
BDDrFVIII 0 PUNCT T
) 0 PUNCT F
increases 0 NOUN F
the 0 DET F
manufacturing 0 VERB F
yield 0 NOUN F
of 0 ADP F
the 0 DET F
product 0 NOUN F
but 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
impair 0 CCONJ F
in 0 ADP F
vitro 0 ADJ F
or 0 CCONJ F
in 0 PUNCT F
vivo 0 ADJ F
functionality 0 NOUN F
. 0 PUNCT F

BDDrFVIII 0 PUNCT T
( 0 PUNCT F
ReFacto 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
developed 0 VERB F
with 0 ADP F
the 0 DET F
additional 0 ADJ F
benefit 0 NOUN F
of 0 ADP F
being 0 VERB F
formulated 0 VERB F
without 0 ADP F
human 0 NOUN F
albumin 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
primary 0 ADJ F
objective 0 NOUN F
of 0 ADP F
this 0 DET F
three-way 0 PUNCT F
crossover-design 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
pharmacokinetic 0 ADJ F
( 0 PUNCT F
PK 0 NOUN T
) 0 PUNCT F
parameters 0 NOUN F
of 0 ADP F
two 0 NUM F
BDDrFVIII 0 PUNCT T
formulations 0 NOUN F
( 0 PUNCT F
one 0 NUM F
reconstituted 0 VERB F
with 0 ADP F
5 0 NUM F
mL 0 NOUN F
of 0 ADP F
sterile 0 ADJ F
water 0 NOUN F
, 0 PUNCT F
the 0 DET F
other 0 ADP F
reconstituted 0 PROPN F
with 0 ADP F
4 0 NUM F
mL 0 NOUN F
sodium 0 NOUN F
chloride 0 ADP F
0.9 0 NUM F
% 0 SYM F
USP 0 NOUN T
) 0 PUNCT F
with 0 ADP F
those 0 PUNCT F
of 0 ADP F
a 0 DET F
plasma-derived 0 VERB F
, 0 PUNCT F
full-length 0 NOUN F
FVIII 0 NUM T
preparation 0 NOUN F
( 0 PUNCT F
Hemofil 0 NOUN T
M 0 NOUN T
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
haemophilia 0 ADV F
A 0 ADJ T
to 0 PART F
determine 0 NOUN F
bioequivalence 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
series 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
samples I-PHYSICAL NOUN F
were 0 VERB F
collected 0 VERB F
over 0 ADP F
a 0 DET F
period 0 NOUN F
of 0 ADP F
48 0 NUM F
h 0 NOUN F
after 0 ADP F
i.v 0 NUM F
. 0 PUNCT F

administration 0 NOUN F
of 0 ADP F
each 0 PUNCT F
of 0 ADP F
the 0 DET F
FVIII 0 NUM T
preparations 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
FVIII I-PHYSICAL NUM T
activity I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
using 0 VERB F
a 0 DET F
validated 0 VERB F
chromogenic 0 ADJ F
substrate 0 NOUN F
assay 0 NOUN F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
FVIII I-PHYSICAL NUM T
activity I-PHYSICAL NOUN F
vs. 0 CCONJ F
time B-OTHER NOUN F
curves I-OTHER NOUN F
was 0 VERB F
characterized 0 VERB F
for 0 ADP F
a 0 DET F
standard 0 ADJ F
set 0 NOUN F
of 0 ADP F
PK 0 NOUN T
parameter 0 NOUN F
estimates 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
parameter 0 NOUN F
estimates 0 NOUN F
, 0 PUNCT F
the 0 DET F
maximum B-PHYSICAL NOUN F
plasma I-PHYSICAL NOUN F
concentration 0 NOUN F
( B-PHYSICAL PUNCT F
Cmax I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
and 0 CCONJ F
the 0 DET F
area 0 NOUN F
under 0 ADP F
plasma B-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
vs. 0 CCONJ F
time B-PHYSICAL NOUN F
curves I-PHYSICAL NOUN F
( B-PHYSICAL PUNCT F
AUCs I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
were 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
bioequivalence 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
preparations 0 NOUN F
were 0 VERB F
considered 0 NOUN F
bioequivalent 0 ADJ F
if 0 PUNCT F
the 0 DET F
90 0 NUM F
% 0 SYM F
confidence 0 NOUN F
intervals 0 NOUN F
for 0 ADP F
the 0 DET F
ratio 0 NOUN F
of 0 ADP F
geometric B-PHYSICAL ADJ F
means B-PHYSICAL PUNCT F

Extracorporeal 0 ADJ T
shock 0 NOUN F
wave 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
ESWT 0 NOUN T
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
proximal 0 ADJ F
plantar 0 NOUN F
fasciitis 0 NOUN F
: 0 PUNCT F
a 0 DET F
2-year 0 NOUN F
follow-up 0 NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
extracorporeal 0 ADJ F
shock 0 NOUN F
wave 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
ESWT 0 NOUN T
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronically 0 ADV F
painful 0 ADJ F
proximal 0 ADJ F
plantar 0 NOUN F
fasciitis 0 NOUN F
with 0 ADP F
a 0 DET F
further 0 ADJ F
conventional 0 ADJ F
conservative 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Forty-seven 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
49 0 NUM F
feet 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
previously 0 ADV F
unsuccessful 0 ADJ F
nonsurgical 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
at 0 ADJ F
least 0 ADV F
6 0 NUM F
months 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Heel 0 NOUN T
cups 0 NOUN F
had 0 CCONJ F
to 0 PART F
be 0 PUNCT F
worn 0 VERB F
throughout 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Group 0 NOUN T
1 0 NUM F
( 0 PUNCT F
25 0 NUM F
heels 0 NOUN F
) 0 PUNCT F
was 0 VERB F
treated 0 VERB F
immediately 0 ADV F
with 0 ADP F
three 0 NUM F
sessions 0 NOUN F
of 0 ADP F
ESWT 0 NOUN T
( 0 PUNCT F
3000 0 NUM F
shock 0 NOUN F
waves/session 0 NOUN F
of 0 ADP F
0.2 0 NUM F
mJ/mm2 0 NOUN F
) 0 PUNCT F
at 0 ADP F
weekly 0 ADV F
intervals 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
of 0 ADP F
group 0 NOUN F
2 0 NUM F
( 0 PUNCT F
24 0 NUM F
heels 0 NOUN F
) 0 PUNCT F
continued 0 ADP F
nonsurgical 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
iontophoresis 0 NOUN F
with 0 ADP F
diclofenac 0 NOUN F
and 0 CCONJ F
an 0 DET F
oral 0 ADJ F
nonsteroidal 0 ADJ F
anti-inflammatory 0 ADJ F
drug 0 NOUN F
) 0 PUNCT F
for 0 ADP F
12 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

After 0 ADP T
this 0 DET F
period 0 NOUN F
they 0 PUNCT F
were 0 VERB F
treated 0 VERB F
using 0 VERB F
the 0 DET F
protocol 0 NOUN F
of 0 ADP F
group 0 NOUN F
1 0 NUM F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
difference 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
and 0 CCONJ F
walking B-PHYSICAL DET F
time I-PHYSICAL NOUN F
after 0 ADP F
further 0 PUNCT F
nonsurgical 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
3 0 NUM F
months 0 NOUN F
) 0 PUNCT F
was 0 VERB F
seen 0 VERB F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

At 0 ADP T
12 0 NUM F
weeks 0 NOUN F
after 0 ADP F
ESWT 0 NOUN T
, 0 PUNCT F
the 0 DET F
pain 0 NOUN F
estimation 0 NOUN F
on 0 ADP F
the B-PAIN DET F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
( B-PAIN PUNCT F
VAS 0 NOUN T
) B-PAIN PUNCT F
for I-PAIN ADP F
activities B-PAIN NOUN F
of I-PAIN ADP F
daily I-PAIN PUNCT F
living B-PAIN ADP F
diminished 0 VERB F
significantly 0 ADV F
by 0 ADP F
62.9 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
1 0 NUM F
and 0 CCONJ F
by 0 ADP F
63.0 0 NUM F
% 0 SYM F
in 0 ADP F
group 0 NOUN F
2 0 NUM F
. 0 PUNCT F

The 0 DET T
comfortable B-PHYSICAL PUNCT F
walking I-PHYSICAL DET F
time I-PHYSICAL NOUN F
had 0 PUNCT F
increased 0 PUNCT F
significantly 0 ADV F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
years 0 NOUN F
after 0 ADP F
ESWT 0 NOUN T
, 0 PUNCT F
pain 0 NOUN F
during 0 PUNCT F

Reactive 0 ADJ T
balance 0 NOUN F
adjustments 0 NOUN F
to 0 ADP F
unexpected 0 VERB F
perturbations 0 NOUN F
during 0 ADP F
human 0 NOUN F
walking 0 PUNCT F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 PUNCT F
investigation 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
unexpected 0 ADP F
forward 0 PUNCT F
perturbations 0 NOUN F
( 0 PUNCT F
FP 0 NOUN T
) 0 PUNCT F
during 0 ADP F
gait 0 NOUN F
on 0 ADP F
lower 0 PUNCT F
extremity B-PHYSICAL NOUN F
joint I-PHYSICAL NOUN F
mechanics I-PHYSICAL NOUN F
and 0 CCONJ F
muscle B-PHYSICAL NOUN F
Electromyographic I-PHYSICAL ADJ T
( I-PHYSICAL PUNCT F
EMG I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
patterns I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
adults 0 NOUN F
. 0 PUNCT F

The 0 DET T
muscles 0 NOUN F
surrounding 0 VERB F
the 0 DET F
hip 0 NOUN F
were 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
most 0 PUNCT F
important 0 ADJ F
in 0 ADP F
maintaining 0 VERB F
control 0 NOUN F
of 0 ADP F
the 0 DET F
trunk 0 NOUN F
and 0 CCONJ F
preventing B-PHYSICAL ADP F
collapse I-PHYSICAL NOUN F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
the 0 DET F
FP 0 NOUN T
. 0 PUNCT F

Distinct B-PHYSICAL ADJ T
lower 0 PUNCT F
extremity B-PHYSICAL NOUN F
joint I-PHYSICAL NOUN F
moment B-PHYSICAL VERB F
and 0 CCONJ F
power 0 NOUN F
patterns B-PHYSICAL NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
the 0 DET F
FP 0 NOUN T
but 0 CCONJ F
an 0 DET F
overall 0 ADJ F
positive 0 ADJ F
moment 0 NOUN F
of 0 ADP F
support B-PHYSICAL NOUN F
( 0 PUNCT F
M 0 NOUN T
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
) 0 PUNCT F
was 0 VERB F
maintained 0 VERB F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F

Niacin 0 NOUN T
revisited 0 VERB F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
wax-matrix 0 NOUN F
sustained-release 0 NOUN F
niacin 0 NOUN F
in 0 ADP F
hypercholesterolemia 0 NOUN F
. 0 PUNCT F

Two 0 NUM T
hundred 0 NUM F
one 0 NUM F
male 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
subjects 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
20 0 NUM F
to 0 ADP F
70 0 NUM F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
elevated 0 VERB F
low-density 0 NOUN F
lipoprotein 0 NOUN F
cholesterol 0 NOUN F
values 0 NOUN F
( 0 PUNCT F
in 0 ADP F
the 0 DET F
75th 0 PUNCT F
to 0 ADP F
95th 0 ADJ F
percentiles 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
participated 0 DET F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
using 0 VERB F
a 0 DET F
new 0 ADJ F
form 0 NOUN F
of 0 ADP F
niacin 0 NOUN F
( 0 PUNCT F
Enduracin 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
which 0 DET F
employs 0 NOUN F
a 0 DET F
wax-matrix 0 NOUN F
vehicle 0 NOUN F
for 0 ADP F
sustained 0 VERB F
release 0 NOUN F
. 0 PUNCT F

Four 0 NUM T
niacin 0 NOUN F
treatment 0 NOUN F
groups 0 NOUN F
( 0 PUNCT F
daily 0 PUNCT F
doses 0 NOUN F
of 0 ADP F
2000 0 NUM F
, 0 PUNCT F
1500 0 NUM F
, 0 PUNCT F
1250 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
1000 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
placebo- 0 NOUN F
and 0 CCONJ F
diet-treated 0 VERB F
controls 0 NOUN F
to 0 PART F
determine 0 NOUN F
side-effect 0 NOUN F
profile 0 ADJ F
and 0 CCONJ F
optimal 0 ADJ F
range 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
. 0 PUNCT F

The 0 DET T
groups 0 NOUN F
given 0 VERB F
2000 0 NUM F
and 0 CCONJ F
1500 0 NUM F
mg 0 NOUN F
demonstrated 0 VERB F
significant 0 ADJ F
reductions 0 NOUN F
in 0 ADP F
values 0 NOUN F
of 0 ADP F
low-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
( 0 PUNCT F
-26 0 NUM F
% 0 SYM F
and 0 CCONJ F
-19.3 0 ADJ F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
total 0 ADJ F
cholesterol B-PHYSICAL NOUN F
( 0 PUNCT F
-18.4 0 NUM F
% 0 SYM F
and 0 CCONJ F
-13.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
total 0 ADJ F
cholesterol-high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
ratio I-PHYSICAL NOUN F
( 0 PUNCT F
-20.4 0 ADV F
% 0 SYM F
and 0 CCONJ F
-19.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
diet- 0 NOUN F
and 0 CCONJ F
placebo-treated 0 ADP F
controls 0 NOUN F
. 0 PUNCT F

Smaller 0 PUNCT T
improvements 0 NOUN F
were 0 VERB F
seen 0 VERB F
in 0 ADP F
high-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
triglyceride I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

Blood 0 NOUN T
chemistry 0 NOUN F
monitoring 0 PUNCT F
indicated 0 PUNCT F
that 0 ADP F
reduction 0 NOUN F
in 0 ADP F
low-density B-PHYSICAL NOUN F
lipoprotein I-PHYSICAL NOUN F
cholesterol I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
strongly 0 ADV F
correlated 0 VERB F
with 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
baseline 0 NOUN F
levels 0 NOUN F
of 0 ADP F
some 0 DET F
enzymes 0 NOUN F
for 0 ADP F
niacin-treated 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
improved 0 VERB F
side-effect 0 NOUN F
profile 0 NOUN F
of 0 ADP F
the 0 DET F
wax-matrix 0 NOUN F
form 0 ADP F
of 0 ADP F
niacin 0 NOUN F
was 0 VERB F
particularly 0 ADV F
notable 0 ADJ F
. 0 PUNCT F

The 0 DET T
dropout 0 ADP F
rate B-OTHER NOUN F
due 0 PUNCT F
to 0 ADP F
side 0 NOUN F
effects 0 NOUN F
was 0 VERB F
only 0 ADV F
3.4 0 NUM F
% 0 SYM F
and 0 CCONJ F
was 0 VERB F
coupled 0 VERB F
with 0 ADP F
good 0 ADJ F
medication 0 NOUN F
compliance 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
with 0 ADP F
metformin 0 NOUN F
of 0 ADP F
non-diabetic 0 ADJ F
men 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
, 0 PUNCT F
hypertriglyceridaemia 0 NOUN F
and 0 CCONJ F
central 0 ADJ F
fat 0 NOUN F
distribution 0 NOUN F
: 0 PUNCT F
the 0 DET F
BIGPRO 0 NOUN T
1.2 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
In 0 ADP T
the 0 DET F
BIGPRO 0 NOUN T
1 0 NUM F
trial 0 NOUN F
, 0 PUNCT F
one 0 NUM F
year 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
with 0 ADP F
metformin 0 NOUN F
in 0 ADP F
non-diabetic 0 ADJ F
obese 0 ADP F
subjects 0 NOUN F
with 0 ADP F
a 0 DET F
central 0 ADJ F
fat 0 NOUN F
distribution 0 NOUN F
had 0 VERB F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
fasting 0 VERB F
plasma 0 NOUN F
triglyceride 0 NOUN F
concentration 0 NOUN F
or 0 CCONJ F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
despite 0 ADP F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
weight 0 NOUN F
, 0 PUNCT F
fasting 0 VERB F
plasma 0 NOUN F
insulin 0 NOUN F
and 0 CCONJ F
glucose 0 NOUN F
concentrations 0 NOUN F
. 0 PUNCT F

To 0 ADP T
re-evaluate 0 PUNCT F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
metformin 0 NOUN F
on 0 ADP F
fasting 0 VERB F
triglyceride 0 NOUN F
concentration 0 NOUN F
and 0 CCONJ F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
the 0 DET F
BIGPRO 0 NOUN T
1.2 0 NUM F
trial 0 NOUN F
included 0 VERB F
non-diabetic 0 ADJ F
men 0 NOUN F
( 0 PUNCT F
n=168 0 NOUN F
) 0 PUNCT F
with 0 ADP F
a 0 DET F
fasting 0 VERB F
plasma 0 NOUN F
triglyceride 0 NOUN F
concentration 0 NOUN F
> 0 SYM F
or 0 CCONJ F
=1.7 0 ADJ F
and 0 CCONJ F
< 0 SYM F
or 0 CCONJ F
=6.5 0 DET F
mmol/l 0 NOUN F
, 0 PUNCT F
high 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
( 0 PUNCT F
systolic 0 ADJ F
> 0 NOUN F
or 0 CCONJ F
=140 0 NOUN F
and 0 CCONJ F
< 0 SYM F
or 0 CCONJ F
=180 0 ADJ F
and/or 0 CCONJ F
diastolic 0 ADJ F
> 0 SYM F
or 0 CCONJ F
=90 0 ADP F
and 0 CCONJ F
< 0 SYM F
or 0 CCONJ F
=105 0 PUNCT F
mmHg 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
treatment 0 NOUN F
for 0 ADP F
hypertension 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
waist-to-hip 0 PUNCT F
ratio 0 NOUN F
> 0 SYM F
or 0 CCONJ F
=0.95 0 NUM F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
randomised 0 VERB F
double-blind 0 ADJ F
trial 0 NOUN F
comparing 0 VERB F
metformin 0 NOUN F
treatment 0 NOUN F
( 0 PUNCT F
850 0 NUM F
mg 0 NOUN F
bid 0 CCONJ F
) 0 PUNCT F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Metformin 0 NOUN T
had 0 PUNCT F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
either 0 PUNCT F
on 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
or 0 CCONJ F
plasma B-PHYSICAL NOUN F
triglyceride I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
comparison 0 NOUN F
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
fasting B-PHYSICAL VERB F
plasma I-PHYSICAL NOUN F
insulin I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
total 0 ADJ F
cholesterol B-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
Apo B-PHYSICAL NOUN T
B I-PHYSICAL NOUN T
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.008 0 NUM F
) 0 PUNCT F
concentrations 0 NOUN F
decreased 0 VERB F
more 0 ADV F
in 0 ADP F
the 0 DET F
metformin 0 NOUN F
group 0 NOUN F
in 0 ADP F
the 0 DET F
BIGPRO 0 NOUN T
1 0 NUM F
. 0 PUNCT F

2 0 NUM F
trial 0 NOUN F
, 0 PUNCT F
confirming 0 CCONJ F
most 0 PUNCT F
of 0 ADP F
the 0 DET F
previous 0 ADJ F
results 0 NOUN F
of 0 ADP F
the 0 DET F
BIGPRO 0 NOUN T
1 0 NUM F
trial 0 NOUN F
. 0 PUNCT F

Tissue B-PHYSICAL NOUN T
plasminogen I-PHYSICAL NOUN F
activator I-PHYSICAL NOUN F
antigen I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
decreased 0 VERB F
significantly 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
only 0 ADV F
in 0 ADP F
the 0 DET F
metformin 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
this 0 DET F
was 0 NUM F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
from 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.12 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
further 0 ADV F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
change 0 NOUN F
in 0 ADP F
plasminogen 0 NOUN F
activator 0 NOUN F
inhibitor 0 NOUN F
1 0 NUM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
consistency 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
BIGPRO 0 NOUN T
trials 0 NOUN F
supports 0 NOUN F
the 0 DET F
conclusion 0 NOUN F
that 0 ADP F
metformin 0 NOUN F
affects 0 VERB F
several 0 ADJ F
cardiovascular 0 ADJ F
risk 0 NOUN F
factors 0 NOUN F
favourably 0 ADV F
in 0 ADP F
non-diabetic 0 ADJ F
subjects 0 NOUN F
with 0 ADP F
a 0 DET F
central 0 ADJ F
fat 0 NOUN F
distribution 0 NOUN F
. 0 PUNCT F

Bitewing 0 PUNCT T
film 0 NOUN F
quality 0 NOUN F
: 0 PUNCT F
a 0 DET F
clinical 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
loop 0 NOUN F
vs. 0 CCONJ F
holder 0 ADJ F
techniques 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
in 0 DET F
vivo 0 ADJ F
bitewing 0 PUNCT F
film 0 NOUN F
quality 0 NOUN F
using 0 VERB F
the 0 DET F
holder 0 ADJ F
versus 0 CCONJ F
the 0 DET F
paper 0 NOUN F
loop 0 NOUN F
technique 0 NOUN F
. 0 PUNCT F

METHOD 0 NOUN T
AND 0 CCONJ T
MATERIALS 0 NOUN T
Four 0 NUM T
bitewing 0 VERB F
films 0 ADV F
were 0 VERB F
taken 0 VERB F
from 0 ADP F
the 0 DET F
right 0 ADJ F
and 0 CCONJ F
left 0 ADJ F
premolar 0 ADJ F
and 0 CCONJ F
molar 0 ADJ F
regions 0 NOUN F
of 0 ADP F
45 0 NUM F
dental 0 ADJ F
students 0 NOUN F
using 0 VERB F
both 0 CCONJ F
the 0 DET F
bitewing 0 ADJ F
holder 0 ADJ F
and 0 CCONJ F
paper 0 NOUN F
loop 0 NOUN F
techniques 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
360 0 NUM F
films 0 ADV F
were 0 VERB F
taken 0 VERB F
and 0 CCONJ F
assessed 0 VERB F
by 0 ADP F
an 0 DET F
experienced 0 VERB F
practitioner 0 NOUN F
not 0 ADV F
apprised 0 PUNCT F
of 0 ADP F
the 0 DET F
bitewing 0 ADP F
technique 0 NOUN F
used 0 VERB F
. 0 PUNCT F

Of 0 ADP T
interest 0 NOUN F
were 0 VERB F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
the 0 DET F
number 0 NOUN F
of 0 ADP F
overlaps 0 DET F
and 0 CCONJ F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
teeth 0 NOUN F
showing 0 VERB F
the 0 DET F
alveolar 0 ADJ F
crest 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
proper 0 ADJ F
film 0 NOUN F
positioning 0 ADV F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
the 0 DET F
percentage 0 NOUN F
of 0 ADP F
cone 0 NOUN F
cutting 0 PUNCT F
. 0 PUNCT F

A 0 DET T
Poisson 0 PUNCT T
regression 0 NOUN F
using 0 VERB F
generalized 0 VERB F
estimating 0 ADV F
equations 0 NOUN F
( 0 PUNCT F
GEEs 0 PUNCT T
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
difference 0 NOUN F
in 0 ADP F
overlap 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
techniques 0 NOUN F
. 0 PUNCT F

For 0 ADP T
proper 0 ADJ F
positioning 0 PROPN F
and 0 CCONJ F
cone 0 NOUN F
cutting 0 ADP F
, 0 PUNCT F
logistic 0 ADJ F
regressions 0 NOUN F
using 0 VERB F
GEEs 0 NOUN T
were 0 VERB F
used 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
average 0 ADJ F
number 0 NOUN F
of 0 ADP F
horizontal B-OTHER ADJ F
overlaps I-OTHER PUNCT F
for I-OTHER ADP F
the I-OTHER DET F
loop I-OTHER NOUN F
and 0 CCONJ F
holder B-OTHER ADJ F
techniques I-OTHER NOUN F
at 0 ADP F
the 0 DET F
right 0 ADJ F
premolar 0 ADJ F
, 0 PUNCT F
right 0 ADJ F
molar 0 ADJ F
, 0 PUNCT F
left 0 ADJ F
premolar 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
left 0 ADJ F
molar 0 ADJ F
were 0 VERB F
1.64 0 NUM F
, 0 PUNCT F
2.11 0 NUM F
, 0 PUNCT F
2.16 0 NUM F
, 0 PUNCT F
2.78 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
1.64 0 NUM F
, 0 PUNCT F
2.00 0 NUM F
, 0 PUNCT F
2.00 0 NUM F
, 0 PUNCT F
2.18 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
loop 0 NOUN F
technique 0 NOUN F
was 0 VERB F
1.11 0 NUM F
times 0 NOUN F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
cause 0 CCONJ F
overlapping B-OTHER PUNCT F
than 0 PUNCT F
the 0 DET F
holder 0 ADJ F
technique 0 NOUN F
. 0 PUNCT F

The 0 DET T
highest B-OTHER ADP F
percentage I-OTHER NOUN F
of I-OTHER ADP F
teeth I-OTHER NOUN F
showing I-OTHER VERB F
the I-OTHER DET F
alveolar I-OTHER ADJ F
crest I-OTHER NOUN F
by I-OTHER ADP F
the I-OTHER DET F
loop I-OTHER NOUN F
technique I-OTHER NOUN F
was 0 VERB F
97.8 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
mandibular 0 ADJ F
second 0 ADJ F
premolar 0 ADJ F
and 0 CCONJ F
first 0 ADJ F
molar 0 NOUN F
. 0 PUNCT F

With 0 ADP T
respect 0 NOUN F
to 0 ADP F
film 0 NOUN F
positioning 0 ADV F
, 0 PUNCT F
the 0 DET F
loop 0 NOUN F
technique 0 NOUN F
was 0 VERB F
1.12 0 NUM F
times 0 NOUN F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
cause 0 PROPN F
improper B-OTHER ADP F
positioning 0 PUNCT F
than 0 PUNCT F
the 0 DET F
holder 0 ADJ F
technique 0 NOUN F
. 0 PUNCT F

Both 0 DET T
techniques 0 NOUN F
demonstrated 0 VERB F
minimal B-OTHER ADJ F
cone I-OTHER NOUN F
cutting I-OTHER CCONJ F
( 0 PUNCT F
1 0 NUM F
in 0 ADP F
the 0 DET F
loop 0 NOUN F
versus 0 CCONJ F
0 0 NUM F
in 0 ADP F
the 0 DET F
holder 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
quality 0 NOUN F
of 0 ADP F
bitewing 0 ADJ F
films 0 NOUN F
taken 0 VERB F
by 0 ADP F
the 0 DET F
loop 0 NOUN F
and 0 CCONJ F
holder 0 ADJ F
techniques 0 NOUN F
was 0 VERB F
not 0 ADV F
significantly 0 ADV F
different 0 ADJ F
. 0 PUNCT F

Optimization 0 NOUN T
of 0 ADP F
acid 0 NOUN F
suppression 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
peptic 0 ADJ F
ulcer 0 NOUN F
bleeding 0 ADV F
: 0 PUNCT F
an 0 DET F
intragastric 0 ADJ F
pH-metry 0 NOUN F
study 0 NOUN F
with 0 ADP F
omeprazole 0 NUM F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PART T
study 0 NOUN F
whether 0 PUNCT F
an 0 DET F
intravenous 0 ADJ F
infusion 0 NOUN F
dose 0 ADJ F
of 0 ADP F
omeprazole 0 NUM F
( 0 PUNCT F
80 0 NUM F
mg 0 NOUN F
+ 0 SYM F
8 0 NUM F
mg/h 0 NUM F
) 0 PUNCT F
during 0 ADP F
24 0 NUM F
h 0 NOUN F
can 0 VERB F
be 0 VERB F
subsequently 0 ADV F
reduced 0 ADP F
with 0 ADP F
maintained 0 VERB F
effect 0 NOUN F
. 0 PUNCT F

Second 0 NOUN T
, 0 PUNCT F
to 0 VERB F
study 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
oral 0 ADJ F
omeprazole 0 NUM F
20 0 NUM F
mg 0 NOUN F
given 0 NOUN F
once 0 PUNCT F
or 0 CCONJ F
twice 0 PUNCT F
daily 0 ADJ F
up 0 PUNCT F
to 0 ADP F
day 0 NOUN F
10 0 NUM F
, 0 PUNCT F
after 0 ADP F
cessation 0 NOUN F
of 0 ADP F
a 0 DET F
3-day 0 NOUN F
intravenous 0 ADJ F
infusion 0 NOUN F
( 0 PUNCT F
80 0 NUM F
mg 0 NOUN F
+ 0 SYM F
8 0 NUM F
mg/h 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
partly 0 ADV F
blinded 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Twelve 0 PUNCT T
Helicobacter 0 NOUN T
pylori 0 NOUN F
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
and 0 CCONJ F
12 0 NUM F
H. 0 NOUN T
pylori 0 NOUN F
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
subjects 0 NOUN F
were 0 VERB F
included 0 VERB F
. 0 PUNCT F

In 0 ADP T
part 0 NOUN F
I 0 NUM T
the 0 DET F
patients 0 NOUN F
received 0 ADJ F
omeprazole 0 NUM F
, 0 PUNCT F
80 0 NUM F
mg 0 NOUN F
+ 0 SYM F
8 0 NUM F
mg/h 0 NUM F
, 0 PUNCT F
during 0 ADP F
24 0 NUM F
h 0 NOUN F
followed 0 VERB F
by 0 ADP F
8 0 NUM F
, 0 PUNCT F
4 0 NUM F
or 0 CCONJ F
2 0 NUM F
mg/h 0 NUM F
. 0 PUNCT F

In 0 ADP T
part 0 NOUN F
II 0 NUM T
the 0 DET F
subjects 0 NOUN F
received 0 ADJ F
80 0 NUM F
mg 0 NOUN F
+ 0 SYM F
8 0 NUM F
mg/h 0 ADV F
during 0 ADP F
3 0 NUM F
days 0 NOUN F
followed 0 VERB F
by 0 ADP F
20 0 NUM F
mg 0 NOUN F
omeprazole 0 NUM F
orally 0 ADV F
, 0 PUNCT F
once 0 PUNCT F
or 0 CCONJ F
twice 0 ADV F
daily 0 ADJ F
until 0 ADP F
day 0 NOUN F
10 0 NUM F
. 0 PUNCT F

Intragastric B-PHYSICAL ADJ T
pH I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
All 0 PUNCT T
H. 0 NOUN T
pylori 0 NOUN F
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
showed 0 VERB F
a 0 DET F
rapid 0 ADJ F
increase 0 NOUN F
of 0 ADP F
intragastric B-PHYSICAL ADJ F
pH I-PHYSICAL NOUN F
with I-PHYSICAL ADP F
a I-PHYSICAL DET F
mean 0 NOUN F
intragastric B-PHYSICAL ADJ F
pH B-PHYSICAL NOUN F
of 0 ADP F
6.7 0 NUM F
during 0 ADP F
the 0 DET F
second 0 ADJ F
half 0 NOUN F
of 0 ADP F
the 0 DET F
first 0 ADJ F
day 0 NOUN F
. 0 PUNCT F

After 0 ADP T
the 0 DET F
subsequent 0 ADJ F
dose 0 NOUN F
reduction 0 NOUN F
, 0 PUNCT F
the 0 DET F
mean 0 NOUN F
pH B-PHYSICAL NOUN F
decreased 0 VERB F
to 0 ADP F
6.1-6.2 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
continuing 0 PUNCT F
on 0 ADP F
8 0 NUM F
mg/h 0 NUM F
showed 0 VERB F
the 0 DET F
best 0 PUNCT F
results 0 NOUN F
. 0 PUNCT F

Likewise 0 ADV T
, 0 PUNCT F
all 0 DET F
H. 0 NOUN T
pylori 0 NOUN F
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
subjects 0 NOUN F
showed 0 VERB F
a 0 DET F
rapid 0 ADJ F
and 0 CCONJ F
sustained 0 VERB F
reduction 0 NOUN F
of 0 ADP F
intragastric B-PHYSICAL ADJ F
acidity I-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
infusion 0 NOUN F
. 0 PUNCT F

Subsequent 0 ADJ T
dose 0 NOUN F
reduction 0 NOUN F
to 0 ADP F
20 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 ADJ F
led 0 ADP F
to 0 ADP F
a 0 DET F
stable 0 ADJ F
fraction 0 NOUN F
of 0 ADP F
time 0 NOUN F
with 0 ADP F
pH 0 NOUN F
> 0 SYM F
3 0 NUM F
of 0 ADP F
72 0 NUM F
% 0 SYM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Omeprazole 0 ADV T
given 0 VERB F
as 0 ADP F
a 0 DET F
continuous 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
80 0 NUM F
mg 0 NOUN F
+ 0 SYM F
8 0 NUM F
mg/h 0 ADV F
for 0 ADP F
72 0 NUM F
h 0 NOUN F
followed 0 VERB F
by 0 ADP F
omeprazole 0 NUM F
20 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 PUNCT F
raised 0 PUNCT F
the 0 PUNCT F

The 0 DET T
relationship 0 NOUN F
between 0 ADP F
repetitive B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
and 0 CCONJ F
growth B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
to 0 PUNCT F
sumatriptan 0 NOUN F
challenge 0 NOUN F
in 0 ADP F
adult 0 NOUN F
autistic 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

Autism 0 NOUN T
is 0 VERB F
heterogeneous 0 ADJ F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
clinical 0 ADJ F
symptoms 0 NOUN F
and 0 CCONJ F
etiology 0 NOUN F
. 0 PUNCT F

To 0 ADP T
sort 0 PUNCT F
out 0 DET F
this 0 DET F
heterogeneity 0 NOUN F
in 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
we 0 PRON F
investigated 0 VERB F
whether 0 ADP F
specific B-PHYSICAL ADJ F
neurobiological I-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
vary 0 VERB F
in 0 ADP F
parallel 0 PUNCT F
to 0 ADP F
core B-PHYSICAL NOUN F
symptomatology I-PHYSICAL NOUN F
. 0 PUNCT F

Specifically 0 ADV T
, 0 PUNCT F
we 0 NOUN F
assessed 0 VERB F
growth B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
5-HT 0 NOUN F
1d 0 NOUN F
agonist 0 NOUN F
, 0 PUNCT F
sumatriptan 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
linked B-PHYSICAL ADP F
this I-PHYSICAL DET F
measure I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
serotonergic I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
repetitive B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
in 0 ADP F
adult 0 NOUN F
autistic 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Eleven 0 ADP T
adult 0 NOUN F
patients 0 NOUN F
with 0 ADP F
autism 0 NOUN F
or 0 CCONJ F
Asperger 0 ADJ T
's 0 PUNCT F
disorder 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
single 0 ADJ F
dose 0 NOUN F
sumatriptan 0 NOUN F
( 0 PUNCT F
6 0 NUM F
mg 0 NOUN F
SQ 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
challenges 0 NOUN F
, 0 PUNCT F
separated 0 VERB F
by 0 ADP F
a 0 DET F
one-week 0 NOUN F
interval 0 NOUN F
. 0 PUNCT F

In 0 ADP T
adult 0 NOUN F
autistic 0 ADJ F
disorders 0 NOUN F
, 0 PUNCT F
severity 0 NOUN F
of 0 ADP F
repetitive B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
at I-MENTAL ADP F
baseline I-MENTAL NOUN F
, 0 PUNCT F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
YBOCS-compulsion B-MENTAL NOUN T
score I-MENTAL NOUN F
, 0 PUNCT F
significantly 0 ADV F
positively 0 ADV F
correlated 0 VERB F
with 0 ADP F
both 0 CCONJ F
peak 0 ADJ F
delta B-PHYSICAL NOUN F
growth I-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
and 0 CCONJ F
area 0 NOUN F
under 0 ADP F
the B-PHYSICAL DET F
curve 0 NOUN F
growth B-PHYSICAL NOUN F
hormone I-PHYSICAL NOUN F
response B-PHYSICAL NOUN F
to 0 ADP F
sumatriptan 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
a 0 DET F
specific B-MENTAL ADJ F
behavioral I-MENTAL ADJ F
dimension I-MENTAL NOUN F
in 0 ADP F
autism 0 NOUN F
( 0 PUNCT F
repetitive B-MENTAL ADJ F
behaviors I-MENTAL NOUN F
) 0 PUNCT F
parallels B-MENTAL PUNCT F

0.1 0 NUM F
% 0 SYM F
bupivacaine 0 NOUN F
does 0 PUNCT F
not 0 ADV F
reduce 0 VERB F
the 0 DET F
requirement 0 NOUN F
for 0 ADP F
epidural 0 ADJ F
fentanyl 0 NOUN F
infusion 0 NOUN F
after 0 ADP F
major 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
OBJECTIVES 0 NOUN T
Although 0 PUNCT T
local 0 ADJ F
anesthesia 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
demonstrated 0 VERB F
to 0 PART F
potentiate 0 ADJ F
spinal 0 ADJ F
morphine 0 NOUN F
analgesia 0 NOUN F
in 0 ADP F
animal 0 NOUN F
studies 0 NOUN F
, 0 PUNCT F
results 0 ADP F
comparing 0 VERB F
epidural 0 ADJ F
local 0 ADJ F
anesthesia/opioid 0 NOUN F
mixtures 0 NOUN F
with 0 ADP F
opioid 0 NOUN F
alone 0 ADJ F
are 0 VERB F
contradictory 0 ADJ F
in 0 ADP F
clinical 0 ADJ F
studies 0 NOUN F
. 0 PUNCT F

The 0 DET T
hypothesis 0 NOUN F
was 0 VERB F
that 0 ADP F
, 0 PUNCT F
although 0 ADP F
the 0 DET F
concentration 0 NOUN F
of 0 ADP F
bupivacaine 0 NOUN F
( 0 PUNCT F
0.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
was 0 VERB F
low 0 ADJ F
to 0 ADJ F
minimize 0 NOUN F
its 0 ADP F
adverse 0 ADJ F
effects 0 NOUN F
, 0 PUNCT F
if 0 PUNCT F
the 0 DET F
infusion 0 NOUN F
rate 0 NOUN F
of 0 ADP F
a 0 DET F
fentanyl/bupivacaine 0 NOUN F
solution 0 NOUN F
was 0 VERB F
closely 0 ADV F
adjusted 0 VERB F
according 0 CCONJ F
to 0 PUNCT F
need 0 PUNCT F
, 0 PUNCT F
the 0 DET F
presence 0 NOUN F
bupivacaine 0 NOUN F
would 0 VERB F
reduce 0 VERB F
the 0 DET F
requirement 0 NOUN F
for 0 ADP F
epidural 0 ADJ F
fentanyl 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Forty 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
fentanyl 0 NOUN F
( 0 PUNCT F
10 0 NUM F
micrograms/mL 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
a 0 DET F
fentanyl/bupivacaine 0 NOUN F
( 0 PUNCT F
0.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
mixture 0 NOUN F
epidurally 0 ADV F
corresponding 0 CCONJ F
to 0 ADP F
the 0 DET F
dermatome 0 PUNCT F
of 0 ADP F
the 0 DET F
surgical 0 ADJ F
incision 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
fashion 0 NOUN F
for 0 ADP F
the 0 DET F
first 0 ADJ F
18 0 NUM F
hours 0 NOUN F
after 0 ADP F
major 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
infusion 0 NOUN F
was 0 VERB F
titrated 0 VERB F
for 0 ADP F
each 0 DET F
patient 0 NOUN F
to 0 ADP F
the 0 DET F
rate 0 NOUN F
required 0 VERB F
for 0 ADP F
pain 0 NOUN F
relief 0 NOUN F
during 0 ADP F
forced 0 ADJ F
inspiration 0 NOUN F
( 0 PUNCT F
pain 0 NOUN F
score 0 NOUN F
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
2 0 NUM F
, 0 PUNCT F
maximum 0 NOUN F
10 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pain 0 NOUN T
scores 0 NOUN F
, 0 PUNCT F
the 0 DET F
fentanyl 0 NOUN F
doses 0 NOUN F
required 0 ADP F
, 0 PUNCT F
plasma 0 NOUN F
concentrations 0 NOUN F
of 0 ADP F
fentanyl 0 NOUN F
at 0 ADP F
18 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 DET T
Patients 0 NOUN T
reported 0 ADP F
similar 0 ADJ F
median 0 ADJ F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
and 0 CCONJ F
were 0 VERB F
equally 0 ADV F
satisfied 0 VERB F
with 0 ADP F
pain B-PAIN NOUN F
relief I-PAIN NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
required 0 VERB F
post-operative B-OTHER ADJ F
fentanyl I-OTHER NOUN F
infusion I-OTHER NOUN F
rate I-OTHER NOUN F
( 0 PUNCT F
57.7 0 NUM F
+/- 0 SYM F
19.5 0 NUM F
micrograms/h 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
( 0 PUNCT F
0.84 0 NUM F
+/- 0 SYM F
0.36 0 NUM F
ng/mL 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
fentanyl 0 NOUN F
group 0 NOUN F
were 0 VERB F
comparable 0 ADJ F
to 0 ADP F
the 0 DET F
infusion B-OTHER NOUN F
rate I-OTHER NOUN F
( 0 PUNCT F
54.4 0 NUM F
+/- 0 SYM F
19.2 0 NUM F
micrograms/h 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
plasma B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
( 0 PUNCT F
0.86 0 NUM F
+/- 0 SYM F
0.36 0 NUM F
ng/mL 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
fentanyl/bupivacaine 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Respiratory B-PHYSICAL ADJ T
and I-PHYSICAL CCONJ F
cardiovascular I-PHYSICAL ADJ F
functions I-PHYSICAL NOUN F
were 0 VERB F
preserved 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
nausea B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
pruritus B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
periods 0 NOUN F
of 0 ADP F
drowsiness B-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
sleep B-ADVERSE-EFFECTS NOUN F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
low 0 ADJ F
concentrations 0 NOUN F
( 0 PUNCT F
0.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
bupivacaine 0 NOUN F
did 0 PUNCT F
not 0 ADV F
reduce 0 VERB F
the 0 DET F
titrated 0 ADJ F
dose 0 NOUN F
of 0 ADP F
epidural 0 ADJ F
fentanyl 0 NOUN F
required 0 VERB F
for 0 ADP F
adequate 0 ADJ F
pain 0 NOUN F
relief 0 NOUN F
during 0 ADP F
forced 0 ADJ F
inspiration 0 NOUN F
after 0 ADP F
major 0 ADJ F
abdominal 0 ADJ F
surgery 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
and 0 CCONJ F
severity 0 NOUN F
of 0 ADP F
adverse 0 ADJ F
effects 0 NOUN F
were 0 VERB F
also 0 ADV F
comparable 0 ADJ F
whether 0 PUNCT F
or 0 CCONJ F
not 0 ADV F
low-dose 0 NOUN F
bupivacaine 0 NOUN F
infusion 0 NOUN F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

Factors 0 NOUN T
predictive 0 ADJ F
of 0 ADP F
severe B-PHYSICAL ADJ F
hypoglycemia I-PHYSICAL NOUN F
in 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
: 0 PUNCT F
analysis 0 NOUN F
from 0 ADP F
the 0 DET F
Juvenile 0 ADJ T
Diabetes 0 NOUN T
Research 0 NOUN T
Foundation 0 NOUN T
continuous 0 ADJ F
glucose 0 NOUN F
monitoring 0 VERB F
randomized 0 VERB F
control 0 NOUN F
trial 0 NOUN F
dataset 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Identify 0 ADV T
factors 0 NOUN F
predictive 0 ADJ F
of 0 ADP F
severe B-PHYSICAL ADJ F
hypoglycemia I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
SH I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
and 0 CCONJ F
assess 0 ADJ F
the 0 DET F
clinical B-OTHER ADJ F
utility I-OTHER NOUN F
of 0 ADP F
continuous B-OTHER ADJ F
glucose I-OTHER NOUN F
monitoring I-OTHER VERB F
( I-OTHER PUNCT F
CGM I-OTHER NOUN T
) I-OTHER PUNCT F
to 0 ADP F
warn 0 ADJ F
of 0 ADP F
impending 0 NUM F
SH 0 NOUN T
. 0 PUNCT F

RESEARCH 0 NOUN T
DESIGN 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
multicenter 0 NOUN F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
436 0 NUM F
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
with 0 ADP F
type 0 NOUN F
1 0 NUM F
diabetes 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
a 0 DET F
treatment 0 NOUN F
group 0 NOUN F
that 0 PUNCT F
used 0 PUNCT F
CGM 0 NOUN T
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
224 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
that 0 PUNCT F
used 0 VERB F
standard 0 ADJ F
home 0 NOUN F
blood 0 NOUN F
glucose 0 NOUN F
monitoring 0 VERB F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
212 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
completed 0 VERB F
12 0 NUM F
months 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

After 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
original 0 ADJ F
control 0 NOUN F
group 0 NOUN F
initiated 0 ADP F
CGM 0 NOUN T
while 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
continued 0 ADJ F
use 0 NOUN F
of 0 ADP F
CGM 0 CCONJ T
for 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Baseline 0 NOUN T
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
SH 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
over 0 ADP F
12 0 NUM F
months 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
using 0 SYM F
proportional 0 ADJ F
hazards 0 NOUN F
regression 0 NOUN F
. 0 PUNCT F

CGM-derived B-PHYSICAL ADJ T
indices I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
hypoglycemia I-PHYSICAL NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
predict 0 NOUN F
episodes 0 NOUN F
of 0 ADP F
SH 0 NOUN T
over 0 ADP F
a 0 DET F
24-h 0 NOUN F
time 0 NOUN F
horizon 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
SH B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
was 0 VERB F
17.9 0 ADV F
per 0 ADP F
100 0 NUM F
person-years 0 PROPN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
higher 0 PUNCT F
rate 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
SH B-PHYSICAL NOUN T
in 0 ADP F
the 0 DET F
prior 0 ADP F
6 0 NUM F
months 0 NOUN F
and 0 CCONJ F
female 0 NOUN F
sex 0 NOUN F
. 0 PUNCT F

SH B-PHYSICAL NOUN T
frequency I-PHYSICAL NOUN F
increased 0 VERB F
eightfold 0 ADJ F
when 0 ADP F
30 0 NUM F
% 0 SYM F
of 0 ADP F
CGM B-PHYSICAL NOUN T
values I-PHYSICAL NOUN F
were 0 VERB F
? 0 PUNCT F

70 0 NUM F
mg/dL 0 NOUN F
on 0 ADP F
the 0 DET F
prior 0 PUNCT F
day 0 NOUN F
( 0 PUNCT F
4.5 0 NUM F
vs. 0 CCONJ F
0.5 0 ADP F
% 0 SYM F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
positive 0 ADJ F
predictive 0 ADJ F
value 0 NOUN F
( 0 PUNCT F
PPV 0 NOUN T
) 0 PUNCT F
was 0 VERB F
low 0 ADJ F
( 0 PUNCT F
< 0 PROPN F
5 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
were 0 VERB F
similar 0 ADJ F
for 0 ADP F
hypoglycemic 0 ADJ F
area 0 NOUN F
under 0 ADP F
the 0 DET F
curve 0 NOUN F
and 0 CCONJ F
the 0 DET F
low 0 ADJ F
blood 0 NOUN F
glucose 0 NOUN F
index 0 NOUN F
calculated 0 VERB F
by 0 ADP F
CGM 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
SH 0 NOUN T
in 0 ADP F
the 0 DET F
6 0 NUM F
months 0 NOUN F
prior 0 CCONJ F
to 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
the 0 DET F
strongest 0 PUNCT F
predictor 0 NOUN F
of 0 ADP F
SH 0 NOUN T
during 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

CGM-measured 0 ADJ T
hypoglycemia 0 NOUN F
over 0 ADP F
a 0 DET F
24-h 0 NOUN F
span 0 NOUN F
is 0 VERB F
highly 0 ADV F
associated 0 VERB F
with 0 ADP F
SH 0 NOUN T
the 0 DET F
following 0 PUNCT F
day 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
PPV 0 NOUN T
is 0 VERB F
low 0 ADJ F
. 0 PUNCT F

A 0 DET T
prospective 0 ADJ F
randomised 0 VERB F
comparison 0 NOUN F
of 0 ADP F
sublingual 0 ADJ F
and 0 CCONJ F
vaginal 0 ADJ F
misoprostol 0 NOUN F
in 0 ADP F
second 0 ADJ F
trimester 0 NOUN F
termination 0 NOUN F
of 0 ADP F
pregnancy 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
, 0 PUNCT F
side 0 NOUN F
effects 0 NOUN F
and 0 CCONJ F
acceptability B-OTHER NOUN F
of 0 ADP F
sublingual 0 ADJ F
and 0 CCONJ F
vaginal 0 ADJ F
misoprostol 0 NOUN F
for 0 ADP F
second 0 ADJ F
trimester 0 NOUN F
medical 0 ADJ F
abortion 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Prospective 0 ADJ T
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Tertiary 0 ADJ T
referral 0 NOUN F
unit 0 NOUN F
and 0 CCONJ F
a 0 DET F
teaching 0 VERB F
hospital 0 NOUN F
. 0 PUNCT F

POPULATION 0 NOUN T
Two 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
twenty-four 0 PUNCT F
women 0 NOUN F
at 0 ADP F
12 0 NUM F
to 0 ADP F
20 0 NUM F
weeks 0 NOUN F
of 0 ADP F
gestation 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
women 0 NOUN F
were 0 VERB F
randomised 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
sublingual 0 ADP F
or 0 CCONJ F
vaginal 0 ADJ F
misoprostol 0 NOUN F
400 0 NUM F
microg 0 NOUN F
every 0 DET F
3 0 NUM F
hours 0 NOUN F
for 0 ADP F
a 0 DET F
maximum 0 NOUN F
of 0 ADP F
five 0 NUM F
doses 0 NOUN F
. 0 PUNCT F

The 0 DET T
course 0 NOUN F
of 0 ADP F
misoprostol 0 NOUN F
was 0 VERB F
repeated 0 VERB F
if 0 ADP F
the 0 DET F
woman 0 NOUN F
did 0 PUNCT F
not 0 ADV F
abort 0 PUNCT F
within 0 ADP F
24 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
The 0 DET T
success B-OTHER NOUN F
rate I-OTHER NOUN F
at I-OTHER ADP F
48 I-OTHER NUM F
hours I-OTHER NOUN F
, 0 PUNCT F
induction-to-abortion B-OTHER NOUN F
interval I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
side B-PHYSICAL NOUN F
effects I-PHYSICAL NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
success B-OTHER NOUN F
rate I-OTHER NOUN F
at I-OTHER ADP F
48 I-OTHER NUM F
hours I-OTHER NOUN F
( 0 PUNCT F
sublingual 0 ADP F
: 0 PUNCT F
91 0 NUM F
% 0 SYM F
; 0 PUNCT F
vaginal 0 ADJ F
: 0 PUNCT F
95 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
the 0 DET F
success B-OTHER NOUN F
rate I-OTHER NOUN F
at I-OTHER ADP F
24 I-OTHER NUM F
hours I-OTHER NOUN F
was 0 NUM F
significantly 0 ADV F
higher 0 PUNCT F
in 0 ADP F
the 0 DET F
vaginal 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
85 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
sublingual 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
64 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
median 0 ADJ F
induction-to-abortion B-OTHER NOUN F
interval I-OTHER NOUN F
( 0 PUNCT F
sublingual 0 ADP F
: 0 PUNCT F
13.8 0 NUM F
hours 0 NOUN F
; 0 PUNCT F
vaginal 0 ADJ F
: 0 PUNCT F
12.0 0 NUM F
hours 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Significantly 0 ADV T
more 0 DET F
women 0 NOUN F
in 0 ADP F
the 0 DET F
sublingual 0 ADJ F
group 0 NOUN F
preferred 0 VERB F
the 0 DET F
route 0 NOUN F
to 0 ADP F
which 0 CCONJ F
they 0 PRON F
were 0 VERB F
assigned 0 VERB F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
the 0 DET F
vaginal 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
fever B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
also 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
sublingual 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
use 0 NOUN F
of 0 ADP F
vaginal 0 ADJ F
misoprostol 0 NOUN F
for 0 ADP F
second 0 ADJ F
trimester 0 NOUN F
medical 0 ADJ F
abortion 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
higher 0 PUNCT F
success B-OTHER NOUN F
rate I-OTHER NOUN F
than 0 PUNCT F
sublingual 0 ADJ F
misoprostol 0 NOUN F
at 0 ADP F
24 0 NUM F
hours 0 NOUN F
but 0 CCONJ F
the 0 DET F
abortion B-OTHER NOUN F
rate I-OTHER NOUN F
was 0 VERB F
similar 0 ADJ F
at 0 ADP F
48 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

Vaginal 0 ADJ T
misoprostol 0 NOUN F
should 0 VERB F
be 0 VERB F
the 0 DET F
regimen 0 NOUN F
of 0 ADP F
choice 0 NOUN F
but 0 CCONJ F
sublingual 0 ADJ F
misoprostol 0 NOUN F
is 0 VERB F
also 0 ADV F
an 0 DET F
effective 0 ADJ F
alternative 0 NOUN F
. 0 PUNCT F

18F-FDG 0 NOUN F
PET/CT 0 NOUN T
for 0 ADP F
early 0 ADJ F
prediction 0 NOUN F
of 0 ADP F
response 0 NOUN F
to 0 PUNCT F
neoadjuvant 0 PUNCT F
lapatinib 0 NOUN F
, 0 PUNCT F
trastuzumab 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
their 0 ADJ F
combination 0 NOUN F
in 0 ADP F
HER2-positive 0 ADJ T
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
results 0 CCONJ F
from 0 ADP F
Neo-ALTTO 0 NOUN T
. 0 PUNCT F

UNLABELLED 0 NOUN T
Molecular 0 ADJ T
imaging 0 ADV F
receives 0 VERB F
increased 0 VERB F
attention 0 NOUN F
for 0 ADP F
selecting 0 VERB F
patients 0 NOUN F
who 0 DET F
will 0 VERB F
benefit 0 VERB F
from 0 ADP F
targeted 0 VERB F
anticancer 0 NOUN F
therapies 0 NOUN F
. 0 PUNCT F

Neo-ALTTO 0 ADP T
( 0 PUNCT F
Neoadjuvant 0 ADV T
Lapatinib 0 ADJ T
and/or 0 CCONJ F
Trastuzumab 0 NOUN T
Treatment 0 NOUN T
Optimisation 0 NOUN T
) 0 PUNCT F
enrolled 0 VERB F
455 0 NUM F
women 0 NOUN F
with 0 ADP F
invasive 0 ADJ F
human 0 NOUN F
epidermal 0 ADJ F
growth 0 NOUN F
factor 0 NOUN F
receptor 0 NOUN F
2 0 NUM F
( 0 PUNCT F
HER2 0 NOUN T
) 0 PUNCT F
-positive 0 PUNCT F
breast 0 NOUN F
cancer 0 NOUN F
and 0 CCONJ F
compared 0 VERB F
rates 0 NOUN F
of 0 ADP F
pathologic 0 ADJ F
complete 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
pCR 0 NOUN F
) 0 PUNCT F
to 0 ADP F
neoadjuvant 0 PUNCT F
lapatinib 0 NOUN F
, 0 PUNCT F
trastuzumab 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
their 0 ADJ F
combination 0 NOUN F
. 0 PUNCT F

Each 0 DET T
anti-HER2 0 NOUN F
therapy 0 NOUN F
was 0 VERB F
given 0 VERB F
alone 0 ADJ F
for 0 ADP F
6 0 NUM F
wk 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
by 0 ADP F
12 0 NUM F
wk 0 NOUN F
of 0 ADP F
the 0 DET F
same 0 ADJ F
therapy 0 NOUN F
plus 0 CCONJ F
weekly 0 ADV F
paclitaxel 0 NOUN F
. 0 PUNCT F

The 0 DET T
early 0 ADJ F
metabolic B-PHYSICAL ADJ F
effects I-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
anti-HER2 0 NOUN F
therapies 0 NOUN F
on 0 ADP F
the 0 DET F
primary 0 ADJ F
tumors 0 NOUN F
and 0 CCONJ F
their 0 PUNCT F
predictive 0 ADJ F
values 0 NOUN F
for 0 ADP F
pCR 0 NOUN F
were 0 VERB F
assessed 0 VERB F
in 0 ADP F
a 0 DET F
subset 0 NOUN F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Eighty-six 0 NUM T
patients 0 NOUN F
underwent 0 VERB F
( 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
F-FDG 0 NOUN T
PET/CT 0 NOUN T
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
weeks 0 NOUN F
2 0 NUM F
and 0 CCONJ F
6 0 NUM F
of 0 ADP F
anti-HER2 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

An 0 DET T
imaging 0 ADJ F
core 0 NOUN F
laboratory 0 NOUN F
provided 0 VERB F
central 0 ADJ F
validation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
independent 0 ADJ F
reviewers 0 NOUN F
, 0 PUNCT F
masked 0 ADV F
to 0 ADP F
assigned 0 PUNCT F
treatment 0 NOUN F
arm 0 NOUN F
and 0 CCONJ F
clinical 0 ADJ F
outcomes 0 NOUN F
, 0 PUNCT F
performed 0 ADP F
consensus 0 NOUN F
( 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
F-FDG 0 NOUN T
PET/CT 0 NOUN T
readings 0 NOUN F
. 0 PUNCT F

Maximum 0 NOUN T
standardized 0 VERB F
uptake 0 NOUN F
value 0 NOUN F
( 0 PUNCT F
SUVmax 0 NOUN T
) 0 PUNCT F
reductions 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
measure 0 VERB F
metabolic 0 ADJ F
response 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Seventy-seven 0 PUNCT T
of 0 ADP F
the 0 DET F
86 0 NUM F
enrolled 0 VERB F
patients 0 NOUN F
presented 0 VERB F
an 0 DET F
evaluable 0 ADJ F
baseline 0 NOUN F
( 0 PUNCT F
18 0 NUM F
) 0 PUNCT F
F-FDG 0 NOUN T
PET/CT 0 NOUN T
scan 0 NOUN F
; 0 PUNCT F
of 0 ADP F
these 0 PUNCT F
, 0 PUNCT F
68 0 NUM F
and 0 CCONJ F
66 0 NUM F
were 0 VERB F
evaluable 0 ADJ F
at 0 ADP F
weeks 0 NOUN F
2 0 NUM F
and 0 CCONJ F
6 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Metabolic B-PHYSICAL ADJ T
responses I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
primary 0 ADJ F
tumors 0 NOUN F
were 0 VERB F
evident 0 ADJ F
after 0 ADP F
2 0 NUM F
wk 0 NOUN F
of 0 ADP F
targeted 0 VERB F
therapy 0 NOUN F
and 0 CCONJ F
correlated 0 VERB F
highly 0 ADV F
with 0 ADP F
metabolic 0 ADJ F
responses 0 NOUN F
at 0 ADP F
week 0 NOUN F
6 0 NUM F
( 0 PUNCT F
R 0 NOUN T
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
= 0 SYM F
0.81 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

pCRs 0 ADV F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
greater 0 PUNCT F
SUVmax 0 NOUN T
reductions 0 NOUN F
at 0 ADP F
both 0 CCONJ F
time 0 NOUN F
points 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
SUVmax 0 NOUN T
reductions 0 NOUN F
for 0 ADP F
pCR 0 NOUN F
and 0 CCONJ F
non-pCR 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
were 0 VERB F
54.3 0 NUM F
% 0 SYM F
versus 0 CCONJ F
32.8 0 NUM F
% 0 SYM F
at 0 ADP F
week 0 NOUN F
2 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
61.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
34.1 0 NUM F
% 0 SYM F
at 0 ADP F
week 0 NOUN F
6 0 NUM F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F
( 0 PUNCT F

18 B-PHYSICAL NUM F
) 0 PUNCT F
F-FDG B-PHYSICAL NOUN T
PET/CT I-PHYSICAL NOUN T
metabolic I-PHYSICAL ADJ F
response 0 PUNCT F

Comparing 0 ADP T
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
peer 0 NOUN F
mentoring 0 PUNCT F
and 0 CCONJ F
student 0 ADJ F
mentoring 0 PUNCT F
in 0 ADP F
a 0 DET F
35-week 0 NOUN F
fitness 0 PUNCT F
program 0 NOUN F
for 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
. 0 PUNCT F

To 0 PART T
investigate 0 NOUN F
the 0 DET F
applicability B-OTHER NOUN F
and 0 CCONJ F
effectiveness 0 NOUN F
of 0 ADP F
a 0 DET F
peer-mentored 0 VERB F
exercise 0 NOUN F
program 0 NOUN F
, 0 PUNCT F
this 0 DET F
study 0 NOUN F
compared 0 VERB F
the 0 DET F
retention B-OTHER NOUN F
and 0 CCONJ F
participation B-OTHER NOUN F
rates I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
physical B-PHYSICAL ADJ F
improvements I-PHYSICAL NOUN F
of 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
trained 0 NOUN F
by 0 ADP F
peer 0 NOUN F
mentors 0 NOUN F
( 0 PUNCT F
PM 0 NOUN T
) 0 PUNCT F
to 0 ADP F
a 0 DET F
group 0 NOUN F
trained 0 PUNCT F
by 0 ADP F
young 0 ADJ F
qualified 0 VERB F
student 0 NOUN F
mentors 0 NOUN F
( 0 PUNCT F
SM 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
group 0 NOUN F
of 0 ADP F
older 0 PUNCT F
adults 0 NOUN F
were 0 VERB F
prepared 0 VERB F
as 0 ADP F
peer 0 NOUN F
mentors 0 CCONJ F
through 0 ADP F
a 0 DET F
30-week 0 NOUN F
preparation 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

Later 0 ADJ T
, 0 PUNCT F
60 0 NUM F
older 0 PUNCT F
adults 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
? 0 PUNCT F

SD 0 NOUN T
age 0 NOUN F
: 0 PUNCT F
68.7 0 NUM F
? 0 PUNCT F

6.1 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
recruited 0 VERB F
and 0 CCONJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
either 0 CCONJ F
the 0 DET F
PM 0 NOUN T
or 0 CCONJ F
SM 0 NOUN T
group 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
completed 0 ADV F
an 0 DET F
identical 0 ADJ F
35-week 0 NOUN F
fitness 0 PUNCT F
program 0 NOUN F
. 0 PUNCT F

Pre- 0 ADJ T
, 0 PUNCT F
midterm- 0 ADJ F
and 0 CCONJ F
post-training 0 VERB F
assessments 0 NOUN F
of 0 ADP F
fitness 0 PUNCT F
were 0 VERB F
completed 0 VERB F
and 0 CCONJ F
rates 0 NOUN F
of 0 ADP F
participation 0 NOUN F
and 0 CCONJ F
retention 0 NOUN F
were 0 VERB F
documented 0 VERB F
. 0 PUNCT F

The 0 DET T
same 0 ADJ F
retention 0 NOUN F
rates 0 NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
SM 0 NOUN T
group 0 NOUN F
had 0 VERB F
higher 0 PUNCT F
participation 0 NOUN F
. 0 PUNCT F

Both 0 DET T
groups 0 NOUN F
improved 0 VERB F
significantly 0 ADV F
in 0 ADP F
all 0 DET F
measures 0 NOUN F
of 0 ADP F
fitness 0 PUNCT F
and 0 CCONJ F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
significant 0 ADJ F
post-test 0 ADJ F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
groups 0 NOUN F
in 0 ADP F
the 0 DET F
fitness 0 PUNCT F
measures 0 NOUN F
. 0 PUNCT F

Findings 0 NOUN T
suggest 0 VERB F
that 0 ADP F
the 0 DET F
peer 0 NOUN F
mentor 0 NOUN F
model 0 NOUN F
is 0 VERB F
applicable 0 ADJ F
in 0 ADP F
an 0 DET F
older 0 PUNCT F
adult 0 NOUN F
exercise 0 NOUN F
program 0 NOUN F
and 0 CCONJ F
may 0 VERB F
be 0 PUNCT F
as 0 CCONJ F
effective 0 ADJ F
as 0 ADP F
a 0 DET F
program 0 NOUN F
mentored 0 PUNCT F
by 0 ADP F
young 0 ADJ F
professionals 0 NOUN F
. 0 PUNCT F

Mechanical B-PHYSICAL ADJ T
efficiency I-PHYSICAL NOUN F
and 0 CCONJ F
propulsion B-PHYSICAL NOUN F
technique I-PHYSICAL NOUN F
after 0 ADP F
7 0 NUM F
weeks 0 NOUN F
of 0 ADP F
low-intensity 0 NOUN F
wheelchair 0 ADJ F
training 0 VERB F
. 0 PUNCT F

BACKGROUND 0 NOUN T
To 0 ADV T
evaluate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
7-week 0 NOUN F
low-intensity 0 NOUN F
hand 0 NOUN F
rim 0 NOUN F
wheelchair 0 ADJ F
training 0 VERB F
on 0 ADP F
the 0 DET F
submaximal 0 ADJ F
metabolic 0 ADJ F
cost 0 NOUN F
, 0 PUNCT F
mechanical B-PHYSICAL ADJ F
efficiency I-PHYSICAL NOUN F
and 0 CCONJ F
propulsion 0 NOUN F
technique 0 NOUN F
in 0 ADP F
able-bodied 0 VERB F
participants 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Participants 0 PUNCT T
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
over 0 ADP F
an 0 DET F
experimental 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
n=14 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=7 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
received 0 VERB F
7 0 NUM F
weeks 0 NOUN F
wheelchair 0 ADJ F
training 0 VERB F
( 0 PUNCT F
3 0 NUM F
week 0 NOUN F
( 0 PUNCT F
-1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
70 0 NUM F
min 0 NOUN F
) 0 PUNCT F
at 0 ADP F
a 0 DET F
low 0 ADJ F
intensity 0 NOUN F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
heart 0 NOUN F
rate 0 NOUN F
reserve 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
did 0 VERB F
not 0 ADV F
receive 0 VERB F
training 0 ADV F
. 0 PUNCT F

During 0 ADP T
pre- 0 ADJ F
and 0 CCONJ F
post-tests 0 NOUN F
, 0 PUNCT F
submaximal 0 ADJ F
exercise 0 NOUN F
was 0 VERB F
performed 0 VERB F
on 0 ADP F
a 0 DET F
stationary 0 ADJ F
wheelchair 0 ADJ F
ergometer 0 NOUN F
at 0 ADP F
fixed 0 VERB F
levels 0 NOUN F
of 0 ADP F
power 0 NOUN F
output 0 NOUN F
. 0 PUNCT F

Mechanical B-PHYSICAL ADJ T
efficiency I-PHYSICAL NOUN F
, 0 PUNCT F
oxygen B-PHYSICAL NOUN F
uptake I-PHYSICAL NOUN F
, 0 PUNCT F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
timing B-OTHER PUNCT F
parameters I-OTHER NOUN F
and 0 CCONJ F
stroke B-PHYSICAL NOUN F
angles I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
. 0 PUNCT F

Video 0 PUNCT T
recordings 0 NOUN F
were 0 VERB F
made 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
stroke B-PHYSICAL NOUN F
pattern I-PHYSICAL NOUN F
. 0 PUNCT F

FINDINGS 0 NOUN T
Mechanical B-PHYSICAL ADJ T
efficiency I-PHYSICAL NOUN F
increased 0 VERB F
and 0 CCONJ F
metabolic B-PHYSICAL ADJ F
cost I-PHYSICAL NOUN F
decreased 0 ADP F
significantly 0 ADV F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
compared 0 VERB F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Push B-OTHER NOUN T
time I-OTHER NOUN F
increased 0 VERB F
and 0 CCONJ F
cycle 0 NOUN F
frequency B-OTHER NOUN F
decreased 0 PART F
as 0 ADP F
a 0 DET F
result 0 NOUN F
of 0 ADP F
training 0 VERB F
. 0 PUNCT F

The 0 DET T
stroke B-PHYSICAL NOUN F
angle I-PHYSICAL NOUN F
increased 0 VERB F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
during 0 ADP F
the 0 DET F
training 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
experimental 0 ADJ F
group 0 NOUN F
preferred 0 VERB F
double-looping 0 ADJ F
over 0 ADP F
propulsion 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
mainly 0 ADV F
used 0 PUNCT F
single-looping B-OTHER PUNCT F
over I-OTHER ADP F
propulsion I-OTHER NOUN F
patterns 0 NOUN F
during 0 ADP F
the 0 DET F
post-test 0 ADV F
. 0 PUNCT F

INTERPRETATION 0 NOUN T
A 0 DET T
low-intensity 0 NOUN F
, 0 PUNCT F
7-week 0 NOUN F
training 0 VERB F
protocol 0 NOUN F
has 0 ADJ F
a 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
mechanical B-PHYSICAL ADJ F
efficiency I-PHYSICAL NOUN F
and 0 CCONJ F
metabolic B-PHYSICAL ADJ F
cost I-PHYSICAL NOUN F
of 0 ADP F
wheelchair 0 ADJ F
propulsion 0 NOUN F
in 0 ADP F
able-bodied 0 VERB F
participants 0 NOUN F
. 0 PUNCT F

The 0 DET T
improved 0 VERB F
mechanical 0 ADJ F
efficiency 0 NOUN F
seems 0 NOUN F
to 0 DET F
be 0 PUNCT F
the 0 DET F
result 0 NOUN F
of 0 ADP F
changes 0 NOUN F
in 0 ADP F
propulsion 0 NOUN F
technique 0 NOUN F
that 0 PUNCT F
were 0 VERB F
found 0 VERB F
. 0 PUNCT F

Double-blind 0 ADJ T
randomized 0 VERB F
evaluation 0 NOUN F
of 0 ADP F
intercostal 0 ADJ F
nerve 0 NOUN F
blocks 0 PUNCT F
as 0 ADP F
an 0 DET F
adjuvant 0 NOUN F
to 0 ADP F
subarachnoid 0 NOUN F
administered 0 VERB F
morphine 0 NOUN F
for 0 ADP F
post-thoracotomy 0 NOUN F
analgesia 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
AND 0 CCONJ T
OBJECTIVES 0 NOUN T
Thoracotomy 0 NOUN T
is 0 VERB F
associated 0 VERB F
with 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
compromised 0 VERB F
pulmonary 0 ADJ F
function 0 NOUN F
. 0 PUNCT F

Intercostal 0 ADJ T
nerve 0 NOUN F
blocks 0 PUNCT F
( 0 PUNCT F
INB 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
subarachnoid 0 NOUN F
morphine 0 NOUN F
( 0 PUNCT F
SM 0 NOUN T
) 0 PUNCT F
act 0 VERB F
on 0 ADP F
different 0 ADJ F
portions 0 NOUN F
of 0 ADP F
the 0 DET F
pain 0 NOUN F
pathway 0 NOUN F
. 0 PUNCT F

Each 0 DET T
is 0 ADJ F
effective 0 ADJ F
for 0 ADP F
post-thoracotomy 0 NOUN F
pain B-PAIN NOUN F
relief 0 NOUN F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
of 0 ADP F
these 0 DET F
two 0 NUM F
modalities 0 NOUN F
in 0 ADP F
relieving 0 NUM F
post-thoracotomy B-PAIN NOUN F
pain I-PAIN NOUN F
and 0 CCONJ F
improving 0 VERB F
postoperative B-PHYSICAL ADJ F
pulmonary I-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
has 0 VERB F
not 0 ADV F
been 0 PUNCT F
investigated 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
In 0 ADP T
a 0 DET F
double-blind 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
20 0 NUM F
patients 0 NOUN F
undergoing 0 VERB F
lateral 0 ADJ F
thoracotomy 0 NOUN F
for 0 ADP F
lung 0 NOUN F
resection 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
0.5 0 NUM F
mg 0 NOUN F
SM 0 NOUN T
preoperatively 0 ADV F
and 0 CCONJ F
INB 0 NOUN T
with 0 ADP F
bupivacaine 0 NOUN F
( 0 PUNCT F
INB+ 0 NOUN T
) 0 PUNCT F
prior 0 PUNCT F
to 0 ADP F
wound 0 NOUN F
closure 0 NOUN F
or 0 CCONJ F
0.5 0 NUM F
mg 0 NOUN F
SM 0 NOUN T
with 0 ADP F
INB 0 NOUN T
using 0 VERB F
saline 0 NOUN F
( 0 PUNCT F
INB- 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Visual 0 ADJ T
analog 0 NOUN F
scale 0 NOUN F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
at 0 ADP F
rest 0 NOUN F
, 0 PUNCT F
with 0 ADP F
cough B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
with 0 ADP F
movement B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
ipsilateral I-PHYSICAL ADJ F
arm 0 NOUN F
, 0 PUNCT F
forced B-PHYSICAL VERB F
expiratory I-PHYSICAL ADJ F
volume I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
1 I-PHYSICAL NUM F
second I-PHYSICAL ADJ F
( 0 PUNCT F
FEV1 B-PHYSICAL NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
forced B-PHYSICAL VERB F
vital I-PHYSICAL ADJ F
capacity I-PHYSICAL NOUN F
( 0 PUNCT F
FVC B-PHYSICAL NOUN T
) 0 PUNCT F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
4 0 NUM F
, 0 PUNCT F
24 0 NUM F
, 0 PUNCT F
48 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
72 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
operation 0 NOUN F
. 0 PUNCT F

Opioid B-OTHER NOUN T
use I-OTHER NOUN F
was 0 VERB F
measured 0 VERB F
during 0 ADP F
the 0 DET F
initial 0 ADJ F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
the 0 DET F
operation 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
4 0 NUM F
hours 0 NOUN F
, 0 PUNCT F
the 0 DET F
INB+ 0 NOUN T
group 0 NOUN F
demonstrated 0 ADP F
better 0 CCONJ F
FEV1 B-PHYSICAL NOUN T
( 0 PUNCT F
56.6 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
40.4 0 NUM F
% 0 SYM F
of 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
FVC B-PHYSICAL NOUN T
values 0 NOUN F
( 0 PUNCT F
54.6 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
39.6 0 NUM F
% 0 SYM F
of 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
less 0 ADV F
resting 0 VERB F
and 0 CCONJ F
cough 0 NOUN F
pain 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
FEV1 B-PHYSICAL NOUN T
continued 0 VERB F
to 0 PART F
decline 0 VERB F
in 0 ADP F
the 0 DET F
INB+ 0 NOUN T
group 0 NOUN F
at 0 ADP F
24 0 NUM F
hours 0 NOUN F
to 0 VERB F
lower 0 PUNCT F
than 0 PUNCT F
the 0 DET F
INB- 0 NOUN T
group 0 NOUN F
although 0 ADP F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
were 0 VERB F
similar 0 ADJ F
beyond 0 ADP F
4 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

Opioid B-OTHER NOUN T
usage I-OTHER NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
24 0 NUM F
hours 0 NOUN F
was 0 VERB F
similar 0 ADJ F
( 0 PUNCT F
INB- 0 NOUN T
, 0 PUNCT F
16.7 0 NUM F
mg 0 NOUN F
vs. 0 CCONJ F
INB+ 0 NOUN T
, 0 PUNCT F
13.2 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.7 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Although 0 ADP T
postoperative 0 ADJ F
INB 0 NOUN T
provided 0 VERB F
modest 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
pain 0 NOUN F
and 0 CCONJ F
pulmonary 0 ADJ F
function 0 NOUN F
when 0 ADP F
used 0 VERB F
as 0 ADP F
an 0 DET F
adjuvant 0 NOUN F
to 0 ADP F
0.5 0 NUM F
mg 0 NOUN F
SM 0 NOUN T
for 0 ADP F
post-thoracotomy 0 NOUN F
analgesia 0 NOUN F
, 0 PUNCT F
the 0 DET F
benefits 0 NOUN F
were 0 VERB F
transient 0 ADJ F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
do 0 PUNCT F
not 0 ADV F
recommend 0 VERB F
adding 0 ADP F
INB 0 NOUN T
for 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
lateral 0 ADJ F
thoracotomy 0 NOUN F
who 0 ADP F
receive 0 VERB F
0.5 0 NUM F
mg 0 NOUN F
SM 0 NOUN T
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
evaluation 0 NOUN F
of 0 ADP F
enamel 0 NOUN F
matrix 0 NOUN F
derivative 0 ADJ F
proteins 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
proximal 0 ADJ F
class-II 0 NOUN F
furcation 0 NOUN F
involvements 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
clinical B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
of 0 ADP F
proximal 0 ADJ F
furcations 0 NOUN F
treated 0 VERB F
with 0 ADP F
enamel 0 NOUN F
matrix 0 NOUN F
derivative 0 ADJ F
proteins 0 NOUN F
( 0 PUNCT F
EMD 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

MATERIAL 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Fifteen 0 PUNCT T
patients 0 NOUN F
, 0 PUNCT F
each 0 CCONJ F
with 0 ADP F
a 0 DET F
pair 0 NOUN F
of 0 ADP F
contralateral 0 ADJ F
class-II 0 NOUN F
proximal 0 ADJ F
furcation 0 NOUN F
involvements 0 ADJ F
, 0 PUNCT F
presenting 0 PUNCT F
probing 0 DET F
depths 0 NOUN F
( 0 PUNCT F
PDs 0 NOUN T
) 0 PUNCT F
> 0 SYM F
/=5 0 PUNCT F
mm 0 NOUN F
and 0 CCONJ F
bleeding 0 VERB F
on 0 ADP F
probing 0 ADP F
( 0 PUNCT F
BOP 0 NOUN T
) 0 PUNCT F
were 0 VERB F
selected 0 VERB F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
: 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n=15 0 NOUN F
) 0 PUNCT F
- 0 PUNCT F
open 0 PUNCT F
flap 0 PUNCT F
debridement 0 NOUN F
( 0 PUNCT F
OFD 0 NOUN T
) 0 PUNCT F
+24 0 ADP F
% 0 SYM F
ethylenediaminetetraacetic 0 ADJ F
acid 0 NOUN F
( 0 PUNCT F
EDTA 0 NOUN T
) 0 PUNCT F
conditioning 0 ADV F
; 0 PUNCT F
test 0 ADP F
group 0 NOUN F
( 0 PUNCT F
n=15 0 NOUN F
) 0 PUNCT F
- 0 PUNCT F
OFD+24 0 PUNCT T
% 0 SYM F
EDTA 0 NOUN T
conditioning+EMD 0 PUNCT F
application 0 NOUN F
. 0 PUNCT F

Plaque B-PHYSICAL NOUN T
index 0 NOUN F
( B-PHYSICAL PUNCT F
PI I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
, 0 PUNCT F
BOP B-PHYSICAL NOUN T
, 0 PUNCT F
PD B-PHYSICAL NOUN T
, 0 PUNCT F
gingival B-PHYSICAL ADJ F
margin I-PHYSICAL NOUN F
position 0 NOUN F
( B-PHYSICAL PUNCT F
GMP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
relative B-PHYSICAL ADJ F
vertical I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
horizontal I-PHYSICAL ADJ F
clinical I-PHYSICAL ADJ F
attachment I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
RVCAL B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
RHCAL I-PHYSICAL ADJ T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
vertical B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
horizontal I-PHYSICAL ADJ F
bone I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
( B-PHYSICAL PUNCT F
VBL I-PHYSICAL NOUN T
and B-PHYSICAL CCONJ F
HBL B-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
and 0 CCONJ F
furcation 0 NOUN F
closure 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
immediately 0 ADV F
before 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
and 0 CCONJ F
6 0 NUM F
months 0 NOUN F
after 0 ADP F
the 0 DET F
surgeries 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
6 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
RVCAL B-PHYSICAL ADJ T
gains B-PHYSICAL NOUN F
of 0 ADP F
the 0 DET F
control 0 NOUN F
and 0 CCONJ F
test 0 ADV F
group 0 NOUN F
were 0 VERB F
0.39 0 NUM F
+/- 0 SYM F
1.00 0 NUM F
and 0 CCONJ F
0.54 0 NUM F
+/- 0 SYM F
0.95 0 NUM F
mm 0 NOUN F
, 0 PUNCT F
while 0 ADP F
the 0 DET F
RHCAL B-PHYSICAL PUNCT T
gains 0 NOUN F
were 0 VERB F
1.21 0 NUM F
+/- 0 SYM F
2.28 0 NUM F
and 0 CCONJ F
1.36 0 NUM F
+/- 0 SYM F
1.26 0 NUM F
mm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 PUNCT T

Social 0 ADJ T
support 0 NOUN F
and 0 CCONJ F
abstinence B-MENTAL NOUN F
from 0 ADP F
opiates 0 NOUN F
and 0 CCONJ F
cocaine 0 NOUN F
during 0 ADP F
opioid 0 NOUN F
maintenance 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

Social 0 ADJ T
support 0 NOUN F
may 0 VERB F
play 0 VERB F
an 0 DET F
important 0 ADJ F
role 0 NOUN F
in 0 ADP F
helping 0 ADP F
drug 0 NOUN F
users 0 NOUN F
achieve 0 VERB F
abstinence B-MENTAL ADJ F
; 0 PUNCT F
however 0 ADV F
these 0 DET F
benefits 0 NOUN F
may 0 VERB F
depend 0 VERB F
on 0 ADP F
the 0 DET F
type 0 NOUN F
of 0 ADP F
support 0 NOUN F
experienced 0 VERB F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
prospective 0 ADJ F
observational 0 ADJ F
study 0 NOUN F
, 0 PUNCT F
we 0 PRON F
examined 0 VERB F
the 0 DET F
extent 0 NOUN F
to 0 ADP F
which 0 PUNCT F
general 0 VERB F
and 0 CCONJ F
abstinence-specific 0 ADJ F
support 0 NOUN F
, 0 PUNCT F
both 0 CCONJ F
structural 0 ADJ F
and 0 CCONJ F
functional 0 ADJ F
, 0 PUNCT F
predicted 0 ADP F
opiate 0 ADJ F
and 0 CCONJ F
cocaine 0 NOUN F
abstinence 0 NOUN F
in 0 ADP F
128 0 NUM F
opioid 0 NOUN F
maintenance 0 NOUN F
patients 0 NOUN F
receiving 0 VERB F
either 0 PUNCT F
methadone 0 NOUN F
or 0 CCONJ F
LAAM 0 NOUN T
. 0 PUNCT F

A 0 DET T
new 0 ADJ F
multidimensional 0 ADJ F
self-report 0 ADJ F
instrument 0 ADJ F
assessing 0 ADJ F
abstinence-specific 0 ADJ F
functional 0 ADJ F
support 0 NOUN F
was 0 VERB F
developed 0 VERB F
for 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Previously 0 ADV T
validated 0 VERB F
measures 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
the 0 DET F
remaining 0 ADJ F
types 0 NOUN F
of 0 ADP F
support 0 NOUN F
. 0 PUNCT F

With 0 ADP T
baseline 0 NOUN F
abstinence 0 ADJ F
and 0 CCONJ F
other 0 ADJ F
statistically 0 ADV F
important 0 ADJ F
covariates 0 NOUN F
adjusted 0 VERB F
, 0 PUNCT F
hierarchical 0 ADJ F
logistic 0 ADJ F
regression 0 NOUN F
analyses 0 NOUN F
demonstrated 0 VERB F
that 0 ADP F
the 0 DET F
associations 0 NOUN F
between 0 ADP F
social 0 ADJ F
support 0 NOUN F
at 0 ADP F
study 0 NOUN F
baseline 0 NOUN F
and 0 CCONJ F
biochemically 0 ADV F
confirmed 0 PUNCT F
abstinence 0 ADP F
3 0 NUM F
months 0 NOUN F
later 0 ADJ F
varied 0 VERB F
by 0 ADP F
type 0 NOUN F
of 0 ADP F
support 0 NOUN F
and 0 CCONJ F
by 0 ADP F
drug 0 NOUN F
. 0 PUNCT F

Greater 0 PUNCT T
abstinence-specific B-MENTAL ADJ F
structural I-MENTAL ADJ F
support I-MENTAL NOUN F
( 0 PUNCT F
operationalized 0 PUNCT F
as 0 ADP F
fewer 0 PUNCT F
drug 0 NOUN F
users 0 NOUN F
in 0 ADP F
the 0 DET F
social 0 ADJ F
network 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
decreases 0 NOUN F
in 0 ADP F
three 0 DET F
types 0 NOUN F
of 0 ADP F
negative 0 ADJ F
abstinence-specific B-MENTAL ADJ F
functional I-MENTAL ADJ F
support 0 NOUN F
( 0 PUNCT F
Complaints B-MENTAL PROPN T
about I-MENTAL PUNCT F
Drug I-MENTAL NOUN T
Use B-MENTAL NOUN T
, 0 PUNCT F
Drug B-MENTAL NOUN T
Exposure I-MENTAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
Demoralization B-MENTAL NOUN T
) 0 PUNCT F
predicted B-MENTAL PUNCT F
cocaine B-MENTAL ADV F
, 0 PUNCT F
but 0 CCONJ F
not 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
bifidobacterium 0 NOUN F
breve 0 NOUN F
supplementation 0 NOUN F
on 0 ADP F
intestinal 0 ADJ F
flora 0 NOUN F
of 0 ADP F
low 0 ADJ F
birth 0 NOUN F
weight 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
It 0 PRON T
is 0 VERB F
known 0 VERB F
that 0 ADP F
the 0 DET F
bifidobacteria 0 NOUN F
flora 0 PUNCT F
play 0 NOUN F
important 0 ADJ F
roles 0 NOUN F
in 0 ADP F
mucosal 0 ADJ F
host 0 NOUN F
defense 0 NOUN F
and 0 CCONJ F
can 0 VERB F
prevent 0 ADV F
infectious 0 ADJ F
diseases 0 NOUN F
. 0 PUNCT F

Because 0 PUNCT T
bacterial 0 ADJ F
populations 0 NOUN F
develop 0 VERB F
during 0 ADP F
the 0 DET F
first 0 ADJ F
day 0 NOUN F
of 0 ADP F
life 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
examined 0 VERB F
whether 0 ADP F
the 0 DET F
early 0 ADJ F
administration 0 NOUN F
of 0 ADP F
bifidobacteria 0 NOUN F
has 0 DET F
a 0 DET F
positive 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
health B-PHYSICAL NOUN F
of 0 ADP F
low 0 ADJ F
birth 0 NOUN F
weight 0 NOUN F
infants 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
effects 0 NOUN F
of 0 ADP F
oral 0 ADJ F
administration 0 NOUN F
of 0 ADP F
Bifidobacterium 0 NOUN T
breve 0 NOUN F
( 0 PUNCT F
B. 0 NOUN T
breve 0 PUNCT F
) 0 PUNCT F
supplements 0 NOUN F
were 0 VERB F
studied 0 VERB F
in 0 ADP F
a 0 DET F
controlled 0 VERB F
trial 0 NOUN F
with 0 ADP F
low 0 ADJ F
birth 0 NOUN F
weight 0 NOUN F
infants 0 NOUN F
( 0 PUNCT F
average 0 PUNCT F
birth 0 NOUN F
weight 0 NOUN F
1489 0 NUM F
g 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
infants 0 NOUN F
were 0 VERB F
divided 0 VERB F
into 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
Group 0 NOUN T
A 0 NOUN T
and 0 CCONJ F
B 0 NOUN T
received 0 VERB F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
1.6 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
8 0 NUM F
) 0 PUNCT F
cells 0 NOUN F
of 0 ADP F
B. 0 NOUN T
breve 0 NUM F
supplement 0 NOUN F
twice 0 CCONJ F
a 0 DET F
day 0 NOUN F
, 0 PUNCT F
commencing 0 ADP F
either 0 PUNCT F
from 0 ADP F
several 0 ADJ F
hours 0 NOUN F
after 0 ADP F
birth 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
24 0 NUM F
h 0 NOUN F
after 0 ADP F
birth 0 NOUN F
( 0 PUNCT F
group 0 NOUN F
B 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Group 0 NOUN T
C 0 NOUN T
, 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
received 0 VERB F
no 0 DET F
supplement 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
birth B-PHYSICAL NOUN F
weight I-PHYSICAL NOUN F
, 0 PUNCT F
treatment 0 NOUN F
with 0 ADP F
antibiotics B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
starting 0 DET F
time 0 NOUN F
of 0 ADP F
breast-feeding 0 VERB F
among 0 ADP F
the 0 DET F
three 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

A 0 CCONJ T
Bifidobacterium-predominant 0 ADJ T
flora 0 NOUN F
was 0 VERB F
formed 0 VERB F
at 0 ADP F
an 0 DET F
average 0 NOUN F
of 0 ADP F
2 0 NUM F
weeks 0 NOUN F
after 0 ADP F
birth 0 NOUN F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
at 0 ADP F
an 0 DET F
average 0 NOUN F
of 0 ADP F
4 0 NUM F
weeks 0 NOUN F
after 0 ADP F
birth 0 NOUN F
in 0 ADP F
group 0 NOUN F
B 0 NOUN T
, 0 PUNCT F
while 0 ADP F
no 0 DET F
Bifidobacterium 0 NOUN T
was 0 VERB F
isolated 0 VERB F
in 0 ADP F
eight 0 NUM F
out 0 PUNCT F
of 0 ADP F
10 0 NUM F
infants 0 NOUN F
in 0 ADP F
group 0 NOUN F
C 0 NOUN T
during 0 ADP F
the 0 DET F
observation 0 NOUN F
period 0 NOUN F
of 0 ADP F
7 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

In 0 ADP T
comparison 0 NOUN F
between 0 ADP F
group 0 NOUN F
A 0 NOUN T
and 0 CCONJ F
B 0 NOUN T
, 0 PUNCT F
Bifidobacterium 0 NOUN T
was 0 VERB F
detected 0 ADJ F
significantly 0 ADV F
earlier 0 PUNCT F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
number 0 NOUN F
of 0 ADP F
Enterobacteriaceae 0 NOUN T
present 0 ADJ F
in 0 ADP F
the 0 DET F
infants 0 NOUN F
at 0 ADP F
2 0 NUM F
weeks 0 NOUN F
after 0 ADP F
birth 0 NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
A 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
The 0 DET T
results 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
suggest 0 VERB F
that 0 ADP F
very 0 ADV F
early 0 ADJ F
administration 0 NOUN F
of 0 ADP F
B. 0 NOUN T
breve 0 PUNCT F
to 0 ADP F
low 0 ADJ F
birth 0 NOUN F
weight 0 NOUN F
infants 0 NOUN F
is 0 VERB F
useful 0 ADJ F
in 0 ADP F
promoting 0 VERB F
the 0 DET F
colonization 0 NOUN F
of 0 ADP F
the 0 DET F
Bifidobacterium 0 NOUN T
and 0 CCONJ F
the 0 DET F
formation 0 NOUN F
of 0 ADP F
a 0 DET F
normal 0 ADJ F
intestinal 0 ADJ F
flora 0 ADJ F
. 0 PUNCT F

The 0 DET T
ScanBrit 0 NOUN T
randomised 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
single-blind 0 ADP F
study 0 NOUN F
of 0 ADP F
a 0 DET F
gluten- 0 ADP F
and 0 CCONJ F
casein-free 0 ADJ F
dietary 0 ADJ F
intervention 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
is 0 VERB F
increasing 0 ADJ F
interest 0 NOUN F
in 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
gluten- 0 PUNCT F
and 0 CCONJ F
casein-free 0 ADJ F
diets 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
( 0 PUNCT F
ASDs 0 ADJ T
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
report 0 NOUN F
results 0 PUNCT F
from 0 ADP F
a 0 DET F
two-stage 0 NOUN F
, 0 PUNCT F
24-month 0 NOUN F
, 0 PUNCT F
randomised 0 DET F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
incorporating 0 ADJ F
an 0 DET F
adaptive 0 ADJ F
'catch-up 0 PUNCT F
' 0 PUNCT F
design 0 NOUN F
and 0 CCONJ F
interim 0 ADJ F
analysis 0 NOUN F
. 0 PUNCT F

Stage 0 NOUN T
1 0 NUM F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
saw 0 VERB F
72 0 NUM F
Danish 0 NOUN T
children 0 NOUN F
( 0 PUNCT F
aged 0 DET F
4 0 NUM F
years 0 NOUN F
to 0 ADP F
10 0 NUM F
years 0 NOUN F
11 0 NUM F
months 0 NOUN F
) 0 PUNCT F
assigned 0 PUNCT F
to 0 ADP F
diet 0 NOUN F
( 0 PUNCT F
A 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
non-diet 0 NOUN F
( 0 PUNCT F
B 0 NOUN T
) 0 PUNCT F
groups 0 NOUN F
by 0 ADP F
stratified 0 DET F
randomisation 0 NOUN F
. 0 PUNCT F

Autism B-MENTAL NOUN T
Diagnostic I-MENTAL ADJ T
Observation I-MENTAL NOUN T
Schedule 0 NOUN T
( B-MENTAL PUNCT F
ADOS I-MENTAL NOUN T
) B-MENTAL PUNCT F
and 0 CCONJ F
the 0 DET F
Gilliam 0 NOUN T
Autism 0 NOUN T
Rating 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
GARS 0 NOUN T
) 0 PUNCT F
were 0 VERB F
used 0 VERB F
to 0 PART F
assess 0 NOUN F
core B-MENTAL NOUN F
autism B-MENTAL NOUN F
behaviours B-MENTAL NOUN F
, 0 PUNCT F
Vineland 0 PUNCT T
Adaptive 0 ADJ T
Behaviour 0 NOUN T
Scales 0 NOUN T
( 0 PUNCT F
VABS 0 NOUN T
) 0 PUNCT F
to 0 PART F
ascertain 0 NOUN F
developmental 0 ADJ F
level 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
Attention-Deficit 0 PUNCT T
Hyperactivity 0 NOUN T
Disorder 0 NOUN T
- 0 PUNCT F
IV 0 NUM T
scale 0 NOUN F
( 0 PUNCT F
ADHD-IV 0 NOUN T
) 0 PUNCT F
to 0 PART F
determine 0 NOUN F
inattention 0 NOUN F
and 0 CCONJ F
hyperactivity 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
tested 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Based 0 VERB T
on 0 ADP F
per 0 PUNCT F
protocol 0 NOUN F
repeated 0 VERB F
measures 0 DET F
analysis 0 NOUN F
, 0 PUNCT F
data 0 NOUN F
for 0 ADP F
26 0 NUM F
diet 0 NOUN F
children 0 NOUN F
and 0 CCONJ F
29 0 NUM F
controls 0 NOUN F
were 0 VERB F
available 0 ADJ F
at 0 ADP F
12 0 NUM F
months 0 NOUN F
. 0 PUNCT F

At 0 ADP T
this 0 DET F
point 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
to 0 ADP F
mean 0 NOUN F
diet 0 NOUN F
group 0 NOUN F
scores 0 NOUN F
( 0 PUNCT F
time*treatment 0 DET F
interaction 0 NOUN F
) 0 PUNCT F
on 0 ADP F
sub-domains 0 NOUN F
of 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
neodymium-doped 0 VERB F
yttrium 0 NOUN F
aluminum 0 NOUN F
garnet 0 NOUN F
laser 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
cold 0 ADJ F
knife 0 NOUN F
endoscopic 0 ADJ F
incision 0 NOUN F
of 0 ADP F
urethral 0 ADJ F
strictures 0 CCONJ F
in 0 ADP F
male 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
assess 0 NOUN F
the 0 DET F
effectiveness 0 NOUN F
of 0 ADP F
visual 0 ADJ F
laser 0 NOUN F
ablation 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
neodymium-doped 0 VERB F
yttrium 0 NOUN F
aluminum 0 NOUN F
garnet 0 NOUN F
( 0 PUNCT F
Nd 0 NOUN T
: 0 PUNCT F
YAG 0 NOUN T
) 0 PUNCT F
laser 0 NOUN F
in 0 ADP F
male 0 NOUN F
patients 0 NOUN F
with 0 ADP F
urethral 0 ADJ F
strictures 0 ADP F
and 0 CCONJ F
to 0 PART F
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
with 0 ADP F
those 0 DET F
obtained 0 VERB F
in 0 ADP F
patients 0 NOUN F
treated 0 VERB F
with 0 ADP F
Sachse 0 NOUN T
's 0 PUNCT F
optical 0 ADJ F
urethrotomy 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Fifty 0 PUNCT T
patients 0 NOUN F
aged 0 PROPN F
22 0 NUM F
to 0 ADP F
83 0 NUM F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
61.8 0 NUM F
) 0 PUNCT F
with 0 ADP F
primary 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
26 0 NUM F
, 0 PUNCT F
52 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
recurrent 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
24 0 NUM F
, 0 PUNCT F
48 0 NUM F
% 0 SYM F
) 0 PUNCT F
urethral 0 ADJ F
strictures 0 ADP F
0.3 0 NUM F
to 0 ADP F
2.4 0 NUM F
cm 0 NOUN F
long 0 ADP F
qualified 0 NOUN F
for 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
two 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
30 0 DET F
men 0 NOUN F
treated 0 VERB F
using 0 VERB F
visual 0 ADJ F
laser 0 NOUN F
ablation 0 NOUN F
of 0 ADP F
urethral 0 ADJ F
strictures 0 ADP F
( 0 PUNCT F
VLASU 0 NOUN T
) 0 PUNCT F
with 0 ADP F
Nd 0 NOUN T
: 0 PUNCT F
YAGlaser 0 PUNCT T
and 0 CCONJ F
20 0 NUM F
men 0 NOUN F
treated 0 VERB F
by 0 ADP F
correction 0 NOUN F
of 0 ADP F
urethral 0 ADJ F
strictures 0 ADP F
using 0 SYM F
Sachse 0 NOUN T
's 0 PUNCT F
optical 0 ADJ F
urethrotomy 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
12-month 0 NOUN F
follow-up 0 NOUN F
, 0 PUNCT F
seven 0 NUM F
( 0 PUNCT F
35 0 NUM F
% 0 SYM F
) 0 PUNCT F
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
optical 0 ADJ F
urethrotomy 0 NOUN F
and 0 CCONJ F
21 0 NUM F
( 0 PUNCT F
70 0 NUM F
% 0 SYM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
VLASU 0 NOUN T
group 0 NOUN F
did 0 VERB F
not 0 ADV F
require 0 VERB F
repetition 0 NOUN F
of 0 ADP F
the 0 DET F
procedure B-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
choice 0 NOUN F
of 0 ADP F
VLASU 0 NOUN T
as 0 ADP F
a 0 DET F
method 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
significantly 0 ADV F
decreased 0 VERB F
the 0 DET F
probability 0 NOUN F
of 0 ADP F
therapeutic B-OTHER ADJ F
failure I-OTHER NOUN F
and 0 CCONJ F
recurrence 0 NOUN F
of 0 ADP F
urethral B-PHYSICAL ADJ F
strictures I-PHYSICAL ADP F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
VLASU 0 NOUN T
can 0 VERB F
be 0 VERB F
used 0 VERB F
as 0 ADP F
a 0 DET F
method 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
of 0 ADP F
this 0 PUNCT F
disorder 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
an 0 DET F
effective 0 ADJ F
, 0 PUNCT F
modern 0 NOUN F
, 0 PUNCT F
low-invasive 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
repeatable 0 ADJ F
technique 0 NOUN F
and 0 CCONJ F
is 0 VERB F
technically 0 ADV F
simple 0 ADJ F
and 0 CCONJ F
easy 0 PUNCT F
to 0 ADP F
master 0 NOUN F
. 0 PUNCT F

It 0 PRON T
can 0 VERB F
be 0 VERB F
used 0 VERB F
in 0 ADP F
cases 0 NOUN F
in 0 ADP F
which 0 DET F
introduction 0 NOUN F
of 0 ADP F
a 0 DET F
22 0 NUM F
Char 0 NOUN T
optical 0 ADJ F
urethrotome 0 NOUN F
into 0 ADP F
the 0 DET F
stricture 0 NOUN F
site 0 NOUN F
is 0 VERB F
impossible 0 ADJ F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
multiple 0 ADJ F
strictures 0 CCONJ F
during 0 ADP F
one 0 NUM F
procedure 0 NOUN F
. 0 PUNCT F

The 0 DET T
influence 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
fibre 0 NOUN F
source 0 NOUN F
and 0 CCONJ F
gender 0 NOUN F
on 0 ADP F
the 0 DET F
postprandial B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
and 0 CCONJ F
lipid B-PHYSICAL NOUN F
response I-PHYSICAL NOUN F
in 0 ADP F
healthy 0 ADJ F
subjects 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Consumption 0 NOUN T
of 0 ADP F
soluble 0 ADJ F
dietary 0 ADJ F
fibre 0 NOUN F
is 0 VERB F
correlated 0 VERB F
with 0 ADP F
decreased 0 VERB F
postprandial B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
and 0 CCONJ F
insulin B-PHYSICAL NOUN F
responses I-PHYSICAL NOUN F
and 0 CCONJ F
hence 0 NUM F
has 0 PUNCT F
beneficial 0 ADJ F
effects 0 NOUN F
on 0 ADP F
the 0 DET F
metabolic 0 ADJ F
syndrome 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
OF 0 ADP T
THE 0 DET T
STUDY 0 NOUN T
To 0 PART T
investigate 0 NOUN F
the 0 DET F
effects 0 NOUN F
on 0 ADP F
postprandial B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
, 0 PUNCT F
insulin B-PHYSICAL NOUN F
and 0 CCONJ F
triglyceride B-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
of 0 ADP F
meals 0 NOUN F
enriched 0 VERB F
with 0 ADP F
soluble 0 ADJ F
dietary 0 ADJ F
fibres 0 NOUN F
from 0 ADP F
oats 0 NOUN F
, 0 PUNCT F
rye 0 ADJ F
bran 0 NOUN F
, 0 PUNCT F
sugar 0 NOUN F
beet 0 NOUN F
fibre 0 NOUN F
or 0 CCONJ F
a 0 DET F
mixture 0 NOUN F
of 0 ADP F
these 0 DET F
three 0 NUM F
fibres 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Thirteen 0 PUNCT T
healthy 0 ADJ F
human 0 NOUN F
volunteers 0 NOUN F
( 0 PUNCT F
6 0 NUM F
men 0 NOUN F
and 0 CCONJ F
7 0 NUM F
women 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
20-28 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
subjects 0 NOUN F
came 0 VERB F
to 0 ADP F
the 0 DET F
study 0 ADJ F
centre 0 NOUN F
once 0 PUNCT F
a 0 DET F
week 0 NOUN F
after 0 ADP F
an 0 DET F
overnight 0 CCONJ F
fast 0 ADJ F
to 0 ADP F
ingest 0 ADV F
test 0 VERB F
meals 0 VERB F
and 0 CCONJ F
a 0 DET F
control 0 NOUN F
meal 0 NOUN F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
. 0 PUNCT F

The 0 DET T
meals 0 NOUN F
contained 0 VERB F
either 0 PUNCT F
oat 0 NOUN F
powder 0 NOUN F
( 0 PUNCT F
62 0 NUM F
g 0 NOUN F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
2.7 0 NUM F
soluble 0 ADJ F
fibre 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
rye 0 ADJ F
bran 0 NOUN F
( 0 PUNCT F
31 0 NUM F
g 0 NOUN F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
1.7 0 NUM F
g 0 NOUN F
soluble 0 ADJ F
fibre 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
sugar 0 NOUN F
beet 0 NOUN F
fibre 0 NOUN F
( 0 PUNCT F
19 0 NUM F
g 0 NOUN F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
5 0 NUM F
g 0 NOUN F
soluble 0 ADJ F
fibre 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
a 0 DET F
mixture 0 NOUN F
of 0 ADP F
these 0 DET F
three 0 NUM F
fibres 0 NOUN F
( 0 PUNCT F
74 0 NUM F
g 0 NOUN F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
1.7 0 NUM F
g 0 NOUN F
soluble 0 ADJ F
fibre 0 NOUN F
from 0 ADP F
each 0 DET F
source 0 NOUN F
, 0 PUNCT F
giving 0 VERB F
5 0 NUM F
g 0 NOUN F
soluble 0 ADJ F
fibre 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
no 0 DET F
added 0 PUNCT F
fibre 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
all 0 DET F
adjusted 0 ADV F
to 0 PART F
contain 0 ADJ F
the 0 DET F
same 0 ADJ F
total 0 ADJ F
amount 0 NOUN F
of 0 ADP F
available 0 ADJ F
carbohydrates 0 NOUN F
. 0 PUNCT F

Blood 0 NOUN T
samples 0 NOUN F
were 0 VERB F
drawn 0 VERB F
before 0 ADP F
and 0 CCONJ F
every 0 DET F
30 0 NUM F
min 0 NOUN F
up 0 PUNCT F
to 0 ADP F
180 0 NUM F
min 0 NOUN F
after 0 ADP F
the 0 DET F
meals 0 NOUN F
. 0 PUNCT F

RESULTS 0 DET T
Meals 0 PROPN T
with 0 ADP F
rye 0 ADJ F
bran 0 NOUN F
gave 0 VERB F
a 0 DET F
lower 0 PUNCT F
postprandial B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
peak I-PHYSICAL ADJ F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
meal 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
this 0 DET F
effect 0 NOUN F
was 0 VERB F
more 0 ADV F
pronounced 0 VERB F
in 0 ADP F
women 0 NOUN F
compared 0 VERB F
to 0 ADP F
men 0 NOUN F
. 0 PUNCT F

Oat 0 ADP T
powder 0 NOUN F
, 0 PUNCT F
containing 0 VERB F
a 0 DET F
low 0 ADJ F
amount 0 NOUN F
of 0 ADP F
total 0 ADJ F
fibre 0 NOUN F
and 0 CCONJ F
a 0 DET F
high 0 ADJ F
amount 0 NOUN F
of 0 ADP F
carbohydrates 0 CCONJ F
in 0 ADP F
liquid 0 ADJ F
matrix 0 NOUN F
, 0 PUNCT F
gave 0 VERB F
a 0 DET F
higher 0 PUNCT F
incremental B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
peak 0 ADJ F
concentration B-PHYSICAL NOUN F
compared 0 VERB F
to 0 ADP F
rye 0 CCONJ F
bran 0 ADJ F
and 0 CCONJ F
sugar 0 NOUN F
beet 0 NOUN F
fibre 0 NOUN F
and 0 CCONJ F
higher 0 PUNCT F
insulin B-PHYSICAL NOUN F
incremental I-PHYSICAL ADJ F
area 0 NOUN F
under 0 ADP F
curve 0 NOUN F
compared 0 VERB F
to 0 ADP F
control 0 NOUN F
. 0 PUNCT F

The 0 DET T
oat 0 NOUN F
powder 0 NOUN F
also 0 ADV F
influenced 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
mixed 0 VERB F
meal 0 NOUN F
, 0 PUNCT F
diminishing 0 CCONJ F
the 0 DET F
glucose-lowering B-PHYSICAL VERB F
effects I-PHYSICAL NOUN F
. 0 PUNCT F

Postprandial B-PHYSICAL ADJ T
triglyceride I-PHYSICAL NOUN F
levels B-PHYSICAL NOUN F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
higher 0 PUNCT F
after 0 ADP F
all 0 ADP F
fibre-rich 0 VERB F
meals 0 ADJ F
, 0 PUNCT F
but 0 CCONJ F
only 0 ADV F
significant 0 ADJ F
for 0 ADP F
oat 0 NOUN F
powder 0 NOUN F
and 0 CCONJ F
the 0 DET F
mixed 0 VERB F
meal 0 NOUN F
when 0 ADP F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
meal 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Postprandial B-PHYSICAL PUNCT T
glucose I-PHYSICAL NOUN F
, 0 PUNCT F

VLDL B-PHYSICAL NOUN T
, 0 PUNCT F
apolipoproteins B-PHYSICAL NOUN F
B I-PHYSICAL NOUN T
, 0 PUNCT F
CIII B-PHYSICAL PUNCT T
, 0 PUNCT F
and 0 CCONJ F
E B-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
risk 0 NOUN F
of 0 ADP F
recurrent B-PHYSICAL ADJ F
coronary I-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
Cholesterol 0 NOUN T
and 0 CCONJ F
Recurrent 0 ADJ T
Events 0 NOUN T
( 0 PUNCT F
CARE 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Plasma 0 NOUN T
triglyceride 0 NOUN F
concentration 0 NOUN F
has 0 PUNCT F
been 0 ADP F
an 0 DET F
inconsistent 0 ADP F
independent 0 ADJ F
risk 0 NOUN F
factor 0 NOUN F
for 0 ADP F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
, 0 PUNCT F
perhaps 0 ADV F
because 0 PUNCT F
of 0 ADP F
the 0 DET F
metabolic 0 ADJ F
heterogeneity 0 NOUN F
among 0 ADP F
VLDL 0 NOUN T
particles 0 NOUN F
, 0 PUNCT F
the 0 DET F
main 0 ADJ F
carriers 0 NOUN F
of 0 ADP F
triglycerides 0 NOUN F
in 0 ADP F
plasma 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
nested 0 VERB F
case-control 0 NOUN F
study 0 NOUN F
in 0 ADP F
the 0 DET F
Cholesterol 0 NOUN T
and 0 CCONJ F
Recurrent 0 ADJ T
Events 0 NOUN T
( 0 PUNCT F
CARE 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
, 0 PUNCT F
a 0 DET F
randomized 0 VERB F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
pravastatin 0 NOUN F
in 0 ADP F
4159 0 NUM F
patients 0 NOUN F
with 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
and 0 CCONJ F
average 0 ADJ F
LDL 0 NOUN T
concentrations 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
( 0 PUNCT F
115 0 NUM F
to 0 ADP F
174 0 NUM F
mg/dL 0 NOUN F
, 0 PUNCT F
mean 0 PUNCT F
139 0 NUM F
mg/dL 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Baseline 0 NOUN T
concentrations 0 NOUN F
of 0 ADP F
VLDL-apolipoprotein B-PHYSICAL NOUN T
( 0 PUNCT F
apo 0 NOUN F
) 0 PUNCT F
B B-PHYSICAL NOUN T
( 0 PUNCT F
the B-PHYSICAL DET F
VLDL I-PHYSICAL NOUN T
particle I-PHYSICAL NOUN F
concentration 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
VLDL B-PHYSICAL NOUN T
lipids I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
apoCIII B-PHYSICAL NUM F
and I-PHYSICAL CCONJ F
apoE I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
VLDL+LDL I-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
in I-PHYSICAL ADP F
HDL I-PHYSICAL NOUN T
were 0 VERB F
compared 0 VERB F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
had 0 ADP F
either 0 PUNCT F
a 0 DET F
myocardial 0 ADJ F
infarction 0 NOUN F
or 0 CCONJ F
coronary 0 ADJ F
death 0 NOUN F
( 0 PUNCT F
cases 0 NOUN F
, 0 PUNCT F
n=418 0 NOUN F
) 0 PUNCT F
with 0 ADP F
those 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
who 0 DET F
did 0 CCONJ F
not 0 ADV F
have 0 PUNCT F
a 0 DET F
cardiovascular 0 ADJ F
event 0 NOUN F
( 0 PUNCT F
control 0 NOUN F
subjects 0 NOUN F
, 0 PUNCT F
n=370 0 NOUN F
) 0 PUNCT F
in 0 ADP F
5 0 NUM F
years 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
. 0 PUNCT F

VLDL-cholesterol B-PHYSICAL NOUN T
, 0 PUNCT F
VLDL-triglyceride B-PHYSICAL NOUN T
, 0 PUNCT F
VLDL-apoB B-PHYSICAL NOUN T
, 0 PUNCT F
apoCIII B-PHYSICAL NUM F
and 0 CCONJ F
apoE B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
VLDL+LDL I-PHYSICAL NOUN T
and 0 CCONJ F
apoE B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
HDL I-PHYSICAL NOUN T
were 0 VERB F
all 0 CCONJ F
interrelated 0 ADV F
, 0 PUNCT F
and 0 CCONJ F
each 0 DET F
was 0 VERB F
a 0 DET F
univariate 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
subsequent 0 ADJ F
coronary 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

The 0 DET T
significant 0 ADJ F
independent 0 ADJ F
predictors 0 NOUN F
were 0 VERB F
VLDL-apoB B-PHYSICAL NOUN T
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
[ 0 PUNCT F
RR 0 NOUN T
] 0 PUNCT F
3.2 0 NUM F
for 0 ADP F
highest 0 PUNCT F
to 0 PUNCT F
lowest 0 PUNCT F
quintiles 0 VERB F
, 0 PUNCT F
P 0 NOUN T
: 0 PUNCT F
=0.04 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
apoCIII B-PHYSICAL NUM F
in I-PHYSICAL ADP F
VLDL+LDL I-PHYSICAL NOUN T
( 0 PUNCT F
RR 0 NOUN T
2.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
: 0 PUNCT F
=0.04 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
apoE B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
HDL I-PHYSICAL NOUN T
( 0 PUNCT F
RR 0 NOUN T
1.8 0 NUM F
, 0 PUNCT F
P 0 NOUN T
: 0 PUNCT F
=0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Plasma B-PHYSICAL NOUN T
triglycerides I-PHYSICAL NOUN F
, 0 PUNCT F
a 0 DET F
univariate 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
coronary B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
1.6 0 NUM F
, 0 PUNCT F
P 0 NOUN T
: 0 PUNCT F
=0.03 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
was 0 VERB F
not 0 ADV F
related 0 PUNCT F
to 0 ADP F
coronary B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
( 0 PUNCT F
RR 0 NOUN T
1.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
: 0 PUNCT F
=0.6 0 DET F
) 0 PUNCT F
when 0 ADP F
apoCIII B-PHYSICAL NUM F
in I-PHYSICAL ADP F
VLDL+LDL I-PHYSICAL NOUN T
was 0 ADV F
included 0 VERB F
in 0 ADP F
the 0 DET F
model 0 NOUN F
, 0 PUNCT F
whereas 0 ADP F
apoCIII B-PHYSICAL NOUN F
remained 0 VERB F
significant 0 ADJ F
. 0 PUNCT F

Adjustment 0 NOUN T
for 0 ADP F
LDL- B-PHYSICAL NOUN T
and 0 CCONJ F
HDL-cholesterol B-PHYSICAL NOUN T
did 0 PUNCT F
not 0 ADV F
affect 0 VERB F
these 0 DET F
results 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
plasma 0 NOUN F
concentrations 0 NOUN F
of 0 ADP F
VLDL B-PHYSICAL NOUN T
particles I-PHYSICAL NOUN F
and 0 CCONJ F
apoCIII 0 NUM F
in 0 ADP F
VLDL B-PHYSICAL NOUN T
and 0 CCONJ F
LDL B-PHYSICAL NOUN T
are 0 VERB F
more 0 ADV F
specific 0 ADJ F
measures 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
heart 0 NOUN F
disease 0 NOUN F
risk 0 NOUN F
than 0 ADP F
plasma 0 NOUN F
triglycerides 0 NOUN F
perhaps 0 ADV F
because 0 ADP F
their 0 ADP F
known 0 VERB F
metabolic 0 ADJ F
properties 0 NOUN F
link 0 NOUN F
them 0 PROPN F
more 0 ADV F
closely 0 ADV F
to 0 ADP F
atherosclerosis 0 NOUN F
. 0 PUNCT F

Laser 0 NOUN T
conization 0 NOUN F
versus 0 CCONJ F
cold 0 ADJ F
knife 0 NOUN F
conization 0 NOUN F
. 0 PUNCT F

This 0 DET T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
compares 0 NOUN F
, 0 PUNCT F
for 0 ADP F
the 0 DET F
first 0 ADJ F
time 0 NOUN F
, 0 PUNCT F
measured 0 DET F
blood 0 NOUN F
loss 0 NOUN F
at 0 ADP F
conization 0 NOUN F
and 0 CCONJ F
within 0 ADP F
24 0 NUM F
hours 0 NOUN F
after 0 PUNCT F
using 0 ADP F
either 0 CCONJ F
the 0 DET F
cold 0 ADJ F
knife 0 NOUN F
technique 0 NOUN F
or 0 CCONJ F
the 0 DET F
carbon 0 NOUN F
dioxide 0 PUNCT F
laser 0 NOUN F
scalpel 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
ten 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
laser 0 NOUN F
group 0 NOUN F
of 0 ADP F
55 0 NUM F
patients 0 NOUN F
was 0 VERB F
4.6 0 NUM F
milliliters 0 NOUN F
at 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
within 0 ADP F
, 0 PUNCT F
24 0 NUM F
hours 0 NOUN F
after 0 ADP F
operation 0 NOUN F
compared 0 VERB F
with 0 ADP F
30.1 0 NUM F
milliliters 0 NOUN F
in 0 ADP F
the 0 DET F
cold 0 ADJ F
knife 0 NOUN F
group 0 NOUN F
of 0 ADP F
55 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

More 0 DET T
important 0 ADJ F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
is 0 CCONJ F
that 0 ADP F
the 0 DET F
corresponding 0 VERB F
figures 0 NOUN F
for 0 ADP F
the 0 DET F
range 0 NOUN F
of 0 ADP F
bleeding B-PHYSICAL VERB F
were 0 VERB F
0.4 0 NUM F
to 0 ADP F
155.4 0 ADP F
milliliters 0 ADJ F
and 0 CCONJ F
5.6 0 NUM F
to 0 ADP F
1,570.9 0 NOUN F
milliliters 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
rate 0 NOUN F
for 0 ADP F
bleeding 0 ADP F
complications B-PHYSICAL NOUN F
requiring I-PHYSICAL DET F
surgical I-PHYSICAL ADJ F
intervention I-PHYSICAL NOUN F
was 0 VERB F
1.8 0 NUM F
per 0 CCONJ F
cet 0 ADV F
for 0 ADP F
the 0 DET F
laser 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
14.6 0 NUM F
per 0 ADP F
cent 0 NUM F
for 0 ADP F
the 0 DET F
cold 0 ADJ F
knife 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

This 0 DET T
difference 0 NOUN F
was 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
, 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 ADP F
0.015 0 NUM F
-- 0 PUNCT F
Fischer 0 NOUN T
's 0 PUNCT F
exact 0 ADJ F
test 0 NOUN F
. 0 PUNCT F

Conization 0 NOUN T
for 0 ADP F
treatment 0 NOUN F
of 0 ADP F
premalignant 0 ADJ F
changes 0 NOUN F
of 0 ADP F
the 0 DET F
cervix 0 NOUN F
uteri 0 NOUN F
will 0 PRON F
probably 0 ADV F
remain 0 VERB F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
choice 0 NOUN F
for 0 ADP F
some 0 DET F
time 0 NOUN F
to 0 PUNCT F
come 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
our 0 PUNCT F
opinion 0 NOUN F
that 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
future 0 NOUN F
, 0 PUNCT F
laser 0 NOUN F
conization 0 NOUN F
will 0 VERB F
replace 0 VERB F
cold 0 ADJ F
knife 0 NOUN F
conization 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
long-term 0 NOUN F
vitamin 0 NOUN F
E 0 NOUN T
supplementation 0 NOUN F
on 0 ADP F
cardiovascular B-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
and 0 CCONJ F
cancer B-PHYSICAL NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

CONTEXT 0 NOUN T
Experimental 0 ADJ T
and 0 CCONJ F
epidemiological 0 ADJ F
data 0 NOUN F
suggest 0 VERB F
that 0 ADP F
vitamin 0 NOUN F
E 0 NOUN T
supplementation 0 NOUN F
may 0 VERB F
prevent 0 DET F
cancer 0 NOUN F
and 0 CCONJ F
cardiovascular 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

Clinical 0 ADJ T
trials 0 NOUN F
have 0 ADP F
generally 0 ADV F
failed 0 PUNCT F
to 0 ADP F
confirm 0 DET F
benefits 0 NOUN F
, 0 PUNCT F
possibly 0 ADV F
due 0 CCONJ F
to 0 ADP F
their 0 PUNCT F
relatively 0 ADV F
short 0 ADJ F
duration 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
whether 0 ADP F
long-term 0 NOUN F
supplementation 0 NOUN F
with 0 ADP F
vitamin 0 NOUN F
E 0 NOUN T
decreases 0 NOUN F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
cancer B-PHYSICAL NOUN F
, 0 PUNCT F
cancer B-ADVERSE-EFFECTS NOUN F
death I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
major B-PHYSICAL ADJ F
cardiovascular I-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
, 0 PUNCT F
SETTING 0 VERB T
, 0 PUNCT F
AND 0 CCONJ T
PATIENTS 0 NOUN T
A 0 CCONJ T
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 DET F
international 0 ADJ F
trial 0 NOUN F
( 0 PUNCT F
the 0 DET F
initial 0 ADJ F
Heart 0 NOUN T
Outcomes 0 NOUN T
Prevention 0 NOUN T
Evaluation 0 NOUN T
[ 0 PUNCT F
HOPE 0 NOUN T
] 0 PUNCT F
trial 0 NOUN F
conducted 0 VERB F
between 0 ADP F
December 0 NOUN T
21 0 NUM F
, 0 PUNCT F
1993 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
April 0 NOUN T
15 0 NUM F
, 0 PUNCT F
1999 0 NUM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
at 0 ADP F
least 0 ADV F
55 0 NUM F
years 0 NOUN F
old 0 ADJ F
with 0 ADP F
vascular 0 ADJ F
disease 0 NOUN F
or 0 CCONJ F
diabetes 0 NOUN F
mellitus 0 NOUN F
was 0 VERB F
extended 0 VERB F
( 0 PUNCT F
HOPE-The 0 ADP T
Ongoing 0 PUNCT T
Outcomes 0 NOUN T
[ 0 PUNCT F
HOPE-TOO 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
between 0 ADP F
April 0 NOUN T
16 0 NUM F
, 0 PUNCT F
1999 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
May 0 NOUN T
26 0 NUM F
, 0 PUNCT F
2003 0 NUM F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
initial 0 ADJ F
267 0 NUM F
HOPE 0 NOUN T
centers 0 NOUN F
that 0 ADP F
had 0 PUNCT F
enrolled 0 VERB F
9541 0 NUM F
patients 0 NOUN F
, 0 PUNCT F
174 0 NUM F
centers 0 NOUN F
participated 0 VERB F
in 0 ADP F
the 0 DET F
HOPE-TOO 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
7030 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
at 0 ADP F
these 0 DET F
centers 0 NOUN F
, 0 PUNCT F
916 0 NUM F
were 0 VERB F
deceased 0 VERB F
at 0 ADP F
the 0 DET F
beginning 0 PUNCT F
of 0 ADP F
the 0 DET F
extension 0 NOUN F
, 0 PUNCT F
1382 0 NUM F
refused 0 VERB F
participation 0 NOUN F
, 0 PUNCT F
3994 0 NUM F
continued 0 VERB F
to 0 PART F
take 0 NOUN F
the 0 DET F
study 0 ADJ F
intervention 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
738 0 NUM F
agreed 0 PROPN F
to 0 ADP F
passive 0 ADJ F
follow-up 0 NOUN F
. 0 PUNCT F

Median 0 ADJ T
duration 0 NOUN F
of 0 ADP F
follow-up 0 NOUN F
was 0 VERB F
7.0 0 NUM F
years 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
Daily 0 ADJ T
dose 0 NOUN F
of 0 ADP F
natural 0 ADJ F
source 0 NOUN F
vitamin 0 NOUN F
E 0 NOUN T
( 0 PUNCT F
400 0 NUM F
IU 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
matching 0 VERB F
placebo 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Primary 0 ADJ T
outcomes 0 NOUN F
included 0 DET F
cancer B-PHYSICAL NOUN F
incidence I-PHYSICAL NOUN F
, 0 PUNCT F
cancer B-ADVERSE-EFFECTS NOUN F
deaths I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
major B-PHYSICAL ADJ F
cardiovascular I-PHYSICAL ADJ F
events I-PHYSICAL NOUN F
( 0 PUNCT F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
stroke B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
hydrochlorothiazide 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
cardiac B-PHYSICAL ADJ F
arrhythmias I-PHYSICAL NOUN F
in 0 ADP F
African-American 0 ADJ T
men 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
hypertension 0 NOUN F
and 0 CCONJ F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
left 0 ADJ F
ventricular 0 ADJ F
hypertrophy 0 NOUN F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
hydrochlorothiazide 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
ventricular B-PHYSICAL ADJ F
arrhythmias I-PHYSICAL NOUN F
was 0 VERB F
studied 0 VERB F
in 0 ADP F
45 0 NUM F
hypertensive 0 ADJ F
African-American 0 ADJ T
men 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
left 0 ADJ F
ventricular 0 ADJ F
( 0 PUNCT F
LV 0 NOUN T
) 0 PUNCT F
hypertrophy 0 NOUN F
. 0 PUNCT F

After 0 ADP T
medication 0 NOUN F
washout 0 PUNCT F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
placebo 0 NOUN F
followed 0 VERB F
by 0 ADP F
hydrochlorothiazide 0 NOUN F
. 0 PUNCT F

Clinical B-PHYSICAL ADJ T
, 0 PUNCT F
biochemical B-PHYSICAL ADJ F
, 0 PUNCT F
and 0 CCONJ F
48-hour B-PHYSICAL NOUN F
ambulatory I-PHYSICAL ADJ F
electrocardiographic I-PHYSICAL ADJ F
data I-PHYSICAL NOUN F
was 0 VERB F
collected 0 VERB F
after 0 ADP F
each 0 DET F
treatment 0 NOUN F
phase 0 NOUN F
. 0 PUNCT F

Signal-averaged B-PHYSICAL ADJ T
electrocardiograms I-PHYSICAL NOUN F
were 0 VERB F
recorded 0 VERB F
in 0 ADP F
a 0 DET F
subgroup 0 NOUN F
of 0 ADP F
24 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Average 0 ADJ T
LV B-PHYSICAL NOUN T
posterior I-PHYSICAL ADJ F
wall I-PHYSICAL NOUN F
thickness I-PHYSICAL NOUN F
was 0 VERB F
15 0 NUM F
+/- 0 SYM F
1.1 0 NUM F
mm 0 NOUN F
, 0 PUNCT F
septum 0 NOUN F
16 0 NUM F
+/- 0 SYM F
2 0 NUM F
mm 0 NOUN F
, 0 PUNCT F
LV 0 NOUN T
mass 0 NOUN F
420 0 NUM F
+/- 0 SYM F
90 0 NUM F
g 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
LV 0 NOUN T
mass 0 NOUN F
index 0 NOUN F
212 0 NUM F
= 0 SYM F
51 0 NUM F
g/m2 0 NOUN F
. 0 PUNCT F

Systolic B-PHYSICAL ADJ T
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
was 0 VERB F
168 0 NUM F
+/- 0 SYM F
18 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
after 0 ADP F
the 0 DET F
placebo 0 NOUN F
phase 0 NOUN F
and 0 CCONJ F
146 0 NUM F
+/- 0 SYM F
15 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
after 0 ADP F
hydrochlorothiazide 0 NOUN F
; 0 PUNCT F
diastolic 0 ADJ F
BP 0 NOUN T
was 0 VERB F
103 0 NUM F
+/- 0 SYM F
6 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
and 0 CCONJ F
89 0 NUM F
+/- 0 SYM F
9 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
potassium I-PHYSICAL NOUN F
decreased 0 VERB F
significantly 0 ADV F
from 0 ADP F
4.2 0 NUM F
+/- 0 SYM F
0.4 0 NUM F
mmol/L 0 NOUN F
to 0 ADP F
3.7 0 NUM F
+/- 0 SYM F
0.6 0 NUM F
mmol/L 0 NOUN F
after 0 ADP F
hydrochlorothiazide 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

The 0 DET T
average 0 ADJ F
hourly 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
ventricular B-PHYSICAL ADJ F
premature I-PHYSICAL ADJ F
contractions I-PHYSICAL NOUN F
was 0 VERB F
22 0 PUNCT F
with 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
25 0 NUM F
with 0 ADP F
hydrochlorothiazide 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
3 0 NUM F
and 0 CCONJ F
1 0 NUM F
couplets 0 NOUN F
and 0 CCONJ F
0.2 0 NUM F
and 0 CCONJ F
0.2 0 NUM F
runs 0 NOUN F
of 0 ADP F
ventricular B-PHYSICAL ADJ F
tachycardia I-PHYSICAL NOUN F
per 0 ADP F
patient 0 NOUN F
per 0 ADP F
hour 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Variables 0 NOUN T
of 0 ADP F
signal-averaged B-PHYSICAL VERB F
electrocardiography I-PHYSICAL NOUN F
did 0 PUNCT F
not 0 ADV F
differ 0 VERB F
between 0 ADP F
the 0 DET F
2 0 NUM F
treatments 0 NOUN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
in 0 ADP F
hypertensive 0 ADJ F
African-American 0 ADJ T
men 0 NOUN F
with 0 ADP F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
LV 0 NOUN T
hypertrophy 0 NOUN F
, 0 PUNCT F
hydrochlorothiazide 0 NOUN F
does 0 PUNCT F
not 0 ADP F
worsen 0 PUNCT F
ventricular B-PHYSICAL ADJ F
arrhythmias I-PHYSICAL NOUN F
or 0 CCONJ F
signal-averaged B-PHYSICAL NOUN F
electrocardiographic I-PHYSICAL ADJ F
variables I-PHYSICAL NOUN F
. 0 PUNCT F

Learning 0 PUNCT T
about 0 ADP F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
: 0 PUNCT F
does 0 PUNCT F
comparing 0 ADJ F
with 0 ADP F
inequality 0 NOUN F
symbols 0 NOUN F
help 0 NOUN F
? 0 PUNCT F

This 0 DET T
study 0 NOUN F
investigated 0 VERB F
whether 0 ADP F
instruction 0 NOUN F
that 0 ADJ F
involves 0 PART F
comparing 0 ADP F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
with 0 ADP F
other 0 ADJ F
relational 0 ADJ F
symbols 0 NOUN F
is 0 VERB F
more 0 ADV F
effective 0 ADJ F
at 0 ADP F
imparting 0 PUNCT F
a 0 DET F
relational B-MENTAL ADJ F
interpretation I-MENTAL NOUN F
of I-MENTAL ADP F
the I-MENTAL DET F
equal I-MENTAL ADJ F
sign I-MENTAL NOUN F
than 0 PUNCT F
instruction 0 NOUN F
about 0 PUNCT F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Third- 0 ADV T
and 0 CCONJ F
fourth-grade 0 PUNCT F
students 0 NOUN F
in 0 ADP F
a 0 DET F
comparing 0 PUNCT F
symbols 0 VERB F
group 0 NOUN F
learned 0 ADP F
about 0 PUNCT F
the 0 DET F
greater 0 PUNCT F
than 0 PUNCT F
, 0 PUNCT F
less 0 ADV F
than 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
equal 0 ADJ F
signs 0 NOUN F
and 0 CCONJ F
had 0 PUNCT F
the 0 DET F
opportunity 0 NOUN F
to 0 PART F
compare 0 NOUN F
the 0 DET F
inequality 0 NOUN F
symbols 0 ADJ F
with 0 ADP F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
. 0 PUNCT F

Students 0 NOUN T
in 0 ADP F
an 0 DET F
equal 0 ADJ F
sign 0 ADJ F
group 0 NOUN F
learned 0 ADP F
about 0 PUNCT F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
only 0 ADV F
. 0 PUNCT F

A 0 DET T
third 0 ADJ F
group 0 NOUN F
of 0 ADP F
students 0 NOUN F
served 0 VERB F
as 0 ADP F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
aspects 0 NOUN F
of 0 ADP F
students 0 NOUN F
' 0 PUNCT F
knowledge 0 NOUN F
were 0 VERB F
assessed 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
lesson 0 ADJ F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
conceptual B-MENTAL ADJ F
understanding I-MENTAL VERB F
of I-MENTAL ADP F
the I-MENTAL DET F
equal I-MENTAL ADJ F
sign I-MENTAL NOUN F
, 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
equation B-MENTAL NOUN F
encoding I-MENTAL ADJ F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
problem B-MENTAL NOUN F
solving I-MENTAL PROPN F
. 0 PUNCT F

Students 0 NOUN T
in 0 ADP F
the 0 DET F
comparing 0 PUNCT F
symbols 0 DET F
group 0 NOUN F
showed 0 VERB F
greater 0 PUNCT F
gains 0 NOUN F
in 0 ADP F
conceptual B-MENTAL ADJ F
understanding I-MENTAL VERB F
from 0 ADP F
pretest 0 NOUN F
to 0 ADP F
posttest 0 NOUN F
than 0 VERB F
students 0 NOUN F
in 0 ADP F
the 0 DET F
other 0 ADJ F
two 0 NUM F
groups 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
students 0 NOUN F
in 0 ADP F
the 0 DET F
comparing 0 PUNCT F
symbols 0 DET F
group 0 NOUN F
also 0 ADV F
scored 0 PUNCT F
higher 0 PUNCT F
on 0 ADP F
a 0 DET F
posttest 0 ADV F
that 0 PUNCT F
assessed 0 PUNCT F
knowledge 0 NOUN F
about 0 PUNCT F
inequality B-MENTAL NOUN F
symbols I-MENTAL ADJ F
and 0 CCONJ F
inequality B-MENTAL NOUN F
problem I-MENTAL NOUN F
solving I-MENTAL PROPN F
. 0 PUNCT F

Thus 0 ADV T
, 0 PUNCT F
they 0 PRON F
learned 0 ADP F
about 0 ADP F
three 0 NUM F
symbols 0 ADJ F
in 0 ADP F
the 0 DET F
same 0 ADJ F
amount 0 NOUN F
of 0 ADP F
time 0 NOUN F
as 0 ADP F
other 0 ADJ F
students 0 NOUN F
learned 0 VERB F
about 0 PUNCT F
the 0 DET F
equal 0 ADJ F
sign 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
not 0 ADV F
at 0 ADP F
all 0 PUNCT F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
an 0 DET F
instructional 0 ADJ F
approach 0 NOUN F
involving 0 VERB F
comparison 0 NOUN F
can 0 VERB F
be 0 ADJ F
an 0 DET F
effective 0 ADJ F
tool 0 NOUN F
for 0 ADP F
learning 0 ADP F
about 0 PUNCT F
concepts 0 NOUN F
in 0 ADP F
mathematics 0 NOUN F
. 0 PUNCT F

Sodium 0 NOUN T
bicarbonate 0 NOUN F
, 0 PUNCT F
N-acetylcysteine 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
saline 0 NOUN F
for 0 ADP F
prevention 0 NOUN F
of 0 ADP F
radiocontrast-induced B-ADVERSE-EFFECTS VERB F
nephropathy I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
3 0 NUM F
regimens 0 NOUN F
for 0 ADP F
protecting 0 VERB F
contrast-induced 0 VERB F
nephropathy 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
coronary 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

A 0 DET T
single-center 0 NOUN F
prospective 0 ADJ F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Several 0 ADJ T
protective 0 ADJ F
therapies 0 NOUN F
have 0 ADJ F
been 0 PUNCT F
developed 0 VERB F
to 0 PART F
prevent 0 ADJ F
contrast-induced B-ADVERSE-EFFECTS VERB F
nephropathy I-ADVERSE-EFFECTS NOUN F
( I-ADVERSE-EFFECTS PUNCT F
CIN I-ADVERSE-EFFECTS NOUN T
) I-ADVERSE-EFFECTS PUNCT F
. 0 PUNCT F

We 0 PRON T
aimed 0 VERB F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
bicarbonate 0 NOUN F
by 0 ADP F
comparing 0 VERB F
2 0 NUM F
other 0 ADJ F
regimens 0 NOUN F
, 0 PUNCT F
including 0 ADP F
combination 0 NOUN F
of 0 ADP F
N-acetylcysteine 0 NOUN T
( 0 PUNCT F
NAC 0 NOUN T
) 0 PUNCT F
plus 0 CCONJ F
sodium 0 NOUN F
chloride 0 ADP F
and 0 CCONJ F
sodium 0 NOUN F
chloride 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
to 0 PART F
prevent 0 NOUN F
CIN 0 NOUN T
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
cardiovascular 0 ADJ F
procedures 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 ADP T
prospectively 0 ADV F
enrolled 0 VERB F
264 0 NUM F
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
scheduled 0 VERB F
for 0 ADP F
cardiovascular 0 ADJ F
procedures 0 NOUN F
and 0 CCONJ F
had 0 PUNCT F
a 0 DET F
baseline 0 NOUN F
creatinine 0 NOUN F
level 0 NOUN F
> 0 SYM F
1.2 0 NUM F
mg/dL 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
assigned 0 VERB F
1 0 NUM F
of 0 ADP F
3 0 NUM F
prophylactic 0 ADJ F
regimens 0 NOUN F
: 0 PUNCT F
infusion 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
bicarbonate 0 NOUN F
, 0 PUNCT F
sodium 0 NOUN F
chloride 0 ADP F
, 0 PUNCT F
sodium 0 NOUN F
chloride 0 ADP F
plus 0 CCONJ F
oral 0 ADJ F
NAC 0 NOUN T
( 0 PUNCT F
600 0 NUM F
mg 0 NOUN F
bid 0 CCONJ F
) 0 PUNCT F
. 0 PUNCT F

Contrast-induced B-ADVERSE-EFFECTS VERB T
nephropathy I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
defined 0 VERB F
as 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
serum 0 NOUN F
creatinine 0 NOUN F
level 0 NOUN F
> 0 SYM F
25 0 NUM F
% 0 SYM F
or 0 CCONJ F
0.5 0 NUM F
mg/dL 0 NOUN F
after 0 ADP F
48 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
There 0 CCONJ T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
among 0 ADP F
groups 0 NOUN F
regarding 0 DET F
baseline 0 NOUN F
demographic 0 ADJ F
properties 0 NOUN F
and 0 CCONJ F
nephropathy 0 NOUN F
risk 0 NOUN F
factors 0 NOUN F
. 0 PUNCT F

The 0 DET T
change 0 NOUN F
in 0 ADP F
creatinine B-ADVERSE-EFFECTS NOUN F
clearance I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
sodium 0 NOUN F
bicarbonate 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
other 0 ADJ F
2 0 NUM F
groups 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.007 0 ADP F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
CIN B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
sodium 0 NOUN F
bicarbonate 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
4.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
sodium 0 NOUN F
chloride 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
13.6 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.036 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
tended 0 VERB F
to 0 PART F
be 0 PUNCT F
lower 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
combination 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
12.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.059 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
adjusting 0 VERB F
the 0 DET F
Mehran B-ADVERSE-EFFECTS NOUN T
nephropathy I-ADVERSE-EFFECTS NOUN F
risk 0 NOUN F
score B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
CIN B-ADVERSE-EFFECTS NOUN T
significantly 0 ADV F
reduced 0 VERB F
with 0 ADP F
sodium 0 NOUN F
bicarbonate 0 NOUN F
compared 0 VERB F
with 0 ADP F
sodium 0 NOUN F
chloride 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
adjusted 0 PUNCT F
risk 0 NOUN F
ratio 0 NOUN F
0.29 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.043 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Hydration 0 NOUN T
with 0 ADP F
sodium 0 NOUN F
bicarbonate 0 NOUN F
provides 0 PART F
better 0 PUNCT F
protection 0 NOUN F
against 0 PUNCT F

The 0 DET T
additional 0 ADJ F
value 0 NOUN F
of 0 ADP F
a 0 DET F
night 0 NOUN F
splint 0 VERB F
to 0 ADP F
eccentric 0 ADJ F
exercises 0 NOUN F
in 0 ADP F
chronic 0 ADJ F
midportion 0 NOUN F
Achilles 0 NOUN T
tendinopathy 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
assess 0 NOUN F
whether 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
a 0 DET F
night 0 NOUN F
splint 0 PUNCT F
is 0 ADJ F
of 0 ADP F
added 0 PUNCT F
benefit 0 NOUN F
on 0 ADP F
functional 0 ADJ F
outcome 0 NOUN F
in 0 ADP F
treating 0 VERB F
chronic 0 ADJ F
midportion 0 NOUN F
Achilles 0 NOUN T
tendinopathy 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
single-blind 0 NOUN F
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
single 0 ADJ F
centre 0 NOUN F
, 0 PUNCT F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
set 0 NOUN F
in 0 ADP F
the 0 DET F
Sports 0 NOUN T
Medical 0 ADJ T
Department 0 NOUN T
, 0 PUNCT F
The 0 DET T
Hague 0 NOUN T
Medical 0 ADJ T
Centre 0 NOUN T
, 0 PUNCT F
The 0 DET T
Netherlands 0 ADV T
. 0 PUNCT F

Inclusion 0 NOUN T
criteria 0 NOUN F
were 0 VERB F
: 0 PUNCT F
age 0 NOUN F
18-70 0 NUM F
years 0 NOUN F
, 0 PUNCT F
active 0 ADJ F
participation 0 NOUN F
in 0 ADP F
sports 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
tendon 0 NOUN F
pain 0 NOUN F
localised 0 VERB F
at 0 ADP F
2-7 0 NUM F
cm 0 NOUN F
from 0 ADP F
distal 0 ADJ F
insertion 0 NOUN F
. 0 PUNCT F

Exclusion 0 NOUN T
criteria 0 NOUN F
were 0 ADV F
: 0 PUNCT F
insertional 0 ADJ F
disorders 0 NOUN F
, 0 PUNCT F
partial 0 ADJ F
or 0 CCONJ F
complete 0 ADJ F
ruptures 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
systemic 0 ADJ F
illness 0 NOUN F
. 0 PUNCT F

70 0 NUM F
tendons 0 NOUN F
were 0 VERB F
included 0 VERB F
and 0 CCONJ F
randomised 0 NOUN F
into 0 ADP F
one 0 NUM F
of 0 ADP F
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
eccentric 0 ADJ F
exercises 0 NOUN F
with 0 ADP F
a 0 DET F
night 0 NOUN F
splint 0 PUNCT F
( 0 PUNCT F
night 0 NOUN F
splint 0 PUNCT F
group 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
36 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
eccentric 0 ADJ F
exercises 0 NOUN F
only 0 ADV F
( 0 PUNCT F
eccentric 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n 0 NOUN F
= 0 SYM F
34 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Both 0 PUNCT T
groups 0 NOUN F
completed 0 NOUN F
a 0 DET F
12-week 0 NOUN F
heavy-load 0 NOUN F
eccentric 0 ADJ F
training 0 DET F
programme 0 NOUN F
. 0 PUNCT F

One 0 NUM T
group 0 NOUN F
received 0 VERB F
a 0 DET F
night 0 NOUN F
splint 0 PUNCT F
in 0 ADP F
addition 0 NOUN F
to 0 ADP F
eccentric 0 ADJ F
exercises 0 NOUN F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
at 0 ADP F
12 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
, 0 PUNCT F
Victorian B-PHYSICAL ADJ T
Institute I-PHYSICAL NOUN T
of I-PHYSICAL ADP F
Sport I-PHYSICAL NOUN T
Assessment-Achilles I-PHYSICAL NOUN T
questionnaire 0 NOUN F
( B-PHYSICAL PUNCT F
VISA-A I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
score 0 NOUN F
and 0 CCONJ F
reported B-OTHER VERB F
compliance I-OTHER NOUN F
were 0 VERB F
recorded 0 VERB F
by 0 ADP F
a 0 DET F
single-blind 0 NOUN F
trained 0 ADP F
researcher 0 ADP F
who 0 CCONJ F
was 0 ADV F
blinded 0 ADP F
to 0 ADP F
the 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
After 0 ADP T
12 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
patient B-OTHER NOUN F
satisfaction I-OTHER NOUN F
in 0 ADP F
the 0 DET F
eccentric 0 ADJ F
group 0 NOUN F
was 0 VERB F
63 0 NUM F
% 0 SYM F
compared 0 VERB F
with 0 ADP F
48 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
night 0 NOUN F
splint 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
VISA-A B-PHYSICAL NOUN T
score I-PHYSICAL VERB F
significantly 0 ADV F
improved 0 VERB F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
; 0 PUNCT F
in 0 ADP F
the 0 DET F
eccentric 0 ADJ F
group 0 NOUN F
from 0 ADP F
50.1 0 NUM F
to 0 ADP F
68.8 0 NUM F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
night 0 NOUN F
splint 0 PUNCT F
group 0 NOUN F
from 0 ADP F
49.4 0 NUM F
to 0 ADP F
67.0 0 NUM F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
groups 0 NOUN F
in 0 ADP F
VISA-A B-PHYSICAL NOUN T
score I-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.815 0 PUNCT F
) 0 PUNCT F
and 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
a 0 DET F
vitamin/mineral 0 ADJ F
supplement 0 NOUN F
on 0 ADP F
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Vitamin/mineral 0 ADJ T
supplements 0 NOUN F
are 0 VERB F
among 0 ADP F
the 0 DET F
most 0 PUNCT F
commonly 0 ADV F
used 0 DET F
treatments 0 NOUN F
for 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
the 0 DET F
research 0 NOUN F
on 0 ADP F
their 0 PUNCT F
use 0 NOUN F
for 0 ADP F
treating 0 VERB F
autism 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
limited 0 VERB F
. 0 PUNCT F

METHOD 0 NOUN T
This 0 DET T
study 0 NOUN F
is 0 VERB F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
three 0 NUM F
month 0 NOUN F
vitamin/mineral 0 ADJ F
treatment 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
involved 0 VERB F
141 0 NUM F
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
pre 0 ADP F
and 0 CCONJ F
post 0 PUNCT F
symptoms 0 NOUN F
of 0 ADP F
autism 0 NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

None 0 NUM T
of 0 ADP F
the 0 DET F
participants 0 NOUN F
had 0 PUNCT F
taken 0 VERB F
a 0 DET F
vitamin/mineral 0 ADJ F
supplement 0 NOUN F
in 0 ADP F
the 0 DET F
two 0 NUM F
months 0 NOUN F
prior 0 CCONJ F
to 0 ADP F
the 0 DET F
start 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

For 0 ADP T
a 0 DET F
subset 0 NOUN F
of 0 ADP F
the 0 DET F
participants 0 NOUN F
( 0 PUNCT F
53 0 NUM F
children 0 ADJ F
ages 0 NOUN F
5-16 0 ADJ F
) 0 PUNCT F
pre 0 ADP F
and 0 CCONJ F
post 0 PUNCT F
measurements 0 NOUN F
of 0 ADP F
nutritional 0 ADJ F
and 0 CCONJ F
metabolic 0 ADJ F
status 0 NOUN F
were 0 VERB F
also 0 ADV F
conducted 0 VERB F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
vitamin/mineral 0 ADJ F
supplement 0 NOUN F
was 0 VERB F
generally 0 ADV F
well-tolerated B-OTHER VERB F
, 0 PUNCT F
and 0 CCONJ F
individually 0 ADV F
titrated 0 PROPN F
to 0 ADP F
optimum 0 PUNCT F
benefit 0 PUNCT F
. 0 PUNCT F

Levels B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
many I-PHYSICAL DET F
vitamins I-PHYSICAL NOUN F
, 0 PUNCT F
minerals B-PHYSICAL ADP F
, 0 PUNCT F
and 0 CCONJ F
biomarkers B-PHYSICAL PUNCT F
improved/increased 0 PUNCT F
showing 0 CCONJ F
good 0 ADJ F
compliance B-MENTAL NOUN F
and 0 CCONJ F
absorption B-PHYSICAL NOUN F
. 0 PUNCT F

Statistically 0 ADV T
significant 0 ADJ F
improvements 0 NOUN F
in 0 ADP F
metabolic 0 ADJ F
status 0 NOUN F
were 0 VERB F
many 0 PUNCT F
including 0 CCONJ F
: 0 PUNCT F
total 0 ADJ F
sulfate B-PHYSICAL NOUN F
( 0 PUNCT F
+17 0 CCONJ F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
S-adenosylmethionine B-PHYSICAL NOUN T
( 0 PUNCT F
SAM 0 NOUN T
; 0 PUNCT F
+6 0 VERB F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
reduced 0 VERB F
glutathione B-PHYSICAL NOUN F
( 0 PUNCT F
+17 0 CCONJ F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0008 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
ratio 0 NOUN F
of 0 ADP F
oxidized B-PHYSICAL VERB F
glutathione I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
reduced I-PHYSICAL NOUN F
glutathione I-PHYSICAL NOUN F
( 0 PUNCT F
GSSG 0 NOUN T
: 0 PUNCT F
GSH 0 NOUN T
; 0 PUNCT F
-27 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
nitrotyrosine B-PHYSICAL ADJ F
( 0 PUNCT F
-29 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
ATP B-PHYSICAL NOUN T
( 0 PUNCT F
+25 0 ADP F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.000001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
NADH B-PHYSICAL NOUN T
( 0 PUNCT F
+28 0 ADP F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0002 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
NADPH B-PHYSICAL NOUN T
( 0 PUNCT F
+30 0 NUM F
% 0 SYM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Most 0 PUNCT T
of 0 ADP F
these 0 DET F
metabolic 0 ADJ F
biomarkers 0 CCONJ F
improved 0 ADJ F
to 0 ADP F
normal 0 ADJ F
or 0 CCONJ F
near-normal 0 NOUN F
levels.The 0 PUNCT F
supplement 0 NOUN F
group 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
greater 0 PUNCT F
improvements 0 NOUN F
than 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
on 0 ADP F
the 0 DET F
Parental B-PHYSICAL ADJ T
Global I-PHYSICAL NOUN T
Impressions-Revised I-PHYSICAL PUNCT T
( 0 PUNCT F
PGI-R 0 NOUN T
, 0 PUNCT F
Average 0 ADJ T
Change 0 NOUN T
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.008 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
subscores 0 NOUN F
for 0 ADP F
Hyperactivity B-PHYSICAL NOUN T
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
Tantrumming B-PHYSICAL PUNCT T
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.009 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
Overall B-PHYSICAL ADP T
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
Receptive B-PHYSICAL ADJ T
Language I-PHYSICAL NOUN T
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
the 0 DET F
other 0 ADJ F
three 0 NUM F
assessment 0 NOUN F
tools 0 DET F
the 0 DET F
difference 0 NOUN F
between 0 ADP F
treatment 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
group 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant.Regression 0 NUM F
analysis 0 NOUN F
revealed 0 VERB F
that 0 ADP F
the 0 DET F
degree 0 NOUN F
of 0 ADP F
improvement 0 NOUN F
on 0 ADP F
the 0 DET F
Average 0 ADJ T
Change B-PHYSICAL NOUN T
of I-PHYSICAL ADP F
the I-PHYSICAL DET F
PGI-R I-PHYSICAL NOUN T
was 0 VERB F
strongly 0 ADV F
associated 0 VERB F
with 0 ADP F
several 0 ADJ F
biomarkers 0 CCONJ F
( 0 PUNCT F
adj 0 CCONJ F
. 0 PUNCT F

R2 0 NOUN T
= 0 SYM F
0.61 0 NUM F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0005 0 NUM F
) 0 PUNCT F
with 0 ADP F
the 0 DET F
initial 0 ADJ F
levels 0 NOUN F
of 0 ADP F
biotin 0 NOUN F
and 0 CCONJ F
vitamin 0 NOUN F
K 0 NOUN T
being 0 VERB F
the 0 DET F
most 0 VERB F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
both 0 PUNCT F
biotin 0 NOUN F
and 0 CCONJ F
vitamin 0 NOUN F
K 0 NOUN T
are 0 VERB F
made 0 VERB F
by 0 ADP F
beneficial 0 ADJ F
intestinal 0 ADJ F
flora 0 ADJ F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Oral 0 ADJ T
vitamin/mineral 0 ADJ F
supplementation 0 NOUN F
is 0 VERB F
beneficial 0 ADJ F
in 0 ADP F
improving 0 VERB F
the 0 DET F
nutritional 0 ADJ F
and 0 CCONJ F
metabolic 0 ADJ F
status 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
including 0 VERB F
improvements 0 NOUN F
in 0 ADP F
methylation 0 NOUN F
, 0 PUNCT F
glutathione 0 NOUN F
, 0 PUNCT F
oxidative 0 ADJ F
stress 0 NOUN F
, 0 PUNCT F
sulfation 0 NOUN F
, 0 PUNCT F
ATP 0 NOUN T
, 0 PUNCT F
NADH 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
NADPH 0 NOUN T
. 0 PUNCT F

The 0 DET T
supplement 0 ADJ F
group 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
greater 0 PUNCT F
improvements 0 NOUN F
than 0 CCONJ F
did 0 PUNCT F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
on 0 ADP F
the 0 DET F
PGI-R 0 NOUN T
Average 0 VERB T
Change 0 NOUN T
. 0 PUNCT F

This 0 ADJ T
suggests 0 NOUN F
that 0 ADP F
a 0 DET F
vitamin/mineral 0 ADJ F
supplement 0 NOUN F
is 0 VERB F
a 0 DET F
reasonable 0 ADJ F
adjunct 0 ADJ F
therapy 0 NOUN F
to 0 PART F
consider 0 NOUN F
for 0 ADP F
most 0 PUNCT F
children 0 NOUN F
and 0 CCONJ F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
CLINICAL 0 ADJ T
TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
NUMBER 0 NOUN T
NCT01225198 0 NOUN T
. 0 PUNCT F

Clinically 0 ADV T
relevant 0 ADJ F
improvement 0 NOUN F
of 0 ADP F
recurrence-free B-OTHER ADJ F
survival I-OTHER NOUN F
with 0 ADP F
5-aminolevulinic 0 ADJ F
acid 0 NOUN F
induced 0 VERB F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
tumors 0 NOUN F
. 0 PUNCT F

PURPOSES 0 NOUN T
Fluorescence 0 NOUN T
diagnosis 0 NOUN F
induced 0 VERB F
by 0 ADP F
5-aminolevulinic 0 ADJ F
acid 0 NOUN F
enables 0 VERB F
more 0 DET F
thorough 0 ADP F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
carcinoma 0 NOUN F
compared 0 VERB F
with 0 ADP F
conventional 0 ADJ F
white 0 ADJ F
light 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
single 0 ADJ F
institution 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
trial 0 NOUN F
to 0 PART F
investigate 0 NOUN F
whether 0 ADP F
the 0 DET F
residual 0 ADJ F
tumor 0 NOUN F
rate 0 NOUN F
and 0 CCONJ F
long-term 0 NOUN F
tumor 0 NOUN F
recurrence 0 NOUN F
can 0 VERB F
be 0 VERB F
decreased 0 VERB F
by 0 ADP F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
301 0 NUM F
patients 0 NOUN F
underwent 0 VERB F
transurethral 0 ADJ F
resection 0 NOUN F
of 0 ADP F
bladder 0 NOUN F
tumors 0 NOUN F
with 0 ADP F
white 0 ADJ F
light 0 ADJ F
or 0 CCONJ F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
. 0 PUNCT F

Transurethral 0 ADJ T
resection 0 NOUN F
was 0 VERB F
repeated 0 VERB F
5 0 NUM F
to 0 ADP F
6 0 NUM F
weeks 0 NOUN F
later 0 ADJ F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
residual 0 ADJ F
tumor 0 NOUN F
rate 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 ADP F
recurrence-free B-OTHER ADJ F
survival I-OTHER NOUN F
patient 0 NOUN F
followup 0 NOUN F
was 0 VERB F
performed 0 ADP F
every 0 DET F
3 0 NUM F
months 0 NOUN F
by 0 ADP F
white 0 ADJ F
light 0 ADJ F
cystoscopy 0 NOUN F
and 0 CCONJ F
urine 0 NOUN F
cytology 0 NOUN F
. 0 PUNCT F

Recurrence-free B-OTHER ADJ T
survival I-OTHER NOUN F
was 0 VERB F
analyzed 0 VERB F
via 0 ADP F
Kaplan-Meier 0 ADJ T
methods 0 NOUN F
and 0 CCONJ F
multivariable 0 ADJ F
Cox 0 NOUN T
regression 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
191 0 NUM F
patients 0 NOUN F
with 0 ADP F
superficial 0 ADJ F
bladder 0 NOUN F
carcinoma 0 NOUN F
were 0 VERB F
available 0 ADJ F
for 0 ADP F
efficacy 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
residual 0 ADJ F
tumor B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
was 0 VERB F
25.2 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADP F
arm 0 NOUN F
versus 0 CCONJ F
4.5 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
arm 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Median 0 ADJ T
followup 0 NOUN F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADP F
arm 0 NOUN F
in 0 ADP F
103 0 NUM F
cases 0 NOUN F
was 0 VERB F
21.2 0 NUM F
months 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
4 0 NUM F
to 0 ADP F
40 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
20.5 0 NUM F
( 0 PUNCT F
range 0 NOUN F
3 0 NUM F
to 0 ADP F
40 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
88 0 NUM F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
arm 0 NOUN F
. 0 PUNCT F

Recurrence-free B-OTHER ADJ T
survival I-OTHER NOUN F
in 0 ADP F
the 0 DET F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
group 0 NOUN F
was 0 VERB F
89.6 0 NUM F
% 0 SYM F
after 0 ADP F
12 0 NUM F
and 0 CCONJ F
24 0 NUM F
months 0 NOUN F
compared 0 VERB F
with 0 ADP F
73.8 0 NUM F
% 0 SYM F
and 0 CCONJ F
65.9 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
white 0 ADJ F
light 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
superiority 0 NOUN F
proved 0 VERB F
to 0 PART F
be 0 PUNCT F
independent 0 ADJ F
of 0 ADP F
risk 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

The 0 DET T
adjusted 0 ADV F
hazard 0 NOUN F
ratio 0 NOUN F
of 0 ADP F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
versus 0 CCONJ F
white 0 ADJ F
light 0 ADJ F
transurethral 0 ADJ F
resection 0 NOUN F
was 0 VERB F
0.33 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
0.16 0 NUM F
to 0 ADP F
0.67 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Fluorescence 0 NOUN T
diagnosis 0 NOUN F
is 0 VERB F
significantly 0 ADV F
superior 0 ADJ F
to 0 ADP F
conventional 0 ADJ F
white 0 ADJ F
light 0 ADJ F
transurethral 0 ADJ F
resection 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
residual 0 ADJ F
tumor B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
and 0 CCONJ F
recurrence-free B-OTHER ADJ F
survival I-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
differences 0 NOUN F
in 0 ADP F
recurrence-free B-OTHER ADJ F
survival I-OTHER NOUN F
imply 0 PUNCT F
that 0 ADP F
fluorescence 0 NOUN F
diagnosis 0 NOUN F
is 0 VERB F
a 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
procedure 0 NOUN F
for 0 ADP F
decreasing 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
tumor B-PHYSICAL NOUN F
recurrences I-PHYSICAL NOUN F
. 0 PUNCT F

Echocardiographic 0 ADJ T
evaluation 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
ventricular 0 ADJ F
dysfunction 0 NOUN F
treated 0 VERB F
with 0 ADP F
carvedilol 0 NOUN F
. 0 PUNCT F

Echocardiography 0 NOUN T
is 0 VERB F
used 0 VERB F
to 0 PART F
measure 0 VERB F
the 0 DET F
therapeutic 0 ADJ F
effectiveness 0 NOUN F
of 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
adults 0 NOUN F
and 0 CCONJ F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
purposes 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
were 0 VERB F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
to 0 PART F
assess 0 ADJ F
baseline 0 NOUN F
echocardiographic 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
outcome 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
to 0 PART F
investigate 0 NOUN F
changes 0 NOUN F
in 0 ADP F
echocardiographic 0 ADJ F
parameters 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
to 0 PART F
compare 0 NOUN F
these 0 DET F
echocardiographic 0 ADJ F
changes 0 NOUN F
with 0 ADP F
changes 0 NOUN F
in 0 ADP F
plasma 0 NOUN F
levels 0 NOUN F
of 0 ADP F
b-type 0 NOUN F
natriuretic 0 ADJ F
peptide 0 NOUN F
( 0 PUNCT F
BNP 0 NOUN T
) 0 PUNCT F
in 0 ADP F
a 0 DET F
population 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
ventricular 0 ADJ F
dysfunction 0 NOUN F
and 0 CCONJ F
symptomatic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
treated 0 VERB F
with 0 ADP F
carvedilol 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

All 0 DET T
available 0 ADJ F
baseline 0 NOUN F
and 0 CCONJ F
6-month 0 NOUN F
echocardiograms 0 NOUN F
from 0 ADP F
Pediatric 0 ADJ T
Carvedilol 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
PCT 0 NOUN T
) 0 PUNCT F
participants 0 NOUN F
( 0 PUNCT F
carvedilol 0 NOUN F
n 0 NOUN F
= 0 SYM F
161 0 NUM F
; 0 PUNCT F
placebo 0 NOUN F
n 0 NOUN F
= 0 SYM F
55 0 NUM F
) 0 PUNCT F
were 0 VERB F
reviewed 0 VERB F
. 0 PUNCT F

Systolic B-PHYSICAL ADJ T
and 0 CCONJ F
diastolic B-PHYSICAL ADJ F
sphericity I-PHYSICAL NOUN F
index I-PHYSICAL NOUN F
( 0 PUNCT F
SI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
110 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
TEI 0 NOUN T
index 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
145 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
systemic 0 ADJ F
ventricular 0 ADJ F
dP/dt 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
70 0 NUM F
) 0 PUNCT F
were 0 VERB F
measured 0 VERB F
. 0 PUNCT F

The 0 DET T
PCT 0 NOUN T
composite 0 NOUN F
definition 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
outcome 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
worsened 0 VERB F
, 0 PUNCT F
improved 0 DET F
, 0 PUNCT F
or 0 CCONJ F
unchanged 0 ADJ F
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
. 0 PUNCT F

For 0 ADP T
all 0 DET F
patients 0 NOUN F
, 0 PUNCT F
baseline 0 NOUN F
TEI 0 NOUN T
index 0 NOUN F
was 0 VERB F
a 0 DET F
predictor 0 NOUN F
of 0 ADP F
worsened B-PHYSICAL VERB F
outcome I-PHYSICAL NOUN F
. 0 PUNCT F

Only 0 ADV T
children 0 ADJ F
treated 0 VERB F
with 0 ADP F
carvedilol 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
systolic B-PHYSICAL ADJ F
SI I-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
B 0 NOUN T
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
diastolic B-PHYSICAL ADJ F
SI I-PHYSICAL NOUN T
( 0 PUNCT F
P 0 NOUN T
B 0 NOUN T
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
TEI B-PHYSICAL NOUN T
index I-PHYSICAL NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

An 0 DET T
inverse 0 ADJ F
correlation 0 NOUN F
between 0 ADP F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
BNP I-PHYSICAL NOUN T
and 0 CCONJ F
changes B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
dP/dt I-PHYSICAL NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
-0.45 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
was 0 VERB F
found 0 VERB F
only 0 ADV F
in 0 ADP F
the 0 DET F
carvedilol 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

In 0 ADP T
conclusion 0 NOUN F
, 0 PUNCT F
TEI 0 NOUN T
index 0 NOUN F
predicted 0 VERB F
outcome 0 NOUN F
in 0 ADP F
children 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
ventricular 0 ADJ F
dysfunction 0 NOUN F
and 0 CCONJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

Carvedilol 0 NOUN T
may 0 VERB F
have 0 PUNCT F
a 0 DET F
beneficial 0 ADJ F
effect 0 NOUN F
on 0 ADP F
reversal 0 NOUN F
of 0 ADP F
left 0 ADJ F
ventricular 0 ADJ F
remodeling 0 VERB F
and 0 CCONJ F
global 0 ADJ F
ventricular 0 ADJ F
function 0 NOUN F
in 0 ADP F
pediatric 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

The 0 DET T
dipeptidyl 0 PUNCT F
peptidase-4 0 NOUN F
inhibitor 0 NOUN F
PHX1149 0 NOUN T
improves 0 NOUN F
blood B-PHYSICAL NOUN F
glucose I-PHYSICAL NOUN F
control I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
mellitus 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
PHX1149 0 NOUN T
, 0 PUNCT F
a 0 DET F
novel 0 ADJ F
dipeptidyl 0 PUNCT F
peptidase-4 0 NOUN F
( 0 PUNCT F
DPP4 0 NOUN T
) 0 PUNCT F
inhibitor 0 NOUN F
, 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 ADV T
is 0 VERB F
a 0 DET F
multicentre 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
4-week 0 NOUN F
study 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
type 0 NOUN F
2 0 NUM F
diabetes 0 PUNCT F
with 0 ADP F
suboptimal 0 ADJ F
metabolic 0 ADJ F
control 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
baseline 0 NOUN F
haemoglobin 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
1c 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
HbA 0 NOUN T
( 0 PUNCT F
1c 0 NOUN F
) 0 PUNCT F
) 0 PUNCT F
of 0 ADP F
7.3 0 NUM F
to 0 ADP F
11.0 0 NUM F
% 0 SYM F
were 0 VERB F
randomized 0 VERB F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
to 0 PART F
receive 0 VERB F
once-daily 0 ADV F
oral 0 ADJ F
therapy 0 NOUN F
with 0 ADP F
either 0 CCONJ F
PHX1149 0 NOUN T
( 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
200 0 NUM F
or 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
; 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
on 0 ADP F
a 0 DET F
constant 0 ADJ F
background 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
either 0 CCONJ F
metformin 0 NOUN F
alone 0 ADJ F
or 0 CCONJ F
metformin 0 NOUN F
plus 0 CCONJ F
a 0 DET F
glitazone 0 ADJ F
. 0 PUNCT F

RESULTS 0 NOUN T
Treatment 0 NOUN T
with 0 ADP F
100 0 NUM F
, 0 PUNCT F
200 0 NUM F
or 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
of 0 ADP F
PHX1149 0 NOUN T
significantly 0 ADV F
decreased 0 ADV F
postprandial B-PHYSICAL ADJ F
glucose I-PHYSICAL NOUN F
area 0 NOUN F
under B-PHYSICAL ADP F
the I-PHYSICAL DET F
curve 0 NOUN F
AUC B-PHYSICAL NOUN T
( 0 PUNCT F
0-2 B-PHYSICAL NUM F
h 0 NOUN F
) 0 PUNCT F
by 0 ADP F
approximately 0 ADV F
20 0 NUM F
% 0 SYM F
( 0 PUNCT F
+0.11 0 PUNCT F
+/- 0 ADP F
0.50 0 NUM F
, 0 PUNCT F
-2.08 0 NUM F
+/- 0 SYM F
0.51 0 NUM F
, 0 PUNCT F
-1.73 0 NUM F
+/- 0 SYM F
0.49 0 NUM F
and 0 CCONJ F
-1.88 0 NUM F
+/- 0 SYM F
0.48 0 NUM F
mmol/l 0 NOUN F
x 0 SYM F
h 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
for 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
100 0 NUM F
, 0 PUNCT F
200 0 NUM F
and 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.002 0 NUM F
, 0 PUNCT F
0.008 0 NUM F
and 0 CCONJ F
0.004 0 NUM F
vs. 0 CCONJ F
placebo 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Postprandial B-PHYSICAL ADJ T
AUC I-PHYSICAL NOUN T
( 0 PUNCT F
0-2 B-PHYSICAL NUM F
h B-PHYSICAL NOUN F
) 0 PUNCT F
of B-PHYSICAL ADP F
intact I-PHYSICAL ADJ F
glucagon-like B-PHYSICAL ADJ F
peptide-1 I-PHYSICAL NOUN F
, 0 PUNCT F
the 0 DET F
principal 0 ADJ F
mediator 0 NOUN F
of 0 ADP F
the 0 DET F
biological 0 ADJ F
effects 0 NOUN F
of 0 ADP F
DPP4 0 NOUN T
inhibitors 0 NOUN F
, 0 PUNCT F
was 0 VERB F
increased 0 VERB F
by 0 ADP F
3.90 0 NUM F
+/- 0 SYM F
2.83 0 NUM F
, 0 PUNCT F
11.63 0 NUM F
+/- 0 SYM F
2.86 0 NUM F
, 0 PUNCT F
16.42 0 NUM F
+/- 0 SYM F
2.72 0 NUM F
and 0 CCONJ F
15.75 0 NUM F
+/- 0 SYM F
2.71 0 NUM F
pmol/l 0 NOUN F
x 0 SYM F
h 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
for 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
100 0 NUM F
, 0 PUNCT F
200 0 NUM F
and 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.053 0 NUM F
, 0 PUNCT F
0.001 0 NUM F
and 0 CCONJ F
0.002 0 NUM F
vs. 0 CCONJ F
placebo 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Mean 0 ADJ T
HbA B-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
1c I-PHYSICAL PUNCT F

Dose 0 NOUN T
response 0 NOUN F
effect 0 NOUN F
of 0 ADP F
cyclical 0 ADJ F
medroxyprogesterone 0 NOUN F
on 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
with 0 ADP F
placebo 0 NOUN F
the 0 DET F
dose-response 0 NOUN F
effect 0 NOUN F
of 0 ADP F
cyclical 0 ADJ F
doses 0 NOUN F
of 0 ADP F
the 0 DET F
C21 0 NOUN T
progestogen 0 NOUN F
, 0 PUNCT F
medroxyprogesterone 0 NOUN F
acetate 0 NOUN F
( 0 PUNCT F
MPA 0 NOUN T
) 0 PUNCT F
on 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
( 0 PUNCT F
BP 0 NOUN T
) 0 PUNCT F
when 0 ADP F
administered 0 VERB F
to 0 PUNCT F
normotensive 0 ADJ F
postmenopausal 0 ADJ F
women 0 NOUN F
receiving 0 VERB F
a 0 DET F
fixed 0 VERB F
mid-range 0 NOUN F
daily 0 ADJ F
dose 0 NOUN F
of 0 ADP F
conjugated 0 PUNCT F
equine 0 ADJ F
oestrogen 0 NOUN F
( 0 PUNCT F
CEE 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Twenty 0 NUM T
normotensive 0 ADJ F
postmenopausal 0 ADJ F
women 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
age 0 NOUN F
53 0 NUM F
years 0 NOUN F
) 0 PUNCT F
participated 0 PUNCT F
in 0 ADP F
the 0 DET F
study 0 NOUN F
which 0 DET F
used 0 VERB F
a 0 DET F
double-blind 0 ADJ F
crossover 0 NOUN F
design 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
four 0 NUM F
randomised 0 VERB F
treatment 0 NOUN F
phases 0 NOUN F
, 0 PUNCT F
each 0 ADP F
of 0 ADP F
4 0 NUM F
weeks 0 ADJ F
duration 0 NOUN F
. 0 PUNCT F

The 0 DET T
four 0 NUM F
blinded 0 DET F
treatments 0 NOUN F
were 0 VERB F
MPA 0 NOUN T
2.5 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
MPA 0 NOUN T
5 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
MPA 0 NOUN T
10 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
matching 0 PRON F
placebo 0 NOUN F
, 0 PUNCT F
taken 0 VERB F
for 0 ADP F
the 0 DET F
last 0 ADJ F
14 0 NUM F
days 0 NOUN F
of 0 ADP F
each 0 DET F
28 0 NUM F
day 0 NOUN F
treatment 0 NOUN F
cycle 0 NOUN F
. 0 PUNCT F

CEE 0 NOUN T
0.625 0 NUM F
mg 0 NOUN F
was 0 VERB F
also 0 ADV F
administered 0 VERB F
once 0 PUNCT F
daily 0 VERB F
as 0 PUNCT F
open 0 PUNCT F
labelled 0 VERB F
tablets 0 NOUN F
to 0 ADP F
all 0 DET F
subjects 0 NOUN F
throughout 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Clinic B-PHYSICAL ADJ T
BP I-PHYSICAL NOUN T
was 0 VERB F
measured 0 VERB F
weekly 0 ADV F
with 0 ADP F
the 0 DET F
mean 0 NOUN F
values 0 NOUN F
of 0 ADP F
weeks 0 NOUN F
3 0 NUM F
and 0 CCONJ F
4 0 NUM F
of 0 ADP F
each 0 DET F
phase 0 NOUN F
used 0 VERB F
for 0 ADP F
analysis 0 NOUN F
. 0 PUNCT F

Ambulatory B-PHYSICAL ADJ T
BP I-PHYSICAL NOUN T
was 0 VERB F
performed 0 VERB F
in 0 ADP F
the 0 DET F
final 0 ADJ F
week 0 NOUN F
of 0 ADP F
each 0 DET F
phase 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Compared 0 VERB T
with 0 ADP F
the 0 DET F
placebo 0 NOUN F
phase 0 NOUN F
, 0 PUNCT F
end 0 NOUN F
of 0 ADP F
phase 0 NOUN F
clinic B-PHYSICAL VERB F
BP I-PHYSICAL NOUN T
was 0 VERB F
unchanged 0 VERB F
by 0 ADP F
any 0 PUNCT F
of 0 ADP F
the 0 DET F
progestogen 0 NOUN F
treatments 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
dose-dependent 0 ADJ F
decrease 0 NOUN F
in 0 ADP F
ambulatory B-PHYSICAL ADJ F
daytime I-PHYSICAL NOUN F
diastolic I-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
mean 0 NOUN F
arterial B-PHYSICAL ADJ F
BP B-PHYSICAL NOUN T
with 0 ADP F
the 0 DET F
progestogen 0 NOUN F
treatments 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
In 0 ADP T
a 0 DET F
regimen 0 NOUN F
of 0 ADP F
postmenopausal 0 ADJ F
hormone 0 NOUN F
replacement 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
a 0 DET F
fixed 0 VERB F
mid-range 0 NOUN F
daily 0 ADJ F
dose 0 NOUN F
of 0 ADP F
CEE 0 NOUN T
combined 0 VERB F
with 0 ADP F
a 0 DET F
cyclical 0 ADJ F
regimen 0 NOUN F
of 0 ADP F
a 0 DET F
C21 0 NOUN T
progestogen 0 NOUN F
spanning 0 PROPN F
the 0 DET F
current 0 ADJ F
clinical 0 ADJ F
dose 0 NOUN F
range 0 NOUN F
, 0 PUNCT F
the 0 DET F
progestogen 0 NOUN F
has 0 PUNCT F
either 0 PUNCT F
no 0 DET F
effect 0 NOUN F
or 0 CCONJ F
a 0 DET F
small 0 ADJ F
dose-dependent 0 ADJ F
reduction 0 NOUN F
in 0 PUNCT F

LNH-84 0 NOUN T
regimen 0 NOUN F
: 0 PUNCT F
a 0 DET F
multicenter 0 NOUN F
study 0 NOUN F
of 0 ADP F
intensive 0 ADJ F
chemotherapy 0 NOUN F
in 0 ADP F
737 0 NUM F
patients 0 NOUN F
with 0 ADP F
aggressive 0 ADJ F
malignant 0 ADJ F
lymphoma 0 NOUN F
. 0 PUNCT F

From 0 ADP T
July 0 NOUN T
1984 0 NUM F
to 0 ADP F
September 0 NOUN T
1987 0 NUM F
, 0 PUNCT F
737 0 NUM F
patients 0 NOUN F
with 0 ADP F
aggressive 0 ADJ F
malignant 0 ADJ F
lymphoma 0 NOUN F
( 0 PUNCT F
ML 0 NOUN T
) 0 PUNCT F
were 0 VERB F
treated 0 VERB F
by 0 ADP F
an 0 DET F
intensive 0 ADJ F
regimen 0 NOUN F
( 0 PUNCT F
LNH-84 0 NOUN T
) 0 PUNCT F
comprising 0 CCONJ F
three 0 NUM F
or 0 CCONJ F
four 0 NUM F
courses 0 NOUN F
of 0 ADP F
doxorubicin 0 NOUN F
, 0 PUNCT F
75 0 NUM F
mg/m2 0 ADV F
; 0 PUNCT F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
1,200 0 NUM F
mg/m2 0 ADV F
; 0 PUNCT F
vindesine 0 NOUN F
, 0 PUNCT F
2 0 NUM F
mg/m2 0 NOUN F
x 0 ADJ F
2 0 NUM F
; 0 PUNCT F
bleomycin 0 NOUN F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
x 0 SYM F
2 0 NUM F
; 0 PUNCT F
and 0 CCONJ F
prednisolone 0 NOUN F
, 0 PUNCT F
60 0 NUM F
mg/m2 0 NOUN F
x 0 SYM F
5 0 NUM F
( 0 PUNCT F
ACVB 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
consolidation 0 NOUN F
with 0 ADP F
high-dose 0 NOUN F
methotrexate 0 NOUN F
, 0 PUNCT F
ifosfamide 0 PUNCT F
, 0 PUNCT F
etoposide 0 NOUN F
, 0 PUNCT F
asparaginase 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
cytarabine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
randomized 0 VERB F
late 0 ADJ F
intensification 0 NOUN F
with 0 ADP F
two 0 NUM F
courses 0 NOUN F
of 0 ADP F
cytarabine 0 NOUN F
, 0 PUNCT F
cyclophosphamide 0 NOUN F
, 0 PUNCT F
teniposide 0 NOUN F
, 0 PUNCT F
bleomycin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
prednisone 0 NOUN F
( 0 PUNCT F
AraCVmB 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Four 0 NUM T
hundred 0 NUM F
forty-two 0 PUNCT F
patients 0 NOUN F
had 0 PUNCT F
intermediate-grade 0 NOUN F
ML 0 NOUN T
, 0 PUNCT F
221 0 NUM F
highgrade 0 PUNCT F
ML 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
74 0 NUM F
unclassified 0 VERB F
ML 0 NOUN T
. 0 PUNCT F

Most 0 PUNCT T
of 0 ADP F
the 0 DET F
patients 0 NOUN F
had 0 PUNCT F
advanced 0 VERB F
disease 0 NOUN F
: 0 PUNCT F
stage 0 NOUN F
IIE 0 NOUN T
( 0 PUNCT F
23 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
III 0 NUM T
( 0 PUNCT F
13 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
IV 0 NUM T
( 0 PUNCT F
47 0 NUM F
% 0 SYM F
) 0 PUNCT F
; 0 PUNCT F
38 0 NUM F
% 0 SYM F
disseminated 0 VERB F
nodes 0 NOUN F
; 0 PUNCT F
38 0 NUM F
% 0 SYM F
two 0 NUM F
or 0 CCONJ F
more 0 DET F
extranodal 0 ADJ F
sites 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
41 0 NUM F
% 0 SYM F
a 0 DET F
tumoral 0 ADJ F
mass 0 NOUN F
greater 0 PUNCT F
than 0 CCONJ F
10 0 NUM F
cm 0 NOUN F
. 0 PUNCT F

Five 0 NUM T
hundred 0 NUM F
fifty-three 0 ADP F
patients 0 NOUN F
( 0 PUNCT F
75 0 NUM F
% 0 SYM F
) 0 PUNCT F
went 0 VERB F
into 0 ADP F
complete B-PHYSICAL ADJ F
remission I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
63 0 NUM F
( 0 PUNCT F
9 0 NUM F
% 0 SYM F
) 0 PUNCT F
into 0 ADP F
partial B-PHYSICAL ADJ F
remission I-PHYSICAL NOUN F
, 0 PUNCT F
62 0 NUM F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
failed B-PHYSICAL VERB F
to I-PHYSICAL PART F
respond I-PHYSICAL ADP F
, 0 PUNCT F
and 0 CCONJ F
59 0 NUM F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
) 0 PUNCT F
died B-MORTALITY VERB F
during 0 ADP F
ACVB 0 NOUN T
courses 0 NOUN F
, 0 PUNCT F
17 0 NUM F
of 0 ADP F
them 0 PRON F
from 0 ADP F
progression 0 NOUN F
of 0 ADP F
the 0 DET F
disease 0 NOUN F
. 0 PUNCT F

With 0 ADP T
a 0 DET F
median 0 ADJ F
follow-up 0 NOUN F
of 0 ADP F
23 0 NUM F
months 0 NOUN F
, 0 PUNCT F
the 0 DET F
estimated 0 VERB F
2-year 0 NOUN F
overall 0 ADJ F
survival 0 NOUN F
time 0 NOUN F
to 0 ADP F
failure 0 NOUN F
( 0 PUNCT F
TTF 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
time B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
relapse I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
TTR I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
survival I-PHYSICAL NOUN F
are 0 ADP F
67 0 NUM F
% 0 SYM F
, 0 PUNCT F
56 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
67 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Patients 0 NOUN T
receiving 0 VERB F
a 0 DET F
late 0 ADJ F
intensification 0 NOUN F
had 0 PUNCT F
the 0 DET F
same 0 ADJ F
relapse B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
as 0 PUNCT F
the 0 DET F
other 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

A 0 DET T
persistent B-PHYSICAL ADJ F
fibronecrotic I-PHYSICAL ADJ F
mass I-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
150 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
20 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
did 0 DET F
not 0 ADV F
influence 0 VERB F
the 0 DET F
relapse B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

Toxicity B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
mainly 0 ADV F
neutropenia B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
infection B-PHYSICAL NOUN F
during 0 ADP F
the 0 DET F
ACVB 0 NOUN T
courses 0 NOUN F
, 0 PUNCT F
with 0 ADP F
40 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
5 0 NUM F
% 0 SYM F
) 0 PUNCT F
dying 0 CCONJ F
from 0 ADP F
septic B-MORTALITY ADJ F
complications I-MORTALITY NOUN F
while 0 ADP F
responding 0 PUNCT F
to 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Fifty-three 0 PUNCT T
percent 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
had 0 DET F
a 0 DET F
neutropenia B-ADVERSE-EFFECTS NOUN F
less 0 ADV F
than 0 PUNCT F
0.500 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
9 0 NUM F
) 0 PUNCT F
/L 0 PUNCT F
, 0 PUNCT F
58 0 NUM F
% 0 SYM F
fever 0 NOUN F
( 0 PUNCT F
6 0 NUM F
% 0 SYM F
grade 0 NOUN F
4 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
49 0 NUM F
% 0 SYM F
a 0 DET F
documented B-ADVERSE-EFFECTS VERB F
infection I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
8 0 NUM F
% 0 SYM F
grade 0 NOUN F
4 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
obtained 0 VERB F
with 0 ADP F
the 0 DET F
LNH-84 0 NOUN T
regimen 0 NOUN F
demonstrate 0 VERB F
that 0 ADP F
this 0 DET F
therapeutic 0 ADJ F
scheme 0 NOUN F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
treatment 0 NOUN F
for 0 ADP F
aggressive 0 ADJ F
ML 0 NOUN T
. 0 PUNCT F

Smoking B-MENTAL VERB T
cessation I-MENTAL NOUN F
with 0 ADP F
smokeless 0 PUNCT F
tobacco 0 NOUN F
and 0 CCONJ F
group 0 NOUN F
therapy 0 NOUN F
: 0 PUNCT F
an 0 DET F
open 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Smokeless 0 NOUN T
tobacco 0 NOUN F
might 0 VERB F
be 0 NOUN F
effective 0 ADJ F
as 0 ADP F
an 0 DET F
adjunct 0 NOUN F
for 0 ADP F
smoking B-MENTAL VERB F
cessation I-MENTAL NOUN F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
smokeless 0 PUNCT F
tobacco 0 NOUN F
and 0 CCONJ F
group 0 NOUN F
support 0 NOUN F
for 0 ADP F
smoking B-MENTAL VERB F
cessation I-MENTAL NOUN F
in 0 ADP F
an 0 DET F
open 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
study 0 NOUN F
that 0 PUNCT F
compared 0 PUNCT F
smokeless 0 ADP F
tobacco 0 NOUN F
plus 0 CCONJ F
group 0 NOUN F
support 0 NOUN F
versus 0 CCONJ F
group 0 NOUN F
support 0 NOUN F
only 0 ADV F
. 0 PUNCT F

The 0 DET T
study 0 NOUN F
enrolled 0 VERB F
263 0 NUM F
healthy 0 ADJ F
smokers 0 NOUN F
( 0 PUNCT F
M 0 NOUN T
( 0 PUNCT F
age 0 NOUN F
) 0 PUNCT F
= 0 ADP F
49 0 NUM F
years 0 NOUN F
) 0 PUNCT F
who 0 ADP F
smoked 0 PROPN F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
24 0 NUM F
cigarettes/day 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
mean 0 NOUN F
of 0 ADP F
31 0 NUM F
pack-years 0 ADP F
. 0 PUNCT F

Smokeless 0 NOUN T
tobacco 0 NOUN F
was 0 VERB F
provided 0 VERB F
for 0 ADP F
7 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
or 0 CCONJ F
up 0 PUNCT F
to 0 ADP F
12 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
combined 0 VERB F
with 0 ADP F
eight 0 NUM F
group 0 NOUN F
support 0 NOUN F
visits 0 NOUN F
provided 0 VERB F
by 0 ADP F
nurses 0 NOUN F
. 0 PUNCT F

The 0 DET T
control 0 NOUN F
group 0 NOUN F
received 0 ADV F
group 0 NOUN F
support 0 NOUN F
only 0 ADV F
. 0 PUNCT F

Smoking B-OTHER VERB T
cessation I-OTHER NOUN F
rates I-OTHER NOUN F
were 0 VERB F
statistically 0 ADV F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
smokeless 0 PUNCT F
tobacco 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
during 0 ADP F
the 0 DET F
first 0 ADJ F
7 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

Point-prevalence B-OTHER NOUN T
abstinence I-OTHER ADJ F
rates I-OTHER NOUN F
at 0 ADP F
7 0 NUM F
weeks 0 NOUN F
were 0 VERB F
36.4 0 NUM F
% 0 SYM F
versus 0 CCONJ F
20.8 0 NUM F
% 0 SYM F
( 0 PUNCT F
OR 0 NOUN T
= 0 ADP F
2.52 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
and 0 CCONJ F
continuous B-OTHER ADJ F
abstinence I-OTHER ADJ F
rates I-OTHER NOUN F
from 0 ADP F
weeks 0 NOUN F
4 0 NUM F
to 0 ADP F
7 0 PUNCT F
were 0 VERB F
31.5 0 NUM F
% 0 SYM F
versus 0 CCONJ F
19.2 0 NUM F
% 0 SYM F
( 0 PUNCT F
OR 0 NOUN T
= 0 SYM F
1.94 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
.023 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcomes 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
6-month B-OTHER NOUN F
point I-OTHER NOUN F
prevalence I-OTHER NOUN F
) 0 PUNCT F
were 0 VERB F
23.1 0 NUM F
% 0 SYM F
versus 0 CCONJ F
20.8 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
OR 0 NOUN T
= 0 ADP F
1.31 0 PUNCT F
, 0 PUNCT F
ns 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Smokeless 0 NOUN T
tobacco 0 NOUN F
was 0 ADJ F
relatively 0 VERB F
well 0 VERB F
tolerated B-OTHER ADP F
, 0 PUNCT F
although 0 ADP F
15 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
11.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
stopped 0 CCONJ F
use 0 NOUN F
due 0 VERB F
to 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
25 0 NUM F
subjects 0 NOUN F
( 0 PUNCT F
17.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
still 0 ADV F
using 0 ADJ F
smokeless 0 NOUN F
tobacco 0 NOUN F
after 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

This 0 DET T
trial 0 NOUN F
demonstrated 0 VERB F
short-term B-OTHER NOUN F
efficacy 0 NOUN F
of B-OTHER ADP F
smokeless I-OTHER PUNCT F
tobacco B-OTHER NOUN F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
group 0 NOUN F
support 0 NOUN F
for 0 ADP F
smoking 0 VERB F
cessation 0 NOUN F
but 0 CCONJ F
no 0 PUNCT F

Brief 0 ADP T
report 0 NOUN F
: 0 PUNCT F
imitation 0 NOUN F
effects 0 NOUN F
on 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Twenty 0 NUM T
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
, 0 PUNCT F
5 0 NUM F
years 0 NOUN F
) 0 PUNCT F
were 0 VERB F
recruited 0 VERB F
for 0 ADP F
the 0 DET F
study 0 NOUN F
from 0 ADP F
a 0 DET F
school 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

The 0 DET T
children 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
an 0 DET F
imitation 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
contingently 0 ADV F
responsive 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
10 0 NUM F
) 0 PUNCT F
interaction 0 NOUN F
group 0 NOUN F
based 0 VERB F
on 0 ADP F
a 0 DET F
stratification 0 NOUN F
table 0 NOUN F
for 0 ADP F
gender 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
and 0 CCONJ F
chronological 0 ADJ F
age 0 NOUN F
. 0 PUNCT F

The 0 DET T
sessions 0 NOUN F
consisted 0 DET F
of 0 ADP F
four 0 NUM F
phases 0 NOUN F
, 0 PUNCT F
with 0 ADP F
each 0 DET F
phase 0 NOUN F
lasting 0 ADP F
3 0 NUM F
minutes 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
first 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
the 0 DET F
child 0 NOUN F
walked 0 ADP F
into 0 ADP F
a 0 DET F
room 0 NOUN F
that 0 PUNCT F
was 0 VERB F
furnished 0 VERB F
with 0 ADP F
a 0 DET F
sofa 0 NOUN F
, 0 PUNCT F
a 0 DET F
table 0 NOUN F
, 0 PUNCT F
chairs 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
two 0 NUM F
sets 0 NOUN F
of 0 ADP F
identical 0 ADJ F
toys 0 NOUN F
. 0 PUNCT F

An 0 DET T
adult 0 NOUN F
was 0 VERB F
in 0 ADP F
the 0 DET F
room 0 NOUN F
sitting 0 PUNCT F
very 0 ADV F
still 0 ADV F
like 0 ADP F
a 0 DET F
statue 0 NOUN F
( 0 PUNCT F
first 0 ADJ F
still-face 0 NOUN F
condition 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
second 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
the 0 DET F
adult 0 ADJ F
either 0 CCONJ F
imitated 0 VERB F
the 0 DET F
child 0 NOUN F
or 0 CCONJ F
was 0 VERB F
contingently 0 ADV F
responsive 0 ADJ F
to 0 ADP F
the 0 DET F
child 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
third 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
the 0 DET F
adult 0 NOUN F
sat 0 VERB F
still 0 ADP F
again 0 ADV F
( 0 PUNCT F
second 0 ADJ F
still-face 0 NOUN F
condition 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
the 0 DET F
fourth 0 ADJ F
phase 0 NOUN F
, 0 PUNCT F
the 0 DET F
adult 0 NOUN F
engaged 0 VERB F
in 0 ADP F
a 0 DET F
spontaneous 0 ADJ F
interaction 0 NOUN F
. 0 PUNCT F

During 0 ADP T
the 0 DET F
third 0 ADJ F
phase 0 NOUN F
( 0 PUNCT F
the 0 DET F
second 0 ADJ F
still-face 0 NOUN F
condition 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
children 0 NOUN F
in 0 ADP F
the 0 DET F
imitation 0 NOUN F
group 0 NOUN F
spent 0 ADJ F
less 0 DET F
time 0 NOUN F
in 0 ADP F
gross 0 ADJ F
motor 0 NOUN F
activity 0 NOUN F
and 0 CCONJ F
more 0 DET F
time B-OTHER NOUN F
touching I-OTHER PUNCT F
the I-OTHER DET F
adult I-OTHER NOUN F
, 0 PUNCT F
as 0 PUNCT F
if 0 PUNCT F
attempting 0 VERB F
to 0 ADJ F
initiate 0 NOUN F
an 0 DET F
interaction 0 NOUN F
. 0 PUNCT F

The 0 DET T
contingency 0 NOUN F
condition 0 NOUN F
appeared 0 VERB F
to 0 PART F
be 0 PUNCT F
a 0 DET F
more 0 ADV F
effective 0 ADJ F
way 0 NOUN F
to 0 PART F
facilitate 0 NOUN F
a 0 DET F
distal B-MENTAL ADJ F
social I-MENTAL ADJ F
behavior I-MENTAL NOUN F
( I-MENTAL PUNCT F
attention I-MENTAL NOUN F
) I-MENTAL PUNCT F
, 0 PUNCT F
whereas 0 ADP F
the 0 DET F
imitative 0 ADJ F
condition 0 NOUN F
was 0 VERB F
a 0 DET F
more 0 ADV F
effective 0 ADJ F
way 0 NOUN F
to 0 PART F
facilitate 0 NOUN F
a 0 DET F
proximal B-MENTAL ADJ F
social I-MENTAL ADJ F
behavior I-MENTAL NOUN F
( 0 PUNCT F
touching B-MENTAL VERB F
) 0 PUNCT F
. 0 PUNCT F

Study 0 NOUN T
of 0 ADP F
the 0 DET F
vaginal 0 ADJ F
tolerance 0 NOUN F
to 0 ADP F
Acidform 0 PUNCT T
, 0 PUNCT F
an 0 DET F
acid-buffering 0 ADJ F
, 0 PUNCT F
bioadhesive 0 ADJ F
gel 0 NOUN F
. 0 PUNCT F

Vaginal 0 ADJ T
tolerance 0 NOUN F
tests 0 NOUN F
were 0 VERB F
performed 0 VERB F
with 0 ADP F
a 0 DET F
new 0 ADJ F
potential 0 ADJ F
microbicidal 0 ADJ F
and 0 CCONJ F
spermicidal 0 ADJ F
product 0 NOUN F
, 0 PUNCT F
an 0 DET F
acid-buffering 0 ADJ F
vaginal 0 ADJ F
gel 0 NOUN F
( 0 PUNCT F
Acidform 0 NOUN T
) 0 PUNCT F
without 0 ADP F
or 0 CCONJ F
with 0 ADP F
nonoxynol-9 0 NOUN F
( 0 PUNCT F
N-9 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
potential 0 ADJ F
advantages 0 NOUN F
over 0 ADP F
other 0 ADJ F
vaginal 0 ADJ F
products 0 NOUN F
include 0 VERB F
keeping 0 ADP F
a 0 DET F
low 0 ADJ F
pH 0 NOUN F
, 0 PUNCT F
decrease 0 NOUN F
of 0 ADP F
the 0 DET F
irritating 0 ADJ F
effect 0 NOUN F
of 0 ADP F
N-9 0 NOUN T
on 0 ADP F
the 0 DET F
cervix 0 NOUN F
or 0 CCONJ F
vaginal 0 ADJ F
mucosa 0 NOUN F
associated 0 VERB F
with 0 ADP F
greater 0 PUNCT F
retention 0 NOUN F
of 0 ADP F
the 0 DET F
product 0 NOUN F
after 0 PUNCT F
application 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
decreasing 0 VERB F
messiness 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
to 0 ADP F
other 0 CCONJ F
vaginal 0 ADJ F
products 0 NOUN F
. 0 PUNCT F

Three 0 DET T
groups 0 NOUN F
of 0 ADP F
six 0 NUM F
women 0 NOUN F
were 0 VERB F
admitted 0 VERB F
and 0 CCONJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 PUNCT F
use 0 NOUN F
Acidform 0 NOUN T
with 0 ADP F
0 0 NUM F
% 0 SYM F
, 0 PUNCT F
2.5 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
5 0 NUM F
% 0 SYM F
N-9 0 NOUN T
. 0 PUNCT F

Colposcopic 0 ADJ T
evaluation 0 NOUN F
for 0 ADP F
vulvar 0 CCONJ F
, 0 PUNCT F
vaginal 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
cervical 0 ADJ F
signs 0 NOUN F
of 0 ADP F
irritation 0 NOUN F
was 0 VERB F
performed 0 VERB F
and 0 CCONJ F
photographs 0 PUNCT F
were 0 ADP F
taken 0 VERB F
, 0 PUNCT F
following 0 VERB F
a 0 DET F
specific 0 ADJ F
World 0 NOUN T
Health 0 NOUN T
Organization 0 NOUN T
protocol 0 NOUN F
, 0 PUNCT F
at 0 ADP F
time 0 NOUN F
0 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
24 0 NUM F
h 0 NOUN F
and 0 CCONJ F
6 0 NUM F
days 0 NOUN F
of 0 ADP F
application 0 NOUN F
of 0 ADP F
the 0 DET F
gel 0 NOUN F
. 0 PUNCT F

No 0 DET T
irritation B-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
symptom B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
reported 0 VERB F
by 0 ADP F
users 0 NOUN F
of 0 ADP F
Acidform 0 NOUN T
without 0 ADP F
N-9 0 NOUN T
. 0 PUNCT F

A 0 DET T
generalized B-ADVERSE-EFFECTS VERB F
and I-ADVERSE-EFFECTS CCONJ F
intense I-ADVERSE-EFFECTS ADJ F
erythema I-ADVERSE-EFFECTS NOUN F
in I-ADVERSE-EFFECTS ADP F
cervix I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
10 0 NUM F
of 0 ADP F
12 0 NUM F
Acidform/N-9 0 PUNCT T
users 0 NOUN F
and 0 CCONJ F
abrasion 0 NOUN F
occurred 0 VERB F
in 0 ADP F
nine 0 NUM F
of 0 ADP F
them 0 PRON F
. 0 PUNCT F

Vulvar B-ADVERSE-EFFECTS NOUN T
irritation I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
seen 0 VERB F
in 0 ADP F
seven 0 NUM F
of 0 ADP F
these 0 DET F
10 0 NUM F
volunteers 0 NOUN F
. 0 PUNCT F

N-9 0 NOUN T
concentration 0 NOUN F
in 0 ADP F
the 0 DET F
gel 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
% 0 SYM F
or 0 CCONJ F
5.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
was 0 VERB F
not 0 ADV F
related 0 PUNCT F
to 0 ADP F
the 0 DET F
findings 0 NOUN F
. 0 PUNCT F

No 0 DET T
ulcer B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
exulceration B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
or 0 CCONJ F
de-epithelialization B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Acidform 0 NOUN T
without 0 ADP F
N-9 0 NOUN T
was 0 VERB F
well 0 VERB F
tolerated 0 VERB F
by 0 ADP F
volunteers 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
was 0 VERB F
unable 0 ADJ F
to 0 ADJ F
protect 0 ADV F
the 0 DET F
cervix 0 NOUN F
, 0 PUNCT F
vagina 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
vulva 0 NOUN F
from 0 ADP F
the 0 DET F
N-9 0 NOUN T
effects 0 NOUN F
. 0 PUNCT F

Tetracaine 0 NOUN T
( 0 PUNCT F
ametop 0 NOUN F
) 0 PUNCT F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
for 0 ADP F
reducing 0 VERB F
pain 0 NOUN F
associated 0 VERB F
with 0 ADP F
intramuscular 0 ADJ F
injection 0 NOUN F
of 0 ADP F
palivizumab 0 NOUN F
( 0 PUNCT F
synagis 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Infants 0 NOUN T
receive 0 VERB F
many 0 DET F
painful 0 ADJ F
immunizations 0 NOUN F
before 0 PUNCT F
they 0 PRON F
are 0 VERB F
2 0 NUM F
years 0 NOUN F
old 0 ADJ F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 ADP F
if 0 PUNCT F
topical 0 ADJ F
tetracaine 0 NOUN F
reduces 0 NOUN F
the 0 DET F
pain 0 NOUN F
of 0 ADP F
intramuscular 0 ADJ F
palivizumab 0 NOUN F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
two 0 NUM F
study 0 ADV F
injections 0 NOUN F
, 0 PUNCT F
one 0 NUM F
with 0 ADP F
tetracaine 0 NOUN F
and 0 CCONJ F
one 0 NUM F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

Pain B-PAIN NOUN T
was 0 VERB F
scored 0 VERB F
by 0 ADP F
their 0 PUNCT F
parents 0 NOUN F
and 0 CCONJ F
a 0 DET F
pediatric 0 ADJ F
nurse 0 PUNCT F
. 0 PUNCT F

Topical 0 ADJ T
tetracaine 0 NOUN F
was 0 VERB F
not 0 ADV F
associated 0 VERB F
with 0 ADP F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
pain B-PAIN NOUN F
score I-PAIN NOUN F
, 0 PUNCT F
although 0 ADP F
it 0 PRON F
did 0 PUNCT F
lead 0 PUNCT F
to 0 ADP F
faster 0 PUNCT F
recovery B-OTHER NOUN F
times 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
pain-reduction 0 NOUN F
strategies 0 NOUN F
are 0 VERB F
required 0 VERB F
. 0 PUNCT F

Long-term 0 NOUN T
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
using 0 VERB F
repetitive 0 ADJ F
education 0 NOUN F
at 0 ADP F
six-month 0 NOUN F
intervals 0 NOUN F
and 0 CCONJ F
monitoring 0 VERB F
for 0 ADP F
adherence 0 NOUN F
in 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
outpatients 0 ADJ F
: 0 PUNCT F
the 0 DET F
REMADHE 0 NOUN T
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
effectiveness 0 NOUN F
of 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
disease 0 NOUN F
management 0 NOUN F
programs 0 NOUN F
in 0 ADP F
patients 0 NOUN F
under 0 ADP F
cardiologists 0 NOUN F
' 0 PUNCT F
care 0 NOUN F
over 0 ADP F
long-term 0 NOUN F
follow-up 0 NOUN F
is 0 VERB F
not 0 ADV F
established 0 VERB F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 NOUN T
We 0 PRON T
investigated 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
a 0 DET F
disease 0 NOUN F
management 0 NOUN F
program 0 NOUN F
with 0 ADP F
repetitive 0 ADJ F
education 0 NOUN F
and 0 CCONJ F
telephone 0 NOUN F
monitoring 0 VERB F
on 0 ADP F
primary 0 ADJ F
( 0 PUNCT F
combined B-PHYSICAL PUNCT F
death B-OTHER NOUN F
or 0 CCONJ F
unplanned B-OTHER VERB F
first I-OTHER ADJ F
hospitalization I-OTHER NOUN F
and 0 CCONJ F
quality-of-life B-OTHER NOUN F
changes I-OTHER NOUN F
) 0 PUNCT F
and 0 CCONJ F
secondary 0 ADJ F
end 0 NOUN F
points 0 NOUN F
( 0 PUNCT F
hospitalization B-OTHER NOUN F
, 0 PUNCT F
death B-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
adherence B-MENTAL NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
REMADHE 0 NOUN T
[ 0 PUNCT F
Repetitive 0 ADJ T
Education 0 NOUN T
and 0 CCONJ F
Monitoring 0 PROPN T
for 0 ADP F
ADherence 0 NOUN T
for 0 ADP F
Heart 0 NOUN T
Failure 0 NOUN T
] 0 PUNCT F
trial 0 NOUN F
is 0 VERB F
a 0 DET F
long-term 0 NOUN F
randomized 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
parallel 0 ADJ F
trial 0 NOUN F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
intervention 0 NOUN F
with 0 ADP F
control 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
seventeen 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
usual 0 ADJ F
care 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
233 0 NUM F
to 0 ADP F
additional 0 ADJ F
intervention 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
follow-up 0 NOUN F
was 0 VERB F
2.47+/-1.75 0 NUM F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
54 0 NUM F
% 0 SYM F
adherence 0 NOUN F
to 0 ADP F
the 0 DET F
program 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
composite B-MORTALITY NOUN F
of I-MORTALITY ADP F
death I-MORTALITY NOUN F
or 0 CCONJ F
unplanned B-MORTALITY VERB F
hospitalization I-MORTALITY NOUN F
was 0 VERB F
reduced 0 VERB F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
0.64 0 NUM F
; 0 PUNCT F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.43 0 NUM F
to 0 ADP F
0.88 0 NUM F
; 0 PUNCT F
P=0.008 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
driven 0 VERB F
by 0 ADP F
reduction 0 NOUN F
in 0 ADP F
hospitalization B-OTHER NOUN F
. 0 PUNCT F

The 0 DET T
quality-of-life B-OTHER NOUN F
questionnaire 0 NOUN F
score B-OTHER NOUN F
improved 0 VERB F
only 0 ADV F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.003 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Mortality B-MORTALITY NOUN T
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

Number B-ADVERSE-EFFECTS NOUN T
of I-ADVERSE-EFFECTS ADP F
hospitalizations I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
1.3+/-1.7 0 NOUN F
versus 0 PUNCT F
0.8+/-1.3 0 ADP F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
total 0 ADJ F
hospital B-OTHER NOUN F
days I-OTHER NOUN F
during B-OTHER ADP F
the I-OTHER DET F
follow-up B-OTHER NOUN F
( 0 PUNCT F
19.9+/-51 0 NUM F
versus 0 CCONJ F
11.1+/-24 0 PUNCT F
days 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
need 0 NOUN F
for 0 ADP F
emergency B-OTHER NOUN F
visits I-OTHER NOUN F
( 0 PUNCT F
4.5+/-10.6 0 VERB F
versus 0 CCONJ F
1.6+/-2.4 0 ADP F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.0001 0 NUM F
) 0 PUNCT F
were 0 VERB F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Beneficial B-OTHER ADJ T
effects I-OTHER NOUN F
were 0 VERB F
homogeneous 0 ADJ F
for 0 ADP F
sex 0 NOUN F
, 0 PUNCT F
race 0 ADP F
, 0 PUNCT F
diabetes 0 NOUN F
and 0 CCONJ F
no 0 DET F
diabetes 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
functional 0 ADJ F
class 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
etiology 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
For 0 ADP T
a 0 DET F
longer 0 PUNCT F
follow-up 0 NOUN F
period 0 NOUN F
than 0 PUNCT F
in 0 ADP F
previous 0 ADJ F
studies 0 NOUN F
, 0 PUNCT F
this 0 DET F
heart 0 NOUN F
failure 0 NOUN F
disease 0 NOUN F
management 0 NOUN F
program 0 NOUN F
model 0 NOUN F
of 0 ADP F
patients 0 NOUN F
under 0 ADP F
the 0 DET F
supervision 0 NOUN F
of 0 ADP F
a 0 DET F
cardiologist 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
unplanned B-OTHER VERB F
hospitalization B-OTHER NOUN F
, 0 PUNCT F
a 0 DET F
reduction 0 NOUN F
of 0 PUNCT F
total 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
weight-bearing 0 ADP F
versus 0 CCONJ F
nonweight-bearing 0 VERB F
exercise 0 NOUN F
on 0 ADP F
function B-PHYSICAL NOUN F
, 0 PUNCT F
walking B-PHYSICAL ADJ F
speed I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
position 0 NOUN F
sense B-PHYSICAL NOUN F
in 0 ADP F
participants 0 NOUN F
with 0 ADP F
knee 0 NOUN F
osteoarthritis 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 ADJ F
whether 0 ADP F
weight-bearing 0 VERB F
( 0 PUNCT F
WB 0 NOUN T
) 0 PUNCT F
exercise 0 NOUN F
enhances 0 NOUN F
functional B-PHYSICAL ADJ F
capacity I-PHYSICAL NOUN F
to 0 ADP F
a 0 DET F
greater 0 PUNCT F
extent 0 NOUN F
than 0 PUNCT F
nonweight-bearing 0 PUNCT F
( 0 PUNCT F
NWB 0 NOUN T
) 0 PUNCT F
exercise 0 NOUN F
in 0 ADP F
participants 0 NOUN F
with 0 ADP F
knee 0 NOUN F
osteoarthritis 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Randomized 0 PROPN T
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 NUM T
Kinesiology 0 NOUN T
laboratory 0 NOUN F
. 0 PUNCT F

PARTICIPANTS 0 ADP T
Participants 0 NOUN T
( 0 PUNCT F
N=106 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
WB 0 NOUN T
exercise 0 NOUN F
, 0 PUNCT F
NWB 0 NOUN T
exercise 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
no 0 DET F
exercise 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

INTERVENTION 0 NOUN T
WB 0 NOUN T
exercise 0 NOUN F
and 0 CCONJ F
NWB 0 NOUN T
exercise 0 NOUN F
groups 0 NOUN F
underwent 0 VERB F
an 0 DET F
8-week 0 NOUN F
knee 0 NOUN F
extension-flexion 0 NOUN F
exercise 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Western 0 NOUN T
Ontario 0 NOUN T
and 0 CCONJ F
McMaster 0 ADJ T
Universities 0 PROPN T
Osteoarthritis 0 NOUN T
Index 0 NOUN T
( 0 PUNCT F
WOMAC 0 ADJ T
) 0 PUNCT F
function 0 ADV F
scale 0 NOUN F
, 0 PUNCT F
walking B-PHYSICAL ADJ F
speed I-PHYSICAL NOUN F
, 0 PUNCT F
muscle B-PHYSICAL NOUN F
torque I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
knee B-PHYSICAL NOUN F
reposition I-PHYSICAL NOUN F
error I-PHYSICAL NOUN F
were 0 VERB F
assessed 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Equally 0 PUNCT T
significant 0 ADJ F
improvements 0 NOUN F
were 0 VERB F
apparent 0 ADJ F
for 0 ADP F
all 0 DET F
outcomes 0 NOUN F
after 0 ADP F
WB 0 NOUN T
exercise 0 NOUN F
and 0 CCONJ F
NWB 0 NOUN T
exercise 0 NOUN F
, 0 PUNCT F
except 0 PUNCT F
for 0 ADP F
reposition B-PHYSICAL NOUN F
error I-PHYSICAL NOUN F
, 0 PUNCT F
for 0 ADP F
which 0 ADP F
improvement 0 NOUN F
was 0 VERB F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
WB 0 NOUN T
exercise 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

In 0 ADP T
contrast 0 NOUN F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
improvements 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Simple 0 ADJ T
knee 0 NOUN F
flexion 0 NOUN F
and 0 CCONJ F
extension 0 NOUN F
exercises 0 NOUN F
( 0 PUNCT F
WB 0 NOUN T
and 0 CCONJ F
NWB 0 NOUN T
) 0 PUNCT F
performed 0 VERB F
over 0 ADP F
8 0 NUM F
weeks 0 NOUN F
resulted 0 VERB F
in 0 ADP F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
WOMAC B-PHYSICAL PUNCT T
function I-PHYSICAL ADV F
scale I-PHYSICAL NOUN F
and 0 CCONJ F
knee 0 NOUN F
strength 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

NWB 0 NOUN T
exercise 0 NOUN F
alone 0 ADJ F
may 0 ADP F
be 0 VERB F
sufficient 0 ADJ F
enough 0 DET F
to 0 ADP F
improve 0 CCONJ F
function B-PHYSICAL NOUN F
and 0 CCONJ F
muscle B-PHYSICAL NOUN F
strength I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
additional 0 ADJ F
benefit 0 NOUN F
of 0 ADP F
WB 0 NOUN T
exercise 0 NOUN F
was 0 VERB F
improved 0 VERB F
position 0 NOUN F
sense B-PHYSICAL NOUN F
, 0 PUNCT F
which 0 DET F
may 0 VERB F
enhance 0 VERB F
complex B-PHYSICAL ADJ F
walking I-PHYSICAL ADJ F
tasks I-PHYSICAL NOUN F
( 0 PUNCT F
walking 0 ADP F
on 0 ADP F
figure 0 NOUN F
of 0 ADP F
8 0 NUM F
route 0 NOUN F
and 0 CCONJ F
spongy 0 NOUN F
surface 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
effect 0 NOUN F
of 0 ADP F
body 0 NOUN F
positioning 0 ADV F
upon 0 ADP F
maximal 0 ADJ F
oxygenation 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
unilateral 0 ADJ F
lung 0 NOUN F
pathology 0 NOUN F
. 0 PUNCT F

A 0 DET T
quasi-experimental 0 ADJ F
, 0 PUNCT F
repeated-measures 0 ADP F
cross-over 0 NOUN F
design 0 NOUN F
study 0 NUM F
on 0 ADP F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
body 0 NOUN F
position 0 NOUN F
on 0 ADP F
oxygenation 0 NOUN F
( 0 PUNCT F
SaO2 0 NOUN T
) 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
respiration 0 NOUN F
and 0 CCONJ F
pulse 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
unilateral 0 ADJ F
lung 0 NOUN F
pathology 0 NOUN F
was 0 VERB F
conducted 0 VERB F
. 0 PUNCT F

Previous 0 ADJ T
research 0 NOUN F
strongly 0 ADV F
suggests 0 NOUN F
that 0 ADP F
positioning 0 VERB F
with 0 ADP F
the 0 DET F
healthy 0 ADJ F
( 0 PUNCT F
unaffected 0 PUNCT F
) 0 PUNCT F
lung 0 NOUN F
in 0 ADP F
the 0 DET F
dependent 0 ADJ F
lateral 0 ADJ F
( 0 PUNCT F
down 0 ADJ F
) 0 PUNCT F
position 0 NOUN F
is 0 VERB F
related 0 VERB F
to 0 ADP F
improved 0 PUNCT F
oxygenation 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
knowledge 0 NOUN F
about 0 PUNCT F
whether 0 VERB F
this 0 DET F
effect 0 NOUN F
is 0 VERB F
maintained 0 VERB F
over 0 PUNCT F
time 0 NOUN F
is 0 VERB F
lacking 0 ADJ F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 PUNCT F
investigation 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 ADP F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Is 0 PUNCT T
positioning 0 VERB F
with 0 ADP F
the 0 DET F
unaffected 0 VERB F
lung 0 NOUN F
in 0 ADP F
the 0 DET F
dependent 0 ADJ F
lateral 0 ADJ F
position 0 NOUN F
related 0 VERB F
to 0 ADP F
increased 0 VERB F
arterial 0 ADJ F
blood 0 NOUN F
saturation 0 NOUN F
levels 0 NOUN F
and 0 CCONJ F
decreased 0 VERB F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
pulse 0 NOUN F
and 0 CCONJ F
respiration 0 NOUN F
? 0 PUNCT F
( 0 PUNCT F

2 0 NUM F
) 0 PUNCT F
What 0 PUNCT T
is 0 VERB F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
the 0 DET F
dependent 0 ADJ F
variables 0 NOUN F
-- 0 PUNCT F
oxygenation 0 NOUN F
saturation 0 NOUN F
levels 0 NOUN F
, 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
pulse 0 NOUN F
and 0 CCONJ F
respiration 0 NOUN F
-- 0 PUNCT F
and 0 CCONJ F
the 0 DET F
independent 0 ADJ F
variables 0 NOUN F
-- 0 PUNCT F
body 0 NOUN F
position 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
in 0 ADP F
the 0 DET F
position 0 NOUN F
? 0 PUNCT F

Thirty-nine 0 NUM T
patients 0 NOUN F
with 0 ADP F
unilateral 0 ADJ F
lung 0 NOUN F
pathology 0 NOUN F
were 0 VERB F
positioned 0 VERB F
on 0 ADP F
their 0 ADP F
sides 0 NOUN F
with 0 ADP F
the 0 DET F
unaffected 0 VERB F
lung 0 NOUN F
down 0 ADJ F
, 0 PUNCT F
on 0 ADP F
their 0 ADP F
sides 0 NOUN F
with 0 ADP F
the 0 DET F
affected 0 VERB F
lung 0 NOUN F
down 0 ADJ F
, 0 PUNCT F
and 0 CCONJ F
also 0 ADV F
in 0 ADP F
semi-Fowler 0 ADJ F
's 0 PUNCT F
position 0 NOUN F
. 0 PUNCT F

Arterial B-PHYSICAL ADJ T
( I-PHYSICAL PUNCT F
SaO2 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
blood I-PHYSICAL NOUN F
saturation 0 NOUN F
and 0 CCONJ F
vital B-PHYSICAL ADJ F
signs I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
at 0 ADP F
baseline 0 NOUN F
0 0 NUM F
, 0 PUNCT F
15 0 NUM F
and 0 CCONJ F
30 0 NUM F
minutes 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
relationship 0 NOUN F
between 0 ADP F
oxygenation 0 NOUN F
level 0 NOUN F
or 0 CCONJ F
systolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
. 0 PUNCT F

Diastolic 0 ADJ T
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
respiration 0 NOUN F
and 0 CCONJ F
pulse 0 NOUN F
did 0 PUNCT F
vary 0 VERB F
significantly 0 ADV F
with 0 ADP F
position 0 NOUN F
. 0 PUNCT F

Whole-body 0 NOUN T
CT 0 NOUN T
screening 0 ADV F
: 0 PUNCT F
scan 0 NOUN F
delay 0 NOUN F
and 0 CCONJ F
contrast 0 NOUN F
injection 0 NOUN F
duration 0 NOUN F
for 0 ADP F
optimal B-OTHER ADJ F
enhancement I-OTHER NOUN F
of I-OTHER ADP F
abdominal I-OTHER ADJ F
organs I-OTHER NOUN F
and 0 CCONJ F
deep B-OTHER ADJ F
vessels I-OTHER NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
To 0 ADJ T
assess 0 NOUN F
the 0 DET F
optimal 0 ADJ F
scan 0 NOUN F
delays 0 ADP F
and 0 CCONJ F
contrast 0 NOUN F
injection 0 NOUN F
durations 0 NOUN F
for 0 ADP F
contrast-enhanced 0 VERB F
whole-body 0 NOUN F
computed 0 PUNCT F
tomography 0 NOUN F
( 0 PUNCT F
CT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
One 0 NUM T
hundred 0 NUM F
forty-two 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
three 0 NUM F
groups 0 NOUN F
: 0 PUNCT F
protocol 0 NOUN F
A-scan 0 ADJ T
delay 0 NOUN F
of 0 ADP F
65 0 NUM F
s 0 NOUN F
after 0 ADP F
starting 0 ADP F
contrast 0 NOUN F
injection 0 NOUN F
over 0 ADP F
30 0 NUM F
s 0 NOUN F
; 0 PUNCT F
protocol 0 NOUN F
B-105 0 NOUN T
and 0 CCONJ F
70 0 NUM F
s 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
protocol 0 NOUN F
C-145 0 NOUN T
and 0 CCONJ F
110 0 NUM F
s 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

Contrast 0 NOUN T
enhancement B-OTHER NOUN F
and 0 CCONJ F
diagnostic B-OTHER ADJ F
acceptability I-OTHER NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 ADJ T
Qualitative B-OTHER ADJ T
assessment I-OTHER NOUN F
was 0 VERB F
subtle 0 ADJ F
among 0 ADP F
the 0 DET F
three 0 NUM F
protocols 0 NOUN F
. 0 PUNCT F

Homogenous B-OTHER ADJ T
enhancement I-OTHER NOUN F
of I-OTHER ADP F
deep I-OTHER ADJ F
veins I-OTHER NOUN F
was 0 VERB F
more 0 ADV F
assuredly 0 ADV F
achieved 0 VERB F
with 0 ADP F
protocol 0 ADJ F
C. 0 NOUN T
CONCLUSION 0 NOUN T
With 0 ADP T
protocol 0 NOUN F
C 0 NOUN T
, 0 PUNCT F
qualitatively 0 CCONJ F
acceptable 0 ADJ F
enhancement 0 NOUN F
can 0 VERB F
be 0 VERB F
obtained 0 VERB F
in 0 ADP F
whole-body 0 NOUN F
CT 0 NOUN T
. 0 PUNCT F

Clofarabine 0 VERB T
? 0 PUNCT F

fludarabine 0 NOUN F
with 0 ADP F
once 0 PUNCT F
daily 0 PUNCT F
i.v 0 NUM F
. 0 PUNCT F

busulfan 0 VERB F
as 0 PUNCT F
pretransplant 0 PUNCT F
conditioning 0 DET F
therapy 0 NOUN F
for 0 ADP F
advanced 0 VERB F
myeloid 0 NOUN F
leukemia 0 NOUN F
and 0 CCONJ F
MDS 0 NOUN T
. 0 PUNCT F

Although 0 ADP T
a 0 DET F
combination 0 NOUN F
of 0 ADP F
i.v 0 NUM F
. 0 PUNCT F

busulfan 0 ADJ F
( 0 PUNCT F
Bu 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
fludarabine 0 NOUN F
( 0 PUNCT F
Flu 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
safe 0 ADJ F
, 0 PUNCT F
reduced-toxicity 0 NOUN F
conditioning 0 PUNCT F
program 0 NOUN F
for 0 ADP F
acute 0 ADJ F
myelogenous 0 ADJ F
leukemia/myelodysplastic 0 ADJ F
syndromes 0 NOUN F
( 0 PUNCT F
AML/MDS 0 ADP T
) 0 PUNCT F
, 0 PUNCT F
recurrent 0 ADJ F
leukemia 0 NOUN F
posttransplantation 0 NOUN F
remains 0 NOUN F
a 0 DET F
problem 0 NOUN F
. 0 PUNCT F

To 0 PART T
enhance 0 NOUN F
the 0 DET F
conditioning 0 VERB F
regimen 0 NOUN F
's 0 PUNCT F
antileukemic 0 ADJ F
effect 0 NOUN F
, 0 PUNCT F
we 0 PRON F
decided 0 VERB F
to 0 ADP F
supplant 0 PUNCT F
Flu 0 NOUN T
with 0 ADP F
clofarabine 0 VERB F
( 0 PUNCT F
Clo 0 ADV T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
assayed 0 VERB F
the 0 DET F
interactions 0 NOUN F
of 0 ADP F
these 0 DET F
nucleoside 0 NOUN F
analogs 0 NOUN F
alone 0 ADJ F
and 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
with 0 ADP F
Bu 0 PUNCT T
in 0 ADP F
Bu-resistant 0 ADJ T
human 0 NOUN F
cell 0 NOUN F
lines 0 NOUN F
in 0 DET F
vitro 0 ADV F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
pronounced 0 VERB F
synergy 0 NOUN F
between 0 ADP F
each 0 DET F
nucleoside 0 NOUN F
and 0 CCONJ F
the 0 DET F
alkylator 0 NOUN F
but 0 CCONJ F
even 0 ADV F
more 0 ADV F
enhanced 0 ADP F
cytotoxic 0 ADJ F
synergy 0 NOUN F
when 0 ADP F
the 0 DET F
nucleoside 0 NOUN F
analogs 0 NOUN F
were 0 VERB F
combined 0 VERB F
prior 0 PUNCT F
to 0 ADP F
exposing 0 PUNCT F
the 0 DET F
cells 0 NOUN F
to 0 ADP F
Bu 0 PUNCT T
. 0 PUNCT F

We 0 PRON T
then 0 ADV F
designed 0 PUNCT F
a 0 DET F
4-arm 0 NOUN F
clinical 0 ADJ F
trial 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
myeloid 0 NOUN F
leukemia 0 NOUN F
undergoing 0 SYM F
allogeneic 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
transplantation 0 NOUN F
( 0 PUNCT F
allo-SCT 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
adaptively 0 CCONJ F
randomized 0 ADP F
as 0 ADP F
follows 0 DET F
: 0 PUNCT F
Arm 0 NOUN T
I-Clo 0 NOUN T
: 0 PUNCT F
Flu 0 NOUN T
10:30 0 NOUN F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
Arm 0 NOUN T
II-20:20 0 PUNCT T
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
Arm 0 NOUN T
III-30:10 0 PUNCT T
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
Arm 0 NOUN T
IV-single-agent 0 NOUN T
Clo 0 ADV T
at 0 ADP F
40 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
nucleoside 0 NOUN F
analog 0 NOUN F
( 0 PUNCT F
s 0 NOUN F
) 0 PUNCT F
were/was 0 PUNCT F
infused 0 VERB F
over 0 ADP F
1 0 NUM F
hour 0 NOUN F
once 0 PUNCT F
daily 0 ADJ F
for 0 ADP F
4 0 NUM F
days 0 NOUN F
, 0 PUNCT F
followed 0 VERB F
on 0 ADP F
each 0 DET F
day 0 NOUN F
by 0 ADP F
Bu 0 NOUN T
, 0 PUNCT F
infused 0 VERB F
over 0 ADP F
3 0 NUM F
hours 0 NOUN F
to 0 ADP F
a 0 DET F
pharmacokinetically 0 ADV F
targeted 0 VERB F
daily 0 ADJ F
area 0 NOUN F
under 0 ADP F
the 0 DET F
curve 0 NOUN F
( 0 PUNCT F
AUC 0 NOUN T
) 0 PUNCT F
of 0 ADP F
6000 0 NUM F
?Mol-min 0 PUNCT F
? 0 PUNCT F

10 0 NUM F
% 0 SYM F
. 0 PUNCT F

Fifty-one 0 NUM T
patients 0 NOUN F
have 0 VERB F
been 0 PUNCT F
enrolled 0 VERB F
with 0 ADP F
a 0 DET F
minimum 0 NOUN F
follow-up 0 NOUN F
exceeding 0 VERB F
100 0 NUM F
days 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
32 0 NUM F
males 0 NOUN F
and 0 CCONJ F
19 0 NUM F
females 0 NOUN F
, 0 PUNCT F
with 0 ADP F
a 0 DET F
median 0 ADJ F
age 0 NOUN F
of 0 ADP F
45 0 NUM F
years 0 NOUN F
( 0 PUNCT F
range 0 NOUN F
: 0 PUNCT F
6-59 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Nine 0 NUM T
patients 0 NOUN F
had 0 VERB F
chronic 0 ADJ F
myeloid 0 NOUN F
leukemia 0 NOUN F
( 0 PUNCT F
CML 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
BC 0 NOUN T
: 0 PUNCT F
2 0 NUM F
, 0 PUNCT F
second 0 ADJ F
AP 0 NOUN T
: 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
tyrosine-kinase 0 NOUN F
inhibitor 0 NOUN F
refractory 0 ADJ F
first 0 ADJ F
chronic 0 ADJ F
phase 0 NOUN F
[ 0 PUNCT F
CP 0 NOUN T
] 0 PUNCT F
: 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Forty-two 0 NUM T
patients 0 NOUN F
had 0 PUNCT F
AML 0 NOUN T
: 0 PUNCT F
14 0 NUM F
were 0 VERB F
induction 0 NOUN F
failures 0 NOUN F
, 0 PUNCT F
8 0 NUM F
in 0 ADP F
first 0 ADJ F
chemotherapy-refractory 0 ADJ F
relapse 0 NOUN F
, 0 PUNCT F
7 0 NUM F
in 0 ADP F
untreated 0 VERB F
relapse 0 NOUN F
, 0 PUNCT F
3 0 NUM F
in 0 ADP F
second 0 ADJ F
or 0 CCONJ F
subsequent 0 ADJ F
relapse 0 NOUN F
, 0 PUNCT F
4 0 NUM F
were 0 VERB F
in 0 ADP F
second 0 ADJ F
complete 0 ADJ F
remission 0 NOUN F
( 0 PUNCT F
CR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
in 0 ADP F
second 0 ADJ F
CR 0 NOUN T
without 0 ADP F
platelet 0 NOUN F
recovery 0 NOUN F
( 0 PUNCT F
CRp 0 ADP T
) 0 PUNCT F
, 0 PUNCT F
2 0 NUM F
were 0 VERB F
in 0 ADP F
high-risk 0 NOUN F
CR1 0 NOUN T
. 0 PUNCT F

Finally 0 ADV T
, 0 PUNCT F
1 0 NUM F
patient 0 NOUN F
was 0 VERB F
in 0 ADP F
first 0 ADJ F
CRp 0 NOUN T
. 0 PUNCT F

Graft-versus-host 0 ADJ T
disease 0 NOUN F
( 0 PUNCT F
GVHD 0 NOUN T
) 0 PUNCT F
prophylaxis 0 NOUN F
was 0 VERB F
tacrolimus 0 NOUN F
and 0 CCONJ F
mini-methorexate 0 NOUN F
( 0 PUNCT F
MTX 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
those 0 ADP F
who 0 ADP F
had 0 ADJ F
an 0 DET F
unrelated 0 ADV F
or 0 CCONJ F
1 0 NUM F
antigen-mismatched 0 ADJ F
donor 0 NOUN F
received 0 PUNCT F
low-dose 0 NOUN F
rabbit-ATG 0 NOUN F
( 0 PUNCT F
Thymoglobulin? 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
engrafted 0 VERB F
. 0 PUNCT F

Forty-one 0 NUM T
patients 0 NOUN F
had 0 ADP F
active 0 ADJ F
leukemia 0 NOUN F
at 0 ADP F
the 0 DET F
time 0 NOUN F
of 0 ADP F
transplant 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
35 0 NUM F
achieved 0 PUNCT F
CR 0 NOUN T
( 0 PUNCT F
85 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Twenty 0 PUNCT T
of 0 ADP F
the 0 DET F
42 0 NUM F
AML 0 NOUN T
patients 0 NOUN F
and 0 CCONJ F
5 0 NUM F
of 0 ADP F
9 0 NUM F
CML 0 NOUN T
patients 0 NOUN F
are 0 VERB F
alive 0 ADJ F
with 0 ADP F
a 0 DET F
projected 0 VERB F
median 0 ADJ F
overall B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
OS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
of 0 ADP F
23 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Marrow 0 NOUN T
and 0 CCONJ F
blood 0 NOUN F
( 0 PUNCT F
T 0 NOUN T
cell 0 NOUN F
) 0 PUNCT F
chimerism 0 NOUN F
studies 0 NOUN F
at 0 ADP F
day 0 NOUN F
+100 0 PUNCT F
revealed 0 VERB F
that 0 ADP F
both 0 CCONJ F
in 0 ADP F
the 0 DET F
lower-dose 0 NOUN F
Clo 0 NOUN T
groups 0 NOUN F
( 0 PUNCT F
groups 0 NOUN F
1+2 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
higher-dose 0 PUNCT F
Clo 0 NOUN T
groups 0 NOUN F
( 0 PUNCT F
groups 0 NOUN F
3+4 0 PUNCT F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
had 0 VERB F
a 0 DET F
median 0 ADJ F
of 0 ADP F
100 0 NUM F
% 0 SYM F
donor 0 NOUN F
( 0 PUNCT F
T 0 NOUN T
cell 0 NOUN F
) 0 PUNCT F
-derived 0 VERB F
DNA 0 NOUN T
. 0 PUNCT F

There 0 PUNCT T
has 0 PUNCT F
been 0 ADP F
no 0 CCONJ F
secondary B-ADVERSE-EFFECTS ADJ F
graft I-ADVERSE-EFFECTS NOUN F
failure I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
first 0 ADJ F
100 0 NUM F
days 0 NOUN F
, 0 PUNCT F
1 0 NUM F
patient 0 NOUN F
died 0 VERB F
of 0 ADP F
pneumonia 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
1 0 NUM F
of 0 ADP F
liver 0 NOUN F
GVHD 0 NOUN T
. 0 PUNCT F

We 0 PRON T
conclude 0 VERB F
that 0 ADP F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
Clo 0 ADV T
? 0 PUNCT F

Flu 0 ADP T
with 0 ADP F
i.v 0 NUM F
. 0 PUNCT F

Bu 0 PUNCT T
as 0 PUNCT F
pretransplant 0 PUNCT F
conditioning 0 VERB F
is 0 VERB F
safe 0 ADJ F
in 0 ADP F
high-risk 0 NOUN F
myeloid 0 NOUN F
leukemia 0 NOUN F
patients 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
clofarabine 0 VERB F
is 0 VERB F
sufficiently 0 ADV F
immunosuppressive 0 ADJ F
to 0 ADP F
support 0 ADJ F
allo-SCT 0 NOUN F
in 0 ADP F
myeloid 0 NOUN F
leukemia 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
the 0 DET F
median 0 ADJ F
OS 0 NOUN T
of 0 ADP F
23 0 NUM F
months 0 NOUN F
in 0 ADP F
this 0 DET F
high-risk 0 NOUN F
patient 0 NOUN F
population 0 NOUN F
is 0 VERB F
encouraging 0 PUNCT F
. 0 PUNCT F

Additional 0 ADJ T
studies 0 NOUN F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
antileukemic 0 ADJ F
efficacy 0 NOUN F
of 0 ADP F
Clo 0 ADV T
? 0 PUNCT F

Flu 0 ADP T
with 0 ADP F
i.v 0 NUM F
. 0 PUNCT F

Bu 0 PUNCT T
as 0 PUNCT F
pretransplant 0 PUNCT F
conditioning 0 VERB F
therapy 0 NOUN F
are 0 VERB F
warranted 0 VERB F
. 0 PUNCT F

Mechanisms 0 NOUN T
underlying 0 VERB F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
effect 0 NOUN F
of 0 ADP F
implantable 0 ADJ F
cardioverter-defibrillator 0 NOUN F
therapy 0 NOUN F
on 0 ADP F
mortality B-MORTALITY NOUN F
in 0 ADP F
high-risk 0 NOUN F
patients 0 NOUN F
with 0 ADP F
recent 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
: 0 PUNCT F
insights 0 NOUN F
from 0 ADP F
the 0 DET F
Defibrillation 0 NOUN T
in 0 ADP F
Acute 0 ADJ T
Myocardial 0 ADJ T
Infarction 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
DINAMIT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
although 0 ADP F
implantable 0 ADJ F
cardioverter-defibrillators 0 NOUN F
( 0 PUNCT F
ICDs 0 NOUN T
) 0 PUNCT F
lower 0 PUNCT F
mortality 0 NOUN F
in 0 ADP F
stable 0 ADJ F
patients 0 NOUN F
with 0 ADP F
low 0 ADJ F
ejection 0 NOUN F
fraction 0 NOUN F
late 0 ADJ F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
trials 0 NOUN F
of 0 ADP F
ICD 0 NOUN T
versus 0 CCONJ F
control 0 NOUN F
subjects 0 NOUN F
implanted 0 VERB F
early 0 DET F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
do 0 PUNCT F
not 0 ADV F
show 0 VERB F
mortality 0 NOUN F
benefit 0 NOUN F
. 0 PUNCT F

Our 0 PUNCT T
objective 0 ADJ F
was 0 VERB F
to 0 PART F
investigate 0 ADV F
possible 0 ADJ F
mechanisms 0 NOUN F
underlying 0 VERB F
the 0 DET F
lack 0 NOUN F
of 0 ADP F
mortality B-MORTALITY NOUN F
benefit 0 NOUN F
in 0 ADP F
the 0 DET F
Defibrillation 0 NOUN T
in 0 ADP F
Acute 0 ADJ T
Myocardial 0 ADJ T
Infarction 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
DINAMIT 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PUNCT T
this 0 ADP F
is 0 VERB F
a 0 DET F
secondary 0 ADJ F
analysis 0 NOUN F
of 0 ADP F
the 0 DET F
prospective 0 ADJ F
randomized 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

Outpatients 0 ADJ T
with 0 ADP F
recent 0 ADJ F
( 0 PUNCT F
6 0 NUM F
to 0 ADP F
40 0 NUM F
days 0 NOUN F
) 0 PUNCT F
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
, 0 PUNCT F
left 0 ADJ F
ventricular 0 ADJ F
dysfunction 0 NOUN F
( 0 PUNCT F
ejection 0 NOUN F
fraction 0 NOUN F
< 0 SYM F
35 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
low 0 ADJ F
heart 0 NOUN F
rate 0 NOUN F
variability 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
ICD 0 NOUN T
( 0 PUNCT F
n=311 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
standard 0 ADJ F
medical 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
n=342 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
competing-risks 0 VERB F
analysis 0 NOUN F
, 0 PUNCT F
those 0 PUNCT F
factors 0 NOUN F
that 0 ADP F
increased 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
arrhythmic B-MORTALITY ADJ F
death I-MORTALITY NOUN F
also 0 ADV F
increased 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
nonarrhythmic B-MORTALITY ADJ F
deaths I-MORTALITY NOUN F
. 0 PUNCT F

After 0 ADP T
adjustment 0 NOUN F
for 0 ADP F
these 0 DET F
factors 0 NOUN F
, 0 PUNCT F
receiving 0 VERB F
an 0 DET F
ICD 0 NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
a 0 DET F
decreased 0 VERB F
risk 0 NOUN F
of 0 ADP F
arrhythmic B-MORTALITY ADJ F
death I-MORTALITY NOUN F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
0.33 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.15 0 NUM F
to 0 ADP F
0.71 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
nonarrhythmic B-MORTALITY ADJ F
death I-MORTALITY NOUN F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
1.70 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
1.00 0 NUM F
to 0 ADP F
2.80 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
an 0 DET F
adjusted 0 VERB F
time-dependent 0 ADJ F
analysis 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
receiving 0 VERB F
an 0 DET F
ICD 0 NOUN T
and 0 CCONJ F
having 0 VERB F
appropriate 0 ADJ F
ICD 0 NOUN T
therapy 0 NOUN F
had 0 PUNCT F
a 0 DET F
15.1 0 NUM F
% 0 ADP F
yearly B-MORTALITY ADJ F
hazard 0 NOUN F
of B-MORTALITY ADP F
mortality B-MORTALITY NOUN F
compared 0 VERB F
with 0 ADP F
5.2 0 NUM F
% 0 SYM F
in 0 ADP F
ICD 0 NOUN T
patients 0 NOUN F
with 0 ADP F
no 0 DET F
appropriate 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
reduction 0 NOUN F
in 0 ADP F
sudden B-MORTALITY ADJ F
death I-MORTALITY NOUN F
in 0 ADP F
ICD 0 NOUN T
patients 0 NOUN F
was 0 VERB F
completely 0 ADV F
offset 0 PUNCT F
by 0 ADP F
increased 0 CCONJ F
nonarrhythmic B-MORTALITY ADJ F
deaths I-MORTALITY NOUN F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
greatest 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
ICD 0 NOUN T
shock 0 NOUN F
therapy 0 NOUN F
( 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
, 0 PUNCT F
6.0 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
2.8 0 NUM F
to 0 ADP F
12.7 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
in 0 ADP F
patients 0 NOUN F
receiving 0 VERB F
ICDs 0 NOUN T
early 0 ADJ F
after 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
, 0 PUNCT F
those 0 PUNCT F
factors 0 NOUN F
that 0 ADP F
are 0 VERB F
associated 0 VERB F
with 0 ADP F
arrhythmia 0 NOUN F
requiring 0 PUNCT F
ICD 0 NOUN T
therapy 0 NOUN F
are 0 VERB F
also 0 ADV F
associated 0 VERB F
with 0 ADP F
a 0 DET F
high 0 ADJ F
risk 0 NOUN F
of 0 PUNCT F

Menopausal B-OTHER PUNCT T
quality I-OTHER NOUN F
of I-OTHER ADP F
life I-OTHER NOUN F
: 0 PUNCT F
RCT 0 NOUN T
of 0 ADP F
yoga 0 NOUN F
, 0 PUNCT F
exercise 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
omega-3 0 NOUN F
supplements 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
3 0 NUM F
nonhormonal 0 ADJ F
therapies 0 NOUN F
for 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
menopause-related B-OTHER VERB F
quality I-OTHER NOUN F
of I-OTHER ADP F
life I-OTHER NOUN F
in 0 ADP F
women 0 NOUN F
with 0 ADP F
vasomotor 0 NOUN F
symptoms 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
We 0 PRON T
conducted 0 VERB F
a 0 DET F
12-week 0 NOUN F
3 0 NUM F
? 0 PUNCT F

2 0 NUM F
randomized 0 VERB F
, 0 PUNCT F
controlled 0 PUNCT F
, 0 PUNCT F
factorial 0 ADJ F
design 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Peri- 0 PUNCT T
and 0 CCONJ F
postmenopausal 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
40-62 0 DET F
years 0 NOUN F
old 0 ADJ F
, 0 PUNCT F
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 PUNCT F
yoga 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
107 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
exercise 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
106 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
usual 0 ADJ F
activity 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
142 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
also 0 ADV F
assigned 0 PUNCT F
randomly 0 ADV F
to 0 ADP F
a 0 DET F
double-blind 0 ADJ F
comparison 0 NOUN F
of 0 ADP F
omega-3 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
177 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
178 0 NUM F
) 0 PUNCT F
capsules 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
the 0 DET F
following 0 PUNCT F
interventions 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
weekly 0 ADP F
90-minute 0 CCONJ F
yoga 0 NOUN F
classes 0 NOUN F
with 0 ADP F
daily 0 CCONJ F
at-home 0 DET F
practice 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
individualized 0 ADP F
facility-based 0 NOUN F
aerobic 0 ADJ F
exercise 0 NOUN F
training 0 VERB F
3 0 NUM F
times/week 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
3 0 NUM F
) 0 PUNCT F
0.615 0 NUM F
g 0 NOUN F
omega-3 0 NOUN F
supplement 0 NOUN F
, 0 PUNCT F
3 0 NUM F
times/day 0 NOUN F
. 0 PUNCT F

The 0 DET T
outcomes 0 NOUN F
were 0 VERB F
assessed 0 VERB F
with 0 ADP F
the 0 DET F
following 0 PUNCT F
scores 0 NOUN F
: 0 PUNCT F
Menopausal 0 PUNCT T
Quality 0 NOUN T
of 0 ADP F
Life 0 NOUN T
Questionnaire 0 NOUN T
( 0 PUNCT F
MENQOL 0 NOUN T
) 0 PUNCT F
total 0 ADP F
and 0 CCONJ F
domain 0 NOUN F
( 0 PUNCT F
vasomotor 0 NOUN F
symptoms 0 NOUN F
, 0 PUNCT F
psychosocial 0 ADJ F
, 0 PUNCT F
physical 0 ADJ F
and 0 CCONJ F
sexual 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Among 0 ADP T
355 0 NUM F
randomly 0 ADV F
assigned 0 PUNCT F
women 0 NOUN F
who 0 ADP F
average 0 PUNCT F
age 0 NOUN F
was 0 VERB F
54.7 0 NUM F
years 0 NOUN F
, 0 PUNCT F
338 0 NUM F
women 0 NOUN F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
) 0 PUNCT F
completed 0 DET F
12-week 0 NOUN F
assessments 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
baseline 0 NOUN F
vasomotor 0 NOUN F
symptoms 0 NOUN F
frequency 0 NOUN F
was 0 VERB F
7.6/day 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
mean 0 NOUN F
baseline 0 NOUN F
total 0 ADJ F
MENQOL 0 NOUN T
score 0 NOUN F
was 0 ADV F
3.8 0 NUM F
( 0 PUNCT F
range 0 NOUN F
, 0 PUNCT F
1-8 0 NUM F
from 0 ADP F
better 0 PUNCT F
to 0 ADP F
worse 0 ADJ F
) 0 PUNCT F
with 0 ADP F
no 0 DET F
between-group 0 NOUN F
differences 0 NOUN F
. 0 PUNCT F

For 0 ADP T
yoga 0 NOUN F
compared 0 VERB F
to 0 ADP F
usual 0 ADJ F
activity 0 NOUN F
, 0 PUNCT F
baseline 0 NOUN F
to 0 PUNCT F
12-week 0 NOUN F
improvements 0 NOUN F
were 0 VERB F
seen 0 VERB F
for 0 ADP F
MENQOL 0 NOUN T
total 0 VERB F
-0.3 0 ADP F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
-0.6 0 ADJ F
to 0 ADP F
0 0 NUM F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
vasomotor 0 NOUN F
symptom 0 NOUN F
domain 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
sexuality 0 NOUN F
domain 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.03 0 NUM F
) 0 PUNCT F
scores 0 NOUN F
. 0 PUNCT F

For 0 ADP T
women 0 NOUN F
who 0 ADP F
underwent 0 PROPN F
exercise 0 NOUN F
and 0 CCONJ F
omega-3 0 NOUN F
therapy 0 NOUN F
compared 0 VERB F
with 0 ADP F
control 0 NOUN F
subjects 0 NOUN F
, 0 PUNCT F
improvements 0 ADJ F
in 0 ADP F
baseline 0 NOUN F
to 0 PUNCT F
12-week 0 NOUN F
total 0 ADJ F
MENQOL 0 NOUN T
scores 0 NOUN F
were 0 VERB F
not 0 ADV F
observed 0 VERB F
. 0 PUNCT F

Exercise 0 NOUN T
showed 0 CCONJ F
benefit 0 NOUN F
in 0 ADP F
the 0 DET F
MENQOL 0 NOUN T
physical 0 ADJ F
domain 0 NOUN F
score 0 NOUN F
at 0 ADP F
12 0 NUM F
weeks 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
All 0 DET T
women 0 NOUN F
become 0 VERB F
menopausal 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
many 0 DET F
of 0 ADP F
them 0 PRON F
seek 0 PUNCT F
medical 0 ADJ F
advice 0 NOUN F
on 0 ADP F
ways 0 NOUN F
to 0 DET F
improve 0 ADP F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
; 0 PUNCT F
little 0 DET F
evidence-based 0 ADJ F
information 0 NOUN F
exists 0 NOUN F
. 0 PUNCT F

We 0 PRON T
found 0 VERB F
that 0 ADP F
, 0 PUNCT F
among 0 ADP F
healthy 0 ADJ F
sedentary 0 ADJ F
menopausal 0 ADJ F
women 0 NOUN F
, 0 PUNCT F
yoga 0 NOUN F
appears 0 NOUN F
to 0 PART F
improve 0 PUNCT F
menopausal 0 ADJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
; 0 PUNCT F
the 0 DET F
clinical 0 ADJ F
significance 0 NOUN F
of 0 ADP F
our 0 PUNCT F
finding 0 ADP F
is 0 ADP F
uncertain 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
the 0 DET F
modest 0 ADJ F
effect 0 NOUN F
. 0 PUNCT F

Short- B-PHYSICAL PUNCT T
and I-PHYSICAL CCONJ F
long-term I-PHYSICAL NOUN F
effects I-PHYSICAL NOUN F
of 0 ADP F
tactile 0 NOUN F
massage 0 NOUN F
on 0 ADP F
salivary B-PHYSICAL ADJ F
cortisol I-PHYSICAL NOUN F
concentrations I-PHYSICAL NOUN F
in 0 ADP F
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
: 0 PUNCT F
a 0 DET F
randomised 0 VERB F
controlled 0 DET F
pilot 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Parkinson 0 NOUN T
's 0 PUNCT F
disease 0 NOUN F
( 0 PUNCT F
PD 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
chronic 0 ADJ F
neurodegenerative 0 ADJ F
disorder 0 NOUN F
with 0 ADP F
limited 0 VERB F
knowledge 0 NOUN F
about 0 PUNCT F
the 0 DET F
normal 0 ADJ F
function 0 NOUN F
and 0 CCONJ F
effects 0 NOUN F
of 0 ADP F
non-pharmacological 0 ADJ F
therapies 0 NOUN F
on 0 ADP F
the 0 DET F
hypothalamic-pituitary-adrenal B-PHYSICAL ADJ F
( I-PHYSICAL PUNCT F
HPA I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
axis I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
aim 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 ADJ F
analyse 0 ADJ F
the 0 DET F
basal B-PHYSICAL ADJ F
diurnal I-PHYSICAL ADJ F
and 0 CCONJ F
total 0 ADJ F
secretion B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
salivary I-PHYSICAL ADJ F
cortisol I-PHYSICAL NOUN F
in 0 ADP F
short- 0 ADJ F
and 0 CCONJ F
long-term 0 NOUN F
aspects 0 NOUN F
of 0 ADP F
tactile 0 NOUN F
massage 0 NOUN F
( 0 PUNCT F
TM 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
Controlled 0 PROPN T
and 0 CCONJ F
Randomised 0 PROPN T
Multicentre 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

SETTING 0 VERB T
AND 0 CCONJ T
INTERVENTIONS 0 NOUN T
Forty-five 0 PUNCT T
women 0 NOUN F
and 0 CCONJ F
men 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
50-79 0 NUM F
years 0 NOUN F
, 0 PUNCT F
were 0 VERB F
recruited 0 VERB F
. 0 PUNCT F

Twenty-nine 0 PUNCT T
of 0 ADP F
them 0 PRON F
were 0 VERB F
blindly 0 ADV F
randomised 0 PROPN F
to 0 PUNCT F
tactile 0 NOUN F
massage 0 NOUN F
( 0 PUNCT F
TM 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
16 0 NUM F
of 0 ADP F
them 0 PRON F
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
rest 0 PUNCT F
to 0 ADP F
music 0 ADJ F
( 0 PUNCT F
RTM 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Ten 0 NUM T
interventions 0 NOUN F
were 0 VERB F
given 0 VERB F
during 0 ADP F
8 0 NUM F
weeks 0 NOUN F
followed 0 VERB F
by 0 ADP F
a 0 DET F
26 0 NUM F
weeks 0 NOUN F
of 0 ADP F
follow 0 PUNCT F
up 0 PUNCT F
. 0 PUNCT F

Salivary B-PHYSICAL ADJ T
cortisol I-PHYSICAL NOUN F
was 0 VERB F
collected 0 VERB F
at 0 ADP F
8 0 NUM F
am 0 ADP F
, 0 PUNCT F
1 0 NUM F
pm 0 NOUN F
, 0 PUNCT F
8 0 NUM F
pm 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
8 0 NUM F
am 0 PUNCT F
the 0 DET F
next 0 ADJ F
day 0 NOUN F
, 0 PUNCT F
on 0 ADP F
five 0 NUM F
occasions 0 NOUN F
. 0 PUNCT F

With 0 ADP T
the 0 DET F
first 0 ADJ F
and 0 CCONJ F
eighth 0 PUNCT F
interventions 0 NOUN F
, 0 PUNCT F
it 0 PUNCT F
was 0 VERB F
collected 0 VERB F
immediately 0 ADV F
before 0 PUNCT F
and 0 CCONJ F
after 0 ADP F
intervention 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
The 0 DET T
primary 0 ADJ F
aim 0 NOUN F
was 0 VERB F
to 0 PART F
assess 0 NOUN F
and 0 PUNCT F
compare 0 PUNCT F

Sunbathing 0 ADP T
and 0 CCONJ F
sunbed 0 PUNCT F
use 0 NOUN F
related 0 PRON F
to 0 ADP F
self-image 0 NOUN F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
sample 0 NOUN F
of 0 ADP F
Swedish 0 PUNCT T
adolescents 0 NOUN F
. 0 PUNCT F

In 0 ADP T
1996 0 NUM F
a 0 DET F
randomized 0 VERB F
sample 0 NOUN F
of 0 ADP F
4,020 0 NUM F
Swedish 0 PUNCT T
adolescents 0 NOUN F
from 0 ADP F
three 0 NUM F
birth 0 NOUN F
cohorts 0 NOUN F
were 0 VERB F
sent 0 NOUN F
a 0 DET F
questionnaire 0 NOUN F
consisting 0 PUNCT F
of 0 ADP F
50 0 NUM F
items 0 ADJ F
concerning 0 PRON F
habitual 0 ADJ F
sun-related 0 VERB F
behaviours 0 NOUN F
and 0 CCONJ F
attitudes 0 ADP F
, 0 PUNCT F
knowledge 0 NOUN F
about 0 PUNCT F
melanoma 0 NOUN F
, 0 PUNCT F
risk 0 NOUN F
perception 0 NOUN F
and 0 CCONJ F
self-image 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
2,615 0 NUM F
questionnaires 0 NOUN F
were 0 VERB F
returned 0 PUNCT F
. 0 PUNCT F

Girls 0 PROPN T
sunbathed 0 PUNCT F
and 0 CCONJ F
used 0 VERB F
sunbeds 0 ADJ F
more 0 ADV F
than 0 ADP F
boys 0 NOUN F
at 0 ADP F
all 0 DET F
ages 0 NOUN F
. 0 PUNCT F

Sunbathing B-MENTAL ADP T
and 0 CCONJ F
sunbed B-MENTAL PUNCT F
use I-MENTAL NOUN F
increased 0 VERB F
with 0 ADP F
age 0 NOUN F
. 0 PUNCT F

Boys 0 ADP T
who 0 ADP F
were 0 VERB F
most 0 PUNCT F
satisfied 0 ADP F
and 0 CCONJ F
girls 0 PUNCT F
least 0 DET F
satisfied 0 VERB F
with 0 ADP F
themselves 0 PUNCT F
sunbathed B-MENTAL ADP F
most 0 PUNCT F
. 0 PUNCT F

Those 0 ADV T
who 0 PROPN F
were 0 VERB F
least 0 ADV F
satisfied 0 VERB F
with 0 ADP F
themselves 0 ADV F
used B-MENTAL VERB F
sunbeds I-MENTAL ADP F
most 0 PUNCT F
frequently 0 ADV F
. 0 PUNCT F

Girls 0 PROPN T
reported 0 VERB F
a 0 DET F
higher 0 PUNCT F
perceived 0 DET F
susceptibility B-MENTAL NOUN F
to I-MENTAL ADP F
melanoma I-MENTAL NOUN F
than 0 PUNCT F
did 0 PUNCT F
boys 0 ADP F
. 0 PUNCT F

The 0 DET T
perception B-MENTAL NOUN F
of I-MENTAL ADP F
susceptibility I-MENTAL NOUN F
increased 0 VERB F
with 0 ADP F
age 0 NOUN F
. 0 PUNCT F

Those 0 ADV T
who 0 PROPN F
were 0 VERB F
least 0 ADV F
satisfied 0 VERB F
with 0 ADP F
themselves 0 ADP F
reported 0 VERB F
feeling 0 CCONJ F
most 0 PUNCT F
susceptible B-MENTAL ADJ F
. 0 PUNCT F

The 0 DET T
overall 0 ADJ F
main 0 ADJ F
reason B-MENTAL NOUN F
for I-MENTAL ADP F
sunbathing I-MENTAL VERB F
was 0 DET F
appearance 0 NOUN F
, 0 PUNCT F
both 0 PUNCT F
for 0 ADP F
own 0 ADJ F
sunbathing 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
to 0 ADP F
an 0 DET F
even 0 ADV F
higher 0 PUNCT F
degree 0 NOUN F
, 0 PUNCT F
as 0 ADP F
a 0 DET F
supposed 0 VERB F
reason 0 NOUN F
for 0 ADP F
other 0 ADJ F
adolescents 0 NOUN F
' 0 PUNCT F
behaviour 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
was 0 VERB F
reported 0 VERB F
most 0 PUNCT F
frequently 0 ADV F
by 0 ADP F
girls 0 NOUN F
and 0 CCONJ F
the 0 DET F
older 0 PUNCT F
age 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
second 0 ADJ F
most 0 ADP F
'important 0 PUNCT F
' 0 PUNCT F
reason 0 NOUN F
for 0 ADP F
sunbathing 0 VERB F
was 0 ADJ F
'feeling 0 PUNCT F
warm 0 NUM F
and 0 CCONJ F
comfortable 0 ADJ F
' 0 PUNCT F
. 0 PUNCT F

Preventive 0 ADJ T
programmes 0 NOUN F
aimed 0 VERB F
at 0 ADP F
a 0 DET F
change 0 NOUN F
of 0 ADP F
sun 0 PUNCT F
related 0 VERB F
behaviours 0 NOUN F
among 0 ADP F
Swedish 0 PUNCT T
adolescents 0 NOUN F
have 0 PUNCT F
to 0 ADJ F
be 0 PUNCT F
tailored 0 VERB F
to 0 ADP F
the 0 DET F
climate 0 NOUN F
and 0 CCONJ F
cultural 0 ADJ F
conditions 0 NOUN F
and 0 CCONJ F
must 0 VERB F
take 0 PUNCT F
into 0 ADP F
account 0 PUNCT F
that 0 VERB F
having 0 VERB F
a 0 DET F
tan 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
warmth 0 ADP F
of 0 ADP F
the 0 DET F
sun 0 ADJ F
, 0 PUNCT F
are 0 VERB F
highly 0 ADV F
valued 0 PUNCT F
by 0 ADP F
most 0 DET F
adolescents 0 NOUN F
. 0 PUNCT F

Predictors 0 NOUN T
of 0 ADP F
postdischarge 0 NOUN F
outcomes 0 NOUN F
from 0 ADP F
information 0 NOUN F
acquired 0 VERB F
shortly 0 ADV F
after 0 ADP F
admission 0 NOUN F
for 0 ADP F
acute 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
: 0 PUNCT F
a 0 DET F
report 0 NOUN F
from 0 ADP F
the 0 DET F
Placebo-Controlled 0 ADV T
Randomized 0 NOUN T
Study 0 NOUN T
of 0 ADP F
the 0 DET F
Selective 0 ADJ T
A1 0 NOUN T
Adenosine 0 NOUN T
Receptor 0 NOUN T
Antagonist 0 NOUN T
Rolofylline 0 NOUN T
for 0 ADP F
Patients 0 NOUN T
Hospitalized 0 PROPN T
With 0 ADP T
Acute 0 ADJ T
Decompensated 0 ADJ T
Heart 0 NOUN T
Failure 0 NOUN T
and 0 CCONJ F
Volume 0 NOUN T
Overload 0 PUNCT T
to 0 DET F
Assess 0 NOUN T
Treatment 0 NOUN T
Effect 0 NOUN T
on 0 ADP F
Congestion 0 NOUN T
and 0 CCONJ F
Renal 0 ADJ T
Function 0 NOUN T
( 0 PUNCT F
PROTECT 0 NOUN T
) 0 PUNCT F
Study 0 NOUN T
. 0 PUNCT F

BACKGROUND 0 NOUN T
Acute 0 ADJ T
heart 0 NOUN F
failure 0 NOUN F
is 0 VERB F
a 0 DET F
common 0 ADJ F
reason 0 NOUN F
for 0 ADP F
admission 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
outcome 0 NOUN F
is 0 VERB F
often 0 ADV F
poor 0 ADJ F
. 0 PUNCT F

Improved 0 VERB T
prognostic 0 ADJ F
risk 0 NOUN F
stratification 0 NOUN F
may 0 VERB F
assist 0 PUNCT F
in 0 ADP F
the 0 DET F
design 0 NOUN F
of 0 ADP F
future 0 ADJ F
trials 0 NOUN F
and 0 CCONJ F
in 0 ADP F
patient 0 NOUN F
management 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
data 0 NOUN F
from 0 ADP F
a 0 DET F
large 0 ADJ F
randomized 0 VERB F
trial 0 NOUN F
, 0 PUNCT F
we 0 PRON F
explored 0 PUNCT F
the 0 DET F
prognostic 0 ADJ F
value 0 NOUN F
of 0 ADP F
clinical 0 ADJ F
variables 0 NOUN F
, 0 PUNCT F
measured 0 VERB F
at 0 ADP F
hospital 0 NOUN F
admission 0 NOUN F
for 0 ADP F
acute 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
, 0 PUNCT F
to 0 PART F
determine 0 NOUN F
whether 0 ADP F
a 0 DET F
few 0 ADJ F
selected 0 VERB F
variables 0 NOUN F
were 0 VERB F
inferior 0 ADJ F
to 0 ADP F
an 0 DET F
extended 0 ADJ F
data 0 NOUN F
set 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PUNCT T
The 0 DET T
prognostic 0 ADJ F
model 0 NOUN F
included 0 VERB F
37 0 NUM F
clinical 0 ADJ F
characteristics 0 NOUN F
collected 0 VERB F
at 0 ADP F
baseline 0 NOUN F
in 0 ADP F
PROTECT 0 NOUN T
, 0 PUNCT F
a 0 DET F
study 0 NOUN F
comparing 0 ADP F
rolofylline 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
2033 0 NUM F
patients 0 NOUN F
admitted 0 VERB F
with 0 ADP F
acute 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

Prespecified 0 ADJ T
outcomes 0 NOUN F
at 0 ADP F
30 0 NUM F
days 0 NOUN F
were 0 VERB F
death B-MORTALITY NOUN F
or 0 CCONJ F
rehospitalization B-MORTALITY NOUN F
for I-MORTALITY ADP F
any I-MORTALITY DET F
reason I-MORTALITY NOUN F
; 0 PUNCT F
death B-MORTALITY NOUN F
or 0 CCONJ F
rehospitalization 0 NOUN F
for 0 ADP F
cardiovascular B-MORTALITY ADJ F
or 0 CCONJ F
renal B-MORTALITY ADJ F
reasons I-MORTALITY NOUN F
; 0 PUNCT F
and 0 CCONJ F
, 0 PUNCT F
at 0 ADP F
both 0 CCONJ F
30 0 NUM F
and 0 CCONJ F
180 0 NUM F
days 0 NOUN F
, 0 PUNCT F
all-cause 0 NOUN F
mortality 0 NOUN F
. 0 PUNCT F

No 0 DET T
variable 0 ADJ F
had 0 PUNCT F
a 0 DET F
c-index 0 NOUN F
> 0 SYM F
0.70 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
few 0 ADJ F
had 0 PUNCT F
values 0 NOUN F
> 0 SYM F
0.60 0 NUM F
; 0 PUNCT F
c-indices 0 ADV F
were 0 VERB F
lower 0 PUNCT F
for 0 ADP F
composite 0 ADJ F
outcomes 0 NOUN F
than 0 PUNCT F
for 0 ADP F
mortality 0 NOUN F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
urea I-PHYSICAL NOUN F
was 0 VERB F
generally 0 PUNCT F
the 0 DET F
strongest 0 PUNCT F
single 0 ADJ F
predictor 0 NOUN F
. 0 PUNCT F

Eighteen 0 PUNCT T
variables 0 NOUN F
contributed 0 DET F
independent 0 ADJ F
prognostic 0 ADJ F
information 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
a 0 DET F
reduced 0 VERB F
model 0 NOUN F
using 0 VERB F
only 0 ADV F
8 0 NUM F
items 0 ADJ F
( 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
previous 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
hospitalization 0 NOUN F
, 0 PUNCT F
peripheral 0 ADJ F
edema 0 NOUN F
, 0 PUNCT F
systolic 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
serum 0 NOUN F
sodium 0 NOUN F
, 0 PUNCT F
urea 0 NOUN F
, 0 PUNCT F
creatinine 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
albumin 0 NOUN F
) 0 PUNCT F
performed 0 PART F
similarly 0 ADV F
. 0 PUNCT F

For 0 ADP T
prediction 0 NOUN F
of 0 ADP F
all-cause B-MORTALITY NOUN F
mortality I-MORTALITY NOUN F
at 0 ADP F
180 0 NUM F
days 0 NOUN F
, 0 PUNCT F
the 0 DET F
model 0 NOUN F
c-index 0 NOUN F
using 0 VERB F
all 0 DET F
variables 0 NOUN F
was 0 VERB F
0.72 0 NUM F
and 0 CCONJ F
for 0 ADP F
the 0 DET F
simplified 0 ADJ F
model 0 NOUN F
, 0 PUNCT F
also 0 ADV F
0.72 0 NUM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
A 0 PUNCT T
few 0 ADJ F
simple 0 ADJ F
clinical 0 ADJ F
variables 0 NOUN F
measured 0 VERB F
on 0 ADP F
admission 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
acute 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
predict 0 VERB F
a 0 DET F
variety 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
outcomes I-ADVERSE-EFFECTS NOUN F
with 0 ADP F
accuracy 0 NOUN F
similar 0 ADJ F
to 0 ADP F
more 0 DET F
complex 0 PUNCT F
models 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
predictive 0 ADJ F
models 0 NOUN F
were 0 ADJ F
of 0 ADP F
only 0 ADV F
moderate B-OTHER ADJ F
accuracy I-OTHER NOUN F
, 0 PUNCT F
especially 0 ADV F
for 0 ADP F
outcomes 0 NOUN F
that 0 ADP F
included B-ADVERSE-EFFECTS ADJ F
nonfatal I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Better 0 PUNCT T
methods 0 NOUN F
of 0 ADP F
risk 0 NOUN F
stratification 0 NOUN F
are 0 VERB F
required 0 VERB F
. 0 PUNCT F

CLINICAL 0 ADJ T
TRIAL 0 NOUN T
REGISTRATION 0 NOUN T
URL 0 NOUN T
: 0 PUNCT F
http 0 PUNCT F
: 0 PUNCT F
//www.clinicaltrials.gov 0 PUNCT F
. 0 PUNCT F

Unique 0 ADJ T
identifiers 0 NOUN F
: 0 PUNCT F
NCT00328692 0 PUNCT T
and 0 CCONJ F
NCT00354458 0 NOUN T
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
testosterone 0 NOUN F
and 0 CCONJ F
a 0 DET F
nutritional 0 ADJ F
supplement 0 NOUN F
, 0 PUNCT F
alone 0 ADJ F
and 0 CCONJ F
in 0 ADP F
combination 0 NOUN F
, 0 PUNCT F
on 0 ADP F
hospital B-OTHER NOUN F
admissions I-OTHER NOUN F
in 0 ADP F
undernourished 0 NOUN F
older 0 PUNCT F
men 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
In 0 ADP T
older 0 PUNCT F
people 0 NOUN F
, 0 PUNCT F
undernutrition 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
hospitalization B-PHYSICAL NOUN F
rates I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Because 0 PUNCT T
weight 0 NOUN F
loss 0 NOUN F
in 0 ADP F
older 0 PUNCT F
people 0 NOUN F
often 0 ADV F
reflects 0 NOUN F
a 0 DET F
disproportionate 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
skeletal 0 ADJ F
muscle 0 NOUN F
, 0 PUNCT F
anabolic 0 ADJ F
treatments 0 NOUN F
may 0 VERB F
be 0 VERB F
beneficial 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
aim 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
hypothesis 0 NOUN F
that 0 ADP F
testosterone 0 NOUN F
treatment 0 NOUN F
and 0 CCONJ F
a 0 DET F
nutritional 0 ADJ F
supplement 0 NOUN F
have 0 PUNCT F
additive 0 ADJ F
benefits 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Oral 0 ADJ T
testosterone 0 NOUN F
undecanoate 0 NOUN F
( 0 PUNCT F
40 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
for 0 ADP F
women 0 NOUN F
, 0 PUNCT F
80 0 NUM F
mg 0 NOUN F
twice 0 ADV F
daily 0 ADJ F
for 0 ADP F
men 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
an 0 DET F
oral 0 ADJ F
nutritional 0 ADJ F
supplement 0 NOUN F
( 0 PUNCT F
475 0 NUM F
kcal/d 0 ADJ F
) 0 PUNCT F
were 0 VERB F
administered 0 VERB F
, 0 PUNCT F
alone 0 ADJ F
or 0 CCONJ F
combined 0 ADV F
, 0 PUNCT F
for 0 ADP F
1 0 NUM F
y 0 NUM F
to 0 ADP F
49 0 NUM F
community-dwelling 0 PUNCT F
, 0 PUNCT F
undernourished 0 DET F
people 0 NOUN F
[ 0 PUNCT F
Mini 0 NOUN T
Nutritional 0 ADJ T
Assessment 0 NOUN T
score 0 NOUN F
< 0 SYM F
24 0 NUM F
and 0 CCONJ F
low 0 ADJ F
body 0 NOUN F
weight 0 NOUN F
( 0 PUNCT F
body 0 NOUN F
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
in 0 ADP F
kg/m 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
: 0 PUNCT F
< 0 SYM F
22 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
recent 0 ADJ F
weight 0 NOUN F
loss 0 NOUN F
( 0 PUNCT F
> 0 PROPN F
7.5 0 NUM F
% 0 SYM F
over 0 ADP F
3 0 NUM F
mo 0 NOUN F
) 0 PUNCT F
] 0 PUNCT F
aged 0 DET F
> 0 ADP F
65 0 NUM F
y 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
age 0 NOUN F
: 0 PUNCT F
77 0 NUM F
y 0 NOUN F
; 0 PUNCT F
26 0 DET F
women 0 NOUN F
and 0 CCONJ F
23 0 NUM F
men 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Hospital B-OTHER NOUN T
admissions I-OTHER NOUN F
and 0 CCONJ F
other 0 ADJ F
variables B-OTHER NOUN F
were 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
In 0 ADP T
subjects 0 NOUN F
receiving 0 DET F
combined 0 VERB F
testosterone 0 NOUN F
and 0 CCONJ F
nutritional 0 ADJ F
supplements 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
11 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
hospital B-OTHER NOUN F
admissions I-OTHER NOUN F
, 0 PUNCT F
whereas 0 ADP F
there 0 PUNCT F
were 0 VERB F
9 0 NUM F
admissions 0 NOUN F
( 0 PUNCT F
2 0 NUM F
elective 0 ADJ F
) 0 PUNCT F
in 0 ADP F
13 0 NUM F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
no-treatment 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
4 0 NUM F
in 0 ADP F
the 0 DET F
testosterone-treated 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
5 0 NUM F
in 0 ADP F
the 0 DET F
supplement-treated 0 VERB F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
13 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.06 0 NUM F
with 0 ADP F
no-treatment 0 NOUN F
compared 0 VERB F
with 0 ADP F
combined 0 VERB F
treatment 0 NOUN F
. 0 PUNCT F

When 0 ADP T
compared 0 VERB F
with 0 ADP F
the 0 DET F
no-treatment 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
combined-treatment 0 PUNCT F
group 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
fewer 0 PUNCT F
subjects B-OTHER NOUN F
admitted I-OTHER VERB F
to I-OTHER ADP F
hospital I-OTHER NOUN F
( 0 PUNCT F
0 0 NUM F
compared 0 VERB F
with 0 ADP F
5 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
fewer 0 PUNCT F
days B-OTHER NOUN F
in I-OTHER ADP F
hospital I-OTHER NOUN F
( 0 PUNCT F
0 0 NUM F
compared 0 VERB F
with 0 ADP F
74 0 NUM F
, 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.041 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
longer 0 PUNCT F
time 0 NOUN F
to 0 ADP F
hospital 0 NOUN F
admission 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.017 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
undernourished 0 NOUN F
older 0 PUNCT F
people 0 NOUN F
, 0 PUNCT F
combined 0 ADP F
treatment 0 NOUN F
with 0 ADP F
testosterone 0 NOUN F
and 0 CCONJ F
nutritional 0 ADJ F
supplementation 0 NOUN F
reduced 0 VERB F
the 0 DET F
number 0 NOUN F
of 0 ADP F
people 0 NOUN F
hospitalized 0 ADP F
and 0 CCONJ F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
hospital 0 NOUN F
admissions 0 NOUN F
, 0 PUNCT F
which 0 ADP F
are 0 VERB F
important 0 ADJ F
endpoints 0 NOUN F
in 0 ADP F
this 0 DET F
group 0 NOUN F
. 0 PUNCT F

Larger 0 PUNCT T
, 0 PUNCT F
confirmatory 0 ADJ F
studies 0 NOUN F
are 0 VERB F
now 0 ADV F
needed 0 VERB F
. 0 PUNCT F

This 0 DET T
trial 0 NOUN F
was 0 VERB F
registered 0 PUNCT F
before 0 ADP F
commencement 0 ADJ F
at 0 ADP F
clinical 0 ADJ F
trials.gov 0 NOUN F
as 0 VERB F
NCT00117000 0 NOUN T
. 0 PUNCT F

Double-blind 0 ADJ T
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
trandolapril 0 NOUN F
2 0 NUM F
mg 0 NOUN F
and 0 CCONJ F
hydrochlorothiazide 0 NOUN F
25 0 NUM F
mg 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
mild-to-moderate 0 ADJ F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Investigator 0 NOUN T
Study 0 NOUN T
Group 0 NOUN T
. 0 PUNCT F

This 0 DET T
multicenter 0 NOUN F
international 0 ADJ F
trial 0 NOUN F
recruited 0 VERB F
205 0 NUM F
patients 0 NOUN F
from 0 ADP F
16 0 NUM F
investigators 0 NOUN F
. 0 PUNCT F

After 0 ADP T
a 0 DET F
4-week 0 NOUN F
, 0 PUNCT F
single-blind 0 NUM F
placebo 0 NOUN F
run-in 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
16 0 DET F
weeks 0 NOUN F
of 0 ADP F
trandolapril 0 NOUN F
2 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
68 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
hydrochlorothiazide 0 NOUN F
( 0 PUNCT F
HCTZ 0 NOUN T
) 0 PUNCT F
25 0 NUM F
mg/day 0 NOUN F
( 0 PUNCT F
68 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
combination 0 NOUN F
( 0 PUNCT F
69 0 NUM F
patients 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Morning B-PHYSICAL NOUN T
predosing I-PHYSICAL ADV F
supine I-PHYSICAL NOUN F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
DBP B-PHYSICAL NOUN T
) 0 PUNCT F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
efficacy 0 NOUN F
measurement 0 NOUN F
. 0 PUNCT F

Intention-to-treat 0 NOUN T
analysis 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
decreases 0 NOUN F
in 0 ADP F
all 0 DET F
three 0 NUM F
groups 0 NOUN F
in 0 ADP F
mean 0 NOUN F
( 0 PUNCT F
+/- 0 PROPN F
SEM 0 NOUN T
) 0 PUNCT F
supine B-PHYSICAL NOUN F
DBP I-PHYSICAL NOUN T
throughout 0 ADP F
the 0 DET F
study 0 NOUN F
, 0 PUNCT F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
at 0 ADP F
week 0 NOUN F
16 0 NUM F
between 0 ADP F
trandolapril 0 NOUN F
( 0 PUNCT F
-10.6 0 NUM F
+/- 0 SYM F
1.3 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
HCTZ 0 ADJ T
( 0 PUNCT F
-10.9 0 ADV F
+/- 0 SYM F
1.3 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
gave 0 VERB F
a 0 DET F
significantly 0 ADV F
greater 0 PUNCT F
reduction 0 NOUN F
than 0 ADP F
either 0 PUNCT F
drug 0 NOUN F
alone 0 ADJ F
( 0 PUNCT F
-15.1 0 NUM F
+/- 0 SYM F
1.13 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Blood B-PHYSICAL NOUN T
pressure I-PHYSICAL NOUN F
was 0 VERB F
normalized 0 VERB F
in 0 ADP F
the 0 DET F
combination 0 NOUN F
group 0 NOUN F
in 0 ADP F
67 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
a 0 DET F
significantly 0 ADV F
higher 0 PUNCT F
proportion 0 NOUN F
than 0 PUNCT F
either 0 PUNCT F
trandolapril 0 NOUN F
( 0 PUNCT F
63 0 NUM F
% 0 SYM F
) 0 PUNCT F
or 0 CCONJ F
HCTZ 0 ADJ T
( 0 PUNCT F
60 0 NUM F
% 0 SYM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Each 0 DET T
treatment 0 NOUN F
was 0 VERB F
well 0 VERB F
tolerated 0 ADP F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
similar 0 ADJ F
in 0 ADP F
all 0 DET F
three 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

Trandolapril 0 NOUN T
2 0 NUM F
mg 0 NOUN F
once 0 PUNCT F
daily 0 ADP F
is 0 VERB F
an 0 DET F
effective 0 ADJ F
antihypertensive 0 ADJ F
agent 0 NOUN F
, 0 PUNCT F
comparable 0 ADJ F
to 0 ADP F
HCTZ 0 PUNCT T
. 0 PUNCT F

Furthermore 0 ADV T
, 0 PUNCT F
the 0 DET F
combination 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
was 0 VERB F
shown 0 VERB F
to 0 PART F
enhance 0 NOUN F
the 0 DET F
antihypertensive B-PHYSICAL ADJ F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
two 0 NUM F
compounds 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Direct 0 ADJ T
trocar 0 ADJ F
insertion 0 NOUN F
vs. 0 CCONJ F
Verres 0 ADJ T
needle 0 NOUN F
use 0 NOUN F
for 0 ADP F
laparoscopic 0 ADJ F
sterilization 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
prospective 0 ADJ F
trial 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
compare 0 NOUN F
direct 0 ADJ F
trocar 0 ADJ F
insertion 0 NOUN F
with 0 ADP F
prior 0 CCONJ F
peritoneal 0 ADJ F
insufflation 0 NOUN F
with 0 ADP F
a 0 DET F
Verres 0 ADJ T
needle 0 NOUN F
for 0 ADP F
laparoscopic 0 ADJ F
tubal 0 ADJ F
sterilization 0 NOUN F
. 0 PUNCT F

Direct 0 ADJ T
trocar 0 ADJ F
insertion 0 NOUN F
resulted 0 VERB F
in 0 ADP F
fewer 0 PUNCT F
instrument B-OTHER ADP F
insertions I-OTHER NOUN F
( 0 PUNCT F
21.8 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
7.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
use 0 NOUN F
of 0 ADP F
smaller 0 PUNCT F
volumes 0 NOUN F
of 0 ADP F
CO2 B-OTHER NOUN T
( 0 PUNCT F
2.67 0 NUM F
vs. 0 CCONJ F
2.32 0 NUM F
L 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Direct 0 ADJ T
trocar 0 ADJ F
use 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
operating B-OTHER DET F
time I-OTHER NOUN F
from 0 ADP F
9 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
40 0 NUM F
seconds 0 NOUN F
in 0 ADP F
the 0 DET F
needle 0 NOUN F
group 0 NOUN F
to 0 ADP F
7 0 NUM F
minutes 0 NOUN F
, 0 PUNCT F
30 0 NUM F
seconds 0 NOUN F
in 0 ADP F
the 0 DET F
trocar 0 ADJ F
group 0 NOUN F
. 0 PUNCT F

Minor B-ADVERSE-EFFECTS ADJ T
omental I-ADVERSE-EFFECTS ADJ F
injuries I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
in 0 ADP F
a 0 DET F
small 0 ADJ F
percentage 0 NOUN F
of 0 ADP F
each 0 DET F
group 0 NOUN F
, 0 PUNCT F
while 0 ADP F
serious 0 ADJ F
complications 0 NOUN F
occurred 0 VERB F
once 0 PUNCT F
in 0 ADP F
each 0 DET F
group 0 NOUN F
. 0 PUNCT F

How 0 ADP T
does 0 PUNCT F
Cash 0 NOUN T
and 0 CCONJ F
Counseling 0 PROPN T
affect 0 PUNCT F
costs 0 NOUN F
? 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
test 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
consumer-directed 0 VERB F
model 0 NOUN F
( 0 PUNCT F
Cash 0 NOUN T
and 0 CCONJ F
Counseling 0 NOUN T
) 0 PUNCT F
of 0 ADP F
Medicaid 0 NOUN T
personal 0 ADJ F
care 0 NOUN F
services 0 NOUN F
( 0 PUNCT F
PCS 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
home- 0 NOUN F
and 0 CCONJ F
community-based 0 PUNCT F
waiver 0 PUNCT F
services 0 NOUN F
( 0 PUNCT F
HCBS 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
cost 0 NOUN F
of 0 ADP F
Medicaid 0 NOUN T
services 0 NOUN F
. 0 PUNCT F

DATA 0 NOUN T
SOURCES/STUDY 0 CCONJ T
SETTING 0 NUM T
Medicaid 0 NOUN T
claims 0 NOUN F
data 0 NOUN F
were 0 VERB F
collected 0 VERB F
for 0 ADP F
all 0 DET F
enrollees 0 NOUN F
in 0 ADP F
the 0 DET F
Cash 0 NOUN T
and 0 CCONJ F
Counseling 0 PUNCT T
demonstration 0 NOUN F
. 0 PUNCT F

Demonstration 0 NOUN T
enrollees 0 NOUN F
included 0 PUNCT F
those 0 ADP F
eligible 0 ADJ F
for 0 ADP F
PCS 0 NOUN T
( 0 PUNCT F
in 0 ADP F
Arkansas 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
those 0 PUNCT F
assessed 0 VERB F
to 0 PART F
receive 0 NOUN F
such 0 DET F
services 0 NOUN F
( 0 PUNCT F
in 0 ADP F
New 0 ADJ T
Jersey 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
recipients 0 NOUN F
of 0 ADP F
Medicaid 0 NOUN T
HCBS 0 NOUN T
( 0 PUNCT F
in 0 ADP F
Florida 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Enrollment 0 NOUN T
occurred 0 VERB F
from 0 ADP F
December 0 NOUN T
1998 0 NUM F
through 0 ADP F
April 0 NOUN T
2001 0 NUM F
. 0 PUNCT F

The 0 DET T
follow-up 0 NOUN F
period 0 NOUN F
covered 0 VERB F
up 0 PUNCT F
to 0 ADP F
24 0 NUM F
months 0 NOUN F
after 0 ADP F
enrollment 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Demonstration 0 NOUN T
volunteers 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 PUNCT F
have 0 PUNCT F
the 0 DET F
option 0 NOUN F
to 0 PART F
participate 0 NOUN F
in 0 ADP F
Cash 0 NOUN T
and 0 CCONJ F
Counseling 0 PUNCT T
( 0 PUNCT F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
to 0 PART F
receive 0 NOUN F
Medicaid 0 NOUN T
services 0 NOUN F
as 0 VERB F
usual 0 ADJ F
from 0 ADP F
an 0 DET F
agency 0 NOUN F
( 0 PUNCT F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Ordinary 0 PUNCT T
least 0 ADJ F
squares 0 NOUN F
regressions 0 NOUN F
were 0 VERB F
used 0 VERB F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
program 0 NOUN F
on 0 ADP F
costs 0 NOUN F
for 0 ADP F
Medicaid B-OTHER NOUN T
PCS/waiver I-OTHER NOUN T
services I-OTHER NOUN F
and 0 CCONJ F
other 0 ADJ F
Medicaid B-OTHER NOUN T
services I-OTHER NOUN F
, 0 PUNCT F
while 0 ADP F
controlling 0 ADJ F
for 0 ADP F
consumers 0 NOUN F
' 0 PUNCT F
preenrollment 0 ADJ F
characteristics 0 NOUN F
and 0 CCONJ F
preenrollment 0 ADJ F
Medicaid 0 NOUN T
spending 0 PROPN F
. 0 PUNCT F

Models 0 NOUN T
were 0 VERB F
estimated 0 VERB F
separately 0 ADV F
for 0 ADP F
nonelderly 0 PUNCT F
and 0 CCONJ F
elderly 0 ADJ F
adults 0 NOUN F
in 0 ADP F
each 0 DET F
state 0 NOUN F
and 0 CCONJ F
for 0 ADP F
children 0 NOUN F
in 0 ADP F
Florida 0 NOUN T
. 0 PUNCT F

DATA 0 NOUN T
EXTRACTION 0 NOUN T
METHODS 0 NOUN T
Each 0 PUNCT T
state 0 NOUN F
supplied 0 PUNCT F
claims 0 NOUN F
data 0 NOUN F
for 0 ADP F
demonstration 0 NOUN F
enrollees 0 NOUN F
. 0 PUNCT F

PRINCIPAL 0 NOUN T
FINDINGS 0 NOUN T
Largely 0 PROPN T
because 0 PUNCT F
the 0 DET F
program 0 NOUN F
increased 0 ADJ F
consumers 0 NOUN F
' 0 PUNCT F
ability 0 NOUN F
to 0 DET F
get 0 CCONJ F
the 0 DET F
authorized 0 DET F
amount 0 NOUN F
of 0 ADP F
paid 0 NOUN F
care 0 NOUN F
, 0 PUNCT F
expenditures 0 PUNCT F
for 0 ADP F
personal B-OTHER ADJ F
care/waiver I-OTHER NOUN F
services I-OTHER NOUN F
were 0 VERB F
higher 0 PUNCT F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
in 0 ADP F
each 0 DET F
state 0 NOUN F
and 0 CCONJ F
age 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
except 0 PUNCT F
among 0 ADP F
the 0 DET F
elderly 0 ADJ F
in 0 ADP F
Florida 0 NOUN T
. 0 PUNCT F

Higher 0 PUNCT T
costs 0 NOUN F
for 0 ADP F
personal B-OTHER ADJ F
care/waiver I-OTHER NOUN F
services I-OTHER NOUN F
were 0 VERB F
partially 0 ADV F
offset 0 CCONJ F
by 0 ADP F
savings 0 NOUN F
in 0 ADP F
other 0 ADJ F
Medicaid 0 NOUN T
services 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
those 0 ADJ F
related 0 VERB F
to 0 ADP F
long-term 0 NOUN F
care 0 NOUN F
. 0 PUNCT F

During 0 ADP T
year 0 NOUN F
1 0 NUM F
, 0 PUNCT F
total 0 ADJ F
Medicaid B-OTHER NOUN T
costs I-OTHER NOUN F
were 0 VERB F
generally 0 ADV F
higher 0 PUNCT F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
for 0 ADP F
the 0 DET F
control 0 ADV F
group 0 NOUN F
, 0 PUNCT F
with 0 ADP F
treatment-control 0 NOUN F
cost 0 NOUN F
differences 0 NOUN F
ranging 0 VERB F
from 0 ADP F
1 0 NUM F
percent 0 NOUN F
( 0 PUNCT F
and 0 CCONJ F
statistically 0 ADV F
insignificant 0 ADJ F
) 0 PUNCT F
for 0 ADP F
the 0 DET F
elderly 0 ADJ F
in 0 ADP F
Florida 0 NOUN T
to 0 ADP F
17 0 NUM F
percent 0 NOUN F
for 0 ADP F
the 0 DET F
elderly 0 ADJ F
in 0 ADP F
Arkansas 0 NOUN T
. 0 PUNCT F

In 0 ADP T
year 0 NOUN F
2 0 NUM F
, 0 PUNCT F
these 0 DET F
cost B-OTHER NOUN F
differences I-OTHER NOUN F
were 0 VERB F
generally 0 ADV F
greater 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
year 0 NOUN F
1 0 NUM F
. 0 PUNCT F

Only 0 ADV T
in 0 ADP F
Arkansas 0 NOUN T
did 0 PUNCT F
the 0 DET F
treatment-control 0 NOUN F
difference 0 NOUN F
in 0 ADP F
total 0 ADJ F
cost B-OTHER NOUN F
shrink I-OTHER NOUN F
over I-OTHER ADP F
time-to I-OTHER ADJ F
less 0 ADP F
than 0 CCONJ F
5 0 NUM F
percent 0 NOUN F
( 0 PUNCT F
and 0 CCONJ F
statistically 0 ADV F
insignificant 0 ADJ F
) 0 PUNCT F
in 0 ADP F
year 0 NOUN F
2 0 NUM F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Medicaid B-OTHER NOUN T
costs I-OTHER NOUN F
were 0 VERB F
generally 0 ADV F
higher 0 PUNCT F
under 0 ADP F
Cash 0 NOUN T
and 0 CCONJ F
Counseling 0 PROPN T
because 0 PUNCT F
those 0 PUNCT F
in 0 ADP F
the 0 DET F
traditional 0 ADJ F
system 0 NOUN F
did 0 VERB F
not 0 ADV F
get 0 PUNCT F
the 0 ADP F
services 0 NOUN F
they 0 ADJ F
were 0 VERB F
entitled 0 VERB F
to 0 DET F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
the 0 DET F
treatment 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
control 0 NOUN F
group 0 NOUN F
members 0 NOUN F
were 0 VERB F
less 0 ADV F
likely 0 ADJ F
to 0 PART F
receive B-OTHER NOUN F
any I-OTHER DET F
services I-OTHER NOUN F
at 0 ADP F
all 0 PUNCT F
( 0 PUNCT F
despite 0 ADP F
being 0 VERB F
authorized 0 ADJ F
for 0 ADP F
them 0 PRON F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
service 0 NOUN F
recipients 0 NOUN F
received 0 VERB F
a 0 DET F
lower 0 PUNCT F
proportion 0 NOUN F
of B-OTHER ADP F
the I-OTHER DET F
amount I-OTHER NOUN F
of I-OTHER PUNCT F

Effects 0 NOUN T
of 0 ADP F
interaction 0 NOUN F
of 0 ADP F
RRR-alpha-tocopheryl 0 NOUN T
acetate 0 NOUN F
and 0 CCONJ F
fish 0 NOUN F
oil 0 NOUN F
on 0 ADP F
low-density-lipoprotein 0 NOUN F
oxidation 0 NOUN F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
hormone-replacement 0 ADJ F
therapy 0 NOUN F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
RRR-alpha-tocpheryl 0 NOUN T
acetate 0 NOUN F
( 0 PUNCT F
alpha-tocopheryl 0 NOUN F
acetate 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
hormone-replacement 0 ADJ F
therapy 0 NOUN F
( 0 PUNCT F
HRT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
oxidative 0 ADJ F
susceptibility 0 NOUN F
of 0 ADP F
low-density 0 NOUN F
lipoprotein 0 NOUN F
( 0 PUNCT F
LDL 0 NOUN T
) 0 PUNCT F
in 0 ADP F
postmenopausal 0 ADJ F
women 0 NOUN F
consuming 0 PUNCT F
a 0 DET F
fish 0 NOUN F
oil 0 NOUN F
supplement 0 NOUN F
. 0 PUNCT F

The 0 DET T
independent 0 ADJ F
effect 0 NOUN F
of 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
was 0 VERB F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

Forty-eight 0 ADJ T
women 0 NOUN F
, 0 PUNCT F
equally 0 ADV F
divided 0 VERB F
between 0 ADP F
women 0 NOUN F
using 0 VERB F
and 0 CCONJ F
not 0 ADV F
using 0 PUNCT F
HRT 0 NOUN T
, 0 PUNCT F
participated 0 DET F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
crossover 0 ADP F
trial 0 NOUN F
. 0 PUNCT F

Each 0 PUNCT T
of 0 ADP F
the 0 DET F
four 0 PUNCT F
periods 0 NOUN F
lasted 0 ADP F
5 0 NUM F
wk 0 NOUN F
and 0 CCONJ F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
a 0 DET F
4-wk 0 PUNCT F
washout 0 PUNCT F
interval 0 NOUN F
. 0 PUNCT F

During 0 ADP T
each 0 DET F
period 0 NOUN F
all 0 DET F
subjects 0 NOUN F
were 0 VERB F
given 0 VERB F
a 0 DET F
15-g 0 NOUN F
supplement 0 NOUN F
of 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
and 0 CCONJ F
either 0 CCONJ F
0 0 NUM F
( 0 PUNCT F
placebo 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
100 0 NUM F
, 0 PUNCT F
200 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
alpha-tocopheryl 0 NOUN F
acetate 0 NOUN F
daily 0 ADJ F
. 0 PUNCT F

LDL B-PHYSICAL NOUN T
resistance I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
oxidative I-PHYSICAL ADJ F
modification I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
calculating B-PHYSICAL ADP F
lag 0 NOUN F
time B-PHYSICAL NOUN F
, 0 PUNCT F
propagation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
maximum B-PHYSICAL NOUN F
production B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
conjugated I-PHYSICAL VERB F
dienes B-PHYSICAL NOUN F
. 0 PUNCT F

Supplementation 0 NOUN T
with 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
shortened 0 VERB F
lag 0 NOUN F
time 0 NOUN F
and 0 CCONJ F
slowed B-PHYSICAL PUNCT F
propagation I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
in 0 ADP F
women 0 NOUN F
both 0 CCONJ F
using 0 VERB F
and 0 CCONJ F
not 0 ADV F
using 0 PUNCT F
HRT 0 NOUN T
. 0 PUNCT F

After 0 ADP T
subjects 0 NOUN F
consumed 0 PUNCT F
fish 0 NOUN F
oil 0 NOUN F
, 0 PUNCT F
supplementation 0 NOUN F
with 0 ADP F
alpha-tocopheryl 0 NOUN F
acetate 0 NOUN F
increased 0 ADV F
plasma B-PHYSICAL NOUN F
and 0 CCONJ F
LDL B-PHYSICAL NOUN T
alpha-tocopherol I-PHYSICAL ADJ F
contents B-PHYSICAL ADJ F
significantly 0 ADV F
and 0 CCONJ F
lengthened B-PHYSICAL ADJ F
lag 0 NOUN F
time B-PHYSICAL NOUN F
( 0 PUNCT F
at 0 ADP F
even 0 ADV F
the 0 DET F
lowest 0 PUNCT F
concentration 0 NOUN F
) 0 PUNCT F
but 0 CCONJ F
had 0 VERB F
no 0 DET F
significant 0 ADJ F
effect 0 NOUN F
on 0 ADP F
propagation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
or 0 CCONJ F
maximum B-PHYSICAL NOUN F
production I-PHYSICAL NOUN F
compared 0 VERB F
with 0 ADP F
values 0 NOUN F
measured 0 VERB F
after 0 ADP F
consumption 0 NOUN F
of 0 ADP F
fish 0 NOUN F
oil 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

Women 0 NOUN T
not 0 ADV F
using 0 PUNCT F
HRT 0 NOUN T
had 0 PUNCT F
faster 0 PUNCT F

Perioperative B-PHYSICAL PUNCT T
fever 0 NOUN F
and 0 CCONJ F
outcome 0 NOUN F
in 0 ADP F
surgical 0 ADJ F
patients 0 NOUN F
with 0 ADP F
aneurysmal 0 ADJ F
subarachnoid 0 NOUN F
hemorrhage 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
We 0 PRON T
examined 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
perioperative 0 ADJ F
fever 0 NOUN F
and 0 CCONJ F
its 0 PUNCT F
relationship 0 NOUN F
to 0 ADP F
outcome 0 NOUN F
among 0 ADP F
patients 0 NOUN F
enrolled 0 VERB F
in 0 ADP F
the 0 DET F
Intraoperative 0 ADJ T
Hypothermia 0 NOUN T
for 0 ADP F
Aneurysm 0 NOUN T
Surgery 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

METHODS 0 NOUN T
One 0 NUM T
thousand 0 CCONJ F
patients 0 NOUN F
with 0 ADP F
initial 0 ADJ F
World 0 NOUN T
Federation 0 NOUN T
of 0 ADP F
Neurological 0 ADJ T
Surgeons 0 NOUN T
grades 0 PUNCT F
of 0 ADP F
I 0 NUM T
to 0 ADP F
III 0 PUNCT T
undergoing 0 ADP F
clipping 0 VERB F
of 0 ADP F
intracranial 0 ADJ F
aneurysms 0 NOUN F
after 0 ADP F
subarachnoid 0 NOUN F
hemorrhage 0 NOUN F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
intraoperative 0 ADJ F
normothermia 0 NOUN F
( 0 PUNCT F
36 0 NUM F
degrees 0 ADJ F
C-37 0 NOUN T
degrees 0 PUNCT F
C 0 NUM T
) 0 PUNCT F
or 0 CCONJ F
hypothermia 0 NOUN F
( 0 PUNCT F
32.5 0 NUM F
degrees 0 NOUN F
C-33.5 0 PUNCT T
degrees 0 NOUN F
C 0 NUM T
) 0 PUNCT F
. 0 PUNCT F

Fever B-PHYSICAL NOUN T
( 0 PUNCT F
> 0 ADJ F
or 0 CCONJ F
=38.5 0 PUNCT F
degrees 0 NOUN F
C 0 NUM T
) 0 PUNCT F
and 0 CCONJ F
other 0 ADJ F
complications B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
including B-ADVERSE-EFFECTS PUNCT F
infections I-ADVERSE-EFFECTS NOUN F
) 0 PUNCT F
occurring B-PHYSICAL CCONJ F
between I-PHYSICAL ADP F
admission I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
discharge I-PHYSICAL NOUN F
( 0 PUNCT F
or 0 CCONJ F
death B-ADVERSE-EFFECTS NOUN F
) 0 PUNCT F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

Functional B-PHYSICAL ADJ T
and 0 CCONJ F
neuropsychologic B-MENTAL ADJ F
outcomes I-MENTAL NOUN F
were 0 VERB F
assessed 0 VERB F
3 0 NUM F
months 0 NOUN F
postoperatively 0 ADV F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
outcome 0 NOUN F
variable 0 ADJ F
for 0 ADP F
the 0 DET F
trial 0 NOUN F
was 0 VERB F
dichotomized 0 NUM F
Glasgow 0 PUNCT T
Outcome 0 NOUN T
Scale 0 NOUN T
( 0 PUNCT F
good 0 ADJ F
outcome 0 NOUN F
versus 0 CCONJ F
all 0 DET F
others 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 DET T
Fever B-PHYSICAL NOUN T
was 0 VERB F
reported 0 VERB F
in 0 ADP F
41 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

In 0 ADP T
97 0 NUM F
% 0 SYM F
of 0 ADP F
these 0 PUNCT F
, 0 PUNCT F
fever B-PHYSICAL NOUN F
occurred 0 VERB F
in 0 ADP F
the 0 DET F
postoperative 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
time B-PHYSICAL NOUN F
from I-PHYSICAL ADP F
surgery I-PHYSICAL NOUN F
to I-PHYSICAL ADP F
first I-PHYSICAL ADJ F
fever I-PHYSICAL NOUN F
was 0 VERB F
3 0 NUM F
days 0 NOUN F
. 0 PUNCT F

All 0 DET T
measures 0 NOUN F
of 0 ADP F
outcome 0 NOUN F
were 0 VERB F
worse 0 ADJ F
in 0 ADP F
patients 0 NOUN F
who 0 PROPN F
developed 0 VERB F
fever 0 NOUN F
, 0 PUNCT F
even 0 ADV F
in 0 ADP F
those 0 PUNCT F
without 0 ADP F
infections B-ADVERSE-EFFECTS NOUN F
or 0 CCONJ F
who 0 ADP F
were 0 VERB F
World 0 NOUN T
Federation 0 NOUN T
of 0 ADP F
Neurological 0 ADJ T
Surgeons 0 NOUN T
grade 0 NOUN F
I. 0 ADV T
Logistic 0 ADJ T
regression 0 NOUN F
analyses 0 NOUN F
were 0 VERB F
performed 0 VERB F
to 0 ADP F
adjust 0 PUNCT F
for 0 ADP F
differences 0 NOUN F
in 0 ADP F
preoperative 0 ADJ F
factors 0 NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
age 0 NOUN F
, 0 PUNCT F
Fisher 0 NOUN T
grade 0 NOUN F
, 0 PUNCT F
initial 0 ADJ F
neurological 0 ADJ F
status 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

This 0 DET T
demonstrated 0 VERB F
that 0 ADP F
fever B-PHYSICAL ADP F
continued 0 VERB F
to 0 PART F
be 0 PUNCT F
significantly 0 ADV F
associated 0 VERB F
with 0 ADP F
most 0 DET F
outcome 0 NOUN F
measures 0 NOUN F
, 0 PUNCT F
even 0 ADV F
when 0 ADP F
infection B-ADVERSE-EFFECTS NOUN F
was 0 VERB F
added 0 VERB F
to 0 ADP F
the 0 DET F
model 0 NOUN F
. 0 PUNCT F

An 0 DET T
alternative 0 ADJ F
stepwise 0 ADJ F
model 0 NOUN F
selection 0 NOUN F
process 0 NOUN F
including 0 DET F
all 0 DET F
fever-related B-PHYSICAL VERB F
measures 0 NOUN F
from 0 ADP F
the 0 DET F
preoperative 0 ADJ F
and 0 CCONJ F
intraoperative 0 ADJ F
period 0 NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
hydrocephalus 0 NOUN F
, 0 PUNCT F
duration 0 NOUN F
of 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
intraoperative 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
) 0 PUNCT F
resulted 0 VERB F
in 0 ADP F
the 0 DET F
loss 0 NOUN F
of 0 ADP F
significance 0 NOUN F
for 0 ADP F
dichotomized 0 PUNCT F
Glasgow 0 PUNCT T
Outcome 0 NOUN T
Scale 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
significant 0 ADJ F
associations 0 NOUN F
between 0 ADP F
fever B-PHYSICAL NOUN F
and 0 CCONJ F
several 0 ADJ F
other 0 ADJ F
outcome 0 NOUN F
measures 0 NOUN F
remained 0 VERB F
. 0 PUNCT F

After 0 ADP T
adding 0 VERB F
postoperative 0 ADJ F
delayed 0 VERB F
ischemic B-PHYSICAL ADJ F
neurological I-PHYSICAL ADJ F
deficits I-PHYSICAL CCONJ F
to 0 ADP F
the 0 DET F
model 0 NOUN F
, 0 PUNCT F
only 0 ADV F
worsened 0 VERB F
National B-PHYSICAL ADJ T
Institutes I-PHYSICAL NOUN T
of I-PHYSICAL ADP F
Health I-PHYSICAL NOUN T
Stroke I-PHYSICAL NOUN T
Scale I-PHYSICAL NOUN T
score 0 NOUN F
, 0 PUNCT F
Barthel B-PHYSICAL PUNCT T
Activities I-PHYSICAL PROPN T
of I-PHYSICAL ADP F
Daily I-PHYSICAL PUNCT T
Living I-PHYSICAL PROPN T
index I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
discharge B-OTHER NOUN F
destination I-OTHER NOUN F
( 0 PUNCT F
home 0 NOUN F
versus 0 CCONJ F
other 0 PUNCT F
) 0 PUNCT F
remained 0 VERB F
independently 0 ADV F
associated 0 VERB F
with 0 ADP F
fever 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
fever B-PHYSICAL NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
worsened 0 VERB F
outcome 0 NOUN F
in 0 ADP F
surgical 0 ADJ F
subarachnoid 0 NOUN F
hemorrhage 0 NOUN F
patients 0 NOUN F
, 0 PUNCT F
although 0 ADP F
, 0 PUNCT F
because 0 PUNCT F
the 0 DET F
association 0 NOUN F
between 0 ADP F
fever B-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
primary 0 ADJ F
outcome 0 NOUN F
measure 0 NOUN F
for 0 ADP F
the 0 DET F
trial 0 NOUN F
is 0 VERB F
dependent 0 ADJ F
on 0 ADP F
the 0 DET F
covariates 0 ADJ F
used 0 VERB F
in 0 ADP F
the 0 DET F
analysis 0 NOUN F
( 0 PUNCT F
particularly 0 ADV F
operative 0 ADJ F
events 0 NOUN F
and 0 CCONJ F
delayed B-PHYSICAL ADV F
ischemic I-PHYSICAL ADJ F
neurological I-PHYSICAL ADJ F
deficits I-PHYSICAL NOUN F
) 0 PUNCT F
, 0 PUNCT F
we 0 PRON F
can 0 ADP F
not 0 NOUN F
rule 0 NOUN F
out 0 PUNCT F
the 0 DET F
possibility 0 NOUN F
that 0 ADP F
fever B-PHYSICAL NOUN F
is 0 VERB F
a 0 DET F
marker 0 NOUN F
for 0 ADP F
other 0 ADJ F
events 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
a 0 DET F
formal 0 ADJ F
trial 0 NOUN F
of 0 ADP F
fever B-PHYSICAL NOUN F
treatment 0 NOUN F
or 0 CCONJ F
prevention 0 NOUN F
can 0 VERB F
address 0 VERB F
this 0 DET F
issue 0 NOUN F
. 0 PUNCT F

Cytokine B-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
and 0 CCONJ F
systemic B-ADVERSE-EFFECTS ADJ F
toxicity I-ADVERSE-EFFECTS NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
isolated 0 VERB F
limb 0 NOUN F
perfusion 0 NOUN F
with 0 ADP F
high-dose 0 NOUN F
tumor 0 NOUN F
necrosis 0 NOUN F
factor 0 NOUN F
, 0 PUNCT F
interferon 0 NOUN F
gamma 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
melphalan 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Isolated 0 VERB T
limb 0 NOUN F
perfusion 0 NOUN F
( 0 PUNCT F
ILP 0 NOUN T
) 0 PUNCT F
with 0 ADP F
tumor 0 NOUN F
necrosis 0 NOUN F
factor 0 NOUN F
( 0 PUNCT F
TNF 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
interferon 0 NOUN F
gamma 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
melphalan 0 NOUN F
( 0 PUNCT F
M 0 NOUN T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
reported 0 VERB F
to 0 PART F
result 0 NOUN F
in 0 ADP F
high 0 ADJ F
response 0 NOUN F
rates B-PHYSICAL NOUN F
for 0 ADP F
extremity 0 NOUN F
melanoma 0 NOUN F
and 0 CCONJ F
sarcoma 0 NOUN F
. 0 PUNCT F

We 0 PRON T
have 0 VERB F
evaluated 0 VERB F
the 0 DET F
relationship 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
TNF 0 NOUN T
exposure 0 NOUN F
to 0 ADP F
induction 0 NOUN F
of 0 ADP F
several 0 ADJ F
secondary B-PHYSICAL ADJ F
mediators I-PHYSICAL NOUN F
and 0 CCONJ F
incidence 0 NOUN F
of 0 ADP F
systemic B-ADVERSE-EFFECTS ADJ F
toxicity I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Nineteen 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
extremity 0 NOUN F
melanoma 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
16 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
sarcoma 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
underwent 0 VERB F
90-minute 0 ADJ F
ILP 0 NOUN T
with 0 ADP F
TNF-alpha 0 NOUN T
, 0 PUNCT F
interferon 0 NOUN F
gamma 0 NOUN F
( 0 PUNCT F
0.2 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
M 0 NOUN T
( 0 PUNCT F
10 0 NUM F
to 0 ADP F
13 0 NUM F
mg/L 0 NOUN F
of 0 ADP F
limb 0 NOUN F
volume 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
TNF/IFN/M 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
12 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
M 0 NOUN T
alone 0 ADJ F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
7 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Continuous 0 ADJ T
intraoperative 0 ADJ F
monitoring 0 VERB F
( 0 PUNCT F
CIM 0 NOUN T
) 0 PUNCT F
for 0 ADP F
systemic 0 ADJ F
leak 0 ADJ F
from 0 ADP F
the 0 DET F
perfusion 0 NOUN F
circuit 0 NOUN F
was 0 VERB F
performed 0 VERB F
using 0 VERB F
radioactive 0 ADJ F
iodine-131 0 NOUN F
albumin 0 NOUN F
. 0 PUNCT F

Cytokine 0 NOUN T
levels 0 NOUN F
in 0 ADP F
the 0 DET F
perfusate 0 NOUN F
and 0 CCONJ F
systemic 0 ADJ F
circulation 0 NOUN F
during 0 ADP F
and 0 CCONJ F
after 0 ADP F
ILP 0 NOUN T
were 0 VERB F
measured 0 VERB F
by 0 ADP F
enzyme-linked 0 VERB F
immunosorbent 0 ADJ F
assay 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Systemic 0 ADJ T
leaks 0 PUNCT F
> 0 SYM F
or 0 CCONJ F
= 0 SYM F
1 0 NUM F
% 0 SYM F
from 0 ADP F
the 0 DET F
perfusion 0 NOUN F
circuit 0 NOUN F
occurred 0 VERB F
in 0 ADP F
six 0 NUM F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
TNF/IFN/M 0 NOUN T
and 0 CCONJ F
in 0 ADP F
four 0 NUM F
who 0 ADP F
received 0 VERB F
M 0 NOUN T
alone 0 ADJ F
. 0 PUNCT F

Hypotension 0 NOUN T
that 0 ADP F
required B-ADVERSE-EFFECTS DET F
vasopressor I-ADVERSE-EFFECTS NOUN F
support I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
in 0 ADP F
six 0 NUM F
of 0 ADP F
six 0 NUM F
patients 0 NOUN F
with 0 ADP F
evidence 0 NOUN F
of 0 ADP F
a 0 DET F
leak 0 ADP F
( 0 PUNCT F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
1 0 NUM F
% 0 SYM F
) 0 PUNCT F
and 0 CCONJ F
zero 0 NUM F
of 0 ADP F
six 0 NUM F
patients 0 NOUN F
without 0 ADP F
a 0 DET F
leak 0 ADP F
( 0 PUNCT F
< 0 PROPN F
1 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

These 0 DET T
six 0 NUM F
patients 0 NOUN F
had 0 PUNCT F
significantly 0 ADV F
higher 0 PUNCT F
peak 0 ADJ F
systemic B-PHYSICAL ADJ F
TNF I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
during 0 ADP F
and 0 CCONJ F
after 0 ADP F
perfusion 0 NOUN F
than 0 ADP F
patients 0 NOUN F
without 0 ADP F
a 0 DET F
leak 0 ADP F
( 0 PUNCT F
2.8 0 NUM F
and 0 CCONJ F
8.2 0 NUM F
ng/mL 0 NOUN F
v 0 CCONJ F
0.7 0 NUM F
and 0 CCONJ F
2.0 0 NUM F
ng/mL 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

All 0 DET T
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
TNF/IFN/M 0 NOUN T
had 0 PUNCT F
significantly 0 ADV F
greater 0 PUNCT F
increases 0 CCONJ F
in 0 ADP F
systemic B-PHYSICAL ADJ F
interleukin-6 I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
IL-6 I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
levels I-PHYSICAL NOUN F
than 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
M 0 NOUN T
alone 0 ADJ F
( 0 PUNCT F
12,395 0 NUM F
+/- 0 SYM F
10,374 0 ADJ F
pg/mL 0 ADJ F
v 0 NUM F
79.4 0 NUM F
+/- 0 SYM F
7.2 0 NUM F
pg/mL 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
; 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Intracellular B-PHYSICAL ADJ T
adhesion I-PHYSICAL NOUN F
molecule I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ICAM I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, I-PHYSICAL PUNCT F
IL-8 I-PHYSICAL NOUN T
, I-PHYSICAL PUNCT F
and I-PHYSICAL CCONJ F
TNF-R I-PHYSICAL NOUN T
levels I-PHYSICAL NOUN F
were 0 VERB F
also 0 ADV F
increased 0 VERB F
after 0 ADP F
ILP 0 NOUN T
with 0 ADP F
TNF/IFN/M 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
ILP 0 NOUN T
with 0 ADP F
TNF/IFN/M 0 NOUN T
can 0 VERB F
be 0 VERB F
safely 0 ADV F
performed 0 VERB F
, 0 PUNCT F
as 0 PUNCT F
I131 0 NOUN T
albumin 0 NOUN F
provides 0 NOUN F
a 0 DET F
sensitive 0 ADJ F
measure 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
leakage 0 NOUN F
from 0 ADP F
the 0 DET F
perfusion 0 NOUN F
circuit 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
a 0 DET F
measured 0 PUNCT F
leak 0 ADJ F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
1 0 NUM F
% 0 ADJ F
develop 0 VERB F
mild 0 ADJ F
and 0 CCONJ F
transient 0 ADJ F
postoperative 0 ADJ F
hypotension 0 NOUN F
with 0 ADP F
significantly 0 ADV F
higher 0 PUNCT F
systemic 0 ADJ F
TNF 0 NOUN T
levels 0 NOUN F
and 0 CCONJ F
lower 0 PUNCT F
perfusate 0 NOUN F
TNF 0 NOUN T
levels 0 NOUN F
than 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
without 0 PUNCT F
leaks 0 PUNCT F
. 0 PUNCT F

Epirubicin 0 NOUN T
and 0 CCONJ F
cyclophosphamide 0 NOUN F
versus 0 CCONJ F
epirubicin 0 NOUN F
and 0 CCONJ F
docetaxel 0 PUNCT F
as 0 ADP F
first-line 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
women 0 NOUN F
with 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
: 0 PUNCT F
final 0 ADJ F
results 0 NOUN F
of 0 ADP F
a 0 DET F
randomised 0 VERB F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
This 0 PUNCT T
randomised 0 VERB F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
to 0 ADP F
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
epirubicin 0 NOUN F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
EC 0 NOUN T
) 0 PUNCT F
with 0 ADP F
epirubicin 0 NOUN F
and 0 CCONJ F
docetaxel 0 VERB F
( 0 PUNCT F
Taxotere 0 ADV T
) 0 PUNCT F
( 0 PUNCT F
ED 0 NOUN T
) 0 PUNCT F
as 0 ADP F
first-line 0 NOUN F
chemotherapy 0 NOUN F
for 0 ADP F
metastatic 0 ADJ F
breast 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
Patients 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
240 0 NUM F
) 0 PUNCT F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
ED 0 NOUN T
( 0 PUNCT F
epirubicin 0 NOUN F
75 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
docetaxel 0 PUNCT F
75 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
EC 0 NOUN T
( 0 PUNCT F
epirubicin 0 NOUN F
90 0 PUNCT F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
cyclophosphamide 0 NOUN F
600 0 NUM F
mg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 VERB F
objective B-PHYSICAL ADJ F
response 0 NOUN F
rate B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
ORR I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
. 0 PUNCT F

Secondary 0 ADJ T
end 0 NOUN F
points 0 NOUN F
were 0 VERB F
progression-free B-MORTALITY ADJ F
survival I-MORTALITY NOUN F
( I-MORTALITY PUNCT F
PFS I-MORTALITY NOUN T
) I-MORTALITY PUNCT F
, 0 PUNCT F
overall B-MORTALITY ADJ F
survival B-MORTALITY NOUN F
( B-MORTALITY PUNCT F
OS B-MORTALITY NOUN T
) B-MORTALITY PUNCT F
, 0 PUNCT F
and 0 CCONJ F
safety B-MORTALITY NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
ORR B-PHYSICAL NOUN T
for 0 ADP F
patients 0 NOUN F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
EC 0 NOUN T
and 0 CCONJ F
ED 0 NOUN T
were 0 VERB F
42 0 NUM F
% 0 SYM F
and 0 CCONJ F
47 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.63 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Median 0 ADJ T
PFS B-MORTALITY NOUN T
[ 0 PUNCT F
10.1 0 ADP F
versus 0 CCONJ F
10.3 0 NUM F
months 0 NOUN F
; 0 PUNCT F
hazard 0 NOUN F
ratio 0 NOUN F
( 0 PUNCT F
HR 0 NOUN T
) 0 PUNCT F
0.98 0 NUM F
; 0 PUNCT F
log-rank 0 NOUN F
P 0 NOUN T
= 0 SYM F
0.38 0 NUM F
] 0 PUNCT F
and 0 CCONJ F
OS B-MORTALITY PUNCT T
( 0 PUNCT F
19.9 0 ADJ F
versus 0 CCONJ F
30.0 0 NUM F
months 0 NOUN F
; 0 PUNCT F
HR 0 NOUN T
0.663 0 NUM F
; 0 PUNCT F
log-rank 0 NOUN F
P 0 NOUN T
= 0 SYM F
0.21 0 NUM F
) 0 PUNCT F
were 0 VERB F
comparable 0 ADJ F
in 0 ADP F
both 0 PUNCT F
arms 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
grade 0 NOUN F
3/4 0 PUNCT F

Anxiety 0 NOUN T
sensitivity 0 NOUN F
as 0 ADP F
an 0 DET F
incremental 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
later 0 ADJ F
anxiety 0 NOUN F
symptoms 0 NOUN F
and 0 CCONJ F
syndromes 0 NOUN F
. 0 PUNCT F

Although 0 ADP T
anxiety 0 NOUN F
sensitivity 0 NOUN F
( 0 PUNCT F
AS 0 ADP T
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
predict 0 PUNCT F
anxiety 0 NOUN F
symptoms 0 NOUN F
and 0 CCONJ F
panic 0 ADJ F
, 0 PUNCT F
this 0 DET F
literature 0 NOUN F
is 0 VERB F
limited 0 VERB F
in 0 ADP F
regard 0 NOUN F
to 0 ADP F
evaluating 0 VERB F
AS 0 PUNCT T
as 0 PUNCT F
an 0 DET F
incremental 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
anxiety 0 NOUN F
psychopathology 0 NOUN F
relative 0 ADJ F
to 0 ADP F
other 0 PUNCT F
established 0 PUNCT F
risk 0 NOUN F
factors 0 NOUN F
including 0 VERB F
sex 0 NOUN F
and 0 CCONJ F
negative 0 ADJ F
affect 0 ADP F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
report 0 NOUN F
prospectively 0 ADV F
evaluated 0 ADJ F
whether 0 PUNCT F
AS 0 CCONJ T
was 0 VERB F
predictive 0 ADJ F
of 0 ADP F
later 0 PUNCT F
changes 0 NOUN F
in 0 ADP F
anxiety B-MENTAL NOUN F
symptoms I-MENTAL NOUN F
after 0 PUNCT F
controlling 0 ADJ F
for 0 ADP F
potential 0 ADJ F
confounding 0 VERB F
factors 0 NOUN F
. 0 PUNCT F

Consistent 0 ADJ T
with 0 ADP F
hypothesis 0 NOUN F
, 0 PUNCT F
AS 0 PUNCT T
was 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
a 0 DET F
significant 0 ADJ F
, 0 PUNCT F
incremental 0 ADJ F
predictor 0 NOUN F
of 0 ADP F
anxiety B-MENTAL NOUN F
symptoms I-MENTAL NOUN F
over 0 ADP F
time 0 NOUN F
, 0 PUNCT F
even 0 ADV F
after 0 PUNCT F
controlling 0 ADJ F
for 0 ADP F
sex 0 NOUN F
and 0 CCONJ F
negative 0 ADJ F
affectivity 0 NOUN F
. 0 PUNCT F

These 0 DET T
data 0 NOUN F
provide 0 VERB F
novel 0 ADJ F
evidence 0 NOUN F
for 0 ADP F
the 0 DET F
unique 0 ADJ F
association 0 NOUN F
between 0 ADP F
AS 0 CCONJ T
of 0 ADP F
the 0 DET F
development 0 NOUN F
of 0 ADP F
anxiety 0 NOUN F
symptoms 0 NOUN F
. 0 PUNCT F

A 0 DET T
randomized 0 VERB F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
Endeavor 0 PUNCT T
zotarolimus-eluting 0 ADP F
stent 0 NOUN F
versus 0 CCONJ F
the 0 DET F
TAXUS 0 NOUN T
paclitaxel-eluting 0 VERB F
stent 0 NOUN F
in 0 ADP F
de 0 PUNCT F
novo 0 ADJ F
native 0 ADJ F
coronary 0 ADJ F
lesions 0 NOUN F
12-month 0 NOUN F
outcomes 0 NOUN F
from 0 ADP F
the 0 DET F
ENDEAVOR 0 NOUN T
IV 0 NUM T
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
ENDEAVOR 0 NOUN T
IV 0 NUM T
( 0 PUNCT F
Randomized 0 NOUN T
Comparison 0 NOUN T
of 0 ADP F
Zotarolimus-Eluting 0 PUNCT T
and 0 CCONJ F
Paclitaxel-Eluting 0 PUNCT T
Stents 0 NOUN T
in 0 ADP F
Patients 0 NOUN T
with 0 ADP F
Coronary 0 ADJ T
Artery 0 NOUN T
Disease 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
evaluated 0 VERB F
the 0 DET F
safety B-OTHER NOUN F
and 0 CCONJ F
efficacy 0 NOUN F
of 0 ADP F
the 0 DET F
zotarolimus-eluting 0 ADP F
stent 0 NOUN F
( 0 PUNCT F
ZES 0 NOUN T
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
paclitaxel-eluting 0 VERB F
stent 0 NOUN F
( 0 PUNCT F
PES 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
First-generation 0 NOUN T
drug-eluting 0 ADP F
stents 0 NOUN F
have 0 ADP F
reduced 0 VERB F
angiographic 0 ADJ F
and 0 CCONJ F
clinical 0 ADJ F
restenosis 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
long-term 0 NOUN F
safety 0 NOUN F
remains 0 NOUN F
controversial 0 ADJ F
. 0 PUNCT F

A 0 DET T
second-generation 0 NOUN F
drug-eluting 0 PART F
stent 0 NOUN F
, 0 PUNCT F
which 0 DET F
delivers 0 PUNCT F
zotarolimus 0 NOUN F
, 0 PUNCT F
a 0 DET F
potent 0 ADJ F
antiproliferative 0 ADJ F
agent 0 NOUN F
, 0 PUNCT F
via 0 ADP F
a 0 DET F
biocompatible 0 PUNCT F
phosphorylcholine 0 NOUN F
polymer 0 NOUN F
on 0 ADP F
a 0 DET F
cobalt 0 NOUN F
alloy 0 NOUN F
thin-strut 0 NOUN F
stent 0 NOUN F
has 0 PUNCT F
shown 0 VERB F
promising 0 VERB F
experimental 0 ADJ F
and 0 CCONJ F
early 0 ADJ F
clinical 0 ADJ F
results 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 ADV T
is 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 ADP F
( 0 PUNCT F
1:1 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
single-blind 0 ADP F
, 0 PUNCT F
controlled 0 VERB F
trial 0 NOUN F
comparing 0 VERB F
outcomes 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
single 0 ADJ F
de 0 PUNCT F
novo 0 ADJ F
coronary 0 ADJ F
lesions 0 NOUN F
treated 0 VERB F
with 0 ADP F
ZES 0 NOUN T
or 0 CCONJ F
PES 0 NOUN T
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 ADP F
noninferiority 0 NOUN F
of 0 ADP F
9-month B-PHYSICAL NOUN F
target I-PHYSICAL NOUN F
vessel I-PHYSICAL NOUN F
failure I-PHYSICAL NOUN F
defined I-PHYSICAL VERB F
as 0 DET F
cardiac B-ADVERSE-EFFECTS ADJ F
death I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
myocardial B-PHYSICAL ADJ F
infarction I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 PUNCT F

Hyperbaric 0 ADJ T
oxygen 0 NOUN F
attenuation 0 NOUN F
of 0 ADP F
lipopolysaccharide-induced 0 VERB F
acute 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
involves 0 NOUN F
heme 0 NOUN F
oxygenase-1 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Hyperbaric 0 ADJ T
oxygen 0 NOUN F
( 0 PUNCT F
HBO 0 NOUN T
) 0 PUNCT F
attenuates 0 PUNCT F
lipopolysaccharide 0 NOUN F
( 0 PUNCT F
LPS 0 NOUN T
) 0 PUNCT F
-induced 0 VERB F
acute 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
. 0 PUNCT F

This 0 DET T
beneficial 0 ADJ F
effect 0 NOUN F
of 0 ADP F
HBO 0 NOUN T
involves 0 NOUN F
inhibition 0 NOUN F
of 0 ADP F
inducible 0 ADJ F
nitric 0 ADJ F
oxide 0 NOUN F
synthase 0 NOUN F
( 0 PUNCT F
iNOS 0 NOUN F
) 0 PUNCT F
expression 0 NOUN F
and 0 CCONJ F
subsequent 0 ADJ F
nitric 0 ADJ F
oxide 0 NOUN F
( 0 PUNCT F
NO 0 NOUN T
) 0 PUNCT F
biosynthesis 0 NOUN F
. 0 PUNCT F

We 0 PRON T
sought 0 PROPN F
to 0 PART F
investigate 0 NOUN F
the 0 DET F
role 0 NOUN F
of 0 ADP F
heme 0 NOUN F
oxygenase-1 0 NOUN F
( 0 PUNCT F
HO-1 0 NOUN T
) 0 PUNCT F
on 0 ADP F
this 0 DET F
HBO 0 NOUN T
inhibition 0 NOUN F
of 0 ADP F
iNOS 0 NOUN F
induction 0 NOUN F
and 0 CCONJ F
acute 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
in 0 ADP F
septic 0 ADJ F
rat 0 NOUN F
lungs 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Before 0 ADP T
the 0 DET F
experiment 0 NOUN F
, 0 PUNCT F
72 0 NUM F
rats 0 NOUN F
were 0 VERB F
randomly 0 ADV F
allocated 0 VERB F
to 0 PART F
receive 0 NOUN F
HBO 0 NOUN T
or 0 CCONJ F
air 0 NOUN F
treatment 0 NOUN F
. 0 PUNCT F

With 0 ADP T
or 0 CCONJ F
without 0 ADP F
HBO 0 NOUN T
pre-treatment 0 NOUN F
, 0 PUNCT F
the 0 DET F
rats 0 NOUN F
were 0 VERB F
further 0 ADV F
divided 0 VERB F
into 0 ADP F
the 0 DET F
following 0 PUNCT F
subgroups 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
: 0 PUNCT F
( 0 PUNCT F
i 0 NUM F
) 0 PUNCT F
LPS 0 NOUN T
injection 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
ii 0 NUM F
) 0 PUNCT F
normal 0 ADJ F
saline 0 NOUN F
( 0 PUNCT F
N/S 0 PUNCT T
) 0 PUNCT F
injection 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
iii 0 NUM F
) 0 PUNCT F
hemin 0 NOUN F
( 0 PUNCT F
a 0 DET F
HO-1 0 NOUN T
inducer 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
LPS 0 NOUN T
, 0 PUNCT F
( 0 PUNCT F
iv 0 PUNCT F
) 0 PUNCT F
hemin 0 NOUN F
alone 0 ADJ F
, 0 PUNCT F
( 0 PUNCT F
v 0 NUM F
) 0 PUNCT F
tin 0 NOUN F
protoporphyrin 0 NOUN F
( 0 PUNCT F
SnPP 0 NOUN T
; 0 PUNCT F
a 0 DET F
HO-1 0 NOUN T
inhibitor 0 NOUN F
) 0 PUNCT F
plus 0 CCONJ F
LPS 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
vi 0 PUNCT F
) 0 PUNCT F
SnPP 0 NOUN T
alone 0 ADJ F
. 0 PUNCT F

All 0 DET T
rats 0 NOUN F
were 0 VERB F
maintained 0 VERB F
for 0 ADP F
6 0 NUM F
h 0 NOUN F
and 0 CCONJ F
then 0 ADV F
sacrificed 0 VERB F
with 0 ADP F
a 0 DET F
high-dose 0 NOUN F
pentobarbital 0 ADJ F
injection 0 NOUN F
. 0 PUNCT F

Lung 0 NOUN T
injuries 0 NOUN F
and 0 CCONJ F
relevant 0 ADJ F
enzymes 0 NOUN F
expression 0 NOUN F
were 0 VERB F
thus 0 ADV F
assayed 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Histological B-PHYSICAL ADJ T
analysis I-PHYSICAL NOUN F
, 0 PUNCT F
PMNs/alveoli B-PHYSICAL NOUN T
ratio I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
wet/dry B-PHYSICAL PUNCT F
weight 0 NOUN F
ratio B-PHYSICAL NOUN F
measurements B-OTHER NOUN F
demonstrated 0 VERB F
that 0 ADP F
LPS 0 NOUN T
caused 0 VERB F
significant 0 ADJ F
lung 0 NOUN F
injury 0 NOUN F
and 0 CCONJ F
HBO 0 NOUN T
and/or 0 CCONJ F
hemin 0 NOUN F
significantly 0 ADV F
attenuated 0 ADP F
this 0 ADP F
LPS-induced 0 VERB T
lung 0 NOUN F
injury 0 NOUN F
. 0 PUNCT F

Increased 0 VERB T
pulmonary 0 ADJ F
iNOS B-PHYSICAL NOUN F
expression I-PHYSICAL NOUN F
and 0 PUNCT F

Small 0 ADJ T
but 0 CCONJ F
important 0 ADJ F
errors 0 NOUN F
in 0 ADP F
cardiovascular 0 ADJ F
risk 0 NOUN F
calculation 0 NOUN F
by 0 ADP F
practice 0 NOUN F
nurses 0 NOUN F
: 0 PUNCT F
a 0 DET F
cross-sectional 0 ADJ F
study 0 NOUN F
in 0 ADP F
randomised 0 VERB F
trial 0 NOUN F
setting 0 VERB F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Practice 0 NOUN T
nurses 0 NOUN F
play 0 VERB F
an 0 DET F
increasingly 0 ADV F
important 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
cardiovascular 0 ADJ F
diseases 0 NOUN F
but 0 CCONJ F
we 0 NOUN F
do 0 PUNCT F
not 0 ADV F
have 0 VERB F
evidence 0 NOUN F
about 0 ADP F
the 0 DET F
accuracy 0 NOUN F
of 0 ADP F
their 0 ADP F
cardiovascular 0 ADJ F
risk 0 NOUN F
assessments 0 NOUN F
during 0 ADP F
real 0 ADJ F
practice 0 NOUN F
consultations 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
examine 0 NOUN F
how 0 ADP F
nurses 0 NOUN F
perform 0 PUNCT F
with 0 ADP F
regard 0 NOUN F
to 0 ADP F
absolute 0 PUNCT F
10-year 0 ADP F
cardiovascular B-OTHER ADJ F
risk 0 NOUN F
assessment B-OTHER NOUN F
in 0 ADP F
actual 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
Cross-sectional 0 ADJ T
study 0 NOUN F
. 0 PUNCT F

SETTING 0 ADP T
This 0 DET T
study 0 NOUN F
was 0 VERB F
nested 0 VERB F
in 0 ADP F
the 0 DET F
IMPALA 0 NOUN T
study 0 ADP F
, 0 PUNCT F
a 0 DET F
clustered 0 ADJ F
randomised 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
involving 0 VERB F
24 0 NUM F
general 0 ADJ F
practices 0 NOUN F
in 0 ADP F
The 0 DET T
Netherlands 0 ADV T
. 0 PUNCT F

PARTICIPANTS 0 VERB T
24 0 NUM F
practice 0 NOUN F
nurses 0 NOUN F
, 0 PUNCT F
trained 0 PUNCT F
in 0 ADP F
10-year 0 ADJ F
cardiovascular 0 ADJ F
risk 0 NOUN F
assessment 0 NOUN F
, 0 PUNCT F
calculated 0 VERB F
the 0 DET F
risk 0 NOUN F
of 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
421 0 NUM F
patients 0 NOUN F
without 0 ADP F
established 0 ADP F
cardiovascular 0 ADJ F
diseases 0 NOUN F
but 0 CCONJ F
eligible 0 ADJ F
for 0 ADP F
cardiovascular B-OTHER ADJ F
risk 0 NOUN F
assessment B-OTHER NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
The 0 DET T
main 0 ADJ F
outcome 0 NOUN F
measure 0 ADV F
was 0 VERB F
the 0 DET F
accuracy 0 NOUN F
of 0 ADP F
risk 0 NOUN F
assessments B-OTHER NOUN F
, 0 PUNCT F
defined 0 SYM F
as 0 PUNCT F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
the 0 DET F
difference 0 NOUN F
between 0 ADP F
the 0 DET F
10-year B-OTHER ADP F
cardiovascular I-OTHER ADJ F
risk 0 NOUN F
percentage B-OTHER NOUN F
calculated I-OTHER PRON F
by B-OTHER ADP F
nurses B-OTHER NOUN F
and 0 CCONJ F
an B-OTHER DET F
independent B-OTHER ADJ F
assessor I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
the 0 DET F
agreement 0 NOUN F
between 0 ADP F
the B-OTHER DET F
treatment 0 PUNCT F

Perioperative 0 ADJ T
myocardial 0 ADJ F
infarctions 0 NOUN F
are 0 PROPN F
common 0 ADJ F
and 0 CCONJ F
often 0 ADV F
unrecognized 0 ADP F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
hip 0 NOUN F
fracture 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
aim 0 NOUN F
of 0 ADP F
this 0 DET F
prospective 0 ADJ F
cohort 0 NOUN F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
assess 0 NOUN F
the 0 DET F
incidence 0 NOUN F
and 0 CCONJ F
characteristics 0 NOUN F
of 0 ADP F
acute 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
surgery 0 NOUN F
for 0 ADP F
acute 0 ADJ F
hip 0 NOUN F
fracture 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 CCONJ T
consecutive 0 ADJ F
cohort 0 NOUN F
of 0 ADP F
patients 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 ADP F
200 0 NUM F
, 0 PUNCT F
68 0 NUM F
men 0 NOUN F
) 0 PUNCT F
referred 0 VERB F
to 0 ADP F
acute 0 ADJ F
surgical 0 ADJ F
correction 0 NOUN F
of 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
was 0 VERB F
studied 0 VERB F
. 0 PUNCT F

Troponin 0 NOUN T
T 0 NOUN T
( 0 PUNCT F
TnT 0 NOUN T
) 0 PUNCT F
measurements 0 NOUN F
and 0 CCONJ F
electrocardiographic 0 ADJ F
( 0 PUNCT F
ECG 0 NOUN T
) 0 PUNCT F
recordings 0 NOUN F
were 0 VERB F
performed 0 VERB F
at 0 ADP F
admission 0 NOUN F
, 0 PUNCT F
before 0 ADP F
operation 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
first 0 ADJ F
and 0 CCONJ F
2nd 0 ADJ F
postoperative 0 ADJ F
days 0 NOUN F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
used 0 VERB F
for 0 ADP F
diagnosis 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
age 0 NOUN F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
ranged 0 VERB F
from 0 ADP F
32 0 NUM F
to 0 ADP F
98 0 NUM F
years 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
, 0 PUNCT F
80.8 0 NUM F
years 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
65 0 NUM F
patients 0 NOUN F
had 0 ADP F
a 0 DET F
history 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

A 0 DET T
significant 0 ADJ F
rise B-PHYSICAL NOUN F
in I-PHYSICAL ADP F
TnT I-PHYSICAL NOUN T
as 0 ADP F
a 0 DET F
sign 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
71 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
35.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
25 0 NUM F
of 0 ADP F
them 0 PRON F
had 0 PUNCT F
a 0 DET F
TnT B-PHYSICAL NOUN T
elevation I-PHYSICAL NOUN F
exceeding 0 VERB F
five 0 PUNCT F
times 0 NOUN F
the 0 DET F
upper 0 ADJ F
normal 0 ADJ F
limit 0 NOUN F
. 0 PUNCT F

TnT B-PHYSICAL NOUN T
elevation I-PHYSICAL NOUN F
was 0 VERB F
observed 0 VERB F
in 0 ADP F
36 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
51 0 NUM F
% 0 SYM F
) 0 PUNCT F
already 0 ADV F
before 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Seven 0 NUM T
patients 0 NOUN F
( 0 PUNCT F
10 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
ST 0 NOUN T
elevation 0 NOUN F
myocardial 0 ADJ F
infarction 0 NOUN F
, 0 PUNCT F
23 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
32 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
new B-PHYSICAL ADJ F
ST I-PHYSICAL NOUN T
depressions I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
21 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
30 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 DET F
no 0 DET F
new 0 ADJ F
ST 0 NOUN T
segment 0 NOUN F
changes 0 NOUN F
in 0 ADP F
the 0 DET F
serial 0 ADJ F
electrocardiographic 0 ADJ F
recordings 0 NOUN F
. 0 PUNCT F

In 0 ADP T
40 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
56 0 NUM F
% 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
perioperative 0 ADJ F
myocardial 0 ADJ F
infarction 0 NOUN F
was 0 VERB F
the 0 DET F
first 0 ADJ F
manifestation 0 NOUN F
of 0 ADP F
coronary 0 ADJ F
artery 0 NOUN F
disease 0 NOUN F
. 0 PUNCT F

Multivariate 0 ADJ T
logistic 0 ADJ F
regression 0 NOUN F
revealed 0 VERB F
that 0 ADP F
old 0 ADJ F
age 0 NOUN F
( 0 PUNCT F
odds 0 NOUN F
ratio 0 NOUN F
[ 0 PUNCT F
OR 0 CCONJ T
] 0 PUNCT F
, 0 PUNCT F
1.06 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
[ 0 PUNCT F
CI 0 NOUN T
] 0 PUNCT F
, 0 PUNCT F
1.02-1.10 0 NUM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.002 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
earlier 0 PUNCT F
revascularization 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
, 0 PUNCT F
3.29 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.12-9.73 0 NUM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
heart 0 NOUN F
failure 0 NOUN F
( 0 PUNCT F
OR 0 NOUN T
, 0 PUNCT F
2.42 0 NUM F
; 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
1.04-5.61 0 NUM F
; 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.04 0 NUM F
) 0 PUNCT F
were 0 VERB F
independent 0 ADJ F
predictors 0 NOUN F
of 0 ADP F
TnT 0 NOUN T
elevation 0 NOUN F
. 0 PUNCT F

Majority 0 NOUN T
of 0 ADP F
myocardial B-PHYSICAL ADJ F
infarctions I-PHYSICAL NOUN F
were 0 VERB F
asymptomatic 0 ADJ F
or 0 CCONJ F
unrecognized 0 DET F
. 0 PUNCT F

Evidence-based 0 ADJ T
medications 0 NOUN F
of 0 ADP F
myocardial 0 ADJ F
infarction 0 NOUN F
were 0 PUNCT F
seldom 0 ADV F
started 0 PUNCT F
and 0 CCONJ F
cardiologist 0 NOUN F
was 0 VERB F
consulted 0 VERB F
in 0 ADP F
12 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
16.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
often 0 ADV F
develop 0 VERB F
asymptomatic 0 ADJ F
and 0 CCONJ F
clinically 0 ADV F
unrecognized 0 VERB F
perioperative 0 ADJ F
myocardial 0 ADJ F
infarctions 0 NOUN F
. 0 PUNCT F

Earlier 0 PUNCT T
diagnosis 0 NOUN F
and 0 CCONJ F
appropriate 0 ADJ F
treatment 0 NOUN F
of 0 ADP F
cardiac 0 ADJ F
infarction 0 NOUN F
may 0 VERB F
improve 0 VERB F
survival 0 NOUN F
of 0 ADP F
hip 0 NOUN F
fracture 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

LEVEL 0 NOUN T
OF 0 ADP T
EVIDENCE 0 NOUN T
Epidemiologic 0 ADJ T
study 0 NOUN F
, 0 PUNCT F
level 0 NOUN F
III 0 NUM T
. 0 PUNCT F

Failure 0 NOUN T
of 0 ADP F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
to 0 PART F
reduce 0 NOUN F
self-injurious 0 PUNCT F
and 0 CCONJ F
autistic 0 ADJ F
behavior 0 NOUN F
in 0 ADP F
mentally 0 ADV F
retarded 0 PRON F
adults 0 ADP F
. 0 PUNCT F

Double-blind 0 ADJ T
placebo-controlled 0 DET F
studies 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
It 0 PRON T
is 0 VERB F
hypothesized 0 VERB F
that 0 ADP F
self-injurious 0 ADJ F
behavior 0 NOUN F
( 0 PUNCT F
SIB 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
symptoms 0 NOUN F
of 0 ADP F
autism 0 NOUN F
may 0 VERB F
be 0 VERB F
due 0 PUNCT F
to 0 ADP F
overactivity 0 NOUN F
in 0 ADP F
some 0 DET F
opioid 0 NOUN F
systems 0 NOUN F
in 0 ADP F
the 0 DET F
brain 0 NOUN F
. 0 PUNCT F

We 0 PRON T
examined 0 VERB F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
of 0 ADP F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
, 0 PUNCT F
an 0 DET F
opioid 0 NOUN F
antagonist 0 NOUN F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
SIB 0 NOUN T
and 0 CCONJ F
autism 0 NOUN F
in 0 ADP F
mentally 0 ADV F
retarded 0 PRON F
adults 0 ADP F
. 0 PUNCT F

METHOD 0 NOUN T
Thirty-three 0 PUNCT T
mentally 0 ADV F
retarded 0 PRON F
adults 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and/or 0 CCONJ F
SIB 0 NOUN T
participated 0 DET F
in 0 ADP F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
crossover 0 NOUN F
studies 0 NOUN F
. 0 PUNCT F

Active 0 ADJ T
treatment 0 NOUN F
was 0 VERB F
first 0 CCONJ F
a 0 DET F
single 0 ADJ F
100-mg 0 NOUN F
dose 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
. 0 PUNCT F

Subsequently 0 ADV T
, 0 PUNCT F
19 0 NUM F
subjects 0 NOUN F
were 0 VERB F
treated 0 VERB F
with 0 ADP F
50 0 NUM F
mg/d 0 NOUN F
and 0 CCONJ F
14 0 NUM F
with 0 ADP F
150 0 NUM F
mg/d 0 NOUN F
of 0 ADP F
naltrexone 0 NUM F
hydrochloride 0 NOUN F
for 0 ADP F
4 0 NUM F
weeks 0 NOUN F
. 0 PUNCT F

The 0 DET T
outcome 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
direct 0 ADJ F
observations 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
11 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
scores 0 NOUN F
on 0 ADP F
a 0 DET F
list 0 NOUN F
of 0 CCONJ F
target B-MENTAL NOUN F
behaviors I-MENTAL NOUN F
, 0 PUNCT F
the 0 DET F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist I-MENTAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Clinical B-MENTAL ADJ T
Global I-MENTAL ADJ T
Impression I-MENTAL NOUN T
Scale 0 NOUN T
. 0 PUNCT F

RESULTS 0 NOUN T
Thirty-two 0 ADJ T
subjects 0 NOUN F
( 0 PUNCT F
seven 0 NUM F
with 0 ADP F
autism 0 NOUN F
, 0 PUNCT F
16 0 NUM F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
SIB 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
nine 0 NUM F
with 0 ADP F
SIB 0 NOUN T
) 0 PUNCT F
completed 0 VERB F
the 0 DET F
trial 0 NOUN F
. 0 PUNCT F

Naltrexone 0 PUNCT T
treatment 0 NOUN F
failed 0 VERB F
to 0 ADP F
have 0 PUNCT F
therapeutic 0 ADJ F
effects 0 NOUN F
on 0 ADP F
SIB 0 NOUN T
and 0 CCONJ F
autism 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
contrary 0 PUNCT F
, 0 PUNCT F
naltrexone 0 NUM F
increased 0 VERB F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
stereotypic B-MENTAL ADJ F
behavior I-MENTAL NOUN F
on 0 ADP F
the 0 DET F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist I-MENTAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
care 0 NOUN F
staff 0 NOUN F
evaluated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
the 0 DET F
50-mg/d 0 NUM F
treatment 0 NOUN F
as 0 VERB F
being 0 VERB F
significantly 0 ADV F
worse 0 ADJ F
than 0 CCONJ F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
placebo 0 NOUN F
treatment 0 NOUN F
as 0 PUNCT F
measured 0 VERB F
by 0 ADP F
the 0 DET F
Clinical B-MENTAL ADJ T
Global I-MENTAL ADJ T
Impression I-MENTAL NOUN T
Scale 0 NOUN T
. 0 PUNCT F

CONCLUSION 0 NOUN T
Our 0 PUNCT T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
naltrexone 0 NUM F
has 0 VERB F
no 0 DET F
clinical 0 ADJ F
value 0 NOUN F
for 0 ADP F
a 0 DET F
broad 0 ADJ F
group 0 NOUN F
of 0 ADP F
mentally 0 ADV F
retarded 0 VERB F
subjects 0 NOUN F
with 0 ADP F
SIB 0 NOUN T
and/or 0 CCONJ F
autism 0 NOUN F
. 0 PUNCT F

Oral 0 ADJ T
health 0 NOUN F
impacts 0 NOUN F
on 0 ADP F
daily 0 PUNCT F
living 0 ADP F
related 0 VERB F
to 0 ADP F
four 0 NUM F
different 0 ADJ F
treatment 0 NOUN F
protocols 0 NOUN F
for 0 ADP F
chronic 0 ADJ F
periodontitis 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
aims 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
were 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
oral 0 ADJ F
health 0 NOUN F
impacts 0 NOUN F
perceived 0 VERB F
by 0 ADP F
patients 0 NOUN F
submitted 0 VERB F
to 0 ADP F
different 0 ADJ F
treatments 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
periodontitis 0 NOUN F
and 0 CCONJ F
their 0 ADP F
association 0 NOUN F
with 0 ADP F
clinical 0 ADJ F
parameters 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Sixty 0 PUNCT T
patients 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 ADP F
one 0 PUNCT F
of 0 ADP F
the 0 DET F
following 0 PUNCT F
therapeutic 0 ADJ F
groups 0 NOUN F
: 0 PUNCT F
control 0 NOUN F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
full-mouth 0 NOUN F
scaling 0 PUNCT F
and 0 CCONJ F
root 0 NOUN F
planing 0 PUNCT F
( 0 PUNCT F
SRP 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
test 0 PUNCT F
1 0 NUM F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
SRP 0 NOUN T
and 0 CCONJ F
400 0 NUM F
mg 0 NOUN F
systemically 0 ADV F
administered 0 VERB F
metronidazole 0 NOUN F
( 0 PUNCT F
MET 0 NOUN T
) 0 PUNCT F
three 0 NUM F
times 0 NOUN F
per 0 ADP F
day 0 NOUN F
for 0 ADP F
10 0 NUM F
days 0 NOUN F
; 0 PUNCT F
test 0 CCONJ F
2 0 NUM F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
SRP 0 NOUN T
and 0 CCONJ F
professional 0 ADJ F
supragingival 0 ADP F
plaque 0 NOUN F
removal 0 NOUN F
( 0 PUNCT F
PP 0 NOUN T
) 0 PUNCT F
every 0 DET F
week 0 NOUN F
for 0 ADP F
3 0 NUM F
months 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
test 0 ADP F
3 0 NUM F
, 0 PUNCT F
treated 0 VERB F
with 0 ADP F
SRP 0 NOUN T
and 0 CCONJ F
MET 0 NOUN T
plus 0 CCONJ F
PP 0 NOUN T
. 0 PUNCT F

Clinical 0 ADJ T
periodontal 0 ADJ F
measurements 0 NOUN F
and 0 CCONJ F
data 0 NOUN F
regarding 0 VERB F
patients 0 NOUN F
' 0 PUNCT F
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
impacts I-PHYSICAL NOUN F
( 0 PUNCT F
perceived B-PHYSICAL PUNCT F
impacts I-PHYSICAL NOUN F
on I-PHYSICAL ADP F
bleeding I-PHYSICAL ADP F
gums I-PHYSICAL ADJ F
, 0 PUNCT F
gingival B-PHYSICAL ADJ F
recession I-PHYSICAL NOUN F
, 0 PUNCT F
sensitivity B-PHYSICAL NOUN F
to I-PHYSICAL ADP F
cold I-PHYSICAL ADP F
, 0 PUNCT F
packing B-PHYSICAL VERB F
foods I-PHYSICAL NOUN F
, 0 PUNCT F
aesthetics B-PHYSICAL ADJ F
, 0 PUNCT F
bad B-PHYSICAL CCONJ F
breath I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
tooth B-PHYSICAL NOUN F
mobility I-PHYSICAL NOUN F
) 0 PUNCT F
were 0 VERB F
collected 0 VERB F
at 0 ADP F
baseline 0 NOUN F
and 0 CCONJ F
3 0 NUM F
months 0 NOUN F
after 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
All 0 DET T
groups 0 NOUN F
presented 0 VERB F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
perceived I-PHYSICAL VERB F
impacts I-PHYSICAL NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
improvement 0 NOUN F
of 0 ADP F
oral B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
impacts I-PHYSICAL NOUN F
among 0 DET F
groups 0 NOUN F
subjected 0 VERB F
to 0 ADP F
different 0 ADJ F
treatments 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
data 0 NOUN F
of 0 ADP F
percentage 0 NOUN F
of 0 ADP F
deep 0 ADJ F
probing 0 VERB F
depth 0 NOUN F
, 0 PUNCT F
deep 0 ADJ F
clinical 0 ADJ F
attachment 0 NOUN F
level 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
bleeding 0 VERB F
on 0 ADP F
probing 0 VERB F
were 0 VERB F
found 0 VERB F
to 0 PART F
be 0 PUNCT F
correlated 0 VERB F
significantly 0 ADV F
with 0 ADP F
oral 0 ADJ F
health 0 NOUN F
impacts 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Periodontal 0 PUNCT T
treatment 0 NOUN F
leads 0 NOUN F
to 0 ADP F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
of 0 ADP F
self-perceived B-PHYSICAL VERB F
impacts I-PHYSICAL NOUN F
regardless 0 CCONJ F
of 0 ADP F
the 0 DET F
non-surgical 0 ADJ F
treatment 0 NOUN F
protocol 0 NOUN F
employed 0 VERB F
. 0 PUNCT F

Most 0 PUNCT T
of 0 ADP F
the 0 DET F
clinical 0 ADJ F
data 0 NOUN F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
oral 0 ADJ F
health 0 NOUN F
impacts 0 NOUN F
. 0 PUNCT F

A 0 DET T
description 0 NOUN F
of 0 ADP F
the 0 DET F
clinical 0 ADJ F
characteristics 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
of 0 ADP F
patients 0 NOUN F
recruited 0 VERB F
into 0 ADP F
the 0 DET F
Carvedilol 0 NOUN T
or 0 CCONJ F
Metoprolol 0 NOUN T
European 0 NOUN T
Trial 0 NOUN T
( 0 PUNCT F
COMET 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

BACKGROUND 0 NOUN T
& 0 CCONJ F
AIMS 0 PUNCT T
The 0 DET T
COMET 0 NOUN T
trial 0 NOUN F
was 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
randomised 0 VERB F
trial 0 NOUN F
comparing 0 VERB F
carvedilol 0 NOUN F
, 0 PUNCT F
a 0 DET F
comprehensive 0 ADJ F
adrenergic 0 ADJ F
receptor 0 NOUN F
antagonist 0 NOUN F
, 0 PUNCT F
with 0 ADP F
metoprolol 0 NOUN F
, 0 PUNCT F
a 0 DET F
beta-1-selective 0 ADJ F
agent 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
and 0 CCONJ F
left 0 ADJ F
ventricular 0 ADJ F
systolic 0 ADJ F
dysfunction 0 NOUN F
. 0 PUNCT F

The 0 DET T
trial 0 NOUN F
showed 0 VERB F
a 0 DET F
reduction 0 NOUN F
in 0 ADP F
mortality B-MORTALITY NOUN F
with 0 ADP F
carvedilol 0 NOUN F
that 0 ADP F
was 0 VERB F
consistent 0 ADJ F
across 0 ADP F
subgroups 0 NOUN F
. 0 PUNCT F

The 0 DET T
purpose 0 NOUN F
of 0 ADP F
this 0 DET F
report 0 NOUN F
is 0 PUNCT F
to 0 PART F
describe 0 ADP F
in 0 ADP F
greater 0 PUNCT F
detail 0 NOUN F
the 0 DET F
heterogeneity 0 NOUN F
of 0 ADP F
this 0 DET F
population 0 NOUN F
at 0 ADP F
baseline 0 NOUN F
with 0 ADP F
particular 0 ADJ F
reference 0 NOUN F
to 0 ADP F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
symptomatic 0 ADJ F
severity 0 NOUN F
, 0 PUNCT F
age 0 NOUN F
and 0 CCONJ F
gender 0 NOUN F
on 0 ADP F
patient 0 NOUN F
characteristics 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 DET T
descriptive 0 ADJ F
report 0 NOUN F
using 0 PUNCT F
data 0 NOUN F
entered 0 VERB F
in 0 ADP F
the 0 DET F
COMET 0 NOUN T
study 0 PUNCT F
data-base 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
characteristics 0 NOUN F
of 0 ADP F
the 0 DET F
population 0 NOUN F
studied 0 VERB F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
those 0 DET F
reported 0 VERB F
in 0 ADP F
previous 0 ADJ F
trials 0 NOUN F
of 0 ADP F
beta-blockers 0 NOUN F
. 0 PUNCT F

Almost 0 ADV T
all 0 DET F
patients 0 NOUN F
were 0 VERB F
receiving 0 PROPN F
diuretics 0 NOUN F
and 0 CCONJ F
ACE 0 NOUN T
inhibitors 0 NOUN F
with 0 ADP F
few 0 ADJ F
patients 0 NOUN F
taking 0 ADJ F
angiotensin 0 NOUN F
receptor 0 NOUN F
blockers 0 NOUN F
. 0 PUNCT F

As 0 PUNCT T
expected 0 PUNCT F
, 0 PUNCT F
older 0 PUNCT F
patients 0 NOUN F
had 0 PUNCT F
more 0 DET F
co-morbidity B-PHYSICAL NOUN F
. 0 PUNCT F

Older 0 PUNCT T
patients 0 NOUN F
and 0 CCONJ F
women 0 NOUN F
reported 0 ADP F
worse 0 ADJ F
symptoms B-PHYSICAL NOUN F
and 0 CCONJ F
poorer 0 PUNCT F
well-being B-PHYSICAL CCONJ F
despite 0 ADP F
similar 0 ADJ F
ventricular B-PHYSICAL ADJ F
dimensions I-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
systolic I-PHYSICAL ADJ F
dysfunction I-PHYSICAL NOUN F
. 0 PUNCT F

NT-proBNP B-PHYSICAL NOUN T
was 0 VERB F
higher 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
more 0 ADV F
severe 0 ADJ F
symptoms 0 NOUN F
and 0 CCONJ F
older 0 PUNCT F
patients 0 NOUN F
but 0 CCONJ F
not 0 ADV F
in 0 ADP F
women 0 NOUN F
, 0 PUNCT F
although 0 ADP F
differences 0 NOUN F
in 0 ADP F
NT-proBNP 0 NOUN T
may 0 VERB F
have 0 PUNCT F
been 0 PUNCT F
confounded 0 VERB F
by 0 ADP F
differences 0 NOUN F
in 0 ADP F
renal B-PHYSICAL ADJ F
function I-PHYSICAL NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Age 0 NOUN T
and 0 CCONJ F
gender 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
cardiac 0 ADJ F
dysfunction 0 NOUN F
, 0 PUNCT F
appear 0 VERB F
to 0 DET F
have 0 PUNCT F
an 0 DET F
important 0 ADJ F
effect 0 NOUN F
on 0 ADP F
the 0 DET F
severity 0 NOUN F
of 0 ADP F
heart B-PHYSICAL NOUN F
failure I-PHYSICAL PUNCT F

Long-term 0 NOUN T
exposure 0 NOUN F
to 0 ADP F
belatacept 0 PUNCT F
in 0 ADP F
recipients 0 NOUN F
of 0 ADP F
extended 0 VERB F
criteria 0 NOUN F
donor 0 NOUN F
kidneys 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
in 0 ADP F
the 0 DET F
BENEFIT-EXT 0 PUNCT T
study 0 NOUN F
received 0 VERB F
extended 0 VERB F
criteria 0 NOUN F
donor 0 NOUN F
kidneys 0 NOUN F
and 0 CCONJ F
a 0 DET F
more 0 ADV F
intensive 0 ADJ F
( 0 PUNCT F
MI 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
less 0 DET F
intensive 0 ADJ F
( 0 PUNCT F
LI 0 NOUN T
) 0 PUNCT F
belatacept 0 PUNCT F
immunosuppression 0 NOUN F
regimen 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
cyclosporine 0 NOUN F
A 0 NOUN T
( 0 PUNCT F
CsA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
who 0 ADP F
remained 0 VERB F
on 0 ADP F
assigned 0 PUNCT F
therapy 0 NOUN F
through 0 ADP F
year 0 NOUN F
3 0 NUM F
were 0 VERB F
eligible 0 ADJ F
to 0 PART F
enter 0 NOUN F
a 0 DET F
long-term 0 NOUN F
extension 0 NOUN F
( 0 PUNCT F
LTE 0 NOUN T
) 0 PUNCT F
study 0 NOUN F
. 0 PUNCT F

Three 0 NUM T
hundred 0 NUM F
four 0 NUM F
patients 0 NOUN F
entered 0 VERB F
the 0 DET F
LTE 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
104 0 NUM F
MI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
113 0 NUM F
LI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
87 0 NUM F
CsA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
260 0 NUM F
continued 0 VERB F
treatment 0 NOUN F
through 0 ADP F
year 0 NOUN F
5 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
91 0 NUM F
MI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
100 0 NUM F
LI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
69 0 NUM F
CsA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Twenty 0 NUM T
patients 0 NOUN F
died B-MORTALITY VERB F
during 0 ADP F
the 0 DET F
LTE 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
MI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
9 0 NUM F
LI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
CsA 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
eight 0 NUM F
experienced 0 ADJ F
graft B-ADVERSE-EFFECTS NOUN F
loss I-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
2 0 NUM F
MI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1 0 NUM F
LI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
5 0 NUM F
CsA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Three 0 NUM T
patients 0 NOUN F
experienced 0 VERB F
an 0 DET F
acute B-ADVERSE-EFFECTS ADJ F
rejection I-ADVERSE-EFFECTS NOUN F
episode 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
2 0 NUM F
MI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1 0 NUM F
LI 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
incidence 0 NOUN F
rate 0 NOUN F
of 0 ADP F
serious B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
viral B-ADVERSE-EFFECTS ADJ F
infections 0 NOUN F
and 0 CCONJ F
fungal B-ADVERSE-EFFECTS ADJ F
infections I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
similar 0 ADJ F
across 0 ADP F
groups 0 NOUN F
during 0 ADP F
the 0 DET F
LTE 0 NOUN T
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
four 0 NUM F
cases 0 NOUN F
of 0 ADP F
posttransplant B-ADVERSE-EFFECTS NOUN F
lymphoproliferative 0 ADJ F
disorder B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
PTLD 0 NOUN T
) 0 PUNCT F
from 0 ADP F
the 0 DET F
beginning 0 PUNCT F
of 0 ADP F
the 0 DET F
LTE 0 NOUN T
to 0 ADP F
year 0 NOUN F
5 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
3 0 NUM F
LI 0 NOUN T
; 0 PUNCT F
n 0 NOUN F
= 0 SYM F
1 0 NUM F
CsA 0 NOUN T
) 0 PUNCT F
; 0 PUNCT F
two 0 NUM F
of 0 ADP F
three 0 NUM F
PTLD 0 NOUN T
cases 0 NOUN F
in 0 ADP F
the 0 DET F
LI 0 NOUN T
group 0 NOUN F
were 0 VERB F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
were 0 VERB F
seronegative 0 PUNCT F
for 0 ADP F
Epstein-Barr 0 NOUN T
virus 0 NOUN F
( 0 PUNCT F
EBV 0 NOUN T
( 0 PUNCT F
- 0 SYM F
) 0 PUNCT F
) 0 PUNCT F
at 0 ADP F
transplantation 0 NOUN F
. 0 PUNCT F

Mean 0 NOUN T
? 0 PUNCT F

SD 0 NOUN T
calculated 0 VERB F
GFR 0 NOUN T
at 0 ADP F
year 0 NOUN F
5 0 NUM F
was 0 VERB F
55.9 0 NUM F
? 0 PUNCT F

17.5 0 NUM F
( 0 PUNCT F
MI 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
59.0 0 NUM F
? 0 PUNCT F

29.1 0 NUM F
( 0 PUNCT F
LI 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
44.6 0 NUM F
? 0 PUNCT F

16.4 0 NUM F
( 0 PUNCT F
CsA 0 NOUN T
) 0 PUNCT F
mL/min/1.73 0 NOUN F
m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Continued 0 DET T
treatment 0 NOUN F
with 0 ADP F
belatacept 0 CCONJ F
was 0 ADV F
associated 0 VERB F
with 0 ADP F
a 0 DET F
consistent 0 ADJ F
safety 0 NOUN F
profile 0 ADJ F
and 0 CCONJ F
sustained 0 VERB F
improvement 0 NOUN F
in 0 ADP F
renal 0 ADJ F
function 0 NOUN F
versus 0 CCONJ F
CsA 0 NOUN T
over 0 PUNCT F
time 0 NOUN F
. 0 PUNCT F

Induction 0 NOUN T
chemotherapy 0 NOUN F
in 0 ADP F
head 0 NOUN F
and 0 CCONJ F
neck 0 ADJ F
cancer 0 NOUN F
: 0 PUNCT F
results 0 NOUN F
of 0 ADP F
a 0 DET F
phase 0 NOUN F
III 0 NUM T
trial 0 NOUN F
. 0 PUNCT F

Between 0 ADP T
December 0 NOUN T
1982 0 NUM F
and 0 CCONJ F
October 0 NOUN T
1986 0 NUM F
, 0 PUNCT F
131 0 NUM F
patients 0 NOUN F
with 0 ADP F
stage 0 NOUN F
II-III-IV 0 NOUN T
squamous 0 ADJ F
cell 0 NOUN F
carcinoma 0 NOUN F
of 0 ADP F
the 0 DET F
oropharynx 0 ADJ F
or 0 CCONJ F
oral 0 ADJ F
cavity 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
induction 0 NOUN F
chemotherapy 0 NOUN F
, 0 PUNCT F
consisting 0 SYM F
of 0 ADP F
bleomycin 0 NOUN F
( 0 PUNCT F
10 0 NUM F
mg/m2/day 0 NOUN F
in 0 ADP F
continuous 0 ADJ F
infusion 0 NOUN F
from 0 ADP F
day 0 NOUN F
1 0 NUM F
to 0 ADP F
day 0 NOUN F
5 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
methotrexate 0 NOUN F
( 0 PUNCT F
120 0 ADP F
mg/m2 0 ADV F
on 0 ADP F
day 0 NOUN F
2 0 NUM F
) 0 PUNCT F
followed 0 VERB F
by 0 ADP F
folinic 0 ADJ F
acid 0 NOUN F
, 0 PUNCT F
5-fluorouracil 0 NOUN F
( 0 PUNCT F
5 0 NUM F
FU 0 NOUN T
) 0 PUNCT F
( 0 PUNCT F
600 0 NUM F
mg/m2 0 NUM F
on 0 ADP F
day 0 NOUN F
2 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
cisplatin 0 NOUN F
( 0 PUNCT F
120 0 ADP F
mg/m2 0 ADV F
on 0 ADP F
day 0 NOUN F
4 0 NUM F
) 0 PUNCT F
every 0 DET F
4 0 NUM F
weeks 0 NOUN F
for 0 ADP F
a 0 DET F
total 0 NOUN F
of 0 ADP F
three 0 NUM F
cycles 0 NOUN F
followed 0 VERB F
by 0 ADP F
definitive 0 ADJ F
locoregional 0 ADJ F
treatment 0 NOUN F
versus 0 CCONJ F
locoregional 0 ADJ F
treatment 0 NOUN F
alone 0 ADJ F
. 0 PUNCT F

The 0 DET T
modalities 0 NOUN F
of 0 ADP F
definitive 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
radiotherapy 0 NOUN F
+/- 0 SYM F
surgery 0 NOUN F
) 0 PUNCT F
were 0 VERB F
chosen 0 VERB F
prior 0 PUNCT F
to 0 ADP F
randomization 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
116 0 NUM F
patients 0 NOUN F
were 0 VERB F
evaluable 0 ADJ F
. 0 PUNCT F

Of 0 ADP T
55 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
arm 0 ADP F
, 0 PUNCT F
four 0 NUM F
( 0 PUNCT F
7 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 PUNCT F
a 0 DET F
complete 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
CR 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
23 0 NUM F
( 0 PUNCT F
42 0 NUM F
% 0 SYM F
) 0 PUNCT F
a 0 DET F
partial 0 ADJ F
response 0 NOUN F
( 0 PUNCT F
PR 0 NOUN T
) 0 PUNCT F
following 0 VERB F
the 0 DET F
induction 0 NOUN F
regimen 0 NOUN F
. 0 PUNCT F

At 0 ADP T
the 0 DET F
completion 0 NOUN F
of 0 ADP F
locoregional 0 ADJ F
treatment 0 NOUN F
, 0 PUNCT F
76 0 NUM F
% 0 SYM F
( 0 PUNCT F
42 0 NUM F
of 0 ADP F
55 0 NUM F
) 0 PUNCT F
of 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
group 0 NOUN F
were 0 VERB F
in 0 ADP F
CR 0 NOUN T
compared 0 VERB F
to 0 ADP F
89 0 NUM F
% 0 SYM F
( 0 PUNCT F
54 0 NUM F
of 0 ADP F
61 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
survival B-OTHER NOUN F
, 0 PUNCT F
cause-specific B-OTHER ADJ F
survival I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
pattern B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
relapse I-PHYSICAL NOUN F
between 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
survival B-OTHER NOUN F
was 0 ADV F
22 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
chemotherapy 0 NOUN F
group 0 NOUN F
and 0 CCONJ F
29 0 NUM F
months 0 NOUN F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Responders 0 NOUN T
to 0 ADP F
chemotherapy 0 NOUN F
did 0 PUNCT F
not 0 ADV F
fare 0 DET F
better 0 PUNCT F
than 0 VERB F
nonresponders 0 NOUN F
. 0 PUNCT F

Chemotherapy-related B-ADVERSE-EFFECTS VERB T
toxicities I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
few 0 ADJ F
and 0 CCONJ F
most 0 PUNCT F
of 0 ADP F
them 0 PRON F
related 0 PUNCT F
to 0 ADP F
cisplatin 0 NOUN F
which 0 PUNCT F
was 0 VERB F
reduced 0 VERB F
to 0 ADP F
100 0 NUM F
mg/m2 0 NOUN F
for 0 ADP F
35 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
treatment-related 0 ADV F
deaths B-MORTALITY NOUN F
and 0 CCONJ F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
arm 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
, 0 PUNCT F
no 0 DET F
increased 0 ADV F
morbidity B-ADVERSE-EFFECTS NOUN F
from 0 ADP F
locoregional 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

This 0 DET T
induction 0 NOUN F
regimen 0 NOUN F
does 0 PUNCT F
not 0 ADV F
offer 0 VERB F
any 0 DET F
advantages 0 NOUN F
over 0 ADP F
standard 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Comparative 0 ADJ T
drug 0 NOUN F
effects 0 NOUN F
and 0 CCONJ F
abuse 0 NOUN F
liability 0 NOUN F
of 0 ADP F
lorazepam 0 NOUN F
, 0 PUNCT F
buspirone 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
secobarbital 0 ADJ F
in 0 ADP F
nondependent 0 VERB F
subjects 0 NOUN F
. 0 PUNCT F

The 0 DET T
pharmacologic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
lorazepam 0 NOUN F
( 0 PUNCT F
2 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
buspirone 0 NOUN F
( 0 PUNCT F
20 0 NUM F
mg 0 NOUN F
, 0 PUNCT F
10 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
secobarbital 0 ADJ F
( 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
placebo 0 NOUN F
were 0 VERB F
compared 0 VERB F
in 0 ADP F
15 0 NUM F
male 0 NOUN F
, 0 PUNCT F
experienced 0 ADP F
, 0 PUNCT F
intermittent 0 ADJ F
nontherapeutic 0 ADJ F
drug 0 NOUN F
users 0 NOUN F
. 0 PUNCT F

All 0 DET T
drugs 0 NOUN F
produced 0 VERB F
a 0 DET F
drug 0 NOUN F
effect 0 NOUN F
, 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
buspirone 0 NOUN F
20 0 NUM F
mg 0 NOUN F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
liked 0 VERB F
than 0 PUNCT F
were 0 ADP F
lorazepam 0 NOUN F
, 0 PUNCT F
secobarbital 0 ADJ F
, 0 PUNCT F
or 0 CCONJ F
buspirone 0 NOUN F
10 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
.05 0 NUM F
) 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
placebo 0 NOUN F
. 0 PUNCT F

Lorazepam 0 NOUN T
was 0 VERB F
liked 0 ADP F
better 0 PUNCT F
than 0 VERB F
were 0 VERB F
other 0 ADJ F
drugs 0 NOUN F
only 0 ADV F
at 0 ADP F
1 0 NUM F
hour 0 NOUN F
and 0 CCONJ F
only 0 ADV F
compared 0 VERB F
with 0 ADP F
buspirone 0 NOUN F
20 0 NUM F
and 0 CCONJ F
placebo 0 NOUN F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
other 0 ADJ F
drugs 0 NOUN F
, 0 PUNCT F
lorazepam 0 NOUN F
drug B-OTHER NOUN F
effects I-OTHER NOUN F
were 0 VERB F
greater 0 PUNCT F
and 0 CCONJ F
resulted 0 VERB F
in 0 ADP F
more 0 DET F
prolonged B-PHYSICAL ADJ F
impairment I-PHYSICAL NOUN F
of 0 ADP F
a 0 DET F
motor B-PHYSICAL NOUN F
tracking I-PHYSICAL PUNCT F
task I-PHYSICAL NOUN F
, 0 PUNCT F
standing B-PHYSICAL ADP F
steadiness I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
memory B-MENTAL NOUN F
. 0 PUNCT F

Buspirone 0 NOUN T
20 0 NUM F
mg 0 NOUN F
significantly B-MENTAL ADV F
impaired I-MENTAL PUNCT F
memory I-MENTAL NOUN F
at 0 ADP F
1 0 NUM F
hour 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
identify 0 NOUN F
buspirone 0 NOUN F
as 0 ADP F
unfamiliar 0 ADJ F
. 0 PUNCT F

Because 0 PUNCT T
buspirone 0 NOUN F
20 0 NUM F
mg 0 NOUN F
was 0 VERB F
less 0 ADV F
liked 0 VERB F
than 0 PUNCT F
were 0 VERB F
other 0 ADJ F
drugs 0 NOUN F
, 0 PUNCT F
dose 0 NOUN F
escalation 0 NOUN F
as 0 ADP F
part 0 NOUN F
of 0 ADP F
drug B-MENTAL NOUN F
abuse I-MENTAL NOUN F
is 0 VERB F
not 0 ADV F
likely 0 ADJ F
to 0 PART F
occur 0 ADV F
. 0 PUNCT F

Lorazepam 0 NOUN T
also 0 ADV F
was 0 VERB F
not 0 ADV F
particularly 0 ADV F
liked 0 ADP F
and 0 CCONJ F
was 0 ADJ F
not 0 ADV F
different 0 ADJ F
from 0 ADP F
placebo 0 NOUN F
on 0 ADP F
most 0 PUNCT F
subjective B-OTHER ADJ F
abuse-relevant I-OTHER ADJ F
measures I-OTHER NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
patient-controlled 0 VERB F
and 0 CCONJ F
nurse-administered 0 DET F
analgesia 0 NOUN F
using 0 SYM F
intravenous 0 ADJ F
fentanyl 0 NOUN F
during 0 ADP F
labor 0 NOUN F
. 0 PUNCT F

Preliminary 0 ADJ T
observations 0 NOUN F
have 0 PUNCT F
shown 0 VERB F
that 0 ADP F
fentanyl 0 NOUN F
citrate 0 NOUN F
, 0 PUNCT F
a 0 DET F
potent 0 ADJ F
narcotic 0 ADJ F
, 0 PUNCT F
is 0 VERB F
helpful 0 ADJ F
during 0 ADP F
labor 0 NOUN F
without 0 ADP F
undue 0 NOUN F
side 0 NOUN F
effects 0 NOUN F
. 0 PUNCT F

This 0 DET T
randomized 0 VERB F
prospective 0 ADJ F
investigation 0 NOUN F
compared 0 VERB F
the 0 DET F
patient-controlled 0 VERB F
administration 0 NOUN F
of 0 ADP F
fentanyl 0 NOUN F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
administration 0 NOUN F
by 0 ADP F
nurses 0 NOUN F
on 0 ADP F
request 0 ADV F
. 0 PUNCT F

Eighty 0 PUNCT T
healthy 0 ADJ F
women 0 NOUN F
beginning 0 VERB F
active 0 ADJ F
labor 0 NOUN F
( 0 PUNCT F
cervical 0 ADJ F
dilation 0 NOUN F
4 0 NUM F
cm 0 NOUN F
) 0 PUNCT F
at 0 ADP F
term 0 NOUN F
were 0 VERB F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
fentanyl 0 NOUN F
intravenously 0 ADV F
by 0 ADP F
either 0 CCONJ F
patient-controlled 0 VERB F
administration 0 NOUN F
( 0 PUNCT F
n=37 0 PUNCT F
) 0 PUNCT F
or 0 CCONJ F
nurse 0 ADJ F
administration 0 NOUN F
on 0 ADP F
demand 0 NOUN F
( 0 PUNCT F
n=43 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Pain B-PAIN NOUN T
intensity 0 NOUN F
measurements B-PAIN NOUN F
during 0 ADP F
early 0 ADJ F
and 0 CCONJ F
late 0 ADJ F
labor 0 NOUN F
revealed 0 VERB F
the 0 DET F
degree B-PAIN NOUN F
of I-PAIN ADP F
analgesia I-PAIN NOUN F
to 0 PART F
be 0 PUNCT F
the 0 DET F
same 0 ADP F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
delay 0 NOUN F
in 0 ADP F
setting B-OTHER VERB F
up I-OTHER PUNCT F
the I-OTHER DET F
infusion I-OTHER NOUN F
system I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
short 0 ADJ F
time B-OTHER NOUN F
between I-OTHER ADP F
requesting B-OTHER PUNCT F
analgesia B-OTHER NOUN F
and I-OTHER CCONJ F
vaginal I-OTHER ADJ F
delivery B-OTHER NOUN F
were 0 DET F
limitations 0 NOUN F
with 0 ADP F
self-administration 0 NOUN F
. 0 PUNCT F

Maternal B-ADVERSE-EFFECTS ADJ T
oversedation I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
vomiting B-ADVERSE-EFFECTS ADP F
did 0 PUNCT F
not 0 ADV F
occur 0 VERB F
. 0 PUNCT F

Neonatal B-OTHER ADJ T
naloxone B-OTHER PUNCT F

Salbutamol 0 NOUN T
or 0 CCONJ F
mist 0 NOUN F
in 0 ADP F
acute 0 ADJ F
bronchiolitis 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
The 0 DET T
role 0 NOUN F
of 0 ADP F
bronchodilators 0 NOUN F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
bronchiolitis 0 NOUN F
remains 0 NOUN F
controversial 0 ADJ F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
double-blind 0 ADJ F
, 0 PUNCT F
placebo 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
performed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
clinical 0 ADJ F
response 0 NOUN F
to 0 ADP F
nebulized 0 ADJ F
salbutamol 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
and 0 CCONJ F
fifty-six 0 PUNCT F
infants 0 NOUN F
aged 0 VERB F
between 0 ADP F
7 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
24 0 NUM F
months 0 NOUN F
who 0 ADP F
had 0 ADP F
had 0 PUNCT F
an 0 DET F
episode 0 NOUN F
of 0 ADP F
wheezing 0 PROPN F
and 0 CCONJ F
other 0 ADJ F
signs 0 NOUN F
and 0 CCONJ F
symptoms 0 NOUN F
of 0 ADP F
bronchiolitis 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
three 0 NUM F
groups 0 NOUN F
as 0 ADP F
follows 0 VERB F
: 0 PUNCT F
( 0 PUNCT F
i 0 NUM F
) 0 PUNCT F
nebulized 0 VERB F
salbutamol 0 NOUN F
was 0 VERB F
administered 0 VERB F
to 0 ADP F
52 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
0.15 0 NUM F
mg/kg 0 NOUN F
in 0 ADP F
2 0 NUM F
mL 0 NOUN F
saline 0 NOUN F
; 0 PUNCT F
( 0 PUNCT F
ii 0 NUM F
) 0 PUNCT F
saline 0 NOUN F
was 0 VERB F
nebulized 0 VERB F
to 0 ADP F
52 0 NUM F
patients 0 NOUN F
in 0 ADP F
group 0 NOUN F
II 0 NUM T
and 0 CCONJ F
( 0 PUNCT F
iii 0 NUM F
) 0 PUNCT F
in 0 ADP F
group 0 NOUN F
III 0 NUM T
52 0 NUM F
patients 0 NOUN F
received 0 VERB F
mist 0 NOUN F
in 0 ADP F
a 0 DET F
tent 0 ADJ F
. 0 PUNCT F

All 0 DET T
three 0 NUM F
groups 0 NOUN F
were 0 VERB F
administered 0 VERB F
oxygen 0 NOUN F
during 0 ADP F
the 0 DET F
procedures 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
was 0 VERB F
repeated 0 VERB F
with 0 ADP F
the 0 DET F
same 0 ADJ F
agent 0 NOUN F
after 0 ADP F
30 0 NUM F
min 0 NOUN F
if 0 ADP F
the 0 DET F
respiratory 0 ADJ F
score 0 NOUN F
was 0 VERB F
5 0 NUM F
or 0 CCONJ F
more 0 DET F
. 0 PUNCT F

Respiratory B-PHYSICAL ADJ T
rate I-PHYSICAL NOUN F
, 0 PUNCT F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
, 0 PUNCT F
oxygen B-PHYSICAL NOUN F
saturation I-PHYSICAL NOUN F
and 0 CCONJ F
presence 0 NOUN F
of 0 ADP F
cyanosis B-PHYSICAL NOUN F
, 0 PUNCT F
wheezing B-PHYSICAL PUNCT F
, 0 PUNCT F
retractions B-PHYSICAL ADP F
were 0 VERB F
recorded 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
each 0 DET F
treatment 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
decrease 0 NOUN F
in 0 ADP F
the 0 DET F
respiratory B-PHYSICAL ADJ F
score I-PHYSICAL NOUN F
was 0 VERB F
5.2 0 NUM F
+/- 0 SYM F
1.8 0 NUM F
, 0 PUNCT F
0.82 0 NUM F
+/- 0 SYM F
2.4 0 NUM F
and 0 CCONJ F
1.7 0 NUM F
+/- 0 SYM F
1.3 0 NUM F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
, 0 PUNCT F
II 0 NUM T
and 0 CCONJ F
III 0 NUM T
, 0 PUNCT F
respectively 0 ADV F
. 0 PUNCT F

The 0 DET T
decrease 0 NOUN F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
was 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
other 0 ADJ F
groups 0 NOUN F
. 0 PUNCT F

Heart B-PHYSICAL NOUN T
rate I-PHYSICAL NOUN F
was 0 VERB F
similar 0 ADJ F
between 0 ADP F
groups 0 NOUN F
. 0 PUNCT F

Oxygen B-PHYSICAL NOUN T
saturation I-PHYSICAL NOUN F
decreased 0 VERB F
in 0 ADP F
group 0 NOUN F
I 0 NUM T
without 0 ADP F
reaching 0 VERB F
statistical 0 ADJ F
significance 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Salbutamol 0 NOUN T
was 0 VERB F
shown 0 VERB F
to 0 PART F
be 0 PUNCT F
effective 0 ADJ F
and 0 CCONJ F
safe B-OTHER ADJ F
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
acute 0 ADJ F
bronchiolitis 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
the 0 DET F
time B-OTHER NOUN F
required I-OTHER ADV F
to 0 PART F
administer 0 NOUN F
three 0 NUM F
different 0 ADJ F
fluke 0 PUNCT F
and 0 CCONJ F
worm 0 NOUN F
combination 0 NOUN F
products 0 NOUN F
to 0 ADP F
commercial 0 ADJ F
beef 0 NOUN F
cattle 0 NOUN F
at 0 ADP F
housing 0 VERB F
. 0 PUNCT F

Larger 0 PUNCT T
livestock 0 NOUN F
units 0 NOUN F
, 0 PUNCT F
a 0 DET F
decline 0 NOUN F
in 0 ADP F
the 0 DET F
farm 0 NOUN F
labor 0 NOUN F
force 0 NOUN F
, 0 PUNCT F
animal 0 NOUN F
welfare 0 ADP F
concerns 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
more 0 DET F
selective 0 ADJ F
use 0 NOUN F
of 0 ADP F
drugs 0 NOUN F
have 0 PUNCT F
increased 0 DET F
the 0 DET F
focus 0 NOUN F
on 0 ADP F
animal 0 NOUN F
handling 0 PROPN F
, 0 PUNCT F
time 0 NOUN F
management 0 NOUN F
, 0 PUNCT F
convenience 0 ADP F
, 0 PUNCT F
and 0 CCONJ F
compliance 0 NOUN F
in 0 ADP F
administering 0 NOUN F
veterinary 0 ADJ F
therapeutics 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
was 0 VERB F
undertaken 0 VERB F
to 0 PART F
quantify B-OTHER NOUN F
and 0 CCONJ F
compare 0 ADJ F
the 0 DET F
time 0 NOUN F
needed 0 ADP F
to 0 PART F
treat 0 NOUN F
commercial 0 PUNCT F
beef 0 NOUN F
cattle 0 NOUN F
with 0 ADP F
three 0 PUNCT F
fluke 0 PUNCT F
and 0 CCONJ F
worm 0 NOUN F
combination 0 NOUN F
products 0 NOUN F
with 0 ADP F
different 0 ADJ F
administration 0 NOUN F
profiles 0 NOUN F
. 0 PUNCT F

Young 0 ADJ T
beef 0 NOUN F
cattle 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
270 0 NUM F
) 0 PUNCT F
weighing 0 PUNCT F
approximately 0 ADV F
400 0 NUM F
kg 0 NOUN F
were 0 VERB F
allocated 0 VERB F
to 0 PUNCT F
batches 0 NOUN F
of 0 ADP F
five 0 NUM F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
ivermectin 0 NOUN F
+ 0 SYM F
clorsulon 0 NOUN F
injection 0 NOUN F
, 0 PUNCT F
ivermectin 0 NOUN F
+ 0 ADJ F
closantel 0 PUNCT F
injection 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
levamisole 0 NOUN F
+ 0 SYM F
triclabendazole 0 NOUN F
oral 0 ADJ F
drench 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 ADV F
time B-OTHER NOUN F
needed I-OTHER ADP F
to 0 PART F
administer 0 ADJ F
ivermectin 0 NOUN F
+ 0 SYM F
clorsulon 0 NOUN F
( 0 PUNCT F
single 0 ADJ F
injection 0 NOUN F
) 0 PUNCT F
to 0 ADP F
five 0 NUM F
cattle 0 NOUN F
was 0 VERB F
31 0 NUM F
seconds 0 NOUN F
, 0 PUNCT F
which 0 ADP F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
than 0 PUNCT F
the 0 DET F
100 0 NUM F
seconds 0 NOUN F
needed 0 VERB F
for 0 ADP F
ivermectin 0 NOUN F
+ 0 ADJ F
closantel 0 CCONJ F
( 0 PUNCT F
two 0 NUM F
injections 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
the 0 DET F
126 0 ADJ F
seconds 0 NOUN F
needed 0 VERB F
for 0 ADP F
levamisole 0 NOUN F
+ 0 SYM F
triclabendazole 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Such 0 DET T
quantitative 0 ADJ F
data 0 NOUN F
can 0 VERB F
allow 0 VERB F
for 0 ADP F
better 0 PUNCT F
planning 0 VERB F
and 0 CCONJ F
selection 0 NOUN F
of 0 ADP F
parasiticide 0 NOUN F
treatment 0 NOUN F
approaches 0 CCONJ F
at 0 ADP F
the 0 DET F
farm 0 NOUN F
level 0 NOUN F
. 0 PUNCT F

B-type 0 NOUN T
natriuretic 0 ADJ F
peptide 0 NOUN F
in 0 ADP F
the 0 DET F
evaluation 0 NOUN F
and 0 CCONJ F
management 0 NOUN F
of 0 ADP F
dyspnoea 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 NOUN T
The 0 DET T
rapid 0 ADJ F
and 0 CCONJ F
accurate 0 ADJ F
diagnosis 0 NOUN F
of 0 ADP F
heart 0 NOUN F
failure 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
is 0 VERB F
a 0 DET F
major 0 ADJ F
unmet 0 VERB F
clinical 0 ADJ F
need 0 NOUN F
. 0 PUNCT F

We 0 PRON T
evaluated 0 VERB F
the 0 DET F
additional 0 ADJ F
use 0 NOUN F
of 0 ADP F
B-type B-PHYSICAL NOUN T
natriuretic I-PHYSICAL ADJ F
peptide I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
BNP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
A 0 NOUN T
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
Twenty-nine 0 NUM T
primary 0 ADJ F
care 0 NOUN F
physicians 0 NOUN F
in 0 ADP F
Switzerland 0 ADV T
and 0 CCONJ F
Germany 0 PUNCT T
coordinated 0 PROPN F
by 0 ADP F
the 0 DET F
University 0 NOUN T
Hospital 0 NOUN T
Basel 0 NOUN T
, 0 PUNCT F
Switzerland 0 PUNCT T
. 0 PUNCT F

SUBJECTS 0 NOUN T
A 0 PUNCT T
total 0 NOUN F
of 0 ADP F
323 0 NUM F
consecutive 0 ADJ F
patients 0 NOUN F
presenting 0 VERB F
with 0 ADP F
dyspnoea 0 NOUN F
. 0 PUNCT F

INTERVENTIONS 0 NOUN T
Assignment 0 NOUN T
in 0 ADP F
a 0 DET F
1 0 NUM F
: 0 PUNCT F
1 0 NUM F
ratio 0 NOUN F
to 0 ADP F
a 0 DET F
diagnostic 0 ADJ F
strategy 0 NOUN F
including 0 VERB F
point-of-care 0 PUNCT F
measurement 0 NOUN F
of 0 ADP F
BNP 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
163 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
standard 0 PUNCT F
assessment 0 NOUN F
without 0 ADP F
BNP 0 NOUN T
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
160 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
total 0 ADJ F
medical B-OTHER ADJ F
cost I-OTHER NOUN F
at I-OTHER ADP F
3 I-OTHER NUM F
months I-OTHER NOUN F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
end-point 0 NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
end-points 0 NOUN F
were 0 VERB F
diagnostic B-OTHER ADJ F
certainty I-OTHER NOUN F
, 0 PUNCT F
time B-OTHER NOUN F
to I-OTHER ADP F
appropriate I-OTHER ADJ F
therapy I-OTHER NOUN F
, 0 PUNCT F
functional B-OTHER ADJ F
capacity I-OTHER NOUN F
, 0 PUNCT F
hospitalization B-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
. 0 PUNCT F

The 0 DET T
final 0 ADJ F
diagnosis 0 NOUN F
was 0 VERB F
adjudicated 0 VERB F
by 0 ADP F
a 0 DET F
physician 0 NOUN F
blinded 0 PUNCT F
to 0 ADP F
the 0 DET F
BNP 0 NOUN T
levels 0 NOUN F
. 0 PUNCT F

RESULTS 0 VERB T
Heart B-PHYSICAL NOUN T
failure I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
final 0 ADJ F
diagnosis 0 NOUN F
in 0 ADP F
34 0 NUM F
% 0 SYM F
of 0 ADP F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
number B-OTHER NOUN F
of I-OTHER ADP F
hospitalizations I-OTHER NOUN F
, 0 PUNCT F
functional B-OTHER ADJ F
status I-OTHER NOUN F
and 0 CCONJ F
total 0 ADJ F
medical B-OTHER ADJ F
cost I-OTHER NOUN F
at I-OTHER ADP F
3 I-OTHER NUM F
months I-OTHER NOUN F
[ 0 PUNCT F
median 0 ADJ F
$ 0 SYM F
1655 0 NUM F
, 0 PUNCT F
interquartile 0 NOUN F
range 0 NOUN F
( 0 PUNCT F
IQR 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
850-3331 0 NOUN F
vs. 0 CCONJ F
$ 0 SYM F
1541 0 NUM F
, 0 PUNCT F
IQR 0 NOUN T
859-2827 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.68 0 NUM F
] 0 PUNCT F
were 0 VERB F
similar 0 ADJ F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
. 0 PUNCT F

BNP B-PHYSICAL NOUN T
increased 0 DET F
diagnostic B-OTHER ADJ F
certainty I-OTHER NOUN F
as 0 PUNCT F
defined 0 VERB F
by 0 ADP F
the 0 DET F
need 0 NOUN F
for 0 ADP F
further 0 PUNCT F
diagnostic 0 ADJ F
work-up 0 ADJ F
( 0 PUNCT F
33 0 NUM F
% 0 SYM F
vs. 0 CCONJ F
45 0 NUM F
% 0 ADJ F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
accelerated 0 VERB F
the 0 DET F
initiation 0 NOUN F
of 0 ADP F
the 0 DET F
appropriate 0 ADJ F
treatment 0 NOUN F
( 0 PUNCT F
13 0 NUM F
days 0 NOUN F
vs. 0 CCONJ F
25 0 NUM F
days 0 NOUN F
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
area 0 NOUN F
under 0 ADP F
the 0 DET F
receiver-operating 0 ADJ F
characteristics 0 NOUN F
curve 0 NOUN F
for 0 ADP F
BNP 0 NOUN T
to 0 PART F
identify 0 NOUN F
heart 0 NOUN F
failure 0 NOUN F
was 0 VERB F
0.87 0 NUM F
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
0.81-0.93 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
The 0 DET T
use 0 NOUN F
of 0 ADP F
BNP 0 NOUN T
levels 0 NOUN F
in 0 ADP F
primary 0 ADJ F
care 0 NOUN F
did 0 PUNCT F
not 0 ADV F
reduce 0 VERB F
total 0 ADJ F
medical 0 ADJ F
cost 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
improved 0 PROPN F
some 0 ADP F
of 0 ADP F
the 0 DET F
secondary 0 ADJ F
end-points 0 NOUN F
including 0 VERB F
diagnostic 0 ADJ F
certainty 0 NOUN F
and 0 CCONJ F
time 0 NOUN F
to 0 ADP F
initiation 0 NOUN F
of 0 ADP F
appropriate 0 ADJ F
treatment 0 NOUN F
. 0 PUNCT F

Warfarin 0 NOUN T
for 0 ADP F
atrial 0 ADJ F
fibrillation 0 NOUN F
. 0 PUNCT F

The 0 DET T
patient 0 NOUN F
's 0 PUNCT F
perspective 0 ADJ F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
determine 0 NOUN F
the 0 DET F
minimal B-OTHER ADJ F
clinically I-OTHER ADV F
important I-OTHER ADJ F
difference I-OTHER NOUN F
( I-OTHER PUNCT F
MCID I-OTHER NOUN T
) I-OTHER PUNCT F
of 0 ADP F
warfarin 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
nonvalvular 0 ADJ F
atrial 0 ADJ F
fibrillation 0 NOUN F
from 0 ADP F
the 0 DET F
perspective 0 ADJ F
of 0 ADP F
patients 0 NOUN F
using 0 VERB F
2 0 NUM F
different 0 ADJ F
elicitation 0 NOUN F
methods 0 NOUN F
. 0 PUNCT F

DESIGN 0 NOUN T
All 0 DET T
patients 0 NOUN F
completed 0 DET F
2 0 NUM F
face-to-face 0 PUNCT F
interviews 0 NOUN F
, 0 PUNCT F
which 0 ADP F
were 0 VERB F
2 0 NUM F
weeks 0 NOUN F
apart 0 PUNCT F
. 0 PUNCT F

For 0 ADP T
each 0 DET F
interview 0 NOUN F
, 0 PUNCT F
they 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
1 0 NUM F
of 0 ADP F
2 0 NUM F
elicitation 0 NOUN F
methods 0 NOUN F
: 0 PUNCT F
ping-ponging 0 ADP F
or 0 CCONJ F
starting 0 VERB F
at 0 ADP F
the 0 DET F
known 0 VERB F
efficacy 0 NOUN F
. 0 PUNCT F

SETTING 0 VERB T
The 0 DET T
practices 0 NOUN F
of 0 ADP F
2 0 NUM F
university-affiliated 0 VERB F
family 0 NOUN F
medicine 0 NOUN F
centers 0 NOUN F
( 0 PUNCT F
8 0 NUM F
physicians 0 NOUN F
each 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
14 0 NUM F
community-based 0 VERB F
family 0 NOUN F
physicians 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2 0 NUM F
cardiologists 0 NOUN F
. 0 PUNCT F

PATIENTS 0 ADP T
Sixty-four 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
nonvalvular 0 ADJ F
atrial 0 ADJ F
fibrillation 0 NOUN F
who 0 ADP F
were 0 VERB F
initiated 0 VERB F
with 0 ADP F
warfarin 0 NOUN F
therapy 0 NOUN F
at 0 ADP F
least 0 ADV F
3 0 NUM F
months 0 NOUN F
before 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

INTERVENTION 0 NOUN T
During 0 ADP T
each 0 DET F
interview 0 NOUN F
, 0 PUNCT F
the 0 DET F
patients 0 NOUN F
' 0 PUNCT F
MCIDs 0 ADV T
were 0 VERB F
determined 0 VERB F
by 0 ADP F
using 0 SYM F
( 0 PUNCT F
1 0 NUM F
) 0 PUNCT F
a 0 DET F
pictorial B-OTHER ADJ F
flip I-OTHER NOUN F
chart I-OTHER PUNCT F
to I-OTHER ADJ F
describe I-OTHER NOUN F
atrial 0 ADJ F
fibrillation B-PHYSICAL NOUN F
; 0 PUNCT F
the 0 DET F
consequences 0 NOUN F
of 0 ADP F
a B-PHYSICAL DET F
minor I-PHYSICAL ADJ F
stroke B-PHYSICAL NOUN F
, 0 PUNCT F
a B-PHYSICAL DET F
major B-PHYSICAL ADJ F
stroke I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
a B-PHYSICAL DET F
major I-PHYSICAL ADJ F
bleeding I-PHYSICAL ADJ F
episode I-PHYSICAL NOUN F
; 0 PUNCT F
the 0 DET F
chance 0 NOUN F
of 0 ADP F
stroke B-PHYSICAL NOUN F
if I-PHYSICAL ADP F
not I-PHYSICAL PUNCT F
taking I-PHYSICAL CCONJ F
warfarin I-PHYSICAL NOUN F
; 0 PUNCT F
the 0 DET F
chance 0 NOUN F
of 0 ADP F
a 0 DET F
major B-PHYSICAL ADJ F
bleeding B-PHYSICAL ADJ F
episode I-PHYSICAL NOUN F
if I-PHYSICAL PUNCT F
taking B-PHYSICAL PUNCT F
warfarin I-PHYSICAL NOUN F
; 0 PUNCT F
examples 0 NOUN F
of 0 ADP F
the 0 DET F
inconvenience B-OTHER NOUN F
, 0 PUNCT F
minor B-PHYSICAL ADJ F
side I-PHYSICAL NOUN F
effects I-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
costs 0 NOUN F
of B-OTHER ADP F
warfarin I-OTHER NOUN F
therapy I-OTHER NOUN F
; 0 PUNCT F
and 0 CCONJ F
then 0 ADV F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
1 0 NUM F
of 0 ADP F
the 0 DET F
2 0 NUM F
elicitation 0 NOUN F
methods 0 NOUN F
to 0 PART F
determine 0 NOUN F
their 0 ADP F
MCIDs B-OTHER NOUN T
( 0 PUNCT F
the B-OTHER DET F
smallest I-OTHER ADV F
reduction I-OTHER NOUN F
in I-OTHER ADP F
stroke B-OTHER NOUN F
risk 0 NOUN F
at B-OTHER ADP F
which I-OTHER ADP F
the I-OTHER DET F
patients B-OTHER NOUN F
were I-OTHER VERB F
willing I-OTHER ADP F
to I-OTHER ADV F
take B-OTHER ADJ F
warfarin B-OTHER NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients B-MENTAL NOUN T
' 0 PUNCT F
knowledge B-MENTAL NOUN F
of I-MENTAL ADP F
their I-MENTAL ADJ F
stroke B-MENTAL NOUN F
risk B-MENTAL NOUN F
, 0 PUNCT F
acceptability B-OTHER NOUN F
of I-OTHER ADP F
the I-OTHER DET F
interview I-OTHER NOUN F
process I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
factors B-OTHER NOUN F
determining I-OTHER VERB F
their I-OTHER PUNCT F
preferences B-OTHER NOUN F
were 0 NUM F
also 0 ADV F
assessed 0 VERB F
. 0 PUNCT F

MAIN 0 ADJ T
RESULTS 0 NOUN T
Given 0 PROPN T
a 0 DET F
baseline 0 NOUN F
risk 0 NOUN F
of 0 ADP F
having 0 VERB F
a 0 DET F
stroke 0 NOUN F
in 0 ADP F
the 0 DET F
next 0 ADJ F
2 0 NUM F
years 0 NOUN F
, 0 PUNCT F
if 0 CCONJ F
not 0 PUNCT F
taking 0 CCONJ F
warfarin 0 NOUN F
, 0 PUNCT F
of 0 ADP F
10 0 NUM F
of 0 ADP F
100 0 NUM F
, 0 PUNCT F
the 0 DET F
mean 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
hypoxemia 0 NOUN F
on 0 ADP F
cardiac 0 ADJ F
output 0 NOUN F
. 0 PUNCT F

A 0 DET T
dose-response 0 NOUN F
curve 0 NOUN F
. 0 PUNCT F

To 0 PART T
establish 0 ADJ F
a 0 DET F
dose-response 0 NOUN F
curve 0 NOUN F
for 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
isocapnic 0 ADJ F
hypoxemia 0 NOUN F
on 0 ADP F
cardiac B-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CO I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
, 0 PUNCT F
we 0 PRON F
studied 0 VERB F
20 0 NUM F
healthy 0 ADJ F
men 0 NOUN F
, 0 PUNCT F
aged 0 ADP F
20 0 NUM F
to 0 ADP F
34 0 NUM F
years 0 NOUN F
, 0 PUNCT F
using 0 VERB F
a 0 DET F
tight-fitting 0 VERB F
face 0 NOUN F
mask 0 NOUN F
and 0 CCONJ F
an 0 DET F
isocapnic 0 ADJ F
partial 0 ADJ F
rebreathing 0 VERB F
system 0 NOUN F
( 0 PUNCT F
a 0 DET F
modified 0 VERB F
anesthesia 0 NOUN F
machine 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

We 0 PRON T
blended 0 VERB F
oxygen 0 NOUN F
and 0 CCONJ F
hypoxic 0 ADJ F
gas 0 NOUN F
to 0 PART F
achieve 0 NOUN F
arterial 0 ADJ F
oxygen 0 NOUN F
saturations 0 NOUN F
( 0 PUNCT F
SaO2 0 NOUN T
) 0 PUNCT F
of 0 ADP F
80 0 NUM F
, 0 PUNCT F
85 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
90 0 NUM F
percent 0 NOUN F
; 0 PUNCT F
subjects 0 NOUN F
also 0 ADV F
breathed 0 PUNCT F
100 0 NUM F
percent 0 NOUN F
oxygen 0 NOUN F
and 0 CCONJ F
room 0 NOUN F
air 0 NOUN F
( 0 PUNCT F
RA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Target 0 NOUN T
SaO2 0 NOUN T
and 0 CCONJ F
end-tidal 0 PUNCT F
carbon 0 NOUN F
dioxide 0 NOUN F
were 0 VERB F
continuously 0 ADV F
monitored 0 VERB F
using 0 VERB F
an 0 DET F
ear 0 NOUN F
oximeter 0 NOUN F
and 0 CCONJ F
CO2 0 NOUN T
gas 0 NOUN F
analyzer 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
experienced 0 VERB F
the 0 DET F
five 0 NUM F
SaO2 0 NOUN T
measurements 0 NOUN F
in 0 ADP F
random 0 ADJ F
order 0 NOUN F
. 0 PUNCT F

CO B-PHYSICAL NOUN T
was 0 VERB F
measured 0 VERB F
noninvasively 0 ADV F
at 0 ADP F
approximately 0 ADV F
two-minute 0 ADJ F
intervals 0 NOUN F
, 0 PUNCT F
using 0 SYM F
continuous-wave 0 PUNCT F
Doppler 0 NOUN T
echocardiography 0 NOUN F
. 0 PUNCT F

Mean 0 DET T
cardiac B-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
increased 0 VERB F
with 0 ADP F
increasing 0 ADJ F
hypoxemia B-PHYSICAL NOUN F
from 0 ADP F
6.84 0 NUM F
L/min 0 NOUN T
at 0 ADP F
FIo2 0 NOUN T
1.0 0 NUM F
to 0 ADP F
8.44 0 NUM F
L/min 0 NOUN T
at 0 ADP F
SaO2 0 NOUN T
80 0 NUM F
percent 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.0005 0 NUM F
) 0 PUNCT F
; 0 PUNCT F
the 0 DET F
increase 0 NOUN F
was 0 VERB F
entirely 0 ADV F
due 0 CCONJ F
to 0 ADP F
increased 0 NOUN F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

We 0 PRON T
concluded 0 VERB F
that 0 ADP F
cardiac B-PHYSICAL ADJ F
output I-PHYSICAL NOUN F
increases 0 PART F
significantly 0 ADV F
in 0 ADP F
a 0 DET F
dose-response 0 NOUN F
manner 0 NOUN F
in 0 ADP F
response 0 NOUN F
to 0 ADP F
acute 0 ADJ F
isocapnic 0 ADJ F
hypoxemia 0 NOUN F
in 0 ADP F
normal 0 ADJ F
persons 0 NOUN F
. 0 PUNCT F

Cyclosporin 0 NOUN T
versus 0 CCONJ F
cyclophosphamide 0 NOUN F
for 0 ADP F
patients 0 NOUN F
with 0 ADP F
steroid-dependent 0 ADJ F
and 0 CCONJ F
frequently 0 ADV F
relapsing 0 VERB F
idiopathic 0 ADJ F
nephrotic 0 ADJ F
syndrome 0 NOUN F
: 0 PUNCT F
a 0 DET F
multicentre 0 NOUN F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
( 0 PUNCT F
maintenance B-OTHER NOUN F
of I-OTHER ADP F
remission I-OTHER NOUN F
) 0 PUNCT F
, 0 PUNCT F
safety B-OTHER NOUN F
and 0 CCONJ F
tolerability B-OTHER NOUN F
of 0 ADP F
cyclosporin 0 NOUN F
( 0 PUNCT F
CsA 0 NOUN T
) 0 PUNCT F
with 0 ADP F
those 0 PUNCT F
of 0 ADP F
cyclophosphamide 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
steroid-dependent 0 ADJ F
or 0 CCONJ F
frequently 0 ADV F
relapsing 0 VERB F
nephrotic 0 ADJ F
syndrome 0 NOUN F
( 0 PUNCT F
NS 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
Open 0 VERB T
, 0 PUNCT F
prospective 0 ADJ F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
multicentre 0 NOUN F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
for 0 ADP F
parallel 0 PUNCT F
groups 0 NOUN F
, 0 PUNCT F
stratified 0 VERB F
for 0 ADP F
adults 0 NOUN F
and 0 CCONJ F
children 0 NOUN F
. 0 PUNCT F

The 0 DET T
setting 0 VERB F
was 0 VERB F
in 0 ADP F
nephrological 0 ADJ F
departments 0 NOUN F
in 0 ADP F
Italy 0 PUNCT T
. 0 PUNCT F

SUBJECTS 0 NOUN T
AND 0 CCONJ T
INTERVENTIONS 0 NOUN T
Seventy-three 0 NUM T
patients 0 NOUN F
with 0 ADP F
steroid-sensitive 0 ADJ F
idiopathic 0 ADJ F
NS 0 NOUN T
admitted 0 VERB F
to 0 ADP F
the 0 DET F
study 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
2.5 0 ADP F
mg/kg/day 0 NOUN F
) 0 PUNCT F
for 0 ADP F
8 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
CsA 0 NOUN T
( 0 PUNCT F
5 0 NUM F
mg/kg/day 0 PUNCT F
in 0 ADP F
adults 0 NOUN F
, 0 PUNCT F
6 0 NUM F
mg/kg/day 0 PUNCT F
in 0 ADP F
children 0 NOUN F
) 0 PUNCT F
for 0 ADP F
9 0 NUM F
months 0 NOUN F
, 0 PUNCT F
tapered 0 CCONJ F
off 0 PUNCT F
by 0 ADP F
25 0 NUM F
% 0 SYM F
every 0 DET F
month 0 NOUN F
until 0 ADP F
complete 0 ADJ F
discontinuation 0 NOUN F
at 0 ADP F
month 0 NOUN F
12 0 NUM F
. 0 PUNCT F

Seven 0 NUM T
patients 0 NOUN F
lost 0 ADJ F
to 0 ADP F
follow 0 ADV F
up 0 PUNCT F
were 0 ADV F
not 0 ADV F
considered 0 PUNCT F
in 0 ADP F
the 0 DET F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
remaining 0 VERB F
66 0 NUM F
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
up 0 ADJ F
for 0 ADP F
3-24 0 NUM F
months 0 NOUN F
after 0 ADP F
randomization 0 NOUN F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Relapse-free B-MORTALITY PUNCT T
survival I-MORTALITY NOUN F
; 0 PUNCT F
number 0 NOUN F
of 0 ADP F
N.S 0 NOUN T
. 0 PUNCT F

relapses/patient/year B-PHYSICAL ADJ F
; 0 PUNCT F
cumulative B-OTHER ADJ F
dose I-OTHER NOUN F
of I-OTHER ADP F
prednisone/patient I-OTHER ADJ F
; 0 PUNCT F
laboratory B-PHYSICAL NOUN F
investigations I-PHYSICAL NOUN F
( 0 PUNCT F
kidney B-PHYSICAL NOUN F
and 0 CCONJ F
liver B-PHYSICAL NOUN F
functions I-PHYSICAL NOUN F
, 0 PUNCT F
haematological B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
) 0 PUNCT F
; 0 PUNCT F
incidence 0 NOUN F
of 0 PUNCT F

Enhancing 0 ADP T
the 0 DET F
self-esteem B-MENTAL CCONJ F
of 0 ADP F
inpatient 0 NOUN F
alcoholics 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
examined 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
pairing 0 VERB F
inpatient 0 NOUN F
alcoholics 0 NOUN F
with 0 ADP F
nursing 0 VERB F
home 0 NOUN F
residents 0 NOUN F
( 0 PUNCT F
NHRs 0 ADJ T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
alcoholics B-MENTAL ADJ F
' 0 PUNCT F
self-esteem B-MENTAL CCONJ F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
PALS 0 PUNCT T
program 0 NOUN F
, 0 PUNCT F
the 0 DET F
alcoholic 0 ADJ F
inpatients 0 NOUN F
assumed 0 VERB F
a 0 DET F
helping-companion 0 NOUN F
relationship 0 NOUN F
with 0 ADP F
the 0 DET F
NHRs 0 PUNCT T
for 0 ADP F
2 0 NUM F
hr 0 NOUN F
per 0 ADP F
day 0 NOUN F
during 0 ADP F
their 0 ADP F
last 0 ADJ F
2 0 NUM F
weeks 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Fifty 0 NUM T
alcoholic 0 ADJ F
inpatients 0 NOUN F
were 0 ADJ F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
PALS 0 PUNCT T
program 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
25 0 NUM F
) 0 PUNCT F
or 0 CCONJ F
to 0 ADP F
the 0 DET F
library 0 NOUN F
for 0 ADP F
free 0 ADJ F
reading 0 PART F
time 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
25 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
Tennessee 0 PUNCT T
Self-Concept 0 PUNCT T
Scale 0 NOUN T
( 0 PUNCT F
TSCS 0 NOUN T
) 0 PUNCT F
was 0 VERB F
administered 0 VERB F
to 0 ADP F
all 0 DET F
subjects 0 NOUN F
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
interventions 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
nine 0 NUM F
TSCS B-MENTAL NOUN T
scales I-MENTAL NOUN F
, 0 PUNCT F
the 0 DET F
improvement 0 NOUN F
on 0 ADP F
the 0 DET F
Moral-Ethical B-MENTAL PUNCT T
scale I-MENTAL NOUN F
was 0 VERB F
significantly 0 ADV F
greater 0 PUNCT F
in 0 ADP F
the 0 DET F
PALS 0 PUNCT T
group 0 NOUN F
. 0 PUNCT F

Because 0 PUNCT T
the 0 DET F
alcoholic 0 ADJ F
inpatients 0 NOUN F
in 0 ADP F
the 0 DET F
PALS 0 PUNCT T
group 0 NOUN F
engaged 0 PUNCT F
in 0 PUNCT F

Information 0 NOUN T
source 0 NOUN F
affects 0 NOUN F
peers 0 NOUN F
' 0 PUNCT F
initial 0 ADJ F
attitudes 0 NOUN F
toward 0 ADP F
autism B-PHYSICAL NOUN F
. 0 PUNCT F

Authors 0 NOUN T
examined 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
information 0 NOUN F
source 0 NOUN F
on 0 ADP F
peers 0 NOUN F
' 0 PUNCT F
cognitive B-MENTAL ADJ F
and I-MENTAL CCONJ F
behavioral I-MENTAL ADJ F
attitudes I-MENTAL NOUN F
toward 0 ADP F
an 0 DET F
unfamiliar 0 ADJ F
child 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
( 0 PUNCT F
N=296 0 NOUN T
; 0 PUNCT F
M 0 NOUN T
age=10.21 0 PUNCT F
years 0 NOUN F
) 0 PUNCT F
received 0 ADP F
information 0 NOUN F
about 0 PUNCT F
an 0 DET F
unfamiliar 0 ADJ F
child 0 NOUN F
with 0 ADP F
autism 0 NOUN F
from 0 ADP F
one 0 NUM F
of 0 ADP F
the 0 DET F
following 0 PUNCT F
sources 0 NOUN F
: 0 PUNCT F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
videotape 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
teacher 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
hypothetical 0 ADJ F
mother 0 NOUN F
, 0 PUNCT F
( 0 PUNCT F
d 0 NOUN F
) 0 PUNCT F
hypothetical 0 ADJ F
father 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
( 0 PUNCT F
e 0 NOUN F
) 0 PUNCT F
hypothetical 0 ADJ F
doctor 0 NOUN F
. 0 PUNCT F

Interactive 0 ADJ T
effects 0 NOUN F
between 0 ADP F
source 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
sex 0 NOUN F
and 0 CCONJ F
grade 0 NOUN F
were 0 VERB F
found 0 VERB F
for 0 ADP F
cognitive 0 ADJ F
and 0 CCONJ F
behavioral 0 ADJ F
attitudes 0 NOUN F
. 0 PUNCT F

Fifth-graders 0 NOUN T
reported 0 PUNCT F
more 0 ADV F
favorable 0 ADJ F
cognitive B-MENTAL ADJ F
and I-MENTAL CCONJ F
behavioral I-MENTAL ADJ F
attitudes I-MENTAL NOUN F
when 0 ADP F
information 0 NOUN F
was 0 VERB F
provided 0 VERB F
by 0 ADP F
extra-familial 0 PUNCT F
sources 0 NOUN F
( 0 PUNCT F
i.e. 0 CCONJ F
, 0 PUNCT F
doctor 0 NOUN F
) 0 PUNCT F
versus 0 CCONJ F
parent 0 NOUN F
sources 0 NOUN F
. 0 PUNCT F

Mother 0 NOUN T
yielded 0 VERB F
more 0 ADV F
persuasive B-MENTAL ADJ F
effects I-MENTAL NOUN F
on I-MENTAL ADP F
behavioral I-MENTAL ADJ F
attitudes I-MENTAL NOUN F
for 0 ADP F
third-graders 0 NOUN F
versus 0 CCONJ F
fifth-graders 0 NOUN F
. 0 PUNCT F

Attitudes 0 NOUN T
toward 0 ADP F
autism 0 NOUN F
differ 0 VERB F
depending 0 PUNCT F
on 0 ADP F
who 0 ADP F
provides 0 NOUN F
information 0 NOUN F
about 0 PUNCT F
the 0 DET F
disability 0 NOUN F
. 0 PUNCT F

Persuasion 0 NOUN T
theory 0 NOUN F
appears 0 NOUN F
useful 0 ADJ F
to 0 PART F
guide 0 NOUN F
evaluation 0 NOUN F
of 0 ADP F
educational 0 ADJ F
interventions 0 NOUN F
to 0 PROPN F
improve 0 ADP F
attitudes 0 NOUN F
towards 0 ADP F
autism B-MENTAL NOUN F
. 0 PUNCT F

Implications 0 NOUN T
of 0 ADP F
the 0 DET F
findings 0 NOUN F
, 0 PUNCT F
study 0 PUNCT F
limitations 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
recommendations 0 NOUN F
for 0 ADP F
future 0 ADJ F
research 0 NOUN F
are 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

Effect 0 NOUN T
of 0 ADP F
a 0 DET F
multi-faceted 0 VERB F
intervention 0 NOUN F
on 0 ADP F
gingival B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
among 0 ADP F
adults 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
sclerosis 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
evaluate B-OTHER NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
adaptive 0 ADJ F
oral 0 ADJ F
hygiene 0 NOUN F
devices 0 NOUN F
and 0 CCONJ F
orofacial 0 ADP F
exercise 0 NOUN F
to 0 PART F
improve 0 PUNCT F
gingival B-PHYSICAL ADJ F
health I-PHYSICAL NOUN F
among 0 ADP F
adults 0 NOUN F
with 0 ADP F
systemic 0 ADJ F
sclerosis 0 NOUN F
( 0 PUNCT F
SSc 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Forty-eight 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
SSc 0 NOUN T
were 0 VERB F
assigned 0 VERB F
randomly 0 ADV F
to 0 ADP F
the 0 DET F
multifaceted 0 ADP F
oral 0 ADJ F
health 0 NOUN F
intervention 0 NOUN F
or 0 CCONJ F
usual 0 ADJ F
dental 0 ADJ F
care 0 NOUN F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
in 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
received 0 VERB F
a 0 DET F
rechargeable 0 PUNCT F
, 0 PUNCT F
powered 0 ADJ F
Oral-B? 0 NOUN T
oscillating-rotating-pulsating 0 NOUN F
toothbrush 0 NOUN F
and 0 CCONJ F
a 0 DET F
Reach? 0 NOUN T
Access? 0 NOUN T
Flosser 0 NOUN T
that 0 PUNCT F
has 0 ADJ F
a 0 DET F
toothbrush-like 0 ADJ F
handle 0 NOUN F
. 0 PUNCT F

For 0 ADP T
those 0 PUNCT F
with 0 ADP F
an 0 DET F
oral 0 ADJ F
aperture 0 ADJ F
of 0 ADP F
less 0 ADV F
than 0 ADP F
40 0 NUM F
mm 0 NOUN F
, 0 PUNCT F
orofacial 0 ADP F
exercises 0 NOUN F
were 0 VERB F
taught 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
were 0 VERB F
each 0 DET F
given 0 VERB F
a 0 DET F
manual 0 ADJ F
toothbrush 0 NOUN F
and 0 CCONJ F
dental 0 ADJ F
floss 0 ADP F
. 0 PUNCT F

Participants 0 NOUN T
in 0 ADP F
both 0 CCONJ F
groups 0 NOUN F
received 0 VERB F
instructions 0 NOUN F
and 0 CCONJ F
demonstration 0 NOUN F
on 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
the 0 DET F
devices 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
were 0 VERB F
requested 0 VERB F
to 0 PART F
perform 0 NOUN F
the 0 DET F
respective 0 ADJ F
intervention 0 NOUN F
twice 0 ADV F
a 0 DET F
day 0 NOUN F
for 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Evaluations 0 NOUN T
were 0 VERB F
at 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
3- 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
6-months 0 NOUN F
. 0 PUNCT F

The 0 DET T
main 0 ADJ F
outcome 0 NOUN F
was 0 VERB F
gingival B-PHYSICAL ADJ F
index 0 NOUN F
( B-PHYSICAL PUNCT F
GI I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
, 0 PUNCT F
an 0 DET F
indicator 0 NOUN F
of 0 ADP F
gingival 0 ADJ F
inflammation 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Both 0 PUNCT T
groups 0 NOUN F
showed 0 VERB F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
GI 0 NOUN T
scores 0 NOUN F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
ps 0 NOUN F
< 0 SYM F
0.005 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Reduction 0 NOUN T
in 0 ADP F
GI 0 NOUN T
scores 0 NOUN F
of 0 ADP F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
was 0 VERB F
20.8 0 NUM F
% 0 SYM F
which 0 ADP F
is 0 VERB F
considered 0 VERB F
to 0 PART F
be 0 PUNCT F
clinically 0 ADV F
significant 0 ADJ F
. 0 PUNCT F

Compared 0 VERB T
to 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
intervention 0 NOUN F
group 0 NOUN F
showed 0 VERB F
a 0 DET F
significant 0 ADJ F
and 0 CCONJ F
larger 0 PUNCT F
reduction 0 NOUN F
in 0 ADP F
GI 0 NOUN T
score 0 NOUN F
by 0 ADP F
8 0 NUM F
% 0 SYM F
at 0 ADP F
6 0 NUM F
months 0 NOUN F
( 0 PUNCT F
p=0.0007 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 DET T
Results 0 ADJ T
support 0 VERB F
the 0 DET F
use 0 NOUN F
of 0 ADP F
adaptive 0 ADJ F
devices 0 NOUN F
and 0 CCONJ F
orofacial 0 ADP F
exercise 0 NOUN F
to 0 PUNCT F
improve 0 PUNCT F

Monitoring 0 ADV T
tumour 0 NOUN F
cells 0 NOUN F
in 0 ADP F
the 0 DET F
peripheral 0 ADJ F
blood 0 NOUN F
of 0 ADP F
small 0 ADJ F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Flow 0 NOUN T
cytometry 0 NOUN F
was 0 VERB F
used 0 VERB F
to 0 PUNCT F
enumerate 0 ADJ F
tumour 0 NOUN F
cells 0 NOUN F
in 0 ADP F
longitudinal 0 ADJ F
studies 0 NOUN F
of 0 ADP F
peripheral 0 ADJ F
blood 0 NOUN F
from 0 ADP F
small 0 ADJ F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
( 0 PUNCT F
SCLC 0 NOUN T
) 0 PUNCT F
patients 0 NOUN F
, 0 PUNCT F
together 0 ADV F
with 0 ADP F
magnetic 0 ADJ F
bead 0 NOUN F
selection 0 NOUN F
to 0 ADJ F
isolate 0 NOUN F
and 0 CCONJ F
identify 0 ADJ F
these 0 DET F
cells 0 NOUN F
. 0 PUNCT F

As 0 ADP T
part 0 NOUN F
of 0 ADP F
a 0 DET F
trial 0 NOUN F
, 0 PUNCT F
11 0 NUM F
patients 0 NOUN F
received 0 VERB F
either 0 CCONJ F
standard 0 ADJ F
( 0 PUNCT F
four 0 NUM F
weekly 0 ADV F
) 0 PUNCT F
chemotherapy 0 NOUN F
with 0 ADP F
ifosfamide 0 PUNCT F
, 0 PUNCT F
carboplatin 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
etoposide 0 NOUN F
( 0 PUNCT F
ICE 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
accelerated 0 VERB F
( 0 PUNCT F
two 0 NUM F
weekly 0 ADV F
) 0 PUNCT F
ICE 0 NOUN T
with 0 ADP F
filgrastim 0 NOUN F
( 0 PUNCT F
granulocyte 0 NOUN F
colony-stimulating 0 VERB F
factor 0 NOUN F
[ 0 PUNCT F
G-CSF 0 NOUN T
] 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
autologous 0 ADJ F
stem 0 NOUN F
cell 0 NOUN F
support 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Fresh 0 ADJ T
venous 0 ADJ F
blood 0 NOUN F
was 0 VERB F
taken 0 VERB F
throughout 0 ADP F
treatment 0 NOUN F
and 0 CCONJ F
follow-up 0 NOUN F
. 0 PUNCT F

Aliquots 0 NOUN T
were 0 VERB F
stained 0 VERB F
with 0 ADP F
a 0 DET F
tumour-specific 0 ADJ F
antibody 0 NOUN F
against 0 ADP F
epithelial 0 ADJ F
tissue 0 NOUN F
( 0 PUNCT F
Ber 0 NOUN T
EP4 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
verified 0 VERB F
as 0 ADP F
a 0 DET F
good 0 ADJ F
marker 0 NOUN F
of 0 ADP F
SCLC 0 NOUN T
cells 0 NOUN F
by 0 ADP F
immunohistochemistry 0 NOUN F
. 0 PUNCT F

Matched 0 VERB T
samples 0 NOUN F
labelled 0 VERB F
with 0 ADP F
Ber 0 NOUN T
EP4 0 NOUN T
were 0 VERB F
separated 0 VERB F
magnetically 0 ADV F
by 0 ADP F
adding 0 VERB F
a 0 DET F
secondary 0 ADJ F
bead-antibody 0 NOUN F
conjugate 0 ADP F
for 0 ADP F
confirmation 0 NOUN F
of 0 ADP F
tumour 0 NOUN F
cell 0 NOUN F
identity 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Circulating B-PHYSICAL ADP T
tumour I-PHYSICAL NOUN F
cells I-PHYSICAL NOUN F
were 0 VERB F
detected 0 VERB F
and 0 CCONJ F
monitored 0 VERB F
throughout 0 ADP F
treatment 0 NOUN F
periods 0 NOUN F
. 0 PUNCT F

An 0 DET T
initial 0 ADJ F
rise 0 NOUN F
in 0 ADP F
circulating B-PHYSICAL VERB F
cells I-PHYSICAL NOUN F
after 0 ADP F
the 0 DET F
first 0 ADJ F
cycle 0 NOUN F
was 0 VERB F
followed 0 VERB F
by 0 ADP F
a 0 DET F
fall 0 NOUN F
in 0 ADP F
both 0 CCONJ F
treatment 0 NOUN F
arms 0 NOUN F
to 0 ADP F
baseline 0 NOUN F
levels 0 NOUN F
set 0 PUNCT F
by 0 ADP F
normal 0 ADJ F
controls 0 NOUN F
. 0 PUNCT F

This 0 DET T
was 0 VERB F
achieved 0 VERB F
by 0 ADP F
week 0 NOUN F
12 0 NUM F
in 0 ADP F
the 0 DET F
accelerated 0 VERB F
treatment 0 NOUN F
arm 0 NOUN F
and 0 CCONJ F
by 0 ADP F
week 0 NOUN F
24 0 NUM F
in 0 ADP F
the 0 DET F
standard 0 ADJ F
arm 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Flow 0 NOUN T
cytometry 0 NOUN F
and 0 CCONJ F
magnetic 0 ADJ F
bead 0 NOUN F
isolation 0 NOUN F
can 0 PROPN F
be 0 VERB F
used 0 VERB F
to 0 PART F
identify 0 NOUN F
changes 0 NOUN F
in 0 ADP F
numbers 0 NOUN F
of 0 ADP F
circulating 0 VERB F
tumour 0 NOUN F
cells 0 NOUN F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
chemotherapy 0 NOUN F
for 0 ADP F
SCLC 0 NOUN T
and 0 CCONJ F
thereafter 0 ADV F
during 0 ADP F
follow-up 0 NOUN F
periods 0 NOUN F
. 0 PUNCT F

Absence 0 NOUN T
of 0 ADP F
tumour 0 NOUN F
cells 0 NOUN F
may 0 VERB F
indicate 0 VERB F
a 0 DET F
more 0 ADV F
favourable 0 ADJ F
patient 0 NOUN F
group 0 NOUN F
who 0 DET F
would 0 VERB F
benefit 0 VERB F
from 0 ADP F
a 0 DET F
more 0 DET F
intense 0 ADJ F
course 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

Behavioral B-MENTAL ADJ T
effects I-MENTAL NOUN F
of 0 ADP F
Org 0 PUNCT T
2766 0 NUM F
, 0 PUNCT F
a 0 DET F
synthetic 0 ADJ F
analog 0 NOUN F
of 0 ADP F
the 0 DET F
adrenocorticotrophic 0 ADJ F
hormone 0 NOUN F
( 0 PUNCT F
4-9 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
in 0 ADP F
14 0 NUM F
outpatient 0 ADJ F
autistic 0 ADJ F
children 0 NOUN F
. 0 PUNCT F

Fourteen 0 NUM T
children 0 NOUN F
( 0 PUNCT F
12 0 NUM F
infantile 0 ADJ F
autism 0 NOUN F
full 0 ADJ F
syndrome 0 NOUN F
present 0 VERB F
, 0 PUNCT F
2 0 NUM F
atypical 0 ADJ F
pervasive 0 ADJ F
developmental 0 ADJ F
disorder 0 NOUN F
) 0 PUNCT F
between 0 ADP F
5 0 NUM F
and 0 CCONJ F
13 0 NUM F
years 0 NOUN F
of 0 ADP F
age 0 NOUN F
participated 0 PUNCT F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
placebo-controlled 0 VERB F
cross-over 0 NOUN F
trial 0 NOUN F
. 0 PUNCT F

Each 0 DET T
child 0 NOUN F
received 0 VERB F
20 0 NUM F
mg 0 NOUN F
Org 0 PUNCT T
2766 0 NUM F
( 0 PUNCT F
synthetic 0 ADJ F
analog 0 NOUN F
of 0 ADP F
ACTH 0 NOUN T
4-9 0 PUNCT F
) 0 PUNCT F
/day 0 NOUN F
during 0 ADP F
4 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
in 0 ADP F
a 0 DET F
randomly 0 ADV F
assigned 0 PUNCT F
sequence 0 NOUN F
. 0 PUNCT F

Drug B-MENTAL NOUN T
effects I-MENTAL NOUN F
were 0 VERB F
monitored 0 VERB F
by 0 ADP F
ethological B-MENTAL CCONJ F
playroom I-MENTAL NOUN F
observation I-MENTAL NOUN F
and 0 CCONJ F
by 0 ADP F
Aberrant B-MENTAL ADJ T
Behavior I-MENTAL NOUN T
Checklist I-MENTAL NOUN T
ratings I-MENTAL NOUN F
by 0 ADP F
parents 0 NOUN F
and 0 CCONJ F
teachers 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
of 0 ADP F
the 0 DET F
playroom 0 CCONJ F
observation 0 NOUN F
pointed 0 PRON F
to 0 ADP F
an 0 DET F
activating B-MENTAL VERB F
influence I-MENTAL NOUN F
of 0 ADP F
Org 0 PUNCT T
2766 0 NUM F
, 0 PUNCT F
as 0 PUNCT F
revealed 0 VERB F
by 0 ADP F
a 0 DET F
significant 0 ADJ F
decrease 0 NOUN F
of 0 ADP F
stereotypic B-MENTAL ADJ F
behavior I-MENTAL NOUN F
and 0 CCONJ F
significant 0 ADJ F
increases 0 NOUN F
in 0 ADP F
change B-MENTAL NUM F
toys I-MENTAL NOUN F
, 0 PUNCT F
locomote B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
talk B-MENTAL NOUN F
. 0 PUNCT F

Checklist 0 NOUN T
ratings 0 NOUN F
did 0 CCONJ F
not 0 ADV F
show 0 VERB F
significant 0 ADJ F
changes 0 NOUN F
. 0 PUNCT F

The 0 DET T
clinical 0 ADJ F
implications 0 NOUN F
of 0 ADP F
these 0 DET F
findings 0 NOUN F
are 0 VERB F
discussed 0 VERB F
. 0 PUNCT F

Controlled 0 VERB T
clinical 0 ADJ F
trial 0 NOUN F
of 0 ADP F
IV 0 NUM T
cyclophosphamide 0 NOUN F
versus 0 CCONJ F
IV 0 NUM T
methylprednisolone 0 NUM F
in 0 ADP F
severe 0 ADJ F
neurological 0 ADJ F
manifestations 0 NOUN F
in 0 ADP F
systemic 0 ADJ F
lupus 0 NOUN F
erythematosus 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Severe 0 ADJ T
neurological 0 ADJ F
involvement 0 NOUN F
in 0 ADP F
systemic 0 ADJ F
lupus 0 NOUN F
erythematosus 0 NOUN F
( 0 PUNCT F
NPSLE 0 NOUN T
) 0 PUNCT F
is 0 VERB F
one 0 NUM F
of 0 ADP F
the 0 DET F
most 0 PUNCT F
dreadful 0 ADJ F
complications 0 NOUN F
of 0 ADP F
the 0 DET F
disease 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
identify 0 NOUN F
the 0 DET F
best 0 PUNCT F
drug 0 NOUN F
, 0 PUNCT F
dose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
treatment 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
The 0 DET T
study 0 NOUN F
was 0 ADV F
a 0 DET F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
at 0 ADP F
two 0 NUM F
tertiary 0 ADJ F
care 0 NOUN F
centres 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
SLE 0 NOUN T
according 0 PUNCT F
to 0 ADP F
the 0 DET F
ACR 0 NOUN T
criteria 0 NOUN F
, 0 PUNCT F
with 0 ADP F
incident 0 ADJ F
( 0 PUNCT F
no 0 ADP F
more 0 ADV F
than 0 ADP F
15 0 DET F
days 0 NOUN F
) 0 PUNCT F
onset 0 NOUN F
of 0 ADP F
severe 0 ADJ F
NP 0 NOUN T
manifestations 0 NOUN F
such 0 CCONJ F
as 0 ADP F
seizures 0 NOUN F
, 0 PUNCT F
optic 0 ADJ F
neuritis 0 NOUN F
, 0 PUNCT F
peripheral 0 ADJ F
or 0 CCONJ F
cranial 0 ADJ F
neuropathy 0 NOUN F
, 0 PUNCT F
coma 0 NOUN F
, 0 PUNCT F
brainstem 0 NOUN F
disease 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
transverse 0 ADJ F
myelitis 0 NOUN F
. 0 PUNCT F

Induction 0 NOUN T
treatment 0 NOUN F
with 0 ADP F
3 0 NUM F
g 0 NOUN F
of 0 ADP F
IV 0 NUM T
methylprednisolone 0 NOUN F
( 0 PUNCT F
MP 0 NOUN T
) 0 PUNCT F
followed 0 VERB F
by 0 ADP F
either 0 CCONJ F
IV 0 NUM T
monthly 0 ADV F
cyclophosphamide 0 NOUN F
( 0 PUNCT F
Cy 0 NOUN T
) 0 PUNCT F
versus 0 CCONJ F
IV 0 NUM T
MP 0 NOUN T
bimonthly 0 PUNCT F
every 0 DET F
4 0 NUM F
months 0 NOUN F
for 0 ADP F
1 0 NUM F
year 0 NOUN F
and 0 CCONJ F
then 0 ADV F
IV 0 NUM T
Cy 0 NOUN T
or 0 CCONJ F
IV 0 NUM T
MP 0 NOUN T
every 0 DET F
3 0 NUM F
months 0 NOUN F
for 0 ADP F
another 0 DET F
year 0 NOUN F
. 0 PUNCT F

The 0 DET T
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
was 0 ADP F
response 0 NOUN F
to 0 ADP F
treatment B-PHYSICAL NOUN F
: 0 PUNCT F
at 0 VERB F
least 0 ADV F
20 0 NUM F
% B-PHYSICAL SYM F
improvement I-PHYSICAL NOUN F
from I-PHYSICAL ADP F
basal I-PHYSICAL ADJ F
conditions I-PHYSICAL NOUN F
on 0 ADP F
clinical 0 ADJ F
, 0 PUNCT F
laboratory 0 NOUN F
, 0 PUNCT F
or 0 CCONJ F
specific 0 ADJ F
neurological 0 ADJ F
testing 0 ADJ F
variables 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Overall 0 ADJ T
, 0 PUNCT F
a 0 DET F
response 0 NOUN F
rate B-PHYSICAL NOUN F
of 0 ADP F
75 0 NUM F
% 0 SYM F
was 0 VERB F
observed 0 VERB F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
32 0 NUM F
patients 0 NOUN F
studied 0 VERB F
, 0 PUNCT F
18/19 0 PUNCT F
receiving 0 DET F
Cy 0 NOUN T
and 0 CCONJ F
7/13 0 NOUN F
receiving 0 ADP F
MP 0 NOUN T
responded 0 VERB F
to 0 ADP F
treatment 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.03 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Cy 0 NOUN T
seems 0 NOUN F
to 0 DET F
be 0 PUNCT F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
MP 0 NOUN T
in 0 ADP F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
acute 0 ADJ F
, 0 PUNCT F
severe 0 ADJ F
NPSLE 0 NOUN T
. 0 PUNCT F

Acute 0 ADJ T
exposure 0 NOUN F
to 0 ADP F
acid 0 NOUN F
fog 0 NOUN F
: 0 PUNCT F
influence 0 NOUN F
of 0 ADP F
breathing 0 PUNCT F
pattern 0 NOUN F
on 0 ADP F
effective B-PHYSICAL ADJ F
dose I-PHYSICAL NOUN F
. 0 PUNCT F

Concern 0 ADJ T
about 0 ADP F
the 0 DET F
possible 0 ADJ F
adverse B-ADVERSE-EFFECTS ADJ F
health I-ADVERSE-EFFECTS NOUN F
effects I-ADVERSE-EFFECTS NOUN F
of 0 ADP F
acid 0 NOUN F
fog 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
fed 0 ADJ F
by 0 ADP F
two 0 NUM F
observations 0 NOUN F
: 0 PUNCT F
air 0 NOUN F
pollution 0 NOUN F
disasters 0 PUNCT F
earlier 0 PUNCT F
in 0 ADP F
this 0 DET F
century 0 NOUN F
were 0 VERB F
typically 0 ADV F
associated 0 VERB F
with 0 ADP F
fog 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
current 0 ADJ F
samples 0 NOUN F
of 0 ADP F
fog 0 NOUN F
water 0 NOUN F
can 0 VERB F
be 0 ADP F
strongly 0 ADV F
acid 0 NOUN F
. 0 PUNCT F

To 0 ADJ T
study 0 NOUN F
the 0 DET F
acute 0 ADJ F
effects 0 NOUN F
of 0 ADP F
acid 0 NOUN F
fog 0 NOUN F
on 0 ADP F
the 0 DET F
lung 0 NOUN F
, 0 PUNCT F
the 0 DET F
authors 0 NOUN F
generated 0 VERB F
a 0 DET F
monodisperse 0 ADJ F
10 0 NUM F
microM 0 NOUN F
MMAD 0 NOUN T
aerosol 0 NOUN F
of 0 ADP F
H2SO4 0 NOUN T
with 0 ADP F
a 0 DET F
pH 0 NOUN F
of 0 ADP F
2.0 0 NUM F
and 0 CCONJ F
a 0 DET F
nominal 0 ADJ F
concentration 0 NOUN F
of 0 ADP F
500 0 NUM F
micrograms/m3 0 NUM F
. 0 PUNCT F

They 0 PRON T
exposed 0 ADP F
seven 0 NUM F
healthy 0 ADJ F
young 0 ADJ F
men 0 NOUN F
on 0 ADP F
alternate 0 NOUN F
days 0 NOUN F
to 0 ADP F
acid 0 NOUN F
or 0 CCONJ F
control 0 NOUN F
equiosmolar 0 ADJ F
NaCl 0 NOUN T
aerosol 0 NOUN F
during 0 ADP F
40 0 NUM F
min 0 NOUN F
of 0 ADP F
resting 0 ADP F
ventilation 0 NOUN F
and 0 CCONJ F
20 0 NUM F
min 0 NOUN F
of 0 ADP F
exercise 0 NOUN F
; 0 PUNCT F
the 0 DET F
latter 0 NOUN F
was 0 VERB F
sufficiently 0 ADV F
intense 0 ADJ F
to 0 PART F
induce 0 NOUN F
oronasal B-PHYSICAL ADJ F
breathing I-PHYSICAL VERB F
. 0 PUNCT F

Exposure 0 NOUN T
was 0 VERB F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
a 0 DET F
head 0 NOUN F
dome 0 NOUN F
, 0 PUNCT F
a 0 DET F
head-only 0 PUNCT F
exposure 0 NOUN F
device 0 NOUN F
that 0 PUNCT F
permitted 0 ADJ F
continuous 0 ADJ F
measurement 0 NOUN F
( 0 PUNCT F
unfettered 0 PUNCT F
breathing 0 VERB F
) 0 PUNCT F
of 0 ADP F
Vr 0 NOUN T
, 0 PUNCT F
f 0 NOUN F
, 0 PUNCT F
VE 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
onset 0 NOUN F
and 0 CCONJ F
persistence 0 NOUN F
of 0 ADP F
oronasal B-PHYSICAL ADJ F
breathing I-PHYSICAL VERB F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
article 0 NOUN F
the 0 DET F
authors 0 NOUN F
compare 0 VERB F
the 0 DET F
relative 0 ADJ F
importance 0 NOUN F
of 0 ADP F
parameters 0 NOUN F
contributing 0 VERB F
to 0 ADP F
the 0 DET F
between-subject 0 NOUN F
variability 0 NOUN F
in 0 ADP F
estimated 0 VERB F
hydrogen 0 NOUN F
ion 0 NOUN F
dose 0 ADJ F
to 0 ADP F
the 0 DET F
lower 0 PUNCT F
airways 0 NOUN F
( 0 PUNCT F
H+LAW 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
. 0 PUNCT F

Physiologic 0 ADJ T
parameters 0 NOUN F
accounted 0 VERB F
for 0 ADP F
70 0 NUM F
% 0 SYM F
of 0 ADP F
the 0 DET F
variability 0 NOUN F
, 0 PUNCT F
of 0 ADP F
which 0 ADP F
34 0 NUM F
% 0 SYM F
was 0 VERB F
due 0 CCONJ F
to 0 ADP F
differences 0 NOUN F
in 0 ADP F
duration 0 NOUN F
of 0 ADP F
oronasal B-PHYSICAL ADJ F
breathing I-PHYSICAL DET F
( I-PHYSICAL PUNCT F
tON I-PHYSICAL NOUN F
) I-PHYSICAL PUNCT F
and 0 CCONJ F
36 0 NUM F
% 0 SYM F
to 0 ADP F
differences 0 NOUN F
in 0 ADP F
ventilation B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
during I-PHYSICAL ADP F
oronasal I-PHYSICAL ADJ F
breathing I-PHYSICAL DET F
( I-PHYSICAL PUNCT F
VE I-PHYSICAL NOUN T
( I-PHYSICAL PUNCT F
ON I-PHYSICAL PUNCT T
) I-PHYSICAL PUNCT F
) I-PHYSICAL PUNCT F
; 0 PUNCT F
inhaled B-PHYSICAL VERB F
hydrogen I-PHYSICAL NOUN F
ion I-PHYSICAL NOUN F
concentration 0 NOUN F
[ B-PHYSICAL PUNCT F
H+ I-PHYSICAL PUNCT T

The 0 DET T
prophylactic B-OTHER ADJ F
effect 0 NOUN F
of 0 ADP F
valproate 0 NOUN F
on 0 ADP F
glyceryltrinitrate B-PHYSICAL NOUN F
induced I-PHYSICAL PUNCT F
migraine I-PHYSICAL NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
the 0 DET F
human 0 NOUN F
glyceryltrinitrate 0 NOUN F
( 0 PUNCT F
GTN 0 NOUN T
) 0 PUNCT F
model 0 NOUN F
of 0 ADP F
migraine 0 NOUN F
was 0 VERB F
for 0 ADP F
the 0 DET F
first 0 ADJ F
time 0 NOUN F
used 0 ADV F
to 0 PART F
test 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
a 0 DET F
prophylactic 0 ADJ F
drug 0 NOUN F
. 0 PUNCT F

We 0 PRON T
chose 0 PUNCT F
to 0 PART F
test 0 NOUN F
valproate 0 NOUN F
due 0 CCONJ F
to 0 ADP F
its 0 PUNCT F
well 0 VERB F
documented 0 CCONJ F
effect 0 NOUN F
as 0 ADP F
a 0 DET F
migraine 0 NOUN F
prophylactic 0 ADJ F
drug 0 NOUN F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
this 0 DET F
compound 0 NOUN F
would 0 PUNCT F
support 0 VERB F
the 0 DET F
usefulness 0 NOUN F
of 0 ADP F
the 0 DET F
model 0 NOUN F
in 0 ADP F
prophylactic 0 ADJ F
antimigraine 0 ADJ F
drug 0 NOUN F
development 0 NOUN F
. 0 PUNCT F

Twelve 0 NUM T
patients 0 NOUN F
with 0 ADP F
migraine 0 NOUN F
without 0 ADP F
aura 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
double 0 PUNCT F
blind 0 ADJ F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

Valproate 0 NOUN T
1000 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
placebo 0 NOUN F
was 0 VERB F
given 0 VERB F
daily 0 ADJ F
, 0 PUNCT F
each 0 CCONJ F
for 0 ADP F
a 0 DET F
minimum 0 NOUN F
of 0 ADP F
13 0 NUM F
days 0 NOUN F
. 0 PUNCT F

On 0 ADP T
the 0 DET F
last 0 ADJ F
treatment 0 NOUN F
day 0 NOUN F
of 0 ADP F
each 0 DET F
arm 0 NOUN F
a 0 DET F
20 0 NUM F
min 0 NOUN F
intravenous 0 ADJ F
infusion 0 NOUN F
of 0 ADP F
GTN 0 NOUN T
( 0 PUNCT F
0.25 0 NUM F
microg/kg/min 0 NOUN F
) 0 PUNCT F
was 0 VERB F
given 0 VERB F
. 0 PUNCT F

Headache B-ADVERSE-EFFECTS NOUN T
was 0 VERB F
registered 0 PUNCT F
for 0 ADP F
12 0 NUM F
h 0 NOUN F
after 0 ADP F
the 0 DET F
infusion 0 NOUN F
and 0 CCONJ F
headache B-ADVERSE-EFFECTS ADJ F
intensity I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
scored 0 VERB F
on 0 ADP F
a 0 DET F
scale 0 NOUN F
from 0 ADP F
0 0 NUM F
to 0 ADP F
10 0 NUM F
. 0 PUNCT F

Fulfillment 0 NOUN T
of 0 ADP F
IHS 0 NOUN T
criteria 0 NOUN F
was 0 VERB F
recorded 0 VERB F
for 0 ADP F
24 0 NUM F
h. 0 NOUN F
The 0 DET T
middle B-PHYSICAL ADJ F
cerebral I-PHYSICAL ADJ F
arteries I-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
by 0 ADP F
transcranial B-PHYSICAL ADJ F
Doppler I-PHYSICAL NOUN T
and 0 CCONJ F
the 0 DET F
diameter 0 NOUN F
of 0 ADP F
the 0 DET F
superficial B-PHYSICAL ADJ F
temporal I-PHYSICAL ADJ F
and 0 CCONJ F
radial B-PHYSICAL ADJ F
arteries I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
with 0 ADP F
high B-PHYSICAL ADJ F
frequency 0 NOUN F
ultrasound B-PHYSICAL NOUN F
. 0 PUNCT F

GTN B-PHYSICAL NOUN T
evoked I-PHYSICAL DET F
migraine B-PAIN NOUN F
fulfilling I-PAIN PROPN F
IHS B-PAIN NOUN T
criteria I-PAIN NOUN F
1.1 0 NUM F
in 0 ADP F
6 0 NUM F
patients 0 NOUN F
after 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
in 0 ADP F
2 0 NUM F
patients 0 NOUN F
after 0 ADP F
valproate 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.125 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Including 0 VERB T
additionally 0 ADV F
3 0 NUM F
patients 0 NOUN F
on 0 ADP F
placebo 0 NOUN F
and 0 CCONJ F
1 0 NUM F
patient 0 NOUN F
on 0 ADP F
valproate 0 NOUN F
who 0 PROPN F
felt 0 PUNCT F
they 0 ADJ F
had 0 PUNCT F
suffered 0 PUNCT F
a 0 DET F
migraine B-ADVERSE-EFFECTS NOUN F
attack B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
but 0 CCONJ F
who 0 ADP F
had 0 PUNCT F
as 0 PUNCT F
associated 0 PUNCT F
symptoms 0 NOUN F
only 0 ADV F
photophobia B-PHYSICAL PUNCT F
or 0 CCONJ F
phonophobia B-PHYSICAL PUNCT F
, 0 PUNCT F
a 0 DET F
significant 0 ADJ F
reduction 0 NOUN F
in 0 ADP F
the 0 DET F
number 0 NOUN F
of 0 ADP F
patients B-OTHER NOUN F
with I-OTHER ADP F
induced B-OTHER VERB F
migraine B-OTHER NOUN F
after 0 ADP F
valproate 0 NOUN F
was 0 VERB F
seen 0 VERB F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.031 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Median 0 ADJ T
peak 0 ADJ F
headache B-PHYSICAL NOUN F
intensity I-PHYSICAL NOUN F
was 0 VERB F
1 0 NUM F
( 0 PUNCT F
range 0 NOUN F
0-9 0 NUM F
) 0 PUNCT F
after 0 ADP F
valproate 0 NOUN F
compared 0 VERB F
to 0 ADP F
4.5 0 DET F
( 0 PUNCT F
range 0 NOUN F
0-8 0 NUM F
) 0 PUNCT F
after 0 ADP F
placebo 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
0.120 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Pretreatment 0 NOUN T
with 0 ADP F
valproate 0 NOUN F
as 0 PUNCT F
compared 0 VERB F
to 0 ADP F
placebo 0 NOUN F
reduced 0 VERB F
the 0 DET F
velocity B-PHYSICAL NOUN F
in 0 ADP F
both 0 CCONJ F
middle B-OTHER ADJ F
cerebral I-OTHER PUNCT F

White 0 ADJ T
coat 0 NOUN F
effect 0 NOUN F
detected 0 ADJ F
using 0 SYM F
self-monitoring 0 PUNCT F
of 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
at 0 ADP F
home 0 NOUN F
: 0 PUNCT F
comparison 0 NOUN F
with 0 ADP F
ambulatory 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
. 0 PUNCT F

The 0 DET T
objective 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
was 0 VERB F
to 0 PART F
investigate 0 NOUN F
whether 0 PUNCT F
home B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
HBP 0 NOUN T
) 0 PUNCT F
is 0 VERB F
a 0 DET F
reliable 0 ADJ F
alternative 0 ADJ F
to 0 ADP F
ambulatory 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
ABP 0 NOUN T
) 0 PUNCT F
for 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
the 0 DET F
white 0 ADJ F
coat 0 NOUN F
effect 0 NOUN F
( 0 PUNCT F
WCE 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Hypertensive 0 ADJ T
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
measure 0 VERB F
HBP 0 NOUN T
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
ABP 0 NOUN T
for 0 ADP F
24 0 NUM F
h. 0 NOUN F
The 0 DET T
alternative 0 ADJ F
measurement 0 NOUN F
was 0 ADJ F
then 0 ADV F
performed 0 VERB F
. 0 PUNCT F

Clinic B-PHYSICAL PUNCT T
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CBP I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
was 0 VERB F
measured 0 VERB F
in 0 ADP F
the 0 DET F
beginning 0 PUNCT F
and 0 CCONJ F
end 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
with 0 ADP F
a 0 DET F
difference 0 NOUN F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
20 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
systolic 0 ADJ F
or 0 CCONJ F
> 0 ADJ F
or 0 CCONJ F
= 0 SYM F
10 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
diastolic 0 ADJ F
BP 0 NOUN T
between 0 ADP F
CBP 0 NOUN T
and 0 CCONJ F
awake 0 NOUN F
ABP 0 NOUN T
or 0 CCONJ F
CBP 0 NOUN T
and 0 CCONJ F
HBP 0 NOUN T
, 0 PUNCT F
were 0 VERB F
classified 0 VERB F
as 0 ADP F
clinic 0 ADJ F
reactors 0 NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
189 0 NUM F
patients 0 NOUN F
completed 0 NOUN F
the 0 DET F
study 0 NOUN F
( 0 PUNCT F
79 0 NUM F
on 0 ADP F
stable 0 ADJ F
antihypertensive 0 ADJ F
treatment 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
no 0 DET F
difference 0 NOUN F
in 0 ADP F
the 0 DET F
magnitude 0 NOUN F
of 0 ADP F
WCE B-PHYSICAL NOUN T
assessed 0 VERB F
using 0 SYM F
the 0 DET F
ABP B-OTHER NOUN T
or 0 CCONJ F
the 0 DET F
HBP B-OTHER NOUN T
method 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
discrepancy 0 NOUN F
, 0 PUNCT F
systolic B-PHYSICAL ADJ F
BP I-PHYSICAL NOUN T
: 0 PUNCT F
-1.5 0 NUM F
+/- 0 SYM F
11.7 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
-3.2 0 NUM F
, 0 PUNCT F
0.2 0 NUM F
; 0 PUNCT F
diastolic B-PHYSICAL ADJ F
BP I-PHYSICAL NOUN T
: 0 PUNCT F
0.9 0 NUM F
+/- 0 SYM F
7.0 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
CI 0 NOUN T
-0.1 0 NUM F
, 0 PUNCT F
1.9 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
strong 0 ADJ F
association 0 NOUN F
existed 0 VERB F
between 0 ADP F
WCE B-PHYSICAL NOUN T
calculated 0 ADV F
using 0 VERB F
the 0 DET F
HBP B-OTHER NOUN T
or 0 CCONJ F
the 0 DET F
ABP B-OTHER NOUN T
method 0 NOUN F
( 0 PUNCT F
r 0 NOUN F
= 0 SYM F
0.64/0.59 0 ADV F
systolic/diastolic 0 ADJ F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
classified 0 PUNCT F
as 0 ADP F
clinic B-PHYSICAL ADJ F
reactors I-PHYSICAL NOUN F
was 0 VERB F
identical 0 VERB F
using 0 VERB F
the 0 DET F
HBP 0 NOUN T
or 0 CCONJ F
the 0 DET F
ABP 0 NOUN T
method 0 NOUN F
( 0 PUNCT F
25.9 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

Agreement 0 NOUN T
between 0 ADP F
methods 0 NOUN F
in 0 ADP F
the 0 DET F
classification 0 NOUN F
of 0 ADP F
clinic 0 NOUN F
reactors 0 NOUN F
was 0 VERB F
found 0 VERB F
in 0 ADP F
147 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
78 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
sensitivity 0 NOUN F
and 0 CCONJ F
specificity 0 NOUN F
of 0 ADP F
the 0 DET F
HBP 0 NOUN T
method 0 NOUN F
to 0 PART F
classify 0 ADJ F
correctly 0 DET F
clinic 0 PUNCT F
reactors 0 NOUN F
( 0 PUNCT F
ABP 0 NOUN T
method 0 NOUN F
used 0 ADV F
as 0 ADP F
the 0 DET F
standard 0 ADJ F
) 0 PUNCT F
were 0 VERB F
57 0 NUM F
% 0 SYM F
and 0 CCONJ F
85 0 NUM F
% 0 SYM F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
whereas 0 ADP F
its 0 PUNCT F
positive 0 ADJ F
and 0 CCONJ F
negative 0 ADJ F
predictive 0 ADJ F
value 0 NOUN F
were 0 VERB F
57 0 NUM F
% 0 SYM F
and 0 CCONJ F
85 0 NUM F
% 0 SYM F
. 0 PUNCT F

These 0 DET T
results 0 NOUN F
indicate 0 VERB F
that 0 ADP F
HBP B-OTHER NOUN T
is 0 VERB F
not 0 ADV F
appropriate 0 ADJ F
as 0 ADP F
an 0 DET F
alternative 0 ADJ F
to 0 ADP F
ABP 0 NOUN T
diagnostic 0 ADJ F
testing 0 VERB F
in 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
WCE 0 NOUN T
. 0 PUNCT F

Nevertheless 0 ADV T
, 0 PUNCT F
HBP B-OTHER NOUN T
appears 0 NOUN F
useful 0 ADJ F
as 0 ADP F
a 0 DET F
screening 0 VERB F
test 0 NOUN F
for 0 ADP F
the 0 DET F
detection 0 NOUN F
of 0 ADP F
this 0 DET F
phenomenon 0 NOUN F
. 0 PUNCT F

Physostigmine 0 ADP T
reverses 0 ADV F
propofol-induced 0 VERB F
unconsciousness 0 NOUN F
and 0 CCONJ F
attenuation 0 NOUN F
of 0 ADP F
the 0 DET F
auditory 0 ADJ F
steady 0 ADJ F
state 0 NOUN F
response 0 NOUN F
and 0 CCONJ F
bispectral 0 ADJ F
index 0 NOUN F
in 0 ADP F
human 0 NOUN F
volunteers 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
It 0 PRON T
is 0 VERB F
postulated 0 ADV F
that 0 ADP F
alteration 0 NOUN F
of 0 ADP F
central 0 ADJ F
cholinergic 0 ADJ F
transmission 0 NOUN F
plays 0 NOUN F
an 0 DET F
important 0 ADJ F
role 0 NOUN F
in 0 ADP F
the 0 DET F
mechanism 0 NOUN F
by 0 ADP F
which 0 DET F
anesthetics 0 NOUN F
produce 0 VERB F
unconsciousness 0 NOUN F
. 0 PUNCT F

The 0 DET T
authors 0 NOUN F
investigated 0 VERB F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
altering 0 VERB F
central 0 ADJ F
cholinergic 0 ADJ F
transmission 0 NOUN F
, 0 PUNCT F
by 0 ADP F
physostigmine 0 NOUN F
and 0 CCONJ F
scopolamine 0 NOUN F
, 0 PUNCT F
on 0 ADP F
unconsciousness 0 NOUN F
produced 0 VERB F
by 0 ADP F
propofol 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
Propofol 0 NOUN T
was 0 VERB F
administered 0 VERB F
to 0 ADP F
American 0 ADJ T
Society 0 NOUN T
of 0 ADP F
Anesthesiologists 0 PROPN T
physical 0 ADJ F
status 0 NOUN F
1 0 NUM F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
volunteers 0 NOUN F
with 0 ADP F
use 0 NOUN F
of 0 ADP F
a 0 DET F
computer-controlled 0 VERB F
infusion 0 NOUN F
pump 0 NOUN F
at 0 ADP F
increasing 0 ADJ F
concentrations 0 NOUN F
until 0 ADP F
unconsciousness 0 NOUN F
resulted 0 VERB F
( 0 PUNCT F
inability 0 NOUN F
to 0 PART F
respond 0 ADP F
to 0 ADP F
verbal 0 ADJ F
commands 0 NOUN F
, 0 PUNCT F
abolition 0 NOUN F
of 0 ADP F
spontaneous 0 ADJ F
movement 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Central B-PHYSICAL ADJ T
nervous I-PHYSICAL ADJ F
system I-PHYSICAL NOUN F
function I-PHYSICAL NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
use 0 NOUN F
of 0 ADP F
the 0 DET F
Auditory B-PHYSICAL ADJ T
Steady I-PHYSICAL CCONJ T
State I-PHYSICAL NOUN T
Response 0 NOUN T
( B-PHYSICAL PUNCT F
ASSR I-PHYSICAL NOUN T
) B-PHYSICAL PUNCT F
and 0 CCONJ F
Bispectral B-PHYSICAL PUNCT T
Index 0 NOUN T
( B-PHYSICAL PUNCT F
BIS I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
analysis B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
electrooculogram I-PHYSICAL NOUN F
. 0 PUNCT F

During 0 ADP T
continuous 0 ADJ F
administration 0 NOUN F
of 0 ADP F
propofol 0 NOUN F
, 0 PUNCT F
reversal B-PHYSICAL NOUN F
of B-PHYSICAL ADP F
unconsciousness B-PHYSICAL NOUN F
produced 0 VERB F
by 0 ADP F
physostigmine 0 NOUN F
( 0 PUNCT F
28 0 NUM F
microgram/kg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
block 0 NOUN F
of 0 ADP F
this 0 DET F
reversal B-PHYSICAL NOUN F
by 0 ADP F
scopolamine 0 NOUN F
( 0 PUNCT F
8.6 0 NUM F
microgram/kg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Propofol 0 NOUN T
produced 0 PUNCT F
unconsciousness B-PHYSICAL NOUN F
at 0 ADP F
a 0 DET F
plasma 0 NOUN F
concentration 0 NOUN F
of 0 ADP F
3.2 0 NUM F
+/- 0 SYM F
0.8 0 NUM F
( 0 PUNCT F
+/- 0 SYM F
SD 0 NOUN T
) 0 PUNCT F
microgram/ml 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
17 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Unconsciousness B-PHYSICAL NOUN T
was 0 VERB F
associated 0 VERB F
with 0 ADP F
reductions 0 NOUN F
in 0 ADP F
ASSR B-PHYSICAL NOUN T
( 0 PUNCT F
0.10 0 NUM F
+/- 0 SYM F
0.08 0 NUM F
microV 0 NOUN F
[ 0 PUNCT F
awake 0 NOUN F
baseline 0 NOUN F
0.32 0 NUM F
+/- 0 SYM F
0.18 0 NUM F
microV 0 NOUN F
] 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
BIS B-PHYSICAL NOUN T
( 0 PUNCT F
55.7 0 NUM F
+/- 0 SYM F
8.8 0 NUM F
[ 0 PUNCT F
awake 0 NOUN F
baseline 0 NOUN F
92.4 0 NUM F
+/- 0 SYM F
3.9 0 NUM F
] 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Physostigmine 0 ADP T
restored B-PHYSICAL PUNCT F
consciousness I-PHYSICAL NOUN F
in 0 ADP F
9 0 NUM F
of 0 ADP F
11 0 NUM F
subjects 0 NOUN F
, 0 PUNCT F
with 0 ADP F
concomitant 0 ADJ F
increases 0 CCONJ F
in 0 ADP F
ASSR B-PHYSICAL NOUN T
( 0 PUNCT F
0.38 0 NUM F
+/- 0 SYM F
0.17 0 NUM F
microV 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
BIS B-PHYSICAL NOUN T
( 0 PUNCT F
75.3 0 NUM F
+/- 0 SYM F
8.3 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
all 0 DET F
subjects 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
6 0 NUM F
) 0 PUNCT F
scopolamine 0 NOUN F
blocked 0 VERB F
the 0 DET F
physostigmine-induced B-PHYSICAL VERB F
reversal B-PHYSICAL NOUN F
of B-PHYSICAL ADP F
unconsciousness B-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
increase 0 NOUN F
of 0 ADP F
the 0 PUNCT F

A 0 DET T
randomized 0 VERB F
, 0 PUNCT F
evaluator-blind 0 PUNCT F
, 0 PUNCT F
multicenter 0 NOUN F
comparison 0 NOUN F
of 0 ADP F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
tolerability 0 NOUN F
of 0 ADP F
Perlane 0 NOUN T
versus 0 CCONJ F
Zyplast 0 NOUN T
in 0 ADP F
the 0 DET F
correction 0 NOUN F
of 0 ADP F
nasolabial 0 ADJ F
folds 0 PUNCT F
. 0 PUNCT F

Bovine 0 ADJ T
collagen 0 NOUN F
is 0 VERB F
widely 0 ADV F
used 0 VERB F
as 0 ADP F
a 0 DET F
dermal 0 ADJ F
filler 0 ADP F
for 0 ADP F
facial 0 ADJ F
soft-tissue 0 NOUN F
augmentation 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
provides 0 NOUN F
only 0 ADV F
temporary 0 PUNCT F
cosmetic 0 ADJ F
improvement 0 NOUN F
. 0 PUNCT F

Nonanimal 0 ADJ T
stabilized 0 ADP F
hyaluronic 0 ADJ F
acid 0 NOUN F
has 0 PUNCT F
reduced 0 PUNCT F
potential 0 NOUN F
for 0 ADP F
immunogenicity 0 ADJ F
and 0 CCONJ F
hypersensitivity 0 NOUN F
and 0 CCONJ F
may 0 VERB F
provide 0 VERB F
a 0 DET F
more 0 PUNCT F
durable 0 ADJ F
aesthetic 0 ADJ F
result 0 NOUN F
. 0 PUNCT F

Sixty-eight 0 PUNCT T
patients 0 NOUN F
with 0 ADP F
prominent 0 ADJ F
nasolabial 0 ADJ F
folds 0 VERB F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
intradermal 0 ADJ F
treatment 0 NOUN F
with 0 ADP F
nonanimal 0 ADJ F
stabilized 0 ADP F
hyaluronic 0 ADJ F
acid 0 NOUN F
gel 0 NOUN F
( 0 PUNCT F
Perlane 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
bovine 0 ADJ F
collagen 0 NOUN F
( 0 PUNCT F
Zyplast 0 NOUN T
) 0 PUNCT F
on 0 ADP F
contralateral 0 ADJ F
sides 0 NOUN F
of 0 ADP F
the 0 DET F
face 0 NOUN F
. 0 PUNCT F

On 0 ADP T
achievement 0 NOUN F
of 0 ADP F
optimal B-PHYSICAL ADJ F
cosmetic I-PHYSICAL ADJ F
result I-PHYSICAL NOUN F
( 0 PUNCT F
baseline 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
patients 0 NOUN F
were 0 VERB F
followed 0 VERB F
up 0 ADJ F
for 0 ADP F
6 0 NUM F
months 0 NOUN F
; 0 PUNCT F
bilateral 0 ADJ F
retreatment 0 ADJ F
with 0 ADP F
Perlane 0 NOUN T
was 0 VERB F
offered 0 VERB F
at 0 ADP F
6 0 NUM F
or 0 CCONJ F
9 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Responses 0 NOUN T
were 0 VERB F
evaluated 0 VERB F
at 0 ADP F
2 0 NUM F
, 0 PUNCT F
4 0 NUM F
, 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
9 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
. 0 PUNCT F

Investigator-based B-OTHER VERB T
and I-OTHER CCONJ F
patient-based I-OTHER VERB F
ratings I-OTHER NOUN F
indicated 0 VERB F
that 0 ADP F
Perlane 0 NOUN T
was 0 VERB F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
Zyplast 0 NOUN T
in 0 ADP F
maintaining 0 VERB F
cosmetic 0 ADJ F
correction 0 NOUN F
. 0 PUNCT F

According 0 CCONJ T
to 0 ADP F
investigator-based 0 VERB F
Wrinkle 0 NOUN T
Severity 0 NOUN T
Rating 0 PUNCT T
Scale 0 NOUN T
assessments 0 NOUN F
at 0 ADP F
6 0 NUM F
and 0 CCONJ F
9 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
, 0 PUNCT F
Perlane 0 NOUN T
was 0 VERB F
superior B-OTHER ADJ F
in 0 ADP F
50.0 0 NUM F
percent 0 NOUN F
and 0 CCONJ F
48.8 0 NUM F
percent 0 NOUN F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
, 0 PUNCT F
whereas 0 CCONJ F
Zyplast 0 NOUN T
was 0 VERB F
superior B-OTHER ADJ F
in 0 ADP F
10.3 0 NUM F
percent 0 NOUN F
and 0 CCONJ F
14.0 0 NUM F
percent 0 NOUN F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.0004 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Investigator-based 0 VERB T
Global 0 PUNCT T
Aesthetic 0 ADJ T
Improvement 0 NOUN T
Scale 0 NOUN T
assessment 0 NOUN F
at 0 ADP F
9 0 NUM F
months 0 NOUN F
after 0 ADP F
baseline 0 NOUN F
indicated 0 VERB F
that 0 ADP F
Perlane 0 NOUN T
was 0 VERB F
superior B-OTHER ADJ F
in 0 ADP F
48.8 0 NUM F
percent 0 NOUN F
of 0 ADP F
patients 0 NOUN F
, 0 PUNCT F
whereas 0 CCONJ F
Zyplast 0 NOUN T
was 0 VERB F
superior B-OTHER ADJ F
in 0 ADP F
14.0 0 NUM F
percent 0 NOUN F
of 0 ADP F
patients 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0025 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Optimal B-PHYSICAL ADJ T
cosmetic I-PHYSICAL ADJ F
result I-PHYSICAL NOUN F
was 0 VERB F
achieved 0 VERB F
with 0 ADP F
a 0 DET F
smaller 0 PUNCT F
volume 0 NOUN F
of 0 ADP F
Perlane 0 NOUN T
than 0 VERB F
Zyplast 0 NOUN T
( 0 PUNCT F
mean 0 NOUN F
, 0 PUNCT F
1.2 0 NUM F
ml 0 NOUN F
versus 0 CCONJ F
2.1 0 NUM F
ml 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Local 0 ADJ T
injection-site 0 NOUN F
reactions B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
redness B-ADVERSE-EFFECTS PUNCT F
, 0 PUNCT F
swelling B-ADVERSE-EFFECTS VERB F
, 0 PUNCT F
pruritus B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 CCONJ F
induration B-ADVERSE-EFFECTS NOUN F
) 0 PUNCT F
were 0 VERB F
less 0 ADV F
frequent 0 ADP F
with 0 ADP F
Perlane 0 NOUN T
than 0 PUNCT F
with 0 ADP F
Zyplast 0 NOUN T
. 0 PUNCT F

Delayed-onset 0 NOUN T
reactions 0 NOUN F
were 0 VERB F
rare 0 ADJ F
and 0 CCONJ F
did 0 PUNCT F
not 0 ADV F
reoccur 0 PUNCT F
after 0 ADP F
Perlane 0 NOUN T
retreatment 0 ADJ F
. 0 PUNCT F

Perlane 0 NOUN T
has 0 PUNCT F
acceptable 0 ADJ F
long-term B-OTHER NOUN F
safety I-OTHER NOUN F
and 0 CCONJ F
offers 0 NUM F
a 0 DET F
longer-lasting 0 ADV F
aesthetic 0 ADJ F
improvement 0 NOUN F
than 0 PUNCT F
Zyplast 0 NOUN T
. 0 PUNCT F

The 0 DET T
aging 0 ADJ F
motor 0 NOUN F
system 0 NOUN F
as 0 ADP F
a 0 DET F
model 0 NOUN F
for 0 ADP F
plastic 0 NOUN F
changes 0 NOUN F
of 0 ADP F
GABA-mediated 0 VERB T
intracortical 0 ADJ F
inhibition 0 NOUN F
and 0 CCONJ F
their 0 ADP F
behavioral 0 ADJ F
relevance 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
GABAA-mediated 0 VERB T
intracortical 0 ADJ F
inhibition 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
to 0 PART F
underlie 0 ADP F
plastic 0 NOUN F
changes 0 NOUN F
throughout 0 ADP F
the 0 DET F
lifespan 0 CCONJ F
from 0 ADP F
development 0 NOUN F
to 0 ADP F
aging 0 DET F
, 0 PUNCT F
here 0 ADV F
, 0 PUNCT F
the 0 DET F
aging 0 ADJ F
motor 0 NOUN F
system 0 NOUN F
was 0 VERB F
used 0 VERB F
as 0 ADP F
a 0 DET F
model 0 NOUN F
to 0 PART F
analyze 0 NOUN F
the 0 DET F
interdependence 0 NOUN F
of 0 ADP F
plastic 0 NOUN F
alterations 0 NOUN F
within 0 ADP F
the 0 DET F
inhibitory 0 ADJ F
motorcortical 0 ADJ F
network 0 NOUN F
and 0 CCONJ F
level 0 NOUN F
of 0 ADP F
behavioral 0 ADJ F
performance 0 NOUN F
. 0 PUNCT F

Double-pulse 0 PUNCT T
transcranial 0 ADJ F
magnetic 0 ADJ F
stimulation 0 NOUN F
( 0 PUNCT F
dpTMS 0 NOUN F
) 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
examine 0 NOUN F
inhibition 0 NOUN F
by 0 ADP F
means 0 NOUN F
of 0 ADP F
short-interval 0 PUNCT F
intracortical 0 ADJ F
inhibition 0 NOUN F
( 0 PUNCT F
SICI 0 CCONJ T
) 0 PUNCT F
of 0 ADP F
the 0 DET F
contralateral 0 ADJ F
primary 0 ADJ F
motor 0 NOUN F
cortex 0 NOUN F
in 0 ADP F
a 0 DET F
sample 0 NOUN F
of 0 ADP F
64 0 NUM F
healthy 0 ADJ F
right-handed 0 VERB F
human 0 NOUN F
subjects 0 NOUN F
covering 0 ADP F
a 0 DET F
wide 0 ADJ F
range 0 NOUN F
of 0 ADP F
the 0 DET F
adult 0 NOUN F
lifespan 0 NOUN F
( 0 PUNCT F
age 0 NOUN F
range 0 NOUN F
20-88 0 ADV F
years 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
47.6 0 NUM F
? 0 PUNCT F

20.7 0 NUM F
, 0 PUNCT F
34 0 NUM F
female 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

SICI 0 ADJ T
was 0 VERB F
evaluated 0 VERB F
during 0 ADP F
resting 0 VERB F
state 0 NOUN F
and 0 CCONJ F
in 0 ADP F
an 0 DET F
event-related 0 VERB F
condition 0 NOUN F
during 0 ADP F
movement 0 NOUN F
preparation 0 NOUN F
in 0 ADP F
a 0 DET F
visually 0 ADV F
triggered 0 PUNCT F
simple 0 ADJ F
reaction 0 NOUN F
time 0 NOUN F
task 0 NOUN F
. 0 PUNCT F

In 0 ADP T
a 0 DET F
subgroup 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
23 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
manual 0 ADJ F
motor B-PHYSICAL NOUN F
performance I-PHYSICAL NOUN F
was 0 VERB F
tested 0 VERB F
with 0 ADP F
tasks 0 NOUN F
of 0 ADP F
graded 0 VERB F
dexterous 0 ADJ F
demand 0 NOUN F
. 0 PUNCT F

Weak 0 ADJ T
resting-state 0 NOUN F
inhibition 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
an 0 DET F
overall 0 ADJ F
lower 0 PUNCT F
manual 0 ADJ F
motor 0 NOUN F
performance 0 NOUN F
. 0 PUNCT F

Better 0 PUNCT T
event-related 0 VERB F
modulation 0 NOUN F
of 0 ADP F
inhibition 0 NOUN F
correlated 0 VERB F
with 0 ADP F
better 0 PUNCT F
performance 0 NOUN F
in 0 ADP F
more 0 PUNCT F
demanding 0 PUNCT F
tasks 0 NOUN F
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
fast 0 ADJ F
alternating 0 ADP F
activation 0 NOUN F
of 0 ADP F
cortical 0 ADJ F
representations 0 NOUN F
are 0 VERB F
necessary 0 ADJ F
. 0 PUNCT F

Declining 0 PROPN T
resting-state 0 NOUN F
inhibition 0 NOUN F
was 0 VERB F
associated 0 VERB F
with 0 ADP F
weakened 0 VERB F
event-related 0 VERB F
modulation 0 NOUN F
of 0 ADP F
inhibition 0 NOUN F
. 0 PUNCT F

Therefore 0 ADV T
, 0 PUNCT F
reduced 0 VERB F
resting-state 0 NOUN F
inhibition 0 NOUN F
might 0 VERB F
lead 0 VERB F
to 0 ADP F
a 0 DET F
subsequent 0 ADJ F
loss 0 NOUN F
of 0 ADP F
modulatory 0 ADJ F
capacity 0 NOUN F
, 0 PUNCT F
possibly 0 ADV F
reflecting 0 ADJ F
malfunctioning 0 DET F
precision 0 NOUN F
in 0 ADP F
GABAAergic 0 ADJ T
neurotransmission 0 NOUN F
; 0 PUNCT F
the 0 DET F
consequence 0 NOUN F
is 0 VERB F
an 0 DET F
inevitable 0 ADJ F
decline 0 NOUN F
in 0 ADP F
motor 0 NOUN F
function 0 NOUN F
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
thiopentone/guaifenesin 0 NOUN F
, 0 PUNCT F
ketamine/guaifenesin 0 NOUN F
and 0 CCONJ F
ketamine/midazolam 0 NOUN F
for 0 ADP F
the 0 DET F
induction 0 NOUN F
of 0 ADP F
horses 0 NOUN F
to 0 PART F
be 0 PUNCT F
anaesthetised 0 VERB F
with 0 ADP F
isoflurane 0 NOUN F
. 0 PUNCT F

Forty-eight 0 ADJ T
horses 0 NOUN F
subjected 0 VERB F
to 0 ADP F
elective 0 ADJ F
surgery 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
three 0 DET F
groups 0 NOUN F
of 0 ADP F
16 0 NUM F
horses 0 NOUN F
. 0 PUNCT F

After 0 ADP T
premedication 0 NOUN F
with 0 ADP F
0.1 0 NUM F
mg/kg 0 NOUN F
acepromazine 0 NOUN F
intramuscularly 0 ADV F
and 0 CCONJ F
0.6 0 NUM F
mg/kg 0 NOUN F
xylazine 0 NOUN F
intravenously 0 ADV F
, 0 PUNCT F
anaesthesia 0 NOUN F
was 0 VERB F
induced 0 ADP F
either 0 PUNCT F
with 0 ADP F
2 0 NUM F
g 0 NOUN F
thiopentone 0 NOUN F
in 0 ADP F
500 0 NUM F
ml 0 NOUN F
of 0 ADP F
a 0 DET F
10 0 NUM F
per 0 ADP F
cent 0 ADP F
guaifenesin 0 NOUN F
solution 0 NOUN F
, 0 PUNCT F
given 0 VERB F
intravenously 0 ADV F
at 0 ADP F
a 0 DET F
dose 0 NOUN F
of 0 ADP F
1 0 NUM F
ml/kg 0 NUM F
( 0 PUNCT F
group 0 NOUN F
TG 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
100 0 NUM F
mg/kg 0 NOUN F
guaifenesin 0 NOUN F
and 0 CCONJ F
2.2 0 NUM F
mg/kg 0 NOUN F
ketamine 0 NOUN F
given 0 ADJ F
intravenously 0 DET F
( 0 PUNCT F
group 0 NOUN F
KG 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
with 0 ADP F
0.06 0 NUM F
mg/kg 0 NOUN F
midazolam 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
2.2 0 NUM F
mg/kg 0 NOUN F
ketamine 0 NOUN F
given 0 ADJ F
intravenously 0 DET F
( 0 PUNCT F
group 0 NOUN F
KM 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Anaesthesia B-OTHER NOUN T
was 0 VERB F
maintained 0 VERB F
with 0 ADP F
isoflurane 0 NOUN F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
( B-OTHER PUNCT F
sd I-OTHER NOUN F
) I-OTHER PUNCT F
end I-OTHER NOUN F
tidal I-OTHER ADJ F
isoflurane I-OTHER ADJ F
concentration 0 NOUN F
( B-OTHER PUNCT F
per I-OTHER ADP F
cent I-OTHER NUM F
) B-OTHER PUNCT F
needed 0 ADV F
to 0 PART F
maintain 0 ADV F
a 0 DET F
light B-OTHER PUNCT F
surgical I-OTHER ADJ F
anaesthesia I-OTHER NOUN F
( 0 PUNCT F
stage 0 NOUN F
III 0 NUM T
, 0 PUNCT F
plane 0 NOUN F
2 0 NUM F
) 0 PUNCT F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
KM 0 NOUN T
( 0 PUNCT F
0.91 0 NUM F
[ 0 PUNCT F
0.03 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
groups 0 NOUN F
TG 0 NOUN T
( 0 PUNCT F
1.11 0 NUM F
[ 0 PUNCT F
0.03 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
KG 0 NOUN T
( 0 PUNCT F
1.14 0 NUM F
[ 0 PUNCT F
0.03 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
( B-PHYSICAL PUNCT F
sd I-PHYSICAL NOUN F
) B-PHYSICAL PUNCT F
arterial I-PHYSICAL ADJ F
pressure B-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
mmHg I-PHYSICAL NOUN F
) B-PHYSICAL PUNCT F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
group 0 NOUN F
KG 0 NOUN T
( 0 PUNCT F
67.4 0 NUM F
[ 0 PUNCT F
2.07 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
groups 0 NOUN F
TC 0 NOUN T
( 0 PUNCT F
75.6 0 NUM F
[ 0 PUNCT F
2.23 0 NUM F
] 0 PUNCT F
) 0 PUNCT F
and 0 CCONJ F
KM 0 NOUN T
( 0 PUNCT F
81.0 0 NUM F
[ 0 PUNCT F
2.16 0 ADP F
] 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
the 0 DET F
logarithm 0 NOUN F
of 0 ADP F
the 0 PUNCT F

Junctional B-PHYSICAL ADJ T
ectopic I-PHYSICAL ADJ F
tachycardia I-PHYSICAL NOUN F
after 0 ADP F
congenital 0 ADJ F
heart 0 NOUN F
surgery 0 NOUN F
in 0 ADP F
the 0 DET F
current 0 ADJ F
surgical 0 ADJ F
era 0 NOUN F
. 0 PUNCT F

To 0 PART T
determine 0 NOUN F
the 0 DET F
incidence 0 NOUN F
of 0 ADP F
postoperative B-PHYSICAL ADJ F
junctional I-PHYSICAL ADJ F
ectopic I-PHYSICAL ADJ F
tachycardia I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
JET I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
in 0 ADP F
a 0 DET F
modern 0 ADJ F
cohort 0 NOUN F
of 0 ADP F
pediatric 0 ADJ F
patients 0 NOUN F
, 0 PUNCT F
evaluate 0 ADP F
possible 0 ADJ F
risk 0 NOUN F
factors B-PHYSICAL NOUN F
for I-PHYSICAL ADP F
JET I-PHYSICAL NOUN T
, 0 PUNCT F
and 0 CCONJ F
examine 0 VERB F
the 0 DET F
effects B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
JET I-PHYSICAL NOUN T
on 0 ADP F
postoperative B-PHYSICAL ADJ F
morbidity I-PHYSICAL NOUN F
and 0 CCONJ F
mortality B-MORTALITY NOUN F
. 0 PUNCT F

JET 0 NOUN T
is 0 ADJ F
common 0 ADJ F
after 0 ADP F
congenital 0 ADJ F
heart 0 NOUN F
surgery 0 NOUN F
. 0 PUNCT F

JET-related 0 VERB T
mortality 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
a 0 DET F
rare 0 ADJ F
event 0 NOUN F
at 0 ADP F
our 0 PUNCT F
center 0 NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
different 0 ADJ F
from 0 ADP F
previous 0 ADJ F
reports 0 NOUN F
. 0 PUNCT F

We 0 PRON T
reviewed 0 VERB F
records 0 NOUN F
for 0 ADP F
pediatric 0 ADJ F
patients 0 NOUN F
who 0 ADP F
had 0 PUNCT F
postoperative 0 ADJ F
arrhythmias 0 NOUN F
between 0 ADP F
January 0 NOUN T
2006 0 NUM F
and 0 CCONJ F
June 0 NOUN T
2010 0 NUM F
at 0 ADP F
a 0 DET F
large 0 ADJ F
tertiary-care 0 PUNCT F
children 0 NOUN F
's 0 PUNCT F
hospital 0 NOUN F
. 0 PUNCT F

We 0 PRON T
performed 0 VERB F
a 0 DET F
matched 0 VERB F
case-control 0 NOUN F
study 0 ADP F
to 0 PART F
identify 0 NOUN F
risk 0 NOUN F
factors 0 NOUN F
for 0 ADP F
JET 0 NOUN T
and 0 CCONJ F
a 0 DET F
matched-cohort 0 ADJ F
study 0 NOUN F
to 0 PART F
compare 0 NOUN F
outcomes 0 NOUN F
between 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
controls 0 NOUN F
. 0 PUNCT F

Whenever 0 NOUN T
possible 0 ADJ F
, 0 PUNCT F
each 0 DET F
JET 0 NOUN T
case 0 NOUN F
was 0 VERB F
randomly 0 ADV F
matched 0 VERB F
to 0 ADP F
two 0 ADJ F
controls 0 NOUN F
on 0 ADP F
the 0 DET F
basis 0 NOUN F
of 0 ADP F
lesion 0 NOUN F
, 0 PUNCT F
repair 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
surgical 0 ADJ F
period 0 NOUN F
. 0 PUNCT F

We 0 PRON T
identified 0 VERB F
54 0 NUM F
patients 0 NOUN F
with 0 ADP F
JET 0 NOUN T
( 0 PUNCT F
incidence 0 NOUN F
= 0 SYM F
1.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
. 0 PUNCT F

After 0 ADP T
multivariate 0 PUNCT F
logistic 0 ADJ F
regression 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
low B-PHYSICAL ADJ F
operative I-PHYSICAL ADJ F
weight I-PHYSICAL NOUN F
, 0 PUNCT F
cardiopulmonary B-PHYSICAL ADJ F
bypass I-PHYSICAL NOUN F
( I-PHYSICAL PUNCT F
CPB I-PHYSICAL NOUN T
) I-PHYSICAL PUNCT F
duration I-PHYSICAL NOUN F
> 0 SYM F
100 0 NUM F
min 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
immediate B-PHYSICAL ADJ F
postoperative I-PHYSICAL ADJ F
serum I-PHYSICAL NOUN F
lactic I-PHYSICAL ADJ F
acid I-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
> 0 SYM F
20 0 NUM F
mg/dl 0 NOUN F
were 0 VERB F
associated 0 VERB F
with 0 ADP F
increased 0 VERB F
odds 0 NOUN F
of 0 ADP F
developing 0 ADJ F
JET 0 NOUN T
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
JET 0 NOUN T
had 0 PUNCT F
longer 0 PUNCT F
mechanical B-PHYSICAL ADJ F
ventilation I-PHYSICAL NOUN F
time I-PHYSICAL NOUN F
, 0 PUNCT F
cardiac B-OTHER ADJ F
intensive I-OTHER ADJ F
care I-OTHER NOUN F
unit I-OTHER NOUN F
( I-OTHER PUNCT F
CICU I-OTHER NOUN T
) I-OTHER PUNCT F
stay I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
hospital B-OTHER NOUN F
stay I-OTHER NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
only 0 ADV F
one 0 NUM F
death B-MORTALITY NOUN F
in 0 ADP F
JET 0 NOUN T
group 0 NOUN F
( 0 PUNCT F
1.8 0 NUM F
% 0 SYM F
) 0 PUNCT F
with 0 ADP F
no 0 DET F
significant 0 ADJ F
difference 0 NOUN F
compared 0 VERB F
with 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

JET 0 NOUN T
remains 0 NOUN F
a 0 DET F
relatively 0 ADV F
common 0 ADJ F
postoperative B-PHYSICAL ADJ F
arrhythmia I-PHYSICAL NOUN F
, 0 PUNCT F
but 0 CCONJ F
it 0 PRON F
is 0 VERB F
less 0 ADV F
frequent 0 ADP F
than 0 PUNCT F
previously 0 ADV F
reported 0 VERB F
. 0 PUNCT F

JET 0 NOUN T
occurs 0 NOUN F
more 0 ADV F
commonly 0 ADV F
in 0 ADP F
smaller 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
longer 0 PUNCT F
CPB 0 NOUN T
runs 0 NOUN F
and 0 CCONJ F
significant 0 ADJ F
postoperative B-PHYSICAL ADJ F
lactic I-PHYSICAL ADJ F
acidosis I-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
. 0 PUNCT F

Mortality B-MORTALITY NOUN T
associated 0 VERB F
with 0 ADP F
JET 0 NOUN T
is 0 VERB F
lower 0 VERB F
than 0 PUNCT F
historically 0 ADV F
reported 0 ADP F
, 0 PUNCT F
but 0 CCONJ F
morbidity B-PHYSICAL NOUN F
remains 0 NOUN F
high 0 ADJ F
. 0 PUNCT F

[ 0 PUNCT F
Long 0 ADJ T
term 0 NOUN F
observation 0 NOUN F
in 0 ADP F
effects 0 NOUN F
of 0 ADP F
potassium 0 NOUN F
and 0 CCONJ F
calcium 0 NOUN F
supplementation 0 NOUN F
on 0 ADP F
arterial B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
sodium B-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
in 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
investigate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
potassium 0 NOUN F
and 0 CCONJ F
calcium 0 NOUN F
supplementation 0 NOUN F
in 0 ADP F
table 0 ADJ F
salt 0 NOUN F
on 0 ADP F
reduction 0 NOUN F
of 0 ADP F
arterial B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
sodium B-PHYSICAL NOUN F
metabolism I-PHYSICAL NOUN F
in 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
A 0 PUNCT T
single 0 ADJ F
blind 0 ADJ F
placebo-controlled 0 VERB F
trial 0 NOUN F
was 0 VERB F
carried 0 VERB F
out 0 ADP F
for 0 ADP F
two 0 NUM F
years 0 NOUN F
in 0 ADP F
220 0 NUM F
adolescents 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
aged 0 PUNCT F
18 0 NUM F
- 0 PUNCT F
22 0 NUM F
years 0 NOUN F
, 0 PUNCT F
who 0 ADP F
were 0 VERB F
randomly 0 ADV F
divided 0 VERB F
into 0 ADP F
supplementary 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
110 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
110 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Each 0 PUNCT T
of 0 ADP F
the 0 DET F
subjects 0 NOUN F
in 0 ADP F
the 0 DET F
supplementary 0 ADJ F
group 0 NOUN F
and 0 CCONJ F
their 0 ADJ F
family 0 NOUN F
members 0 NOUN F
was 0 VERB F
given 0 VERB F
10 0 NUM F
mmol 0 NOUN F
of 0 ADP F
potassium 0 NOUN F
and 0 CCONJ F
10 0 NUM F
mmol 0 NOUN F
of 0 ADP F
calcium 0 NOUN F
mixed 0 PROPN F
in 0 ADP F
their 0 PUNCT F
table 0 PUNCT F
salt 0 NOUN F
daily 0 ADJ F
for 0 ADP F
24 0 NUM F
months 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Night B-PHYSICAL NOUN T
urinary I-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
and 0 CCONJ F
potassium B-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
increased 0 VERB F
( 0 PUNCT F
urinary 0 ADJ F
Na 0 NOUN T
( 0 PUNCT F
+ 0 ADV F
) 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
; 0 PUNCT F
urinary 0 ADJ F
K 0 NOUN T
( 0 PUNCT F
+ 0 SYM F
) 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
lowered 0 VERB F
by 0 ADP F
5.3 0 NUM F
mm 0 NOUN F
Hg/1.8 0 PUNCT T
mm 0 NOUN F
Hg 0 NOUN T
in 0 ADP F
average 0 CCONJ F
from 0 ADP F
the 0 DET F
baseline 0 NOUN F
in 0 ADP F
the 0 DET F
supplementary 0 ADJ F
group 0 NOUN F
two 0 NUM F
years 0 NOUN F
after 0 ADP F
potassium 0 NOUN F
and 0 CCONJ F
calcium 0 NOUN F
supplementation 0 NOUN F
, 0 PUNCT F
as 0 PUNCT F
compared 0 VERB F
with 0 ADP F
that 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
increased 0 VERB F
by 0 ADP F
( 0 PUNCT F
1.3/1.7 0 NUM F
) 0 PUNCT F
mm 0 NOUN F
Hg 0 NOUN T
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
Adequate 0 ADJ T
supplement 0 NOUN F
of 0 ADP F
potassium 0 NOUN F
and 0 CCONJ F
calcium 0 NOUN F
in 0 ADP F
daily 0 PUNCT F
table 0 ADJ F
salt 0 NOUN F
intake 0 NOUN F
was 0 VERB F
an 0 DET F
effective 0 ADJ F
way 0 NOUN F
to 0 PUNCT F
prevent 0 CCONJ F
form 0 VERB F
hypertension B-PHYSICAL NOUN F
and 0 CCONJ F
could 0 VERB F
promote 0 VERB F
their 0 ADP F
urinary B-PHYSICAL ADJ F
sodium I-PHYSICAL NOUN F
excretion I-PHYSICAL NOUN F
and 0 CCONJ F
reduction 0 NOUN F
of 0 ADP F
arterial B-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
higher 0 PUNCT F
blood 0 NOUN F
pressure 0 NOUN F
. 0 PUNCT F

Immunologic B-PHYSICAL ADJ T
response I-PHYSICAL NOUN F
after 0 ADP F
laparoscopic 0 ADJ F
colon 0 NOUN F
cancer 0 NOUN F
operation 0 NOUN F
within 0 ADP F
an 0 DET F
enhanced 0 VERB F
recovery 0 NOUN F
program 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
It 0 PRON T
has 0 PUNCT F
been 0 PUNCT F
demonstrated 0 VERB F
that 0 ADP F
colon 0 NOUN F
operation 0 NOUN F
combined 0 VERB F
with 0 ADP F
fast-track 0 NOUN F
( 0 PUNCT F
FT 0 NOUN T
) 0 PUNCT F
surgery 0 NOUN F
and 0 CCONJ F
laparoscopic 0 ADJ F
technique 0 NOUN F
can 0 PUNCT F
shorten 0 VERB F
the 0 DET F
length 0 NOUN F
of B-PHYSICAL ADP F
hospital I-PHYSICAL NOUN F
stay B-PHYSICAL NOUN F
, 0 PUNCT F
accelerate 0 VERB F
recovery B-PHYSICAL NOUN F
of B-PHYSICAL ADP F
intestinal I-PHYSICAL ADJ F
function B-PHYSICAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
reduce 0 VERB F
the 0 DET F
occurrence 0 NOUN F
of 0 ADP F
post-operative B-PHYSICAL ADJ F
complications I-PHYSICAL NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
there 0 PUNCT F
are 0 VERB F
no 0 DET F
reports 0 NOUN F
regarding 0 VERB F
the 0 DET F
combined 0 VERB F
effects 0 NOUN F
of 0 ADP F
FT 0 NOUN T
colon 0 NOUN F
operation 0 NOUN F
and 0 CCONJ F
laparoscopic 0 ADJ F
technique 0 NOUN F
on 0 ADP F
humoral B-PHYSICAL ADJ F
inflammatory I-PHYSICAL ADJ F
cellular I-PHYSICAL ADJ F
immunity I-PHYSICAL NOUN F
. 0 PUNCT F

METHODS 0 NOUN T
This 0 PUNCT T
was 0 VERB F
a 0 DET F
prospective 0 ADJ F
, 0 PUNCT F
controlled 0 ADP F
study 0 NOUN F
. 0 PUNCT F

One 0 NUM T
hundred 0 NUM F
sixty-three 0 PUNCT F
colon 0 NOUN F
cancer 0 NOUN F
patients 0 NOUN F
underwent 0 VERB F
the 0 DET F
traditional 0 ADJ F
protocol 0 NOUN F
and 0 CCONJ F
open 0 VERB F
operation 0 NOUN F
( 0 PUNCT F
traditional 0 ADJ F
open 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n=42 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
traditional 0 ADJ F
protocol 0 NOUN F
and 0 CCONJ F
laparoscopic 0 ADJ F
operation 0 NOUN F
( 0 PUNCT F
traditional 0 ADJ F
laparoscopic 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n=40 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
the 0 DET F
FT 0 NOUN T
protocol 0 NOUN F
and 0 CCONJ F
open 0 VERB F
operation 0 NOUN F
( 0 PUNCT F
FT 0 NUM T
open 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n=41 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
the 0 DET F
FT 0 NOUN T
protocol 0 NOUN F
and 0 CCONJ F
laparoscopic 0 ADJ F
operation 0 NOUN F
( 0 PUNCT F
FT 0 PUNCT T
laparoscopic 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
n=40 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Blood 0 NOUN T
samples 0 NOUN F
were 0 VERB F
taken 0 VERB F
prior 0 PUNCT F
to 0 ADP F
operation 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
on 0 ADP F
days 0 NOUN F
1 0 NUM F
, 0 PUNCT F
3 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
5 0 NUM F
after 0 ADP F
operation 0 NOUN F
. 0 PUNCT F

The 0 DET T
number 0 NOUN F
of 0 ADP F
lymphocyte B-PHYSICAL NOUN F
subpopulations I-PHYSICAL NOUN F
was 0 VERB F
determined 0 VERB F
by 0 ADP F
flow 0 NOUN F
cytometry 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
serum B-PHYSICAL NOUN F
interleukin-6 I-PHYSICAL NOUN F
and B-PHYSICAL CCONJ F
C-reactive I-PHYSICAL ADJ T
protein B-PHYSICAL NOUN F
levels I-PHYSICAL NOUN F
were 0 VERB F
measured 0 VERB F
. 0 PUNCT F

Post-operative B-OTHER ADP T
hospital I-OTHER NOUN F
stay I-OTHER NOUN F
, 0 PUNCT F
post-operative B-PHYSICAL ADP F
morbidity I-PHYSICAL NOUN F
, 0 PUNCT F
readmission B-OTHER NOUN F
rate I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
in-hospital B-MORTALITY NOUN F
mortality B-MORTALITY NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Compared 0 VERB T
with 0 ADP F
open 0 ADJ F
operation 0 NOUN F
, 0 PUNCT F
laparoscopic 0 ADJ F
colon 0 NOUN F
operation 0 NOUN F
effectively 0 ADV F
inhibited 0 VERB F
the 0 DET F
release 0 NOUN F
of 0 ADP F
post-operative B-PHYSICAL ADJ F
inflammatory I-PHYSICAL ADJ F
factors B-PHYSICAL NOUN F
and 0 CCONJ F
yielded 0 VERB F
good 0 ADJ F
protection 0 NOUN F
via 0 ADP F
post-operative 0 ADJ F
cell 0 NOUN F
immunity 0 NOUN F
. 0 PUNCT F

FT 0 NUM T
surgery 0 NOUN F
had 0 PUNCT F
a 0 DET F
better 0 PUNCT F
protective 0 ADJ F
role 0 NOUN F
with 0 ADP F
respect 0 NOUN F
to 0 ADP F
the 0 DET F
post-operative 0 ADJ F
immune 0 ADJ F
system 0 NOUN F
compared 0 VERB F
with 0 ADP F
traditional 0 ADJ F
peri-operative 0 ADJ F
care 0 NOUN F
. 0 PUNCT F

Inflammatory B-PHYSICAL ADJ T
reactions I-PHYSICAL NOUN F
, 0 PUNCT F
based 0 VERB F
on 0 ADP F
interleukin-6 B-PHYSICAL NOUN F
and I-PHYSICAL CCONJ F
C-reactive B-PHYSICAL ADJ T
protein I-PHYSICAL NOUN F
levels B-PHYSICAL NOUN F
, 0 PUNCT F
were 0 VERB F
less 0 ADV F
intense 0 ADJ F
following 0 ADP F
FT 0 NOUN T
laparoscopic 0 ADJ F
operation 0 NOUN F
compared 0 VERB F
to 0 ADP F
FT 0 CCONJ T
open 0 PUNCT F
operation 0 NOUN F
; 0 PUNCT F
however 0 ADV F
, 0 PUNCT F
there 0 PUNCT F
were 0 VERB F
no 0 DET F
differences 0 NOUN F
in 0 ADP F
specific B-PHYSICAL ADJ F
immunity B-PHYSICAL NOUN F
( 0 PUNCT F
CD3+ B-PHYSICAL NOUN T
and I-PHYSICAL CCONJ F
CD4+ I-PHYSICAL NOUN T
counts I-PHYSICAL NOUN F
, 0 PUNCT F
and B-PHYSICAL CCONJ F
the I-PHYSICAL PUNCT F

Randomized 0 VERB T
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
oral 0 ADJ F
sirolimus 0 NOUN F
for 0 ADP F
restenosis B-PHYSICAL NOUN F
prevention 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
in-stent 0 NOUN F
restenosis 0 NOUN F
: 0 PUNCT F
the 0 DET F
Oral 0 ADJ T
Sirolimus 0 NOUN T
to 0 ADJ F
Inhibit 0 PROPN T
Recurrent 0 ADJ T
In-stent 0 NOUN T
Stenosis 0 NOUN T
( 0 PUNCT F
OSIRIS 0 NOUN T
) 0 PUNCT F
trial 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Despite 0 ADP T
recent 0 ADJ F
advances 0 NOUN F
in 0 ADP F
interventional 0 ADJ F
cardiology 0 NOUN F
, 0 PUNCT F
including 0 VERB F
the 0 DET F
introduction 0 NOUN F
of 0 ADP F
drug-eluting 0 VERB F
stents 0 NOUN F
for 0 ADP F
de 0 PUNCT F
novo 0 ADJ F
coronary 0 ADJ F
lesions 0 NOUN F
, 0 PUNCT F
the 0 DET F
treatment 0 NOUN F
of 0 ADP F
in-stent 0 NOUN F
restenosis 0 NOUN F
( 0 PUNCT F
ISR 0 PUNCT T
) 0 PUNCT F
remains 0 NOUN F
a 0 DET F
challenging 0 VERB F
clinical 0 ADJ F
issue 0 NOUN F
. 0 PUNCT F

Given 0 VERB T
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
systemic 0 ADJ F
sirolimus 0 NOUN F
administration 0 NOUN F
to 0 PUNCT F
prevent 0 ADJ F
neointimal B-PHYSICAL ADJ F
hyperplasia I-PHYSICAL NOUN F
in 0 ADP F
animal 0 NOUN F
models 0 NOUN F
and 0 CCONJ F
to 0 ADP F
halt 0 PROPN F
and 0 CCONJ F
even 0 ADV F
reverse 0 CCONJ F
the 0 DET F
progression 0 NOUN F
of 0 ADP F
allograft 0 NOUN F
vasculopathy 0 NOUN F
, 0 PUNCT F
the 0 DET F
aim 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
was 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
efficacy 0 NOUN F
of 0 ADP F
a 0 DET F
10-day 0 NOUN F
oral 0 ADJ F
sirolimus 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
2 0 NUM F
different 0 ADJ F
loading 0 ADV F
regimens 0 NOUN F
for 0 ADP F
the 0 DET F
prevention 0 NOUN F
of 0 ADP F
recurrent 0 ADJ F
restenosis 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
ISR 0 PUNCT T
. 0 PUNCT F

METHODS 0 NOUN T
AND 0 CCONJ T
RESULTS 0 PROPN T
Three 0 NUM T
hundred 0 NUM F
symptomatic 0 ADJ F
patients 0 NOUN F
with 0 ADP F
ISR 0 PUNCT T
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
1 0 PUNCT F
of 0 ADP F
3 0 NUM F
treatment 0 NOUN F
arms 0 NOUN F
: 0 PUNCT F
placebo 0 NOUN F
or 0 CCONJ F
usual-dose 0 NOUN F
or 0 CCONJ F
high-dose 0 NOUN F
sirolimus 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
a 0 DET F
cumulative 0 ADJ F
loading 0 PART F
dose 0 NOUN F
of 0 ADP F
0 0 NUM F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
24 0 NUM F
mg 0 NOUN F
of 0 ADP F
sirolimus 0 NOUN F
2 0 NUM F
days 0 NOUN F
before 0 ADP F
and 0 CCONJ F
the 0 DET F
day 0 NOUN F
of 0 ADP F
repeat 0 NOUN F
intervention 0 NOUN F
followed 0 VERB F
by 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
of 0 ADP F
2 0 NUM F
mg/d 0 NOUN F
for 0 ADP F
7 0 NUM F
days 0 NOUN F
. 0 PUNCT F

Angiographic B-PHYSICAL ADJ T
restenosis I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
6-month I-PHYSICAL NOUN F
angiography I-PHYSICAL NOUN F
was 0 VERB F
the 0 DET F
primary 0 ADJ F
end 0 NOUN F
point 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Restenosis B-PHYSICAL NOUN T
was 0 VERB F
significantly 0 ADV F
reduced 0 VERB F
from 0 ADP F
42.2 0 NUM F
% 0 SYM F
to 0 ADP F
38.6 0 NUM F
% 0 SYM F
and 0 CCONJ F
to 0 ADP F
22.1 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
, 0 PUNCT F
usual-dose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
high-dose 0 NOUN F
sirolimus 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P=0.005 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Similarly 0 ADV T
, 0 PUNCT F
the 0 DET F
need 0 NOUN F
for 0 ADP F
target B-OTHER NOUN F
vessel I-OTHER NOUN F
revascularization I-OTHER NOUN F
was 0 VERB F
reduced 0 VERB F
from 0 ADP F
25.5 0 NUM F
% 0 SYM F
to 0 ADP F
24.2 0 NUM F
% 0 SYM F
and 0 CCONJ F
to 0 ADP F
15.2 0 NUM F
% 0 SYM F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
, 0 PUNCT F
usual-dose 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
high-dose 0 NOUN F
groups 0 NOUN F
, 0 PUNCT F
respectively 0 ADV F
( 0 PUNCT F
P=0.08 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
sirolimus B-PHYSICAL NOUN F
blood I-PHYSICAL NOUN F
concentration I-PHYSICAL NOUN F
on 0 ADP F
the 0 DET F
day 0 NOUN F
of 0 ADP F
the 0 DET F
procedure 0 NOUN F
correlated 0 VERB F
significantly 0 ADV F
with 0 ADP F
the 0 DET F
late 0 ADJ F
lumen 0 NOUN F
loss 0 NOUN F
at 0 ADP F
follow-up 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
In 0 ADP T
patients 0 NOUN F
with 0 ADP F
ISR 0 PUNCT T
, 0 PUNCT F
an 0 DET F
oral 0 ADJ F
adjunctive 0 ADJ F
sirolimus 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
an 0 DET F
intensified 0 ADP F
loading 0 PROPN F
regimen 0 NOUN F
before 0 ADP F
coronary 0 ADJ F
intervention 0 NOUN F
resulted 0 VERB F
in 0 ADP F
a 0 DET F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
the 0 DET F
angiographic B-PHYSICAL ADJ F
parameters I-PHYSICAL NOUN F
of I-PHYSICAL ADP F
restenosis I-PHYSICAL NOUN F
. 0 PUNCT F

Step-down 0 NOUN T
approach 0 NOUN F
using 0 VERB F
either 0 CCONJ F
cyclosporin 0 NOUN F
A 0 DET T
or 0 CCONJ F
methotrexate 0 ADJ F
as 0 PUNCT F
maintenance 0 NOUN F
therapy 0 NOUN F
in 0 ADP F
early 0 ADJ F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
evaluate 0 NOUN F
the 0 DET F
feasibility B-OTHER NOUN F
and 0 CCONJ F
outcome 0 NOUN F
of 0 ADP F
the 0 DET F
step-down 0 NOUN F
approach 0 NOUN F
using 0 VERB F
either 0 CCONJ F
cyclosporin 0 NOUN F
A 0 DET T
( 0 PUNCT F
CSA 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
methotrexate 0 NOUN F
( 0 PUNCT F
MTX 0 NOUN T
) 0 PUNCT F
as 0 ADP F
maintenance 0 NOUN F
therapy 0 NOUN F
following 0 VERB F
6 0 NUM F
months 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
these 0 DET F
2 0 NUM F
agents 0 NOUN F
in 0 ADP F
combination 0 NOUN F
in 0 ADP F
early 0 ADJ F
, 0 PUNCT F
nonerosive 0 PUNCT F
rheumatoid 0 ADJ F
arthritis 0 NOUN F
( 0 PUNCT F
RA 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
Fifty-seven 0 PUNCT T
patients 0 NOUN F
younger 0 PUNCT F
than 0 PUNCT F
65 0 NUM F
years 0 NOUN F
with 0 ADP F
early 0 ADJ F
, 0 PUNCT F
nonerosive 0 ADJ F
RA 0 NOUN T
were 0 VERB F
first 0 ADJ F
treated 0 VERB F
with 0 ADP F
CSA 0 NOUN T
and 0 CCONJ F
MTX 0 NOUN T
in 0 ADP F
combination 0 NOUN F
for 0 ADP F
6 0 NUM F
months 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
then 0 ADV F
randomly 0 ADV F
stepped 0 PUNCT F
down 0 ADJ F
to 0 ADP F
single-agent 0 PUNCT F
maintenance 0 NOUN F
treatment 0 NOUN F
for 0 ADP F
another 0 CCONJ F
18 0 NUM F
months 0 NOUN F
. 0 PUNCT F

Safety B-OTHER NOUN T
, 0 PUNCT F
clinical B-OTHER ADJ F
efficacy I-OTHER NOUN F
, 0 PUNCT F
survival B-OTHER NOUN F
on I-OTHER ADP F
treatment I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
radiographic B-PHYSICAL ADJ F
progression I-PHYSICAL NOUN F
were 0 VERB F
evaluated 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
When 0 ADP T
being 0 DET F
treated 0 VERB F
with 0 ADP F
combination 0 NOUN F
therapy 0 NOUN F
, 0 PUNCT F
7 0 NUM F
of 0 ADP F
the 0 DET F
57 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
12.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
withdrew 0 PUNCT F
because 0 PUNCT F
of 0 ADP F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
remaining 0 VERB F
50 0 DET F
patients 0 NOUN F
, 0 PUNCT F
42 0 NUM F
( 0 PUNCT F
84.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 ADP F
American 0 ADJ T
College 0 NOUN T
of 0 ADP F
Rheumatology 0 NOUN T
( 0 PUNCT F
ACR 0 NOUN T
) 0 PUNCT F
20 0 NUM F
% 0 SYM F
responders 0 NOUN F
, 0 PUNCT F
30 0 NUM F
( 0 PUNCT F
60.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
ACR 0 NOUN T
50 0 NUM F
% 0 SYM F
responders 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
23 0 NUM F
( 0 PUNCT F
46.0 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 ADP F
ACR 0 NOUN T
70 0 NUM F
% 0 SYM F
responders 0 NOUN F
. 0 PUNCT F

At 0 ADP T
month 0 NOUN F
6 0 NUM F
, 0 PUNCT F
22 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 ADP F
CSA 0 NOUN T
and 0 CCONJ F
27 0 NUM F
to 0 ADP F
MTX 0 NOUN T
. 0 PUNCT F

During 0 ADP T
this 0 DET F
trial 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
the 0 DET F
treatment 0 NOUN F
was 0 VERB F
discontinued 0 VERB F
by 0 ADP F
16 0 NUM F
patients 0 NOUN F
taking 0 ADP F
CSA 0 NOUN T
( 0 PUNCT F
mainly 0 ADV F
because 0 PUNCT F
of 0 ADP F
loss 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
by 0 ADP F
4 0 NUM F
taking 0 ADJ F
MTX 0 NOUN T
. 0 PUNCT F

At 0 ADP T
month 0 NOUN F
24 0 NUM F
, 0 PUNCT F
the 0 DET F
probability 0 NOUN F
( 0 PUNCT F
+/- 0 ADP F
SEM 0 NOUN T
) 0 PUNCT F
of 0 ADP F
survival B-MORTALITY NOUN F
on 0 ADP F
treatment 0 NOUN F
was 0 VERB F
0.273 0 NUM F
+/- 0 SYM F
0.09 0 NUM F
for 0 ADP F
CSA 0 NOUN T
and 0 CCONJ F
0.852 0 NUM F
+/- 0 SYM F
0.07 0 NUM F
for 0 ADP F
MTX 0 NOUN T
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
6 0 NUM F
CSA 0 NOUN T
patients 0 NOUN F
who 0 PROPN F
completed 0 PROPN F
the 0 DET F
trial 0 NOUN F
, 0 PUNCT F
4 0 NUM F
( 0 PUNCT F
66.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
ACR 0 NOUN T
20 0 NUM F
% 0 SYM F
responders 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
3 0 NUM F
( 0 PUNCT F
50 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 ADP F
both 0 CCONJ F
ACR 0 NOUN T
50 0 NUM F
% 0 SYM F
and 0 CCONJ F
ACR 0 NOUN T
70 0 NUM F
% 0 SYM F
responders 0 NOUN F
. 0 PUNCT F

Of 0 ADP T
the 0 DET F
23 0 NUM F
completers 0 NOUN F
in 0 ADP F
the 0 DET F
MTX 0 NOUN T
arm 0 ADP F
, 0 PUNCT F
21 0 NUM F
( 0 PUNCT F
91.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
ACR 0 NOUN T
20 0 NUM F
% 0 SYM F
responders 0 NOUN F
, 0 PUNCT F
18 0 NUM F
( 0 PUNCT F
78.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 VERB F
ACR 0 NOUN T
50 0 NUM F
% 0 SYM F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
( 0 PUNCT F
43.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
were 0 ADP F
ACR 0 NOUN T
70 0 NUM F
% 0 SYM F
responders 0 NOUN F
. 0 PUNCT F

The 0 DET T
treatment 0 NOUN F
was 0 VERB F
not 0 ADV F
responsible 0 ADJ F
for 0 ADP F
severe 0 ADJ F
adverse B-ADVERSE-EFFECTS ADJ F
events I-ADVERSE-EFFECTS NOUN F
. 0 PUNCT F

Radiography 0 NOUN T
showed 0 VERB F
a 0 DET F
slow 0 ADJ F
progression 0 NOUN F
in 0 ADP F
the 0 DET F
damage B-PHYSICAL ADV F
score I-PHYSICAL NOUN F
and 0 CCONJ F
number 0 NOUN F
of 0 ADP F
eroded B-PHYSICAL VERB F
joints I-PHYSICAL NOUN F
in 0 ADP F
both 0 CCONJ F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Stepping 0 PUNCT T
down 0 ADJ F
to 0 ADP F
single 0 ADJ F
agent 0 NOUN F
maintenance 0 NOUN F
therapy 0 NOUN F
following 0 VERB F
6 0 NUM F
months 0 NOUN F
of 0 ADP F
combination 0 NOUN F
treatment 0 NOUN F
with 0 ADP F
CSA 0 NOUN T
and 0 CCONJ F
MTX 0 NOUN T
in 0 ADP F
early 0 ADJ F
RA 0 NOUN T
was 0 VERB F
only 0 ADV F
successful 0 ADJ F
with 0 ADP F
MTX 0 NOUN T
. 0 PUNCT F

Because 0 PUNCT T
this 0 DET F
treatment 0 NOUN F
did 0 VERB F
not 0 ADV F
prevent 0 VERB F
some 0 DET F
radiographic B-PHYSICAL ADJ F
progression I-PHYSICAL NOUN F
, 0 PUNCT F
other 0 ADJ F
approaches 0 NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
step-up 0 ADV F
approach 0 NOUN F
) 0 PUNCT F
may 0 VERB F
be 0 VERB F
more 0 ADV F
appropriate 0 ADJ F
in 0 ADP F
early 0 ADJ F
RA 0 NOUN T
. 0 PUNCT F

Pilot 0 NOUN T
comparison 0 NOUN F
between 0 ADP F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
and 0 CCONJ F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
in 0 ADP F
paediatric 0 ADJ F
tonsillectomy 0 NOUN F
. 0 PUNCT F

OBJECTIVES 0 ADP T
To 0 PROPN T
compare 0 NOUN F
the 0 DET F
advantages 0 NOUN F
and 0 CCONJ F
disadvantages 0 NOUN F
of 0 ADP F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
with 0 ADP F
those 0 PUNCT F
of 0 ADP F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
techniques 0 NOUN F
, 0 PUNCT F
in 0 ADP F
paediatric 0 ADJ F
tonsillectomy 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Prospective 0 ADJ T
, 0 PUNCT F
randomised 0 DET F
, 0 PUNCT F
clinical 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

PATIENTS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
From 0 ADP T
July 0 NOUN T
2004 0 NUM F
to 0 ADP F
April 0 NOUN T
2006 0 NUM F
, 0 PUNCT F
80 0 NUM F
patients 0 NOUN F
aged 0 VERB F
between 0 ADP F
10 0 NUM F
and 0 CCONJ F
15 0 NUM F
years 0 NOUN F
, 0 PUNCT F
with 0 ADP F
tonsillectomy 0 NOUN F
planned 0 PUNCT F
for 0 ADP F
chronic 0 ADJ F
tonsillitis 0 NOUN F
, 0 PUNCT F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Children 0 NOUN T
were 0 VERB F
prospectively 0 ADV F
randomised 0 ADP F
into 0 ADP F
two 0 NUM F
equal 0 ADJ F
groups 0 NOUN F
: 0 PUNCT F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
tonsillectomy 0 NOUN F
and 0 CCONJ F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
tonsillectomy 0 NOUN F
. 0 PUNCT F

Operative 0 ADJ T
time 0 NOUN F
and 0 CCONJ F
intra-operative 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

Patients 0 NOUN T
were 0 VERB F
scheduled 0 VERB F
for 0 ADP F
follow 0 PUNCT F
up 0 CCONJ F
during 0 ADP F
the 0 DET F
first 0 ADJ F
, 0 PUNCT F
second 0 ADJ F
and 0 CCONJ F
fourth 0 ADJ F
post-operative 0 ADJ F
weeks 0 NOUN F
. 0 PUNCT F

They 0 PRON T
were 0 VERB F
asked 0 ADV F
to 0 PUNCT F
record 0 PUNCT F
their 0 PUNCT F
pain 0 NOUN F
and 0 CCONJ F
discomfort 0 NOUN F
on 0 ADP F
a 0 DET F
standardised 0 VERB F
visual 0 ADJ F
analogue 0 NOUN F
scale 0 NOUN F
, 0 PUNCT F
from 0 ADP F
zero 0 NUM F
( 0 PUNCT F
no 0 DET F
pain 0 NOUN F
) 0 PUNCT F
to 0 ADP F
10 0 NUM F
( 0 PUNCT F
severe 0 ADJ F
pain 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Post-operative 0 ADP T
complications 0 NOUN F
were 0 VERB F
also 0 ADV F
recorded 0 ADP F
and 0 CCONJ F
managed 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
group 0 NOUN F
showed 0 VERB F
a 0 DET F
slightly 0 ADV F
longer B-OTHER PUNCT F
operative I-OTHER ADJ F
time I-OTHER NOUN F
( 0 PUNCT F
mean 0 NOUN F
12 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
10 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Intra-operative B-PHYSICAL PUNCT T
blood I-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
in 0 ADP F
the 0 DET F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
21 0 NUM F
cm3 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
mean 0 NOUN F
30 0 NUM F
cm3 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
first 0 ADJ F
week 0 NOUN F
, 0 PUNCT F
post-operative B-PAIN ADP F
pain I-PAIN NOUN F
scores I-PAIN NOUN F
were 0 VERB F
less 0 ADV F
in 0 ADP F
the 0 DET F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
means 0 NOUN F
7.5 0 NUM F
and 0 CCONJ F
8.5 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
in 0 ADP F
the 0 DET F
second 0 ADJ F
week 0 NOUN F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
increased 0 VERB F
more 0 ADV F
in 0 ADP F
the 0 DET F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
means 0 NOUN F
8.5 0 NUM F
and 0 CCONJ F
6 0 NUM F
, 0 PUNCT F
respectively 0 ADV F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
fourth 0 ADJ F
week 0 NOUN F
, 0 PUNCT F
both 0 CCONJ F
groups 0 NOUN F
showed 0 VERB F
equal 0 ADJ F
and 0 CCONJ F
nearly 0 ADV F
normal 0 ADJ F
pain B-PAIN NOUN F
scores I-PAIN NOUN F
. 0 PUNCT F

No 0 DET T
case 0 NOUN F
of 0 ADP F
reactionary B-ADVERSE-EFFECTS ADJ F
post-tonsillectomy I-ADVERSE-EFFECTS NOUN F
haemorrhage I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
recorded 0 VERB F
in 0 ADP F
either 0 PUNCT F
group 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
one 0 NUM F
case 0 NOUN F
of 0 ADP F
secondary B-ADVERSE-EFFECTS ADJ F
post-tonsillectomy I-ADVERSE-EFFECTS NOUN F
haemorrhage I-ADVERSE-EFFECTS NOUN F
was 0 VERB F
recorded 0 VERB F
, 0 PUNCT F
in 0 ADP F
the 0 DET F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
2.5 0 NUM F
per 0 ADP F
cent 0 ADP F
) 0 PUNCT F
, 0 PUNCT F
managed 0 ADV F
conservatively 0 ADV F
. 0 PUNCT F

CONCLUSION 0 NOUN T
Both 0 CCONJ T
the 0 DET F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
and 0 CCONJ F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
techniques 0 NOUN F
were 0 VERB F
safe B-OTHER ADJ F
and 0 CCONJ F
easy B-OTHER PUNCT F
to I-OTHER ADP F
use I-OTHER PUNCT F
for 0 ADP F
tonsillectomy 0 NOUN F
, 0 PUNCT F
with 0 ADP F
reduced 0 VERB F
operative B-OTHER ADJ F
time I-OTHER NOUN F
, 0 PUNCT F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
and 0 CCONJ F
complication B-ADVERSE-EFFECTS NOUN F
rates I-ADVERSE-EFFECTS NOUN F
and 0 CCONJ F
better 0 PUNCT F
post-operative 0 ADJ F
general 0 ADJ F
patient 0 NOUN F
condition 0 NOUN F
. 0 PUNCT F

Potassium 0 NOUN T
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
resulted 0 VERB F
in 0 ADP F
reduced 0 VERB F
operative B-PHYSICAL ADJ F
bleeding I-PHYSICAL VERB F
and 0 CCONJ F
immediate B-PAIN ADJ F
post-operative I-PAIN ADJ F
pain I-PAIN NOUN F
, 0 PUNCT F
compared 0 VERB F
with 0 ADP F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
technique 0 NOUN F
. 0 PUNCT F

However 0 ADV T
, 0 PUNCT F
potassium 0 NOUN F
titanyl 0 NOUN F
phosphate 0 NOUN F
laser 0 NOUN F
required 0 PUNCT F
slightly 0 ADV F
more 0 ADV F
operative B-OTHER ADJ F
time I-OTHER NOUN F
and 0 CCONJ F
caused 0 VERB F
more 0 DET F
late B-PAIN ADJ F
post-operative I-PAIN ADJ F
pain I-PAIN NOUN F
than 0 VERB F
the 0 DET F
bipolar 0 ADJ F
radiofrequency 0 NOUN F
technique 0 NOUN F
. 0 PUNCT F

The 0 DET T
low 0 ADJ F
rate 0 NOUN F
of 0 ADP F
recorded 0 VERB F
complications 0 NOUN F
showed 0 VERB F
that 0 PUNCT F
both 0 PUNCT F
techniques 0 NOUN F
cause 0 DET F
little 0 DET F
damage 0 NOUN F
to 0 ADP F
the 0 DET F
tonsillar 0 ADJ F
bed 0 PUNCT F
during 0 ADP F
dissection 0 NOUN F
, 0 PUNCT F
thus 0 ADV F
minimising 0 PUNCT F
complications 0 NOUN F
. 0 PUNCT F

Teacher 0 NOUN T
and 0 CCONJ F
child 0 NOUN F
predictors 0 NOUN F
of 0 ADP F
achieving 0 NUM F
IEP 0 NOUN T
goals 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
. 0 PUNCT F

It 0 PRON T
is 0 VERB F
encouraging 0 VERB F
that 0 PUNCT F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
show 0 VERB F
a 0 DET F
strong 0 ADJ F
response 0 NOUN F
to 0 ADP F
early 0 ADJ F
intervention 0 NOUN F
, 0 PUNCT F
yet 0 ADV F
more 0 DET F
research 0 NOUN F
is 0 VERB F
needed 0 VERB F
for 0 ADP F
understanding 0 VERB F
the 0 DET F
variability 0 NOUN F
in 0 ADP F
responsiveness 0 NOUN F
to 0 ADP F
specialized 0 ADP F
programs 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
predictor 0 NOUN F
variables 0 NOUN F
from 0 ADP F
47 0 NUM F
teachers 0 NOUN F
and 0 CCONJ F
children 0 NOUN F
who 0 PROPN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
the 0 DET F
COMPASS 0 NOUN T
intervention 0 NOUN F
( 0 PUNCT F
Ruble 0 PUNCT T
et 0 CCONJ F
al 0 NOUN F
. 0 PUNCT F

in 0 ADP F
The 0 DET T
collaborative 0 ADJ F
model 0 NOUN F
for 0 ADP F
promoting 0 VERB F
competence 0 NOUN F
and 0 CCONJ F
success 0 NOUN F
for 0 ADP F
students 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

Springer 0 ADV T
, 0 PUNCT F
New 0 ADJ T
York 0 NOUN T
, 0 PUNCT F
2012a 0 NOUN F
) 0 PUNCT F
were 0 VERB F
analyzed 0 VERB F
. 0 PUNCT F

Predictors 0 PROPN T
evaluated 0 VERB F
against 0 ADP F
child B-OTHER NOUN F
IEP I-OTHER NOUN T
goal I-OTHER NOUN F
attainment I-OTHER NOUN F
included 0 ADP F
child 0 NOUN F
, 0 PUNCT F
teacher 0 NOUN F
, 0 PUNCT F
intervention 0 NOUN F
practice 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
implementation 0 NOUN F
practice 0 NOUN F
variables 0 NOUN F
based 0 VERB F
on 0 ADP F
an 0 DET F
implementation 0 NOUN F
science 0 NOUN F
framework 0 NOUN F
( 0 PUNCT F
Dunst 0 NOUN T
and 0 CCONJ F
Trivette 0 ADJ T
in 0 ADP F
J 0 NOUN T
Soc 0 NOUN T
Sci 0 NOUN T
8:143-148 0 NOUN F
, 0 PUNCT F
2012 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

Findings 0 NOUN T
revealed 0 VERB F
one 0 NUM F
child 0 NOUN F
( 0 PUNCT F
engagement 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
one 0 NUM F
teacher 0 NOUN F
( 0 PUNCT F
exhaustion 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
two 0 NUM F
intervention 0 NOUN F
quality 0 NOUN F
( 0 PUNCT F
IEP 0 NOUN T
quality 0 NOUN F
for 0 ADP F
targeted 0 VERB F
and 0 CCONJ F
not 0 ADV F
targeted 0 VERB F
elements 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
no 0 DET F
implementation 0 NOUN F
quality 0 NOUN F
variables 0 NOUN F
accounted 0 VERB F
for 0 ADP F
variance 0 NOUN F
in 0 ADP F
child 0 NOUN F
outcomes 0 NOUN F
when 0 ADP F
analyzed 0 VERB F
separately 0 ADV F
. 0 PUNCT F

When 0 ADP T
the 0 DET F
four 0 ADV F
significant 0 ADJ F
variables 0 NOUN F
were 0 VERB F
compared 0 VERB F
against 0 ADP F
each 0 ADP F
other 0 PUNCT F
in 0 ADP F
a 0 DET F
single 0 ADJ F
regression 0 NOUN F
analysis 0 NOUN F
, 0 PUNCT F
IEP 0 NOUN T
quality 0 NOUN F
accounted 0 VERB F
for 0 ADP F
one 0 NUM F
quarter 0 NOUN F
of 0 ADP F
the 0 DET F
variance 0 NOUN F
in 0 ADP F
child 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

A 0 DET T
comparison 0 NOUN F
of 0 ADP F
intermittent 0 ADJ F
vaginal 0 ADJ F
administration 0 NOUN F
of 0 ADP F
misoprostol 0 NOUN F
with 0 ADP F
continuous 0 ADJ F
dinoprostone 0 NUM F
for 0 ADP F
cervical B-PHYSICAL ADJ F
ripening I-PHYSICAL PROPN F
and 0 CCONJ F
labor B-PHYSICAL NOUN F
induction 0 NOUN F
. 0 PUNCT F

OBJECTIVE 0 NOUN T
Our 0 PUNCT T
purpose 0 NOUN F
was 0 VERB F
to 0 ADV F
compare 0 NOUN F
the 0 DET F
effect 0 NOUN F
of 0 ADP F
vaginal 0 ADJ F
administration 0 NOUN F
of 0 ADP F
misoprostol 0 NOUN F
( 0 PUNCT F
Cytotec 0 NOUN T
) 0 PUNCT F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
dinoprostone 0 NUM F
( 0 PUNCT F
Cervidil 0 PUNCT T
) 0 PUNCT F
on 0 ADP F
cervical B-PHYSICAL ADJ F
ripening I-PHYSICAL PROPN F
and 0 CCONJ F
labor B-PHYSICAL NOUN F
induction 0 NOUN F
. 0 PUNCT F

STUDY 0 NOUN T
DESIGN 0 NOUN T
Two 0 NUM T
hundred 0 NUM F
patients 0 NOUN F
with 0 ADP F
indications 0 NOUN F
for 0 ADP F
induction 0 NOUN F
of 0 ADP F
labor 0 NOUN F
and 0 CCONJ F
unfavorable 0 ADJ F
cervical 0 ADJ F
examinations 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 ADV F
vaginally 0 ADV F
administered 0 VERB F
misoprostol 0 NOUN F
( 0 PUNCT F
prostaglandin 0 NOUN F
E1 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
the 0 DET F
dinoprostone 0 NUM F
( 0 PUNCT F
prostaglandin 0 NOUN F
E2 0 NOUN T
) 0 PUNCT F
vaginal 0 ADJ F
insert 0 PUNCT F
. 0 PUNCT F

Twenty-five 0 PUNCT T
microgram 0 NOUN F
tablets 0 NOUN F
of 0 ADP F
misoprostol 0 NOUN F
were 0 VERB F
placed 0 VERB F
in 0 ADP F
the 0 DET F
posterior 0 ADJ F
vaginal 0 ADJ F
fornix 0 PUNCT F
every 0 DET F
4 0 NUM F
hours 0 NOUN F
for 0 ADP F
a 0 DET F
maximum 0 NOUN F
of 0 ADP F
six 0 NUM F
doses 0 NOUN F
. 0 PUNCT F

Additional 0 ADJ T
misoprostol 0 NOUN F
was 0 VERB F
not 0 ADV F
given 0 VERB F
after 0 ADP F
either 0 CCONJ F
spontaneous 0 ADJ F
rupture 0 NOUN F
of 0 ADP F
membranes 0 NOUN F
, 0 PUNCT F
adequate 0 PUNCT F
cervical 0 ADJ F
ripening 0 PROPN F
( 0 PUNCT F
Bishop 0 ADJ T
score 0 NOUN F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
8 0 NUM F
or 0 CCONJ F
cervical 0 ADJ F
dilatation 0 NOUN F
of 0 ADP F
> 0 PROPN F
or 0 CCONJ F
= 0 SYM F
3 0 NUM F
cm 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
or 0 CCONJ F
beginning 0 PUNCT F
of 0 ADP F
active 0 ADJ F
labor 0 NOUN F
. 0 PUNCT F

The 0 DET T
vaginal 0 ADJ F
insert 0 PUNCT F
, 0 PUNCT F
Cervidil 0 PUNCT T
, 0 PUNCT F
containing 0 VERB F
10 0 NUM F
mg 0 NOUN F
of 0 ADP F
dinoprostone 0 NUM F
in 0 ADP F
a 0 DET F
timed-release 0 NOUN F
preparation 0 NOUN F
was 0 VERB F
placed 0 VERB F
in 0 ADP F
the 0 DET F
posterior 0 ADJ F
vaginal 0 ADJ F
formix 0 PUNCT F
for 0 ADP F
a 0 DET F
maximum 0 NOUN F
period 0 NOUN F
of 0 ADP F
24 0 NUM F
hours 0 NOUN F
. 0 PUNCT F

The 0 DET T
vaginal 0 ADJ F
insert 0 PUNCT F
was 0 VERB F
removed 0 VERB F
for 0 ADP F
spontaneous 0 ADJ F
rupture 0 NOUN F
of 0 ADP F
membranes 0 NOUN F
, 0 PUNCT F
entry 0 NOUN F
into 0 ADP F
active 0 ADJ F
labor 0 NOUN F
, 0 PUNCT F
adequate 0 PUNCT F
cervical 0 ADJ F
ripening 0 PROPN F
, 0 PUNCT F
or 0 CCONJ F
abnormality 0 NOUN F
of 0 ADP F
uterine 0 ADJ F
contractile 0 ADJ F
pattern 0 NOUN F
or 0 CCONJ F
fetal 0 ADJ F
cardiac 0 ADJ F
activity 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
200 0 NUM F
patients 0 NOUN F
enrolled 0 VERB F
, 0 PUNCT F
99 0 NUM F
were 0 VERB F
randomized 0 ADP F
to 0 ADP F
misoprostol 0 NOUN F
and 0 CCONJ F
101 0 NUM F
to 0 ADP F
dinoprostone 0 NUM F
. 0 PUNCT F

The 0 DET T
average 0 ADJ F
interval 0 NOUN F
from 0 ADP F
start B-PHYSICAL NOUN F
of I-PHYSICAL ADP F
induction 0 NOUN F
to B-PHYSICAL ADP F
vaginal I-PHYSICAL ADJ F
delivery B-PHYSICAL NOUN F
was 0 VERB F
1 0 NUM F
hour 0 NOUN F
shorter 0 PUNCT F
in 0 ADP F
the 0 DET F
misoprostol 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
1296.7 0 NOUN F
+/- 0 SYM F
722.1 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
dinoprostone 0 NUM F
group 0 NOUN F
( 0 PUNCT F
1360.0 0 NOUN F
+/- 0 SYM F
792.0 0 NUM F
minutes 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
this 0 DET F
difference 0 NOUN F
was 0 VERB F
not 0 ADV F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.97 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Oxytocin B-OTHER NOUN T
augmentation I-OTHER NOUN F
of I-OTHER ADP F
labor B-OTHER NOUN F
was 0 VERB F
used 0 VERB F
in 0 ADP F
50 0 NUM F
( 0 PUNCT F
50.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
misoprostol-treated 0 ADP F
patients 0 NOUN F
and 0 CCONJ F
43 0 NUM F
( 0 PUNCT F
43.5 0 NUM F
% 0 SYM F
) 0 PUNCT F
dinoprostone-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
1.14 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
0.86 0 NUM F
to 0 ADP F
1.51 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.35 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
between 0 ADP F
routes B-OTHER NOUN F
of I-OTHER ADP F
delivery I-OTHER NOUN F
with 0 ADP F
misoprostol 0 NOUN F
or 0 CCONJ F
dinoprostone 0 NUM F
. 0 PUNCT F

Overall 0 ADJ T
, 0 PUNCT F
38 0 NUM F
patients 0 NOUN F
( 0 PUNCT F
19.3 0 NUM F
% 0 SYM F
) 0 PUNCT F
had 0 DET F
cesarean 0 NOUN F
deliveries 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
significantly 0 ADV F
lower 0 PUNCT F
prevalence 0 NOUN F
of 0 ADP F
tachysystole B-PHYSICAL NOUN F
( 0 PUNCT F
six 0 NUM F
or 0 CCONJ F
more 0 DET F
uterine 0 ADJ F
contractions 0 NOUN F
in 0 ADP F
a 0 DET F
10-minute 0 ADJ F
window 0 NOUN F
for 0 ADP F
two 0 NUM F
consecutive 0 ADJ F
10-minute 0 ADJ F
periods 0 NOUN F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
misoprostol 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
7.1 0 NUM F
% 0 SYM F
) 0 PUNCT F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
dinoprostone 0 NUM F
group 0 NOUN F
( 0 PUNCT F
18.4 0 NUM F
% 0 SYM F
) 0 PUNCT F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
0.52 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
0.31 0 NUM F
to 0 ADP F
0.89 0 NUM F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
frequency 0 NOUN F
of 0 ADP F
uterine B-PHYSICAL ADJ F
hyperstimulation I-PHYSICAL NOUN F
or B-PHYSICAL CCONJ F
hypertonus I-PHYSICAL NOUN F
. 0 PUNCT F

Abnormal B-PHYSICAL ADJ T
fetal I-PHYSICAL ADJ F
heart I-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
tracings I-PHYSICAL NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
23 0 NUM F
( 0 PUNCT F
23.2 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
misoprostol-treated 0 VERB F
patients 0 NOUN F
and 0 CCONJ F
35 0 NUM F
( 0 PUNCT F
35.7 0 NUM F
% 0 SYM F
) 0 PUNCT F
of 0 ADP F
dinoprostone-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
relative 0 ADJ F
risk 0 NOUN F
0.73 0 NUM F
, 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
0.52 0 NUM F
to 0 ADP F
1.01 0 PUNCT F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.0546 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

No 0 DET T
significant 0 ADJ F
differences 0 NOUN F
were 0 VERB F
found 0 VERB F
in 0 ADP F
meconium B-PHYSICAL NOUN F
passage I-PHYSICAL PUNCT F
, 0 PUNCT F
1- 0 NUM F
or 0 CCONJ F
5-minute 0 PUNCT F
Apgar B-PHYSICAL NOUN T
scores I-PHYSICAL NOUN F
< 0 SYM F
7 0 NUM F
, 0 PUNCT F
neonatal B-PHYSICAL ADJ F
resuscitations I-PHYSICAL NOUN F
, 0 PUNCT F
or 0 CCONJ F
admissions B-OTHER NOUN F
to I-OTHER ADP F
the I-OTHER DET F
neonatal B-OTHER ADJ F
intensive I-OTHER PUNCT F

Moderate 0 ADJ T
sodium 0 NOUN F
restriction 0 NOUN F
, 0 PUNCT F
angiotensin 0 NOUN F
converting 0 VERB F
enzyme 0 NOUN F
inhibition 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
thiazide 0 NOUN F
diuretic 0 NOUN F
in 0 ADP F
the 0 DET F
management 0 NOUN F
of 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Dietary 0 ADJ T
sodium 0 NOUN F
restriction 0 NOUN F
alone 0 ADJ F
is 0 CCONJ F
effective 0 ADJ F
in 0 ADP F
lowering 0 VERB F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
in 0 ADP F
some 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
not 0 ADV F
all 0 PUNCT F
, 0 PUNCT F
patients 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
. 0 PUNCT F

Homeostatic 0 ADJ T
mechanisms 0 NOUN F
, 0 PUNCT F
including 0 VERB F
activation 0 NOUN F
of 0 ADP F
the 0 DET F
renin-aldosterone 0 ADJ F
system 0 NOUN F
, 0 PUNCT F
may 0 VERB F
counteract 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
sodium 0 NOUN F
restriction 0 NOUN F
. 0 PUNCT F

Angiotensin 0 NOUN T
converting 0 VERB F
enzyme 0 NOUN F
( 0 PUNCT F
ACE 0 NOUN T
) 0 PUNCT F
inhibitors 0 NOUN F
are 0 VERB F
also 0 ADV F
effective 0 ADJ F
as 0 ADP F
sole 0 ADJ F
therapy 0 NOUN F
in 0 ADP F
many 0 DET F
patients 0 NOUN F
with 0 ADP F
essential 0 ADJ F
hypertension 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
may 0 VERB F
be 0 VERB F
less 0 ADV F
effective 0 ADJ F
in 0 ADP F
those 0 PUNCT F
with 0 ADP F
low-renin 0 NOUN F
hypertension 0 NOUN F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
of 0 ADP F
dietary 0 ADJ F
sodium 0 NOUN F
restriction 0 NOUN F
with 0 ADP F
blockade 0 NOUN F
of 0 ADP F
the 0 DET F
renin 0 NOUN F
system 0 NOUN F
by 0 ADP F
an 0 DET F
ACE 0 NOUN T
inhibitor 0 NOUN F
is 0 VERB F
a 0 DET F
particularly 0 ADV F
effective 0 ADJ F
way 0 NOUN F
to 0 PROPN F
improve 0 PUNCT F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
control 0 NOUN F
. 0 PUNCT F

Addition 0 NOUN T
of 0 ADP F
a 0 DET F
thiazide 0 NOUN F
diuretic 0 NOUN F
will 0 ADV F
reduce 0 VERB F
pressure 0 NOUN F
further 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
' 0 PUNCT F
state 0 NOUN F
and 0 CCONJ F
trait 0 NOUN F
anxiety 0 NOUN F
: 0 PUNCT F
relationships 0 NOUN F
with 0 ADP F
anxiety B-MENTAL NOUN F
severity I-MENTAL NOUN F
and 0 CCONJ F
treatment 0 NOUN F
response 0 NOUN F
in 0 ADP F
adolescents 0 NOUN F
with 0 ADP F
autism 0 NOUN F
spectrum 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

Comorbid 0 ADJ T
anxiety 0 NOUN F
is 0 ADJ F
common 0 ADJ F
among 0 ADP F
children 0 NOUN F
with 0 ADP F
Autism 0 NOUN T
Spectrum 0 NOUN T
Disorder 0 NOUN T
( 0 PUNCT F
ASD 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
parents 0 NOUN F
of 0 ADP F
children 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
are 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
have 0 PUNCT F
anxiety 0 NOUN F
disorders 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
investigated 0 VERB F
the 0 DET F
relationship 0 NOUN F
between 0 ADP F
parents 0 NOUN F
' 0 PUNCT F
state B-MENTAL NOUN F
and 0 CCONJ F
trait B-MENTAL NOUN F
anxiety I-MENTAL NOUN F
and 0 CCONJ F
parent-reported 0 ADP F
internalizing 0 VERB F
and 0 CCONJ F
externalizing 0 PUNCT F
symptoms 0 NOUN F
among 0 ADP F
adolescents 0 NOUN F
( 0 PUNCT F
n 0 NOUN F
= 0 SYM F
30 0 NUM F
) 0 PUNCT F
with 0 ADP F
ASD 0 NOUN T
, 0 PUNCT F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
the 0 DET F
relationship 0 NOUN F
of 0 ADP F
parents 0 NOUN F
' 0 PUNCT F
anxiety 0 NOUN F
symptoms 0 NOUN F
and 0 CCONJ F
adolescent 0 NOUN F
treatment 0 NOUN F
response 0 NOUN F
in 0 ADP F
the 0 DET F
context 0 NOUN F
of 0 ADP F
a 0 DET F
randomized 0 VERB F
controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

Parental 0 ADJ T
state 0 NOUN F
anxiety 0 NOUN F
correlated 0 VERB F
with 0 ADP F
severity 0 NOUN F
of 0 ADP F
adolescent 0 NOUN F
anxiety 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
trait 0 NOUN F
anxiety 0 NOUN F
in 0 ADP F
parents 0 NOUN F
correlated 0 VERB F
with 0 ADP F
parent-reported 0 VERB F
adolescent 0 NOUN F
internalizing 0 SYM F
and 0 CCONJ F
externalizing 0 PUNCT F
symptoms 0 NOUN F
. 0 PUNCT F

Also 0 ADV T
, 0 PUNCT F
parents 0 NOUN F
of 0 ADP F
adolescent 0 NOUN F
treatment 0 NOUN F
responders 0 ADP F
experienced 0 VERB F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
their 0 PUNCT F
own 0 ADJ F
trait 0 NOUN F
anxiety 0 NOUN F
. 0 PUNCT F

Findings 0 NOUN T
highlight 0 VERB F
the 0 DET F
importance 0 NOUN F
of 0 ADP F
considering 0 PUNCT F
parental 0 ADJ F
anxiety 0 NOUN F
when 0 ADP F
targeting 0 VERB F
anxiety 0 NOUN F
among 0 ADP F
youth 0 NOUN F
with 0 ADP F
ASD 0 NOUN T
. 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
the 0 DET F
in B-OTHER ADP F
vitro I-OTHER ADJ F
and I-OTHER CCONJ F
in I-OTHER ADP F
vivo I-OTHER ADJ F
release I-OTHER NOUN F
of I-OTHER ADP F
digoxin B-OTHER NOUN F
from 0 ADP F
four 0 NUM F
different 0 ADJ F
soft 0 ADJ F
gelatin 0 NOUN F
capsule 0 NOUN F
formulations 0 NOUN F
. 0 PUNCT F

A 0 DET T
blinded 0 VERB F
, 0 PUNCT F
four-treatment 0 ADJ F
crossover 0 NOUN F
study 0 NOUN F
in 0 ADP F
16 0 NUM F
normal 0 ADJ F
adult 0 NOUN F
male 0 NOUN F
volunteers 0 NOUN F
compared 0 PUNCT F
plasma 0 NOUN F
concentrations 0 NOUN F
and 0 CCONJ F
urinary B-OTHER ADJ F
excretion I-OTHER NOUN F
of B-OTHER ADP F
digoxin I-OTHER NOUN F
, 0 PUNCT F
measured 0 VERB F
by 0 ADP F
radioimmunoassay 0 NOUN F
, 0 PUNCT F
after 0 ADP F
oral 0 ADJ F
administration 0 NOUN F
of 0 ADP F
soft 0 ADJ F
gelatin 0 NOUN F
capsule 0 NOUN F
formulations 0 NOUN F
of 0 ADP F
digoxin 0 NOUN F
. 0 PUNCT F

Four 0 NUM T
0.4-mg 0 NOUN F
formulations 0 NOUN F
with 0 ADP F
different 0 ADJ F
in 0 ADP F
vitro 0 ADJ F
burst 0 NOUN F
times 0 NOUN F
and 0 CCONJ F
dissolution 0 NOUN F
rates 0 NOUN F
were 0 VERB F
administered 0 VERB F
, 0 PUNCT F
with 0 ADP F
2-week 0 NOUN F
intervals 0 NOUN F
between 0 ADP F
treatments 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
capsules 0 NOUN F
with 0 ADP F
lowest 0 PUNCT F
in 0 PUNCT F
vitro 0 ADJ F
burst 0 NOUN F
times 0 NOUN F
( 0 PUNCT F
2.9 0 NUM F
and 0 CCONJ F
16 0 NUM F
min 0 NOUN F
) 0 PUNCT F
gave 0 VERB F
comparable 0 ADJ F
in 0 PUNCT F
vivo 0 ADJ F
results 0 CCONJ F
. 0 PUNCT F

The 0 DET T
other 0 ADJ F
two 0 NUM F
capsules 0 NOUN F
, 0 PUNCT F
with 0 ADP F
in 0 PUNCT F
vitro 0 ADJ F
burst 0 NOUN F
times 0 NOUN F
of 0 ADP F
62 0 NUM F
and 0 CCONJ F
229 0 NUM F
min 0 NOUN F
, 0 PUNCT F
produced 0 DET F
significant 0 ADJ F
delays 0 NOUN F
in 0 ADP F
digoxin 0 NOUN F
absorption 0 NOUN F
. 0 PUNCT F

In 0 ADP T
vitro-in 0 ADJ F
vivo 0 ADP F
correlations 0 NOUN F
were 0 VERB F
obtained 0 VERB F
by 0 ADP F
comparing 0 ADP F
the 0 DET F
logarithm 0 NOUN F
of 0 ADP F
the 0 DET F
in 0 PUNCT F
vitro 0 ADJ F
burst 0 NOUN F
time 0 NOUN F
with 0 ADP F
time 0 NOUN F
to 0 ADP F
peak 0 ADJ F
plasma B-OTHER NOUN F
level I-OTHER NOUN F
and 0 CCONJ F
the 0 DET F
time 0 NOUN F
to 0 ADP F
the 0 DET F
first 0 ADJ F
measurable 0 PUNCT F

[ 0 PUNCT F
Radiotherapy 0 NOUN T
of 0 ADP F
malignant 0 ADJ F
brain 0 NOUN F
gliomas 0 NOUN F
using 0 VERB F
teniposide 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Efficacy 0 NOUN T
of 0 ADP F
radiochemotherapy 0 NOUN F
of 0 ADP F
malignantly-converted 0 VERB F
brain 0 NOUN F
gliomas 0 NOUN F
using 0 SYM F
teniposide 0 NOUN F
was 0 VERB F
evaluated 0 VERB F
in 0 ADP F
a 0 DET F
randomized 0 VERB F
prospective 0 ADJ F
study 0 NOUN F
. 0 PUNCT F

Combined 0 VERB T
use 0 NOUN F
of 0 ADP F
cytostatics 0 NOUN F
and 0 CCONJ F
irradiation 0 NOUN F
appeared 0 VERB F
safe 0 ADJ F
, 0 PUNCT F
tolerable 0 ADJ F
and 0 CCONJ F
significantly 0 ADV F
more 0 ADV F
effective 0 ADJ F
than 0 PUNCT F
radiotherapy 0 NOUN F
alone 0 ADJ F
as 0 PUNCT F
assessed 0 VERB F
by 0 ADP F
local B-PHYSICAL VERB F
control 0 NOUN F
of B-PHYSICAL ADP F
tumor B-PHYSICAL NOUN F
and 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
on 0 ADP F
adherence 0 NOUN F
to 0 ADP F
a 0 DET F
low-fat 0 NOUN F
dietary 0 ADJ F
pattern 0 NOUN F
in 0 ADP F
the 0 DET F
Women 0 NOUN T
's 0 PUNCT F
Health 0 NOUN T
Initiative 0 NOUN T
. 0 PUNCT F

OBJECTIVE 0 NOUN T
To 0 PROPN T
examine 0 NOUN F
whether 0 ADP F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
on 0 ADP F
adherance 0 NOUN F
to 0 ADP F
a 0 DET F
low-fat 0 NOUN F
( 0 PUNCT F
20 0 NUM F
% 0 ADV F
energy 0 NOUN F
) 0 PUNCT F
dietary 0 ADJ F
pattern 0 NOUN F
are 0 VERB F
mediated 0 VERB F
by 0 ADP F
participation 0 NOUN F
in 0 ADP F
an 0 DET F
intervention 0 NOUN F
program 0 NOUN F
( 0 PUNCT F
attending 0 ADJ F
sessions 0 NOUN F
and 0 CCONJ F
self-monitoring 0 PUNCT F
) 0 PUNCT F
. 0 PUNCT F

DESIGN 0 NOUN T
The 0 DET T
Baron 0 NOUN T
and 0 CCONJ F
Kenny 0 NOUN T
mediator 0 NOUN F
model 0 NOUN F
, 0 PUNCT F
a 0 DET F
series 0 NOUN F
of 0 ADP F
4 0 NUM F
regression 0 NOUN F
analyses 0 NOUN F
, 0 PUNCT F
was 0 VERB F
used 0 VERB F
to 0 PART F
evaluate 0 NOUN F
whether 0 ADP F
: 0 PUNCT F
a 0 PUNCT F
) 0 PUNCT F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
predicted 0 ADP F
program 0 NOUN F
participation 0 NOUN F
, 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
program 0 NOUN F
participation 0 NOUN F
predicted 0 PUNCT F
dietary 0 ADJ F
adherence 0 NOUN F
, 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
factors 0 NOUN F
predicted 0 VERB F
dietary 0 ADJ F
adherence 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
, 0 PUNCT F
ultimately 0 ADV F
d 0 NOUN F
) 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
on 0 ADP F
dietary 0 ADJ F
adherence 0 NOUN F
were 0 VERB F
mediated 0 VERB F
by 0 ADP F
program 0 NOUN F
participation 0 NOUN F
. 0 PUNCT F

SUBJECTS/SETTING 0 PUNCT T
Data 0 NOUN T
from 0 ADP F
13,277 0 NUM F
postmenopausal 0 ADJ F
women 0 NOUN F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
low-fat 0 NOUN F
intervention 0 NOUN F
arm 0 NOUN F
of 0 ADP F
the 0 DET F
Women 0 NOUN T
's 0 PUNCT F
Health 0 NOUN T
Initiative 0 NOUN T
Dietary 0 ADJ T
Modification 0 NOUN T
Trial 0 NOUN T
. 0 PUNCT F

INTERVENTION 0 NOUN T
The 0 DET T
nutrition 0 NOUN F
goals 0 NOUN F
for 0 ADP F
women 0 NOUN F
randomly 0 ADV F
assigned 0 VERB F
to 0 ADP F
the 0 DET F
low-fat 0 NOUN F
intervention 0 NOUN F
were 0 VERB F
to 0 PART F
reduce 0 NOUN F
total 0 ADJ F
fat 0 NOUN F
intake 0 ADJ F
to 0 ADP F
20 0 NUM F
% 0 SYM F
or 0 CCONJ F
less 0 DET F
of 0 ADP F
energy 0 NOUN F
from 0 ADP F
fat 0 NOUN F
and 0 CCONJ F
to 0 VERB F
consume 0 VERB F
5 0 NUM F
or 0 CCONJ F
more 0 DET F
fruit/vegetable 0 ADJ F
servings 0 NOUN F
daily 0 ADJ F
and 0 CCONJ F
6 0 NUM F
or 0 CCONJ F
more 0 DET F
grain 0 NOUN F
servings 0 NOUN F
daily 0 ADJ F
. 0 PUNCT F

MAIN 0 ADJ T
OUTCOME 0 NOUN T
MEASURES 0 NOUN T
Year 0 ADJ T
1 0 NUM F
program 0 NOUN F
participation 0 NOUN F
( 0 PUNCT F
degree 0 NOUN F
of 0 ADP F
attending 0 PUNCT F
group 0 NOUN F
sessions 0 NOUN F
and 0 CCONJ F
submitting 0 VERB F
fat 0 NOUN F
scores 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
adherence B-MENTAL NOUN F
to I-MENTAL ADP F
the I-MENTAL DET F
low-fat I-MENTAL NOUN F
dietary I-MENTAL ADJ F
pattern I-MENTAL NOUN F
( 0 PUNCT F
percent B-MENTAL NOUN F
energy I-MENTAL NOUN F
from I-MENTAL ADP F
fat I-MENTAL NOUN F
) 0 PUNCT F
as 0 PUNCT F
predicted 0 VERB F
by 0 ADP F
baseline 0 NOUN F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
( 0 PUNCT F
eight 0 NUM F
SF-36 0 NOUN T
Health 0 NOUN T
Survey 0 NOUN T
subscales 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

RESULTS 0 NOUN T
Participating 0 PUNCT T
in 0 ADP F
the 0 DET F
dietary 0 ADJ F
intervention 0 NOUN F
program 0 NOUN F
reduced 0 VERB F
( 0 PUNCT F
mediated 0 ADP F
) 0 PUNCT F
the 0 DET F
negative 0 ADJ F
effect 0 NOUN F
of 0 ADP F
poorer B-MENTAL PUNCT F
mental I-MENTAL ADJ F
health I-MENTAL NOUN F
on 0 ADP F
dietary B-MENTAL ADJ F
adherence I-MENTAL NOUN F
by 0 ADP F
15 0 NUM F
% 0 SYM F
. 0 PUNCT F

Additional 0 ADJ T
findings 0 NOUN F
included 0 VERB F
that 0 ADP F
a 0 DET F
10 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
physical B-PHYSICAL ADJ F
functioning I-PHYSICAL PART F
increased 0 VERB F
session B-MENTAL NOUN F
attendance I-MENTAL NOUN F
by 0 ADP F
0.4 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
10 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
mental B-MENTAL ADJ F
health I-MENTAL NOUN F
predicted 0 VERB F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
percent 0 NOUN F
energy 0 NOUN F
from 0 ADP F
fat 0 NOUN F
of 0 ADP F
0.3 0 NUM F
% 0 SYM F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Program 0 NOUN T
participation 0 NOUN F
had 0 PUNCT F
a 0 DET F
marked 0 VERB F
effect 0 NOUN F
on 0 ADP F
dietary B-MENTAL ADJ F
adherence I-MENTAL NOUN F
: 0 PUNCT F
a 0 DET F
10 0 NUM F
% 0 SYM F
increase 0 NOUN F
in 0 ADP F
session B-MENTAL NOUN F
attendance I-MENTAL NOUN F
predicted 0 VERB F
a 0 DET F
1.2 0 NUM F
% 0 SYM F
decrease 0 NOUN F
in 0 ADP F
percent 0 NOUN F
energy 0 NOUN F
from 0 ADP F
fat 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

APPLICATIONS/CONCLUSIONS 0 ADJ T
Understanding 0 PROPN T
and 0 CCONJ F
using 0 PUNCT F
instruments 0 NOUN F
to 0 PART F
assess 0 NOUN F
the 0 DET F
physical 0 ADJ F
and 0 CCONJ F
emotional 0 ADJ F
status 0 NOUN F
of 0 ADP F
a 0 DET F
target 0 NOUN F
population 0 NOUN F
will 0 VERB F
help 0 VERB F
dietetic 0 ADJ F
professionals 0 NOUN F
promote 0 VERB F
healthful 0 ADJ F
dietary 0 ADJ F
change 0 NOUN F
and 0 CCONJ F
maintenance 0 NOUN F
. 0 PUNCT F

Concurrent 0 ADJ T
alcohol 0 NOUN F
dependence 0 NOUN F
among 0 ADP F
methadone-maintained 0 ADJ F
cocaine 0 NOUN F
abusers 0 NOUN F
is 0 VERB F
associated 0 VERB F
with 0 ADP F
greater 0 PUNCT F
abstinence B-MENTAL NOUN F
. 0 PUNCT F

Concurrent 0 ADJ T
alcohol 0 NOUN F
dependence 0 NOUN F
( 0 PUNCT F
AD 0 NOUN T
) 0 PUNCT F
among 0 ADP F
polysubstance 0 NOUN F
abusers 0 NOUN F
has 0 PUNCT F
been 0 PUNCT F
associated 0 VERB F
with 0 ADP F
negative 0 ADJ F
consequences 0 NOUN F
, 0 PUNCT F
although 0 ADP F
it 0 PRON F
may 0 ADP F
not 0 ADV F
necessarily 0 ADV F
lead 0 VERB F
to 0 ADP F
poor 0 ADJ F
treatment 0 NOUN F
outcomes 0 NOUN F
. 0 PUNCT F

One 0 PUNCT T
of 0 ADP F
the 0 DET F
most 0 PUNCT F
efficacious 0 ADJ F
treatments 0 NOUN F
for 0 ADP F
cocaine 0 NOUN F
abuse 0 NOUN F
is 0 VERB F
contingency 0 NOUN F
management 0 NOUN F
( 0 PUNCT F
CM 0 NOUN T
) 0 PUNCT F
, 0 PUNCT F
but 0 CCONJ F
little 0 DET F
research 0 NOUN F
has 0 PUNCT F
explored 0 VERB F
the 0 DET F
impact 0 NOUN F
of 0 ADP F
AD 0 NOUN T
on 0 ADP F
abstinence B-MENTAL PUNCT F
outcomes I-MENTAL NOUN F
, 0 PUNCT F
particularly 0 ADV F
among 0 ADP F
patients 0 NOUN F
in 0 ADP F
methadone 0 NOUN F
maintenance 0 NOUN F
. 0 PUNCT F

Using 0 VERB T
data 0 NOUN F
from 0 ADP F
three 0 NUM F
trials 0 NOUN F
of 0 ADP F
CM 0 NOUN T
for 0 ADP F
cocaine 0 PUNCT F
use 0 NOUN F
, 0 PUNCT F
we 0 NOUN F
compared 0 VERB F
baseline 0 NOUN F
characteristics 0 NOUN F
and 0 CCONJ F
posttreatment 0 ADJ F
and 0 CCONJ F
follow-up 0 NOUN F
cocaine B-PHYSICAL NOUN F
outcomes I-PHYSICAL NOUN F
between 0 ADP F
methadone-maintained 0 PUNCT F
, 0 PUNCT F
cocaine-dependent 0 DET F
patients 0 NOUN F
( 0 PUNCT F
N 0 NOUN T
= 0 SYM F
193 0 NUM F
) 0 PUNCT F
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
concurrent 0 ADJ F
AD 0 NOUN T
, 0 PUNCT F
randomized 0 PUNCT F
to 0 ADP F
standard 0 ADJ F
care 0 NOUN F
( 0 PUNCT F
SC 0 NOUN T
) 0 PUNCT F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
CM 0 NOUN T
. 0 PUNCT F

Patients 0 NOUN T
with 0 ADP F
and 0 CCONJ F
without 0 ADP F
concurrent 0 ADJ F
AD 0 NOUN T
had 0 PUNCT F
similar 0 ADJ F
baseline 0 NOUN F
characteristics 0 NOUN F
, 0 PUNCT F
with 0 ADP F
the 0 DET F
exception 0 NOUN F
that 0 PUNCT F
AD 0 NOUN T
patients 0 NOUN F
reported 0 VERB F
more 0 DET F
alcohol 0 NOUN F
use 0 NOUN F
. 0 PUNCT F

AD 0 NOUN T
patients 0 NOUN F
achieved 0 VERB F
longer 0 PUNCT F
durations 0 NOUN F
of 0 ADP F
cocaine B-MENTAL NOUN F
abstinence I-MENTAL NOUN F
and 0 CCONJ F
were 0 VERB F
more 0 ADV F
likely 0 ADJ F
to 0 PART F
submit 0 PUNCT F
a 0 DET F
cocaine-negative B-MENTAL ADJ F
sample I-MENTAL NOUN F
at 0 ADP F
follow-up 0 NOUN F
than 0 PUNCT F
non-AD 0 NUM F
patients 0 NOUN F
. 0 PUNCT F

Patients 0 NOUN T
randomized 0 DET F
to 0 ADP F
CM 0 NOUN T
achieved 0 VERB F
better 0 CCONJ F
outcomes 0 NOUN F
than 0 CCONJ F
those 0 PUNCT F
randomized 0 VERB F
to 0 ADP F
SC 0 NOUN T
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
no 0 DET F
interaction 0 NOUN F
between 0 ADP F
treatment 0 NOUN F
condition 0 NOUN F
and 0 CCONJ F
AD 0 NOUN T
status 0 NOUN F
. 0 PUNCT F

These 0 DET T
findings 0 NOUN F
suggest 0 VERB F
that 0 ADP F
cocaine-using 0 VERB F
methadone 0 NOUN F
patients 0 NOUN F
with 0 ADP F
AD 0 NOUN T
achieve 0 VERB F
greater 0 PUNCT F
cocaine B-MENTAL NOUN F
abstinence I-MENTAL PUNCT F
than 0 ADP F
their 0 CCONJ F
non-AD 0 NUM F
counterparts 0 NOUN F
and 0 CCONJ F
should 0 ADP F
not 0 ADV F
necessarily 0 ADV F
be 0 ADP F
viewed 0 VERB F
as 0 PUNCT F
more 0 VERB F
difficult 0 ADJ F
to 0 DET F
treat 0 CCONJ F
. 0 PUNCT F

Co-administration 0 NOUN T
of 0 ADP F
pethidine 0 ADJ F
and 0 CCONJ F
clonidine 0 NOUN F
: 0 PUNCT F
a 0 DET F
spinal 0 ADJ F
anaesthetic 0 ADJ F
technique 0 NOUN F
for 0 ADP F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
. 0 PUNCT F

Co-administration 0 NOUN T
of 0 ADP F
pethidine 0 ADJ F
0.75 0 NUM F
mg 0 NOUN F
kg-1 0 NOUN F
and 0 CCONJ F
clonidine 0 NOUN F
75 0 NUM F
micrograms 0 NOUN F
intrathecally 0 ADV F
provided 0 PUNCT F
good 0 ADJ F
intraoperative 0 ADJ F
anaesthesia 0 NOUN F
for 0 ADP F
total 0 ADJ F
hip 0 NOUN F
replacement 0 NOUN F
, 0 PUNCT F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
obtained 0 VERB F
using 0 VERB F
0.5 0 NUM F
% 0 ADJ F
isobaric 0 ADJ F
bupivacaine 0 NOUN F
. 0 PUNCT F

Sensory 0 ADJ T
and 0 CCONJ F
motor 0 NOUN F
block 0 NOUN F
were 0 DET F
of 0 ADP F
shorter 0 PUNCT F
duration 0 NOUN F
than 0 ADP F
that 0 PUNCT F
after 0 ADP F
0.5 0 NUM F
% 0 ADJ F
isobaric 0 ADJ F
bupivacaine 0 NOUN F
and 0 CCONJ F
0.5 0 NUM F
% 0 ADJ F
isobaric 0 ADJ F
bupivacaine 0 NOUN F
with 0 ADP F
morphine 0 NOUN F
0.5 0 NUM F
mg 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
sensory 0 ADJ F
block 0 NOUN F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
motor 0 NOUN F
block 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Postoperative B-OTHER ADJ T
morphine I-OTHER NOUN F
consumption I-OTHER NOUN F
, 0 PUNCT F
measured 0 VERB F
using 0 SYM F
a 0 DET F
patient-controlled 0 VERB F
system 0 NOUN F
, 0 PUNCT F
was 0 VERB F
similar 0 ADJ F
to 0 ADP F
that 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
bupivacaine 0 NOUN F
only 0 PUNCT F
group 0 NOUN F
( 0 PUNCT F
pethidine-clonidine 0 NOUN F
: 0 PUNCT F
median 0 ADJ F
39 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
; 0 PUNCT F
bupivacaine 0 NOUN F
: 0 PUNCT F
median 0 ADJ F
34 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
) 0 PUNCT F
but 0 CCONJ F
greater 0 PUNCT F
than 0 VERB F
that 0 CCONJ F
in 0 ADP F
the 0 DET F
bupivacaine-morphine 0 ADJ F
group 0 NOUN F
( 0 PUNCT F
median 0 ADJ F
8 0 NUM F
mg/24 0 NOUN F
h 0 NOUN F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Visual B-PAIN ADJ T
analogue I-PAIN NOUN F
pain I-PAIN NOUN F
scores 0 NOUN F
after 0 ADP F
operation 0 NOUN F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
those 0 PUNCT F
with 0 ADP F
bupivacaine 0 NOUN F
alone 0 ADJ F
at 0 ADP F
all 0 ADP F
but 0 CCONJ F
one 0 NUM F
of 0 ADP F
the 0 DET F
recording 0 VERB F
times 0 NOUN F
but 0 CCONJ F
were 0 VERB F
greater 0 PUNCT F
than 0 VERB F
those 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
who 0 ADP F
received 0 VERB F
bupivacaine 0 NOUN F
and 0 CCONJ F
morphine 0 NOUN F
at 0 ADP F
4 0 NUM F
, 0 PUNCT F
6 0 NUM F
and 0 CCONJ F
10 0 NUM F
h 0 NOUN F
after 0 ADP F
operation 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.001 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.04 0 NUM F
, 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.02 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
combination 0 NOUN F
did 0 PUNCT F
not 0 ADV F
offer 0 VERB F
any 0 DET F
major 0 ADJ F
advantage 0 NOUN F
over 0 ADP F
conventional 0 ADJ F
agents 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Effect 0 NOUN T
of 0 ADP F
liu 0 NOUN F
wei 0 CCONJ F
di 0 NOUN F
huang 0 NOUN F
or 0 CCONJ F
jin 0 NOUN F
gui 0 NOUN F
shen 0 NOUN F
qi 0 CCONJ F
decoction 0 NOUN F
as 0 PUNCT F
on 0 ADP F
adjuvant 0 NOUN F
treatment 0 NOUN F
in 0 ADP F
small 0 ADJ F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

Eighty-three 0 VERB T
patients 0 NOUN F
with 0 ADP F
small 0 ADJ F
cell 0 NOUN F
lung 0 NOUN F
cancer 0 NOUN F
were 0 VERB F
randomized 0 VERB F
with 0 ADP F
or 0 CCONJ F
without 0 ADP F
using 0 ADP F
a 0 DET F
traditional 0 ADJ F
Chinese 0 NOUN T
Kidney-tonifying 0 PUNCT T
decoction 0 NOUN F
( 0 PUNCT F
Liu 0 NOUN T
Wei 0 CCONJ T
Di 0 ADP T
Huang 0 PUNCT T
or 0 CCONJ F
Jin 0 NOUN T
Gui 0 NOUN T
Shen 0 NOUN T
Qi 0 NOUN T
medicinal 0 ADJ F
decoction 0 NOUN F
) 0 PUNCT F
in 0 ADP F
chemotherapy 0 NOUN F
or 0 CCONJ F
radiotherapy 0 NOUN F
courses 0 ADP F
. 0 PUNCT F

74 0 NUM F
patients 0 NOUN F
were 0 VERB F
availble 0 ADJ F
to 0 PART F
be 0 PUNCT F
analysis 0 NOUN F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
were 0 VERB F
well-matched 0 ADV F
in 0 ADP F
age 0 NOUN F
, 0 PUNCT F
sex 0 NOUN F
, 0 PUNCT F
stage 0 NOUN F
and 0 CCONJ F
performance 0 NOUN F
status 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
difference 0 NOUN F
in 0 ADP F
response 0 NOUN F
rate B-PHYSICAL NOUN F
and 0 CCONJ F
the 0 DET F
median 0 ADJ F
survival B-MORTALITY NOUN F
between 0 ADP F
two 0 NUM F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
overall B-PHYSICAL ADJ F
response 0 NOUN F
rate B-PHYSICAL NOUN F
( 0 PUNCT F
CR+PR 0 NOUN T
) 0 PUNCT F
was 0 VERB F
91.5 0 NUM F
% 0 SYM F
for 0 ADP F
Chinese 0 NOUN T
herb 0 PUNCT F
group 0 NOUN F
and 0 CCONJ F
46.9 0 NUM F
% 0 SYM F
for 0 ADP F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 ADP F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
median 0 ADJ F
survival B-MORTALITY NOUN F
was 0 ADV F
16 0 NUM F
months 0 NOUN F
for 0 ADP F
the 0 DET F
traditional 0 ADJ F
Chinese 0 NOUN T
Kidney-tonifying 0 PUNCT T
decoction 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
10 0 NUM F
months 0 NOUN F
for 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Survival B-MORTALITY NOUN T
curve 0 NOUN F
( B-MORTALITY PUNCT F
Kaplan-meire I-MORTALITY ADV T
's 0 PUNCT F
) B-MORTALITY PUNCT F
of 0 ADP F
the 0 DET F
Chinese 0 NOUN T
herb 0 ADJ F
group 0 NOUN F
was 0 VERB F
better 0 PUNCT F
than 0 PUNCT F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

10 0 NUM F
patients 0 NOUN F
of 0 ADP F
Chinese 0 NOUN T
herb 0 ADJ F
group 0 NOUN F
was 0 VERB F
alive 0 ADJ F
beyond 0 ADP F
more 0 ADV F
than 0 ADP F
2 0 NUM F
years 0 NOUN F
. 0 PUNCT F

Until 0 ADP T
now 0 ADV F
, 0 PUNCT F
4 0 NUM F
patients 0 NOUN F
in 0 ADP F
the 0 DET F
Chinese 0 NOUN T
herb 0 ADJ F
group 0 NOUN F
, 0 PUNCT F
one 0 NUM F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
are 0 VERB F
still 0 ADV F
enjoying 0 PUNCT F
their 0 PUNCT F

Is 0 PUNCT T
chronic 0 ADJ F
sildenafil 0 NOUN F
therapy 0 NOUN F
safe 0 ADJ F
and 0 CCONJ F
clinically 0 ADV F
beneficial 0 ADJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
systolic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
? 0 PUNCT F

Sildenafil 0 NOUN T
is 0 VERB F
a 0 DET F
selective 0 ADJ F
phosphodiesterase-5 0 NOUN F
inhibitor 0 NOUN F
and 0 CCONJ F
causes 0 PUNCT F
vasodilatation 0 NOUN F
, 0 PUNCT F
particularly 0 ADV F
in 0 ADP F
pulmonary 0 ADJ F
circulation 0 NOUN F
. 0 PUNCT F

Since 0 ADP T
left 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
may 0 VERB F
be 0 VERB F
associated 0 VERB F
with 0 ADP F
pulmonary 0 ADJ F
hypertension 0 NOUN F
out 0 PUNCT F
of 0 ADP F
proportion 0 NOUN F
to 0 ADP F
left 0 PUNCT F
heart 0 NOUN F
disease 0 NOUN F
, 0 PUNCT F
sildenafil 0 NOUN F
may 0 PUNCT F
have 0 PUNCT F
beneficial 0 ADJ F
effect 0 NOUN F
in 0 ADP F
such 0 DET F
patients 0 NOUN F
. 0 PUNCT F

The 0 DET T
present 0 ADJ F
investigation 0 NOUN F
was 0 VERB F
designed 0 VERB F
as 0 ADP F
a 0 DET F
12-week 0 NOUN F
, 0 PUNCT F
single-center 0 NOUN F
, 0 PUNCT F
randomized 0 VERB F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
study 0 NOUN F
evaluating 0 PUNCT F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
sildenafil 0 NOUN F
on 0 ADP F
mean 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
( 0 PUNCT F
primary 0 ADJ F
endpoint 0 NOUN F
) 0 PUNCT F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
left 0 ADJ F
systolic 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
. 0 PUNCT F

Secondary 0 ADJ T
endpoints 0 NOUN F
included 0 DET F
exercise B-PHYSICAL NOUN F
capacity I-PHYSICAL NOUN F
assessed 0 VERB F
by 0 ADP F
6-minute B-PHYSICAL PUNCT F
walk I-PHYSICAL NOUN F
test I-PHYSICAL NOUN F
. 0 PUNCT F

A 0 DET T
total 0 NOUN F
of 0 ADP F
106 0 NUM F
patients 0 NOUN F
were 0 VERB F
randomized 0 ADJ F
1:1 0 NUM F
to 0 ADP F
sildenafil 0 NOUN F
( 0 PUNCT F
n=53 0 NOUN F
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
( 0 PUNCT F
n=53 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

Patients 0 NOUN T
received 0 VERB F
sildenafil 0 NOUN F
25 0 NUM F
mg 0 NOUN F
twice 0 ADV F
a 0 DET F
day 0 NOUN F
or 0 CCONJ F
matching 0 PUNCT F
placebo 0 NOUN F
for 0 ADP F
the 0 DET F
first 0 ADJ F
2 0 NUM F
weeks 0 NOUN F
and 0 CCONJ F
50 0 NUM F
mg 0 NOUN F
3 0 NUM F
times 0 NOUN F
a 0 DET F
week 0 NOUN F
for 0 ADP F
the 0 DET F
remainder 0 NOUN F
of 0 ADP F
the 0 DET F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
placebo-corrected 0 VERB F
effect 0 NOUN F
on 0 ADP F
mean 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
was 0 VERB F
1.16 0 NUM F
mm 0 NOUN F
Hg 0 NOUN T
( 0 PUNCT F
95 0 NUM F
% 0 SYM F
confidence 0 NOUN F
interval 0 NOUN F
, 0 PUNCT F
-1.6 0 VERB F
to 0 ADP F
5.1 0 PUNCT F
, 0 PUNCT F
P 0 NOUN T
> 0 SYM F
.05 0 NUM F
) 0 PUNCT F
, 0 PUNCT F
demonstrating 0 VERB F
that 0 ADP F
sildenafil 0 NOUN F
did 0 PUNCT F
not 0 ADV F
decrease 0 VERB F
mean 0 NOUN F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

Compared 0 VERB T
with 0 ADP F
placebo 0 NOUN F
, 0 PUNCT F
sildenafil 0 NOUN F
increased 0 VERB F
the 0 DET F
6-minute B-PHYSICAL PUNCT F
walk I-PHYSICAL NOUN F
test I-PHYSICAL NOUN F
by 0 ADP F
a 0 DET F
nonsignificant 0 ADJ F
treatment 0 NOUN F
effect 0 NOUN F
of 0 ADP F
14 0 NUM F
m 0 NOUN F
( 0 PUNCT F
P=.67 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

Adverse B-ADVERSE-EFFECTS ADJ T
effects I-ADVERSE-EFFECTS NOUN F
occurred 0 VERB F
in 0 ADP F
a 0 DET F
comparable 0 ADJ F
proportion 0 NOUN F
of 0 ADP F
patients 0 NOUN F
taking 0 ADJ F
sildenafil 0 NOUN F
and 0 CCONJ F
placebo 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
none 0 NUM F
of 0 ADP F
the 0 DET F
patients 0 NOUN F
needed 0 NUM F
to 0 ADP F
discontinue 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

Sildenafil 0 NOUN T
is 0 VERB F
well 0 ADP F
tolerated B-OTHER ADP F
in 0 ADP F
left 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
patients 0 NOUN F
and 0 CCONJ F
does 0 PUNCT F
not 0 ADV F
decrease 0 NUM F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
. 0 PUNCT F

It 0 PRON T
can 0 VERB F
be 0 VERB F
safely 0 ADV F
added 0 ADP F
to 0 ADP F
standard 0 ADJ F
heart 0 NOUN F
failure 0 NOUN F
therapy 0 NOUN F
. 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
sibutramine 0 NOUN F
on 0 ADP F
thermogenesis 0 NOUN F
in 0 ADP F
obese 0 PUNCT F
patients 0 NOUN F
assessed 0 VERB F
via 0 ADP F
immersion 0 NOUN F
calorimetry 0 NOUN F
. 0 PUNCT F

Glucose 0 NOUN T
utilization 0 NOUN F
studies 0 NOUN F
show 0 VERB F
that 0 ADP F
sibutramine-induced 0 VERB F
thermogenesis 0 NOUN F
is 0 VERB F
mediated 0 VERB F
via 0 ADP F
selective 0 ADJ F
sympathetic 0 ADJ F
activation 0 NOUN F
of 0 ADP F
brown 0 ADJ F
adipose 0 ADJ F
tissue 0 NOUN F
. 0 PUNCT F

The 0 DET T
goal 0 NOUN F
of 0 ADP F
the 0 DET F
present 0 ADJ F
study 0 NOUN F
was 0 VERB F
to 0 ADV F
use 0 VERB F
a 0 DET F
new 0 ADJ F
calorimetry 0 NOUN F
method 0 NOUN F
in 0 ADP F
which 0 ADP F
resting 0 PUNCT F
metabolic 0 ADJ F
rate 0 NOUN F
is 0 VERB F
enhanced 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
sibutramine 0 NOUN F
treatment 0 NOUN F
on 0 ADP F
thermogenesis 0 NOUN F
. 0 PUNCT F

Sixty 0 NUM T
obese 0 PUNCT F
women 0 NOUN F
were 0 VERB F
included 0 VERB F
in 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
divided 0 VERB F
into 0 ADP F
2 0 NUM F
equal 0 ADJ F
groups-the 0 VERB F
placebo 0 NOUN F
and 0 CCONJ F
sibutramine 0 NOUN F
treatment 0 NOUN F
groups 0 NOUN F
. 0 PUNCT F

The 0 DET T
sibutramine 0 NOUN F
group 0 NOUN F
was 0 VERB F
given 0 VERB F
sibutramine 0 NOUN F
10 0 NUM F
mg 0 NOUN F
daily 0 ADJ F
for 0 ADP F
12 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

At 0 ADP T
baseline 0 NOUN F
and 0 CCONJ F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
the 0 DET F
12-wk 0 PUNCT F
treatment 0 NOUN F
period 0 NOUN F
, 0 PUNCT F
thermogenic 0 ADJ F
measurements 0 NOUN F
were 0 VERB F
taken 0 VERB F
with 0 ADP F
the 0 DET F
use 0 NOUN F
of 0 ADP F
water B-PHYSICAL NOUN F
immersion I-PHYSICAL NOUN F
calorimetry I-PHYSICAL NOUN F
. 0 PUNCT F

Subjects 0 NOUN T
were 0 VERB F
examined 0 VERB F
at 0 ADP F
weeks 0 NOUN F
4 0 NUM F
, 0 PUNCT F
8 0 NUM F
, 0 PUNCT F
and 0 CCONJ F
12 0 NUM F
of 0 ADP F
treatment 0 NOUN F
to 0 PART F
identify 0 ADJ F
adverse 0 ADJ F
effects 0 NOUN F
. 0 PUNCT F

Body 0 NOUN T
mass 0 NOUN F
index 0 NOUN F
, 0 PUNCT F
measured 0 VERB F
at 0 ADP F
31.5+/-2.05 0 NUM F
kg/m2 0 NOUN F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
decreased 0 PRON F
to 0 ADP F
30.4+/-2.94 0 PUNCT F
kg/m 0 NOUN F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
after 0 ADP F
12 0 NUM F
wk 0 NOUN F
( 0 PUNCT F
P=.07 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
sibutramine 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
it 0 PRON F
decreased 0 VERB F
from 0 ADP F
33.5+/-4.1 0 NOUN F
kg/m 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
to 0 PUNCT F
30.9+/-4.8 0 PUNCT F
kg/m 0 NUM F
( 0 PUNCT F
2 0 NUM F
) 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
sibutramine 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
mean 0 NOUN F
thermogenic B-PHYSICAL ADJ F
response I-PHYSICAL NOUN F
changed 0 VERB F
from 0 ADP F
a 0 DET F
baseline 0 NOUN F
value 0 NOUN F
of 0 ADP F
1.27+/-0.29 0 NOUN F
kcal/kg/h 0 NOUN F
to 0 ADP F
1.44+/-0.13 0 PUNCT F
kcal/kg/h 0 NOUN F
after 0 ADP F
12 0 NUM F
wk 0 NOUN F
of 0 ADP F
treatment 0 NOUN F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
, 0 PUNCT F
the 0 DET F
baseline 0 NOUN F
value 0 NOUN F
was 0 VERB F
1.56+/-0.27 0 PUNCT F
kcal/kg/h 0 NOUN F
; 0 PUNCT F
it 0 PUNCT F
changed 0 DET F
to 0 ADP F
1.33+/-0.36 0 NOUN F
kcal/kg/h 0 NOUN F
at 0 ADP F
the 0 DET F
end 0 NOUN F
of 0 ADP F
12 0 NUM F
wk 0 NOUN F
. 0 PUNCT F

The 0 DET T
findings 0 NOUN F
of 0 ADP F
this 0 DET F
study 0 NOUN F
suggest 0 VERB F
that 0 ADP F
sibutramine 0 NOUN F
treatment 0 NOUN F
promotes 0 NOUN F
thermogenesis B-PHYSICAL NOUN F
, 0 PUNCT F
thus 0 ADV F
facilitating 0 VERB F
weight 0 NOUN F
loss B-PHYSICAL NOUN F
. 0 PUNCT F

Calorimetry 0 NOUN T
enhances 0 ADP F
resting B-PHYSICAL VERB F
metabolism I-PHYSICAL NOUN F
through 0 ADP F
more 0 ADV F
efficient 0 ADJ F
heat 0 NOUN F
transfer 0 NOUN F
from 0 ADP F
the 0 DET F
body 0 NOUN F
. 0 PUNCT F

Transurethral 0 ADJ T
prostate 0 NOUN F
resection 0 NOUN F
and 0 CCONJ F
bleeding 0 VERB F
: 0 PUNCT F
a 0 DET F
randomized 0 VERB F
, 0 PUNCT F
placebo 0 NOUN F
controlled 0 VERB F
trial 0 NOUN F
of 0 ADP F
role 0 NOUN F
of 0 ADP F
finasteride 0 PUNCT F
for 0 ADP F
decreasing 0 ADP F
operative 0 ADJ F
blood 0 NOUN F
loss 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Bleeding 0 PUNCT T
associated 0 VERB F
with 0 ADP F
transurethral 0 ADJ F
prostate 0 NOUN F
resection 0 NOUN F
can 0 ADP F
often 0 ADV F
be 0 ADP F
significant 0 ADJ F
and 0 CCONJ F
lead 0 NOUN F
to 0 ADP F
increased 0 VERB F
morbidity 0 NOUN F
and 0 CCONJ F
occasionally 0 ADV F
mortality 0 NOUN F
. 0 PUNCT F

It 0 PRON T
has 0 PUNCT F
been 0 PUNCT F
shown 0 VERB F
that 0 ADP F
finasteride 0 PUNCT F
decreases 0 ADP F
bleeding 0 ADP F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
hematuria 0 NOUN F
of 0 ADP F
prostatic 0 ADJ F
origin 0 NOUN F
. 0 PUNCT F

We 0 PRON T
hypothesized 0 VERB F
that 0 ADP F
bleeding 0 VERB F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
transurethral 0 ADJ F
prostate 0 NOUN F
resection 0 NOUN F
could 0 VERB F
be 0 VERB F
decreased 0 VERB F
by 0 ADP F
giving 0 ADP F
finasteride 0 ADP F
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

MATERIALS 0 NOUN T
AND 0 CCONJ T
METHODS 0 NOUN T
A 0 PUNCT T
total 0 VERB F
70 0 NUM F
patients 0 NOUN F
scheduled 0 DET F
to 0 PART F
undergo 0 NOUN F
elective 0 ADJ F
transurethral 0 ADJ F
prostate 0 NOUN F
resection 0 NOUN F
were 0 VERB F
randomized 0 VERB F
to 0 PART F
receive 0 NOUN F
5 0 DET F
mg. 0 NOUN F
finasteride 0 PUNCT F
daily 0 ADJ F
or 0 CCONJ F
placebo 0 NOUN F
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
before 0 ADP F
surgery 0 NOUN F
. 0 PUNCT F

Serum B-PHYSICAL NOUN T
hemoglobin I-PHYSICAL NOUN F
was 0 VERB F
measured 0 VERB F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
following 0 PUNCT F
day 0 NOUN F
. 0 PUNCT F

The 0 DET T
volume 0 NOUN F
of 0 ADP F
irrigation B-OTHER NOUN F
fluid I-OTHER NOUN F
used 0 ADP F
and 0 CCONJ F
its 0 VERB F
hemoglobin 0 NOUN F
concentration 0 NOUN F
as 0 PUNCT F
well 0 PUNCT F
as 0 CCONJ F
resected 0 PUNCT F
prostate 0 NOUN F
weight 0 NOUN F
were 0 VERB F
recorded 0 VERB F
. 0 PUNCT F

RESULTS 0 NOUN T
Of 0 ADP T
the 0 DET F
68 0 NUM F
patients 0 NOUN F
who 0 ADP F
underwent 0 VERB F
transurethral 0 ADJ F
prostate 0 NOUN F
resection 0 NOUN F
2 0 NUM F
were 0 VERB F
withdrawn 0 ADP F
before 0 ADP F
surgery 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
so 0 ADP F
32 0 NUM F
received 0 ADP F
finasteride 0 ADP F
and 0 CCONJ F
36 0 NUM F
received 0 PUNCT F
placebo 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
significantly 0 ADV F
less 0 ADV F
mean 0 NOUN F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
in I-PHYSICAL ADP F
irrigation I-PHYSICAL NOUN F
fluid I-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
finasteride 0 ADP F
group 0 NOUN F
than 0 PUNCT F
in 0 ADP F
the 0 DET F
control 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
43.6 0 NUM F
versus 0 CCONJ F
69.3 0 NUM F
gm 0 NOUN F
. 0 PUNCT F

hemoglobin 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
= 0 SYM F
0.011 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
mean 0 NOUN F
difference 0 NOUN F
was 0 VERB F
more 0 DET F
significant 0 ADJ F
when 0 ADP F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
per 0 ADP F
gm 0 NOUN F
. 0 PUNCT F

resected 0 PUNCT F
prostate 0 NOUN F
was 0 VERB F
calculated 0 VERB F
( 0 PUNCT F
2.65 0 NUM F
versus 0 CCONJ F
4.65 0 NUM F
gm 0 NOUN F
. 0 PUNCT F

hemoglobin 0 NOUN F
per 0 ADP F
gm 0 NOUN F
. 0 PUNCT F

prostate 0 NOUN F
, 0 PUNCT F
p 0 NOUN F
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
This 0 DET T
study 0 NOUN F
shows 0 NOUN F
that 0 ADP F
finasteride 0 PUNCT F
given 0 VERB F
for 0 ADP F
2 0 NUM F
weeks 0 NOUN F
preoperatively 0 ADP F
decreases 0 VERB F
bleeding B-PHYSICAL ADP F
in 0 ADP F
patients 0 NOUN F
undergoing 0 VERB F
transurethral 0 ADJ F
prostate 0 NOUN F
resection 0 NOUN F
. 0 PUNCT F

Further 0 DET T
study 0 NOUN F
is 0 VERB F
required 0 VERB F
to 0 PART F
determine 0 NOUN F
the 0 DET F
optimal 0 ADJ F
timing 0 VERB F
and 0 CCONJ F
dose 0 NOUN F
duration 0 NOUN F
to 0 PART F
minimize 0 NOUN F
blood B-PHYSICAL NOUN F
loss I-PHYSICAL NOUN F
and 0 CCONJ F
identify 0 ADJ F
how 0 ADP F
relevant 0 ADJ F
such 0 PUNCT F
a 0 ADP F
decrease 0 NOUN F
in 0 ADP F
bleeding 0 PUNCT F
is 0 VERB F
in 0 ADP F
clinical 0 ADJ F
practice 0 NOUN F
. 0 PUNCT F

Treatment 0 NOUN T
of 0 ADP F
stable 0 ADJ F
angina 0 NOUN F
of 0 ADP F
effort 0 NOUN F
with 0 ADP F
verapamil 0 NOUN F
: 0 PUNCT F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 DET F
randomized 0 VERB F
crossover 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

The 0 DET T
effects 0 NOUN F
of 0 ADP F
verapamil 0 NOUN F
were 0 VERB F
assessed 0 VERB F
in 0 ADP F
26 0 NUM F
patients 0 NOUN F
with 0 ADP F
stable 0 ADJ F
exertional 0 ADJ F
angina 0 NOUN F
pectoris 0 NOUN F
in 0 ADP F
a 0 DET F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
, 0 PUNCT F
randomized 0 VERB F
crossover 0 NOUN F
protocol 0 NOUN F
using 0 VERB F
serial 0 ADJ F
treadmill 0 NOUN F
tests 0 NOUN F
. 0 PUNCT F

Verapamil 0 NOUN T
, 0 PUNCT F
480 0 NUM F
mg/day 0 NOUN F
, 0 PUNCT F
reduced 0 ADV F
anginal B-PHYSICAL ADJ F
frequency I-PHYSICAL NOUN F
from 0 ADP F
5.6 0 NUM F
+/- 0 SYM F
7.3 0 NUM F
to 0 ADP F
2.2 0 NUM F
+/- 0 SYM F
3.9 0 NUM F
attacks 0 NOUN F
per 0 ADP F
week 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
nitroglycerin B-OTHER NOUN F
consumption I-OTHER NOUN F
from 0 ADP F
3.4 0 ADP F
+/- 0 SYM F
4.9 0 NUM F
to 0 ADP F
1.2 0 NUM F
+/- 0 SYM F
2.5 0 NUM F
tablets 0 ADV F
per 0 ADP F
week 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
compared 0 VERB F
with 0 ADP F
placebo 0 NOUN F
. 0 PUNCT F

Treadmill B-PHYSICAL ADP T
time I-PHYSICAL NOUN F
increased 0 VERB F
from 0 ADP F
6.4 0 NUM F
+/- 0 SYM F
2.1 0 NUM F
minutes 0 NOUN F
during 0 ADP F
the 0 DET F
placebo 0 NOUN F
phase 0 NOUN F
to 0 ADP F
7.5 0 PUNCT F
+/- 0 SYM F
1.8 0 NUM F
minutes 0 NOUN F
during 0 ADP F
the 0 DET F
verapamil 0 NOUN F
phase 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Verapamil 0 NOUN T
's 0 PUNCT F
beneficial 0 ADJ F
effect 0 NOUN F
appeared 0 VERB F
to 0 PART F
be 0 PUNCT F
related 0 VERB F
, 0 PUNCT F
in 0 ADP F
part 0 NOUN F
, 0 PUNCT F
to 0 ADP F
a 0 DET F
10 0 NUM F
% 0 SYM F
reduction 0 NOUN F
of 0 ADP F
the 0 DET F
rate-pressure B-PHYSICAL NOUN F
product I-PHYSICAL NOUN F
at 0 ADP F
rest 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
a 0 DET F
12 0 NUM F
% 0 SYM F
reduction 0 NOUN F
during 0 ADP F
submaximal 0 ADJ F
exercise 0 NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.001 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Verapamil 0 NOUN T
also 0 ADV F
caused 0 ADJ F
less 0 DET F
marked 0 VERB F
ST-segment B-PHYSICAL ADJ T
depressions I-PHYSICAL NOUN F
at I-PHYSICAL ADP F
peak 0 ADJ F
exercise B-PHYSICAL NOUN F
( 0 PUNCT F
p 0 NOUN F
less 0 ADV F
than 0 PUNCT F
0.05 0 NUM F
) 0 PUNCT F
at 0 ADP F
a 0 DET F
similar 0 ADJ F
rate-pressure 0 NOUN F
product 0 NOUN F
, 0 PUNCT F
suggesting 0 VERB F
a 0 DET F
favorable 0 ADJ F
redistribution 0 NOUN F
of 0 ADP F
coronary B-PHYSICAL ADJ F
blood B-PHYSICAL NOUN F
flow B-PHYSICAL NOUN F
to 0 ADP F
the 0 DET F
ischemic 0 ADJ F
zone 0 NOUN F
. 0 PUNCT F

Side 0 NOUN T
effects 0 NOUN F
from 0 ADP F
verapamil 0 NOUN F
were 0 VERB F
minimal 0 ADJ F
, 0 PUNCT F
consisting 0 PUNCT F
mainly 0 DET F
of 0 PUNCT F

Comparison 0 NOUN T
of 0 ADP F
rectal 0 ADJ F
midazolam 0 NOUN F
and 0 CCONJ F
diazepam 0 NOUN F
for 0 ADP F
premedication 0 NOUN F
in 0 ADP F
pediatric 0 ADJ F
dental 0 ADJ F
patients 0 NOUN F
. 0 PUNCT F

Rectally 0 ADV T
administered 0 ADP F
midazolam 0 NOUN F
( 0 PUNCT F
0.35 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
and 0 CCONJ F
diazepam 0 NOUN F
( 0 PUNCT F
0.70 0 NUM F
mg/kg 0 NOUN F
) 0 PUNCT F
were 0 VERB F
compared 0 VERB F
with 0 ADP F
each 0 DET F
other 0 ADJ F
and 0 CCONJ F
with 0 ADP F
placebo 0 NOUN F
for 0 ADP F
preanesthetic 0 ADJ F
medication 0 NOUN F
in 0 ADP F
children 0 NOUN F
undergoing 0 SYM F
dental 0 ADJ F
extractions 0 NOUN F
. 0 PUNCT F

All 0 DET T
rectal 0 ADJ F
medications 0 NOUN F
were 0 VERB F
very 0 VERB F
well 0 VERB F
accepted 0 ADP F
, 0 PUNCT F
but 0 CCONJ F
mask B-MENTAL NOUN F
acceptance I-MENTAL NOUN F
, 0 PUNCT F
improvement 0 NOUN F
in 0 ADP F
anxiety B-MENTAL NOUN F
, 0 PUNCT F
and 0 CCONJ F
sedation B-MENTAL NOUN F
were 0 VERB F
best 0 PUNCT F
in 0 ADP F
the 0 DET F
midazolam 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

Improvement 0 NOUN T
in 0 ADP F
anxiety B-MENTAL NOUN F
and 0 CCONJ F
sedation B-MENTAL NOUN F
were 0 VERB F
significantly 0 ADV F
better 0 PUNCT F
in 0 ADP F
the 0 DET F
two 0 NUM F
drug 0 NOUN F
groups 0 NOUN F
than 0 CCONJ F
in 0 ADP F
those 0 PUNCT F
patients 0 NOUN F
who 0 PROPN F
had 0 PUNCT F
received 0 PUNCT F
placebo 0 NOUN F
. 0 PUNCT F

Thirty 0 NUM T
minutes 0 NOUN F
after 0 ADP F
rectal 0 ADJ F
administration 0 NOUN F
of 0 ADP F
midazolam 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
showed 0 VERB F
a 0 DET F
decrease 0 NOUN F
in 0 ADP F
both 0 CCONJ F
systolic B-PHYSICAL ADJ F
and I-PHYSICAL CCONJ F
diastolic I-PHYSICAL ADJ F
blood I-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
and 0 CCONJ F
heart B-PHYSICAL NOUN F
rate I-PHYSICAL NOUN F
. 0 PUNCT F

Although 0 ADP T
these 0 DET F
decreases 0 NOUN F
differed 0 VERB F
significantly 0 ADV F
from 0 ADP F
the 0 DET F
premedication 0 NOUN F
values 0 NOUN F
, 0 PUNCT F
they 0 PUNCT F
were 0 VERB F
probably 0 DET F
of 0 ADP F
little 0 DET F
clinical 0 ADJ F
importance 0 NOUN F
. 0 PUNCT F

Only 0 ADV T
minor B-ADVERSE-EFFECTS ADJ F
adverse I-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
were 0 VERB F
observed 0 VERB F
in 0 ADP F
this 0 DET F
study 0 NOUN F
. 0 PUNCT F

Overall 0 ADJ T
rectally 0 ADV F
administered 0 ADP F
midazolam 0 NOUN F
appeared 0 VERB F
to 0 PART F
be 0 PUNCT F
somewhat 0 ADV F
more 0 ADV F
efficacious 0 ADJ F
than 0 ADP F
diazepam 0 NOUN F
. 0 PUNCT F

[ 0 PUNCT F
Dose-reduced 0 PROPN T
antihypertensive 0 ADJ F
agents 0 NOUN F
-- 0 PUNCT F
use 0 CCONJ F
in 0 ADP F
complex 0 PUNCT F
nonmedicamentous 0 ADJ F
therapy 0 NOUN F
of 0 ADP F
hypertension 0 NOUN F
] 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
order 0 NOUN F
to 0 PART F
estimate 0 NOUN F
the 0 DET F
influence 0 NOUN F
of 0 ADP F
a 0 DET F
non-medicamentous 0 ADP F
therapy 0 NOUN F
( 0 PUNCT F
CNT 0 NOUN T
) 0 PUNCT F
on 0 ADP F
the 0 DET F
consumption 0 NOUN F
of 0 ADP F
medicaments 0 NOUN F
and 0 CCONJ F
coronary 0 ADJ F
risk 0 NOUN F
in 0 ADP F
high 0 ADJ F
blood 0 NOUN F
pressure 0 NOUN F
73 0 VERB F
hypertensives 0 NOUN F
of 0 ADP F
a 0 DET F
medicamentously 0 ADV F
stabilized 0 VERB F
CNT-group 0 NOUN T
were 0 VERB F
examined 0 VERB F
in 0 ADP F
comparison 0 NOUN F
to 0 ADP F
a 0 DET F
group 0 NOUN F
of 0 ADP F
the 0 DET F
same 0 ADJ F
size 0 NOUN F
of 0 ADP F
patients 0 NOUN F
with 0 ADP F
hypertension 0 NOUN F
who 0 ADP F
were 0 VERB F
managed 0 PROPN F
exclusively 0 ADV F
medicamentously 0 ADV F
for 0 ADP F
behaviour 0 NOUN F
of 0 ADP F
blood 0 NOUN F
pressure 0 NOUN F
, 0 PUNCT F
need 0 VERB F
of 0 ADP F
antihypertensive 0 ADJ F
drugs 0 NOUN F
and 0 CCONJ F
changes 0 NOUN F
of 0 ADP F
hypertension-associated 0 VERB F
risk 0 NOUN F
factors 0 NOUN F
. 0 PUNCT F

After 0 ADP T
an 0 DET F
exactly 0 ADV F
controlled 0 VERB F
6-month 0 NOUN F
treatment 0 NOUN F
hypertensives 0 DET F
with 0 ADP F
additionally 0 ADJ F
recommended 0 DET F
far-reaching 0 ADP F
CNT 0 NOUN T
showed 0 VERB F
an 0 DET F
economization 0 NOUN F
of 0 ADP F
medicaments 0 NOUN F
by 0 ADP F
scarcely 0 PUNCT F
the 0 DET F
half 0 NOUN F
in 0 ADP F
comparison 0 NOUN F
to 0 ADP F
the 0 DET F
reference 0 NOUN F
group 0 NOUN F
. 0 PUNCT F

By 0 ADP T
means 0 NOUN F
of 0 ADP F
suitable 0 ADJ F
control 0 NOUN F
methods 0 CCONJ F
a 0 DET F
causal 0 ADJ F
non-medicamentously 0 NOUN F
conditioned 0 VERB F
decrease 0 NOUN F
of 0 ADP F
blood B-PHYSICAL NOUN F
pressure I-PHYSICAL NOUN F
could 0 VERB F
be 0 VERB F
excluded 0 VERB F
. 0 PUNCT F

A 0 DET T
different 0 ADJ F
need 0 NOUN F
of 0 ADP F
antihypertensive 0 ADJ F
drugs 0 NOUN F
was 0 VERB F
simulated 0 VERB F
by 0 ADP F
the 0 DET F
exacter 0 ADJ F
intake 0 NOUN F
of 0 ADP F
medicaments 0 NOUN F
in 0 ADP F
the 0 DET F
index-patients 0 NOUN F
. 0 PUNCT F

Notwithstanding 0 PUNCT T
the 0 DET F
metabolic 0 ADJ F
effects 0 NOUN F
of 0 ADP F
the 0 DET F
additional 0 ADJ F
therapy 0 NOUN F
have 0 PUNCT F
induced 0 VERB F
a 0 DET F
positive 0 ADJ F
change 0 NOUN F
of 0 ADP F
atherogenic B-PHYSICAL ADJ F
lipids I-PHYSICAL NOUN F
. 0 PUNCT F

The 0 DET T
examinations 0 NOUN F
indicate 0 VERB F
in 0 ADP F
general 0 NOUN F
the 0 DET F
difficulty 0 NOUN F
of 0 ADP F
the 0 DET F
judgement 0 NOUN F
of 0 ADP F
efficacy 0 NOUN F
of 0 ADP F
non-medicamentous 0 ADJ F
therapeutic 0 ADJ F
measures 0 NOUN F
in 0 ADP F
connection 0 NOUN F
with 0 ADP F
a 0 DET F
rational 0 ADJ F
dose-reduced 0 VERB F
long-term 0 NOUN F
therapy 0 NOUN F
with 0 ADP F
antihypertensive 0 ADJ F
drugs 0 NOUN F
. 0 PUNCT F

Pegfilgrastim 0 NOUN T
for 0 ADP F
peripheral 0 ADJ F
CD34+ 0 NOUN T
mobilization 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
solid 0 ADJ F
tumours 0 NOUN F
. 0 PUNCT F

The 0 DET T
efficacy 0 NOUN F
of 0 ADP F
pegfilgrastim+/-chemotherapy 0 NOUN F
for 0 ADP F
mobilizing 0 PUNCT F
stem 0 NOUN F
cells 0 NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
solid 0 ADJ F
tumours 0 NOUN F
was 0 VERB F
assessed 0 VERB F
. 0 PUNCT F

In 0 ADP T
cycle 0 NOUN F
0 0 NUM F
, 0 PUNCT F
a 0 DET F
14-day 0 NOUN F
prechemotherapy 0 NOUN F
cycle 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
( 0 PUNCT F
N=61 0 NOUN T
) 0 PUNCT F
were 0 VERB F
randomized 0 VERB F
open-label 0 NOUN F
to 0 VERB F
single 0 ADJ F
doses 0 NOUN F
of 0 ADP F
pegfilgrastim 0 NOUN F
( 0 PUNCT F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
or 0 CCONJ F
18 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
, 0 PUNCT F
or 0 CCONJ F
daily 0 ADJ F
filgrastim 0 NOUN F
( 0 PUNCT F
10 0 NUM F
microg/kg 0 NOUN F
) 0 PUNCT F
for 0 ADP F
< 0 SYM F
or 0 CCONJ F
=7 0 ADP F
days 0 NOUN F
. 0 PUNCT F

Mean 0 ADJ T
peak 0 ADJ F
peripheral B-PHYSICAL ADJ F
CD34+ I-PHYSICAL NOUN T
cell I-PHYSICAL NOUN F
counts I-PHYSICAL NOUN F
increased 0 VERB F
with 0 ADP F
pegfilgrastim 0 ADJ F
dose 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
were 0 VERB F
significantly 0 ADV F
higher 0 PUNCT F
than 0 PUNCT F
filgrastim 0 NOUN F
only 0 ADV F
at 0 ADP F
the 0 DET F
18 0 NUM F
mg 0 NOUN F
dose 0 NOUN F
( 0 PUNCT F
10.17 0 ADJ F
vs 0 CCONJ F
4.96 0 NUM F
x 0 ADJ F
10 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
/ml 0 ADV F
; 0 PUNCT F
P=0.014 0 ADV T
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
the 0 DET F
clinically 0 ADV F
relevant 0 ADJ F
period 0 NOUN F
of 0 ADP F
days 0 NOUN F
3-7 0 NUM F
, 0 PUNCT F
both 0 PUNCT F
12 0 NUM F
and 0 CCONJ F
18 0 NUM F
mg 0 NOUN F
pegfilgrastim 0 NOUN F
doses 0 NOUN F
produced 0 VERB F
significantly B-PHYSICAL ADV F
higher 0 PUNCT F
peak 0 ADJ F
CD34+ B-PHYSICAL NOUN T
counts I-PHYSICAL NOUN F
( 0 PUNCT F
8.18 0 ADP F
and 0 CCONJ F
9.96 0 NUM F
vs 0 CCONJ F
4.51 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
/ml 0 NOUN F
for 0 ADP F
filgrastim 0 NOUN F
; 0 PUNCT F
P=0.034 0 ADP T
and 0 CCONJ F
0.006 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
cycle 0 NOUN F
1 0 NUM F
, 0 PUNCT F
patients 0 NOUN F
received 0 VERB F
carboplatin/paclitaxel 0 NOUN F
on 0 ADP F
day 0 NOUN F
1 0 NUM F
, 0 PUNCT F
followed 0 VERB F
from 0 ADP F
day 0 NOUN F
2 0 NUM F
by 0 ADP F
pegfilgrastim 0 NOUN F
6-18 0 NUM F
mg 0 NOUN F
or 0 CCONJ F
daily 0 ADJ F
filgrastim 0 NOUN F
( 0 PUNCT F
5 0 NUM F
microg/kg/day 0 NOUN F
for 0 ADP F
< 0 SYM F
or 0 CCONJ F
=14 0 ADP F
days 0 NOUN F
) 0 PUNCT F
as 0 PUNCT F
per 0 ADP F
randomization 0 NOUN F
in 0 ADP F
cycle 0 NOUN F
0 0 NUM F
. 0 PUNCT F

There 0 PUNCT T
were 0 VERB F
no 0 DET F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
mean 0 NOUN F
peak 0 ADJ F
CD34+ B-PHYSICAL NOUN T
count I-PHYSICAL NOUN F
between 0 ADP F
pegfilgrastim 0 NOUN F
and 0 CCONJ F
filgrastim 0 NOUN F
, 0 PUNCT F
but 0 CCONJ F
there 0 PUNCT F
was 0 VERB F
an 0 DET F
advantage 0 NOUN F
for 0 ADP F
pegfilgrastim 0 NOUN F
18 0 NUM F
mg 0 NOUN F
in 0 ADP F
the 0 DET F
relevant 0 ADJ F
period 0 NOUN F
of 0 ADP F
days 0 NOUN F
7-12 0 NUM F
( 0 PUNCT F
3.14 0 NUM F
vs 0 CCONJ F
1.19 0 NUM F
x 0 SYM F
10 0 NUM F
( 0 PUNCT F
4 0 NUM F
) 0 PUNCT F
/ml 0 ADV F
; 0 PUNCT F
P=0.043 0 NOUN T
) 0 PUNCT F
. 0 PUNCT F

A 0 DET T
single 0 ADJ F
pegfilgrastim 0 ADJ F
dose 0 NOUN F
( 0 PUNCT F
> 0 ADJ F
or 0 CCONJ F
=6 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
could 0 VERB F
be 0 VERB F
substituted 0 VERB F
for 0 ADP F
daily 0 ADJ F
filgrastim 0 NOUN F
in 0 PUNCT F

Genotyping 0 SYM T
of 0 ADP F
CYP21 0 NOUN T
, 0 PUNCT F
linked 0 VERB F
chromosome 0 NOUN F
6p 0 PUNCT F
markers 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
sex-specific 0 ADJ F
gene 0 NOUN F
in 0 ADP F
neonatal 0 ADJ F
screening 0 VERB F
for 0 ADP F
congenital 0 ADJ F
adrenal 0 ADJ F
hyperplasia 0 NOUN F
. 0 PUNCT F

We 0 PRON T
investigated 0 VERB F
the 0 DET F
feasibility B-OTHER NOUN F
and I-OTHER CCONJ F
diagnostic I-OTHER ADJ F
utility I-OTHER NOUN F
of 0 ADP F
genotyping 0 VERB F
9 0 NUM F
CYP21 0 NOUN T
mutations 0 NOUN F
, 0 PUNCT F
linked 0 VERB F
chromosome 0 NOUN F
6p 0 PUNCT F
markers 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
a 0 DET F
dimorphic 0 ADJ F
X-Y 0 NOUN T
marker 0 NOUN F
from 0 ADP F
neonatal 0 ADJ F
screening 0 VERB F
samples 0 NOUN F
. 0 PUNCT F

Blood-impregnated 0 VERB T
filter 0 PUNCT F
papers 0 NOUN F
( 0 PUNCT F
Guthrie 0 NOUN T
cards 0 ADJ F
) 0 PUNCT F
from 0 ADP F
603 0 NUM F
randomly 0 ADV F
chosen 0 PUNCT F
New 0 ADJ T
Zealand 0 NOUN T
neonates 0 NOUN F
were 0 ADV F
genotyped 0 VERB F
blind 0 ADJ F
to 0 ADP F
17-hydroxyprogesterone 0 NOUN F
( 0 PUNCT F
17-OHP 0 ADV F
) 0 PUNCT F
levels 0 NOUN F
. 0 PUNCT F

Another 0 DET T
50 0 NUM F
samples 0 NOUN F
from 0 ADP F
Swiss 0 NOUN T
and 0 CCONJ F
North 0 NOUN T
American 0 ADJ T
infants 0 NOUN F
with 0 ADP F
correlative 0 ADJ F
hormonal 0 ADJ F
data 0 NOUN F
were 0 VERB F
also 0 ADV F
genotyped 0 VERB F
. 0 PUNCT F

DNA 0 NOUN T
was 0 VERB F
extracted 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
gene-specific 0 ADJ F
PCR 0 NOUN T
was 0 VERB F
performed 0 VERB F
. 0 PUNCT F

CYP21 0 NOUN T
PCR 0 NOUN T
products 0 NOUN F
were 0 VERB F
subjected 0 VERB F
to 0 ADP F
ligase 0 NOUN F
detection 0 NOUN F
reaction 0 NOUN F
, 0 PUNCT F
simultaneously 0 ADP F
analyzing 0 PROPN F
9 0 NUM F
CYP21 0 NOUN T
mutations 0 NOUN F
; 0 PUNCT F
PCR 0 NOUN T
products 0 NOUN F
of 0 ADP F
other 0 ADJ F
genes 0 NOUN F
were 0 VERB F
subjected 0 VERB F
to 0 ADP F
direct 0 ADJ F
gel 0 NOUN F
analysis 0 NOUN F
. 0 PUNCT F

CYP21 0 NOUN T
genotyping 0 VERB F
indicated 0 VERB F
a 0 DET F
heterozygote B-PHYSICAL ADJ F
rate I-PHYSICAL NOUN F
of 0 ADP F
2.8 0 NUM F
% 0 SYM F
for 0 ADP F
classic 0 ADJ F
mutations 0 NOUN F
( 0 PUNCT F
excluding 0 ADJ F
CYP21 0 NOUN T
deletions 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
and 0 CCONJ F
2.0 0 NUM F
% 0 SYM F
for 0 ADP F
nonclassic 0 ADJ F
mutations 0 NOUN F
in 0 ADP F
New 0 ADJ T
Zealanders 0 NOUN T
. 0 PUNCT F

Ten 0 NUM T
full-term 0 NOUN F
affected 0 VERB F
neonates 0 NOUN F
showed 0 VERB F
a 0 DET F
wide B-PHYSICAL ADJ F
range 0 NOUN F
of B-PHYSICAL ADP F
17-OHP I-PHYSICAL ADJ F
levels B-PHYSICAL NOUN F
( 0 PUNCT F
15-1400 0 NUM F
nmol/L 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

Sick 0 NOUN T
or 0 CCONJ F
preterm 0 NOUN F
infants 0 NOUN F
or 0 CCONJ F
infants 0 NOUN F
screened 0 VERB F
on 0 ADP F
the 0 DET F
first 0 ADJ F
day 0 NOUN F
of 0 ADP F
life 0 NOUN F
with 0 ADP F
high 0 ADJ F
17-OHP B-PHYSICAL ADV F
proved 0 PUNCT F
genetically 0 ADV F
unaffected 0 VERB F
. 0 PUNCT F

Genetic B-PHYSICAL ADJ T
linkage 0 NOUN F
disequilibrium B-PHYSICAL NOUN F
was 0 VERB F
found 0 VERB F
between 0 ADP F
two 0 NUM F
CYP21 0 NOUN T
mutations 0 NOUN F
and 0 CCONJ F
chromosome 0 NOUN F
6p 0 PUNCT F
markers 0 NOUN F
. 0 PUNCT F

Guthrie 0 NOUN T
cards 0 NOUN F
can 0 VERB F
be 0 VERB F
used 0 VERB F
to 0 PUNCT F
accurately 0 ADJ F
genotype 0 NOUN F
CYP21 B-PHYSICAL NOUN T
and B-PHYSICAL CCONJ F
other I-PHYSICAL ADJ F
relevant I-PHYSICAL ADJ F
markers I-PHYSICAL NOUN F
, 0 PUNCT F
potentially 0 ADV F
enhancing 0 ADP F
the 0 DET F
specificity 0 NOUN F
and 0 PUNCT F

Randomized 0 VERB T
trial 0 NOUN F
of 0 ADP F
tailored 0 VERB F
skin 0 NOUN F
cancer 0 NOUN F
prevention 0 NOUN F
for 0 ADP F
children 0 NOUN F
: 0 PUNCT F
the 0 DET F
Project 0 NOUN T
SCAPE 0 NOUN T
family 0 NOUN F
study 0 NOUN F
. 0 PUNCT F

This 0 DET T
study 0 NOUN F
evaluated 0 VERB F
a 0 DET F
tailored 0 VERB F
intervention 0 NOUN F
to 0 ADJ F
promote 0 PUNCT F
sun 0 PUNCT F
protection 0 NOUN F
in 0 ADP F
parents 0 NOUN F
and 0 CCONJ F
their 0 PROPN F
children 0 NOUN F
, 0 PUNCT F
hypothesizing 0 PUNCT F
that 0 ADP F
the 0 DET F
tailored 0 VERB F
intervention 0 NOUN F
would 0 VERB F
lead 0 VERB F
to 0 ADP F
improved 0 NOUN F
skin B-MENTAL NOUN F
cancer I-MENTAL NOUN F
prevention I-MENTAL NOUN F
behaviors I-MENTAL NOUN F
compared 0 VERB F
to 0 ADP F
generic 0 ADJ F
materials 0 NOUN F
. 0 PUNCT F

Families 0 NOUN T
were 0 VERB F
recruited 0 VERB F
through 0 ADP F
schools 0 NOUN F
and 0 CCONJ F
community 0 NOUN F
centers 0 NOUN F
and 0 CCONJ F
were 0 VERB F
included 0 VERB F
if 0 PUNCT F
there 0 PUNCT F
was 0 VERB F
1 0 NUM F
child 0 NOUN F
in 0 ADP F
Grades 0 PROPN T
1-3 0 NUM F
at 0 ADP F
moderate 0 ADJ F
to 0 ADP F
high 0 ADJ F
risk 0 NOUN F
for 0 ADP F
skin 0 NOUN F
cancer 0 NOUN F
. 0 PUNCT F

Participants 0 NOUN T
were 0 VERB F
randomized 0 VERB F
into 0 ADP F
one 0 NUM F
of 0 ADP F
two 0 NUM F
intervention 0 NOUN F
groups 0 NOUN F
: 0 PUNCT F
a 0 DET F
tailored 0 VERB F
intervention 0 NOUN F
, 0 PUNCT F
in 0 ADP F
which 0 ADP F
they 0 PRON F
received 0 VERB F
personalized 0 VERB F
skin 0 NOUN F
cancer 0 NOUN F
education 0 NOUN F
through 0 ADP F
the 0 DET F
mail 0 NOUN F
; 0 PUNCT F
or 0 CCONJ F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
who 0 ADP F
received 0 VERB F
generic 0 ADP F
skin 0 NOUN F
cancer 0 NOUN F
information 0 NOUN F
materials 0 NOUN F
. 0 PUNCT F

Before 0 ADP T
and 0 CCONJ F
after 0 ADP F
intervention 0 NOUN F
, 0 PUNCT F
parents 0 NOUN F
completed 0 VERB F
questionnaires 0 NOUN F
about 0 ADP F
their 0 VERB F
and 0 CCONJ F
their 0 ADP F
children 0 NOUN F
's 0 PUNCT F
skin 0 NOUN F
cancer 0 NOUN F
risk 0 NOUN F
and 0 CCONJ F
prevention 0 NOUN F
knowledge 0 NOUN F
and 0 CCONJ F
behaviors 0 NOUN F
. 0 PUNCT F

Parents 0 NOUN T
also 0 ADV F
completed 0 ADP F
4-day 0 NOUN F
sun 0 PUNCT F
exposure 0 NOUN F
and 0 CCONJ F
protection 0 NOUN F
diaries 0 NOUN F
for 0 ADP F
their 0 PUNCT F
child 0 NOUN F
and 0 CCONJ F
themselves 0 PUNCT F
. 0 PUNCT F

Tailored 0 VERB T
group 0 NOUN F
participants 0 NOUN F
demonstrated 0 VERB F
significantly B-MENTAL ADP F
greater 0 PUNCT F
positive 0 ADJ F
changes B-MENTAL NOUN F
in I-MENTAL ADP F
prevention B-MENTAL NOUN F
behavior I-MENTAL NOUN F
after 0 ADP F
the 0 DET F
intervention 0 NOUN F
, 0 PUNCT F
including 0 PUNCT F

Effects 0 NOUN T
of 0 ADP F
three 0 NUM F
oral 0 ADJ F
analgesics 0 NOUN F
on 0 ADP F
postoperative 0 ADJ F
pain 0 NOUN F
following 0 VERB F
root 0 NOUN F
canal 0 NOUN F
preparation 0 NOUN F
: 0 PUNCT F
a 0 DET F
controlled 0 VERB F
clinical 0 ADJ F
trial 0 NOUN F
. 0 PUNCT F

AIM 0 NOUN T
To 0 ADV T
compare 0 NOUN F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
single 0 ADJ F
doses 0 NOUN F
of 0 ADP F
three 0 NUM F
oral 0 ADJ F
medications 0 NOUN F
on 0 ADP F
postoperative 0 ADJ F
pain B-PAIN NOUN F
following 0 VERB F
instrumentation 0 NOUN F
of 0 ADP F
root 0 NOUN F
canals 0 ADJ F
in 0 ADP F
teeth 0 NOUN F
with 0 ADP F
irreversible 0 ADJ F
pulpitis 0 NOUN F
. 0 PUNCT F

METHODOLOGY 0 NOUN T
In 0 ADP T
this 0 DET F
double-blind 0 ADJ F
clinical 0 ADJ F
trial 0 NOUN F
, 0 PUNCT F
100 0 NUM F
patients 0 NOUN F
who 0 ADP F
had 0 VERB F
anterior 0 ADJ F
or 0 CCONJ F
premolar 0 ADJ F
teeth 0 NOUN F
with 0 ADP F
irreversible 0 ADJ F
pulpitis 0 NOUN F
without 0 ADP F
any 0 DET F
signs 0 NOUN F
and 0 CCONJ F
symptoms 0 NOUN F
of 0 ADP F
acute 0 ADJ F
or 0 CCONJ F
chronic 0 ADJ F
apical 0 ADJ F
periodontitis 0 NOUN F
and 0 CCONJ F
moderate 0 ADJ F
to 0 ADP F
severe 0 ADJ F
pain 0 NOUN F
were 0 VERB F
divided 0 VERB F
by 0 ADP F
balanced 0 PUNCT F
block 0 ADP F
random 0 ADJ F
allocation 0 NOUN F
into 0 ADP F
four 0 NUM F
groups 0 NOUN F
of 0 ADP F
25 0 NUM F
each 0 PUNCT F
, 0 PUNCT F
a 0 DET F
control 0 NOUN F
group 0 NOUN F
receiving 0 VERB F
a 0 DET F
placebo 0 NOUN F
medication 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
three 0 NUM F
experimental 0 ADJ F
groups 0 NOUN F
receiving 0 VERB F
a 0 DET F
single 0 ADJ F
dose 0 NOUN F
of 0 ADP F
either 0 PUNCT F
Tramadol 0 NOUN T
( 0 PUNCT F
100 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
, 0 PUNCT F
Novafen 0 NOUN T
( 0 PUNCT F
325 0 NUM F
mg 0 NOUN F
of 0 ADP F
paracetamol 0 NOUN F
, 0 PUNCT F
200 0 NUM F
mg 0 NOUN F
ibuprofen 0 NOUN F
and 0 CCONJ F
40 0 NUM F
mg 0 NOUN F
caffeine 0 NOUN F
anhydrous 0 ADJ F
) 0 PUNCT F
or 0 CCONJ F
Naproxen 0 NOUN T
( 0 PUNCT F
500 0 NUM F
mg 0 NOUN F
) 0 PUNCT F
immediately 0 ADV F
after 0 ADP F
the 0 DET F
first 0 ADJ F
appointment 0 NOUN F
where 0 ADP F
the 0 DET F
pulp 0 NOUN F
was 0 VERB F
removed 0 VERB F
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
canals 0 NUM F
were 0 VERB F
fully 0 ADV F
prepared 0 VERB F
. 0 PUNCT F

The 0 DET T
intensity 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
was 0 VERB F
scored 0 VERB F
based 0 VERB F
on 0 ADP F
10-point 0 NOUN F
VAS 0 NOUN T
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
for 0 ADP F
up 0 PUNCT F
to 0 ADP F
24 0 NUM F
h 0 NOUN F
postoperatively 0 NOUN F
. 0 PUNCT F

Data 0 NOUN T
were 0 VERB F
submitted 0 VERB F
to 0 ADP F
repeated 0 VERB F
analysis 0 NOUN F
of 0 ADP F
variance 0 NOUN F
. 0 PUNCT F

RESULTS 0 NOUN T
At 0 ADP T
the 0 DET F
6 0 NUM F
, 0 PUNCT F
12 0 NUM F
and 0 CCONJ F
24 0 NUM F
h 0 NOUN F
postoperative 0 ADJ F
intervals 0 NOUN F
after 0 ADP F
drug 0 NOUN F
administration 0 NOUN F
, 0 PUNCT F
the 0 DET F
intensity 0 NOUN F
of 0 ADP F
pain B-PAIN NOUN F
was 0 VERB F
significantly 0 ADV F
lower 0 PUNCT F
in 0 ADP F
the 0 DET F
experimental 0 ADJ F
groups 0 NOUN F
than 0 CCONJ F
in 0 ADP F
the 0 DET F
placebo 0 NOUN F
group 0 NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.01 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

Tramadol 0 ADV T
was 0 ADV F
significantly 0 ADV F
less 0 ADV F
effective 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
than 0 PUNCT F
Naproxen 0 NOUN T
, 0 PUNCT F
and 0 CCONJ F
Novafen 0 NOUN T
that 0 PUNCT F
were 0 VERB F
similar 0 ADJ F
to 0 ADP F
each 0 DET F
other 0 PUNCT F
( 0 PUNCT F
P 0 NOUN T
> 0 SYM F
0.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

CONCLUSION 0 NOUN T
A 0 PUNCT T
single 0 ADJ F
oral 0 ADJ F
dose 0 NOUN F
of 0 ADP F
Naproxen 0 NOUN T
, 0 PUNCT F
Novafen 0 NOUN T
and 0 CCONJ F
Tramadol 0 PUNCT T
taken 0 VERB F
immediately 0 CCONJ F
after 0 ADP F
treatment 0 NOUN F
reduced 0 VERB F
postoperative 0 ADJ F
pain 0 NOUN F
following 0 VERB F
pulpectomy 0 NOUN F
and 0 CCONJ F
root 0 NOUN F
canal 0 NOUN F
preparation 0 NOUN F
of 0 ADP F
teeth 0 NOUN F
with 0 ADP F
irreversible 0 ADJ F
pulpitis 0 NOUN F
. 0 PUNCT F

Recombinant 0 ADJ T
human 0 NOUN F
erythropoietin 0 NOUN F
therapy 0 NOUN F
for 0 ADP F
anemic 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
on 0 ADP F
combination 0 NOUN F
chemotherapy 0 NOUN F
. 0 PUNCT F

BACKGROUND 0 NOUN T
Patients 0 NOUN T
with 0 ADP F
advanced 0 VERB F
cancer 0 NOUN F
frequently 0 ADV F
experience 0 ADP F
clinically 0 ADV F
significant 0 ADJ F
anemia B-PHYSICAL NOUN F
, 0 PUNCT F
which 0 ADP F
is 0 VERB F
often 0 ADV F
exacerbated 0 VERB F
by 0 ADP F
myelosuppressive 0 ADJ F
chemotherapy 0 NOUN F
. 0 PUNCT F

Consistent 0 ADJ T
with 0 ADP F
the 0 DET F
anemia 0 NOUN F
of 0 ADP F
chronic 0 ADJ F
disease 0 NOUN F
, 0 PUNCT F
studies 0 NOUN F
have 0 PUNCT F
documented 0 ADP F
serum 0 NOUN F
erythropoietin 0 NOUN F
levels 0 NOUN F
that 0 ADP F
are 0 VERB F
inappropriately 0 ADV F
low 0 ADJ F
for 0 ADP F
the 0 DET F
degree 0 NOUN F
of 0 ADP F
anemia 0 NOUN F
in 0 ADP F
cancer 0 NOUN F
patients 0 NOUN F
. 0 PUNCT F

Myelosuppressive 0 ADJ T
chemotherapy 0 NOUN F
impairs 0 ADV F
erythropoiesis 0 NOUN F
, 0 PUNCT F
which 0 ADP F
may 0 VERB F
not 0 ADV F
fully 0 ADV F
recover 0 PART F
between 0 ADP F
treatment 0 NOUN F
cycles 0 NOUN F
. 0 PUNCT F

Recombinant 0 ADJ T
human 0 NOUN F
erythropoietin 0 NOUN F
( 0 PUNCT F
rHuEPO 0 ADV F
) 0 PUNCT F
has 0 PUNCT F
been 0 PUNCT F
used 0 VERB F
safely 0 ADV F
and 0 CCONJ F
effectively 0 ADV F
to 0 PART F
treat 0 CCONJ F
anemia 0 PUNCT F
in 0 ADP F
AIDS 0 NOUN T
patients 0 NOUN F
receiving 0 ADP F
zidovudine 0 NOUN F
( 0 PUNCT F
AZT 0 NOUN T
) 0 PUNCT F
and 0 CCONJ F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
chronic 0 ADJ F
renal 0 ADJ F
failure 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
This 0 DET T
study 0 NOUN F
was 0 VERB F
designed 0 VERB F
to 0 PART F
evaluate 0 NOUN F
the 0 DET F
clinical 0 ADJ F
role 0 NOUN F
of 0 ADP F
rHuEPO 0 ADV F
in 0 ADP F
reducing 0 VERB F
symptomatic B-PHYSICAL ADJ F
anemia I-PHYSICAL NOUN F
in 0 ADP F
patients 0 NOUN F
with 0 ADP F
advanced 0 VERB F
cancer 0 NOUN F
who 0 ADP F
were 0 VERB F
receiving 0 ADP F
myelosuppressive 0 ADJ F
chemotherapy 0 NOUN F
( 0 PUNCT F
excluding 0 ADP F
cisplatin 0 NOUN F
) 0 PUNCT F
. 0 PUNCT F

METHODS 0 NOUN T
We 0 PRON T
studied 0 VERB F
153 0 NUM F
anemic 0 ADJ F
cancer 0 NOUN F
patients 0 NOUN F
receiving 0 VERB F
cyclic 0 ADJ F
combination 0 NOUN F
chemotherapy 0 NOUN F
in 0 ADP F
a 0 DET F
prospective 0 ADJ F
multicenter 0 NOUN F
, 0 PUNCT F
double-blind 0 ADJ F
, 0 PUNCT F
placebo-controlled 0 VERB F
trial 0 NOUN F
. 0 PUNCT F

The 0 DET T
patients 0 NOUN F
were 0 VERB F
randomly 0 ADV F
assigned 0 VERB F
to 0 PART F
receive 0 NOUN F
either 0 PUNCT F
rHuEPO 0 ADV F
( 0 PUNCT F
150 0 NUM F
U/kg 0 NOUN T
) 0 PUNCT F
or 0 CCONJ F
placebo 0 NOUN F
subcutaneously 0 ADV F
three 0 NUM F
times 0 NOUN F
a 0 DET F
week 0 NOUN F
for 0 ADP F
a 0 DET F
maximum 0 NOUN F
of 0 ADP F
12 0 NUM F
weeks 0 NOUN F
or 0 CCONJ F
until 0 ADP F
the 0 DET F
hematocrit B-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
increased 0 VERB F
to 0 ADP F
38 0 NUM F
% 0 SYM F
-40 0 NUM F
% 0 SYM F
. 0 PUNCT F

If 0 PUNCT T
the 0 DET F
hematocrit B-PHYSICAL NOUN F
reached 0 ADP F
this 0 DET F
target 0 NOUN F
level 0 NOUN F
before 0 ADP F
12 0 NUM F
weeks 0 NOUN F
, 0 PUNCT F
the 0 DET F
rHuEPO 0 PUNCT F
dose 0 NOUN F
could 0 VERB F
be 0 VERB F
reduced 0 VERB F
to 0 PART F
maintain 0 ADV F
the 0 DET F
hematocrit 0 NOUN F
at 0 ADP F
that 0 PUNCT F
level 0 NOUN F
for 0 ADP F
the 0 DET F
duration 0 NOUN F
of 0 ADP F
the 0 DET F
study 0 NOUN F
. 0 PUNCT F

Response 0 NOUN T
to 0 ADP F
rHuEPO 0 ADV F
therapy 0 NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
measuring 0 VERB F
changes 0 NOUN F
in 0 ADP F
hematocrit B-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
, 0 PUNCT F
transfusion B-OTHER NOUN F
requirements I-OTHER NOUN F
, 0 PUNCT F
and 0 CCONJ F
quality 0 NOUN F
of 0 ADP F
life 0 NOUN F
. 0 PUNCT F

Quality-of-life B-OTHER NOUN T
assessment 0 NOUN F
was 0 VERB F
based 0 VERB F
on 0 ADP F
patients 0 NOUN F
' 0 PUNCT F
responses 0 CCONJ F
to 0 ADP F
questionnaires 0 NOUN F
before 0 ADP F
and 0 CCONJ F
after 0 ADP F
the 0 DET F
courses 0 NOUN F
of 0 ADP F
therapy 0 NOUN F
. 0 PUNCT F

RESULTS 0 PUNCT T
The 0 DET T
increase 0 NOUN F
in 0 ADP F
hematocrit B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
rHuEPO-treated 0 VERB F
group 0 NOUN F
compared 0 VERB F
with 0 ADP F
hematocrit B-PHYSICAL NOUN F
in 0 ADP F
the 0 DET F
placebo-treated 0 DET F
group 0 NOUN F
was 0 VERB F
statistically 0 ADV F
significant 0 ADJ F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.0001 0 NUM F
) 0 PUNCT F
as 0 VERB F
measured 0 VERB F
by 0 ADP F
percentage 0 NOUN F
point 0 NOUN F
of 0 ADP F
change 0 NOUN F
from 0 ADP F
baseline 0 NOUN F
to 0 ADP F
final 0 ADJ F
evaluation 0 NOUN F
, 0 PUNCT F
by 0 ADP F
an 0 DET F
increase 0 NOUN F
in 0 ADP F
hematocrit B-PHYSICAL NOUN F
level 0 NOUN F
of 0 ADP F
six 0 NUM F
percentage 0 NOUN F
points 0 DET F
or 0 CCONJ F
more 0 DET F
unrelated 0 VERB F
to 0 ADP F
transfusion 0 NOUN F
, 0 PUNCT F
and 0 CCONJ F
by 0 ADP F
a 0 DET F
rise 0 NOUN F
in 0 ADP F
hematocrit B-PHYSICAL NOUN F
level I-PHYSICAL NOUN F
to 0 ADP F
38 0 NUM F
% 0 SYM F
or 0 CCONJ F
more 0 DET F
unrelated 0 VERB F
to 0 ADP F
transfusion 0 NOUN F
. 0 PUNCT F

There 0 PUNCT T
was 0 VERB F
a 0 DET F
trend 0 NOUN F
toward 0 ADP F
the 0 DET F
reduction 0 NOUN F
in 0 ADP F
mean 0 NOUN F
units 0 NOUN F
of 0 ADP F
blood B-OTHER NOUN F
transfused I-OTHER PUNCT F
per I-OTHER ADP F
patient I-OTHER NOUN F
during 0 ADP F
months 0 NOUN F
2 0 NUM F
and 0 CCONJ F
3 0 NUM F
of 0 ADP F
therapy 0 NOUN F
combined 0 VERB F
in 0 ADP F
rHuEPO-treated 0 VERB F
patients 0 NOUN F
compared 0 VERB F
with 0 ADP F
placebo-treated 0 VERB F
patients 0 NOUN F
( 0 PUNCT F
0.91 0 NUM F
U 0 NOUN T
versus 0 CCONJ F
1.65 0 NUM F
U 0 NOUN T
; 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.056 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

In 0 ADP T
addition 0 NOUN F
, 0 PUNCT F
rHuEPO-treated 0 PUNCT F
patients 0 NOUN F
experienced 0 VERB F
a 0 DET F
statistically 0 ADV F
significant 0 ADJ F
improvement 0 NOUN F
in 0 ADP F
energy B-OTHER NOUN F
level I-OTHER NOUN F
and 0 CCONJ F
ability B-OTHER NOUN F
to I-OTHER PART F
perform I-OTHER NOUN F
daily I-OTHER DET F
activities I-OTHER NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
or 0 CCONJ F
= 0 SYM F
.05 0 NUM F
) 0 PUNCT F
. 0 PUNCT F

The 0 DET T
two 0 NUM F
treatment 0 NOUN F
groups 0 NOUN F
showed 0 VERB F
no 0 DET F
statistically 0 ADV F
significant 0 ADJ F
differences 0 NOUN F
in 0 ADP F
toxic B-ADVERSE-EFFECTS ADJ F
effects I-ADVERSE-EFFECTS NOUN F
except 0 PUNCT F
for 0 ADP F
increased 0 CCONJ F
incidence 0 NOUN F
of 0 ADP F
diaphoresis B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
P 0 NOUN T
< 0 SYM F
.05 0 NUM F
) 0 PUNCT F
and 0 CCONJ F
diarrhea B-ADVERSE-EFFECTS NOUN F
( 0 PUNCT F
P 0 NOUN T
= 0 SYM F
.05 0 NUM F
) 0 PUNCT F
in 0 ADP F
the 0 DET F
rHuEPO-treated 0 VERB F
group 0 NOUN F
. 0 PUNCT F

CONCLUSIONS 0 NOUN T
We 0 PRON T
conclude 0 VERB F
that 0 ADP F
rHuEPO 0 ADV F
is 0 ADJ F
safe 0 ADJ F
and 0 CCONJ F
effective 0 ADJ F
for 0 ADP F
reversing 0 VERB F
anemia B-PHYSICAL NOUN F
related 0 VERB F
to 0 ADP F
advanced 0 VERB F
cancer 0 NOUN F
or 0 CCONJ F
to 0 ADP F
chemotherapy 0 NOUN F
for 0 ADP F
cancer 0 NOUN F
. 0 PUNCT F

Enhanced 0 DET T
small 0 ADJ F
group 0 NOUN F
instruction 0 NOUN F
using 0 PUNCT F
choral 0 PUNCT F
responding 0 PUNCT F
and 0 CCONJ F
student 0 ADJ F
interaction 0 NOUN F
for 0 ADP F
children 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
disabilities 0 NOUN F
. 0 PUNCT F

The 0 DET T
use 0 NOUN F
of 0 ADP F
effective 0 ADJ F
instructional 0 ADJ F
strategies 0 NOUN F
in 0 ADP F
small 0 ADJ F
groups 0 NOUN F
was 0 VERB F
investigated 0 VERB F
to 0 PART F
determine 0 NOUN F
learning 0 ADP F
effects 0 NOUN F
for 0 ADP F
24 0 NUM F
elementary 0 ADP F
age 0 NOUN F
students 0 NOUN F
with 0 ADP F
autism 0 NOUN F
and 0 CCONJ F
developmental 0 ADJ F
disabilities 0 NOUN F
. 0 PUNCT F

Effective 0 ADJ T
strategies 0 NOUN F
included 0 VERB F
( 0 PUNCT F
a 0 NOUN F
) 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
choral 0 ADJ F
responding 0 PUNCT F
; 0 PUNCT F
( 0 PUNCT F
b 0 NOUN F
) 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
student-to-student 0 ADJ F
responding 0 ADV F
; 0 PUNCT F
( 0 PUNCT F
c 0 NOUN F
) 0 PUNCT F
the 0 DET F
rotation 0 NOUN F
of 0 ADP F
materials 0 NOUN F
every 0 DET F
5 0 NUM F
minutes 0 NOUN F
during 0 ADP F
the 0 DET F
30-minute 0 NOUN F
group 0 NOUN F
while 0 ADP F
teaching 0 ADP F
2 0 NUM F
to 0 ADP F
3 0 NUM F
concepts 0 NOUN F
; 0 PUNCT F
and 0 CCONJ F
( 0 PUNCT F
d 0 NOUN F
) 0 PUNCT F
the 0 DET F
use 0 NOUN F
of 0 ADP F
random 0 ADJ F
, 0 PUNCT F
unpredictable 0 ADP F
trials 0 NOUN F
for 0 ADP F
student 0 NOUN F
responding 0 PUNCT F
. 0 PUNCT F

Thirty-minute 0 PUNCT T
language 0 NOUN F
groups 0 NOUN F
were 0 VERB F
targeted 0 VERB F
to 0 VERB F
teach 0 ADP F
receptive 0 ADJ F
and 0 CCONJ F
expressive 0 ADJ F
skills 0 NOUN F
using 0 VERB F
pictures 0 VERB F
and 0 CCONJ F
common 0 ADJ F
objects 0 ADV F
across 0 ADP F
five 0 NUM F
categories 0 NOUN F
( 0 PUNCT F
e.g. 0 ADP F
, 0 PUNCT F
household 0 NOUN F
items 0 ADJ F
, 0 PUNCT F
foods 0 ADJ F
) 0 PUNCT F
. 0 PUNCT F

Results 0 NOUN T
showed 0 VERB F
increased 0 VERB F
opportunities B-MENTAL NOUN F
to I-MENTAL PART F
respond I-MENTAL ADP F
, 0 PUNCT F
increased 0 VERB F
levels B-MENTAL NOUN F
of I-MENTAL ADP F
responding I-MENTAL PUNCT F
and I-MENTAL CCONJ F
academic I-MENTAL ADJ F
engagement I-MENTAL NOUN F
, 0 PUNCT F
higher B-PHYSICAL PUNCT F
gains I-PHYSICAL NOUN F
on 0 ADP F
weekly B-MENTAL ADV F
criterion-referenced I-MENTAL VERB F
pre- I-MENTAL ADJ F
and I-MENTAL CCONJ F
posttests I-MENTAL ADP F
, 0 PUNCT F
and 0 CCONJ F
decreased 0 ADV F
passive B-MENTAL ADJ F
and I-MENTAL CCONJ F
inappropriate I-MENTAL PUNCT F
student I-MENTAL ADJ F
behavior I-MENTAL NOUN F
during 0 ADP F
interventions 0 NOUN F
. 0 PUNCT F

Double-blind 0 ADJ T
comparison 0 NOUN F
of 0 ADP F
doxepin 0 NOUN F
versus 0 CCONJ F
bupropion 0 NOUN F
in 0 ADP F
outpatients 0 ADJ F
with 0 ADP F
a 0 DET F
major 0 ADJ F
depressive 0 ADJ F
disorder 0 NOUN F
. 0 PUNCT F

A 0 DET T
double-blind 0 ADJ F
controlled 0 VERB F
study 0 NOUN F
comparing 0 VERB F
the 0 DET F
effects 0 NOUN F
of 0 ADP F
bupropion 0 NOUN F
to 0 ADP F
doxepin 0 NOUN F
in 0 ADP F
outpatients 0 ADJ F
with 0 ADP F
primary 0 ADJ F
depression 0 NOUN F
was 0 VERB F
conducted 0 VERB F
to 0 PART F
evaluate 0 NOUN F
efficacy 0 NOUN F
and 0 CCONJ F
safety B-OTHER NOUN F
differences 0 NOUN F
between 0 ADP F
the 0 DET F
two 0 NUM F
drugs 0 NOUN F
. 0 PUNCT F

Following 0 VERB T
a 0 DET F
7-day 0 NOUN F
placebo 0 NOUN F
washout 0 PUNCT F
period 0 NOUN F
, 0 PUNCT F
patients 0 NOUN F
could 0 VERB F
be 0 VERB F
treated 0 VERB F
for 0 ADP F
up 0 PUNCT F
to 0 PUNCT F
13 0 NUM F
weeks 0 NOUN F
on 0 ADP F
either 0 CCONJ F
treatment 0 NOUN F
. 0 PUNCT F

Antidepressant B-MENTAL NOUN T
response I-MENTAL NOUN F
was 0 VERB F
assessed 0 VERB F
by 0 ADP F
the 0 DET F
Hamilton B-MENTAL PUNCT T
Depression I-MENTAL NOUN T
and I-MENTAL CCONJ F
Anxiety I-MENTAL NOUN T
Scales 0 PUNCT T
, 0 PUNCT F
Clinical B-MENTAL ADJ T
Global I-MENTAL ADJ T
Severity I-MENTAL NOUN T
and 0 CCONJ F
Improvement B-MENTAL NOUN T
Ratings I-MENTAL PROPN T
, 0 PUNCT F
and 0 CCONJ F
the 0 DET F
Zung B-MENTAL PUNCT T
Self-Rating I-MENTAL PUNCT T
Depression I-MENTAL NOUN T
Scale 0 NOUN T
. 0 PUNCT F

Comparable 0 ADJ T
efficacy 0 NOUN F
between 0 ADP F
the 0 DET F
compounds 0 NOUN F
was 0 VERB F
found 0 VERB F
across 0 ADP F
the 0 DET F
13-week 0 PUNCT F
study 0 NOUN F
. 0 PUNCT F

Doxepin 0 NOUN T
differed 0 VERB F
from 0 ADP F
bupropion 0 NOUN F
mainly 0 ADV F
on 0 ADP F
the 0 DET F
sleep B-MENTAL ADV F
factor 0 NOUN F
of B-MENTAL ADP F
the I-MENTAL DET F
Hamilton I-MENTAL PUNCT T
Depression B-MENTAL NOUN T
Scale 0 NOUN T
, 0 PUNCT F
with 0 ADP F
doxepin 0 NOUN F
improving 0 PUNCT F
sleep 0 ADP F
to 0 ADP F
a 0 DET F
greater 0 PUNCT F
extent 0 NOUN F
than 0 PUNCT F
bupropion 0 NOUN F
. 0 PUNCT F

Doxepin 0 NOUN T
produced 0 VERB F
a 0 DET F
greater 0 PUNCT F
incidence 0 NOUN F
of 0 ADP F
anticholinergic B-ADVERSE-EFFECTS ADJ F
side I-ADVERSE-EFFECTS NOUN F
effects B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
including 0 CCONJ F
dry B-ADVERSE-EFFECTS ADJ F
mouth B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
constipation B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
sleepiness B-ADVERSE-EFFECTS NOUN F
, 0 PUNCT F
and 0 PUNCT F

Effectiveness 0 NOUN T
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
the 0 DET F
Levitan 0 NOUN T
FPS 0 NOUN T
Scope? 0 NOUN T
for 0 ADP F
tracheal 0 ADJ F
intubation 0 NOUN F
under 0 ADP F
general 0 ADJ F
anesthesia 0 NOUN F
with 0 ADP F
a 0 DET F
simulated 0 VERB F
difficult 0 ADJ F
airway 0 NOUN F
. 0 PUNCT F

PURPOSE 0 NOUN T
Studies 0 NOUN T
show 0 VERB F
that 0 ADP F
the 0 DET F
Levitan 0 NOUN T
FPS 0 NOUN T
( 0 PUNCT F
first 0 PUNCT F
pass 0 PUNCT F
success 0 NOUN F
) 0 PUNCT F
Scope? 0 NOUN T
( 0 PUNCT F
LFS 0 NOUN T
) 0 PUNCT F
is 0 VERB F
analogous 0 ADJ F
to 0 ADP F
a 0 DET F
bougie 0 ADJ F
in 0 ADP F
simulated 0 DET F
difficult 0 ADJ F
airways 0 NOUN F
with 0 ADP F
comparable 0 ADJ F
tracheal 0 ADJ F
intubation 0 NOUN F
success 0 NOUN F
rates 0 NOUN F
. 0 PUNCT F

In 0 ADP T
this 0 DET F
study 0 NOUN F
, 0 PUNCT F
the 0 DET F
efficacy 0 NOUN F
and 0 CCONJ F
safety 0 NOUN F
of 0 ADP F
tracheal 0 ADJ F
intubation 0 NOUN F
with 0 ADP F
the 0 DET F
LFS 0 NOUN T
was 0 VERB F
compared 0 VERB F
with 0 ADP F
that 0 PUNCT F
of 0 ADP F
the 0 DET F
Macintosh 0 NOUN T
laryngoscope 0 NOUN F
utilizing 0 ADP F
manual 0 ADJ F
in-line 0 NOUN F
stabilization 0 NOUN F
( 0 PUNCT F
MILS 0 NOUN T
) 0 PUNCT F
to 0 PUNCT F
simulate 0 ADJ F
difficult 0 ADJ F
airways 0 NOUN F
. 0 PUNCT F

